<SEC-DOCUMENT>0001193125-15-375853.txt : 20151112
<SEC-HEADER>0001193125-15-375853.hdr.sgml : 20151112
<ACCEPTANCE-DATETIME>20151112170314
ACCESSION NUMBER:		0001193125-15-375853
CONFORMED SUBMISSION TYPE:	S-1/A
PUBLIC DOCUMENT COUNT:		15
FILED AS OF DATE:		20151112
DATE AS OF CHANGE:		20151112

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			EXAGEN DIAGNOSTICS INC
		CENTRAL INDEX KEY:			0001274737
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MEDICAL LABORATORIES [8071]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE

	FILING VALUES:
		FORM TYPE:		S-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-198850
		FILM NUMBER:		151225704

	BUSINESS ADDRESS:	
		STREET 1:		1261 LIBERTY WAY
		CITY:			VISTA
		STATE:			CA
		ZIP:			92081
		BUSINESS PHONE:		(760) 560-1501

	MAIL ADDRESS:	
		STREET 1:		1261 LIBERTY WAY
		CITY:			VISTA
		STATE:			CA
		ZIP:			92081
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>d693329ds1a.htm
<DESCRIPTION>S-1/A
<TEXT>
<HTML><HEAD>
<TITLE>S-1/A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>As filed with the Securities and Exchange Commission on November 12, 2015 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Registration No.&nbsp;333-198850 </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES
AND EXCHANGE COMMISSION </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Amendment No.&nbsp;6 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>to </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM S-1 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><I>UNDER </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><I>THE
SECURITIES ACT OF 1933 </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>EXAGEN DIAGNOSTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>8071</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>20-0434866</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Primary Standard Industrial</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Classification Code Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>1261 Liberty Way, Suite C </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Vista, California 92081 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(760) 560-1501 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address,
including zip code, and telephone number, including area code, of registrant&#146;s principal executive offices) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Fortunato Ron
Rocca </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>President and Chief Executive Officer </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exagen Diagnostics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>1261 Liberty Way, Suite C </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Vista, California 92081 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(760) 560-1501 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Name,
address, including zip code, and telephone number, including area code, of agent for service) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Copies to:
</I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Cheston J. Larson, Esq.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Steven T. Chinowsky, Esq.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Matthew T. Bush, Esq.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Latham &amp; Watkins LLP</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>12670 High Bluff Drive</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>San Diego, California 92130</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(858) 523-5400</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Jason L. Kent, Esq.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Charles S. Kim, Esq.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Kristin E. VanderPas, Esq.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Cooley LLP</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>4401 Eastgate
Mall</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>San Diego, California 92121</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(858) 550-6000</B></P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Approximate date of commencement of proposed sale to the public: </B>As soon as practicable after this Registration Statement is declared
effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415
under the Securities Act of 1933, check the following box.&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If this form is
filed to register additional securities for an offering pursuant to Rule 462(b)&nbsp;under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the
same offering.&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT><U></U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If this form is a post-effective amendment filed
pursuant to Rule&nbsp;462(c)&nbsp;under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT><U></U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If this form is a post-effective amendment filed pursuant to
Rule&nbsp;462(d)&nbsp;under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering.&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large
accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer&#148; and &#147;smaller reporting company&#148; in Rule 12b-2 of
the Exchange Act. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Non-accelerated filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;(Do not check if a smaller reporting company)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay
its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933 or until the
Registration Statement shall become effective on such date as the Commission, acting pursuant to said Section&nbsp;8(a), may determine. </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow"><FONT COLOR="#de1a1e"><B>The information in this preliminary prospectus is not complete and may be changed. We may
not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities
in any state or other jurisdiction where the offer or sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#de1a1e"><B>Subject to completion, dated November 12, 2015 </B></FONT></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PRELIMINARY PROSPECTUS </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g693329dsp_002.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>SHARES OF COMMON STOCK </B></P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Exagen Diagnostics, Inc. is offering
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of its common stock. This is our initial public offering, and no public market currently exists for our shares. We
anticipate that the initial public offering price will be between $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to this offering, there has been no public market for our common stock. We have applied to list our common stock on The NASDAQ Global
Market under the symbol &#147;EXDX.&#148; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an
&#147;emerging growth company&#148; as that term is used in the Jumpstart Our Business Startups Act of 2012, and, as such, have elected to comply with certain reduced public company reporting requirements. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:12pt; font-family:Times New Roman"><B>Investing in our common stock involves a high degree of risk. Before buying any shares, you should carefully read the discussion of
material risks of investing in our common stock in &#147;<A HREF="#tx693329_2">Risk Factors</A>&#148; beginning on page&nbsp;11 of this prospectus. </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per</B><br><B>Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Initial public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discounts and commissions<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds, before expenses, to us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">We have agreed to reimburse the underwriters for certain expenses in connection with this offering. See &#147;Underwriting.&#148; </TD></TR></TABLE>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have granted the underwriters an option for a period of 30 days to purchase up to an additional shares of common stock to cover any
over-allotments. The underwriters can exercise this right at any time within 30 days after the date of this prospectus. </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the
Securities and Exchange Commission nor any other regulatory body has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters expect to deliver the shares of common stock to investors on or about
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015. </P>  <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:14pt" ALIGN="center">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:14pt"><B>Leerink Partners</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:14pt"><B>Baird</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>William Blair </B></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015. </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g693329dsp_003.jpg" ALT="LOGO">
 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="96%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx693329_1">Prospectus Summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1 </TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx693329_2">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11 </TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx693329_3">Special Note Regarding Forwardlooking Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42 </TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx693329_4">Use Of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43 </TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx693329_5">Dividend Policy</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44 </TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx693329_6">Capitalization</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45 </TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx693329_7">Dilution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47 </TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx693329_8">Selected Consolidated Financial Data</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49 </TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx693329_9">Management&#146;s Discussion And Analysis Of Financial Condition And Results Of Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51 </TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx693329_10">Business</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">71 </TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx693329_11">Management</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">96 </TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx693329_12">Executive And Director Compensation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx693329_13">Certain Relationships And Related Person Transactions</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx693329_14">Principal Stockholders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx693329_15">Description Of Capital Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">131<BR></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;<BR></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx693329_16">Shares Eligible For Future Sale</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx693329_17">Material United States Federal Income Tax Consequences To Non-U.S. Holders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx693329_18">Underwriting</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx693329_19">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx693329_20">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx693329_21">Change In Independent Accountant</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx693329_22">Where You Can Find More Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx693329_23">Index to Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>   <center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should rely
only on the information contained in this prospectus or in any free writing prospectus we may authorize to be delivered or made available to you. We have not authorized anyone to provide you with different information. We are offering to sell, and
seeking offers to buy, shares of our common stock only in jurisdictions where offers and sales are permitted. The information in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this
prospectus or of any sale of shares of our common stock. Our business, financial condition, results of operations and prospects may have changed since that date. </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For investors outside the United States: We have not and the underwriters have not done anything that would permit this offering or possession
or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and
observe any restrictions relating to, the offering of the shares of common stock and the distribution of this prospectus outside the United States. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise
indicated, information contained in this prospectus concerning our industry and the markets in which we operate, including our general expectations and market position, market opportunity and market share, is based on information from our own
management estimates and research, as well as from industry and general publications and research, surveys and studies conducted by third parties. Management estimates are derived from publicly available information, our knowledge of our industry
and assumptions based on such information and knowledge, which we believe to be reasonable. Our management estimates have not been verified by any independent source, and we have not independently verified any third-party information. In addition,
assumptions and estimates of our and our industry&#146;s future performance are necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including those described in &#147;Risk Factors.&#148; These and other factors
could cause our future performance to differ materially from our assumptions and estimates. See &#147;Special Note Regarding Forward-Looking Statements.&#148; </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

<center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We use our trademarks in this prospectus, as well as trademarks, tradenames and service marks that are the property of other organizations.
Solely for convenience, trademarks and tradenames referred to in this prospectus appear without the <SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and &#153; symbols, but those references are not intended to indicate, in any way, that we
will not assert, to the fullest extent under applicable law, our rights or that the applicable owner will not assert its rights, to these trademarks and tradenames. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx693329_1"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights information contained elsewhere in this prospectus. This summary does not contain all of the information you should
consider before investing in our common stock. You should read this entire prospectus carefully, especially the section in this prospectus entitled &#147;Risk Factors&#148; beginning on page&nbsp;11 and our consolidated financial statements and the
related notes thereto included at the end of this prospectus, before making an investment decision. As used in this prospectus, unless the context otherwise requires, references to &#147;we,&#148; &#147;us,&#148; &#147;our,&#148; &#147;our
company&#148; and &#147;Exagen&#148; refer to Exagen Diagnostics, Inc. </I></P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Company Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a commercial-stage diagnostics company committed to addressing the significant unmet need for the accurate diagnosis and monitoring of
patients affected by autoimmune rheumatic diseases. These chronic diseases can cause lifelong inflammation in the joints, tissues and internal organs, resulting in serious complications, such as irreversible organ damage. The accurate, timely and
differential diagnosis for patients suffering from the approximately 30 autoimmune rheumatic diseases, or ARDs, is critical as treatment for each disease can vary, and inappropriate or delayed therapy may expose patients to unnecessary risks or the
hazards of uncontrolled disease activity. Physicians face significant difficulties in making a definitive diagnosis of a specific ARD because patients with different diseases often present with a common set of symptoms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently market five products under our Avise brand to provide an accurate, timely and differential diagnosis and to optimize the
treatment of ARDs. We processed approximately 9,300 patient specimens for our lead diagnostic product line, Avise SLE, in 2013, approximately 27,900 in 2014 and approximately 27,700 in the nine months ended September&nbsp;30, 2015. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The diagnosis and treatment of ARDs is generally provided by the community rheumatologist, a sub-specialty of internal medicine which includes
approximately 3,500 physicians in the United States. Patients often present to a rheumatologist after a lengthy referral process because of the similarity and overlap of symptoms among ARDs, the waxing and waning of these symptoms and the
shortcomings of current diagnostic tests. Establishing a definitive diagnosis is often difficult and can take years. Throughout this time, patients may continue to suffer from the debilitating effects of their disease, receive inappropriate
treatments and may face a significant financial burden. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our lead product, Avise CTD (formerly referred to as Avise SLE+CT), is a
proprietary diagnostic test that provides an enhanced solution for patients presenting with symptoms indicative of a wide variety of ARDs such as Systemic Lupus Erythematosus, or SLE, Rheumatoid Arthritis, or RA, Sj&ouml;gren&#146;s syndrome,
scleroderma and other disorders that mimic ARDs such as fibromyalgia. Avise CTD allows physicians to more accurately rule-in or rule-out SLE, and inform decisions about the presence of other ARDs, all with the convenience of one blood draw.
Differential diagnosis of these diseases is critically important because earlier diagnosis has been shown to improve patient outcomes. Once diagnosed, physicians can tailor therapy to a patient&#146;s specific disease and avoid the &#147;trial and
error&#148; approach that often takes place when a definitive diagnosis cannot be made. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have validated the clinical utility of Avise
Lupus (formerly referred to as Avise SLE 2.0), the proprietary component of our Avise CTD solution, in a multi-center study in an aggregate of 794 subjects. The results of this study, which were presented at the American College of Rheumatology, or
ACR, annual conference in 2013, showed that Avise Lupus demonstrated superior ability to distinguish SLE from other ARDs. Avise Lupus is powered by our proprietary Cell Bound Complement Activation Products, or CB-CAPs, technology, which we
exclusively license from the University of Pittsburgh. This technology is the result of over a decade of extensive research and development conducted at the Lupus Center of Excellence at the University of Pittsburgh Medical Center. In addition, we
have validated the use of CB-CAPs as an effective method for diagnosing SLE, in a study comparing the sensitivity of elevated CB-CAPs to reduced levels of serum complement, such as C3 and C4, which is a standard test used to diagnose SLE. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to develop additional innovative, high value diagnostic solutions for the rheumatologist while continuing to improve the performance
characteristics of our currently marketed products. In particular, we are developing and validating testing solutions that are designed to assist rheumatologists with the monitoring of disease activity in patients with SLE and monitoring the active
drug levels of some of the more commonly prescribed pharmaceuticals for the treatment of ARDs. We are conducting validation studies for these products in collaboration with academic centers of excellence and intend to publish the results of these
studies in peer-reviewed medical journals. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 1 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Market Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Autoimmune Rheumatic Diseases </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ARDs are a
group of approximately 30 chronic disorders which create a significant burden on the healthcare system. These chronic diseases can cause lifelong inflammation in the joints, tissues and internal organs, resulting in serious complications, such as
irreversible organ damage. Untreated chronic inflammation can also lead to premature hardening of the arteries, heart attacks and strokes. It is estimated that 11&nbsp;million patients in the United States suffer from ARDs, and patients afflicted
with fibromyalgia and autoimmune thyroid disease have many of the same clinical symptoms as patients with ARDs. Examples of these disorders include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Systemic Lupus Erythematosus (SLE). </I>A chronic autoimmune disease involving inflammation and destruction of organs such as the brain, kidneys and lungs resulting in irreversible damage and in severe cases death.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Rheumatoid Arthritis (RA).</I> A chronic autoimmune disease involving inflammation and destruction of joints, bone and in some cases organs, including eyes and lungs. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Sj&ouml;gren&#146;s Syndrome. </I>A chronic autoimmune disease involving inflammation and destruction of secretory glands such as salivary glands and tear ducts. This disease can occur with RA and SLE.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Fibromyalgia.</I> A chronic condition characterized by widespread pain and tenderness to touch. Although not an autoimmune disease, this syndrome has been reported to occur in 25% of RA patients, 30% of SLE patients
and 50% of Sj&ouml;gren&#146;s patients. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Autoimmune Thyroid Disease</I>. A chronic autoimmune disease that results in antibodies causing decreased thyroid hormone production, or hypothyroidism, or increased thyroid hormone production, or hyperthyroidism.
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patients with these disorders often present with a common set of symptoms, which can include joint pain, fatigue,
inflammation, stiffness and muscle aches, among others. Additionally, these patients may experience unpredictable periods of disease flares and disease inactivity, which can meaningfully change the patients&#146; symptoms and how they present to the
physician. The combination of overlapping symptoms and disease biology can lead these patients to cycle from physician to physician for months or even years before receiving a definitive diagnosis. Due to this, we believe physicians are in critical
need of objective tests capable of differentially diagnosing these disorders, especially for potentially life threatening ARDs such as SLE. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Systemic
Lupus Erythematosus </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SLE is the most common and one of the most serious forms of lupus. It is estimated that over one million people in
the United States suffer from some form of lupus. SLE is characterized by unpredictable, intermittent increases and decreases of disease activity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Diagnosing SLE is difficult due to overlapping symptoms with other ARDs, fibromyalgia and autoimmune thyroid disease. A Lupus Foundation of
America survey suggests that on average it takes nearly six years to be diagnosed and more than half of those afflicted with lupus saw four or more healthcare providers, before obtaining a correct diagnosis. Earlier diagnosis of SLE allows
physicians to initiate therapies sooner in order to help protect the patient from organ damage. An independent study funded by GlaxoSmithKline plc and published in a peer-reviewed medical journal concluded that early diagnosis of SLE is associated
with better clinical outcomes, including lower flare rates, as well as reduced resource utilization and healthcare costs. Once diagnosed, treatment of SLE generally involves the use of antimalarials, corticosteroids, immunosuppressants and newer
biologic agents to prevent or suppress active disease or flares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is a significant need for frequent monitoring of disease activity
to guide therapeutic choices and optimize drug effectiveness. Physicians and patients are in need of improved, objective testing solutions to help with the diagnosis, prognosis and monitoring of patients with SLE and other ARDs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is estimated that over 14&nbsp;million people in the United States have been diagnosed with ARDs, fibromyalgia and autoimmune thyroid
disease, with approximately 470,000 people diagnosed annually. Additionally, in the United States, over one million patients annually are prescribed methotrexate, or MTX, therapy, and over 700,000 patients annually are prescribed hydroxychloroquine,
or HCQ, therapy. In addition, over 250,000 RA patients are prescribed anti-TNF therapy annually in the United States. We estimate the market potential of our existing products to be as much as $840 million annually, based on our internal research
and analysis utilizing these incidence and prevalence rates, the prescription information of pharmaceuticals for our drug monitoring products and the current Medicare allowable reimbursement rates for our products ($590 for Avise CTD, $25 for each
of Avise MTX and Avise HCQ, and $185 for Avise Anti-TNF). We estimate that five percent of the existing ARD diagnosed population has an uncertain diagnosis requiring confirmation. Therefore, in estimating the market potential of Avise CTD, we have
assumed that the ARD plus fibromyalgia and autoimmune thyroid population diagnosed annually plus five percent of the overall diagnosed </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 2 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
population, excluding the population diagnosed annually, represents the target population for this product. We estimate that patients will receive, on average, our drug monitoring test one to
one-and-a-half times per year. Because these calculations are based on internal estimates and assume rates of reimbursement that may change, there is no guarantee that these assumptions will prove to be accurate and consequently, our actual market
potential may not be as large as we expect. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Solution </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are committed to providing physicians with products that address the significant unmet need for accurate and timely diagnosis, prognosis and
monitoring of ARDs. We market five products under our Avise brand, which facilitate the accurate and timely differential diagnosis and prognosis of certain ARDs and drug-level monitoring of some of the most widely prescribed pharmaceuticals in
rheumatology. These tests are designed to seamlessly integrate with a rheumatologist&#146;s daily workflow and all of our tests are processed in our laboratory in California. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our product offerings include: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="22%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Diagnosis</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Prognosis</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Monitoring</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center">


<IMG SRC="g693329g34j21.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">


<IMG SRC="g693329dsp_084b.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">


<IMG SRC="g693329dsp_084c.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">


<IMG SRC="g693329dsp_084d.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">


<IMG SRC="g693329dsp_084e.jpg" ALT="LOGO">
</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Diagnostic test incorporating our proprietary CB-CAPs technology to rule-in or rule-out SLE from other
ARDs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Comprehensive SLE prognostic panel to assist in determining risk for kidney damage or neurologic or
cardiovascular</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">complications associated with SLE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Test to monitor levels of active MTX, a first-line therapy for&nbsp;RA</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Blood test to monitor levels of HCQ, a commonly prescribed treatment for patients with SLE and other ARDs</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Blood test to measure anti-TNF active drug levels and drug neutralizing antibody activity&nbsp;levels for
infliximab&nbsp;and adalimumab,&nbsp;two of the most commonly</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT STYLE="white-space:nowrap">used&nbsp;anti-TNF&nbsp;biologic</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">therapies for RA.</P></TD></TR>
</TABLE>   <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Avise CTD </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Avise CTD is a proprietary diagnostic test that provides an enhanced solution for patients presenting with symptoms indicative of a wide
variety of ARDs such as SLE, RA, Sj&ouml;gren&#146;s, scleroderma and other disorders that mimic ARDs such as fibromyalgia and autoimmune thyroid disease. Avise CTD is comprised of two distinct components: our proprietary Avise Lupus solution and
other established biomarkers to diagnose ARDs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Avise Lupus is a ten-marker panel test that includes two biomarkers based on our CB-CAPs
technology, which we exclusively license from the University of Pittsburgh, and a proprietary algorithm to optimize its performance. CB-CAPs are relatively stable biomarkers found in the blood that are associated with the presence and activity of
SLE. CB-CAPs, measured by flow cytometry, drive the superior performance of our solution versus the existing standards of diagnosis. We added additional established autoantibodies for assisting in the diagnosis of a broader set of ARDs to our
proprietary Avise Lupus solution. We developed this offering to enhance the clinical utility of our test and in response to our customers&#146; need for a more comprehensive solution to assist in differentially diagnosing ARDs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have demonstrated significant growth in demand for our Avise SLE diagnostic products. For example, in the nine months ended September 30,
2015, our orders for our Avise SLE diagnostic products increased from 19,400 to 27,700, a 43% increase over the same period in the prior year. Annual orders for our Avise SLE diagnostic products increased from 9,300 in 2013 to 27,900 in 2014, a 200%
increase. We believe this strong demand is a reflection of the value proposition we are providing to our physician customers and represents the market need for an enhanced solution to differentially diagnose ARDs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We validated Avise Lupus in a multi-center clinical study involving 794 subjects comprised of 304 SLE patients, 285 patients with other ARDs
and fibromyalgia, and 205 normal healthy subjects from two cohorts. The study was conducted in collaboration with leading academic centers with expertise in SLE and other ARDs including Albert Einstein College of Medicine, Northwestern University,
North Shore-LIJ Health System and NYU College of Medicine, among others, and the preliminary results were presented at the ACR annual conference in 2013. The primary endpoint of the study was the performance characteristics, specifically sensitivity
and specificity, of Avise Lupus compared to common autoantibodies used to diagnose SLE and other ARDs, such as antinuclear </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 3 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
antibodies, or ANA, and anti-double stranded DNA, or anti-dsDNA. Sensitivity measures the proportion of patients who are correctly identified as having a particular condition, while specificity
measures the proportion of patients who are correctly identified as not having a particular condition. The final results of this study showed that Avise Lupus: </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">demonstrated balanced performance consisting of 86% specificity and 80% sensitivity in distinguishing SLE from other ARDs and fibromyalgia; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">was 33% more specific than ANA (53% specificity/89% sensitivity); and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">was 48% more sensitive than anti-dsDNA (32% sensitivity/97% specificity). </TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Thus, this data suggests that
Avise Lupus has improved accuracy as compared to ANA and anti-dsDNA in distinguishing SLE patients from patients with other ARDs. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
have also validated the use of CB-CAPs as an effective method for diagnosing SLE in a study comparing the sensitivity of elevated CB-CAPs to reduced serum levels of C3 and C4 in diagnosing SLE. Measuring reduced serum levels of C3 and C4 is a common
method used to diagnose SLE. In fact, the Systemic Lupus International Collaborating Clinics, or SLICC, uses reduced C3 and C4 as immunologic criteria for classifying SLE. In our study, a total of 288 SLE patients meeting the ACR criteria were
enrolled. Elevated CB-CAPs levels demonstrated a 22% greater sensitivity in determining SLE than reduced levels of C3 and C4. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Avise SLE Prognostic
</I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Avise SLE Prognostic, which we launched in June 2014, is a blood test that complements Avise CTD by providing results that
inform the prognosis of SLE patients and provide physicians with more information to tailor treatment for their patients. This test is a ten-marker panel of autoantibodies that have established predictive value for assessing the potential for
complications affecting the brain, cardiovascular system and kidneys. When physicians are ordering Avise CTD, they can also request that we perform our Avise SLE Prognostic test if the initial Avise CTD result suggests that the patient has SLE. This
provides additional convenience for ordering physicians and their patient. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Avise MTX </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Avise MTX is the first therapeutic drug monitoring test to precisely measure levels of methotrexate polyglutamates, or MTXPG, the active form
of MTX in the patient&#146;s blood. MTX is a first-line therapy for RA, and Avise MTX can allow physicians to personalize therapy by targeting the appropriate dose to individual patients. There is large variability in the way patients absorb and
metabolize MTX, and several studies have shown that low levels of MTXPG in the blood correlate with a lack of response to MTX therapy. Avise MTX provides crucial information as to whether a patient has achieved MTXPG blood levels consistent with an
appropriate response to MTX or if the MTXPG levels are too low to produce adequate effects. The physician can then adjust MTX dosing as necessary to maximize the benefit of MTX therapy. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Avise HCQ </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Avise HCQ, which we
launched in September 2014, is a blood test to help physicians objectively monitor blood levels of HCQ as they treat patients with SLE and other ARDs, including RA. HCQ is typically prescribed daily to patients to control ARD activity and prevent
flares. However, there is a large variability in the response to HCQ therapy, and patients can be poorly compliant. In order to optimize HCQ therapy, it is crucial to determine if the patient is taking the drug as prescribed, and also to determine
whether the blood levels are adequate and consistent with clinical efficacy. By measuring HCQ concentration in the blood, we believe that Avise HCQ will help physicians optimize HCQ therapy, identify noncompliant patients and identify patients that
are not absorbing the drug adequately. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Avise Anti-TNF </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We launched our Avise Anti-TNF blood test in April 2015. This test helps physicians measure the levels of anti-TNF bioactivity in patients with
RA being treated with adalimumab (marketed as Humira<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>) and infliximab (marketed as Remicade<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>). Both Humira and Remicade belong to a
class of biologic therapies that inhibit tumor necrosis factor alpha, or TNF-<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT>. Anti-TNF biologics are estimated to generate more than $5 billion in annual sales in the United States for RA and are used
in an estimated 250,000 RA patients. However, approximately 30% of patients either do not respond at all or have insufficient responses to these therapies. The lack of response can be due to refractoriness to the mechanism of action of the drug
itself, referred to as TNF blockade, or the development of drug neutralizing antibodies. By providing information regarding the potential cause of non-response to anti-TNF therapy, we believe we can assist physicians in better determining when to
adjust the anti-TNF dose or switch to a different drug. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 4 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also believe that we will provide additional value to rheumatologists by offering our Avise
Anti-TNF blood test along with our Avise MTX test because MTX, which is commonly prescribed with anti-TNF biologics, is effective at improving anti-TNF efficacy. Avise Anti-TNF incorporates iLite technology, a cell-based assay that measures anti-TNF
levels and drug neutralizing antibodies. Avise Anti-TNF uses TNF-<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT>-sensitive cells in a bioassay that measures TNF-<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> activity. The key advantage of the iLite
technology compared to other anti-TNF monitoring tests is that it measures functional levels of anti-TNF bioactivity. In addition, the iLite technology determines the presence of antidrug antibodies. The FDA has released guidance indicating that
cell-based assays are the preferred technology platform for determining immunogenicity for therapeutic proteins. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Pipeline </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are focused on delivering meaningful solutions to aid rheumatologists in the diagnosis of patients with ARDs and providing physicians with
additional tools to determine the most appropriate therapy over time to improve patient care. Our pipeline includes solutions that differentially diagnose ARDs, provide prognosis of ARDs and monitor disease activity and active drug levels. We
continue to leverage the value of our CB-CAPs technology platform as it relates to management of ARDs and also the management of diseases involving activation of the complement pathway, a complex network of over 30 soluble and membrane bound
proteins that interact in a highly regulated manner to provide many of the effector functions of immunity and inflammation. Moreover, we are exploring the utility of our CB-CAPs platform in the monitoring of SLE and antibody mediated
transplantation. We are also planning to leverage the iLite and MTXPG technology platforms in the monitoring of disease activity of RA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our goal is to establish ourselves as the preeminent provider of testing solutions to rheumatologists by offering a comprehensive set
of tools to effectively diagnose and optimize the treatment of patients with ARDs. To achieve this objective, we intend to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Accelerate the adoption of our existing products</I>. We plan to expand the use of our Avise product suite by adding new physicians to our customer base as well as increasing utilization among our existing customers.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Further demonstrate the clinical utility of our products to drive adoption and support reimbursement</I>. We are conducting additional clinical studies to drive the adoption and reimbursement of our Avise product
suite and plan to continue to publish results in peer-reviewed medical journals. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Expand our portfolio of high value testing solutions.</I> We are continuing to develop additional products to address the significant challenges in the diagnosis, prognosis and monitoring of patients with ARDs.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Establish ourselves as the trusted partner to the rheumatologist</I>. Our reputation with our physician customers is built on their confidence in the quality of our testing solutions, the timely delivery of our test
reports and the value of our consultative support. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Engage in partnerships to access additional market opportunities</I>. We believe there is meaningful potential for our current and future products beyond the rheumatology specialty, particularly for those physician
groups that see patients earlier in the diagnostic process, and we intend to selectively seek complementary partnerships to address these broader markets. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Business </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
ability to execute our business strategy is subject to numerous risks, as more fully described in the section entitled &#147;Risk Factors&#148; immediately following this prospectus summary. These risks include, among others: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We are at an early stage of commercialization with a history of losses, including an accumulated deficit of $105.9 million as of September 30, 2015, and we expect to incur net losses in the future and may never achieve
or sustain profitability. </TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our financial results depend substantially on sales of our Avise products, and we will need to generate sufficient revenue from these products and other diagnostic, prognostic and monitoring solutions to grow our
business. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We may be unable to manage our future growth effectively, which could make it difficult to execute our business strategy. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our commercial success depends upon attaining significant market acceptance of our products among physicians, patients, and third-party payers. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We rely on sole suppliers for some of the reagents, equipment and other materials used in our Avise products, and we may not be able to find replacements or transition to alternative suppliers. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">If we are unable to support demand for our Avise products or any of our future products or solutions, our business could suffer. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 5 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">If third-party payers do not provide coverage and adequate reimbursement, breach, rescind or modify their contracts or reimbursement policies or delay payments for our tests, or if we are unable to successfully
negotiate payer contracts, our commercial success could be compromised. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We conduct business in a heavily regulated industry, and any changes in regulations or the U.S. Food and Drug Administration&#146;s enforcement discretion with respect to laboratory developed tests, or any other
healthcare policy changes, or violations of healthcare laws and regulations by us that could result in substantial penalties, could adversely affect our business, prospects, results of operations or financial condition. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Developing new products involves a lengthy and complex process, and we may not be able to commercialize on a timely basis, or at all, other products we are developing. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">If we are unable to maintain intellectual property protection, our competitive position could be harmed. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were
incorporated under the laws of the state of New Mexico in 2002, under the name Exagen Corporation. In 2003, we changed our state of incorporation from New Mexico to Delaware by merging with and into Exagen Diagnostics, Inc., pursuant to which we
changed our name to Exagen Diagnostics, Inc. Our principal executive offices are located at 1261 Liberty Way, Suite C, Vista, California 92081, and we also maintain offices in New Mexico, at 800 Bradbury Drive South East, Suite 108, Albuquerque, New
Mexico 87106. Our telephone number is&nbsp;(760)&nbsp;560-1501 for our Vista facility and (505)&nbsp;272-7966 for our Albuquerque facility. Our website address is www.exagen.com<I>.</I> The information contained in, or accessible through, our
website does not constitute part of this prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of Being an Emerging Growth Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a company with less than $1.0 billion in revenue during our last fiscal year, we qualify as an &#147;emerging growth company&#148; as
defined in the Jumpstart Our Business Startups Act, or JOBS Act, enacted in April 2012. An emerging growth company may take advantage of reduced reporting requirements that are otherwise applicable to public companies. These provisions include, but
are not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">being permitted to present only two years of audited financial statements and only two years of related Management&#146;s Discussion&nbsp;&amp; Analysis of Financial Condition and Results of Operations in this
prospectus; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">not being required to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, as amended, or the Sarbanes-Oxley Act; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reduced disclosure obligations regarding executive compensation in our periodic reports, proxy statements and registration statements; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may take advantage of these provisions until the last day of our fiscal year following the fifth anniversary of the date of the first sale
of our common equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended, or the Securities Act, which such fifth anniversary will occur in 2020. However, if certain events occur prior to the end
of such five-year period, including if we become a &#147;large accelerated filer,&#148; our annual gross revenues exceed $1.0 billion or we issue more than $1.0 billion of non-convertible debt in any three-year period, we will cease to be an
emerging growth company prior to the end of such five-year period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have elected to take advantage of certain of the reduced disclosure
obligations in the registration statement of which this prospectus is a part and may elect to take advantage of other reduced reporting requirements in future filings. As a result, the information that we provide to our stockholders may be different
than you might receive from other public reporting companies in which you hold equity interests. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 6 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>The Offering </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Common stock offered by us</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Common stock to be outstanding after this offering</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Over-allotment option</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The underwriters have an option for a period of 30 days to purchase up to additional shares of our common stock to cover over-allotments.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Use of proceeds</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">We estimate that the net proceeds from this offering, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us, will be approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, or approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million if the underwriters exercise their over-allotment option to purchase
additional shares from us in full, assuming an initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this
prospectus. We intend to use the net proceeds from this offering as follows: (1)&nbsp;to fund selling and marketing activities, including expansion of our sales force to support the ongoing commercialization of our current products and future
products; (2)&nbsp;to fund research and development activities, including continued expansion of our Avise product portfolio, as well as clinical studies to demonstrate the utility of our Avise products and support reimbursement efforts; (3)&nbsp;to
fund capital expenditures, including lab infrastructure and information systems; and (4)&nbsp;for working capital and other general corporate purposes. See &#147;Use of Proceeds&#148; for a more complete description of the intended use of proceeds
from this offering.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Risk Factors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">You should read the &#147;Risk Factors&#148; section of this prospectus and the other information in this prospectus for a discussion of factors to consider carefully before deciding to invest in shares of our common
stock.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Proposed NASDAQ Global Market Symbol</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">EXDX</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of our common stock to be outstanding after this offering set forth above includes: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">121,250,410 shares of common stock outstanding as of September 30, 2015 after giving effect to the automatic conversion of all outstanding shares of our redeemable convertible preferred stock as of September 30, 2015
into 109,714,571 shares of our common stock; </TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the issuance of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock in connection with the completion of this offering as a result of the automatic conversion of the $4.5
million in aggregate principal amount of convertible promissory notes (including accrued interest thereon) we issued in the first, second, and third tranche closings under our February 2015 note purchase agreement, or the February 2015 Notes,
assuming an initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and assuming the conversion
occurs on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015 (the expected closing date of this offering); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the issuance of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock in connection with the completion of this offering as a result of the automatic conversion of the $3.0
million in aggregate principal amount of convertible promissory notes (including accrued interest thereon) issued in July 2015, or the July 2015 Notes, assuming an initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and assuming the conversion occurs on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015 (the expected closing date of this offering); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt">the issuance of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock in connection with the completion of
this offering as a result of the automatic conversion of the $3.4 million in aggregate principal amount of convertible promissory notes (including accrued interest thereon) issued in October 2015, or the October 2015 Notes, assuming an initial
public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 7 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-family:Times New Roman; font-size:10pt">
which is the midpoint of the price range set forth on the cover page of this prospectus, and assuming the conversion occurs on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015 (the expected closing date of this offering); and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the issuance of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock as a result of the expected net exercise of outstanding warrants we issued in 2013, or the 2013 Warrants, in
connection with the completion of this offering, assuming an initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of
this prospectus, which 2013 Warrants will terminate if not exercised prior to the completion of this offering. </TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
number of shares of our common stock to be outstanding after this offering set forth above excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">14,038,158 shares of common stock issuable upon exercise of stock options outstanding as of September 30, 2015, at a weighted average exercise price of $0.18 per share; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock issuable upon the exercise of outstanding warrants (other than the 2013 Warrants) as of September 30, 2015, at a weighted
average exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which warrants will terminate upon the completion of this offering if not previously exercised; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock reserved for future issuance under our 2015 incentive award plan, or the 2015 plan, which will become effective on the
day prior to the public trading date of our common stock (including 1,113,581 shares of common stock reserved for future grant or issuance under our 2013 stock option plan as of September 30, 2015, which shares will be added to the shares reserved
under the 2015 plan upon its effectiveness); and </TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock reserved for future issuance under our employee stock purchase plan, or ESPP, which will become effective on the day prior
to the public trading date of our common stock. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, this prospectus reflects and assumes the
following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the filing of our amended and restated certificate of incorporation and the adoption of our amended and restated bylaws, which will occur immediately prior to the completion of this offering; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the automatic conversion of all outstanding shares of our redeemable convertible preferred stock as of September 30, 2015 into 109,714,571 shares of our common stock immediately prior to the completion of this offering
and the resultant reclassification of our redeemable convertible preferred stock warrant liabilities to stockholders&#146; deficit in connection with such conversion; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the issuance of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock in connection with the completion of this offering as a result of the automatic conversion of the
$4.5 million in aggregate principal amount (including accrued interest thereon) of the February 2015 Notes, assuming an initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the
midpoint of the price range set forth on the cover page of this prospectus, and assuming the conversion occurs on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015 (the expected closing date of this offering);
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the issuance of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock in connection with the completion of this offering as a result of the automatic conversion of the
$3.0 million in aggregate principal amount (including accrued interest thereon) of the July 2015 Notes, assuming an initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the
midpoint of the price range set forth on the cover page of this prospectus, and assuming the conversion occurs on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015 (the expected closing date of this offering);
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the issuance of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock in connection with the completion of this offering as a result of the automatic conversion of the
$3.4 million in aggregate principal amount (including accrued interest thereon) of the October 2015 Notes, assuming an initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the
midpoint of the price range set forth on the cover page of this prospectus, and assuming the conversion occurs on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015 (the expected closing date of this offering);
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a one-for-&nbsp;&nbsp;&nbsp;&nbsp; reverse stock split of our common stock to be effected prior to the effectiveness of the registration statement of which this prospectus is a part; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">no exercise of the outstanding options and warrants described above, other than the 2013 Warrants; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">no exercise by the underwriters of their option to purchase additional shares of our common stock to cover over-allotments. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 8 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Summary Consolidated Financial Data </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables set forth a summary of our consolidated historical financial data as of, and for the periods ended on, the dates
indicated. We have derived the consolidated statements of operations data for the years ended December&nbsp;31, 2013 and 2014 and the consolidated balance sheet data as of December&nbsp;31, 2013 and 2014 from our audited consolidated financial
statements included elsewhere in this prospectus. We have derived the consolidated statements of operations data for the year ended December&nbsp;31, 2012 from our audited financial statements not included in this prospectus. The consolidated
statements of operations data for the nine months ended September 30, 2014 and 2015 and the consolidated balance sheet data as of September 30, 2015 have been derived from our unaudited consolidated financial statements included elsewhere in this
prospectus and have been prepared on the same basis as the audited consolidated financial statements. In the opinion of our management, the unaudited data reflects all adjustments, consisting of normal and recurring adjustments, necessary for the
fair statement of results as of and for these periods. You should read this data together with our audited consolidated financial statements and the related notes included elsewhere in this prospectus and the sections in this prospectus entitled
&#147;Selected Consolidated Financial Data&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations.&#148; Our historical results for any prior period are not indicative of our future results. </P>
 <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="56%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended December 31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine Months Ended<BR>September 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Consolidated Statements of Operations Data:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">926</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,055</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,663</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,425</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,497</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Costs of revenue (excluding amortization of purchased technology)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,830</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,885</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,727</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general&nbsp;&amp; administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,993</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,066</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,077</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,055</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">897</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of acquisition-related liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(640</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,265</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(239</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,752</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,826</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,144</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,556</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,741</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,834</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(463</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(941</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,941</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,008</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,533</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on extinguishment of notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,286</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,258</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income / (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(83</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(497</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(626</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,282</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,454</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,994</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,375</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,440</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax (expense) / benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(42</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(42</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(210</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,324</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,496</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(14,981</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,372</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,650</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income / (loss) attributable to common stockholders(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,226</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,759</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,678</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,198</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income / (loss) per share attributable to common stockholders(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.85</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.62</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.37</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.58</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares used to compute net income / (loss) per share attributable to common stockholders&#151;basic and diluted
(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,501,734</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,856,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,350,442</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,984,156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,524,744</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proforma net loss per share attributable to common stockholders&#151;basic and diluted(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares used to compute pro forma net loss per share attributable to common stockholders&#151;basic and
diluted(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">See Note&nbsp;2 to our consolidated financial statements included elsewhere in this prospectus for an explanation of the method used to calculate the historical net income (loss) and the historical and pro forma net
income (loss) per share attributable to common stockholders, basic and diluted, and the number of shares used in the computation of these per share amounts. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 9 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of September 30, 2015</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Pro Forma</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>As&nbsp;Adjusted</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:8pt"><B>Actual</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:8pt"><B>Pro&nbsp;Forma&nbsp;(1)</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:8pt"><B>(1)(2)</B></FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Working capital (deficit)(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28,828</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Borrowings, current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,406</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capital lease obligations, long-term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(55,391</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Gives effect to: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the automatic conversion of all of our outstanding shares of redeemable convertible preferred stock as of September 30, 2015 into an aggregate of 109,714,571 shares of common stock and the resultant reclassification of
our redeemable convertible preferred stock warrant liabilities to stockholders&#146; (deficit) equity in connection with such conversion; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the automatic conversion of (i)&nbsp;the $4.5 million in aggregate principal amount of convertible promissory notes (including accrued interest thereon) we issued in the first, second and third tranche closings of the
February 2015 Notes into &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock in connection with the completion of this offering, assuming an initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and assuming the conversion occurs on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015 (the expected closing date of this offering); (ii)&nbsp;the $3.0 million in aggregate principal amount of convertible promissory notes (including accrued interest
thereon) we issued in the July 2015 Notes into &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock in connection with the completion of this offering, assuming an initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and assuming the conversion occurs on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015 (the expected closing date of this offering); and (iii)&nbsp;the $3.4 million in aggregate principal amount of convertible promissory notes (including accrued interest
thereon) we issued in the October 2015 Notes into &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock in connection with the completion of this offering, assuming an initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and assuming the conversion occurs on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015 (the expected closing date of this offering); and </TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the issuance of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock as a result of the expected net exercise of the 2013 Warrants in connection with the completion of this
offering, assuming an initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, which 2013 Warrants
will terminate if not exercised prior to the completion of this offering. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Gives further effect to the issuance and sale of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock in this offering at the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the midpoint of the price range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts and commissions and estimated
offering expenses payable by us. Each $1.00 increase (decrease) in the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share would increase (decrease) the pro forma as
adjusted amount of each of cash and cash equivalents, working capital (deficit), total assets and total stockholders&#146; deficit by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, assuming that the number
of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each increase (decrease) of
1.0&nbsp;million shares in the number of shares offered by us at the assumed initial public offering price would increase (decrease) each of cash and cash equivalents, working capital (deficit), total assets and total stockholders&#146; deficit by
approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. The pro forma information discussed above is illustrative only and will be adjusted based on the actual initial public offering price and other terms of our
initial public offering determined at pricing. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Working capital (deficit) represents the difference between current assets and current liabilities as follows: </TD></TR></TABLE>   <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Pro Forma</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:8pt"><B>Actual </B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:8pt"><B>Pro&nbsp;Forma</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:8pt"><B>As&nbsp;Adjusted</B></FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,634</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Working capital (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(28,828</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 10 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx693329_2"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Investing in our common stock involves a high degree of risk. You should consider carefully the risks and uncertainties described below,
together with all of the other information in this prospectus, including our consolidated financial statements and related notes included elsewhere in this prospectus, before making an investment decision. If any of the following risks is realized,
our business, financial condition, results of operations and prospects could be materially and adversely affected. In that event, the trading price of our common stock could decline and you could lose part or all of your investment. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Business </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are at an early
stage of commercialization with a history of losses, and we expect to incur net losses in the future and may never achieve or sustain profitability. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have incurred net losses since our inception. For the years ended December&nbsp;31, 2013 and 2014, and for the nine months ended September
30, 2015, we have incurred net losses of $13.5 million, $15.0 million, and $16.7 million, respectively, and we expect to incur additional losses this year and in future years. As of December&nbsp;31, 2014 and September 30, 2015 we had an accumulated
deficits of $89.3 million and $105.9 million, respectively. Over the next several years, we expect to continue to devote substantially all of our resources to increase adoption of, and reimbursement for, our Avise products and to develop future
diagnostic, prognostic and monitoring solutions. To date, we have generated only limited revenue, and we may never achieve or sustain profitability. Our failure to achieve and sustain profitability in the future could cause the market price of our
common stock to decline. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our financial results depend solely on sales of our Avise products, and we will need to generate sufficient revenue
from these products and other diagnostic, prognostic and monitoring solutions to grow our business. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The majority of our
historical revenue has been derived from the sale of our Avise CTD products, the first of which we commercially launched in January 2012. For the foreseeable future, we expect to derive a majority of our revenue from sales of our existing Avise CTD
products. We are in various stages of research and development for other diagnostic, prognostic and monitoring solutions that we may offer, but there can be no assurance that we will be able to commercialize these solutions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The demand for our Avise products may decrease or may not continue to increase at historical rates for a number of reasons. In addition, at
any point in time we may decide to no longer commercialize any of our Avise products for any number of reasons. While we have experienced early revenue growth from the sale of our Avise products, we may not be able to continue revenue growth or
maintain existing revenue levels. Further, we cannot ensure the continued availability of our Avise products in commercial quantities at acceptable costs. If we are unable to increase sales of our Avise products, expand reimbursement for our Avise
products, or successfully develop and commercialize other solutions, our revenue and our ability to achieve and sustain profitability would be impaired, and the market price of our common stock could decline. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may experience limits on our revenue if physicians decide not to order our Avise products or if we are otherwise unable to create or maintain demand
for our Avise products. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are unable to create or maintain demand for our Avise products in sufficient volume, we may not
generate sufficient revenue to become profitable. To generate increased demand, we will need to continue to educate physicians about the benefits of our Avise products through publications in peer-reviewed medical journals, presentations at medical
conferences and one-on-one education by our sales force. We also plan to focus on educating patients about the benefits of our Avise products, which we believe will generate further demand. In addition, our inability to obtain and maintain coverage
and adequate reimbursement from third-party payers may limit physician adoption. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 11 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Physicians may rely on guidelines issued by industry groups regarding the diagnosis, treatment
and monitoring of autoimmune rheumatic diseases, or ARDs, and the monitoring of the effectiveness of therapeutic drugs used to treat such diseases before utilizing any diagnostic test or monitoring solution. Although we have a number of
company-sponsored clinical trials and clinical trials sponsored by individual physicians underway to demonstrate the clinical utility of our Avise products, our products are not yet, and may never be, listed in any such guidelines. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our independent registered public accounting firm has included an explanatory paragraph relating to our ability to continue as a going concern in its
report on our audited financial statements included in this prospectus. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our report from our independent registered public
accounting firm for the year ended December&nbsp;31, 2014, includes an explanatory paragraph stating that our recurring losses from operations since inception and negative cash flows from operating activities raise substantial doubt about our
ability to continue as a going concern. If we are unable to obtain sufficient funding, our business, prospects, financial condition and results of operations will be materially and adversely affected and we may be unable to continue as a going
concern. If we are unable to continue as a going concern, we may have to liquidate our assets and may receive less than the value at which those assets are carried on our audited consolidated financial statements, and it is likely that investors
will lose all or a part of their investment. After this offering, future reports from our independent registered public accounting firm may also contain statements expressing substantial doubt about our ability to continue as a going concern. If we
seek additional financing to fund our business activities in the future and there remains substantial doubt about our ability to continue as a going concern, investors or other financing sources may be unwilling to provide additional funding on
commercially reasonable terms or at all. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be unable to manage our future growth effectively, which could make it difficult to execute our
business strategy. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the need to scale our testing capacity, future growth will impose significant added
responsibilities on management, including the need to identify, recruit, train and integrate additional employees. In addition, rapid and significant growth may strain our administrative and operational infrastructure. Our ability to manage our
business and growth will require us to continue to improve our operational, financial and management controls, reporting systems and procedures. The time and resources required to optimize these systems is uncertain, and failure to complete
optimization in a timely and efficient manner could adversely affect our operations. If we are unable to manage our growth effectively, it may be difficult for us to execute our business strategy and our business could be harmed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our commercial success depends upon attaining significant market acceptance of our products among physicians, patients, and third-party payers.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any product that we offer may not gain market acceptance among physicians, third-party payers, patients and the medical community.
Market acceptance of our products depends on a number of factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the perceived accuracy of our test results by physicians and patients; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the potential and perceived advantages of our products over alternative products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the demonstration in clinical studies of the performance and clinical validity of our products, the results of which studies may not replicate the positive results from earlier studies; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost of our products in relation to alternative products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the availability of coverage and adequate reimbursement and pricing by third parties and government authorities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">relative convenience; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the effectiveness of our sales and marketing efforts. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we had to withdraw a product from
the market, it could harm our business and could impact market acceptance of our other products. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We rely on sole suppliers for some of the
reagents, equipment and other materials used in our Avise products, and we may not be able to find replacements or transition to alternative suppliers. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on sole suppliers for critical supply of reagents, equipment and other materials that we use to perform the tests that comprise our
Avise products. We also purchase components used in our Avise product transportation kits from sole-source suppliers. Some of these items are unique to these suppliers and vendors. While we have developed alternate sourcing strategies for many of
these materials and vendors, we cannot be certain whether these strategies will be effective or the alternative sources will be available when we need them. We are not a major customer of some of our suppliers, and these suppliers may therefore give
other customers&#146; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 12 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
needs higher priority than ours. Avise Anti-TNF incorporates iLite technology, a cell-based assay that measures anti-TNF levels and drug neutralizing antibodies. Euro Diagnostica AB / Biomonitor
A/S, or Biomonitor, is the sole source capable of providing TNF sensitive cells used in such technology. If Biomonitor is unable to meet any of our requirements for such cells, or otherwise completely ceases producing such cells, we would be unable
to develop and sell our Avise Anti-TNF product. If our suppliers can no longer provide us with the materials we need to perform the tests that comprise our Avise products, if the materials do not meet our quality specifications, or if we cannot
obtain acceptable substitute materials, an interruption in test processing could occur and, in certain circumstances, we may be required to amend or cancel test results we have issued. For example, in June 2015, we determined that certain lots of
the anti-MCV analyte we license from a third party failed to meet our performance specifications. Based on this determination, we temporarily replaced the anti-MCV analyte with the anti-CCP analyte in our Avise Lupus test, and we temporarily
discontinued the Avise MCV and Avise MCV+ test offerings. We also identified a subset of results of these tests that required amendment or cancellation, and contacted affected physicians, although we do not believe patient care was impacted. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 13 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, if we should encounter delays or difficulties in securing the quality and quantity
of equipment we require for our tests, we may need to reconfigure our test processes, which could result in an interruption in sales. Any such interruption may significantly affect our future revenue and harm our customer relations and reputation.
In addition, in order to mitigate these risks, we may need to maintain inventories of these supplies at higher levels than would be the case if multiple sources of supply were available. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to support demand for our Avise products or any of our future products or solutions, our business could suffer. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As demand for our Avise products or any of our future products or solutions grows, we will need to continue to scale our testing capacity and
processing technology, expand customer service, billing and systems processes and enhance our internal quality assurance program. We will also need additional certified laboratory scientists and other scientific and technical personnel to process
higher volumes of our tests. We cannot assure you that any increases in scale, related improvements and quality assurance will be successfully implemented or that appropriate personnel will be available. We will also need to purchase additional
equipment, some of which can take several months or more to procure, setup and validate, and increase our software and computing capacity to meet increased demand. Failure to implement necessary procedures, transition to new processes, hire the
necessary personnel, obtain any necessary additional equipment and increase software and computing capacity could result in higher costs of processing tests or inability to meet demand. There can be no assurance that we will be able to perform our
testing on a timely basis at a level consistent with demand, or that our efforts to scale our operations, expand our personnel, equipment, software and computing capacities, or implement process enhancements will be successfully implemented and will
not negatively affect the quality of test results. In addition, there can be no assurance that we will have adequate space in our laboratory facility to accommodate such required expansion. If we encounter difficulty meeting market demand or quality
standards, our reputation could be harmed and our future prospects and our business could suffer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If third-party payers do not provide coverage and
adequate reimbursement, breach, rescind or modify their contracts or reimbursement policies or delay payments for our tests, or if we are unable to successfully negotiate payer contracts, our commercial success could be compromised. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Reimbursement by third-party payers, including governmental payers such as Medicare and Medicaid, may depend on a number of factors, including
the payer&#146;s determination that tests using our technologies are: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">not experimental or investigational; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">medically necessary; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">appropriate for the specific patient; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">cost-effective; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">supported by peer-reviewed medical journals; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">included in clinical practice guidelines. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is uncertainty concerning third-party payer
coverage and reimbursement of any new products that we may launch. Several entities conduct technology assessments of new medical tests and devices and provide the results of their assessments for informational purposes to other parties. These
assessments may be used by third-party payers and health care providers as grounds to deny coverage for a test or procedure. In addition, insurers, including managed care organizations as well as government payers such as Medicare and Medicaid, have
increased their efforts to control the cost, utilization and delivery of healthcare services. These measures have resulted in reduced payment rates and decreased utilization for the diagnostics industry. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective April&nbsp;25, 2012, the then-Medicare contractor for California, Palmetto GBA, LLC, assigned the Avise MTX assay a unique
identifier and determined that our product may meet the applicable Medicare coverage criteria. Our current Medicare contractor, Noridian Healthcare Solutions, or Noridian, has continued to accept this coverage policy. Other payers make their own
decisions as to whether to establish a policy to reimburse our tests, however, and because approvals must be sought on a payer by payer basis, establishing broad coverage is a time-consuming and costly process. A number of Medicare Advantage payers
have also adopted favorable coverage determinations for Avise MTX at this time. There are many payers who have not yet established a coverage policy applicable to our tests. In addition, recently, several Blue Cross Blue Shield plans and Aetna
issued non-coverage policies with respect to Avise Lupus, determining that Avise Lupus does not meet the medical criteria for coverage and is considered investigational. If we are not successful in reversing existing non coverage policies, or if
other third-party payers issue similar policies, these policies could have a material adverse effect on our business and operations. Even if many payers currently reimburse for our tests, such payors may withdraw coverage at any time, review and
adjust the rate of reimbursement, require co-payments from patients or stop paying for our tests altogether, any of which would reduce our revenues. Further, from time to time, payers change processes that may affect timely payment. These changes
may result in uneven cash flow or impact the timing of revenue recognized with these payers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 14 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While our tests are reimbursed by a number of governmental and private payers, we do not have
contracts with any significant large private payers. If we are unable to obtain or maintain coverage and reimbursement from third-party payers for our existing tests or new tests or test enhancements we may develop in the future, our ability to
generate revenues could be limited. We have in the past, and will likely in the future, experience delays and temporary interruptions in the receipt of payments from third-party payers due to changes in their internal processes, documentation
requirements and other issues, which could cause our revenues to fluctuate from period to period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Billing for our products is complex, and we must
dedicate substantial time and resources to the billing process to be paid for our tests. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Billing for our products is complex, time
consuming and expensive. Depending on the billing arrangement and applicable law, we bill various payers, including Medicare, insurance companies and patients, all of which have different billing requirements. We generally bill third-party and
government payers for our products and pursue reimbursement on a case-by-case basis where pricing contracts are not in place. We may also face increased risk in our collection efforts, including long collection cycles, which could adversely affect
our business, results of operations and financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Several factors make the billing process complex, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">differences between the list price for our products and the reimbursement rates of payers; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">compliance with complex federal and state regulations related to billing Medicare; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">disputes among payers as to which party is responsible for payment; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">differences in coverage among payers and the effect of patient co-payments or co-insurance; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">differences in information and billing requirements among payers; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">incorrect or missing billing information; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the resources required to manage the billing and claims appeals process. </TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For example, the
list price for our primary product, Avise CTD, is $1,445 while our reimbursement rates received from third-party payers for this test range from $0 to $1,445 per test. These billing complexities, and the related uncertainty in obtaining payment for
our products could negatively affect our revenue and cash flow, our ability to achieve profitability, and the consistency and comparability of our results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, in the third quarter of 2015, the Centers for Medicare&nbsp;&amp; Medicaid Services, or CMS released the Medicare Physician Fee
Schedule, or MPFS, which establishes the reimbursement rates to be paid by Medicare for specific Current Procedural Terminology, or CPT, codes billed to Medicare by us, commencing January&nbsp;1, 2016. If the proposed rule is implemented as written,
we have estimated that it will result in a 10% reduction in anticipated reimbursements from Medicare from our Avise CTD test. Revenues from Medicare and revenues from the sale of our Avise SLE diagnostic products comprised 35% and 92%, respectively,
of our revenues in the nine months ended September&nbsp;30, 2015. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We rely on a third party for certain portions of our billing and collection
processing, and any delay in transmitting and collecting claims could have an adverse effect on our revenue. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on a
third-party provider to provide systems for certain processing and collection functions. We have previously experienced delays in claims processing when our third-party provider made changes to its invoicing system, and again when it did not submit
claims to payers within the timeframe required. If claims for our products are not submitted to payers on a timely basis, or if we are required to switch to a different systems provider, it could have an adverse effect on our revenue and our
business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We conduct business in a heavily regulated industry, and any changes in regulations or the U.S. Food and Drug Administration&#146;s, or
FDA&#146;s, enforcement discretion, or violations of regulations by us, could adversely affect our business, prospects, results of operations or financial condition. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The diagnostics industry is highly regulated, and we cannot assure you that the regulatory environment in which we operate will not change
significantly and adversely in the future. In particular, the laws and regulations governing the marketing of diagnostic products are extremely complex and in many instances there are no significant regulatory or judicial interpretations of these
laws and regulations. The Federal Food, Drug and Cosmetic Act, or FDCA, defines a medical device to include any instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related article, including a
component, part, or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 15 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
accessory, intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, in man or other animals. Our in vitro diagnostic
products are considered by the FDA to be subject to regulation as medical devices. Among other things, pursuant to the FDCA and its implementing regulations, the FDA regulates the research, testing, manufacturing, safety, labeling, storage,
recordkeeping, premarket clearance or approval, marketing and promotion, and sales and distribution of medical devices in the United States to ensure that medical products distributed domestically are safe and effective for their intended uses. In
addition, the FDA regulates the import and export of medical devices manufactured between the United States and international markets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although the FDA has statutory authority to assure that medical devices are safe and effective for their intended uses, the FDA has generally
exercised its enforcement discretion and not enforced applicable regulations with respect to in vitro diagnostics that are developed, validated, and offered within a single laboratory for use only in that laboratory. These tests are referred to as
laboratory developed tests, or LDTs. We currently market our diagnostic products as LDTs, although some of our assays utilize 510(k)-cleared kits manufactured by third parties, and in other cases we may offer such stand-alone 510(k)-cleared tests
independently from our LDTs. While we believe that we are currently in material compliance with applicable laws and regulations as historically enforced by the FDA, we cannot assure you that the FDA will agree with our determination, and a
determination that we have violated these laws and regulations, or a public announcement that we are being investigated for possible violations, could adversely affect our business, prospects, results of operations or financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Food and Drug Administration Safety and Innovation Act of 2012 prohibited FDA from issuing guidance on the regulation of LDTs unless it
provided Congress with details of the proposed action at least 60&nbsp;days in advance. The FDA provided such notification to Congress on July&nbsp;31, 2014 and proposed to modify its enforcement discretion on LDTs in a risk-based manner. Following
the 60-day notice period, on September&nbsp;30, 2014, the FDA posted on its website two draft guidance documents concerning its proposed risk-based framework for regulating LDTs, and on October&nbsp;3, 2014, the FDA published notices in the Federal
Register formally announcing their release and the beginning of a 120-day public comment period. The comment period for these draft guidance documents, titled &#147;Framework for Regulatory Oversight of Laboratory Developed Tests (LDTs)&#148; and
&#147;FDA Notification and Medical Device reporting for Laboratory Developed Tests (LDTs),&#148; concluded on February&nbsp;2, 2015. When finalized, these draft guidance documents may subject us to the FDA&#146;s requirements for medical devices,
including establishment registration and device listing, premarket clearance or approval, and adverse event reporting. Any new FDA enforcement policies affecting LDTs may result in increased regulatory burdens on our ability to continue marketing
our products and to develop and introduce new products in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the FDA begins to actively regulate our diagnostic tests, we may
be required to obtain premarket clearance under Section&nbsp;510(k) of the FDCA or a premarket approval, or PMA. The process for submitting a 510(k) premarket notification and receiving FDA clearance usually takes from three to twelve months, but it
can take significantly longer and clearance is never guaranteed. The process for submitting and obtaining FDA approval of a PMA is much more costly, lengthy and uncertain. It generally takes from one to three years or even longer, and approval is
not guaranteed. PMA approval typically requires extensive clinical data and can be significantly longer, more expensive and more uncertain than the 510(k) clearance process. Despite the time, effort and expense expended, there can be no assurance
that a particular device ultimately will be cleared or approved by the FDA through either the 510(k) clearance process or the PMA process on a timely basis, or at all. Moreover, there can be no assurance that any cleared or approved labeling claims
will be consistent with our current claims or adequate to support continued adoption of and reimbursement for our products. If premarket review is required for some or all of our products, the FDA may require that we stop selling our products
pending clearance or approval, which would negatively impact our business. Even if our products are allowed to remain on the market prior to clearance or approval, demand or reimbursement for our products may decline if there is uncertainty about
our products, if we are required to label our products as investigational by the FDA, or if the FDA limits the labeling claims we are permitted to make for our products. As a result, we could experience significantly increased development costs and
a delay in generating additional revenue from our Avise products, or from other products now in development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the FDA imposes
significant changes to the regulation of LDTs it could reduce our revenues or increase our costs and adversely affect our business, prospects, results of operations or financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our experience in marketing and selling our products is in the early stages, and if we are unable to expand our direct sales and marketing force to
adequately address our customers&#146; needs, our business may be adversely affected. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We sell our Avise products through our
own sales force. However, we have limited experience in marketing and selling our Avise products, the first of which was commercially launched in January 2012. Our products compete in a concentrated specialty market, that of rheumatology, and as
such, we believe it is necessary to maintain a sales force that includes sales representatives with specific technical backgrounds and industry expertise. Competition for such individuals is intense, and we may not be able to attract and retain
personnel or be able to maintain an efficient and effective sales and marketing force. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 16 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our future sales will depend in large part on our ability to create an effective sales force. If
we are unsuccessful in this regard, it could negatively impact our revenue growth and potential profitability. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to compete
successfully, we may be unable to increase or sustain our revenue or achieve profitability. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our principal competition for our
Avise products comes from traditional methods used by physicians to test patients with rheumatic disease-like symptoms. Such traditional methods include testing for a broad range of diagnostic, immunology and chemistry markers, such as anti-nuclear
antibodies, or ANA and anti-double-stranded DNA, or anti-dsDNA, and serum complement, such as C3 and C4. We also face competition from commercial laboratories, such as Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, ARUP
Laboratories, Inc. and Mayo Clinic, all of which have strong infrastructures to support the commercialization of diagnostic services. Large, multispecialty group medical clinics, health systems and academic medical university-based clinics may
provide in-house clinical laboratories offering autoimmune rheumatic testing services. Additionally, we compete against regional clinical laboratories providing testing in the autoimmune rheumatic field, such as Rheumatology Diagnostics
Laboratories, Inc. Other potential competitors include companies that might develop diagnostic or disease or drug monitoring products, such as Myriad Genetics, Inc., Kypha, LLC, and ImmunArray, Ltd. In the future, we may also face competition from
companies developing new products or technologies. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To compete successfully we must be able to demonstrate, among other things, that
our diagnostic, prognostic and monitoring test results are accurate and cost effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of our potential competitors have widespread
brand recognition and substantially greater financial, technical and research and development resources and selling and marketing capabilities than we do. Others may develop products with prices lower than ours that could be viewed by physicians and
payers as functionally equivalent to our solution, or offer solutions at prices designed to promote market penetration, which could force us to lower the list price of our products and affect our ability to achieve profitability. If we are unable to
change clinical practice in a meaningful way or compete successfully against current and future competitors, we may be unable to increase market acceptance and sales of our products, which could prevent us from increasing our revenue or achieving
profitability and could cause the market price of our common stock to decline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Developing new products involves a lengthy and complex process, and
we may not be able to commercialize on a timely basis, or at all, other products we are developing. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are devoting considerable
resources to the research and development of our planned future Avise products and enhancements to our current Avise products. We may not be able to develop products with the diagnostic or monitoring performance or accuracy necessary to be
clinically useful and commercially successful. There are certain products for which a commercial launch would trigger additional payment obligations to licensors of the technology. In these cases, if the economic projections of the product do not
outweigh the additional obligations, we may not launch these products. In order to develop and commercialize diagnostic, prognostic and monitoring products, we need to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expend significant funds to conduct substantial research and development; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">conduct successful validation studies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">develop and scale our laboratory processes to accommodate different tests; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">achieve and maintain required regulatory certifications; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">develop and scale our infrastructure to be able to analyze increasingly large amounts of data; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">build the commercial infrastructure to market and sell new products. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product development
process involves a high degree of risk and may take several years. Our product development efforts may fail for many reasons, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure to identify additional biomarkers to incorporate into our diagnostic products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure or sub-optimal performance of the product at the research or development stage; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulty in accessing archival patient blood specimens, especially specimens with known clinical results; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure of clinical validation studies to support the effectiveness of the test. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 17 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Typically, few research and development projects result in commercial products, and success in
early clinical studies often is not replicated in later studies. At any point, we may abandon development of a product candidate or we may be required to expend considerable resources repeating clinical studies, which would adversely affect the
timing for generating potential revenue from a new product and our ability to invest in other products in our pipeline. In addition, as we develop products, we will have to make significant investments in product development, marketing and selling
resources. If a clinical validation study fails to demonstrate the prospectively defined endpoints of the study, we might choose to abandon the development of the product or product feature that was the subject of the clinical study, which could
harm our business. Additionally, competitors may develop and commercialize competing products or technologies faster than us or at a lower cost. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We
may acquire businesses or assets, form joint ventures or make investments in other companies or technologies that could harm our operating results, dilute our stockholders&#146; ownership, increase our debt or cause us to incur significant expense.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of our business strategy, we may pursue acquisitions of complementary businesses or assets, as well as technology
licensing arrangements. We also may pursue strategic alliances that leverage our core technology and industry experience to expand our offerings or distribution, or make investments in other companies. To date, other than our acquisition of the
medical diagnostics division of Cypress Bioscience, Inc., we have not acquired other companies and have limited experience with respect to the formation of strategic alliances and joint ventures. If we make any acquisitions, we may not be able to
integrate these acquisitions successfully into our existing business, and we could assume unknown or contingent liabilities. Any future acquisitions by us also could result in significant write-offs or the incurrence of debt and contingent
liabilities, any of which could harm our operating results. Integration of an acquired company or business also may require management resources that otherwise would be available for ongoing development of our existing business. We may not identify
or complete these transactions in a timely manner, on a cost-effective basis, or at all, and we may not realize the anticipated benefits of any acquisition, technology license, strategic alliance, joint venture or investment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To finance any acquisitions or investments, we may choose to issue shares of our stock as consideration, which would dilute the ownership of
our stockholders. Once we become a public company, if the price of our common stock is low or volatile, we may not be able to acquire other companies for stock. Alternatively, it may be necessary for us to raise additional funds for these activities
through public or private financings or through the issuance of debt. Additional funds may not be available on terms that are favorable to us, or at all, and any debt financing may involve covenants limiting or restricting our ability to take
certain actions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The diagnostics industry is subject to rapidly changing technology, which could make our Avise products, and other products we
develop, obsolete. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our industry is characterized by rapid technological changes, frequent new product introductions and
enhancements and evolving industry standards. These advances require us to continuously develop our technology and work to develop new solutions to keep pace with evolving standards of care. Our products could become obsolete unless we continually
innovate and expand our product offerings to include new clinical applications. If we are unable to develop new products or to demonstrate the applicability of our products for other diseases, our sales could decline and our competitive position
could be harmed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our failure to maintain relationships or build new relationships with key opinion leaders could materially adversely impact our
business and prospects. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Key opinion leaders are able to influence clinical practice by publishing research and determining
whether new tests should be integrated into practice guidelines. We have collaborated with key opinion leaders in the field of rheumatology to further expand the clinical utility of our tests, including through their participation in validation
studies for Avise Lupus and supporting the publication of results from such studies in peer-reviewed medical journals. Our failure to maintain or build new relationships with such key opinion leaders could affect physician and patient perception of
our tests and result in a loss of existing and future physician customers and therefore materially adversely impact our business and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are sued for errors and omissions or professional liability, we could face substantial liabilities that exceed our resources. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The marketing, sale and use of our Avise products could lead to liability claims if someone were to allege that any such product failed to
perform as it was designed. We may also be subject to liability for errors in the results we provide to physicians or for a misunderstanding of, or inappropriate reliance upon, the information we provide. We may also be subject to similar types of
claims related to products we may develop in the future. An errors and omissions or professional liability claim could result in substantial damages and be costly and time consuming for us to defend. Although we maintain professional liability
insurance, we cannot assure you that our insurance would fully protect us from the financial impact of defending against these types of claims or any judgments, fines or settlement costs arising out of any such claims. Any errors or omissions or
professional liability claim brought against us, with or without merit, could increase our insurance rates or prevent us from securing insurance coverage in the future. Additionally, any product liability lawsuit could cause injury to our reputation
or cause us to suspend sales of our products and solutions. The occurrence of any of these events could have an adverse effect on our business and results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 18 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The loss of members of our senior management team or our inability to attract and retain highly skilled
scientists, technicians and salespeople could adversely affect our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success depends largely on the skills, experience
and performance of key members of our executive management team, including Fortunato Ron Rocca, our President and Chief Executive Officer, and others in key management positions. The efforts of each of these persons will be critical to us as we
continue to develop our technologies and test processes and focus on our growth. If we were to lose one or more of these key employees, we may experience difficulties in competing effectively, developing our technologies and implementing our
business strategy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our research and development programs and commercial laboratory operations depend on our ability to
attract and retain highly skilled scientists, including licensed clinical laboratory scientists and biostatisticians. We may not be able to attract or retain qualified scientists and technicians in the future due to the intense competition for
qualified personnel among life science businesses, particularly in Southern California. Because it is expected that there will be a shortage of clinical laboratory scientists in coming years, it may become more difficult to hire sufficient numbers
of qualified personnel. We also face competition from universities and public and private research institutions in recruiting and retaining highly qualified scientific personnel. Additionally, our success depends on our ability to attract and retain
qualified salespeople. We may have difficulties locating, recruiting or retaining qualified salespeople, which could cause a delay or decline in the rate of adoption of our products. If we are not able to attract and retain the necessary personnel
to accomplish our business objectives, we may experience constraints that could adversely affect our ability to support our research and development, clinical laboratory and sales efforts. All of our employees are at-will, which means that either we
or the employee may terminate their employment at any time. We do not carry key man insurance for any of our employees. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If our sole laboratory
facility becomes damaged or inoperable, we are required to vacate our existing facility or we are unable to expand our existing facility as needed, we will be unable to perform our testing services and our business will be harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently derive all of our revenue from tests conducted at a single laboratory facility located in Vista, California. Vista is situated on
or near earthquake fault lines. Our facility and equipment could be harmed or rendered inoperable by natural or man-made disasters, including earthquake, fire, flood, power loss, communications failure or terrorism. In particular, we store all of
our flow cytometers, the instrument we use to detect CB-CAPs on cells, at our Vista facility. If all of our flow cytometers were rendered inoperable simultaneously pursuant to a natural or man-made disaster, we would be unable to perform these key
tests as we do in the ordinary course of our business. The inability to perform our tests or to reduce the backlog of analyses that could develop if our facility is inoperable, for even a short period of time, may result in the loss of customers or
harm to our reputation, and we may be unable to regain those customers or repair our reputation in the future. Additionally, we store our bio-repository of specimens, which were collected in collaboration with leading academic institutions and help
us to further validate our Avise products, at our Vista facility. If these specimens were destroyed pursuant to a natural or man-made disaster or otherwise become unavailable, our ability to develop new products may be delayed. Furthermore, our
facility and the equipment we use to perform our research and development work could be unavailable or costly and time-consuming to repair or replace. It would be difficult, time-consuming and expensive to rebuild our facility or license or transfer
our proprietary technology to a third-party, particularly in light of the licensure and accreditation requirements for a commercial laboratory like ours. Even in the unlikely event we are able to find a third party with such qualifications to enable
us to conduct our tests, we may be unable to negotiate commercially reasonable terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to rely on a third party to perform our
tests, we would need to engage another facility with established state licensure and Clinical Laboratory Improvement Amendments of 1988, or CLIA, accreditation under the scope of which tests could be performed following validation and other required
procedures. We cannot assure you that we would be able to find another CLIA-certified facility willing to comply with the required procedures, that any such facility would be willing to perform our tests for us on commercially reasonable terms, or
that it would be able to meet our quality standards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to establish an additional clinical reference laboratory facility, we would
have to spend considerable time and money securing adequate space, constructing the facility, recruiting and training employees, and establishing the additional operational and administrative infrastructure necessary to support a second facility. We
may not be able, or it may take considerable time, to replicate our testing processes or results in a new facility. Additionally, any new clinical reference laboratory facility opened by us would be subject to certification under CLIA and licensing
by several states, including California and New York, which could take a significant amount of time and result in delays in our ability to begin operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expanded our laboratory and office facilities into available space immediately next to our existing laboratory in the third and fourth
quarters of 2014. With this expansion, we believe we have the capacity to meet our projected needs for at least the next 12 months, although we may grow at a rate that is faster than we expect. Beyond this time frame, we may need to further expand
our laboratory space. Any future expansion could disrupt laboratory operations, resulting in an inability to meet customer turnaround time expectations, and could be delayed, resulting in slower realization of laboratory efficiencies anticipated
from the use of the expanded facilities. Adverse consequences resulting from a delay in the laboratory expansion could harm our relationships with our customers and our reputation, and could affect our ability to generate revenue. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 19 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We carry insurance for damage to our property and the disruption of our business, but this
insurance may not cover all of the risks associated with damage or disruption to our business, provide coverage in amounts sufficient to cover our potential losses or continue to be available to us on acceptable terms, if at all. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 20 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our testing process involves the use of sophisticated state-of-the-art equipment that requires precise
calibration, and issues affecting such equipment may delay delivery of the test results to physicians or otherwise adversely affect our operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of our process of determining CB-CAPs, which is part of our Avise Lupus products, we utilize a number of flow cytometers that require
calibration and performance validation according to the requirements of the College of American Pathologists, or CAP, at specified time intervals. While we believe we have implemented appropriate controls and metrics in our laboratory to meet such
requirements, we cannot provide any assurance that our instruments will not fall out of specification, in which case we would be required to re-calibrate them. Patient specimens degrade and become unusable generally within 48 hours of collection.
Therefore, if we do not have other sufficient properly functioning flow cytometers due to failure to meet specifications or they otherwise become inoperable, our ability to process patient specimens in the required timeframe would be compromised and
our business could be harmed. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we cannot enter into new clinical study collaborations, our product development and subsequent
commercialization could be delayed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the past, we have entered into clinical study collaborations, and our success in the future
depends in part on our ability to enter into additional collaborations with highly regarded institutions. This can be difficult due to internal and external constraints placed on these organizations. Some organizations may limit the number of
collaborations they have with any one company so as to not be perceived as biased or conflicted. Organizations may also have insufficient administrative and related infrastructure to enable collaborations with many companies at once, which can
extend the time it takes to develop, negotiate and implement a collaboration. Additionally, organizations often insist on retaining the rights to publish the clinical data resulting from the collaboration. The publication of clinical data in
peer-reviewed medical journals is a crucial step in commercializing and obtaining reimbursement for diagnostic products such as our Avise products, and our inability to control when and if results are published may delay or limit our ability to
derive sufficient revenue from any solution. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we use hazardous materials in a manner that causes contamination or injury, we could be liable for
resulting damages. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to federal, state and local laws, rules and regulations governing the use, discharge, storage,
handling and disposal of biological material, chemicals and waste. We cannot eliminate the risk of accidental contamination or injury to employees or third parties from the use, storage, handling or disposal of these materials. In the event of
contamination or injury, we could be held liable for any resulting damages, remediation costs and any related penalties or fines, and any liability could exceed our resources or any applicable insurance coverage we may have. The cost of compliance
with these laws and regulations may become significant, and our failure to comply may result in substantial fines or other consequences, either of which could negatively affect our operating results. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Failure in our information technology, telephone or other systems could significantly disrupt our operations and adversely affect our business and
financial condition. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Information technology and telephone systems are used extensively in virtually all aspects of our business,
including laboratory testing, sales, billing, customer service, logistics and management of medical data. The success of our business depends on the ability to obtain, process, analyze, maintain and manage this data. Our management relies on our
information systems because: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">patient specimens must be received, tracked and processed on a timely basis; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">test results must be reported on a timely basis; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">billings and collections for all customers must be managed efficiently and accurately; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">third party ancillary billing services require proper tracking and reporting; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">pricing and other information related to our services is needed by our sales force and other personnel in a timely manner to conduct business; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">patient-identifiable health information must be securely held and kept confidential; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory compliance requires proper tracking and reporting; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">proper recordkeeping is required for operating our business, managing employee compensation and other personnel matters. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business, results of operations and financial condition may be adversely affected if, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our information technology, telephone or other systems fail or are interrupted for any extended length of time; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">services relating to our information technology, telephone or other systems are not kept current; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 21 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our information technology, telephone or other systems do not have the capacity to support expanded operations and increased levels of business; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">data is lost or unable to be restored or processed; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">data is corrupted due to a breach of security. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite the precautionary measures we have
taken to prevent breakdowns in our information technology, telephone and other systems, sustained or repeated system failures that interrupt our ability to process test orders, deliver test results or perform testing in a timely manner or that cause
us to inadvertently disclose or lose patient information could adversely affect our business, results of operations and financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Security breaches, loss of data and other disruptions to us or our third-party service providers could compromise sensitive information related to our
business or prevent us from accessing critical information and expose us to liability, which could adversely affect our business and our reputation. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the ordinary course of our business, we and our third-party service providers collect and store sensitive data, including legally protected
health information, personally identifiable information about our patients, credit card information, intellectual property, and our proprietary business and financial information. We manage and maintain our applications and data utilizing a
combination of on-site and vendor-owned systems. We face a number of risks related to our protection of, and our service providers&#146; protection of, this critical information, including loss of access, unauthorized disclosure and unauthorized
access, as well as risks associated with our ability to identify and audit such events. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The secure processing, storage, maintenance and
transmission of this critical information is vital to our operations and business strategy, and we devote significant resources to protecting such information. Although we take measures to protect sensitive information from unauthorized access or
disclosure, our information technology and infrastructure may be vulnerable to attacks by hackers or viruses or otherwise breached due to employee error, malfeasance or other activities. While we have not experienced any such attack or breach, if
such an event were to occur, our networks would be compromised and the information we store on those networks could be accessed by unauthorized parties, publicly disclosed, lost or stolen. Any such access, disclosure or other loss of information
could result in legal claims or proceedings, liability under laws that protect the privacy of personal information, such as the Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended by the Health Information Technology
for Economic and Clinical Health Act, or the HITECH Act, and regulatory penalties. Unauthorized access, loss or dissemination could also disrupt our operations, including our ability to process tests, provide test results, bill payers or patients,
process claims and appeals, provide customer assistance services, conduct research and development activities, collect, process and prepare company financial information, provide information about our products and other patient and physician
education and outreach efforts through our website and manage the administrative aspects of our business and could damage our reputation, any of which could adversely affect our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the interpretation and application of federal and state consumer, health-related and data protection laws in the United States
are often uncertain, contradictory and in flux. It is possible that these laws may be interpreted and applied in a manner that is inconsistent with our practices. If so, this could result in government-imposed fines or orders requiring that we
change our practices, which could adversely affect our business. Complying with these various laws could cause us to incur substantial costs or require us to change our business practices, systems and compliance procedures in a manner adverse to our
business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Performance issues, service interruptions or price increases by our shipping carrier could adversely affect our business, results of
operations and financial condition, and harm our reputation and ability to provide our specialized diagnostic services on a timely basis. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Expedited, reliable shipping is essential to our operations. We rely almost exclusively on a single carrier, Federal Express Corporation, for
reliable and secure point-to-point transport of patient specimens to our laboratory and enhanced tracking of these patient specimens. Should Federal Express, or any other carrier we may use in the future, encounter delivery performance issues such
as loss, damage or destruction of a specimen, it may be difficult to replace our patient specimens in a timely manner and such occurrences may damage our reputation and lead to decreased utilization from physicians for our specialized diagnostic
services and increased cost and expense to our business. In addition, any significant increase in shipping time could adversely affect our ability to receive and process patient specimens on a timely basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we or Federal Express were to terminate our relationship, we would be required to find another party to provide expedited, reliable
point-to-point transport of our patient specimens. There are only a few other providers of such nationwide transport services, and there can be no assurance that we will be able to enter into arrangements with such other providers on acceptable
terms, if at all. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 22 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Finding a new provider of transport services would be time-consuming and costly and result in delays in our ability to provide our specialized diagnostic services. Even if we were to enter into
an arrangement with any such provider, there can be no assurance that they will provide the same level of quality in transport services currently provided to us by Federal Express. If any new provider does not provide, or if Federal Express does not
continue to provide, the required quality and reliability of transport services at the same or similar costs, it could adversely affect our business, reputation, results of operations and financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be further limited. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Section&nbsp;382 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an &#147;ownership change&#148; (generally
defined as a greater than 50% change (by value) in its equity ownership over a three year period), the corporation&#146;s ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes to offset its post-change
income may be limited. Our ability to use a portion of our net operating loss carryforwards is subject to limitation under Section&nbsp;382 as a result of a prior ownership change. If we undergo an ownership change in connection with this offering,
or as a result of subsequent shifts in our stock ownership, our ability to utilize our net operating loss carryforwards and other pre-change tax attributes could be further limited by Section&nbsp;382 and as a result, if we earn net taxable income,
our ability to use such pre-change net operating loss carryforwards and other pre-change tax attributes to offset U.S. federal taxable income may be limited. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our term loan contains restrictions that limit our flexibility in operating our business, and if we fail to comply with the covenants and other
obligations under our loan agreement, the lenders may be able to accelerate amounts owed under the facility and may foreclose upon the assets securing our obligations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2013, we entered into a term loan agreement, or the loan agreement, with Capital Royalty Partners II L.P., Capital Royalty Partners
II&#151;Parallel Fund &#147;A&#148; L.P. and Parallel Investment Opportunities Partners II L.P., which we refer to collectively as Capital Royalty. The loan agreement is collateralized by substantially all of our personal property, including our
intellectual property. The loan agreement also subjects us to certain affirmative and negative covenants, including limitations on our ability to transfer or dispose of assets, merge with or acquire other companies, make investments, pay dividends,
incur additional indebtedness and liens and conduct transactions with affiliates. We are also subject to certain covenants that require us to maintain a minimum liquidity of at least $2.0 million and achieve certain minimum amounts of annual
revenue, and are required under certain conditions to make mandatory prepayments of outstanding principal. As a result of these covenants, we have certain limitations on the manner in which we can conduct our business, and we may be restricted from
engaging in favorable business activities or financing future operations or capital needs until our current debt obligations are paid in full or we obtain the consent of Capital Royalty, which we may not be able to obtain. As of September 30, 2015,
there was $15.0 million in principal outstanding under the term loan and an additional $1.1 million outstanding representing interest at 4%&nbsp;per annum paid in-kind in the form of additional term loans. We are required to repay any outstanding
principal and capitalized interest in quarterly installments over a two-year period, commencing on December&nbsp;31, 2016. We cannot be certain that we will be able to generate sufficient cash flow or revenue to meet the financial covenants or pay
the principal and accrued interest on our debt. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, upon the occurrence of an event of default, Capital Royalty, among
other things, can declare all indebtedness due and payable immediately, which would adversely impact our liquidity and reduce the availability of our cash flows to fund working capital needs, capital expenditures and other general corporate
purposes. An event of default includes, but is not limited to, our failure to pay any amount due and payable under the loan agreement, the occurrence of a material adverse change in our business as defined in the loan agreement, our breach of any
representation or warranty in the loan agreement, our breach of any covenant in the loan agreement (subject to a cure period in some cases), a change in control as defined in the loan agreement, our default on any debt payments to a third party in
an amount exceeding $300,000 or any voluntary or involuntary insolvency proceeding. If an event of default occurs and we are unable to repay amounts due under the loan agreement, Capital Royalty could foreclose on substantially all of our personal
property, including our intellectual property. We cannot be certain that future working capital, borrowings or equity financings will be available to repay or refinance our debt to Capital Royalty or any other debt we may incur in the future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our inability to raise additional capital on acceptable terms in the future may limit our ability to develop and commercialize new solutions and
technologies and expand our operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect capital expenditures and operating expenses to increase over the next several
years as we expand our infrastructure, commercial operations and research and development activities. We believe, based on our current plan, that the net proceeds from this offering, together with our current cash and cash equivalents and
anticipated future product revenue, will be sufficient to meet our anticipated cash requirements over at least the next 18 months, including funding the completion of our ongoing validation studies for the products in our pipeline. However, if our
available cash balances, net proceeds from this offering and anticipated future product revenue are insufficient to satisfy our liquidity requirements, including because of lower demand for our products as a result of lower-than-expected rates of
reimbursement from commercial third-party payers and government payers or if our ongoing validation studies for the products in our pipeline or our ongoing clinical studies of our existing products take longer to complete than we currently
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 23 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
expect or are unsuccessful, or other risks described in this &#147;Risk Factors&#148; section, we may seek to raise additional capital through equity offerings, debt financings, collaborations or
licensing arrangements. We may also consider raising additional capital in the future to expand our business, pursue strategic investments, take advantage of financing opportunities, or for other reasons. The timing and amounts of our future capital
requirements are difficult to forecast and will depend on numerous factors, including our ability to maintain and grow sales of our Avise products, as well as the costs associated with conducting clinical studies to demonstrate the utility of our
products and support reimbursement efforts; fluctuations in working capital; the costs to expand our sales and marketing capabilities; the costs of developing our product pipeline, including the costs associated with conducting our ongoing and
future validation studies; the additional costs we may incur as a result of operating as a public company and the extent to which we in-license, acquire or invest in complementary businesses or products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additional funding may not be available to us on acceptable terms, or at all. In addition, our loan agreement restricts our ability to raise
funds through additional debt financings. If we raise funds by issuing equity securities, dilution to our stockholders could result, and the market price of our common stock could decline. Any equity securities issued also may provide for rights,
preferences or privileges senior to those of holders of our common stock. The incurrence of additional indebtedness or the issuance of certain equity securities could result in increased fixed payment obligations and could also result in restrictive
covenants, such as limitations on our ability to incur additional debt or issue additional equity, limitations on our ability to acquire or license intellectual property rights, and other operating restrictions that could adversely affect our
ability to conduct our business. In the event that we enter into collaborations or licensing arrangements to raise capital, we may be required to accept unfavorable terms. These agreements may require that we relinquish or license to a third party
on unfavorable terms our rights to technologies or product candidates that we otherwise would seek to develop or commercialize ourselves, or reserve certain opportunities for future potential arrangements when we might be able to achieve more
favorable terms. If we are not able to secure additional funding when needed, we may have to delay, reduce the scope of or eliminate one or more research and development programs or selling and marketing initiatives. In addition, we may have to work
with a partner on one or more of our products or market development programs, which could lower the economic value of those programs to our company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The FDA has stated its intention to modify its enforcement discretion policy with respect to LDTs in a risk-based manner, and we may become subject to
extensive regulatory requirements and may be required to conduct additional clinical trials prior to continuing to sell our existing tests or launching any other tests we may develop, which may increase the cost of conducting, or otherwise harm, our
business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;31, 2014, the FDA notified Congress of its intent to modify, in a risk-based manner, its policy of
enforcement discretion with respect to LDTs, and on October&nbsp;3, 2014, the FDA released two draft guidance documents that, if finalized, could subject our diagnostic products to FDA regulation. If our diagnostic products become subject to the
FDA&#146;s requirements for medical devices pursuant to these guidance documents, we may be required to cease commercial sales of our products and conduct additional clinical testing prior to making submissions to the FDA to obtain premarket
clearance or approval. If we are required to conduct such clinical trials, delays in the commencement or completion of clinical testing could significantly increase our test development costs and delay commercialization of any currently-marketed
tests that we may be required to cease selling or the commercialization of any future tests that we may develop. Many of the factors that may cause or lead to a delay in the commencement or completion of clinical trials may also ultimately lead to
delay or denial of regulatory clearance or approval. The commencement of clinical trials may be delayed due to insufficient patient enrollment, which is a function of many factors, including the size of the patient population, the nature of the
protocol, the proximity of patients to clinical sites and the eligibility criteria for the clinical trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may find it necessary to
engage contract research organizations to perform data collection and analysis and other aspects of our clinical trials, which might increase the cost and complexity of our trials. We may also depend on clinical investigators, medical institutions
and contract research organizations to perform the trials, and would control only certain aspects of their activities. Nevertheless, we would be responsible for ensuring that each of our trials is conducted in accordance with the applicable
protocol, legal, regulatory and scientific standards, and our reliance on these third parties would not relieve us of our regulatory responsibilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and our third party contractors are required to comply with good clinical practices, or GCPs, which are regulations and guidelines enforced
by the FDA, the Competent Authorities of the Member States of the European Economic Area, or EEA, and comparable foreign regulatory authorities for products in clinical development. Regulatory authorities enforce these GCPs through periodic
inspections of trial sponsors, principal investigators and trial sites. If we or any third party contractor fails to comply with applicable GCPs, the clinical data generated in clinical trials may be deemed unreliable and the FDA, Competent
Authorities of the Member States of the EEA or comparable foreign regulatory authorities may require us to perform additional clinical trials before clearing or approving our marketing applications. A failure to comply with these regulations may
require us to repeat clinical trials, which would delay the regulatory clearance or approval process. In addition, if these parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, or if the quality,
completeness or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or for other reasons, our clinical trials may have to be extended, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 24 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
delayed or terminated. Many of these factors would be beyond our control. We may not be able to enter into replacement arrangements without undue delays or considerable expenditures. If there are
delays in testing or clearances or approvals as a result of the failure to perform by third parties, our research and development costs would increase, and we may not be able to obtain regulatory clearance or approval for our tests. In addition, we
may not be able to establish or maintain relationships with these parties on favorable terms, if at all. Each of these outcomes would harm our ability to market our tests, or to achieve sustained profitability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA requires medical device manufacturers to comply with, among other things, current good manufacturing practices for medical devices,
known as the Quality System Regulation, which requires manufacturers to follow elaborate design, testing, control, documentation and other quality assurance procedures during the manufacturing process; the medical device reporting regulation, which
requires that manufacturers report to the FDA if their device may have caused or contributed to a death or serious injury or malfunctioned in a way that would likely cause or contribute to a death or serious injury if it were to recur; labeling
regulations, including the FDA&#146;s general prohibition against promoting products for unapproved or &#147;off-label&#148; uses; and the reports of corrections and removals regulation, which requires manufacturers to report to the FDA if a device
correction or removal was initiated to reduce a risk to health posed by the device or to remedy a violation of the FDCA caused by the device which may present a risk to health. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have initiated the process to evaluate a timeline, cost, and probability of success in securing certain FDA approvals. Even if we were able
to obtain FDA clearance or approval for one or more of our products, if required, a product may be subject to limitations on the indications for which it may be marketed or to other regulatory conditions. In addition, such clearance or approval may
contain requirements for costly post-market testing and surveillance to monitor the safety or efficacy of the product. The FDA has broad post-market enforcement powers, and if unanticipated problems with our products arise, or if we or our suppliers
fail to comply with regulatory requirements following FDA clearance or approval, we may become subject to enforcement actions such as: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">restrictions on manufacturing processes; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">restrictions on product marketing; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">warning letters; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">withdrawal or recall of products from the market; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">refusal to approve pending PMAs, 510(k)s or supplements to approved PMAs or cleared 510(k)s that we submit; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">fines, restitution or disgorgement of profits or revenue; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">suspension or withdrawal of regulatory clearances or approvals; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">limitation on, or refusal to permit, import or export of our products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">product seizures; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">injunctions; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">imposition of civil or criminal penalties. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Regulatory and Compliance Matters </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Healthcare policy changes, including recently enacted legislation reforming the U.S. healthcare system, may have a material adverse effect on our
financial condition and results of operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Reimbursement to healthcare providers, such as specialized diagnostic service
providers like us, is subject to continuing change in policies by governmental payers, such as Medicare and Medicaid, private insurers, including managed care organizations, and other private payers, such as hospitals and private medical groups.
Statutory and regulatory changes, retroactive rate adjustments and administrative rulings, and other policy changes may be implemented with little or no prior notice, all of which could materially decrease the range of services for which we are
reimbursed or the reimbursement rates paid for our Avise products. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2014, the U.S. Department of Health&nbsp;&amp; Human
Services, or HHS, issued a rule finalizing October&nbsp;1, 2015 as the implementation date for ICD-10-CM, or ICD-10, which is the set of codes that classify a patient&#146;s diagnosis and procedures on claims for payment submitted to Medicare and
certain other payors. ICD-10 is a significant update to the number of diagnostic codes physicians associate with procedures in all clinical lab settings. The recent implementation of ICD-10 by us, our referring physicians, and payers could result in
a disruption in claims processing and a corresponding adverse impact on reimbursements to be received for our services, and ultimately, a negative impact on our operating cash flows. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, on April&nbsp;1, 2014, the Protecting Access to Medicare Act of 2014, or PAMA, was signed into law, which, among other things,
significantly alters the current payment methodology under the Medicare Clinical Laboratory Fee Schedule, or CLFS. Under the new law, starting January&nbsp;1, 2016 and every three years thereafter (or annually in the case of advanced diagnostic lab
tests), clinical laboratories must report laboratory test payment data for each Medicare-covered clinical diagnostic lab test that it furnishes during a time period to be defined by future regulations. The reported data must include the payment rate
(reflecting all discounts, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 25 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
rebates, coupons and other price concessions) and the volume of each test that was paid by each private payer (including health insurance issuers, group health plans, Medicare Advantage plans and
Medicaid managed care organizations). Beginning in 2017, the Medicare payment rate for each clinical diagnostic lab test will be equal to the weighted median amount for the test, based on data collected by applicable laboratories data collection
period and reported to CMS during a specified data reporting period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the third quarter of 2015, CMS released the proposed rule
governing the Medicare Clinical Diagnostic Laboratory Test Payment System under PAMA. This proposed rule clarified the methodology by which future reimbursement rates on the CLFS would be calculated. If the proposed rule is implemented as proposed,
any significant reductions in reimbursement would be phased-in, as CMS would limit the maximum reimbursement reduction for a test up to an annual reduction of 10% for each year beginning January&nbsp;1, 2017, 2018, 2019, and up to an annual
reduction of 15% for each year beginning January&nbsp;1, 2020, 2021 and 2022. Under the proposed rule, CMS is required to adopt temporary billing codes to identify new clinical diagnostic laboratory tests, or CDLTs, and new advanced diagnostic
laboratory tests, or ADLTs, that do not already have unique diagnostic codes, and that have been cleared or approved by the FDA. In addition to assigning the code, CMS must publicly report and explain the payment rate for the tests no later than
January&nbsp;1, 2017. At this time, we cannot determine the full impact of the new law on our business, financial condition and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other recent laws make changes impacting clinical laboratories, many of which have already gone into effect. The Patient Protection and
Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, collectively, the ACA, enacted in March 2010, includes a reduction in the annual update factor used to adjust payments under the CLFS for inflation. This update
factor reflects the consumer price index for all urban consumers, or CPI-U, and the ACA reduces the CPI-U by 1.75% for the years 2011 through 2015. The ACA also imposes a multifactor productivity adjustment in addition to the CPI-U, which may
further reduce payment rates. In addition, each medical device manufacturer is required to pay an excise tax in an amount equal to 2.3% of the price for which such manufacturer sells its medical devices that are listed with the FDA. Although the FDA
has contended that LDTs, such as our tests, are medical devices, none of our products are currently listed with the FDA. We cannot assure you that the tax will not be extended to services such as ours in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other significant measures contained in the ACA include, for example, coordination and promotion of research on comparative clinical
effectiveness of different technologies and procedures, initiatives to revise Medicare payment methodologies, such as bundling of payments across the continuum of care by providers and physicians, and initiatives to promote quality indicators in
payment methodologies. The ACA also includes significant new fraud and abuse measures, including required disclosures of financial arrangements with physician customers, lower thresholds for violations and increasing potential penalties for such
violations. We are monitoring the impact of the ACA in order to enable us to determine the trends and changes that may be necessitated by the legislation and that, in turn, may potentially impact our business over time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select
Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#146;s automatic reduction (known
as sequestration) to several government programs. This includes aggregate reductions to Medicare payments to providers of 2%&nbsp;per fiscal year, beginning April&nbsp;1, 2013, which will remain in effect through 2024 unless additional congressional
action is taken. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2012, the Middle Class Tax Relief and Job Creation Act of 2012 was passed, which, among other things,
reduced by 2% the 2013 Medicare CLFS, and rebased payments at the reduced rate for subsequent years. Overall, when adding this 2% reduction to the ACA&#146;s 1.75% reduction to the update factor and the productivity adjustment, the payment rates
under the CLFS declined by 2.95% and 0.75% for 2013 and 2014, respectively. This reduction does not include the additional sequestration adjustment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, increased the statute of
limitations period for the government to recover overpayments to providers from three to five years. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 26 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Legislative freezes and updates affect some of our flow cytometry tests, which are reimbursed by
the Medicare program under the Medicare Physician Fee Schedule, or MPFS. The MPFS is updated on an annual basis using a prescribed statutory formula. In the past, when the application of the statutory formula resulted in lower payments, Congress has
passed interim legislation to prevent the reductions. On April&nbsp;16, 2015, President Obama signed the Medicare Access and CHIP Reauthorization Act of 2015, or MACRA, which, among other actions, repealed the previous statutory formula by which CMS
established annual updates to MPFS rates. MACRA extended existing payment MPFS rates to June&nbsp;30, 2015 and provided for a 0.5% update on July&nbsp;1, 2015. The payment rate will be increased by 0.5% on January&nbsp;1, 2016 and annually
thereafter through 2019. MACRA provides that the MPFS will not be increased in calendar years 2020 through 2025. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further with respect
to the MPFS, CMS also reviews from time to time the relative value units, or RVUs, which are translated to payments rates under the schedule for established billing codes, including flow cytometry codes that describe some of our tests. In developing
the RVUs, CMS in 2013 proposed to cap RVUs at rates paid to hospitals under the Medicare hospital outpatient rule, which would have resulted in decreases in payments to independent laboratories. CMS did not adopt the proposal for 2014, 2015 or 2016.
CMS continues to evaluate its proposals, however. In November 2015, CMS released the final 2016 MPFS, which will govern payment for some of our tests beginning January&nbsp;1, 2016. The Company estimates that the rule will result in a 10% reduction
in anticipated reimbursements from Medicare for the Company&#146;s Avise CTD test. In addition, the 2016 MPFS continues to identify at least one flow cytometry billing code as potentially incorrectly valued. We cannot predict how CMS will value RVUs
in the future or whether further downward changes to the MPFS RVUs, if any, will impact our business. Revenues from Medicare and revenues from the sale of Avise SLE diagnostic products comprise 35% and 92%, respectively, of the Company&#146;s
revenues in the nine months ended September&nbsp;30, 2015. Any change in reimbursement that materially lowers reimbursement for our Avise products could materially affect our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Medicare payments are significant to our business, not only because approximately 35% of the total payments we received from payers in the
nine months ended September&nbsp;30, 2015 were derived from the Medicare program, but also because other payers often use the MPFS and CLFS amounts as a benchmark to develop their payment rates. We cannot predict whether Medicare and other
third-party payer reimbursement rates that mirror Medicare&#146;s will be sufficient to make our tests commercially attractive. Moreover, some states have passed or proposed legislation that would revise reimbursement methodology for clinical
laboratory payment rates under their respective Medicaid programs. For example, in October 2011, CMS approved California&#146;s plan to reduce certain Medi-Cal payments by 10% retroactive to June&nbsp;1, 2011. In February 2012, Medi-Cal began the
recoupment process, adjusting payments on new claims. According to the California Department of Health Care Services, the cut applies to various healthcare providers and outpatient services, including laboratory services, with exceptions for certain
acute illness and physician specialties. There is currently pending legislation in California to reverse the 10% cut in Medi-Cal provider rates. In addition, the California legislature introduced an amendment to the state Medicaid plan, which was
approved by CMS in July 2015 and applies an additional reduction to laboratory payments up to 10% retroactive to July&nbsp;1, 2012. Although recent changes to reimbursement for laboratory tests in states outside of California have not changed the
payment rate for our tests to date, we cannot be certain that state payment rates for our tests will not be affected in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also cannot predict whether future healthcare initiatives will be implemented at the federal or state level or in countries outside of the
United States in which we may do business in the future, or the effect any future legislation or regulation will have on us. Although we cannot predict the full effect of the recent legislative changes discussed above, including taxes imposed by the
ACA, cost reduction measures, the expansion in government&#146;s role in the U.S. healthcare industry and PAMA&#146;s changes to the reimbursement methodology under the CLFS, such changes individually or in the aggregate may result in decreased
profits to us and/or lower reimbursement by payers for tests, which may adversely affect our business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Complying with numerous regulations pertaining to our business is an expensive and time-consuming process, and any failure to comply could result in
substantial penalties. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to CLIA, a federal law that regulates clinical laboratories that perform testing on
specimens derived from humans for the purpose of providing information for the diagnosis, prevention or treatment of disease. CLIA regulations mandate specific standards in the areas of personnel qualifications, administration, and participation in
proficiency testing, patient test management, quality control, quality assurance and inspections. We have a current certificate of accreditation under CLIA to perform testing through our accreditation by CAP. To renew this certificate, we are
subject to survey and inspection every two years. Moreover, CLIA inspectors may make random inspections of our clinical reference laboratory. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we are required to hold a certificate of accreditation or compliance under CLIA that allows us to perform high complexity testing, we
are not required to hold a certificate of accreditation through CAP. We could alternatively maintain a certificate of accreditation from another accrediting organization or a certificate of compliance through inspection by surveyors acting on behalf
of the CLIA program. If our accreditation under CAP were to terminate, either voluntarily or involuntarily, we would need to convert our certification under CLIA to a certificate of compliance (or to a certificate of accreditation with another
accreditation organization) in order to maintain our ability to perform clinical testing and to continue commercial operations. Whether we would be able to successfully maintain operations through either of these alternatives would depend upon the
facts and circumstances </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 27 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
surrounding termination of our CAP accreditation, such as whether any deficiencies were identified by CAP as the basis for termination and, if so, whether these were addressed to the satisfaction
of the surveyors for the CLIA program (or another accrediting organization). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The failure to comply with CLIA requirements can result in
enforcement actions, including the revocation, suspension, or limitation of our CLIA certificate of accreditation, as well as a directed plan of correction, state on-site monitoring, civil money penalties, civil injunctive suit and/or criminal
penalties. We must maintain CLIA compliance and certification to be eligible to bill for tests provided to Medicare beneficiaries. If we were to be found out of compliance with CLIA program requirements and subjected to sanctions, our business and
reputation could be harmed. Even if it were possible for us to bring our laboratory back into compliance, we could incur significant expenses and potentially lose revenue in doing so. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also required to maintain a license to conduct testing in California. California laws establish standards for day-to-day operation of
our clinical reference laboratory, including the training and skills required of personnel and quality control. In addition, our clinical reference laboratory is required to be licensed on a product-specific basis by New York as an out of state
laboratory and our products, as LDTs, must be approved by the New York State Department of Health, or NYDOH, on a product-by-product basis before they are offered in New&nbsp;York. Once approved, we would also be subject to periodic inspection by
the NYDOH and required to demonstrate ongoing compliance with NYDOH regulations and standards. To the extent NYDOH identified any non-compliance and we are unable to implement satisfactory corrective actions to remedy such non-compliance, the State
of New York could withdraw approval for our tests. New York law also mandates proficiency testing for laboratories licensed under New York state law, regardless of whether or not such laboratories are located in New York. Moreover, several other
states require that we hold licenses to test specimens from patients in those states. Other states may have similar requirements or may adopt similar requirements in the future. Although we have obtained licenses from states where we believe we are
required to be licensed, we may become aware of other states that require out-of-state laboratories to obtain licensure in order to accept specimens from the state, and it is possible that other states currently have such requirements or will have
such requirements in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we were to lose our CLIA accreditation or California license, whether as a result of a revocation,
suspension or limitation, we would no longer be able to sell our tests, which would limit our revenues and harm our business. If we were to lose our license or fail to obtain or maintain NYDOH approval for our laboratory developed tests in New York
or if we were to lose our license in other states where we are required to hold licenses, we would not be able to test specimens from those states which would limit our revenue. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to comply with healthcare laws and regulations, we could face substantial penalties and our business, operations and financial condition
could be adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and our partners, including those with whom we may enter into co-promotion or co-marketing
arrangements, are also subject to healthcare fraud and abuse regulation by both the federal government and the states in which we or our partners conduct our business. These laws include, without limitation, state and federal anti-kickback,
self-referral, fraud and abuse, false claims, and physician sunshine laws and regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The federal Anti-kickback Statute prohibits,
among other things, knowingly and willfully offering, paying, soliciting or receiving any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or in return for purchasing,
leasing, ordering or arranging for the purchase, lease or order of any good, facility, item or service, including laboratory services, reimbursable, in whole or in part, under Medicare, Medicaid or other federally financed healthcare programs. The
term &#147;remuneration&#148; has been broadly interpreted to include anything of value. The Anti-kickback Statute has been interpreted to apply to arrangements between manufacturers on one hand and prescribers, purchasers and formulary mangers on
the other. Although there are a number of statutory exceptions and regulatory safe harbors protecting certain common activities from prosecution, the exceptions and safe harbors are drawn narrowly. Our practices may not in all cases meet all of the
criteria for safe harbor protection from anti-kickback liability. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor, however, does not make the conduct per se illegal under the
Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all of its facts and circumstances. Several courts have interpreted the statute&#146;s intent requirement to
mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal healthcare covered business, the Anti-Kickback Statute has been violated. Further, the ACA amends the intent requirement of the Federal
Anti-kickback Statute and certain criminal health care fraud statutes. A person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it. In addition, the government may assert that a claim including items
or services resulting from a violation of the federal Anti-kickback Statute constitutes a false or fraudulent claim for purposes of the false claims laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;25, 2014, the Office of Inspector General of the Department of Health and Human Services, or the OIG, released a Special Fraud
Alert, expressing concern regarding laboratory payments made to referring physicians and physician group practices for blood specimen collection, processing, and packaging. Specifically, the OIG expressed concern that such arrangements may implicate
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 28 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Federal Anti-Kickback Statute when laboratories make payments to physicians for services that are already covered and reimbursed by Medicare, or are not commercially reasonable or exceed fair
market value, all in order to induce physicians to order tests from such laboratory. Because the choice of laboratory and the decision to order laboratory tests is made or strongly influenced by the physician, with little or no input from patients,
such payment may induce physicians to order more laboratory tests than are medically necessary, particularly when the payments are tied to, or take into account, the volume or value of business generated by the physician. We had entered into certain
arrangements with physicians for services related to specimen collection, transporting and handling. Effective August 2015, we terminated all such agreements. To the extent our prior arrangements are found to be inconsistent with applicable laws, we
may be subject to significant penalties, including criminal penalties, and exclusion from participation in U.S. federal or state health care programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Federal civil False Claims Act prohibits, among other things, any person from knowingly presenting or causing to be presented a false
claim for payment to the federal government, or knowingly making or causing to be made a false statement to get a false or fraudulent claim paid by the federal government. A claim includes &#147;any request or demand&#148; for money or property
presented to the U.S. government. Penalties for a Federal civil False Claims Act violation include three times the actual damages sustained by the government, plus mandatory civil penalties of between $5,500 and $11,000 for each separate false
claim, the potential for exclusion from participation in federal healthcare programs and criminal liability. If the government were to allege that we were, or convict us of, violating these false claims laws, we could be subject to a substantial
fine and adversely affect our operations. In addition, private individuals have the ability to bring actions under these false claims laws in the name of the government alleging false and fraudulent claims presented to or paid by the government (or
other violations of the statutes) and to share in any amounts paid by the entity to the government in fines or settlement. Such suits, known as qui tam actions, have increased significantly in the healthcare industry in recent years. In addition,
the federal civil monetary penalties statute imposes penalties against any person or entity that, among other things, is determined to have presented or caused to be presented a claim to a federal health program that the person knows or should know
is for an item or service that was not provided as claimed or is false or fraudulent. The majority of states also have statutes or regulations similar to the federal anti-kickback and false claims laws, which apply to items and services reimbursed
under Medicaid and other state programs, or, in several states, apply regardless of the payer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also subject to the federal
physician self-referral prohibitions, commonly known as the Stark Law, which prohibits, among other things, physicians who have a financial relationship, including an investment, ownership or compensation relationship with an entity, from referring
Medicare patients for designated health services, which include clinical laboratory services, unless an exception applies. Similarly, entities may not bill Medicare or any other party for services furnished pursuant to a prohibited referral. Many
states have their own self-referral laws as well, which in some cases apply to all third-party payers, not just Medicare and Medicaid. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
addition, a person who offers or transfers to a Medicare or Medicaid beneficiary any remuneration, including waivers of co-payments and deductible amounts (or any part thereof), that the person knows or should know is likely to influence the
beneficiary&#146;s selection of a particular provider, practitioner or supplier of Medicare or Medicaid payable items or services may be liable for civil monetary penalties of up to $10,000 for each wrongful act. Moreover, in certain cases,
providers who routinely waive copayments and deductibles for Medicare and Medicaid beneficiaries can also be held liable under the Anti-kickback Statute and civil False Claims Act, which can impose additional penalties associated with the wrongful
act. One of the statutory exceptions to the prohibition is non-routine, unadvertised waivers of copayments or deductible amounts based on individualized determinations of financial need or exhaustion of reasonable collection efforts. The Office of
Inspector General of the Department of Health and Human Services emphasizes, however, that this exception should only be used occasionally to address special financial needs of a particular patient. Although this prohibition applies only to federal
healthcare program beneficiaries, the routine waivers of copayments and deductibles offered to patients covered by commercial payers may implicate applicable state laws related to, among other things, unlawful schemes to defraud, excessive fees for
services, tortious interference with patient contracts and statutory or common law fraud. To the extent our programs are found to be inconsistent with applicable laws, we may be required to restructure or discontinue such programs, or be subject to
other significant penalties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ACA, among other things, also imposed new reporting requirements on manufacturers of certain devices,
drugs and biologics for certain payments and transfers of value by them and in some cases their distributors to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members.
Failure to submit required information timely, completely and accurately for all payments, transfers of value and ownership or investment interests may result in civil monetary penalties of up to an aggregate of $150,000 per year (or up to an
aggregate of $1.0 million per year for &#147;knowing failures&#148;). The period between August&nbsp;1, 2013 and December&nbsp;31, 2013 was the first reporting period, and manufacturers were required to report aggregate payment data by June&nbsp;30,
2014. Thereafter, manufacturers must submit reports by the 90th day of each subsequent calendar year. CMS released the data for the first reporting period on a public website in September 2014. Any failure to comply with these reporting requirements
could result in significant fines and penalties. Because we manufacture our own LDTs solely for use by or within our own laboratory, we believe that we are exempt from these reporting requirements. We cannot assure you, however, that
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 29 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
our regulators, principally the federal government, will agree with our determination, and a determination that we have violated these laws and regulations, or a public announcement that we are
being investigated for possible violations, could adversely affect our business, prospects, results of operations or financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is possible that some of our business activities could be subject to challenge under one or more of such laws. Such a challenge, regardless
of the outcome, could have a material adverse effect on our business, business relationships, reputation, financial condition and results of operations. Although an effective compliance program can mitigate the risk of investigation and prosecution
for violations of these laws, the risks cannot be entirely eliminated. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#146;s
attention from the operation of our business. Moreover, achieving and sustaining compliance with these laws may prove costly. If we or our operations, or any of the healthcare providers or entities with whom we do business are found to be in
violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including administrative, civil and/or criminal penalties, damages, fines, disgorgement, individual imprisonment,
exclusion from participation in U.S. federal or state health care programs, and the curtailment or restructuring of our operations, any of which could materially adversely affect our ability to operate our business and our financial results. To the
extent that any of our products are sold in a foreign country, we may be subject to similar foreign laws and regulations, which may include, for instance, applicable post-marketing requirements, including safety surveillance, anti-fraud and abuse
laws, and implementation of corporate compliance programs and reporting of payments or transfers of value to healthcare professionals. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Failure to
comply with HIPAA, the Health Information Technology for Economic and Clinical Health Act, the HITECH Act, their implementing regulations, and similar comparable state laws and regulations affecting the transmission, security and privacy of health
information could result in significant penalties. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Numerous federal and state laws and regulations, including HIPAA and the HITECH
Act, govern the collection, dissemination, security, use and confidentiality of patient-identifiable health information. HIPAA and the HITECH Act require us to comply with standards for the use and disclosure of health information within our company
and with third parties. The Standards for Privacy of Individually Identifiable Health Information, or Privacy Standards, and the Security Standards for the Protection of Electronic Protected Health Information, or Security Standards, under HIPAA
establish a set of basic national privacy and security standards for the protection of individually identifiable health information by health plans, healthcare clearinghouses and certain healthcare providers, referred to as covered entities, and the
business associates with whom such covered entities contract for services. Notably, whereas HIPAA previously directly regulated only these covered entities, the HITECH Act, which was signed into law as part of the stimulus package in February 2009,
made certain of the Security Standards directly applicable to business associates. Further, the HITECH Act and the Final HIPAA Omnibus Rule that was promulgated in 2013, made additional parts of HIPAA directly applicable to business associates. As a
result, both covered entities and business associates are now subject to significant civil and criminal penalties for failure to comply with the Privacy Standards and/or the Security Standards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">HIPAA and the HITECH Act also include standards for common healthcare electronic transactions and code sets, such as claims information, plan
eligibility, payment information and the use of electronic signatures, and privacy and electronic security of individually identifiable health information. Covered entities, such as health care providers, are required to conform to such transaction
set standards, known as the Standards for Electronic Transactions, pursuant to HIPAA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">HIPAA requires covered entities to develop and
maintain policies and procedures with respect to protected health information that is used or disclosed, including the adoption of administrative, physical and technical safeguards to protect such information. The HITECH Act expands the notification
requirement for breaches of patient-identifiable health information, restricts certain disclosures and sales of patient-identifiable health information and provides a tiered system for civil monetary penalties for HIPAA violations. The Final HIPAA
Omnibus Rule modifies the breach reporting standard in a manner that will likely make more data security incidents qualify as reportable breaches. The HITECH Act also increased the civil and criminal penalties that may be imposed against covered
entities, business associates and possibly other persons and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney fees and costs associated
with pursuing federal civil actions. Additionally, certain states have adopted comparable privacy and security laws and regulations, some of which may be more stringent than HIPAA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we do not comply with the requirements of HIPAA, the HITECH Act or applicable state privacy and security laws, we could be subject to
criminal or civil sanctions that could adversely affect our financial condition. The costs of complying with privacy and security related legal and regulatory requirements are burdensome and could have a material adverse effect on our business.
These laws are subject to interpretation by various courts and other governmental authorities, thus creating potentially complex compliance issues for us, as well as our physician clients. In addition, we are unable to predict what changes to the
HIPAA Privacy Standards and Security Standards might be made in the future or how those changes could affect our business. Any new legislation or regulation in the area of privacy and security of personal information, including personal health
information, could also adversely affect our business operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 30 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to our Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to maintain intellectual property protection, our competitive position could be harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to protect our technologies such as CB-CAPs, red blood cell methotrexate polyglutamates, or MTXPG, and exposure assessments,
affects our ability to compete and to achieve sustained profitability. We rely on a combination of U.S. and foreign patents and patent applications, copyrights, trademarks and trademark applications, and contractual restrictions to protect our
intellectual property rights. We cannot be certain that the claims in our granted patents and pending patent applications covering our Avise products will be considered patentable or enforceable by the United States Patent and Trademark Office, or
the USPTO, courts in the United States, or by patent offices and courts in foreign countries. If we fail to protect our intellectual property, third parties may be able to compete more effectively against us and we may incur substantial litigation
costs in our attempts to recover or restrict use of our intellectual property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We apply for patents covering our products and
technologies and uses thereof, as we deem appropriate, however we may fail to apply for patents on important products and technologies in a timely fashion or at all, or we may fail to apply for patents in potentially relevant jurisdictions, or we
may cease our prosecution and maintenance of patents in potentially relevant jurisdictions. Currently, we have an exclusive license to 10 issued U.S. patents, three pending U.S. patent applications, and certain corresponding foreign counterpart
patents and patent applications, relevant to our Avise products. We also own three pending U.S. patent applications, two corresponding foreign counterpart applications, and one pending international Patent Cooperation Treaty, or PCT, application
relevant to our Avise products. While we intend to pursue additional patent applications, it is possible that our pending patent applications and any future applications may not result in issued patents. Even if such patents do successfully issue,
third parties may challenge the validity, enforceability or scope thereof, which may result in such patents being narrowed, invalidated or held unenforceable. Any successful opposition to our patents could deprive us of exclusive rights necessary
for the further development of our Avise products. Furthermore, even if they are unchallenged, our patents may not adequately protect our intellectual property, provide exclusivity for our Avise products or prevent others from designing around our
claims. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We might not have been the first to make the inventions covered by each of our pending patent applications and we might not have
been the first to file patent applications for these inventions. To determine the priority of these inventions, we may have to participate in interference proceedings, derivation proceedings or other post-grant proceedings declared by the USPTO that
could result in substantial cost to us. No assurance can be given that our patent applications will have priority over other patent applications. In addition, recent changes to the patent laws of the United States allow for various post-grant
opposition proceedings that have not been extensively tested, and their outcome is therefore uncertain. Furthermore, if third parties bring these proceedings against our patents, we could experience significant costs and management distraction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary
know-how that is not patentable, or that we elect not to patent, processes for which patents are difficult to enforce and any other elements of our Avise products and development processes that involve proprietary know-how, information or technology
that is not covered by patents. However, trade secrets can be difficult to protect. While we use commercially reasonable efforts to protect our trade secrets, our licensors, employees, consultants, contractors and other advisors may unintentionally
or willfully disclose such trade secret information to third parties and competitors. We attempt to protect our proprietary technology in large part by entering into confidentiality and non-disclosure agreements with our employees, consultants and
other contractors. We cannot assure you, however, that these agreements will not be breached, that we will have adequate remedies for any breach or that competitors will not know of, or independently discover, our trade secrets. We cannot assure you
that others will not independently develop substantially equivalent proprietary information or be issued patents that may prevent the sale of our products, technologies, services or know-how or require licensing and the payment of significant fees
or royalties by us in order to produce our products, technologies or services. Further, we cannot be certain that the steps we have taken will prevent the misappropriation of our trade secrets and other confidential information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Monitoring unauthorized disclosure is difficult, and we do not know whether the steps we have taken to prevent such disclosure are, or will
be, adequate. If we were to enforce a claim that a third party had illegally obtained and was using our trade secrets, it would be expensive and time consuming, and the outcome would be unpredictable. In addition, courts outside the United States
may be less willing to protect trade secrets. If we are unable to prevent unauthorized material disclosure of our trade secrets and other confidential information to third parties, and in particular in jurisdictions where we have not filed for
patent protection, we may not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, operating results and financial condition. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 31 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Certain of our products utilize unpatented technology that is publicly available and can be used by our
competitors. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of our Avise products, such as Avise CTD, utilize both patented technology and publicly available
technology that is not protected by patents or other intellectual property rights. We believe that using certain publicly available technology allows us to offer a better and more comprehensive product. However, the publicly available technology
which we rely upon is also used in, and may continue to be used in, products which are competitive with our Avise products. Our competitors may independently develop competing diagnostic products and services that do not infringe our intellectual
property. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our Avise
products. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As is the case with other diagnostics companies, our success is heavily dependent on intellectual property, particularly
on obtaining and enforcing patents. Obtaining and enforcing patents in the diagnostics industry involves both technological and legal complexity, and is therefore costly, time-consuming and inherently uncertain. From time-to-time the U.S. Supreme
Court, other federal courts, the U.S. Congress or the USPTO, may change the standards of patentability and any such changes could have a negative impact on our business. For instance, on October&nbsp;30, 2008, the Court of Appeals for the Federal
Circuit issued a decision that methods or processes cannot be patented unless they are tied to a machine or involve a physical transformation. The U.S. Supreme Court later reversed that decision in&nbsp;<I>Bilski v. Kappos</I>, finding that the
&#147;machine-or-transformation&#148; test is not the only test for determining patent eligibility. The Court, however, declined to specify how and when processes are patentable. On March&nbsp;30, 2012, in the case&nbsp;<I>Mayo&nbsp;Collaborative
Services v.&nbsp;Prometheus&nbsp;Laboratories, Inc.</I>, the U.S. Supreme Court reversed the Federal Circuit&#146;s application of&nbsp;<I>Bilski</I>&nbsp;and invalidated a patent focused on a diagnostic process because the patent claim embodied a
law of nature. On July&nbsp;30, 2012, the USPTO released a memorandum entitled &#147;2012 Interim Procedure for Subject Matter Eligibility Analysis of Process Claims Involving Laws of Nature,&#148; with guidelines for determining patentability of
diagnostic or other processes in line with the <I>Mayo</I> decision. On June&nbsp;13, 2013, in <I>Association for Molecular Pathology v. Myriad Genetics</I>, the Supreme Court held that a naturally occurring DNA segment is a product of nature and
not patent eligible merely because it has been isolated. The Supreme Court did not address the patentability of any innovative method claims involving the manipulation of isolated genes. On March&nbsp;4, 2014, the USPTO released a memorandum
entitled &#147;2014 Procedure For Subject Matter Eligibility Analysis Of Claims Reciting Or Involving Laws Of Nature/Natural Principles, Natural Phenomena, And/Or Natural Products.&#148; This memorandum provides guidelines for the USPTO&#146;s new
examination procedure for subject matter eligibility under 35 U.S.C. &#167;101 for claims embracing natural products or natural principles. Although the guidelines do not have the force of law, patent examiners have been instructed to follow them.
Some aspects of our technology involve processes that may be subject to this evolving standard and we cannot guarantee that any of our pending process claims will be patentable as a result of such evolving standards. In addition, patents we own or
license that issued before these recent cases may be subject to challenge in court or before the USPTO in view of these current legal standards. Changes in either the patent laws or in interpretations of patent laws in the United States or other
countries could weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. We cannot predict the breadth of claims that may be allowed or enforced in our patents or in third-party
patents. We may not develop additional proprietary products, methods and technologies that are patentable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to protect our
intellectual property rights throughout the world. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Filing, prosecuting and defending patents on our Avise products in all
countries throughout the world would be prohibitively expensive. Moreover, we believe that obtaining foreign patents may be more difficult than obtaining domestic patents because of differences in patent laws and, accordingly, our patent position
may be stronger in the United States than abroad. In addition, the laws of some foreign countries do not protect intellectual property rights in the same manner and to the same extent as laws in the United States. Various countries limit the subject
matter that can be patented and limit the ability of a patent owner to enforce patents in the medical and other related fields. This may limit our ability to obtain or utilize those patents internationally. In order to manage our foreign patent
costs and focus on the U.S. market, we made the decision to cease the prosecution and maintenance of certain of our foreign patents and patent applications related to our CB-CAPs technology, which is used in our Avise products. Consequently, we may
not be able to prevent third parties from practicing our inventions in all countries outside the United States. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and
further, may export otherwise infringing products to territories where we have patent protection but enforcement of such patent protection is not as strong as that in the United States. These products may compete with our Avise products and our
patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many companies have
encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade
secrets and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our
proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 32 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, and could provoke third parties to assert claims against us. We may not
prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a
significant commercial advantage from the intellectual property that we develop or license. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to comply with our obligations in the
agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a party to a number of license agreements under which we are granted intellectual property rights that are important to our business.
For example, certain patent rights related to Avise Lupus are licensed from the University of Pittsburgh, certain patent rights related to Avise MCV are licensed from Orgentec, certain patent rights related to Avise MTX are licensed from Prometheus
Laboratories Inc., or Prometheus. Our existing license agreements as related to our Avise products impose various regulatory and/or commercial diligence obligations, payment of milestones and/or royalties and other obligations. If we fail to comply
with our obligations under a license agreement, the license agreement may be terminated, in which event we would not be able to further develop or market certain Avise products. Additionally, we may not always have the first right to maintain,
enforce or defend our licensed intellectual property rights and, although we would likely have the right to assume the maintenance, enforcement and defense of such intellectual property rights if our licensors do not, our ability to do so may be
compromised by our licensors&#146; acts or omissions. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Licensing of intellectual property rights is of critical importance to our
business and involves complex legal, business and scientific issues. Disputes may arise between us and our licensors regarding intellectual property rights subject to a license agreement, including the scope of rights granted under the license
agreement and other interpretation-related issues, and whether and the extent to which our technology and processes infringe on intellectual property rights of the licensor that are not subject to the licensing agreement. If disputes over
intellectual property rights that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, our business, results of operations, financial condition and prospects may be adversely affected. We
may enter into additional licenses in the future and if we fail to comply with obligations under those agreements, we could suffer adverse consequences. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements
imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other
similar provisions during the patent process. Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on any issued patents and/or applications are due to be paid to the USPTO and foreign patent agencies in several
stages over the lifetime of the patents and/or applications. Our outside counsel has systems in place to monitor deadlines to pay these fees and to remind us of these fees, and our outside counsel employs an outside firm to pay these fees due to the
USPTO and to foreign patent agencies based on our instructions. In the aggregate, these fees can be cost prohibitive for an early-stage company. Accordingly, we made a financially-driven decision to prioritize our payment of these fees and to allow
certain of our applications to lapse, particularly with respect to our ex-U.S. rights licensed from the University of Pittsburgh related to our CB-CAPs technology. The permanent lapse of certain of these ex-U.S. rights may result in our patent
position being stronger in the United States than abroad, such as in countries that are part of the European Patent Convention, and third parties may be able to compete more effectively against us in countries outside the United States, including in
those countries that belong to the European Patent Convention. Additionally, while an inadvertent lapse may sometimes be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which
noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors might be able to enter the market earlier
than should otherwise have been the case, which would have a material adverse effect on our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be successful in obtaining or
maintaining necessary rights to product components and processes for our development pipeline through acquisitions and in-licenses. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Presently we have intellectual property rights, through licenses from third parties and under patents that we own, related to our Avise
products. Because our programs may involve additional products that require the use of proprietary rights held by third parties, the growth of our business will likely depend in part on our ability to acquire, in-license or use these proprietary
rights. We may be unable to acquire or in-license proprietary rights that we identify as being necessary for our Avise products. Even if we are able to obtain a license to such proprietary rights, it may be non-exclusive, thereby giving our
competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 33 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The licensing and acquisition of third-party proprietary rights is a competitive area, and
companies, which may be more established, or have greater resources than we do, may also be pursuing strategies to license or acquire third-party proprietary rights that we may consider necessary or attractive in order to further develop our Avise
products. More established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us, either on reasonable terms, or
at all. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment, or at all. If we are unable to successfully obtain rights to required
third-party intellectual property rights on commercially reasonable terms, our ability to further develop our Avise products, and our business, financial condition and prospects for growth could suffer. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Third-party claims alleging intellectual property infringement may prevent or delay our development efforts. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third parties. There is a
substantial amount of litigation, both within and outside the United States, involving patents and other intellectual property rights in the diagnostics industry, as well as administrative proceedings for challenging patents, including interference
and reexamination proceedings before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions. The Leahy-Smith America Invents Act introduced new procedures including inter partes review and post grant review. The
implementation of these procedures bring the possibility of third party challenges to our patents and the outcome of such challenges could result in a loss or narrowing of our patent rights. In such an event, our competitors might be able to enter
the market earlier than should otherwise have been the case, which would have a material adverse effect on our business. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields
in which we are developing our Avise products. As the diagnostics industry expands and more patents are issued, the risk increases that our activities related to our Avise products may give rise to claims of infringement of the patent rights of
others. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot assure you that any of our current or future Avise products will not infringe existing or future patents. Although we
are not aware of any issued patents that will prevent us from marketing our Avise products, there may be patents that have already issued that a third party might assert are infringed by one of our current or future Avise products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third parties may assert that we are employing their proprietary technology without authorization. There may be third-party patents of which
we are currently unaware with claims to materials or methods of manufacture related to the use or manufacture of our Avise products. Because patent applications can take many years to issue and may be confidential for 18&nbsp;months or more after
filing, there may be currently pending third-party patent applications which may later result in issued patents that our Avise products or our technologies may infringe, or which such third parties claim are infringed by the use of our technologies.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Parties making claims against us for infringement or misappropriation of their intellectual property rights may seek and obtain
injunctive or other equitable relief, which could effectively block our ability to further develop one or more of our Avise products. Defense of these claims, regardless of their merit, would involve substantial expenses and would be a substantial
diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#146; fees if we are found to be willfully infringing a
third party&#146;s patents, obtain one or more licenses from third parties, pay royalties or redesign our infringing products, which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license
would be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or development of our Avise
products. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop our Avise products, which could harm our business significantly. Even if we were able
to obtain a license, the rights may be nonexclusive, which may give our competitors access to the same intellectual property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition
to infringement claims against us, if third parties have prepared and filed patent applications in the United States that also claim technology to which we have rights, we may have to participate in interference proceedings in the USPTO to determine
the priority of invention. Third parties may also attempt to initiate reexamination, post grant review or inter partes review of our patents in the USPTO. We may also become involved in similar proceedings in the patent offices in other
jurisdictions regarding our intellectual property rights with respect to our Avise products and technology. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be involved in proceedings to
protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third
parties may infringe, misappropriate or otherwise violate our existing patents, patents that may issue to us in the future, or the patents of our licensors that are licensed to us. To counter infringement or unauthorized use, we may be required to
file infringement claims, which can be expensive and time-consuming. We may not be able to prevent, alone or with our licensors, misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those
rights as fully as in the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 34 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, if we or one of our licensors initiated legal proceedings against a third party to
enforce a patent covering one of our Avise products, the defendant could counterclaim that the patent covering such Avise product is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity
and/or unenforceability are commonplace, and there are numerous grounds upon which a third party can assert invalidity or unenforceability of a patent. Such proceedings could result in an invalidation of our patents. The outcome following legal
assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. If
a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our Avise products. Such a loss of patent protection could have a material adverse
impact on our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Litigation proceedings may fail and, even if successful, may result in substantial costs and distract our
management and other employees. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure
during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could
have a substantial adverse effect on the price of our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Because of the expense and uncertainty of litigation, we may not be in a
position to enforce our intellectual property rights against third parties. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the expense and uncertainty of litigation,
we may conclude that even if a third party is infringing our patents or other intellectual property rights, the risk-adjusted cost of bringing and enforcing such a claim or action may be too high or not in the best interest of our company or our
stockholders. In addition, there can be no assurance that our licensors will be willing to bring and enforce claims to prevent third parties from infringing intellectual property that is licensed to us, particularly if the affected intellectual
property is less important to the licensor&#146;s business than to ours. In such cases, we may decide that the more prudent course of action is to simply monitor the situation or initiate or seek some other non-litigious action or solution. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of
third parties. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have received confidential and proprietary information from third parties. In addition, we employ individuals
who were previously employed at other companies in our industry. We may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise improperly used or disclosed confidential information of
these third parties or our employees&#146; former employers. Further, we may be subject to ownership disputes in the future arising, for example, from conflicting obligations of consultants or others who are involved in developing our Avise
products. We may also be subject to claims that former employees, collaborators or other third parties have an ownership interest in our patents or other intellectual property. Litigation may be necessary to defend against these and other claims
challenging our right to and use of confidential and proprietary information. If we fail in defending any such claims, in addition to paying monetary damages, we may lose our rights therein. Such an outcome could have a material adverse effect on
our business. Even if we are successful in defending against these claims, litigation could result in substantial cost and be a distraction to our management and employees. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Being a Public Company </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will
incur increased costs and demands on management as a result of compliance with laws and regulations applicable to public companies, which could harm our operating results. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a public company, we will incur significant legal, accounting and other expenses that we did not incur as a private company, including costs
associated with public company reporting requirements. In addition, the Sarbanes-Oxley Act of 2002 and the Dodd-Frank Wall Street Reform and Protection Act, as well as rules implemented by the Securities and Exchange Commission and The NASDAQ Stock
Market, impose a number of requirements on public companies, including with respect to corporate governance practices. Our management and other personnel will need to devote a substantial amount of time to these compliance and disclosure
obligations. Moreover, these rules and regulations will increase our legal, accounting and financial compliance costs and will make some activities more time-consuming and costly. We also expect that it will be more expensive for us to obtain
director and officer liability insurance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 35 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to implement and maintain effective internal control over financial reporting, investors
may lose confidence in the accuracy and completeness of our reported financial information and the market price of our common stock may be negatively affected. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a public company, we will be required to maintain internal control over financial reporting and to report any material weaknesses in such
internal control. Section&nbsp;404 of the Sarbanes-Oxley Act of 2002 requires that we evaluate and determine the effectiveness of our internal control over financial reporting and, beginning with our second annual report following this offering,
which will be for our year ending December&nbsp;31, 2016, provide a management report on the internal control over financial reporting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we have a material weakness in our internal control over financial reporting, we may not detect errors on a timely basis and our
consolidated financial statements may be materially misstated. We are in the process of compiling the system and processing documentation necessary to perform the evaluation needed to comply with Section&nbsp;404 of the Sarbanes-Oxley Act. We may
not be able to complete our evaluation, testing and any required remediation in a timely fashion. During the evaluation and testing process, if we identify one or more material weaknesses in our internal control over financial reporting, our
management will be unable to conclude that our internal control over financial reporting is effective. Moreover, when we are no longer an emerging growth company, our independent registered public accounting firm will be required to issue an
attestation report on the effectiveness of our internal control over financial reporting. Even if our management concludes that our internal control over financial reporting is effective, our independent registered public accounting firm may
conclude that there are material weaknesses with respect to our internal controls or the level at which our internal controls are documented, designed, implemented or reviewed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 36 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are unable to assert that our internal control over financial reporting is effective, or
when we are no longer an emerging growth company, if our independent registered public accounting firm were to express an adverse opinion on the effectiveness of our internal control over financial reporting because we had one or more material
weaknesses, investors could lose confidence in the accuracy and completeness of our financial disclosures, which could cause the price of our common stock to decline. Internal control deficiencies could also result in a restatement of our financial
results in the future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have identified a material weakness in our internal control over financial reporting and may identify additional material
weaknesses in the future that may cause us to fail to meet our reporting obligations or result in material misstatements of our consolidated financial statements. If we fail to remediate one or more of our material weaknesses or if we fail to
establish and maintain effective control over financial reporting, our ability to accurately and timely report our financial results could be adversely affected. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over
financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with U.S. generally accepted accounting principles. A material
weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of annual or interim financial statements will not be prevented or
detected on a timely basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the completion of this offering, we have been a private company with limited accounting personnel
and other resources to address our internal control over financial reporting. During the course of preparing for this offering, we determined that material adjustments to various accounts were necessary, which required us to restate the financial
statements as of and for the years ended December&nbsp;31, 2012, which had been previously audited by another independent audit firm, and December&nbsp;31, 2013. The adjustments leading to the restatements of those financial statements led us to
conclude that we had a material weakness in internal control over financial reporting as of December&nbsp;31, 2012 and 2013 as follows: We did not maintain a sufficient complement of resources with an appropriate level of accounting knowledge,
experience and training commensurate with our structure and financial reporting requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For a discussion of our remediation plan
and the actions that we executed during 2014, see &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#151;Controls and Procedures.&#148; The actions we have taken are subject to continued review,
supported by confirmation and testing by management as well as audit committee oversight. While we have implemented a plan to remediate this weakness we cannot assure you that we will be able to remediate this weakness, which could impair our
ability to accurately and timely report our financial position, results of operations or cash flows. If we are unable to successfully remediate this material weakness, and if we are unable to produce accurate and timely financial statements, our
stock price may be adversely affected and we may be unable to maintain compliance with applicable stock exchange listing requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our failure to remediate the material weakness identified above, or the identification of additional material weaknesses in the future, could
adversely affect our ability to report financial information, including our filing of quarterly or annual reports with the Securities and Exchange Commission on a timely and accurate basis. Moreover, our failure to remediate the material weakness
identified above or the identification of additional material weaknesses, could prohibit us from producing timely and accurate consolidated financial statements, which may adversely affect our stock price and we may be unable to maintain compliance
with exchange listing requirements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are an emerging growth company and may elect to comply with reduced public company reporting requirements
applicable to emerging growth companies, which could make our common stock less attractive to investors. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an emerging growth
company, as defined in the Jumpstart Our Business Startups Act, or the JOBS Act, enacted in April 2012, and, for as long as we continue to be an emerging growth company, we may choose to take advantage of exemptions from various reporting
requirements applicable to other public companies, including, but not limited to, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and exemptions from the requirements of holding a
nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
addition, Section&nbsp;107 of the JOBS Act also provides that an emerging growth company can take advantage of the extended transition period provided in Section&nbsp;7(a)(2)(B) of the Securities Act of 1933, as amended, or the Securities Act, for
complying with new or revised accounting standards. In other words, an &#147;emerging growth company&#148; can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. However, we are
choosing to opt out of such extended transition period, and as a result, we will comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for non-emerging growth companies.
Section&nbsp;107 of the JOBS Act provides that our decision to opt out of the extended transition period for complying with new or revised accounting standards is irrevocable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 37 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We could remain an emerging growth company for up to five years, or until the earliest of
(i)&nbsp;the last day of the first fiscal year in which our annual gross revenues exceed $1.0 billion, (ii)&nbsp;the date that we become a &#147;large accelerated filer&#148; as defined in Rule 12b-2 under the Securities Exchange Act of 1934, as
amended, or the Exchange Act, which would occur if, among other things, the market value of common equity securities held by non-affiliates exceeds $700 million as of the last business day of our most recently completed second fiscal quarter, or
(iii)&nbsp;the date on which we have issued more than $1.0 billion in nonconvertible debt during the preceding three-year period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
cannot predict whether investors will find our common stock less attractive if we choose to rely on one or more of these exemptions. If some investors find our common stock less attractive as a result of any decisions to reduce future disclosure,
there may be a less active trading market for our common stock and our stock price may be more volatile. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to this Offering and Our Common
Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our stock price may be volatile, and you may not be able to sell shares of our common stock at or above the price you paid. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to this offering, there has been no public market for our common stock, and an active public market for our stock may not develop or be
sustained after this offering. We and the representatives of the underwriters will determine the initial public offering price of our common stock through negotiation. This price will not necessarily reflect the price at which investors in the
market will be willing to buy and sell our stock following this offering. In addition, the trading price of our common stock following this offering is likely to be highly volatile and could be subject to wide fluctuations in response to various
factors, some of which are beyond our control. These factors include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">actual or anticipated variations in our and our competitors&#146; financial condition and results of operations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">announcements by us or our competitors of new products, strategic partnerships or capital commitments; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in reimbursement by current or potential payers; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">issuance of new securities analysts&#146; reports or changed recommendations for our stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">actual or anticipated changes in regulatory oversight of our products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">developments or disputes concerning our intellectual property or other proprietary rights; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">commencement of, or our involvement in, litigation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">announced or completed acquisitions of businesses or technologies by us or our competitors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any major change in our management; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in accounting principles; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">announcement or expectation of additional financing efforts; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">future sales of our common stock by our executive officers, directors and other stockholders; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">general economic conditions and slow or negative growth of our markets. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the
stock market in general, and the market for stock of life sciences companies in particular, has experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of those companies.
Broad market and industry factors, as well as general economic, political and market conditions such as recessions or interest rate changes, may seriously affect the market price of our common stock, regardless of our actual operating performance.
These fluctuations may be even more pronounced in the trading market for our stock shortly following this offering. If the market price of our common stock after this offering does not exceed the initial public offering price, you may not realize
any return on your investment in us and may lose some or all of your investment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in the past, following periods of
volatility in the overall market and the market price of a particular company&#146;s securities, securities class action litigation has often been instituted against these companies. This litigation, if instituted against us, could result in
substantial costs and a diversion of our management&#146;s attention and resources. Any adverse determination in any such litigation or any amounts paid to settle any such actual or threatened litigation could require that we make significant
payments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 38 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If securities or industry analysts issue an adverse opinion regarding our stock or do not publish research
or reports about our company, our stock price and trading volume could decline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trading market for our common stock will
depend in part on the research and reports that equity research analysts publish about us and our business. Currently, we do not have any analyst coverage and we may not obtain analyst coverage in the future. In the event we obtain analyst coverage,
we would not have any control over such analysts or the content and opinions included in their reports. Securities analysts may elect not to provide research coverage of our company after the completion of this offering, and such lack of research
coverage may adversely affect the market price of our common stock. The price of our common stock could also decline if one or more equity research analysts downgrade our common stock or if those analysts issue other unfavorable commentary or cease
publishing reports about us or our business. If one or more equity research analysts cease coverage of our company, we could lose visibility in the market, which in turn could cause our stock price to decline. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Future sales of shares by existing stockholders could cause our stock price to decline. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our existing stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market after the
lock-up and other legal restrictions on resale discussed in this prospectus lapse, the trading price of our common stock could decline. Based on the number of shares of common stock outstanding as of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015, upon the completion of this offering, we will have outstanding a total of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock,
assuming the expected net exercise of outstanding warrants we issued in 2013, or the 2013 Warrants, no exercise of the underwriters&#146; over-allotment option and no exercise of outstanding options or warrants (other than the 2013 Warrants). Of
these shares, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;will be freely tradable, without restriction, in the public market immediately after the offering. Each of our directors and officers and substantially all of our
other stockholders has entered into a lock-up agreement with the underwriters described in &#147;Underwriting&#148; elsewhere in this prospectus, which restricts their ability to sell or transfer their shares. The lock-up agreements pertaining to
this offering will expire 180&nbsp;days from the date of this prospectus. The underwriters, however, may, in their sole discretion, waive the contractual lock-up prior to the expiration of the lock-up agreements. After the lock-up agreements expire,
based on shares outstanding as of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015, up to an additional &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock will be eligible for
sale in the public market, of which &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares are held by directors, executive officers and other affiliates and will be subject to volume limitations under Rule&nbsp;144 under the
Securities Act. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock that are
subject to outstanding options as of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015 will become eligible for sale in the public market to the extent permitted by the provisions of various option agreements, the
lock-up agreements and Rules&nbsp;144 and 701 under the Securities Act. We intend to file&nbsp;a registration statement on Form&nbsp;S-8 under the Securities Act covering all of the shares of common stock subject to options outstanding and reserved
for issuance under our employee benefit plans. This registration statement will become effective immediately upon filing, and shares covered by this registration statement will be eligible for sale in the public markets, subject to Rule&nbsp;144
limitations applicable to affiliates, the terms of the applicable plan and the option agreements entered into with option holders, and any lock-up agreements described above. In addition, our directors and executive officers may establish programmed
selling plans under Rule 10b5-1 of the Exchange Act for the purpose of effecting sales of our common stock. Any sales of securities by these stockholders, or the perception that those sales may occur, including the entry into such programmed selling
plans, could have a material adverse effect on the trading price of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the holders of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock and holders of warrants to purchase an aggregate of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock will be
entitled to rights with respect to registration of such shares under the Securities Act pursuant to an investors&#146; rights agreement between such holders and us. See &#147;Certain Relationships and Related Person Transactions&#151;Investors&#146;
Rights Agreement&#148; below. If such holders, by exercising their registration rights, sell a large number of shares, they could adversely affect the market price for our common stock. If we file a registration statement for the purpose of selling
additional shares to raise capital and are required to include shares held by these holders pursuant to the exercise of their registration rights, our ability to raise capital may be impaired. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Insiders have substantial control over us and will be able to influence corporate matters. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon completion of this offering, our existing stockholders, directors, executive officers and their affiliates will beneficially own, in the
aggregate, approximately &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of our outstanding shares of common stock, and if the underwriters&#146; option to purchase additional shares is exercised in full, such persons and their affiliates will
beneficially own, in the aggregate, approximately % of our outstanding shares of common stock. As a result, these stockholders will be able to exercise significant influence over all matters requiring stockholder approval, including the election of
directors and approval of significant corporate transactions, such as a merger or other sale of our company or its assets. This concentration of ownership could limit stockholders&#146; ability to influence corporate matters and may have the effect
of delaying or preventing a third party from acquiring control over us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 39 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us,
which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management and limit the market price of our common stock. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Provisions in our amended and restated certificate of incorporation and amended and restated bylaws, which will become effective upon the
completion of this offering, may have the effect of delaying or preventing a change of control or changes in our management. Some of these provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">authorize our board of directors to issue, without further action by the stockholders, up to 10,000,000 shares of undesignated preferred stock and up to approximately
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of authorized but unissued shares of common stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">require that any action to be taken by our stockholders be effected at a duly called annual or special meeting and not by written consent; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">specify that special meetings of our stockholders can be called only by our board of directors, the Chairman, the Chief Executive Officer or the President; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establish an advance notice procedure for stockholder approvals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to our board of directors;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establish that our board of directors is divided into three classes, Class&nbsp;I, Class&nbsp;II and Class&nbsp;III, with each class serving staggered terms; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provide that our directors may be removed only for cause; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provide that vacancies on our board of directors may, except as otherwise required by law, be filled only by a majority of directors then in office, even if less than a quorum. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we are subject to the provisions of Section&nbsp;203 of the Delaware General Corporation Law, which limits the ability of
stockholders owning in excess of 15% of our outstanding voting stock to merge or combine with us. These anti-takeover provisions and other provisions in our amended and restated certificate of incorporation and amended and restated bylaws could make
it more difficult for stockholders or potential acquirers to obtain control of our board of directors or initiate actions that are opposed by the then-current board of directors and could also delay or impede a merger, tender offer or proxy contest
involving our company. These provisions could also discourage proxy contests and make it more difficult for you and other stockholders to elect directors of your choosing or cause us to take other corporate actions you desire. Any delay or
prevention of a change of control transaction or changes in our board of directors could cause the market price of our common stock to decline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our
management will have discretion in the use of the net proceeds from this offering and may not use them in a way which increases the value of your investment. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to use the net proceeds from this offering as follows: (1)&nbsp;to fund selling and marketing activities, including expansion of our
sales force to support the ongoing commercialization of our current products and future products; (2)&nbsp;to fund research and development activities, including continued expansion of our Avise product portfolio, as well as clinical studies to
demonstrate the utility of our Avise products and support reimbursement efforts; (3)&nbsp;to fund capital expenditures, including lab infrastructure and information systems; and (4)&nbsp;for working capital and other general corporate purposes, as
outlined in &#147;Use of Proceeds&#148; elsewhere in this prospectus. The amounts and timing of our actual expenditures will depend on numerous factors, including the timing and amount of our cash receipts from the sale of our products, the
development efforts for our products and diagnostic solutions and other factors described in this &#147;Risk Factors&#148; section, as well as the amount of cash used in our operations. We therefore cannot predict with certainty the amount of net
proceeds to be used for the purposes described above. The costs and timing of the expansion of our sales and marketing capabilities and the conduct of our research and development activities are highly uncertain, subject to substantial risks and can
often change. Depending on the outcome of these activities, our plans and priorities may change, and we may apply the net proceeds from this offering differently than we currently anticipate. For example, if our research and development of new
testing solutions require more time or resources than we currently anticipate or if we encounter unforeseen difficulties in securing reimbursement for our Avise products, we may allocate additional proceeds of this offering to our research and
development efforts. If our research and development efforts progress faster than we currently expect, or if our sales and marketing needs expand faster than we currently expect, we may elect to reallocate a portion of the proceeds of this offering
from research and development to sales and marketing activities to support the launch and commercialization of our new and existing products. In addition, in the event we identify other opportunities that we believe are in the best interests of our
stockholders, we may also use a portion of the net proceeds to in-license, acquire or invest in complementary businesses or products, although we have no current commitments or obligations to do so. As a result, our management will have considerable
discretion in the application of the net proceeds from this offering and investors will be relying on the judgment of our management regarding the application of those proceeds. Our management may spend the proceeds in ways that do not improve our
results of operations or enhance the value of our common stock, and you will not have the opportunity to influence management&#146;s decisions on how to use the proceeds from this offering. Our failure to apply these funds effectively could have a
material adverse effect on our business, delay the development of new tests and cause the price of our common stock to decline. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 40 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Purchasers in this offering will experience immediate and substantial dilution in the book value of their
investment. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The initial public offering price of our common stock is substantially higher than the net tangible book value per
share of our common stock immediately after this offering. Therefore, if you purchase our common stock in this offering, you will incur an immediate dilution of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;in net
tangible book value per share from the price you paid, based on an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the midpoint of the price range set forth on the
cover page of this prospectus. In addition, new investors who purchase shares in this offering will contribute approximately &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the total amount of equity capital raised by us through the date of
this offering, but will only own approximately &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the outstanding equity capital. The exercise of outstanding options and warrants will result in further dilution. In addition, if we raise additional
funds by issuing equity securities, our stockholders may experience further dilution. For a detailed description of the dilution that you will experience immediately after this offering, see &#147;Dilution.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have never paid dividends on our capital stock, and we do not anticipate paying dividends in the foreseeable future. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never declared or paid any cash dividends on our common stock and do not intend to pay any cash dividends in the foreseeable future. We
currently intend to retain any future earnings to fund the growth of our business. In addition, our loan agreement restricts our ability to pay cash dividends on our common stock and we may also enter into credit agreements or other borrowing
arrangements in the future that will restrict our ability to declare or pay cash dividends on our common stock. Any determination to pay dividends in the future will be at the discretion of our board of directors and will depend on our financial
condition, operating results, capital requirements, general business conditions and other factors that our board of directors may deem relevant. As a result, capital appreciation, if any, of our common stock will be the sole source of gain for the
foreseeable future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If an active, liquid trading market for our common stock does not develop, you may not be able to sell your shares quickly or
at or above the initial offering price. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There has not been a public market for our common stock. An active and liquid trading
market for our common stock may not develop or be sustained following this offering. The lack of an active market may impair your ability to sell your shares at the time you wish to sell them or at a price that you consider reasonable. The lack of
an active market may also reduce the fair market value of your shares. An inactive market may also impair our ability to raise capital to continue to fund operations by selling shares and may impair our ability to acquire other companies or
technologies by using our shares as consideration. You may not be able to sell your shares quickly or at or above the initial offering price. The initial public offering price will be determined by negotiations with the representatives of the
underwriters. This price may not be indicative of the price at which our common stock will trade after this offering, and our common stock could trade below the initial public offering price. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 41 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx693329_3"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus contains forward-looking statements. All statements other than statements of historical facts contained in this prospectus,
including statements regarding our future results of operations and financial position, business strategy, current and future product offerings, reimbursement and coverage, research and development costs, timing and likelihood of success and plans
and objectives of management for future operations are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be
materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In some
cases, you can identify forward-looking statements by terms such as &#147;may,&#148; &#147;will,&#148; &#147;should,&#148; &#147;expect,&#148; &#147;plan,&#148; &#147;anticipate,&#148; &#147;could,&#148; &#147;intend,&#148; &#147;target,&#148;
&#147;project,&#148; &#147;contemplates,&#148; &#147;believes,&#148; &#147;estimates,&#148; &#147;predicts,&#148; &#147;potential&#148; or &#147;continue&#148; or the negative of these terms or other similar expressions. The forward-looking
statements in this prospectus are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial
condition and results of operations. These forward-looking statements speak only as of the date of this prospectus and are subject to a number of risks, uncertainties and assumptions described under the sections in this prospectus entitled
&#147;Risk Factors&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and elsewhere in this prospectus. Because forward-looking statements are inherently subject to risks and
uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our
forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge
from time to time, and it is not possible for management to predict all risk factors and uncertainties. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a
result of any new information, future events, changed circumstances or otherwise. The forward-looking statements contained in this prospectus are excluded from the safe harbor protection provided by the Private Securities Litigation Reform Act of
1995 and Section&nbsp;27A of the Securities Act of 1933, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus also contains estimates and other statistical data
made by independent parties and by us relating to market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition,
projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 42 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx693329_4"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate that the net proceeds to us from the sale of the common stock that we are offering will be approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million (or $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million if the underwriters exercise their over-allotment option to purchase
additional shares in full), assuming an initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the midpoint of the price range listed on the cover page of this prospectus, and after
deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. Each $1.00 increase (decrease) in the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share would increase (decrease) the net proceeds to us from this offering by approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting
discounts and commissions and estimated offering expenses payable by us. We may also increase or decrease the number of shares we are offering. Each increase (decrease) of 1.0&nbsp;million in the number of shares we are offering would increase
(decrease) the net proceeds to us from this offering, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us, by approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming the assumed initial public offering price stays the same. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The principal purposes of this offering are to obtain additional capital to support our operations, to create a public market for our common
stock and to facilitate our future access to the public equity markets. Our estimated use of the net proceeds from this offering are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million for selling and marketing activities, including expansion of our sales force to support the ongoing commercialization
of our current products and future products; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million for research and development activities, including continued expansion of our Avise product portfolio, as well as
clinical studies to demonstrate the utility of our Avise products and support reimbursement efforts; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million for capital expenditures, including lab infrastructure and information systems; and </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the remaining proceeds for working capital and other general corporate purposes. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe,
based on our current operating plan, that the net proceeds from this offering and our existing cash and cash equivalents and anticipated future product revenue, will be sufficient to fund our operations for at least the next 18 months, including
funding the completion of our ongoing validation studies for the products in our pipeline. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amounts and timing of our actual
expenditures will depend on numerous factors, including the timing and amount of our cash receipts from the sale of our products, the development efforts for our products and diagnostic solutions and other factors described under &#147;Risk
Factors&#148; in this prospectus, as well as the amount of cash used in our operations. We therefore cannot predict with certainty the amount of net proceeds to be used for the purposes described above. The costs and timing of the expansion of our
sales and marketing capabilities and the conduct of our research and development activities are highly uncertain, subject to substantial risks and can often change. Depending on the outcome of these activities, our plans and priorities may change,
and we may apply the net proceeds from this offering differently than we currently anticipate. For example, if our research and development of new testing solutions require more time or resources than we currently anticipate or if we encounter
unforeseen difficulties in securing reimbursement for our Avise products, we may allocate additional proceeds of this offering to our research and development efforts. If our research and development efforts progress faster than we currently expect,
or if our sales and marketing needs expand faster than we currently expect, we may elect to reallocate a portion of the proceeds of this offering from research and development to sales and marketing activities to support the launch and
commercialization of our new and existing products. In addition, in the event we identify other opportunities that we believe are in the best interests of our stockholders, we may also use a portion of the net proceeds to in-license, acquire or
invest in complementary businesses or products, although we have no current commitments or obligations to do so. As a result, we will have broad discretion in the application of the net proceeds. Pending the uses described above, we plan to invest
the net proceeds from this offering in short- and intermediate-term, interest-bearing obligations, investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 43 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx693329_5"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never declared or paid any cash dividends on our capital stock. We intend to retain future earnings, if any, to finance the operation
of our business and do not anticipate paying any cash dividends in the foreseeable future. Any future determination related to dividend policy will be made at the discretion of our board of directors after considering our financial condition,
results of operations, capital requirements, business prospects and other factors the board of directors deems relevant, and subject to the restrictions contained in any future financing instruments. In addition, our ability to pay cash dividends is
currently prohibited by the terms of our term loan agreement with Capital Royalty. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 44 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx693329_6"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth our cash and cash equivalents, and our capitalization as of September 30, 2015 as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">on an actual basis; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">on a pro forma basis to reflect (1)&nbsp;the automatic conversion of the $4.5 million in aggregate principal amount (including accrued interest thereon) of the February 2015 Notes into
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock in connection with the completion of this offering, assuming an initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and assuming the conversion occurs
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015 (the expected closing date of this offering), (2)&nbsp;the automatic conversion of the $3.0 million in aggregate principal amount (including accrued interest thereon)
of the July 2015 Notes into &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock in connection with the completion of this offering, assuming an initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and assuming the conversion occurs
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015 (the expected closing date of this offering), (3)&nbsp;the automatic conversion of the $3.4 million in aggregate principal amount (including accrued interest thereon)
of the October 2015 Notes into &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock in connection with the completion of this offering, assuming an initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and assuming the conversion occurs
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015 (the expected closing date of this offering), (4)&nbsp;the automatic conversion of all outstanding shares of our redeemable convertible preferred stock as of September
30, 2015 into 109,714,571 shares of common stock immediately prior to the completion of this offering and the resultant reclassification of our redeemable convertible preferred stock warrant liabilities to stockholders&#146; deficit and additional
paid-in capital in connection with such conversion, (5)&nbsp;the issuance of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock as a result of the expected net exercise of the 2013 Warrants in connection
with the completion of this offering, assuming an initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this
prospectus, which 2013 Warrants will terminate if not exercised prior to the completion of this offering, and (6)&nbsp;the filing of our amended and restated certificate of incorporation immediately prior to the completion of this offering; and
</TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">on a pro forma as adjusted basis to give further effect to our issuance and sale of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock in this offering at an assumed initial
public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the midpoint of the price range set forth on the cover page of this prospectus, after deducting the estimated underwriting discounts and
commissions and estimated offering expenses payable by us. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 45 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The pro forma and pro forma as adjusted information below is illustrative only, and our
capitalization following the completion of this offering will be adjusted based on the actual initial public offering price and other terms of this offering determined at pricing. You should read this information in conjunction with our consolidated
financial statements and the related notes included in this prospectus and the &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; section and other financial information contained in this
prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of September 30, 2015</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:8pt"><B>Actual</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:8pt"><B>Pro&nbsp;Forma</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:8pt"><B>Pro&nbsp;Forma&nbsp;As<BR>Adjusted(1)</B></FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" ALIGN="center"><B>(in thousands)</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Borrowings and capital lease obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,484</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock, $0.001 par value per share; 185,000,000 shares authorized; 109,714,571 shares issued and
outstanding, actual; no shares authorized, issued or outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; deficit:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock, $0.001 par value per share; no shares authorized, issued or outstanding, actual; 10,000,000 shares authorized and no
shares issued or outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.001 par value per share; no shares authorized, 11,535,839 shares issued and outstanding, actual; 203,000,000 shares
authorized; pro forma and pro forma as adjusted; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares issued and outstanding, pro forma; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares issued
and outstanding, pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional paid-in capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,516</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(105,919</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(55,391</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,461</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Each $1.00 increase (decrease) in the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the midpoint of the price range set forth on the
cover page of this prospectus, would increase (decrease) the pro forma as adjusted amount of each of cash and cash equivalents, total stockholders&#146; deficit and total capitalization by approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and
commissions and estimated offering expenses payable by us. Similarly, each increase (decrease) of 1.0&nbsp;million shares in the number of shares offered by us at the assumed initial public offering price per share would increase (decrease) the pro
forma as adjusted amount of each of cash and cash equivalents, total stockholders&#146; deficit and total capitalization by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares in the table above excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">14,038,158 shares of common stock issuable upon exercise of stock options outstanding as of September 30, 2015, at a weighted average exercise price of $0.18 per share; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock issuable upon the exercise of outstanding warrants (other than the 2013 Warrants) as of September 30, 2015, at a weighted
average exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which warrants will terminate upon the completion of this offering if not previously exercised; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock reserved for future issuance under our 2015 incentive award plan, or the 2015 plan, which will become effective on the
day prior to the public trading date of our common stock (including 1,113,581 shares of common stock reserved for future grant or issuance under our 2013 stock option plan as of September 30, 2015, which shares will be added to the shares reserved
under the 2015 plan upon its effectiveness); and </TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock reserved for future issuance under our employee stock purchase plan, or ESPP, which will become effective on the day prior
to the public trading date of our common stock. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 46 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx693329_7"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you invest in our common stock in this offering, your ownership interest will be immediately diluted to the extent of the difference
between the initial public offering price per share and the pro forma as adjusted net tangible book value per share of our common stock after this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September 30, 2015, we had a historical net tangible book deficit of $64.6 million, or $(5.60) per share of common stock. Our historical
net tangible book deficit per share represents total tangible assets less total liabilities, divided by the number of shares of common stock outstanding at September 30, 2015. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On a pro forma basis after giving effect to (1)&nbsp;the automatic conversion of the $4.5 million in aggregate principal amount (including
accrued interest thereon) of the February 2015 Notes into &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock in connection with the completion of this offering, assuming an initial public offering
price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and assuming the conversion occurs
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015 (the expected closing date of this offering), (2)&nbsp;the automatic conversion of the $3.0 million in aggregate principal amount (including accrued interest
thereon) of the July 2015 Notes into &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock in connection with the completion of this offering, assuming an initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and assuming the conversion occurs
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015 (the expected closing date of this offering); (3)&nbsp;the automatic conversion of the $3.4 million in aggregate principal amount (including accrued interest thereon)
of the October 2015 Notes into &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock in connection with the completion of this offering, assuming an initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and assuming the conversion occurs
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015 (the expected closing date of this offering); (4)&nbsp;the automatic conversion of all outstanding shares of our redeemable convertible preferred stock as of September
30, 2015 into 109,714,571 shares of common stock immediately prior to the completion of this offering and the resultant reclassification of our redeemable convertible preferred stock warrant liabilities to stockholders&#146; deficit and additional
paid-in capital in connection with such conversion, and (5)&nbsp;the issuance of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock as a result of the expected net exercise of the 2013 Warrants in
connection with the completion of this offering, assuming an initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of
this prospectus, which 2013 Warrants will terminate if not exercised prior to the completion of this offering, our pro forma net tangible book value (deficit) as of September 30, 2015 would have been approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;or approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After giving further effect to the sale of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock that
we are offering at an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the midpoint of the price range set forth on the cover page of this prospectus, and after deducting
the estimated underwriting discounts and commissions and estimated offering expenses payable by us, our pro forma as adjusted net tangible book value as of September 30, 2015 would have been approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, or approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. This amount represents an immediate increase in pro forma net
tangible book value of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share to our existing stockholders and an immediate dilution in pro forma net tangible book value of approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share to new investors purchasing shares of common stock in this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dilution per share to new investors is determined by subtracting pro forma as adjusted net tangible book value per share after this offering
from the initial public offering price per share paid by new investors. The following table illustrates this dilution (without giving effect to any exercise by the underwriters of their option to purchase additional shares): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="75%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assumed initial public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Historical net tangible book deficit per share as of September 30, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5.60</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma increase in historical net tangible book value per share attributable to the pro forma transactions described in the
preceding paragraphs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net tangible book value per share as of September 30, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in pro forma net tangible book value per share attributable to this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma as adjusted net tangible book value per share after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution per share to new investors in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 47 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each $1.00 increase (decrease) in the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the pro forma as adjusted net tangible book value per share
after this offering by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and dilution in pro forma net tangible book value per share to new investors by approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the estimated underwriting discounts
and commissions and the estimated offering expenses payable by us. Each increase (decrease) of 1.0&nbsp;million shares in the number of shares offered by us would increase (decrease) our pro forma as adjusted net tangible book value per share after
this offering by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share and decrease (increase) the dilution to investors participating in this offering by approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, assuming that the assumed initial public offering price remains the same, and after deducting the estimated underwriting discounts and commissions and the estimated
offering expenses payable by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the underwriters exercise their over-allotment option to purchase additional shares of our common
stock in full in this offering, the pro forma as adjusted net tangible book value after the offering would be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the increase in pro forma net tangible book value per
share to existing stockholders would be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share and the dilution per share to new investors would be
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, in each case assuming an initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the midpoint of the
price range set forth on the cover page of this prospectus. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes on the pro forma as adjusted basis described above, as of
September 30, 2015, the differences between the number of shares purchased from us, the total consideration paid to us in cash and the average price per share paid by existing stockholders for shares issued prior to this offering and the price to be
paid by new investors in this offering. The calculation below is based on the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the midpoint of the price range set
forth on the cover page of the prospectus, before deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;Consideration</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Average&nbsp;Price</B><br><B>Per&nbsp;Share</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Existing stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing tables and calculations exclude: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">14,038,158 shares of common stock issuable upon exercise of stock options outstanding as of September 30, 2015, at a weighted average exercise price of $0.18 per share; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock issuable upon the exercise of outstanding warrants (other than the 2013 Warrants) as of September 30, 2015, at a weighted
average exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which warrants will terminate upon the completion of this offering if not previously exercised; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock reserved for future issuance under the 2015 plan, which will become effective on the day prior to the public trading
date of our common stock (including 1,113,581 shares of common stock reserved for future grant or issuance under our 2013 stock option plan as of September 30, 2015, which shares will be added to the shares reserved under the 2015 plan upon its
effectiveness); and </TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock reserved for future issuance under our ESPP, which will become effective on the day prior to the public trading date of our
common stock. </TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent any outstanding options or warrants are exercised, there will be further dilution to new
investors. If all of such outstanding options and warrants had been exercised as of September 30, 2015, the pro forma as adjusted net tangible book value per share after this offering would be
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and total dilution per share to new investors would be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the underwriters exercise their over-allotment option to purchase additional shares of our common stock in full: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the percentage of shares of common stock held by existing stockholders will decrease to approximately &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the total number of shares of our common stock outstanding after
this offering; and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number of shares held by new investors will increase to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, or approximately &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the total number
of shares of our common stock outstanding after this offering. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 48 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx693329_8"></A>SELECTED CONSOLIDATED FINANCIAL DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables set forth selected consolidated historical financial data as of, and for the periods ended on, the dates indicated. We
have derived the consolidated statements of operations data for the years ended December&nbsp;31, 2013 and 2014 and the consolidated balance sheet data as of December&nbsp;31, 2013 and 2014 from our audited consolidated financial statements included
elsewhere in this prospectus. We have derived the consolidated statements of operations data for the year ended December&nbsp;31, 2012 from our audited financial statements not included in this prospectus. The consolidated statements of operations
data for the nine months ended September 30, 2014 and 2015 and the consolidated balance sheet data as of September 30, 2015 have been derived from our unaudited consolidated financial statements included elsewhere in this prospectus and have been
prepared on the same basis as the audited consolidated financial statements. In the opinion of our management, the unaudited data reflects all adjustments, consisting of normal and recurring adjustments, necessary for the fair statement of results
as of and for these periods. You should read this data together with our audited consolidated financial statements and the related notes included elsewhere in this prospectus and the sections in this prospectus entitled &#147;Management&#146;s
Discussion and Analysis of Financial Condition and Results of Operations.&#148; Our historical results for any prior period are not indicative of our future results. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:8pt"><B>Years Ended December 31,</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:8pt"><B>Nine&nbsp;Months&nbsp;Ended<BR>September 30,</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Statements of Operations Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">926</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,055</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,663</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,425</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,497</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Costs of revenue (excluding amortization of purchased technology)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,830</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,885</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,727</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general&nbsp;&amp; administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,993</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,066</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,077</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,055</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">897</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of acquisition-related liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(640</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,265</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(239</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,752</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,826</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,144</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,556</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,741</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,834</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(463</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(941</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,941</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,008</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,533</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on extinguishment of notes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,286</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,258</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income / (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(83</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(497</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(626</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,282</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,454</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,994</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,375</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,440</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax (expense) / benefit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(42</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(42</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(210</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,324</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,496</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(14,981</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,372</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,650</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income / (loss) attributable to common stockholders(1)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,226</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,759</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,678</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,198</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income / (loss) per share attributable to common stockholders(1)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.85</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.62</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.37</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.58</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares used to compute net income / (loss) per share attributable to common stockholders - basic and diluted
(1)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,501,734</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,856,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,350,442</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,984,156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,524,744</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proforma net loss per share attributable to common stockholders - basic and diluted(1)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares used to compute pro forma net loss per share attributable to common stockholders - basic and
diluted(1)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">See Note 2 to our consolidated financial statements included elsewhere in this prospectus for an explanation of the method used to calculate the historical net income (loss) and the historical and pro forma net income
(loss) per share attributable to common stockholders, basic and diluted, and the number of shares used in the computation of these per share amounts. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 49 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>As of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>September</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>30, 2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,605</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Working capital (deficit)(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,552</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21,182</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28,828</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,451</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Borrowings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,811</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,394</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,406</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,085</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,461</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capital lease obligations, long-term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">488</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">265</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,617</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,388</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(38,673</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(55,391</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)<SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Working capital (deficit) represents the difference between current assets and current liabilities and is computed as follows: </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="71%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>As of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>September</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>30, 2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,079</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,634</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,579</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Working capital (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,552</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(21,182</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(28,828</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 50 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx693329_9"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated
financial statements and the related notes and other financial information included elsewhere in this prospectus. Some of the information contained in this discussion and analysis or set forth elsewhere in this prospectus, including information with
respect to our plans and strategy for our business and future financial performance, includes forward-looking statements that are based on current beliefs, plans and expectations and involve risks, uncertainties and assumptions. You should review
the &#147;Risk Factors&#148; section of this prospectus for a discussion of important factors that could cause our actual results to differ materially from the results described in or implied by the forward-looking statements contained in the
following discussion and analysis. Please also see the section of this prospectus entitled &#147;Special Note Regarding Forward-Looking Statements.&#148; </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a commercial-stage
diagnostics company committed to addressing the significant unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. These chronic diseases can cause lifelong inflammation in the joints, tissues and
internal organs, resulting in serious complications, such as irreversible organ damage. Untreated chronic inflammation can also lead to premature hardening of the arteries, heart attacks and strokes. The accurate, timely and differential diagnosis
for patients suffering from the approximately 30&nbsp;autoimmune rheumatic diseases, or ARDs, is critical as treatment for each disease can vary, and inappropriate or delayed therapy may expose patients to unnecessary risks or the hazards of
uncontrolled disease activity. Physicians face significant difficulties in making a definitive diagnosis of a specific ARD because patients with different diseases often present with a common set of symptoms. We currently market five products under
our Avise brand to provide an accurate, timely and differential diagnosis and to optimize the treatment of ARDs. We processed approximately 9,300 patient specimens for our lead diagnostic product line, Avise SLE, in 2013, approximately 27,900 in
2014 and approximately 27,700 in the nine months ended September&nbsp;30, 2015. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is estimated that 11&nbsp;million adults in the
United States suffer from ARDs, including Rheumatoid Arthritis, or RA, Systemic Lupus Erythematosus, or SLE, Sj&ouml;gren&#146;s syndrome, scleroderma, and Undifferentiated Connective Tissue Disease, or UCTD. In addition, patients afflicted with
fibromyalgia, a chronic neurologic disorder, or autoimmune thyroid disease have many of the same clinical symptoms as patients with ARDs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The diagnosis and treatment of ARDs is generally provided by the community rheumatologist, a sub-specialty of internal medicine which includes
approximately 3,500 physicians in the United States. Patients often present to a rheumatologist after a lengthy referral process because of the similarity and overlap of symptoms among ARDs, the waxing and waning of these symptoms and the
shortcomings of current diagnostic tests. Establishing a definitive diagnosis is often difficult and can take years. Throughout this time, patients may continue to suffer from the debilitating effects of their disease, receive inappropriate
treatments and may face a significant financial burden. As a result, physicians strive to make an accurate diagnosis in a timely manner, especially for more serious ARDs, such as SLE, which can be life threatening. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We market and sell our solutions to community rheumatologists with our approximately 30 person sales force. Reimbursement for our testing
services comes from several sources, including commercial third-party payers, such as insurance companies and health maintenance organizations, government payers, such as Medicare, and patients. Reimbursement rates vary by product and payer. </P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since inception we have devoted substantially all our efforts developing and marketing products for the diagnosis, prognosis and
monitoring of ARDs. Although our revenues have increased sequentially year over year, we have never been profitable and, as of September 30, 2015, had an accumulated deficit of $105.9 million. We incurred net losses of $13.5 million, $15.0 million,
and $16.7 million in the years ended December&nbsp;31, 2013 and 2014, and for the nine months ended September 30, 2015, respectively. As of September 30, 2015, we had cash and cash equivalents of $2.7 million. In their report on our consolidated
financial statements for the year ended December&nbsp;31, 2014, our independent registered public accounting firm included an explanatory paragraph stating that our recurring losses from operations since inception and negative cash flows from
operating activities raise substantial doubt about our ability to continue as a going concern. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 51 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Financial Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We derive our revenue
from the sale of our Avise products, most of which is attributable to our Avise CTD test. We primarily market our products to rheumatologists and their physician assistants. The healthcare professionals who order our tests and to whom results are
reported are generally not responsible for payment for these services. The parties that pay for these services, or payers, consist of commercial third-party payers, government payers, and patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September 30, 2015, substantially all of our revenue is recognized upon the earlier of payment notification, if applicable, or cash
receipt. In those instances where payment notification is received in advance of the cash receipt, the notification received from third-party payers is generally received no more than one business day in advance of the cash receipt. Our service is
completed upon the delivery of test results to the prescribing physician, which triggers billing for the service. Because the timing and amount of cash payments received is difficult to predict, we expect that our revenue could fluctuate
significantly in any given quarter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to increase our revenue will depend on our ability to further penetrate the market for
our current and any future products, and increase our reimbursement and collection rates for tests performed. In the third quarter of 2015, CMS released the Medicare Physician Fee Schedule which establishes the reimbursement rates to be paid by
Medicare for specific CPT codes billed to Medicare by us, commencing January&nbsp;1, 2016. If the proposed rule is implemented as written, we have estimated that it will result in a 10% reduction in anticipated reimbursements from Medicare from our
Avise CTD test. Revenues from Medicare and revenues from the sale of Avise SLE diagnostic products comprised 35% and 92%, respectively, of our revenues in the nine months ended September&nbsp;30, 2015. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Costs of Revenue </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Costs of revenue
represents the expenses associated with obtaining and testing patient specimens. The components of our costs of revenue include materials costs, direct labor, equipment and infrastructure expenses associated with testing specimens, shipping charges
to transport specimens, blood specimen collections fees, royalties, depreciation and allocated overhead, including rent and utilities. Costs associated with performing tests are recorded as the test is processed regardless of whether and when
revenue is recognized with respect to that test. Because we currently recognize substantially all of our revenue upon cash receipt, the costs of our tests are often recognized in advance of any associated revenues. As a result, our cost of revenue
as a percentage of revenue may vary significantly from period to period because we generally do not recognize the corresponding revenue in the period in which the associated costs are incurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect cost of revenue in absolute dollars to increase as the number of tests we perform increases. However, we expect that the cost per
test will decrease over time due to volume discounts on materials and shipping costs and other volume efficiencies we may gain as the number of tests we perform increases. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Selling, General and Administrative Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Selling, general and administrative expenses consist of personnel costs, including stock-based compensation expense, direct marketing expenses,
accounting and legal expenses, consulting costs, and allocated overhead including rent, information technology, depreciation and utilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We anticipate that our selling, general and administrative expenses will increase in absolute dollars in future periods as we expand our sales
and sales support functions. We also expect our selling, general and administrative expenses will increase as a result of operating as a public company, including expenses related to compliance with the rules and regulations of the Securities and
Exchange Commission, additional insurance expenses, investor relations activities and other administrative and professional services. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and
Development Expenses </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses include costs incurred to develop our technology, products and product
candidates, collect clinical specimens and conduct clinical studies to develop and support our products and product candidates. These costs consist of personnel costs, including stock-based compensation expense, materials, laboratory supplies,
consulting costs, costs associated with setting up and conducting clinical studies and allocated overhead including rent and utilities. We expense all research and development costs in the periods in which they are incurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect our research and development expenses will increase in absolute dollars, potentially significantly, in future periods as we continue
to invest in research and development activities related to our existing products and product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 52 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Amortization of Intangible Assets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Amortization of intangible assets represents the total amortization expense for our purchased technologies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect our amortization of intangible assets in absolute dollars to remain relatively constant over the next several years. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revaluation of Acquisition-Related Liabilities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the acquisition of the medical diagnostics division of Cypress Bioscience, Inc., or Cypress, in 2010, we are required to pay
an additional amount not to exceed $9.0&nbsp;million in the event specified revenue, contractual and product launch milestones are achieved. The fair value of this contingent consideration is determined at the end of each reporting period based on
probabilities assigned to the milestones being achieved, and interest rates. Changes in fair value are recorded in the consolidated statements of operations and comprehensive loss. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interest Expense </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense
consists of cash and non-cash interest expense associated with our financing arrangements, including the borrowings under our term loan agreement with Capital Royalty. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense will likely increase in absolute dollars over current levels for the next several years due to the draws we made under our
term loan agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Loss on Extinguishment of Notes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2013 and May 2015, we converted previously outstanding convertible promissory notes into shares of our Series D redeemable
convertible preferred stock. The loss recorded on extinguishment of each of these notes represents the difference in the carrying amount of the convertible promissory notes (including accrued interest thereon and any bifurcated derivatives
associated with the extinguished instrument) and the fair value of the shares of Series D redeemable convertible preferred stock issued upon conversion of the notes. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Income / (Expense), Net </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other income (expense), net, consists primarily of changes in the measurement of the value of the liability associated with outstanding
warrants exercisable for shares of our Series&nbsp;D redeemable convertible preferred stock and changes in the value of embedded derivatives recorded in connection with outstanding convertible promissory notes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The outstanding warrants to purchase shares of our Series D redeemable convertible preferred stock are expected to be exercised in connection
with this offering, or they will terminate, and will no longer be subject to measurement once exercised. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income Tax Expense / (Benefit)
</I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Income taxes include federal and state income taxes in the United States. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Policies and Significant Management Estimates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management&#146;s discussion and analysis of our financial condition and results of operations is based on our consolidated financial
statements, which have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP. The preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts
of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported revenue generated and expenses incurred during the reporting periods. Our estimates are
based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily
apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions and any such differences may be material. We believe that the accounting policies discussed below are critical to understanding our
historical and future performance, as these policies relate to the more significant areas involving management&#146;s judgments and estimates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 53 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue Recognition </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our revenues are derived from sales of our diagnostic, prognostic and monitoring products. We primarily market our testing services to
rheumatologists and their physician assistants. The healthcare professionals who order our products and to whom test results are reported are generally not responsible for payment for these products. The parties that pay for these services consist
of commercial third-party payers, Medicare and other government payers, and patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recognize revenue when the following criteria
have been met: (1)&nbsp;persuasive evidence of an arrangement exists; (2)&nbsp;delivery has occurred or services have been rendered; (3)&nbsp;the fee is fixed or determinable; and (4)&nbsp;collectability is reasonably assured. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our service is completed upon the delivery of test results to the prescribing physician which triggers billing for the service. We recognize
revenue related to billings to third-party payers on an accrual basis, net of contractual adjustments, only when we have established pricing with our third-party payers as indicated by contractual pricing arrangements or predictable patterns of
payments for our services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the absence of a predictable pattern of reimbursement or a contract with a third-party payers, revenue is
recognized upon the earlier of payment notification, if applicable, or cash receipt. In those instances where payment notification is received in advance of the cash receipt, the notification received from third-party payers is generally received no
more than one business day in advance of the cash receipt. We currently recognize revenue on a cash basis from sales of our products. The assessment of the fixed or determinable nature of the fees charged and the collectability of those fees
requires significant judgment by management. Accordingly, we expect to recognize revenue on a cash basis until we have sufficient history to reliably estimate payment patterns. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2013 and 2014 and September 30, 2014 and 2015, our revenue is recognized upon the earlier of payment notification, if
applicable, or cash receipt. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Long Lived Assets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our long lived assets are comprised principally of our property and equipment, finite lived intangible assets, and goodwill. We apply Financial
Accounting Standards Codification, or FASB, Accounting Standards Codification, or ASC, Topic 360, <I>&#147;Property, Plant, and Equipment,&#148;</I> FASB ASC Topic 805, &#147;<I>Business Combinations,</I>&#148; and FASB ASC Topic 350<I>,
</I>&#147;<I>Intangibles&#151;Goodwill and Other,</I>&#148; to account for our property and equipment, goodwill, and intangible assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with these standards, we amortize all finite lived intangible assets over their respective estimated useful lives. In
considering whether intangible assets are impaired, we combine our intangible assets and other long lived assets (excluding goodwill), into groupings, a determination which we principally make on the basis of whether the assets are specific to a
particular test offered by us or technology we are developing. If we identify events or circumstances indicate that the associated carrying amount of assets within a group may not be recoverable, we will consider the assets in the group impaired if
the carrying value of the group&#146;s assets and directly associated liabilities exceed the estimated cash flows expected to be generated over the estimated useful life of the assets in the group. Management&#146;s estimates of future cash flows
are impacted by projected levels of tests and levels of reimbursement, as well as expectations related to the future cost structure of the entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Goodwill is not amortized but is tested for impairment at least annually or more frequently whenever a triggering event or change in
circumstances occurs, at the reporting unit level. For our goodwill impairment analysis, we operate in a single reporting unit, and allocate all goodwill to this reporting unit. We are required to recognize an impairment charge if the carrying
amount of the reporting unit exceeds its fair value. Management uses all available information to make this fair value determination, including the present values of expected future cash flows using discount rates commensurate with the risks
involved in the assets and observed market multiples of operating cash flows. If the estimated fair value of the reporting unit is less than the book value (including the goodwill), further management judgment must be applied in determining the fair
values of individual assets and liabilities for purposes of the hypothetical purchase price allocation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The judgments and estimates
involved in identifying and quantifying the impairment of long lived assets or goodwill involve inherent uncertainties, and the measurement of the fair value is dependent on the accuracy of the assumptions used in making the estimates and how those
estimates compare to our future operating performance. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the completion of this offering, our stock price and associated
market capitalization will also be considered in the determination of reporting unit fair value. A prolonged or significant decline in our share price could provide evidence of a need to record a material impairment of goodwill. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No goodwill or other intangible asset impairments were recorded during the years ended December&nbsp;31, 2013 and 2014. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 54 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2015, we identified that certain lots of the anti-MCV analyte we license from a third
party failed to meet our performance specifications. We replaced the anti-MCV analyte with an anti-CCP analyte in our Avise Lupus test and do not believe patient care was impacted. We have yet to determine whether modifications to the manufacturing
processes will be corrected to our performance standards and until such determination is made, the analyte will not be offered in our testing services. Accordingly, in the three months ended September&nbsp;30, 2015, we determined that the long lived
assets directly associated with the performance of our MCV tests, which consist of intangible assets associated with our license to use the MCV technology, were impaired and recorded an impairment charge of $84,000 representing the net carrying
value of these intangible assets on the date of impairment. The impairment charge was reflected in &#147;amortization of intangible assets&#148; in the consolidated statement of operations and comprehensive loss. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2015, CMS released proposed changes to the Medicare Clinical Diagnostic Laboratory Tests Payment System which governs the
reimbursement amounts providers, including us, receive from billing Medicare for certain testing. In addition, CMS issued the final 2016 Medicare Physician Fee Schedule on October&nbsp;30, 2015, which governs the reimbursement amounts for some of
our flow cytometry tests. Medicare is our largest customer and comprised 35% of our revenues during the nine months ended September&nbsp;30, 2015. The changes proposed by CMS in September 2015 and adopted in October 2015 have negatively impacted our
assumptions on the future levels of reimbursements expected to be received from Medicare from the performance of our tests and were strongly correlated with a decline in the market valuation of our publicly traded comparable peer companies who were
also affected by the announcement from CMS. We believe the totality of these factors negatively impacted our estimates of the fair value of the company during the third quarter of 2015 and required us to consider whether any of our long-lived
assets, including our intangible assets, or goodwill was impaired as of September&nbsp;30, 2015. As a result of our analysis, we did not identify an additional impairment in our long lived assets, including goodwill, as of September&nbsp;30, 2015.
</P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recognize compensation costs related to stock options granted to employees based on the estimated fair value of the awards on the date of
grant, net of estimated forfeitures. We estimate the grant date fair value, and the resulting stock-based compensation expense, using the Black-Scholes-Merton, or BSM, option pricing model. The grant date fair value of stock-based awards is expensed
on a straight-line basis over the vesting period of the respective award. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recorded stock-based compensation expense of
approximately $152,000, $279,000, $171,000 and $215,000 for the years ended December&nbsp;31, 2013, and 2014, and for the nine months ended September 30, 2014 and 2015, respectively. We expect to continue to grant stock options and other
equity-based awards in the future, and to the extent that we do, our stock-based compensation expense recognized in future periods will likely increase. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The BSM option pricing model requires the use of highly subjective and complex assumptions, which determine the fair value of stock-based
awards. If we had made different assumptions, our stock-based compensation expense, net income (loss) and net income (loss) per share of common stock could have been significantly different. Our assumptions are as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Fair value of our common stock.</I> Because our stock was not publicly traded prior to this offering, we estimate the fair value of our common stock. See &#147;&#151;Significant Factors, Assumptions and Methodologies
Used in Determining Fair Value of Our Common Stock&#148; below. Upon the completion of this offering, our common stock will be valued by reference to the publicly traded price of our common stock. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Expected term.</I> The expected term represents the period that the stock-based awards are expected to be outstanding. Our historical share option exercise experience does not provide a reasonable basis upon which to
estimate an expected term because of a lack of sufficient data. Therefore we estimate the expected term by using the simplified method, which calculates the expected term as the average of the time-to-vesting and the contractual life of the options.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Expected volatility.</I> As our common stock has never been publicly traded, the expected volatility is derived from the average historical volatilities of publicly traded companies within our industry that we
consider to be comparable to our business over a period approximately equal to the expected term. We intend to continue to consistently apply this process using the same or similar public companies until a sufficient amount of historical information
regarding the volatility of our own common stock price becomes available, or unless circumstances change such that the identified companies are no longer similar to us, in which case, more suitable companies whose share prices are publicly available
would be utilized in the calculation. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Risk-free interest rate.</I> The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero coupon U.S. Treasury notes with maturities approximately equal to the expected
term. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Expected dividend.</I> The expected dividend is assumed to be zero as we have never paid dividends and have no current plans to pay any dividends on our common stock. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 55 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Expected forfeiture.</I> We use historical data to estimate pre-vesting option forfeitures and record stock-based compensation expense only for those awards that are expected to vest. To the extent actual forfeitures
differ from the estimates, the difference will be recorded as a cumulative adjustment in the period that the estimates are revised. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Significant Factors, Assumptions and Methodologies Used in Determining Fair Value of Our Common Stock </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also required to estimate the fair value of the common stock underlying our stock-based awards when performing the fair value
calculations using the BSM option pricing model. Our board of directors, with the assistance of management, determined the fair value of our common stock on each grant date. All options to purchase shares of our common stock are intended to be
granted with an exercise price per share no less than the fair value per share of our common stock underlying those options on the date of grant, based on the information known to us on the date of grant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because there has been no public market for our common stock, the fair value of the common stock that underlies our stock options has
historically been determined by our board of directors based upon information available to it at the time of grant, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">contemporaneous valuations performed by independent third-party firms; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our current and projected operating and financial performance, including our levels of available capital resources; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">trends and developments in our industry; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the valuation of publicly traded companies in our sector, as well as recently completed initial public offerings and mergers and acquisitions of comparable companies; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">rights, preferences and privileges of our common stock compared to the rights, preferences and privileges of our other outstanding equity securities; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">U.S. and global economic and capital market conditions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the likelihood of achieving a liquidity event for the shares of common stock, such as an initial public offering or an acquisition of our company given prevailing market and sector conditions; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the illiquidity of our securities by virtue of being a private company; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">business risks; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">management and board experience. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The valuations of our common stock performed by independent
third-party firms were performed in accordance with the guidelines outlined in the American Institute of Certified Public Accountants Practice Aid, <I>Valuation of Privately-Held-Company Equity Securities Issued as Compensation</I>. Historically, we
utilized an option pricing method to allocate our business enterprise value to our common stock and common stock equivalents. Beginning in December&nbsp;31, 2012, we began utilizing a probability-weighted expected returns method, or PWERM, valuation
approach. Under this approach, the valuation of our common stock was based upon the probability-weighted present value of expected future returns, considering each of the possible future scenarios available to us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business enterprise value was estimated using a combination of two generally accepted approaches: the income approach and the market-based
approach. The income approach estimates enterprise value based on the estimated present value of future net cash flows the business is expected to generate over its remaining life. The estimated present value is calculated using a discount rate
reflective of the cost of capital associated with an investment in a similar company and risks associated with our cash flow projections. Our discounted cash flow projections are sensitive to highly subjective assumptions that we were required to
make each valuation date. The market-based approach measures the value of a business through an analysis of recent sales or offerings of comparable investments or assets, and in our case, focuses on comparing us to the group of peer companies. In
applying this method, valuation multiples are derived from historical operating data of the peer company group. We then apply multiples to our operating data to arrive at a range of indicated values of the company. For each valuation, we prepared a
financial forecast to be used in the computation of the value of invested capital for both the market approach and income approach. The financial forecasts took into account our past results and expected future financial performance. There is
inherent uncertainty in these estimates as the assumptions used are highly subjective and subject to changes as a result of new operating data and economic and other conditions that impact our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we had made different assumptions than those used, the amount of our stock-based compensation expense, net income (loss) and net income
(loss) per share amounts could have been significantly different. Following the completion of this offering, the fair value per share of our common stock for purposes of determining stock-based compensation expense will be the closing price of our
common stock as reported on the applicable grant date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 56 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, the intrinsic value of stock options outstanding as of September 30, 2015 would be
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, of which $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million and
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million would have been related to stock options that were vested and unvested, respectively, at that date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Estimated Fair Value of Redeemable Convertible Preferred Stock Warrants, Embedded Derivative Liabilities and Acquisition-Related Liabilities
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We account for our redeemable convertible preferred stock warrant liabilities as freestanding instruments for shares that are
puttable or redeemable. These warrants are classified as liabilities on our consolidated balance sheets and are recorded at their estimated fair values. At the end of each reporting period, changes in estimated fair value during the period are
recorded as a component of other income (expense), net in the accompanying statement of operations and comprehensive loss. We will continue to re-measure the fair value of the warrant liabilities until: (i)&nbsp;exercise, (ii)&nbsp;expiration of the
related warrant, or (iii)&nbsp;conversion of the preferred stock underlying the security into common stock, which will occur in connection with this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate the fair values of our warrant liabilities using an option pricing model based on inputs as of the valuation measurement dates,
including the fair value of our redeemable convertible preferred stock, the estimated volatility of the price of our redeemable convertible preferred stock, the expected term of the warrants and the risk-free interest rates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2013, we converted previously outstanding convertible promissory notes into shares of our Series D redeemable convertible preferred stock
at a 20% discount to the issuance price of such shares. We determined this discount to be an embedded put feature derivative requiring bifurcation and separate accounting. Accordingly, we recorded a derivative liability which was remeasured to fair
value through the conversion of the convertible notes. The related remeasurement adjustments were recognized as a change in fair value of derivative liabilities associated with the convertible promissory notes in the consolidated statements of
operations and comprehensive loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The inputs used to determine the estimated fair value of these derivative instruments included the
probability of potential settlement scenarios for the convertible promissory notes, an estimate of the expected timing of settlement, expected volatility and risk-free interest rates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2014, we issued $4.0 million of convertible promissory notes, or the July 2014 Notes, which accrued interest at an annual rate equal
to 12% and which contained a feature such that upon our initial public offering the unpaid principal and interest of these notes would convert into shares of our common stock at a 20% discount to our initial public offering price. In accordance with
authoritative guidance, this conversion feature required bifurcation from the convertible notes and is accounted for as a derivative liability, which we remeasured to fair value until exercise of the conversion feature in May 2015. We previously
classified the derivative liability as current in our consolidated balance sheets as the convertible notes had a maturity date in April 2015. In May 2015, the holders of these notes elected to convert the outstanding principal (and accrued interest
thereon) of these notes into shares of our Series D Preferred redeemable convertible preferred stock at the stated conversion rate of $0.25 per share. Prior to the exercise of the conversion feature, the related remeasurement adjustments were
recognized in other income (expense), net, in the consolidated statements of operations and comprehensive loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The inputs used to
determine the estimated fair value of the derivative liability include our management&#146;s assessment of the probability and timing of our initial public offering and the risk-free interest rate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2015, we entered into a note purchase agreement, or the February 2015 Note Purchase Agreement, with existing holders of our
redeemable convertible preferred stock. Under this agreement, we could issue up to $20.0 million in convertible promissory notes in up to three tranches, which we collectively refer to as the February 2015 Notes. All borrowings under the February
2015 Note Purchase Agreement are subordinated to borrowings under our 2013 term loan with Capital Royalty. Borrowings under each tranche of the February 2015 Note Purchase Agreement accrue interest at 10% per annum, and all principal and interest is
due upon the maturity of the respective tranche. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2015,&nbsp;May 2015 and June 2015, we issued $1.8 million, $1.9
million, and $833,000 in convertible promissory notes representing the first, second, and third tranches of borrowings under the February 2015 Note Purchase Agreement, respectively. Borrowings under the first, second, and third tranches of the
February 2015 Notes mature in December 2015,&nbsp;May 2016, and June 2016, respectively, and have been classified as current liabilities. The February 2015 Notes provide that a majority of holders for a given tranche may elect to extend the maturity
date of such tranche by up to one additional year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The February 2015 Notes contain a feature such that if an IPO occurs prior to the
initial stated maturity date for a tranche, the unpaid principal and accrued interest for that tranche will convert into shares of our common stock at a 20% discount to the IPO price. If investors have previously elected to extend the maturity date
for a tranche, the unpaid principal and interest for that tranche will convert into shares of our common stock at a 30% discount to the IPO price. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 57 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that an IPO has not occurred by the maturity date for a particular tranche of the
February 2015 Notes, and a majority of holders has not elected to extend the maturity date of such tranche, holders of that tranche may elect to either (1)&nbsp;receive all unpaid principal and accrued interest due or (2)&nbsp;convert the unpaid
principal and interest at maturity into shares of our Series D redeemable convertible preferred stock at a rate of $0.25 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
features which allow the conversion of a given tranche into shares at either a 20% discount or a 30% discount to the issuance price upon the IPO were determined to be embedded put features which required bifurcation and separate accounting as these
discounts were substantial. We valued these embedded derivatives using a method that considered the value of an instrument that contained these discount features upon IPO to the value of a similar instrument that did not contain such discount
features upon IPO. The application of this method incorporated management&#146;s assumptions related to the expected timing and probability of an IPO, the likelihood management associated the extension of the maturity of each tranche of the February
2015 Notes, and the appropriate discount rates attributable to each tranche of the February 2015 Notes. The embedded derivatives associated with the first, second, and third tranche closings were recorded as liabilities with fair values of
approximately $218,000, $303,000, and $131,000, respectively, and as a discount to the carrying value of the respective tranche upon issuance in the consolidated balance sheets. The related discounts are being amortized to interest expense using the
effective interest method to the stated maturity date of each tranche. We have classified the bifurcated embedded derivative liabilities as current in the consolidated balance sheets, as borrowings under each tranche mature within one year of the
balance sheet date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with authoritative guidance, we will remeasure the bifurcated embedded derivatives arising from the
issuance of each tranche of the February 2015 Notes to fair value each reporting period until the earlier of the maturity of the respective tranche of the February 2015 Notes or exercise of the conversion feature. The related remeasurement
adjustments are recognized in other income (expense), net, in the consolidated statements of operations and comprehensive loss. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, the feature which allows conversion of the each tranche into shares of our Series&nbsp;D redeemable convertible preferred stock
at a fixed rate of $0.25 per share results in a beneficial conversion feature which is equal to the difference between fair value of underlying shares into which the tranche is convertible and the per share value which the proceeds allocated to the
tranche would be converted into, multiplied by the number of shares into which the tranche would convert on the issuance date. Using this methodology, the beneficial conversion features associated with the first, second, and third tranche closings
were recorded as a component of additional paid in capital in the amounts of $364,000, $303,000, and $131,000, respectively, and as a discount to the carrying value of the respective tranche upon issuance in the consolidated balance sheets. The
related discount is being amortized to interest expense using the effective interest method to the stated maturity date of each tranche. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2015, we issued $3.0 million of convertible promissory notes, or the July 2015 Notes, to certain holders of our redeemable convertible
preferred stock. The July 2015 Notes are subordinated to borrowings under our 2013 term loan with Capital Royalty. The July 2015 Notes accrue interest at 10%&nbsp;per annum, and the principal and accrued interest of the July 2015 Notes is due in
July 2016, and have been classified as current liabilities. The July 2015 Notes provide that a majority of holders may elect to extend the maturity date by up to one additional year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The July 2015 Notes contain a feature such that if an IPO occurs prior to December&nbsp;31, 2015, the unpaid principal and accrued interest
will convert into shares of our common stock at a 20% discount to the IPO price. If the IPO occurs after December&nbsp;31, 2015, the unpaid principal and interest will convert into shares of our common stock at a 30% discount to the IPO price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that an IPO has not occurred by the maturity date for the July 2015 Notes, and a majority of holders has not elected to extend
the maturity date of this debt, holders may elect to either (1)&nbsp;receive all unpaid principal and accrued interest due or (2)&nbsp;convert the unpaid principal and interest at maturity into shares of our Series D redeemable convertible preferred
stock at a rate of $0.25 per share. If a liquidation (as defined in our current amended and restated certificate of incorporation) occurs prior to the completion of this offering, the holders of the July 2015 Notes may elect to (1)&nbsp;receive the
repayment of the notes or (2)&nbsp;convert the notes into shares of Series D redeemable convertible preferred stock at a conversion price of $0.25 per share, subject to adjustment pursuant to the terms thereof. In connection with the completion of
this offering, the aggregate principal amount outstanding (including accrued interest thereon) under the July 2015 Notes will automatically convert into &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common
stock, assuming an initial public offering price of $ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus and assuming the
conversion occurs on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2015 (the expected closing date of this offering). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The feature which allow the conversion of these notes into shares at either a 20% discount or a 30% discount to the issuance price upon the
IPO was determined to be an embedded put feature which requires bifurcation and separate accounting as these discounts were substantial. We valued this embedded derivative using a method that considered the value of an instrument that contained
these discount features upon IPO to the value of a similar instrument that did not contain such discount features upon IPO. The application of this method incorporated management&#146;s assumptions related to the expected timing and probability of
an IPO, the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 58 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
likelihood management associated the extension of the maturity of the July 2015 Notes, and the appropriate discount rates attributable the July 2015 Notes. The embedded derivative associated with
these notes was recorded as a liability with a fair value of approximately $468,000, and as a discount to the carrying value of the July 2015 Notes upon issuance in the consolidated balance sheets. The related discount is being amortized to interest
expense using the effective interest method to the stated maturity date of each these notes. We have classified the bifurcated embedded derivative liability as current in the consolidated balance sheets, as borrowings under these notes mature within
one year of the balance sheet date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with authoritative guidance, we will remeasure the bifurcated embedded derivative
arising from the issuance of the July 2015 Notes to fair value each reporting period until the earlier of the maturity of the July 2015 Notes or exercise of the conversion feature. The related remeasurement adjustments are recognized in other income
(expense), net, in the consolidated statements of operations and comprehensive loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, the feature which allows conversion of
the July 2015 Notes into shares of our Series&nbsp;D redeemable convertible preferred stock at a fixed rate of $0.25 per share results in a beneficial conversion feature which is equal to the difference between fair value of underlying shares into
which the notes are convertible and the per share value which the proceeds allocated to the notes would be converted into, multiplied by the number of shares into which the notes would convert on the issuance date. Using this methodology, the
beneficial conversion features associated with the issuance of the July 2015 Notes was recorded as a component of additional paid in capital in the amount of $468,000, and as a discount to the carrying value of the notes upon issuance in the
consolidated balance sheets. The related discount is being amortized to interest expense using the effective interest method to the stated maturity date of the notes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the acquisition of the medical diagnostics division of Cypress in 2010, we are required to pay an additional amount not to
exceed $9.0&nbsp;million in the event specified revenue, contractual and product launch milestones are achieved. This contingent liability requires the use of inputs which are not observable in the market to assess its fair value at the end of each
reporting period. For this liability, fair value is determined based on probabilities assigned to the milestones being achieved, revenue projections, and interest rates. Changes in fair value are recorded in the consolidated statements of operations
and comprehensive loss. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We operate in, and are subject to tax authorities in, various tax jurisdictions in the United States. To date, we have not been audited by the
Internal Revenue Service or any state income tax authority, however all tax years remain open for examination by federal tax authorities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our deferred tax assets are primarily comprised of federal and state tax net operating loss and tax credit carryfowards. We have performed an
analysis to determine whether an &#147;ownership change&#148; occurred from inception to December&nbsp;31, 2013. Based on this analysis, we determined that we did experience a historical ownership change of greater than 50% in 2008. Therefore, our
ability to utilize our net operating losses incurred prior to this date is limited. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are required to reduce our deferred tax assets
by a valuation allowance if it is more likely than not that some or all of our deferred tax assets will not be realized. We must use judgment in assessing the potential need for a valuation allowance, which requires an evaluation of both negative
and positive evidence. The weight given to the potential effect of negative and positive evidence should be commensurate with the extent to which it can be objectively verified. In determining the need for and amount of our valuation allowance, if
any, we assess the likelihood that we will be able to recover our deferred tax assets using historical levels of income, estimates of future income and tax planning strategies. As a result of historical cumulative losses and uncertainties
surrounding our ability to generate future taxable income and, based on all available evidence, we believe it is more likely than not that our recorded net deferred tax assets will not be realized. Accordingly, we have recorded a valuation allowance
against all of our net deferred tax assets at December&nbsp;31, 2013 and 2014, and September 30, 2015 . We will continue to maintain a full valuation allowance on our deferred tax assets until there is sufficient evidence to support the reversal of
all or some portion of this allowance. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The above listing is not intended to be a comprehensive list of all of our accounting
policies. In many cases, the accounting treatment of a particular transaction is specifically dictated by GAAP. There are also areas in which our management&#146;s judgment in selecting any available alternative would not produce a materially
different result. Please see our audited consolidated financial statements and notes thereto included elsewhere in this prospectus, which contain accounting policies and other disclosures required by GAAP. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 59 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comparison of the Nine Months Ended September 30, 2014 and 2015 </I></B></P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="71%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine Months Ended September 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Dollar<BR>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(In thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,425</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,497</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,072</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Costs of revenue (excluding amortization of purchased technology)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,727</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general&nbsp;&amp; administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,077</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,265</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of acquisition-related liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(500</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,741</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,834</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,907</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,008</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,533</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,525</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on extinguishment of debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,258</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,258</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other (expense) / income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(626</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">811</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,375</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,440</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,065</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax benefit / (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(210</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(213</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,372</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,650</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4,278</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenue increased $6.1 million, or 82%, in the nine months ended September 30, 2015 compared to the nine months ended September 30, 2014,
primarily due to an increase in the number of Avise SLE diagnostic products for which we collected payments and an increase in average reimbursement per test. We increased the number of Avise SLE diagnostic products for which we collected initial
payments by 63% to 22,685 for the nine months ended September 30, 2015 from 13,937 for the nine months ended September 30, 2014, due in part to increased adoption of our products by rheumatologists and improved billing and collection efforts. Our
average reimbursement per test for which we received the initial payment increased by $88 for the nine months ended September 30, 2015 from the nine months ended September 30, 2014 primarily as a result of an increase in the procedures included in
our primary product, Avise CTD (and corresponding increase in the maximum potential reimbursement per test), starting in the first quarter of 2014 and improved billing and collection efforts. Our average reimbursement rate is the ratio of all
payments received in a reporting period over the number of tests for which we received an initial payment during the period. While the payments we receive for a single test may span multiple periods, the initial payment currently represents the
substantial majority of the total amount collected for most tests. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Costs of Revenue </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cost of revenue increased $2.3 million, or 49%, in the nine months ended September 30, 2015 compared to the nine months ended September 30,
2014 primarily due to the increase in the number of Avise SLE diagnostic tests processed and increases in laboratory headcount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Costs
that tend to vary based on the number of tests processed increased $1.8&nbsp;million, or 54%, in the nine months ended September 30, 2015 compared to the nine months ended September 30, 2014 primarily due to the increase in the number of Avise SLE
tests processed, offset by efficiencies gained in the laboratory due to larger testing volumes. Avise&nbsp;SLE diagnostic patient specimens tested increased 43% to 27,700 from 19,400 for the nine months ended September 30, 2015 and 2014,
respectively. In the nine months ended September 30, 2015, costs that tend to vary based on revenues increased at a higher rate than SLE unit sales primarily due to increases in our royalty obligations, the most significant of which depend on the
level of reimbursement received on SLE tests. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Compensation and other employee related expenses increased $470,000, or 33%, in the nine
months ended September 30, 2015 compared to the nine months ended September 30, 2014 resulting primarily from additions to our laboratory headcount, which increased to 21 employees at September 30, 2015 from 14 at September 30, 2014. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 60 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Selling, General and Administrative Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Selling, general and administrative expenses increased $2.3 million, or 21%, in the nine months ended September 30, 2015 compared to the nine
months ended September 30, 2014. This increase was primarily due to increases in selling, general and administrative headcount, which increased to 80 employees at September 30, 2015 from 53 at September 30, 2014. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Costs that tend to vary based on revenue, which include commissions and performance-based compensation and other sales and marketing related
expenses, decreased $85,000 in the nine months ended September 30, 2015 compared to the nine months ended September 30, 2014. This decrease resulted from the offsetting impacts of increases in our marketing efforts, and reductions in spending
resulting from improvements in our management of selling expenses, particularly with respect to sales compensation policies, and reductions in spending associated with our billing and collections function. The reduction in billing and collection
expenses resulted from our transition from the use of a third party billing and collection service to our own in-house billing and collections function in the second quarter of 2015. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Compensation and other employee related expenses for our selling, general and administrative support functions increased $1.7 million in the
nine months ended September 30, 2015 compared to the nine months ended September 30, 2014, resulting primarily from additions to our headcount. Expenses for legal and other professional services increased $124,000 in the nine months ended September
30, 2015 compared to the nine months ended September 30, 2014, primarily in support of our IPO readiness processes. Expenses associated with facilities (including depreciation expense) increased $512,000 in the nine months ended September 30, 2015
as compared to the nine months ended September 30, 2014, primarily as a result of leasing additional corporate office space in the third quarter of 2014. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses increased $10,000, or 1%, in the nine months ended September 30, 2015 compared to the nine months ended
September 30, 2014 primarily from additions to our headcount, offset by reductions in the level of our activities related to evaluating the clinical utility of our diagnostic tests. Research and development headcount increased to seven employees at
September 30, 2015 from five at September&nbsp;30, 2014. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Amortization of Intangible Assets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Amortization of intangible assets increased $90,000, or 58% in the nine months ended September&nbsp;30, 2015 compared to the nine months ended
September&nbsp;30, 2014 primarily as a result of our assessment of intangible assets with a net book value of $84,000 associated with our MCV product license, which were not recoverable as a result our inability to determine whether the anti-MCV
analyte will meet our performance specifications. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Change in Fair Value of Acquisition-Related Liabilities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amount associated with the change in fair value of acquisition-related liabilities decreased $500,000 to an expense of $32,000 in the nine
months ended September 30, 2015 compared to an expense of $532,000 for the nine months ended September 30, 2014. These amounts result from changes in our estimates of the probabilities and timing associated with achieving certain revenue,
contractual, and product launch milestones in connection with our acquisition of the medical diagnostics division of Cypress Bioscience in 2010. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interest Expense </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest
expense increased $1.5 million, or 76%, in the nine months ended September 30, 2015 compared to the nine months ended September 30, 2014 primarily as result of increased interest expense related to $5.0 million of additional borrowings under our
existing term loan, which we drew down in March 2014, and additional interest expense incurred on $4.0 million and $7.5 million of convertible notes issued to existing investors in July 2014 under the July 2014 Notes (which were extinguished in May
2015) and during February 2015,&nbsp;May 2015, and June 2015 under the February 2015 Notes and during July 2015 under the July 2015 Notes, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Loss on Extinguishment of Debt </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
May 2015, we converted the outstanding balance of the July 2014 Notes into shares of our Series&nbsp;D redeemable convertible preferred stock. The loss on extinguishment of these notes of $5.3 million represents the difference between the fair value
of the Series&nbsp;D redeemable convertible preferred stock issued and the carrying value of the July 2014 Notes and the fair value of the bifurcated embedded derivative representing the conversion feature on the conversion date. No comparable
transaction occurred in 2014. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 61 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other (expense) / income, net </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other (expense) / income, net, increased to a benefit of $185,000 in the nine months ended September 30, 2015 compared to an expense of
$626,000 in the nine months ended September 30, 2014. The change was primarily due to a reduction in the estimated fair value of liabilities associated with our redeemable convertible preferred stock warrants that was caused by the reduction in the
estimated fair value of the company due to overall market conditions in the third quarter of 2015. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income tax benefit / (expense) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recorded an income tax expense of $210,000 in the nine months ended September 30, 2015 primarily related to an increase in the deferred tax
liabilities associated with tax deductible amortization of goodwill and intangible assets. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comparison of the Years Ended December&nbsp;31,
2013 and 2014 </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="71%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Years Ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December 31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Dollar</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(In thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,055</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,663</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,608</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Costs of revenue (excluding amortization of purchased technology)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,830</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,885</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,055</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,993</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,066</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,073</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">897</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">390</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revaluation of acquisition-related liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,265</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(239</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,504</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,144</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,556</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,412</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(941</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,941</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on extinguishment of 2013 notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,286</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,286</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(83</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(497</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(414</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,454</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,994</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,540</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax (expense) benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(42</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,496</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(14,981</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,485</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenue increased $8.6 million, or 282%, in the year ended December&nbsp;31, 2014 compared to the year ended December&nbsp;31, 2013, primarily
due to an increase in the number of Avise SLE diagnostic products for which we collected payments and an increase in average reimbursement per test. We increased the number of Avise SLE diagnostic products for which we collected initial payments by
225% to 20,560 for the year ended December&nbsp;31, 2014 compared to 6,326 for the year ended December&nbsp;31, 2013, due in part to increased adoption of our products by rheumatologists and improved billing and collection efforts. Our average
reimbursement per test for which we received the initial payment increased by 40% for the year ended December&nbsp;31, 2014 compared to the year ended December&nbsp;31, 2013, primarily as a result of an increase in the procedures included in our
primary product, Avise CTD (and corresponding increase in the maximum potential reimbursement per test), starting in the first quarter of 2014 and improved billing and collection efforts. Our average reimbursement rate is the ratio of all payments
received in a reporting period over the number of tests for which we received an initial payment during the period. While the payments we receive for a single test may span multiple periods, the initial payment currently represents the substantial
majority of the total amount collected for most tests. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Costs of Revenue </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Costs of revenue increased $4.1 million, or 143%, in the year ended December&nbsp;31, 2014 compared to the year ended December&nbsp;31, 2013.
This increase is primarily due to a 186% increase in variable costs associated with processing more Avise&nbsp;SLE diagnostic patient specimens, offset by efficiencies gained in the laboratory due to larger testing volumes. Avise&nbsp;SLE diagnostic
patient specimens tested increased 200% from 9,300 to 27,900 for the year ended December&nbsp;31, 2013 and December&nbsp;31, 2014, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 62 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Selling, General and Administrative Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Selling, general and administrative expenses increased $8.1 million, or 115%, in the year ended December&nbsp;31, 2014 compared to the year
ended December&nbsp;31, 2013. This increase was primarily due to increases in selling, general and administrative headcount, which increased 54% from December&nbsp;31, 2013 to December&nbsp;31, 2014. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Costs that tend to vary based on revenue, which include commissions and performance-based compensation and other sales and marketing related
expenses, increased $2.2 million in the year ended December&nbsp;31, 2014 compared to the year ended December&nbsp;31, 2013, resulting from continuing expansion of our dedicated sales force. In addition, third-party billing fees increased $0.6
million due to increases in the number of tests performed and billed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Compensation and other employee related expenses for our selling,
general and administrative support functions increased $3.4 million in the year ended December&nbsp;31, 2014 compared to the year ended December&nbsp;31, 2013, resulting primarily from additions to our headcount. Expenses for legal and other
professional services increased $1.3 million in the year ended December&nbsp;31, 2014 compared to the year ended December&nbsp;31, 2013, primarily in support of our financial statement audit and IPO readiness processes. Expenses associated with
facilities (including depreciation expense) also increased $0.4 million in the year ended December&nbsp;31, 2014 as compared to the year ended December&nbsp;31, 2013, primarily as a result of the expansion of our laboratory facilities and corporate
office space in the third quarter of 2014. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses increased $0.4 million, or 43%, in the year ended December&nbsp;31, 2014 compared to the year ended
December&nbsp;31, 2013 primarily from increased clinical trial expenses of $0.3 million incurred in the year ended December&nbsp;31, 2014 in connection with additional studies to further document the performance of our products. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Amortization of Intangible Assets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Amortization of intangible assets remained consistent for the year ended December&nbsp;31, 2014 compared to the year ended December&nbsp;31,
2013. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Change in Fair Value of Acquisition-Related Liabilities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revaluation of acquisition-related liabilities decreased $1.5 million, or 119%, in the year ended December&nbsp;31, 2014 compared to the year
ended December&nbsp;31, 2013. These amounts result from changes in our estimates of the probabilities and timing associated with achieving certain revenue, contractual and product launch milestones in connection with our acquisition of the medical
diagnostics division of Cypress Bioscience in 2010. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interest Expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense increased $2.0 million, or 213%, in the year ended December&nbsp;31, 2014 compared to the year ended December&nbsp;31, 2013
primarily as result of increased interest expense related to $5.0 million of additional borrowings under our existing term loan, which we drew down in March 2014, and additional interest expense incurred on $4.0 million of convertible notes issued
to existing investors in July 2014. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Loss on Extinguishment of 2013 Notes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2013 we converted previously outstanding convertible promissory notes into shares of our Series&nbsp;D redeemable convertible preferred
stock. Loss on extinguishment of 2013 Notes of $3.3 million represents the difference in the carrying amount of the convertible promissory notes and the fair value of the shares of Series&nbsp;D redeemable convertible preferred stock issued upon
conversion of the notes. No comparable transaction occurred in 2014. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Expense, Net </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other income (expense), net, decreased $0.4 million in the year ended December&nbsp;31, 2014 compared to the year ended December&nbsp;31, 2013.
The decrease was primarily due to the increase in the fair value of liabilities associated with our redeemable convertible preferred stock warrants, and the change in fair value of the embedded derivative feature contained within the $4.0 million of
convertible notes we issued in July 2014. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 63 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have incurred net losses since our inception. For the years ended December&nbsp;31, 2013 and 2014, and for the nine months ended September
30, 2015, we incurred a net loss of $13.5 million, $15.0 million and $16.7 million, respectively, and we expect to incur additional losses this year and in future years. As of September 30, 2015, we had an accumulated deficit of $105.9 million. To
date, we have generated only limited revenue, and we may never achieve revenue sufficient to offset our expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since inception, our
operations have been financed primarily by net proceeds of approximately $89.8&nbsp;million from sales of our common and redeemable convertible preferred stock and borrowings under various debt financings. As of September 30, 2015, we had $2.7
million of cash and cash equivalents. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2013, we entered into a term loan agreement, under which we drew down an initial
$10.0&nbsp;million in October 2013 and another $5.0 million in March&nbsp;2014. Loans drawn under the term loan agreement are being used for working capital and general corporate purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The loan accrues interest at an annual rate equal of 14%, 10% of which is payable in cash on a quarterly basis and 4% of which we have elected
to capitalize as part of the outstanding loan obligation. We are required to repay any outstanding principal and capitalized interest in quarterly installments over a two-year period, commencing on December&nbsp;31, 2016. We may, at our option,
prepay the term loan borrowings by paying the lender a prepayment premium. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our obligations under the term loan agreement are secured by a
security interest in substantially all of our personal property, including our intellectual property. The loan and security agreement contains customary conditions to borrowing, events of default, and covenants, including covenants requiring us to
maintain a minimum liquidity of at least $2.0 million and achieve certain minimum amounts of revenue, and limiting our ability to dispose of assets, undergo a change in control, merge with or acquire other entities, incur debt, incur liens, pay
dividends or other distributions to holders of our capital stock, repurchase stock and make investments, in each case subject to certain exceptions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the execution of the term loan agreement, we issued the lenders a ten-year warrant to purchase 3,186,430 shares of our
Series&nbsp;D redeemable convertible preferred stock at an exercise price of $0.25&nbsp;per share, and a ten-year warrant to purchase 3,186,430 shares of our common stock at an exercise price of $0.01 per share. In November 2013, we also issued a
warrant to purchase 988,000 shares of our Series D redeemable convertible preferred stock at an exercise price of $0.25 per share to an investment advisor involved in the consummation of the term loan agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2014, we issued $4.0 million of July 2014 Notes which accrued interest at an annual rate equal to 12% and became due and payable on
April&nbsp;10, 2015. In May 2015, the holders of these notes elected to convert the outstanding principal (and accrued interest thereon) of these notes into 17,384,324 shares of our Series D redeemable convertible preferred stock at the stated
conversion rate of $0.25 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2015, we entered into the February 2015 Note Purchase Agreement with existing holders of
our redeemable convertible preferred stock. Under this agreement, we issued the February 2015 Notes in three tranches. All borrowings under the February 2015 Notes are subordinated to borrowings under our 2013 term loan with Capital Royalty.
Borrowings under each tranche of the February 2015 Notes accrue interest at 10% per annum, and all principal and interest is due upon the maturity of the respective tranche. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2015,&nbsp;May 2015 and June 2015, we issued $1.8 million, $1.9 million, and $833,000 in February 2015 Notes, respectively.
Borrowings under the first, second, and third tranches of the February 2015 Notes mature in December 2015,&nbsp;May 2016, and June 2016, respectively, and have been classified as current liabilities. The February 2015 Notes provide that a majority
of holders for a given tranche may elect to extend the maturity date of such tranche by up to one additional year. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2015, we
issued $3.0 million in July 2015 Notes which accrue interest at 10%&nbsp;per annum. Borrowings under the July 2015 Notes mature in July 2016 and have been classified as current liabilities. The July 2015 Notes provide that a majority of holders may
elect to extend the maturity date of these notes by up to one additional year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2015, we issued $3.4 million in October 2015
Notes which accrue interest at 10%&nbsp;per annum. Borrowings under the October 2015 Notes mature in October 2016 and have been classified as current liabilities. The October 2015 Notes provide that a majority of holders may elect to extend the
maturity date by up to one additional year. In connection with the issuance of the October 2015 Notes, we issued the holders warrants to purchase shares of our preferred stock, or the 2015 Warrants, which 2015 Warrants only become exercisable in
certain circumstances. If the 2015 Warrants are not exercised prior to the completion of the offering, they will terminate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 64 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The February 2015 Notes, the July 2015 Notes, and the October 2015 Notes each contain a
feature such that if an IPO occurs prior to December&nbsp;31, 2015, the unpaid principal and interest for such note will convert into shares of our common stock at a 20% discount to the IPO price. If investors have previously elected to extend the
maturity date for a given tranche of the February 2015 Notes or the July 2015 Notes or October 2015 Notes, as applicable, the unpaid principal and interest for such related notes will convert into shares of our common stock at a 30% discount to the
IPO price. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our primary uses of cash are to fund our operations as we continue to grow our business. We expect to continue to incur
operating losses in the near term as our operating expenses will be increased to support the growth of our business. We expect that our cost of revenue, selling, general and administrative, research and development expenses will continue to increase
as we increase our test volume, expand our marketing efforts and increase our internal sales force to drive increased adoption of and reimbursement for our Avise products, prepare to commercialize new products, continue our research and development
efforts and further develop our product pipeline. We expect that we will use a substantial portion of the net proceeds of this offering, in combination with our existing cash and cash equivalents, for these purposes and for the increased expenses
associated with being a public company. We recently completed the build-out of our laboratory in Vista, California, and further expanded our space in February 2015. We believe we have sufficient laboratory capacity to support increased test volume.
Other than the addition of laboratory equipment, we expect that we will not need to make material capital expenditures in the near term related to our laboratory facilities. Cash used to fund operating expenses is impacted by the timing of when we
pay expenses, as reflected in the change in our outstanding accounts payable and accrued expenses. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that our near- and
longer-term liquidity requirements will continue to consist of working capital and general corporate expenses associated with the growth of our business, including payments we may be required to make upon the achievement of previously negotiated
milestones associated with intellectual property we have licensed. The report of our independent registered public accounting firm on our audited consolidated financial statements for the year ended December&nbsp;31, 2014 includes an explanatory
paragraph stating that our recurring losses from operations and negative cash flows from operating activities raise substantial doubt about our ability to continue as a going concern.&nbsp;Based on our current business plan, we believe that the
estimated net proceeds from this offering, together with our existing cash and cash equivalents as of September 30, 2015 and our anticipated future product revenue, will be sufficient to meet our anticipated cash requirements for at least the next
18&nbsp;months, including funding the completion of our ongoing validation studies for the products in our pipeline. In addition, if these validation studies are successful, we believe that only minimal additional capital investment will be required
in order to launch our other two pipeline products. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our estimate of the period of time through which our financial resources will be
adequate to support our operations is a forward-looking statement and involves risks and uncertainties, and actual results could vary as a result of a number of factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to maintain and grow sales of our Avise products, as well as the costs associated with conducting clinical studies to demonstrate the utility of our products and support reimbursement efforts;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">fluctuations in working capital; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs to expand our sales and marketing capabilities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs of developing our product pipeline, including the costs associated with conducting our ongoing and future validation studies; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the additional costs we may incur as a result of operating as a public company; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the extent to which we in-license, acquire or invest in complementary businesses or products. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have based
this estimate on assumptions that may prove to be wrong, and we may utilize our available capital resources sooner than we currently expect. For example, if our ongoing validation studies for the products in our pipeline or our ongoing clinical
studies of our existing products take longer to complete than we currently expect or are unsuccessful, we may require additional funding on a faster timeline than we currently anticipate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until such time, if ever, as we can generate more substantial revenue, we may be required, or we may elect, to finance operations by utilizing
additional debt or selling equity securities. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or
declaring dividends. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders may be diluted, and the terms of these securities may include liquidation or
other preferences </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 65 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
that adversely affect the rights of our common stockholders. If additional funding is required or desired, there can be no assurance that additional funds will be available to us on acceptable
terms on a timely basis, if at all, or that we will generate sufficient cash from operations to adequately fund our operating needs or achieve or sustain profitability. If we are unable to raise additional capital or generate sufficient cash from
operations to adequately fund our operations, we will need to curtail planned activities to reduce costs. Doing so will likely have an unfavorable effect on our ability to execute on our business plan. If we cannot expand our operations or otherwise
capitalize on our business opportunities because we lack sufficient capital, our business, financial condition, and results of operations could be adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our cash flows for the years ended December&nbsp;31, 2013 and 2014, and the nine months ended September 30,
2014 and 2015: </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Years Ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Nine months ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:8pt"><B>December 31,</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-size:8pt"><B>Dollar</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:8pt"><B>September 30,</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Dollar</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by (used in):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,865</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10,773</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,908</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,330</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,523</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(193</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">549</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(649</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,198</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(606</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(641</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,284</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,030</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,316</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,020</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase (decrease) in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,138</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,136</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(620</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,868</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,248</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cash Flows from Operating Activities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash used in operating activities was $8.5 million for the nine months ended September 30, 2015 compared to $8.3 million for the nine months
ended September 30, 2014. The increase in cash used in operating activities is primarily due to the offsetting impacts of increases in collection levels which resulted from higher period-over-period revenues, offset by cash used in the growth of our
operations, particularly in our headcount, which increased from 72 employees at September 30, 2014 to 108 employees at September 30, 2015. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash used in operating activities was $10.8 million for the year ended December&nbsp;31, 2014 compared to $6.9 million for the year ended
December&nbsp;31, 2013. The $3.9 million increase in cash used in operating activities was primarily due to increases in to the growth in our operations, particularly in our headcount which increased from 40 employees at December&nbsp;31, 2013 to 82
employees at December&nbsp;31, 2014. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cash Flows from Investing Activities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash used in investing activities was $641,000 for the nine months ended September 30, 2015 compared to $606,000&nbsp;for the nine months ended
September 30, 2014. The increase in the cash used in investing activities between these periods is primarily due to the timing of our investment decisions, particularly with respect to the purchase of laboratory equipment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash used in investing activities was $0.6&nbsp;million for the year ended December&nbsp;31, 2014 compared to cash provided by investing
activities of $0.5 million for the year ended December&nbsp;31, 2013. The $1.2&nbsp;million decrease in cash provided by investing activities is primarily attributable to the return of approximately $0.7 million of restricted cash related to the
subsequently retired borrowing facility with a bank received in the year ended December&nbsp;31, 2013 and increased purchases of property and equipment of $0.6&nbsp;million in the year ended December&nbsp;31, 2014 compared to the year ended
December&nbsp;31, 2013. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 66 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cash Flows from Financing Activities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash provided by financing activities was $7.3 million for the nine months ended September 30, 2015 compared to $8.3 million for the nine
months ended September 30, 2014. In 2015, the cash provided by financing activities is primarily attributable to the $7.5 million in proceeds related to convertible promissory notes issued in February 2015,&nbsp;May 2015, June 2015, and July 2015
which was offset by debt issuance costs, principal payments made on capital leases, and payments made on our acquisition related liabilities due to the achievement of a sales based milestone achieved in the fourth quarter of 2014. In 2014, the $5.0
million in cash received from financing activities was due to a $5.0 million draw made under our term loan agreement in March 2014, and $4.0 million in proceeds related to convertible promissory notes issued in July 2014, which was offset by debt
issuance costs and payments made on capital leases. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash provided by financing activities was $8.3 million for the year ended
December&nbsp;31, 2014 as compared to $11.3 million for the year ended December&nbsp;31, 2013. In 2014, the $8.3 million in cash received from financing activities is primarily due to a $5.0 million draw made under our term loan agreement in March
2014 and $4.0 million in proceeds related to convertible promissory notes issued in July 2014. These proceeds were offset by $0.6 million in amounts paid to professional service providers in connection with our contemplated initial public offering.
In 2013, the $11.3 million in cash provided from financing activities is due to a $10.0 million draw made under our term loan agreement in October 2013, the issuance of $2.5 million in preferred stock and $2.4 million in convertible debt, offset by
$2.9 million in payments made on our financial liabilities, and $0.6 million in fees paid in conjunction with the issuance of our debt. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contractual
Obligations </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our contractual obligations as of September 30, 2015: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Payments Due by Period</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Less&nbsp;Than</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>1 to 3</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>3 to 5</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>More&nbsp;Than</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>1 Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>5 Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating leases<SUP STYLE="font-size:85%; vertical-align:top"> (1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">299</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capital leases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2013 Term Loan<SUP STYLE="font-size:85%; vertical-align:top"> (2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,664</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,461</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">First tranche closing of the February 2015 Notes<SUP STYLE="font-size:85%; vertical-align:top"> (3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,984</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,984</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Second tranche closing of the February 2015 Notes<SUP STYLE="font-size:85%; vertical-align:top"> (3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,098</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,098</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Third tranche closing of the February 2015 Notes<SUP STYLE="font-size:85%; vertical-align:top"> (3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">921</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">921</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">July 2015 Notes<SUP STYLE="font-size:85%; vertical-align:top"> (4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,322</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,798</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30,120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">We lease approximately 14,000 square feet of office and laboratory space in Vista, California, under a lease that expires in 2017, with options to extend the lease for two additional 36-month periods. We also lease
approximately 19,500 square feet of office space in Vista, California, under a lease that expires in 2018, with an option to extend the lease for an additional 24 month period. We also lease approximately 3,200 square feet of office space in
Albuquerque, New Mexico, under a lease that expires at the end of November 2015. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">In October 2013, we entered into our term loan agreement for an initial draw of $10.0&nbsp;million with an additional draw of $5.0 million in March 2014. Payments above include principal and interest consisting of
10%&nbsp;per annum in cash and 4%&nbsp;per annum paid in-kind in the form of additional term loans, or PIK Loans. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">In February 2015,&nbsp;May 2015 and June 2015, we issued $1.8 million, $1.9 million, and $833,000 in February 2015 Notes, respectively. Borrowings under the first, second, and third tranches of the February 2015 Notes
mature in December 2015,&nbsp;May 2016, and June 2016, respectively, and provide that a majority of holders for a given tranche may elect to extend the maturity date of that tranche by up to one additional year. All borrowings (including accrued
interest thereon) under the February 2015 Notes will automatically convert into shares of our common stock upon completion of our initial public offering. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">In July 2015 we issued $3.0 million in July 2015 Notes which mature in July 2016 and provide that a majority of holders for a given tranche may elect to extend the maturity date of that tranche by up to one additional
year. All borrowings (including accrued interest thereon) under the July 2015 Notes will automatically convert into shares of our common stock upon completion of our initial public offering. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 67 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The contractual obligations table does not include any potential contingent payments upon the
achievement by us of specified sales-based and other milestones, or royalty payments we may be required to make under license agreements we have entered into pursuant to which we have in-licensed certain intellectual property, including our license
agreements with the University of Pittsburgh, Prometheus, Orgentec and Dr.&nbsp;Dervieux. See &#147;Business&#151;Intellectual Property Overview&#151;License Agreements&#148; and Note 7 to the consolidated financial statements for additional
information. The timing of when these payments will actually be made is uncertain and the payments are contingent upon the completion of future activities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Off-Balance Sheet Arrangements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have
not entered into any off-balance sheet arrangements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Controls and Procedures </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A company&#146;s internal control over financial reporting is a process designed by, or under the supervision of, a company&#146;s principal
executive and principal financial officers, or persons performing similar functions, and effected by a company&#146;s board of directors, management and other personnel to provide reasonable assurance regarding the reliability of financial reporting
and the preparation of financial statements in accordance with generally accepted accounting principles. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any
evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with policies or procedures may deteriorate. In connection with our
preparation for this offering, we concluded that there was a material weakness in our internal control over financial reporting that caused the restatements of our previously issued financial statements as of and for the years ended
December&nbsp;31, 2012 and 2013. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of a company&#146;s annual
or interim financial statements will not be prevented or detected on a timely basis. The material weakness that we identified was that we did not maintain a sufficient complement of resources with an appropriate level of accounting knowledge,
experience and training commensurate with our company&#146;s structure and financial reporting requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the fourth quarter of
2013 and in preparation for this offering, we initiated various remediation efforts, including hiring additional resources with the appropriate public company and technical accounting expertise and have taken other actions that are more fully
described below. As such remediation efforts are still ongoing, we have concluded that the material weakness has not been remediated. Our remediation efforts to date have included the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Addition of employee resources.</I> We continue to add appropriate resources to our finance team and are leveraging external consultants to facilitate accurate and timely accounting closes and to accurately prepare
and review financial statements and related footnote disclosure. Our finance team has been expanded to include a Corporate Controller, Director of Financial Planning and Analysis, both with significant public company and life science industry
experience, a Director of Billing and external consultants with significant financial and accounting technical experience. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Other actions to strengthen the internal control environment.</I> As a result of the additional resources added to the finance function, we are allowing for separate preparation and review of the reconciliations and
other account analyses. In addition, we are implementing a new accounting software system which will allow us to strengthen certain control procedures. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a 2013 restatement was identified in September 2014, we acknowledge that additional planned remediation efforts are necessary. We plan to
provide ongoing technical accounting training to our accounting team to ensure that their knowledge of recent accounting pronouncements is current, and to supplement their existing knowledge of accounting for complex transactions, including complex
debt and equity transactions. We will continue to evaluate the competency and technical acumen of our accounting team and assess the need to hire additional or more specialized employees. Finally, we will continue to supplement our employee
resources by leveraging external consultants who have specialized experience in the life sciences industry. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The actions that have been
taken are subject to continued review, supported by confirmation and testing by management as well as audit committee oversight. While we have implemented a plan to remediate this weakness, we cannot assure you that we will be able to remediate this
weakness, which could impair our ability to accurately and timely report our financial position, results of operations or cash flows. For additional information about this material weakness, see &#147;Risk Factors&#151;Risks Related to this Offering
and the Ownership of Our Common Stock&#148;&#151;We have identified a material weakness in our internal control over financial reporting and may identify additional material weaknesses in the future that may cause us to fail to meet our reporting
obligations or result in material misstatements of our financial statements. If we fail to remediate one or more material weaknesses or if we fail to establish and maintain effective control over financial reporting, our ability to accurately report
our financial results could be adversely affected. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 68 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Quantitative and Qualitative Disclosures about Market Risk </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are exposed to market risks in the ordinary course of our business. These risks primarily relate to interest rates. We had cash and cash
equivalents of $4.6 million and $2.7 million as of December&nbsp;31, 2014 and September 30, 2015, respectively, which consist of bank deposits. Such interest-bearing instruments carry a degree of risk; however, we have not been exposed to, nor do we
anticipate being exposed to, material risks due to changes in interest rates. A hypothetical 10% change in interest rates during any of the periods presented would not have had a material impact on our consolidated financial statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>JOBS Act Accounting Election </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April
2012, the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, was signed into law. The JOBS Act contains provisions that, among other things, reduce certain reporting requirements for an &#147;emerging growth company.&#148; As an emerging
growth company, we are electing not to take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards, and as a result, we will comply with new or revised accounting standards
on the relevant dates on which adoption of such standards is required for non-emerging growth companies. Section&nbsp;107 of the JOBS Act provides that our decision not to take advantage of the extended transition period is irrevocable. In addition,
we are in the process of evaluating the benefits of relying on the other exemptions and reduced reporting requirements provided by the JOBS Act. Subject to certain conditions set forth in the JOBS Act, if as an emerging growth company we choose to
rely on such exemptions, we may not be required to, among other things, (1)&nbsp;provide an auditor&#146;s attestation report on our system of internal controls over financial reporting pursuant to Section&nbsp;404, (2)&nbsp;provide all of the
compensation disclosure that may be required of non-emerging growth public companies under the Dodd-Frank Wall Street Reform and Consumer Protection Act, (3)&nbsp;comply with any requirement that may be adopted by the Public Company Accounting
Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#146;s report providing additional information about the audit and the financial statements (auditor discussion and analysis), and (4)&nbsp;disclose certain
executive compensation-related items such as the correlation between executive compensation and performance and comparisons of the Chief Executive Officer&#146;s compensation to median employee compensation. These exemptions will apply for a period
of five years following the completion of our initial public offering or until we no longer meet the requirements of being an emerging growth company, whichever is earlier. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Accounting Pronouncements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB), or other standard setting
bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company&#146;s consolidated financial
position or results of operations upon adoption. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2013, the FASB issued ASU 2013-11, which provides for changes to the
presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. These changes require an entity to present an unrecognized tax benefit as a liability in the financial
statements if (i)&nbsp;a net operating loss carryforward, a similar tax loss, or a tax credit carryforward is not available at the reporting date under the tax law of the applicable jurisdiction to settle any additional income taxes that would
result from the disallowance of a tax position, or (ii)&nbsp;the tax law of the applicable jurisdiction does not require the entity to use, and the entity does not intend to use, the deferred tax asset to settle any additional income taxes that
would result from the disallowance of a tax position. Otherwise, an unrecognized tax benefit is required to be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or
a tax credit carryforward. These changes became effective for us on January&nbsp;1, 2014. There was no material impact to our consolidated financial statements upon adoption of this ASU. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2014, the FASB issued Accounting Standards Update (ASU) 2014-09, Revenue from Contracts with Customers, which provides a five-step
analysis of transactions to determine when and how revenue is recognized. The core principle is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to
which the entity expects to be entitled in exchange for those goods or services. This ASU is effective for annual periods beginning after December&nbsp;15, 2017 (fiscal 2018 for public companies) and shall be applied retrospectively to each period
presented or as a cumulative-effect adjustment as of the date of adoption. We are currently in the process of evaluating the impact of adoption of this ASU on the consolidated financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2014, the FASB issued ASU 2014-15, <I>Presentation of Financial Statements&#151;Going Concern</I>, which defines management&#146;s
responsibility to evaluate whether there is substantial doubt about an organization&#146;s ability to continue as a going concern and to provide related footnote disclosures. The new standard provides management with principles to evaluate whether
substantial doubt exists by (i)&nbsp;providing a definition of substantial doubt, (ii)&nbsp;requiring an evaluation every annual and interim reporting period, and (iii)&nbsp;providing principles for considering the mitigating effects of
management&#146;s plans. If substantial doubt is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 69 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
identified, the ASU requires that an organization provide enhanced disclosures about (i)&nbsp;principal conditions or events that raise substantial doubt, (ii)&nbsp;management&#146;s evaluation
of the significance of these events in relation to its ability to meet obligations, and (iii)&nbsp;management&#146;s plans that are either intended to mitigate the conditions that raise substantial doubt, or alleviate substantial doubt. The ASU is
effective for annual periods ending after December&nbsp;15, 2017 (fiscal 2018 for public companies). We do not anticipate the adoption of this standard will have a material impact on our financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2015, the FASB issued ASU 2015-03, <I>Interest&#151;Imputation of Interest&#151;Simplifying the Presentation of Debt Issuance Costs,
</I>which requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The amendment is effective
for annual periods beginning after December&nbsp;15, 2015, and shall be applied retrospectively to each period presented. We are in the process of evaluating the impact of adoption of this ASU on its consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 70 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx693329_10"></A>BUSINESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a commercial-stage
diagnostics company committed to addressing the significant unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. These chronic diseases can cause lifelong inflammation in the joints, tissues and
internal organs, resulting in serious complications, such as irreversible organ damage. Untreated chronic inflammation can also lead to premature hardening of the arteries, heart attacks and strokes. The accurate, timely and differential diagnosis
for patients suffering from the approximately 30 autoimmune rheumatic diseases, or ARDs, is critical as treatment for each disease can vary, and inappropriate or delayed therapy may expose patients to unnecessary risks or the hazards of uncontrolled
disease activity. Physicians face significant difficulties in making a definitive diagnosis of a specific ARD because patients with different diseases often present with a common set of symptoms. We currently market five products under our Avise
brand to provide an accurate, timely and differential diagnosis and to optimize the treatment of ARDs. We processed approximately 9,300 patient specimens for our lead diagnostic product line, Avise SLE, in 2013, approximately 27,900 in 2014, and
approximately 27,700 in the nine months ended September 30, 2015. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is estimated that 11&nbsp;million adults in the United States
suffer from ARDs, including Rheumatoid Arthritis, or RA, Systemic Lupus Erythematosus, or SLE, Sj&ouml;gren&#146;s syndrome, scleroderma, and Undifferentiated Connective Tissue Disease, or UCTD. In addition, patients afflicted with fibromyalgia, a
chronic neurologic disorder, and autoimmune thyroid disease have many of the same clinical symptoms as patients with ARDs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The diagnosis
and treatment of ARDs is generally provided by the community rheumatologist, a sub-specialty of internal medicine which includes approximately 3,500 physicians in the United States. Patients often present to a rheumatologist after a lengthy referral
process because of the similarity and overlap of symptoms among ARDs, the waxing and waning of these symptoms and the shortcomings of current diagnostic tests. Establishing a definitive diagnosis is often difficult and can take years. Throughout
this time, patients may continue to suffer from the debilitating effects of their disease, receive inappropriate treatments and may face a significant financial burden. As a result, physicians strive to make an accurate diagnosis in a timely manner,
especially for more serious ARDs, such as SLE, which can be life threatening. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our lead product, Avise CTD (formerly referred to as
Avise SLE + CT), is a proprietary diagnostic test that provides an enhanced solution for patients presenting with symptoms indicative of a wide variety of ARDs, such as SLE, RA, Sj&ouml;gren&#146;s, scleroderma and other disorders that mimic ARDs
such as fibromyalgia and autoimmune thyroid disease. Avise CTD allows physicians to more accurately rule-in or rule-out SLE and inform decisions about the presence of other ARDs, all with the convenience of one blood draw. Differential diagnosis of
these diseases is critically important because earlier diagnosis has been shown to improve patient outcomes. Once diagnosed, physicians can tailor therapy to a patient&#146;s specific disease and avoid the &#147;trial and error&#148; approach that
often takes place when a definitive diagnosis cannot be made. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have validated the clinical utility of Avise Lupus (formerly referred to
as Avise SLE 2.0), the proprietary component of our Avise CTD solution, in a multi-center study in an aggregate of 794 subjects, preliminary results of which were presented at the American College of Rheumatology, or ACR, annual conference in 2013.
The primary endpoint of the study was the performance characteristics, specifically sensitivity and specificity, of Avise Lupus compared to common autoantibodies used to diagnose SLE and other ARDs, such as antinuclear antibodies, or ANA, and
anti-double stranded DNA, or anti-dsDNA. The final results of this study showed that Avise CTD demonstrated 86% specificity and 80% sensitivity in distinguishing SLE from other ARDs, was 33% more specific than ANA (53% specificity/89% sensitivity)
and was 48% more sensitive than anti-dsDNA (32% sensitivity/97% specificity). Avise Lupus includes Cell Bound Complement Activation Products, or CB-CAPs, technology, which we exclusively license from the University of Pittsburgh. This technology is
the result of over a decade of extensive research and development conducted at the Lupus Center of Excellence at the University of Pittsburgh Medical Center. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have also validated the use of CB-CAPs as an effective method for diagnosing SLE in a study comparing the sensitivity of elevated CB-CAPs
to reduced serum levels of C3 and C4 in diagnosing SLE. Measuring reduced serum levels of C3 and C4 is a common method used to diagnose SLE. In fact, the Systemic Lupus International Collaborating Clinics, or SLICC, use reduced C3 and C4 as
immunologic criteria for classifying SLE. In our study, a total of 288 SLE patients meeting the ACR criteria were enrolled. Elevated CB-CAPs levels demonstrated a 22% greater sensitivity in determining SLE than reduced levels of C3 and C4. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to Avise CTD, we also offer Avise SLE Prognostic, a test that provides additional information to better manage patients diagnosed
with SLE. Specifically, our Avise SLE Prognostic report includes information regarding an SLE patient&#146;s risk of developing kidney damage, or neurologic or cardiovascular complications. We offer the Avise SLE Prognostic test, which we launched
in June 2014, to physicians as a complement to Avise CTD. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 71 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also market Avise MTX, a drug monitoring solution that provides physicians with information to
support the optimization of methotrexate, or MTX, a front-line treatment prescribed in over 70% of patients with RA. This solution has been validated prospectively in a number of studies published in peer-reviewed medical journals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also offer Avise&nbsp;HCQ, a blood test we launched in September 2014 to help physicians objectively monitor blood levels of
hydroxychloroquine, or HCQ, which is typically prescribed daily to patients to control ARD activity and prevent flares. By measuring HCQ concentration in the blood, we believe that Avise&nbsp;HCQ will help physicians optimize HCQ therapy, identify
noncompliant patients and identify patients that are not absorbing the drug adequately. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2015, we launched Avise Anti-TNF, blood
tests which help physicians measure the levels of anti-TNF bioactivity in patients with RA being treated with anti-TNF biologic therapies. By providing information regarding the potential cause of non-response to anti-TNF therapy, we believe we can
assist physicians better determine when to adjust the anti-TNF dose or switch to a different drug. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to develop additional
innovative, high value diagnostic solutions for the rheumatologist while continuing to improve the performance characteristics of our currently marketed products. In particular, we are developing and validating testing solutions that are designed to
assist rheumatologists with the monitoring of disease activity in patients with ARDs and monitoring the active drug levels of some of the more commonly prescribed pharmaceuticals used for the treatment of ARDs. We are conducting validation studies
for these products in collaboration with academic centers of excellence and intend to publish the results of these studies in peer-reviewed medical journals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is estimated that over 14&nbsp;million people in the United States have been diagnosed with ARDs, fibromyalgia and autoimmune thyroid
disease, with approximately 470,000 diagnosed annually. Additionally, in the United States, over one million patients annually are prescribed MTX therapy, and over 700,000 patients annually are prescribed HCQ therapy. In addition, over 250,000 RA
patients are prescribed anti-TNF therapy. We estimate the market potential of our existing products to be as much as $840 million annually, based on our internal research and analysis utilizing these incidence and prevalence rates, the prescription
information of pharmaceuticals for our drug monitoring products and the current Medicare allowable reimbursement rates for our products ($590 for Avise CTD and $25 for each of Avise MTX and Avise HCQ, and $185 for anti-TNF). We estimate that
patients will receive, on average, a monitoring test one to one-and-a-half times per year for our drug monitoring products. Because these calculations are based on internal estimates and assume rates of reimbursement that may change, there is no
guarantee that these assumptions will prove to be accurate and consequently, our actual market potential may not be as large as we expect. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our
Strategy </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our goal is to establish ourselves as the preeminent provider of testing solutions to rheumatologists by offering a
comprehensive set of tools to effectively diagnose and optimize the treatment of patients with ARDs. To achieve this objective, we intend to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Accelerate the adoption of our existing products.</I> We plan to expand the use of our Avise product suite by adding new physicians to our customer base as well as increasing utilization among our existing customers.
We have recently increased our specialty sales force and expect to selectively add more sales representatives to extend our reach and frequency of engagement with community rheumatologists. In addition, we are conducting medical education seminars
for physicians through our community speaker programs, where national and regional thought leaders present information regarding the clinical utility of our products. We will continue to heighten awareness by seeking exhibit and speaker sponsorship
opportunities at leading rheumatology medical conferences. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Further demonstrate the clinical utility of our products to drive adoption and support reimbursement.</I> We are conducting additional clinical studies to facilitate the adoption of our testing solutions. We plan to
continue to present the results of our studies at national scientific meetings and publish results in peer-reviewed medical journals. We plan to use data from our ongoing trials combined with existing data and our core expertise in managed care,
claims adjudication and billing to drive broader access and support reimbursement. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Expand our portfolio of high value testing solutions.</I> We are continuing to develop additional products to address the significant challenges in the diagnosis, prognosis and monitoring of patients with ARDs, by
leveraging the CB-CAPs and iLite technology platforms. We believe that by providing a broader set of innovative solutions, we can enhance our value proposition to rheumatologists. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Establish ourselves as the trusted partner to the rheumatologist.</I> We intend to continue to build upon our relationship with the rheumatology community. Our reputation with our physician customers is built on
their confidence in the quality of our testing solutions, the timely delivery of our test reports and the value of our consultative support. Our laboratory reports deliver critical information in a form that is optimized for the physician&#146;s
ease of use. We will also explore opportunities for physicians to access our extensive database of test results. We believe that these measures will position us as a trusted partner to our physician customers and allow us to leverage the resources
and infrastructure that we have dedicated to these customers. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 72 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Engage in partnerships to access additional market opportunities.</I> We believe there is meaningful potential for our current and future products beyond the rheumatology specialty, particularly for those physician
groups that see patients earlier in the diagnostic process. We intend to selectively seek complementary partnerships to address these broader markets. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Autoimmune Rheumatic Diseases </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ARDs are a
group of serious, chronic and debilitating autoimmune diseases involving inflammation of the joints, tissues and internal organs. There are approximately 30 ARDs, many of which have overlapping symptoms. Additionally, other rheumatic disorders such
as autoimmune thyroid disease and those that are not autoimmune in nature, such as fibromyalgia, can present similar symptoms. It is estimated that 11&nbsp;million patients in the United States suffer from ARDs, including RA, SLE,
Sj&ouml;gren&#146;s syndrome, scleroderma and UCTD, and as many as 30&nbsp;million patients may be afflicted with fibromyalgia or autoimmune thyroid disease. These diseases create a significant burden on the healthcare system, due in part to the
difficulty in obtaining a differential diagnosis. These chronic diseases can cause lifelong inflammation in the joints, tissues and internal organs, resulting in serious complications, such as irreversible organ damage. Untreated chronic
inflammation can also lead to premature hardening of the arteries, heart attacks and strokes. Due to the overlapping symptoms, unpredictable periods of disease flares and disease inactivity, patients may cycle from physician to physician for months
or even years before receiving a definitive diagnosis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ARDs and other rheumatic conditions that may be confused in diagnosis include
the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Systemic Lupus Erythematosus (SLE).</I> A chronic autoimmune disease involving inflammation and destruction of organs such as the brain, kidneys and lungs resulting in irreversible damage and in severe cases death.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Rheumatoid Arthritis (RA).</I> A chronic autoimmune disease involving inflammation and destruction of joints, bone and in some cases organs, including eyes and lungs. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Sj&ouml;gren&#146;s Syndrome.</I> A chronic autoimmune disease involving inflammation and destruction of secretory glands such as salivary glands and tear ducts. This disease can occur with RA and SLE.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Scleroderma.</I> A chronic autoimmune disease involving scar tissue build-up in tissues, such as the skin or, in more serious cases, muscles, blood vessels and internal organs. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Undifferentiated Connective Tissue Disease (UCTD).</I> A condition where patients have symptoms and certain laboratory test results that might indicate an ARD but do not satisfy the criteria for a definitive
diagnosis. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Fibromyalgia.</I> A chronic condition characterized by wide-spread pain and tenderness to touch. Although not an autoimmune disease, this disease has been reported to occur in 25% of RA patients, 30% of SLE patients
and 50% of Sj&ouml;gren&#146;s patients. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Autoimmune Thyroid Disease</I>. A chronic autoimmune disease that results in antibodies causing decreased thyroid hormone production, or hypothyroidism, or increased thyroid hormone production, or hyperthyroidism.
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patients with these disorders often present with a common set of symptoms, which can include joint pain, fatigue,
inflammation, stiffness and muscle aches, among others. Additionally, these patients may experience unpredictable periods of disease flares and disease inactivity, which can meaningfully change the patients&#146; symptoms and how they present to the
physician. The combination of overlapping symptoms and disease biology can lead these patients to cycle from physician to physician for months or even years before receiving a definitive diagnosis. Due to this, we believe physicians are in critical
need of objective tests capable of differentially diagnosing these disorders, especially for more potentially life threatening ARDs, such as SLE. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The primary goal in the treatment of ARDs is suppressing disease activity in order to prevent tissue or bone destruction and/or organ damage.
Powerful drugs that suppress the immune system are utilized to minimize the inflammatory process caused by autoantibodies. In RA, these drugs are referred to as Disease-Modifying Anti-Rheumatic Drugs, or DMARDs, because in clinical studies they have
demonstrated the ability to change the natural course of ARDs if utilized effectively. Optimization of DMARDs requires physicians to closely monitor disease activity on an ongoing basis and adjust exposure to active drug to achieve and maintain
disease control. We believe drug monitoring tools allow for the personalization and optimization of biological DMARD therapy which will improve clinical and economic outcomes. DMARDs commonly used by rheumatologists to treat ARDs are: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Methotrexate (MTX)</I>&#151;MTX is one of the most widely used drugs to treat RA. It is estimated that over one&nbsp;million patients annually are prescribed MTX in the United States and over 70% of RA patients
receive this drug. Physicians typically start patients on MTX, but because approximately 40% of patients do not respond adequately, other DMARDs are often added. This variability in effectiveness of MTX can be caused by variable absorption,
metabolism and excretion of the drug. Patient compliance may also be an issue with MTX. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 73 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Hydroxychloroquine (HCQ)</I>&#151;HCQ is one of the most widely used drugs in SLE and RA. It is estimated that over 700,000 patients annually are prescribed HCQ therapy in the United States. HCQ is used in SLE to
control disease activity or flares. HCQ is also regarded as a DMARD and is commonly used in combination with MTX to treat RA. Patient compliance issues with HCQ can lead to loss of disease control in both RA and SLE. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Anti-Tumor Necrosis Factor Alpha (Anti-TNF)</I>&#151;Anti-TNF drugs are biological DMARDs and are regarded as one of the most effective classes of agents for the treatment of RA. In RA alone, it is estimated that
over 250,000 patients in the United States are prescribed anti-TNF therapy annually. In most cases, anti-TNF drugs are used in combination with MTX. The most widely prescribed anti-TNF drugs are etanercept (marketed as Enbrel), adalimumab (marketed
as Humira) and infliximab (marketed as Remicade). These treatments cost approximately $20,000 per patient per year. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Systemic Lupus
Erythematosus </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Overview </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is
estimated that over one million people in the United States suffer from some form of lupus. SLE, the most common and serious form of lupus, is a chronic, inflammatory disorder that can damage any part of the body, including the skin, joints and
internal organs. SLE varies in severity, from mild cases to those in which significant and potentially fatal damage occurs to vital organs such as the brain, heart, kidneys and lungs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SLE is characterized by unpredictable, intermittent increases and decreases of disease activity, or flares, with a rise in symptoms and/or
abnormal laboratory test values. The blood of a person afflicted with SLE contains autoantibodies, which are the cause of the inflammation and organ damage, and are one indicator of immune system abnormalities. Earlier diagnosis of SLE allows
physicians to initiate the most appropriate therapy sooner in order to minimize organ damage. An independent study funded by GlaxoSmithKline plc and published in a peer-reviewed medical journal concluded that early diagnosis of SLE is associated
with better clinical outcomes, including lower flare rates, as well as reduced resource utilization and healthcare costs. However, on average it takes nearly six years to be diagnosed and more than half of those afflicted with lupus saw four or more
healthcare providers before obtaining a correct diagnosis, according to a Lupus Foundation of America survey. Patients with delayed or undiagnosed SLE will often continue to experience disease activity, potentially leading to irreversible tissue or
organ damage. Conversely, patients incorrectly diagnosed with SLE may be unnecessarily prescribed potentially toxic and harmful medications, such as high dose corticosteroids, and often undergo unnecessary referrals and laboratory tests. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SLE is most common in women and usually develops during childbearing years, but men and children can also develop the disease. The cause of
SLE is unknown and, while it is more common in people who have a first-degree relative with SLE, most cases of SLE occur episodically, indicating that both genetic and environmental factors may play a role in disease development. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Diagnosis </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Diagnosing SLE is difficult
due to the fluctuating nature of the disease and overlapping symptoms with other ARDs, fibromyalgia and autoimmune thyroid disease. Compounding this issue, the current immunological tests used to diagnose SLE lack balanced sensitivity and
specificity. The ACR and the Systemic Lupus International Collaborating Clinics, or SLICC, have developed patient classification criteria for clinical trials that are used to support an SLE diagnosis. These criteria, which were created as a
classification tool for clinical studies rather than a diagnostic tool, are difficult to apply in practice due to SLE symptoms that evolve, change, disappear and reappear over time. Many SLE patients do not meet the ACR criteria necessary for SLE
classification at initial disease presentation and may not meet the criteria for months or even years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Standard laboratory tests for
diagnosing SLE include measuring immunological biomarkers, such as ANA or anti-dsDNA, and other autoantibody tests. ANA is a useful screening tool for ARDs in general, including SLE, and the vast majority of SLE patients test positive for ANA.
However, the good sensitivity of ANA for SLE is counterbalanced by somewhat poor specificity. For instance, an analysis of serum samples from 4,754 people aged 12 or older in the National Health and Nutrition Examination Survey taken from 1999-2004
found that 13.8% of these patients tested positive for ANA. The diagnosis of ARDs such as lupus was not determined as part of this study. If this rate was applied generally to the U.S. population over the age of 12, an estimated 32&nbsp;million
Americans would test positive for ANA, but the vast majority of these individuals would not have SLE, as only approximately 11-13% of individuals with a positive ANA test have SLE. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patients who test positive for anti-dsDNA are likely to have SLE, as anti-dsDNA is relatively specific for that disease. However, most
patients with SLE do not have a positive anti-dsDNA test result. Thus, the diagnosis of SLE can be missed if the physician is relying on the presence of a positive anti-dsDNA test. For instance, in our validation study for Avise Lupus, the second
generation of our integrated algorithmic test, 68% of patients with SLE tested negative for anti-dsDNA and would have not been diagnosed with SLE based on the anti-dsDNA test. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 74 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In a published study involving 476 patients, there was less than 50% agreement between the
diagnosis of the referring physician and the final diagnosis by an autoimmune sub-specialist. In the study, 27% of patients referred by a rheumatologist with an initial diagnosis of SLE were found to be misdiagnosed. Moreover, 29% of the patients in
the study with presumptive SLE diagnoses tested positive for ANA, but did not have an ARD. In addition, 39 patients who were positive for ANA but had no ARD were inappropriately treated with corticosteroids at doses as high as 60 mg per day. We
believe the drawbacks with ANA and anti-dsDNA testing contribute to the diagnostic challenges faced by physicians in definitively diagnosing SLE. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Physicians also measure components of the complement system, including serum levels of C3 and C4, to help diagnose SLE and monitor SLE disease
activity. In active SLE, C3 and C4 complement proteins are activated and broken down to fragments, known as complement activation products. Therefore, low levels of C3 and C4 suggest diagnosis of SLE and that the disease is active. However,
variability in the levels of C3 and C4 can occur due to factors unrelated to SLE disease presence or disease activity, making them less reliable as biomarkers for SLE. For example, deficiencies of C4 may occur in SLE patients due to lower natural
production of the C4 protein on a genetic basis, obscuring the impact of the disease on C4 levels. Furthermore, as with anti-dsDNA antibodies, many SLE patients have normal complement levels even when the disease is active. Although relatively
specific for SLE, low complement levels can also be seen in certain chronic infections, including non-lupus related kidney inflammation, severe liver disease and other ARDs. Despite these shortcomings, in 2012 the SLICC added low C3 and low C4 as
immunologic criteria for classifying SLE. The limitations of these tests for SLE diagnosis and the need for additional and better SLE biomarkers are generally recognized by the rheumatology community. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Treatment </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once diagnosed, treatment of
SLE generally involves the use of antimalarials, corticosteroids, immunosuppressants, and newer biologic agents to prevent or suppress active disease or flares. During acute periods of more severe disease flares, physicians use corticosteroids at
high doses to control the autoimmune response and inflammation. While often effective at controlling disease, long-term use of these powerful agents can have serious, wide-ranging and long-term adverse effects, such as diabetes, osteoporosis and
high blood pressure. Due to the unpredictability of disease flares, there is a significant need for frequent monitoring of disease activity to guide therapeutic choices and optimize drug effectiveness. Even in patients who are appropriately
diagnosed, monitoring disease activity is imperfect because of the lack of accurate biomarkers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Large biopharmaceutical companies are
seeking to develop and commercialize new biologic therapies for SLE. In March 2011, the first new biologic drug targeting treatment of SLE in over 50&nbsp;years, Benlysta, was approved by the U.S. Food and Drug Administration, or FDA. Additionally,
four biologic therapies are currently in phase&nbsp;III clinical trials for SLE or Lupus Nephritis, a serious and common complication of SLE. We believe the significant investment made by the companies seeking to develop and commercialize these
therapies will result in a dramatic increase in the awareness and understanding of SLE, and that our products and our strategy of focusing on the rheumatologist and ARDs will benefit from this increased awareness and understanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Due in part to the over and under diagnosis of SLE and the lack of tools to effectively monitor disease flares, treatment and management of
SLE remains suboptimal. Patients misdiagnosed with SLE may be unnecessarily prescribed potentially toxic and harmful medications and often undergo unnecessary referrals and laboratory tests. In addition, patients with a delayed or missed diagnosis
of SLE may continue to experience disease progression potentially leading to serious tissue or irreversible organ damage, such as renal failure or pulmonary fibrosis that could otherwise have been prevented with a prompt and correct initial
diagnosis and treatment. Physicians and patients are in need of improved, objective testing solutions to help with the diagnosis, prognosis and monitoring of patients with SLE. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Solution </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are committed to
providing physicians with products that address the significant unmet need for accurate and timely diagnosis, prognosis and monitoring of ARDs. We market five products under our Avise brand, which facilitate the accurate, timely and differential
diagnosis and prognosis of certain ARDs and drug-level monitoring of one of the most widely prescribed pharmaceuticals in rheumatology. These tests are designed to seamlessly integrate with a rheumatologist&#146;s daily workflow and all of our tests
are processed in our laboratory in California, which is certified under the Clinical Laboratory Improvement Amendments of 1988, or CLIA and accredited by the College of American Pathologists, or CAP. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 75 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our differentiated product offering includes: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="23%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="19%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Diagnosis</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Prognosis</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Monitoring</B></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">


<IMG SRC="g693329g34j21.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">


<IMG SRC="g693329dsp_084b.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">


<IMG SRC="g693329dsp_084c.jpg" ALT="LOGO">
&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">


<IMG SRC="g693329dsp_084d.jpg" ALT="LOGO">
&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">


<IMG SRC="g693329dsp_084e.jpg" ALT="LOGO">
&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Diagnostic test incorporating our proprietary CB-CAPs technology to rule-in or rule-out SLE from other ARDs</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Comprehensive SLE&nbsp;prognostic panel to assist in determining&nbsp;risk for kidney damage or</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">neurologic or</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">cardiovascular</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">complications associated with SLE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Test to monitor levels<BR>of active<BR>methotrexate, a first-<BR>line therapy for&nbsp;RA</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Blood test to monitor<BR>levels of HCQ, a<BR>commonly prescribed<BR>treatment for patients<BR>with SLE and other<BR>ARDs</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Blood&nbsp;test&nbsp;to&nbsp;measure<BR>anti-TNF active drug<BR>levels and drug<BR>neutralizing&nbsp;antibody<BR>activity&nbsp;levels for<BR>infliximab&nbsp;and<BR>adalimumab,&nbsp;two
of<BR>the&nbsp;most&nbsp;commonly<BR>used&nbsp;anti-TNF<BR>biologic&nbsp;therapies&nbsp;for<BR>RA.</TD></TR>
</TABLE>   <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Avise CTD </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Overview </I></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our lead product, which we
market under our Avise CTD brand, is a proprietary diagnostic test that provides an enhanced solution for patients presenting with symptoms indicative of a wide variety of ARDs such as SLE, RA, Sj&ouml;gren&#146;s, scleroderma and other disorders
with similar symptoms, such as fibromyalgia and autoimmune thyroid disease. Avise CTD allows physicians to more accurately rule-in or rule-out SLE, and inform decisions about the presence of other ARDs. Differential diagnosis of these diseases is
critically important because earlier diagnosis has been shown to improve patient outcomes. Once diagnosed, physicians can tailor therapy to a patient&#146;s specific disease and avoid the &#147;trial and error&#148; approach that often takes place
when a definitive diagnosis cannot be made. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Avise CTD is comprised of our proprietary Avise Lupus solution and other established
biomarkers to diagnose ARDs. Avise Lupus is a ten-marker panel test that includes two biomarkers based on our CB-CAPs technology, which we exclusively license from the University of Pittsburgh, and a proprietary algorithm to optimize its
performance. CB-CAPs are relatively stable biomarkers found in the blood that are associated with the presence and activity of SLE. CB-CAPs, measured by flow cytometry, drive superior performance of our solution versus existing standards of
diagnosis, including ANA and anti-dsDNA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We launched Avise Lupus in January 2012, following the completion of our CAPITAL study, which
was published in <I>Arthritis and Rheumatism</I> in 2012. Avise Lupus incorporated our CB-CAPs technology with three existing autoantibodies, ANA, anti-dsDNA and anti-mutated citrullinated vimentin, or anti-MCV, to produce a proprietary five-marker
SLE diagnostic with an enhanced ability to distinguish SLE from selected ARDs, such as RA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2012 we launched Avise CTD, which
added additional established autoantibodies for assisting in the diagnosis of a broader set of ARDs to our proprietary Avise Lupus solution. We developed this offering to enhance the clinical utility of our test and respond to our customer&#146;s
need for a more comprehensive solution to assist in differentially diagnosing ARDs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We launched the second generation of our integrated
algorithmic test, Avise CTD, in February 2014, by integrating five additional autoantibodies into the algorithm of Avise Lupus, resulting in a ten-marker proprietary test. This test further improves the ability to distinguish SLE from other ARDs,
including RA, scleroderma, Sj&ouml;gren&#146;s and polymyositis/dermatomyositis. Similar to our previous version, we added a panel of autoantibodies to Avise Lupus, including extractable nuclear antigens, anti-phospholipid syndrome, RA and thyroid
autoantibodies for the detection of autoimmune thyroid disease. We market this improved second generation test as Avise CTD. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Physicians
are able to order our Avise Lupus or our Avise CTD solution. We believe physicians prefer our comprehensive panel to help diagnose a broader set of ARDs, as well as the associated convenience for patients of a single blood draw. This is evidenced by
Avise CTD representing over 90% of our currently-marketed Avise Lupus diagnostic products ordered in 2014 and in the first half of 2015. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 76 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Test Report </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We provide the results of our Avise SLE diagnostic products to physicians typically within five business days following receipt from the
physician of the blood draw from a patient. Our test&#146;s ability to provide accurate and timely information on a broad range of ARDs is convenient for both physicians and their patients. The results are provided to physicians in an intuitive,
easy to understand report. A sample of an Avise CTD report is shown below: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="position:relative;float:left; width:48%;padding-right:1%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">
  <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g693329tx_pg078a.jpg" ALT="LOGO">
 </P> </DIV><DIV STYLE="position:relative;float:left; margin-left:2%; width:48%;padding-right:1%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">
  <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g693329tx_pg078b.jpg" ALT="LOGO">
 </P> </DIV><div style="clear:both; height:0pt; font-size:0pt">&nbsp;</div>
 <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Commercial Performance </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have demonstrated significant growth in demand for our Avise SLE diagnostic products. For example, in the nine months ended September 30,
2015, orders for our Avise SLE diagnostic products increased 43% over the same period in the prior year. Annual orders for Avise SLE diagnostic products increased from 9,300 in 2013 to 27,900 in 2014, an increase of 200%. Our quarterly test volume
for our Avise SLE diagnostic products was 1,235, 2,129, 2,601 and 3,301 for the first, second, third and fourth quarters of 2013, respectively, 4,494, 6,579, 8,367 and 8,502 for the first, second, third and fourth quarters of 2014, respectively and
8,040, 9,876, and 9,806 for the first, second, and third quarters of 2015, respectively. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have experienced growth in both the number of
physicians utilizing our tests and the number of tests ordered per physician. Each physician ordered an average of approximately 16 tests per quarter in the quarter ended September 30, 2015, as compared to an average of approximately
15&nbsp;tests&nbsp;per quarter in the quarter ended September 30, 2014. Additionally, the number of physicians who order more than 10 tests from us per quarter has increased from 180 during the quarter ended September 30, 2014, to 227 during the
quarter ended September 30, 2015, and the number of physicians who re-order our tests has remained relatively stable at more than 75%. We believe this strong demand is a reflection of the value proposition we are providing to our physician customers
and represents the market need for an enhanced solution to differentially diagnose ARDs. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Clinical Validation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We validated Avise Lupus in a multi-center clinical study involving 794 subjects comprised of 304 SLE patients, 285 patients with other ARDs
and fibromyalgia, and 205 normal healthy subjects from two cohorts. The study was conducted in collaboration with leading academic centers with expertise in SLE and other ARDs, including Albert Einstein College of Medicine, Northwestern University,
North Shore-LIJ Health System and NYU College of Medicine, and the preliminary results were presented at the ACR annual conference in 2013. The primary endpoint of the study was the performance characteristics, specifically sensitivity and
specificity, of Avise Lupus compared to common autoantibodies used to diagnose SLE and other ARDs, such as ANA and anti-dsDNA. Sensitivity measures the proportion of patients who are correctly identified as having a particular condition, while
specificity measures the proportion of patients who are correctly identified as not having a particular condition. The final results of this study showed that Avise Lupus: </P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">demonstrated 86% specificity and 80% sensitivity in distinguishing SLE from other ARDs and fibromyalgia; </TD></TR></TABLE> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">was 33% more specific than ANA (53% specificity/89% sensitivity); and </TD></TR></TABLE> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">was 48% more sensitive than anti-dsDNA (32% sensitivity/97% specificity). </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 77 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This data suggests that Avise Lupus ruled-in SLE effectively, allowing for greater confidence
in diagnosing the disease. The superior performance of Avise Lupus over ANA and anti-dsDNA in this study is further demonstrated on the Receiver Operating Characteristic, or ROC, curve below. Each point on the ROC curve illustrates a possible
combined sensitivity and specificity. On a ROC curve, an ideal test (100% specific and 100% sensitive) would begin in the lower left corner, go straight to the upper left corner, then to the upper right corner, and the area under the curve, or AUC,
would be 1.0. On the other hand, a test without predictive value would be a straight diagonal line from the lower left corner to the upper right corner, with an AUC of 0.5. The superior performance of Avise Lupus compared to ANA and anti-dsDNA alone
is highlighted in the diagram below. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g693329dsp_086.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ROC curve also indicates the superior performance of Avise Lupus compared to Anti-Smith&#146;s
antibody, or Anti-Sm, another common biomarker for SLE due to its high specificity (greater than 99%). However, like anti-dsDNA, Anti-Sm has low sensitivity and is found in only approximately 20% of patients with SLE. In our validation studies for
Avise Lupus, Anti-Sm was 14% sensitive and 100% specific for SLE. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Ongoing Clinical Studies </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of our ongoing efforts to further validate and establish Avise Lupus as the leading diagnostic solution for ARDs, we have initiated
additional studies that will expand the clinical validity of our solution. For example, we have a collaboration with Columbia University on a study to further support the clinical utility of CB-CAPs for the pediatric onset of SLE. We also conducted
a study with a leading fibromyalgia expert to further establish the clinical utility of Avise Lupus in distinguishing SLE from fibromyalgia, a common affliction with overlapping symptoms to ARDs. Both studies have been accepted for podium
presentations at the 2015 annual meeting of the ACR. In addition, we are currently designing a prospective study to establish the clinical utility of CB-CAPs in clinical practice. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Avise SLE Prognostic </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Avise
SLE Prognostic, which was launched in June 2014, is a blood test that complements Avise CTD by providing results which inform the prognosis of SLE patients and provide physicians with more information to tailor treatment for their patients. This
test is a ten-marker panel of autoantibodies that have established predictive value for assessing the potential for complications affecting the kidney, brain and cardiovascular system, including lupus nephritis, lupus psychosis, and thrombosis or
blood clots. When physicians are ordering Avise CTD, they can also request that we perform our Avise SLE Prognostic test if the initial Avise CTD result suggests that the patient has SLE. This provides additional convenience for ordering physicians
and their patients. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 78 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Avise MTX </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Avise MTX is the first therapeutic drug monitoring test to precisely measure levels of methotrexate polyglutamates, or MTXPG, the active form
of MTX in the patient&#146;s blood. MTX is a first-line therapy for RA, and Avise MTX can allow physicians to personalize therapy by targeting the appropriate dose to individual patients. There is large variability in the way patients absorb and
metabolize MTX, and several studies have shown that low levels of MTXPG in the blood correlate with a lower response to MTX therapy. Avise MTX provides crucial information as to whether a patient has achieved MTXPG blood levels consistent with an
appropriate response to MTX, also known as the therapeutic level, or if the MTXPG levels are too low to produce adequate effects, which is known as the sub therapeutic level. The physician can then adjust MTX dosing as necessary to maximize the
benefit of MTX therapy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The clinical validity and utility of Avise MTX has been established in numerous independent studies. In a pivotal
study published in peer-reviewed medical journals and sponsored by Prometheus Laboratories, our licensor and the original developer of the MTXPG technology, 258 patients with RA were treated with MTX. The study demonstrated that patients who
achieved MTXPG levels above 60 nanomoles per liter of red blood cells were five times more likely to respond adequately to MTX than patients who presented with MTXPG levels below 60 nanomoles per liter. Two other independent studies enrolling 500
patients in the aggregate also demonstrated the validity of MTXPG measurement as a drug monitoring solution in RA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Avise HCQ </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Avise HCQ is a blood test to help physicians objectively monitor blood levels of HCQ as they treat patients with SLE and other ARDs, including
RA. HCQ is typically prescribed daily to patients to control ARD activity and prevent flares. However, there is a large variability in the response to HCQ therapy, and patients can be poorly compliant. In order to optimize HCQ therapy, it is crucial
to determine if the patient is taking the drug as prescribed, and also to determine whether the blood levels are adequate and consistent with clinical efficacy. By measuring HCQ concentration in the blood, we believe that Avise HCQ will help
physicians optimize HCQ therapy, identify noncompliant patients and identify patients that are not absorbing the drug adequately. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
launched our Avise HCQ drug monitoring solution in September 2014. By offering Avise HCQ along with our currently marketed Avise MTX test, we now address two drugs commonly prescribed by rheumatologists. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are collaborating with leading academic centers, including Johns Hopkins University, to conduct a clinical study to generate support for
the utility of our test. This study, which is expected to enroll 50 subjects, is designed to evaluate the value of monitoring MTXPG and HCQ in the treatment of patients with SLE. The HCQ assay performance characteristics are supported by multiple
peer-reviewed medical journals, which established that HCQ levels in the blood correlate with disease control in SLE and RA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Avise Anti-TNF
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We launched our Avise Anti-TNF blood test in April 2015. This test helps physicians measure the levels of anti-TNF bioactivity in
patients with RA being treated with adalimumab (marketed as Humira<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>) and infliximab (marketed as Remicade<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>). Both Humira and Remicade
belong to a class of biologic therapies that inhibit tumor necrosis factor alpha, or TNF-<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT>. Anti-TNF biologics are estimated to generate more than $5 billion in annual sales in the United States for RA
and are used in an estimated 250,000 RA patients. However, approximately 30% of patients either do not respond at all or have insufficient responses to these therapies. The lack of response can be due to refractoriness to the mechanism of action of
the drug itself, referred to as TNF blockade, or the development of drug neutralizing antibodies. By providing information regarding the potential cause of non-response to anti-TNF therapy, we believe we can assist physicians in better determining
when to adjust the anti-TNF dose or switch to a different drug. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also believe that we will provide additional value to rheumatologists
by offering our Avise Anti-TNF along with our Avise MTX test because MTX, which is commonly prescribed with anti-TNF biologics, is effective at improving anti-TNF efficacy. Avise Anti-TNF incorporates iLite technology, the only commercially
available cell-based assay that measures anti-TNF levels and drug neutralizing antibodies. Avise Anti-TNF uses TNF-<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT>-sensitive cells in a bioassay that measures
TNF-<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> activity. The key advantage of the iLite technology compared to other currently available anti-TNF monitoring tests is that it measures functional levels of anti-TNF bioactivity. In addition, the
iLite technology determines the presence of antidrug antibodies. The FDA has released guidance indicating that cell-based assays are the preferred technology platform for determining immunogenicity for therapeutic proteins. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 79 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Pipeline </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are focused on delivering meaningful solutions to aid rheumatologists in the diagnosis of patients with ARDs and providing physicians with
additional tools to determine the most appropriate therapy over time to improve patient care. Our pipeline includes solutions that differentially diagnose ARDs, provide prognosis of ARDs and monitor disease activity and active drug levels. We
continue to leverage the value of our CB-CAPs technology platform as it relates to management of ARDs and also the management of diseases involving activation of the complement pathway, a complex network of over 30 soluble and membrane bound
proteins that interact in a highly regulated manner to provide many of the effector functions of immunity and inflammation. Moreover, we are exploring the utility of our CB-CAPs platform in the monitoring of SLE disease and antibody mediated
transplantation. We are also planning to leverage the iLite and MTXPG technology platforms in the monitoring of disease activity in RA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sales and
Marketing </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We target the approximately 3,500 community rheumatologists in the United States. We launched Avise Lupus in January
2012 with a nine-person sales force. In the fourth quarter of 2013, we began the expansion of our sales team to approximately 30&nbsp;sales professionals. This expansion was mostly completed by the end of the first quarter of 2014. Our sales
professionals generally have experience in healthcare sales with backgrounds in rheumatology, therapeutics, and/or laboratory services. Our sales professionals are divided into three regions of the United States, East, Southeast and West, which are
each led by a dedicated regional director. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our sales force has a focused approach that emphasizes execution in three core areas:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Targeting</I>. We utilize market analytics, demographic data and pharmaceutical and historical diagnostic test usage to create the most effective territories for us to target community rheumatologists.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Messaging.</I> We emphasize increased accuracy over current standard of care methodologies, which is achieved through the proprietary components of our Avise products. In addition, we offer timely results along with
the convenience of one blood draw and a transportation kit that we provide to customers. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Frequency.</I> We execute a high-frequency calling strategy for key physician targets and their office personnel. We believe that repetition builds knowledge, understanding and retention of the benefits of our Avise
product suite. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We employ multi-faceted marketing programs to educate and inform physicians, patients and other key
stakeholders of the value of our solutions in order to facilitate adoption. We primarily achieve this through advertising, promotion, social media, working with key opinion leaders at national and regional clinical conventions focused on ARDs and
continuing medical education programs. In these settings, academic and community physicians can educate their peers on the benefits of Avise products and provide personal testimony of the value they have received from using our Avise products. We
participate with patient advocacy organizations, such as the Lupus Foundation of America, and medical societies, such as the ACR, directly through support of their meetings, medical conferences, and direct educational efforts. Finally, our website
provides educational material for healthcare professionals, payers and patients. We intend to expand the scale and scope of our marketing programs to target internet marketing, patient awareness and educational programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we have a centralized, dedicated client services department that augments our sales force and marketing activity by providing
personalized customer support. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our sales strategy is focused on achieving sustainable long-term growth of our market share for products
addressing ARDs. Specifically, we intend to grow our market share by: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">increasing the number of physicians that order our tests; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">increasing the number of tests ordered by each physician; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">increasing the number of products offered to each physician. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Reimbursement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Reimbursement for our testing services comes from several sources, including commercial third-party payers, government payers and patients. We
bill for testing procedures using common Current Procedural Terminology, or CPT, codes that describe the procedures performed in the lab for our Avise SLE diagnostic products, Avise SLE Prognostic, Avise MTX and Avise HCQ. We have received a
positive Local Coverage Determination for Avise MTX from Palmetto GBA, the then-Medicare contractor for California, which became effective in April 2012 and was subsequently adopted by Noridian, our current Medicare Administrative Contractor. In
2014, we have received payments from major payer organizations such as Aetna, Anthem Blue Cross/Blue Shield, Blue Shield, Cigna, Managed Medicaid, Medicare, Medicare Advantage and United Healthcare, along with additional commercial
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 80 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
carriers and patients; however, we do not have contracts with any significant large private payers, with the exception of Blue Cross Blue Shield in Illinois. In addition, recently, several Blue
Cross Blue Shield plans and Aetna, issued non-coverage policies with respect to Avise Lupus, determining that Avise Lupus does not meet the medical criteria for coverage and is considered investigational. If we are not successful in reversing
existing non-coverage policies, or if other third-party payors issue similar policies, this could have a material adverse effect on our business and operations. </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even though we are currently being reimbursed for our tests by many payors, continued reimbursement depends on a number of factors, including
payer determination that our tests are medically necessary, appropriate for the patient, cost effective and clinically valid. In addition, our commercial success depends on payers agreeing to pay for new tests we launch. If we are unable to obtain
or maintain coverage and adequate reimbursement from third-party payers for our existing tests or new tests, our ability to generate revenue may be limited. In addition, we have in the past and will likely in the future experience delays and
temporary interruptions in the receipt of payments from government and other third-party payers due to changes in their internal processes, which could cause our revenues to fluctuate from period to period. </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Protecting Access to Medicare Act of 2014, or PAMA, which was signed into law on April&nbsp;1, 2014, significantly alters the current
payment methodology under the Medicare Clinical Laboratory Fee Schedule, or CLFS. Under PAMA, beginning January&nbsp;1, 2016, clinical laboratories must report laboratory test payment data for each Medicare-covered clinical diagnostic lab test that
it furnishes during a time period to be defined by future regulations. The reported data must include the payment rate (reflecting all discounts, rebates, coupons and other price concessions) and the volume of each test that was paid by each private
payer (including health insurance issuers, group health plans, Medicare Advantage plans and Medicaid managed care organizations). We completed our sample report to comply with the initial timeline and data requirements. Beginning in 2017, the
Medicare payment rate for each clinical diagnostic lab test will be equal to the weighted median amount for the test from the most recent data collection period. In the third quarter of 2015, CMS released the proposed rule governing the Medicare
Clinical Diagnostic Laboratory Test Payment System under PAMA. This proposed rule clarified the methodology by which future reimbursement rates on the CLFS would be calculated. If the proposed rule is implemented as proposed, any significant
reductions in reimbursement would be phased-in, as CMS would limit the maximum reimbursement reduction for a test to an annual reduction of up to 10% for each year beginning January 1, 2017, 2018, 2019, and not greater than 15% for each year
beginning January 1, 2020, 2021 and 2022. Under the proposed rule, CMS is required to adopt temporary billing codes to identify new clinical diagnostic laboratory tests, or CDLTs, and new advanced diagnostic laboratory tests, or ADLTs, that do not
already have unique diagnostic codes, and that have been cleared or approved by the FDA. In addition to assigning the code, CMS must publicly report and explain the payment rate for the tests no later than January 1, 2017. We expect reimbursement
rates to be relatively stable through January&nbsp;1, 2017, at which time implementation of the market-based payment system and separate recognition of advanced diagnostic tests goes into effect. At this time, we cannot determine the full impact of
the new law on our business, financial condition and results of operations. </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to the Medicare Physician Fee Schedule, or MPFS,
CMS reviews from time to time the relative value units, or RVUs, which are translated to payments rates under the MPFS for established billing codes, including flow cytometry codes that describe some of our tests. In developing the RVUs, CMS in 2013
proposed to cap RVUs at rates paid to hospitals under the Medicare hospital outpatient rule, which would have resulted in decreases in payments to independent laboratories. CMS did not adopt the proposal for 2014, 2015, or 2016. CMS continues to
evaluate its proposals, however. In November 2015, CMS released the final 2016 MPFS, which will govern payment for some of our tests beginning January 1, 2016. The Company estimates that the rule will result in a 10% reduction in anticipated
reimbursements from Medicare from the Company&#146;s Avise CTD test. In addition, the 2016 MPFS continues to identify at least one flow cytometry billing code as potentially incorrectly valued. We cannot predict how CMS will value RVUs in the future
or whether further downward changes to the MPFS RVUs, if any, will impact our business. Revenues from Medicare and revenues from the sale of Avise SLE diagnostic products comprise 35% and 92%, respectively, of the Company&#146;s revenues in the nine
months ended September 30, 2015. Any change in reimbursement that materially lowers reimbursement for our Avise products could materially affect our business. </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We employ a multi-pronged strategy designed to achieve broad coverage and reimbursement for our Avise brands. The key elements of our strategy
for Avise CTD, which we also intend to pursue for our other products, include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Demonstrated Product Demand.</I> We intend to facilitate interactions between the expanding base of providers using the test and the payer community to raise payer awareness of the clinical benefits of Avise CTD.
Orders of Avise CTD increased by 200% from 2013 to 2014. In addition, the number of new ordering providers increased by 30% from 2013 to 2014. These trends, along with the high retention rate of frequent users, demonstrate substantial momentum in
the growing demand for this test. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Demonstrated Product Performance.</I> We have conducted clinical studies to help demonstrate the ability of Avise CTD to meet or exceed performance of established testing in the area of ARD diagnosis, which we
believe is important to establishing positive coverage decisions. For example, we conducted a multi-center study which enrolled 794 subjects with a primary endpoint that consisted of performance characteristics, specifically sensitivity and
specificity, of Avise Lupus compared to common autoantibodies used to diagnose SLE and other ARDs, such as ANA and anti-dsDNA. The results of this study showed that Avise Lupus demonstrated 86% specificity and 80% sensitivity in distinguishing SLE
from other ARDs, was 33% more specific than ANA (53% specificity/89% sensitivity) and was 48% more sensitive than anti-dsDNA (32% sensitivity/97% specificity). In addition, our CB-CAPs technology was shown to be 22% more sensitive than standard
complement measures (C3/C4) in our multi-centered study of 288 well characterized SLE patients. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 81 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Expanding our Clinical Data Package</I>. Clinical validation of Avise Lupus was demonstrated through a collaborative effort with multiple centers of excellence specializing in ARDs. We believe that our continued
collaborative efforts with key opinion leaders and ARD centers of excellence to further expand our clinical utility data which we intend to publish in peer-reviewed medical journals to support potential inclusion in clinical guidelines and help
drive payer coverage and reimbursement. We believe that inclusion of Avise Lupus into clinical guidelines will help to establish us as a standard of care for the diagnosis of patients with ARDs. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Execution of an Internal Managed Care Policy and Claims Adjudication Function.</I> We believe that obtaining adequate and widespread coverage and reimbursement is a critical factor to our success. We employ a team of
billing professionals that work with payers to maximize reimbursement. In parallel, a managed care director collaborates with our reimbursement specialists to ensure our payer outreach strategy reacts to and anticipates the changing needs of our
customer base. Our customer service team is an integral part of our reimbursement strategy, working with patients and physician practices to effectively navigate the claims process. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Technology </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our proprietary
technology platform determines the blood levels of complement pathway components stably deposited on cells known as Cell Bound Complement Activation Products, or CB-CAPs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The complement pathway is an important part of the immune system and refers to a complex network of over 30 soluble and membrane bound
proteins that interact in a highly regulated manner to provide many of the effector functions of immunity and inflammation. The integrity of the complement system is critically important for preventing infections and the development of autoimmune
diseases, including SLE. Once activated, the proteins within the complement system perform various functions, including the eradication of pathogens, such as bacteria and fungi, and also the effective removal of cellular debris and immune complexes
from the blood. Additionally, the activation of the complement system releases proteins that mediate inflammation, which is observed in a variety of diseases beyond ARDs, including Alzheimer&#146;s disease, asthma, Crohn&#146;s disease and macular
degeneration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The determination of complement proteins in a patient&#146;s blood is a mainstay in clinical laboratory science, and
state-of-the-art methods traditionally rely on measurement of serum or plasma levels of soluble complements. C3 and C4 are the most commonly determined complement proteins in the blood and the precursors to activation of complement proteins into
biologically active breakdown products. However, there are limitations with measuring C3 and/or C4 blood levels as indicators of complement activation. For example, increased synthesis of C3 and C4 by the liver can offset increased C3 and C4
breakdown during activation of the complement cascade, resulting in no change in serum levels. Conversely, genetic alteration in C4 genes can result in abnormally low serum/plasma levels of C4 due to lack of synthetic capacity that can be
misinterpreted as being due to increased C4 consumption during complement activation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The limitations and drawbacks of measuring standard
components of the complement system, such as C3&nbsp;and C4, are well recognized by the medical community. We believe the availability of novel complement biomarkers supporting or replacing standard C3 and C4 measures will be of great value for the
clinicians and ultimately their patients. Our CB-CAPs technology, which we exclusively license from the University of Pittsburgh, is the result of a decade of extensive research and development conducted in academia and has the potential to fulfill
the unmet need for better biomarkers assessing complement system&#146;s function and role in health and disease. The technology directly measures protein products of complement activation, such as C3d, the product of C3&nbsp;activation, and C4d, the
product of C4 activation. These complement activation products become stably attached to surfaces of circulating blood cells to become CB-CAPs. For example, the deposition of the C4d&nbsp;fragment to erythrocytes forms erythrocyte C4d, or EC4d.
Similarly, the deposition of C4d fragment on B&nbsp;lymphocytes forms BC4d. As such, the determination of CB-CAPs in the blood provides the following benefits when compared to the traditional complement measurement: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">accurate and unequivocal information of complement activation that has occurred in a given patient; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">stable biomarkers of complement activation enabling accurate and consistent measurement after collection and transportation; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">better ability to assess and monitor changes in biological activity related to activation of the complement system. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CB-CAPs are determined using blood collected from the patient by standard venipuncture in collection tubes and shipped overnight to our
central laboratory for processing. Because of their stability, we were able to demonstrate that this transportation process does not impair our ability to accurately measure CB-CAPs levels. The process in our clinical laboratory consists of the
isolation of the cells (e.g. erythrocytes and B-lymphocytes) using techniques such as centrifugation or lysis, followed by their </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 82 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
incubation and processing with a combination of antibodies that specifically label the CB-CAPs with a light emitting compound detectable by fluorescence assisted cell sorting, or FACS. The
instrument used to detect these labeled CB-CAPs is a flow cytometer, which readily measures the fluorescence signal (expressed as mean fluorescence intensity, or MFI) and thus, the level of CB-CAPs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe our differentiated CB-CAPs technology can be used to more effectively diagnose, prognose and monitor patients with certain
inflammatory diseases, including autoimmune, hematologic, vascular, or infectious diseases. For example, CB-CAPs such as EC4d and BC4d are significantly higher in patients with SLE compared to patients with other ARDs and, as such, forms the basis
of the diagnostic value of our Avise SLE diagnostic products. We validated the use of CB-CAPs as an effective method for diagnosing SLE in a study conducted with leading academic centers with expertise in SLE, including Northwestern University,
Albert Einstein College of Medicine, North Shore-LIJ Health System and New York University School of Medicine, to compare the sensitivity of elevated CB-CAPs to reduced serum levels of C3 and C4 in diagnosing SLE. A total of 288&nbsp;SLE patients
meeting the ACR criteria were enrolled. Elevated EC4d and BC4d levels yielded a 66% sensitivity, which was 22% higher than reduced C3 or C4 levels. An abstract of the study and results were accepted by the ACR and presented at their annual meeting
in November 2014. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below highlights several published clinical studies demonstrating the higher CB-CAPs level in patients
with SLE compared to other ARDs. For example, in the Kalunian study, BC4d levels were 3.1 times higher (110.4 versus 34.9 units) in SLE than in patients with other ARDs and 4.7 fold higher than normal subjects (110.4 vs 23.5 units). </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:66.15pt; font-size:8pt; font-family:Times New Roman"><B>Author/Publication</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">CB-CAP</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of</B><br><B>Patients</B><br><B>(SLE/non</B><br><B>SLE)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>SLE*</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Other</B><br><B>ARDs*</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Normals*</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Manzi et al. Arthritis Rheum 2004</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">EC4d</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">100/217</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liu et al., Clin Trans Sci 2009</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">BC4d</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">224/293</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liu et al, Arthritis Rheum 2005</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">EC4d</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">156/299</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Yang et al. Rheumatology 2009</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">EC4d</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">63/69</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kao et al. Arthritis Rheum 2010</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">EC4d</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">157/546</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kalunian et al. Arthritis Rheum 2012</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kalunian et al. Arthritis Rheum 2012</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">EC4d<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">BC4d</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">210/383<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">210/383</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom" ALIGN="right">17.6<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">110.4</P></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom" ALIGN="right">6.3<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">34.9</P></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom" ALIGN="right">5.3<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">23.5</P></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Results are expressed as average or median MFI for each group </TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While we are currently
focusing our CB-CAPs technology on differentially diagnosing SLE (as part of our Avise CTD diagnostic products), this technology has potential applications in many of the disease states in which the complement system plays a role. In addition to
expanding application in ARDs, such as monitoring for disease activity in SLE, we believe that CB-CAPs has the potential to be relevant in broader indications, such as monitoring complications in organ transplantation, pregnancy and vascular
disease. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Research and Development </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our research and development efforts are focused on developing novel solutions for rheumatologists and enhancing our current product offering.
Additionally, we believe there is significant potential to capitalize on our CB-CAPs technology platform and integrate that platform with commercially available markers to create high-value tests with superior clinical utility. We intend to continue
to establish the value of our Avise products, as well as introduce new and improved versions of these tests. For example, in February 2014 we added extractable nuclear antigens to our Avise Lupus test to improve the ability of the test to
distinguish SLE from other ARDs, such as Sj&ouml;gren&#146;s, scleroderma and polymyositis/dermatomyositis. Furthermore, we believe our bio-repository of well-characterized specimens, collected in collaboration with leading academic institutions,
will help us to further validate our Avise products. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have an extensive track record of accomplishments in all phases of research
and development, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Expertise in Assay Development, Validation, and Technology Transfer</I>. Our team of scientists has extensive experience and demonstrated ability with the development of analytical techniques in the areas of drug
monitoring, cellular immunology, immunoassays and molecular diagnostics. We also have expertise with the validation of analytical assays and the establishment of performance characteristics satisfying the standard requirement from regulatory bodies
including CAP. Our analytical techniques have been subjected to rigorous review from the New York State Department of Health, or NYDOH, and are marketed as laboratory developed tests, or LDTs. We are also continuously improving the performance
characteristics of our assays, enhancing throughput and robustness. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 83 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Expertise with the Clinical Development and Validation of Multivariate Index Assays/Algorithms.</I> Our clinical development and validation team has extensive knowledge and a track record in the clinical development
of a wide range of complex tests, including large, well-designed clinical trial in collaboration with leading academic institutions. We have also been successful in publishing the results of our clinical validation studies in peer-reviewed medical
journals. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Laboratory Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We perform all of our Avise tests in our approximately 8,000 square foot CLIA-certified, CAP accredited laboratory located in Vista,
California. Our laboratory is certified for performance of high-complexity testing by the Centers for Medicare and Medicaid Services, or CMS, in accordance with CLIA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When a physician orders an Avise test, the physician or physician&#146;s staff completes a test requisition. A&nbsp;blood draw is performed on
the patient, and the specimen is placed in a temperature-controlled transportation kit provided by us. The specimen is sent to our laboratory via commercial overnight shipment. Upon receipt, we examine each specimen for integrity. We label each
specimen with a unique identifier and pertinent information is entered into our laboratory information system, or LIS. The labeled specimen is then delivered to the flow cytometry and special chemistry laboratory for processing. The results are
entered into the LIS and reviewed by a technical supervisor who ensures they conform to specifications. Following this, the LIS generates a test report, which is reviewed and approved by the laboratory director and is then delivered to the
physician. Reports for our Avise tests are typically delivered to the physician in less than five business days following the receipt of the sample. Despite significant increases in the volume of tests we have performed in recent quarters, we have
maintained our ability to provide timely results to our physician customers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to continue to increase automation, enhance our
information systems and optimize our workflows to enhance and improve the efficiency of our processes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Quality Assurance </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our quality assurance function oversees the quality of our laboratory as well as research and development, client services, billing, sales and
marketing operations. We have established oversight for systems implementation and maintenance procedures, document control processes, supplier qualification, preventive or corrective actions, and employee training processes that we believe achieves
excellence in operations. We continuously monitor and improve our processes and procedures and believe this high quality service leads to customer satisfaction and retention. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Competition </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe the principal
competitive factors in our target market include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">quality and strength of clinical and analytical validation data; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">confidence in diagnostic results; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">sales and marketing capabilities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the extent of reimbursement; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">inclusion in practice guidelines; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">cost-effectiveness; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">ease of use. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe we compete favorably on the factors described above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our principal competition for our Avise products comes from traditional methods used by physicians to test patients with rheumatic
disease-like symptoms. Such traditional methods include testing for a broad range of diagnostic, immunology and chemistry markers, such as ANA and anti-dsDNA, and serum complement, such as C3 and C4. We also face competition from commercial
laboratories, such as Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, ARUP Laboratories, Inc. and Mayo Clinic, all of which have strong infrastructures to support the commercialization of diagnostic services. Large,
multispecialty group medical clinics, health systems and academic medical university-based clinics may provide in-house clinical laboratories offering autoimmune rheumatic testing services. Additionally, we compete against regional clinical
laboratories providing testing in the autoimmune rheumatic field, including Rheumatology Diagnostics Laboratories, Inc.&nbsp;Other potential competitors include companies that might develop diagnostic or disease or drug monitoring products, such as
Myriad Genetics, Inc., Kypha, LLC, and ImmunArray Ltd. In the future, we may also face competition from companies developing new products or technologies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 84 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of our potential competitors have widespread brand recognition and substantially greater
financial, technical and research and development resources and selling and marketing capabilities than we do. Others may develop products with prices lower than ours that could be viewed by physicians and payers as functionally equivalent to our
solution, or offer solutions at prices designed to promote market penetration, which could force us to lower the list price of our products and affect our ability to achieve profitability. If we are unable to change clinical practice in a meaningful
way or compete successfully against current and future competitors, we may be unable to increase market acceptance and sales of our products, which could prevent us from increasing our revenue or achieving profitability and could cause the market
price of our common stock to decline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intellectual Property Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We strive to protect and enhance the proprietary technologies that we believe are important to our business and seek to obtain and maintain
patents for any patentable aspects of our diagnostic products and services and any other inventions that are important to the development of our business. Our success will depend on our ability to obtain and maintain patent and other proprietary
protection for commercially important technology, inventions and know-how related to our business, to defend and enforce our patents, to maintain our licenses to use intellectual property owned by third parties, to preserve the confidentiality of
our trade secrets and to operate without infringing the valid and enforceable patents and other proprietary rights of third parties. We also rely on continuing technological innovation and in-licensing opportunities to develop, strengthen, and
maintain our proprietary position in the fields targeted by our diagnostic products and services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are the owner or licensee of a
portfolio of patents and patent applications and possess substantial know-how and trade secrets which protect various aspects of our business. The patent families comprising our patent portfolio are primarily focused on our Avise products for the
diagnosis and use in treatment of ARDs, and are generally directed to CB-CAPs, red blood cell MTXPG exposure assessments, and anti-MCV antibodies. We intend to leverage the intellectual property surrounding our Avise products as an important
component of our business strategy. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patent Term </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term of individual patents and patent applications listed below will depend upon the legal term of the patents in the countries in which
they are obtained. In most countries, the patent term is 20 years from the date of filing of the patent application (or parent application, if applicable). For example, if an international Patent Cooperation Treaty, or PCT, application is filed, any
patent issuing from the PCT application in a specific country will expire 20 years from the filing date of the PCT application. In the United States, however, if a patent was in force on June&nbsp;8, 1995, or issued on an application that was filed
before June&nbsp;8, 1995, that patent will have a term that is the greater of 20 years from the filing date, or 17 years from the date of issue. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patent Protection for our Avise Products </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our portfolio of patents and patent applications related to our Avise products generally relates to three aspects: CB-CAPs, red blood cell
MTXPG exposure assessments, and anti-MCV antibodies. The patent families which we believe are important for the protection of Avise are summarized below in the section entitled &#147;&#151;License Agreements.&#148; </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Cell Bound Complement Activation Products and Services (CB-CAPs)</I>. We are the exclusive licensee of five patent families related to CB-CAPs technology from the University of Pittsburgh. We expect that these patent
families (U.S. Patent Nos. 7,361,517; 7,390,631; 7,585,640; 7,588,905; 8,080,382; and 8,126,654) will expire in 2024 or 2025. A foreign patent corresponding to U.S. Patent No.&nbsp;7,361,517 has issued in Europe (EP 1,756,571). Foreign patents
corresponding to U.S. Patent No.&nbsp;7,390,631 have issued in Japan (JP 4570872 and JP 4906898). Foreign patents corresponding to U.S. Patent No.&nbsp;7,585,640 have issued in Australia (AU&nbsp;2005242719) and Canada (CA 2,564,492). A foreign
patent corresponding to U.S. Patent Nos. 7,588,905 and 8,126,654 has issued in Japan (JP 45500051). We also own two pending patent application families that relate to our Avise Lupus diagnostic products. In order to manage our foreign filing costs
and focus on the U.S. market, we made the decision to cease the prosecution and maintenance of several of our foreign patents and patent applications related to our CB-CAPs technology, including EP 1,432,731; EP 1,618,379; EP 1,635,692; EP
1,745,287; EP 2,214,014; EP 2,216,650, and certain of their corresponding family members<B><I>. </I></B> </TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Methotrexate (MTX) Exposure Assessment Products and Services</I>. We are the exclusive licensee of four patents and one pending patent application that relate to our Avise MTX product line and methods for monitoring
MTX therapy using red blood cell MTXPG exposure assessments. These patents and patent application are owned by Prometheus Laboratories and are exclusively licensed to us for all uses except for use in gastrointestinal diseases. These patents include
U.S. Patent Nos. 6,921,667; 7,563,590; 7,582,282 and 7,695,908, which are expected to expire between 2023 and 2027. We also own two pending U.S. patent applications and are the exclusive licensee of two pending patent applications that relate to our
Avise MTX product. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 85 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Anti-mutated Citrullinated Vimentin (anti-MCV) Antibodies and Related Services. </I>We are the exclusive licensee of a patent family related to anti-MCV, an autoantibody having diagnostic and prognostic value in RA.
This family, owned by Orgentec Diagnostika, includes a pending U.S. patent application. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Proprietary Rights and Processes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may rely, in some circumstances, on proprietary technology and processes (including trade secrets) to protect our technology. However, these
can be difficult to protect. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with those who have access to our confidential information, including our employees, consultants,
scientific advisors and contractors. We also seek to preserve the integrity and confidentiality of our proprietary technology and processes by maintaining physical security of our premises and physical and electronic security of our information
technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached, and we may not have adequate remedies for any such breach. In addition, our proprietary technology and
processes may otherwise become known or be independently discovered by competitors. To the extent that our employees, consultants, scientific advisors, contractors, or any future collaborators use intellectual property owned by others in their work
for us, disputes may arise as to the rights in related or resulting know-how and inventions. For this and more comprehensive risks related to our proprietary technology and processes, please see &#147;Risk Factors&#151;Risks Related to our
Intellectual Property.&#148; </P>   <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>License Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Amended and Restated Exclusive License Agreement with the University of Pittsburgh </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2011, we entered into an amended and restated exclusive license agreement with the University of Pittsburgh, or UPitt, to amend and
restate the exclusive license agreement we obtained by our purchase of the medical diagnostics division of Cypress Bioscience, Inc., or Cypress, in 2010, or the Cypress Purchase, and to obtain an exclusive license to UPitt&#146;s patent rights in
certain inventions, or the UPitt Patent Rights, related to the use of CB-CAPs technology in the diagnosis, prognosis and monitoring of diseases, including certain patents related to our Avise SLE diagnostic products. The agreement was amended twice,
once in May 2012 to, among other things, limit the territory of the license to the United States and exclude certain foreign patents and applications from the agreement, and once in September 2013 to add (1)&nbsp;an additional U.S. patent to the
UPitt Patent Rights licensed under the agreement and (2)&nbsp;the field of monitoring of organ transplantation and organ rejection to the scope of the license. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the agreement, we are permitted to make, use and sell products and services utilizing the UPitt Patent Rights in the field of SLE and
the field of monitoring of organ transplantation and organ rejection, and to sublicense such rights. UPitt retained the right to practice under the UPitt Patent Rights and to use such rights for non-commercial education and research purposes. In
addition, this agreement is subject to the rights of the United States government, if any, as set forth in 35 U.S.C. &#167;200, et seq. Pursuant to this law, the U.S. government may have acquired a nonexclusive, nontransferable, paid up license to
practice or have practiced for or on behalf of the U.S. government the inventions described in the UPitt Patent Rights throughout the world. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In consideration for the rights granted to us under the agreement, we made certain upfront payments to UPitt on the first and second
anniversaries of the agreement that increase on the third and subsequent anniversaries of the agreement until the first sale of products or services utilizing the UPitt Patent Rights. We are required to pay UPitt a low single-digit royalty on net
sales of products or services utilizing the UPitt Patent Rights sold by us or our affiliates, subject to minimum annual royalty payments and other adjustment in certain circumstances. We also made a $0.2&nbsp;million milestone payment to UPitt with
the achievement of certain levels of net sales which we met in 2014. Our royalty obligations continue for each licensed product or service on a country-by-country basis until the expiration of the last licensed patent covering the applicable
licensed product or service in such country. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event we sublicense any of the UPitt Patent Rights, we are obligated to pay UPitt a
low single-digit percentage sublicense royalty on net sales of products or services sold by our sublicensees that utilize the sublicensed UPitt Patent Rights and a low double-digit percentage of all non-royalty sublicensing income received by us.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The agreement requires that we diligently develop and commercialize products that are covered by the UPitt Patent Rights, and we have
agreed to meet certain development and commercial milestones. UPitt may terminate the agreement if we fail to meet such milestones. In addition, if we fail to meet a milestone relating to development of the UPitt Patent Rights in the monitoring of
organ transplantation and organ rejection field, UPitt may remove that field from our licensed rights. We are currently in compliance with these milestone requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may terminate the agreement upon six months&#146; written notice to UPitt. UPitt may terminate the agreement in the event of our
nonperformance of any of our obligations under the agreement if such nonperformance remains uncured for a certain period of time following our receipt of written notice of such nonperformance or in the event of our insolvency. Absent early
termination, the agreement will continue until the expiration date of the longest-lived patent right included in the UPitt Patent Rights. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 86 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Exclusive License Agreement with the University of Pittsburgh </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We made an economic decision to cease the maintenance and licensing of UPitt Patent Rights outside the United States, which led to such rights
returning to UPitt. We subsequently made the determination to re-license these foreign patent rights from UPitt, but at the time of re-licensing these patent rights, a number of the foreign patent rights had permanently lapsed. Accordingly, in
September 2013, we entered into an exclusive license agreement with UPitt to obtain an exclusive license to UPitt&#146;s remaining ex-U.S. patent rights in certain inventions, or the ex-U.S. UPitt Patent Rights, related to the use of CB-CAPs
technology in the diagnosis, prognosis and monitoring of diseases, including certain patents related to our Avise SLE diagnostic products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the agreement, we are permitted to make, use and sell products and services utilizing the ex-U.S. UPitt Patent Rights in the field of
SLE and the field of monitoring of organ transplantation and organ rejection outside of the United States, and to sublicense such rights. UPitt retained the right to practice under the ex-U.S. UPitt Patent Rights and to use such rights for
non-commercial education and research purposes. In addition, this agreement is subject to the rights of the U.S. government, if any, as set forth in 35 U.S.C. &#167;200, et seq. Pursuant to this law, the U.S. government may have acquired a
nonexclusive, nontransferable, paid up license to practice or have practiced for or on behalf of the U.S. government the inventions described in the ex-U.S. UPitt Patent Rights throughout the world. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In consideration for the rights granted to us under the agreement, we paid an initial license fee to UPitt. We are also required to pay UPitt
a low single-digit royalty on net sales of products or services utilizing the ex-U.S. UPitt Patent Rights sold by us or our affiliates, subject to adjustment in certain circumstances. Our royalty obligations continue for each licensed product or
service on a country-by-country basis until the expiration of the last licensed patent covering the applicable licensed product or service in such country. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event we sublicense any of the ex-U.S. UPitt Patent Rights, we are obligated to pay UPitt a low single-digit percentage sublicense
royalty on net sales of products or services sold by our sublicensees that utilize the sublicensed ex-U.S. UPitt Patent Rights and a low double-digit percentage of all non-royalty sublicensing income received by us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The agreement requires that we diligently develop and commercialize products that are covered by the ex-U.S. UPitt Patent Rights, and we have
agreed to meet certain commercial milestones. UPitt may terminate the agreement if we fail to meet such milestones. We are currently in compliance with these milestone requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may terminate the agreement upon six months&#146; written notice to UPitt. UPitt may terminate the agreement in the event of our
nonperformance of any of our obligations under the agreement if such nonperformance remains uncured for a certain period of time following our receipt of written notice of such nonperformance or in the event of our insolvency. Absent early
termination, the agreement will continue until the expiration date of the longest-lived patent right included in the UPitt Patent Rights. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>License
Agreement with Prometheus Laboratories, Inc. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Cypress Purchase, we acquired a license agreement, dated September
2007, between Prometheus Laboratories, Inc., or Prometheus, and Proprius Pharmaceuticals, Inc., or Proprius, a company which had been previously acquired by Cypress. Pursuant to this agreement, we obtained an exclusive, worldwide license to
Prometheus&#146;s patent rights in certain inventions, or the Prometheus Patent Rights, related to the diagnosis, prognosis and monitoring of diseases, including certain patents related to our Avise products and services. This agreement was
subsequently amended in October 2013. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the agreement, we are permitted to research, develop, manufacture and commercialize products
utilizing the Prometheus Patent Rights and to sublicense such rights; provided, however, that any such sublicenses may only be granted with Prometheus&#146;s consent. We are not permitted to develop or commercialize products utilizing the Prometheus
Patent Rights for use in diagnosing or treating any gastrointestinal diseases or to promote any such products to gastroenterologists. Pursuant to the agreement, we are obligated to use reasonable commercial efforts to undertake certain development
activities with respect to products utilizing the Prometheus Patent Rights, including the completion of certain clinical studies. In addition, in the event that we do not timely complete these studies or approved substitute studies, we will become
obligated to pay to Prometheus a one-time payment of $50,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are required to make a milestone payment of $2.0 million upon the
achievement of certain net sales. In addition, we are required to pay Prometheus tiered royalties in the mid-single-digit range on sales of any products utilizing the Prometheus Patent Rights by us, our affiliates or our sublicensees. Our royalty
obligations continue on a licensed product-by-licensed product and country-by-country basis until the expiration, lapse or invalidation of the last valid claim in a licensed patent covering the applicable licensed product in such country. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 87 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event we sublicense any of the Prometheus Patent Rights, we are obligated to pay to
Prometheus a fee based on a percentage of sublicense fees received by us, which percentage is in the mid-twenties. In addition, we are also required to pay to Prometheus a percentage of the royalty payments we receive from our sublicensees, which
may not be less than a certain low single-digit percentage of net sales of products or services sold by our sublicensees that utilize the sublicensed Prometheus Patent Rights, nor more than a certain mid-single digit percentage of such net sales.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may unilaterally terminate the agreement for any reason upon 60 days&#146; written notice to Prometheus. Either party may terminate
this agreement in the event of the other party&#146;s material breach of the agreement if such breach remains uncured for a certain period of time following receipt of written notice of such breach or in the event of the other party&#146;s
insolvency. Absent early termination, the agreement will continue until the expiration date of the longest-lived patent right included in the Prometheus Patent Rights. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>License Agreement with Orgentec Diagnostika GmbH </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Cypress Purchase, we acquired a license agreement, dated February 2008, between Proprius and Orgentec Diagnostika GmbH,
or Orgentec. Pursuant to this agreement, we obtained an exclusive license to Orgentec&#146;s patent rights and know-how in certain inventions, or the Orgentec Patent Rights, related to anti-MCV, an autoantibody, including certain patent applications
related to our Avise products and services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the agreement, we are permitted to research, develop, manufacture and commercialize
products utilizing the Orgentec Patent Rights for diagnosis, prognosis and monitoring applications, including diagnosis, prognosis and monitoring of RA, in the United States and Mexico, and to sublicense such rights. We are not permitted to use the
Orgentec Patent Rights for therapeutic applications. We have a right of first negotiation to license additional products from Orgentec for use in the diagnostic, prognostic and monitoring field in the United States or Mexico. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are required to pay Orgentec a low single-digit royalty on any products utilizing the Orgentec Patent Rights, subject to adjustment in
certain circumstances. We are also obligated to pay Orgentec a percentage in the mid-twenties of sublicense revenues received by us for products or services sold by our sublicensees that utilize the sublicensed Orgentec Patent Rights. Our royalty
obligations continue on a licensed product-by-licensed product and country-by-country basis until the expiration of the last licensed patent covering the applicable licensed product in such country. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may unilaterally terminate the agreement for any reason upon 90 days&#146; written notice to Orgentec. Either party may terminate this
agreement in the event of the other party&#146;s material breach of the agreement if such breach remains uncured for a certain period of time following receipt of written notice of such breach. Absent early termination, the agreement will continue
until the expiration date of the longest-lived patent right included in the Orgentec Patent Rights. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Asset Purchase Agreement with Cypress and Proprius
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2010, we completed the Cypress Purchase pursuant to an asset purchase agreement with Cypress and its wholly-owned
subsidiary, Proprius, under which we obtained certain assets related to our Avise products and services. The agreement was amended three times, once in March 2011 to change certain obligations relating to certain accounts receivable we acquired from
Cypress, once in August 2012 to convert a one-time payment obligation to a payment plan over four years with interest, and once in February 2013 to convert a one-time contingent milestone payment obligation concerning a CB-CAPs monitoring assay to a
payment plan over two years with interest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In consideration for the acquisition, we made certain initial cash payments to Cypress and we
are currently making payments to Cypress pursuant to the August 2012 amendment, which payments are subject to acceleration in certain circumstances. In addition, we are required to make certain one-time contingent milestone payments for two
third-party commercial programs, for the launch of a CB-CAPs monitoring assay, and for the achievement of an annual, worldwide net sales level for CB-CAPs products, which milestone payments are estimated at an aggregate of between $3.0 and $4.0
million. The agreement requires that we use commercially reasonable efforts to cause each of the milestones to be achieved. We are required to pay Cypress a low double-digit royalty on the world wide net sales of CB-CAPs products and a low
double-digit royalty on the net sales of certain new products in each case, for a period of several years. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 88 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Asset Purchase Agreement With Cellatope </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Cypress Purchase, we acquired an asset purchase agreement, dated February 2009 and amended December 2012, between
Cypress and Cellatope Corporation, or Cellatope. Pursuant to this agreement, we obtained assets related to our Avise products. In the event we or a licensee sells an SLE monitoring product, we are required to issue Cellatope a promissory note for
$3.0&nbsp;million, bearing interest at a rate of 5%&nbsp;per annum. On the first anniversary of such note, accrued interest for the previous 12 months shall be added to the principal amount, and following such first anniversary, the adjusted amount
shall accrue interest at the same rate, and we must pay off the note plus accrued interest in 48 equal monthly payments. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Dr.&nbsp;Thierry Dervieux and
De Novo Diagnostics, Inc. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2011, we entered into a license agreement with Dr.&nbsp;Thierry Dervieux, our Chief Scientific
Officer, and his company De Novo Diagnostics, Inc., under which we obtained an exclusive, worldwide (except for Australia and New Zealand) license to Dr.&nbsp;Dervieux&#146;s patent rights and know-how in certain inventions, or the Dervieux Patent
Rights, related to the diagnosis, prognosis and monitoring of diseases, including certain patents related to our Avise products and services. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the agreement, we are permitted to develop, manufacture and commercialize products utilizing the Dervieux Patent Rights in the human
healthcare market, and to sublicense such rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In considerations for the rights granted to us under the agreement, we are required to
make milestone payments, up to an aggregate of $600,000, upon achievement of certain sales milestones. In addition, we are required to pay Dr.&nbsp;Dervieux a mid-single-digit royalty on net sales by us or our affiliates of any products utilizing
the Dervieux Patent Rights, subject to adjustment in certain circumstances. We are also obligated to pay Dr.&nbsp;Dervieux a percentage in the mid-twenties of sublicense fees and royalties received by us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The agreement requires that we diligently develop and commercialize products that are covered by the Dervieux Patent Rights, and we have
agreed to use commercially reasonable efforts to bring technology covered by the Dervieux Patent Rights to market as soon as practicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may unilaterally terminate the agreement upon 12 months&#146; written notice to Dr.&nbsp;Dervieux. Either party may terminate this
agreement in the event of the other party&#146;s nonperformance of any of its obligations under the agreement if such nonperformance remains uncured for a specified period of time following receipt of written notice of such nonperformance or in the
event of the other party&#146;s insolvency. Absent early termination, the agreement will continue until the expiration date of the longest-lived patent right included in the Dervieux Patent Rights. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Regulations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Clinical Laboratory Improvement
Amendments of 1988 </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a clinical reference laboratory, we are required to hold certain federal, state and local licenses,
certifications and permits to conduct our business. Under CLIA, we are required to hold a certificate applicable to the type of laboratory tests we perform and to comply with standards applicable to our operations, including test processes,
personnel, facilities administration, equipment maintenance, recordkeeping, quality systems and proficiency testing. We must maintain CLIA compliance and certification to be eligible to bill for diagnostic services provided to Medicare
beneficiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have current certification under CLIA to perform testing at our Vista facility. To renew our CLIA certificate, we are
subject to survey and inspection every two years to assess compliance with program standards. The regulatory and compliance standards applicable to the testing we perform may change over time, and any such changes could have a material effect on our
business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our clinical laboratory were to be found to be out of compliance with CLIA requirements, we may be subject to sanctions,
such as suspension, limitation or revocation of our CLIA certificate, as well as directed plan of correction, state on-site monitoring, civil money penalties, civil injunctive suit or criminal penalties, any of which could adversely affect our
business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>California Laboratory Licensing </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to federal certification requirements of laboratories under CLIA, licensure is required and maintained for our Vista clinical
reference laboratory under California law. Such laws establish standards for the day-to-day operation of a clinical reference laboratory, including the training and skills required of personnel and quality control. In addition, California laws
mandate proficiency testing, which involves testing of specimens that have been specifically prepared for the laboratory. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 89 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our clinical reference laboratory were to be found out of compliance with California
standards, the California Department of Health Services, or DHS, may suspend, restrict or revoke our license to operate our clinical reference laboratory, assess substantial civil money penalties, or impose specific corrective action plans, any of
which could materially affect our business. We maintain a current license in good standing with DHS. However, we cannot provide assurance that DHS will at all times in the future find us to be in compliance with all such laws. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>New York Laboratory Licensing </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because
we receive specimens from New York, our clinical reference laboratory is required to be licensed by New York, under New York laws and regulations, which establish standards for: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">day-to-day operation of a clinical laboratory, including training and skill levels required of laboratory personnel; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">physical requirements of a facility; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">equipment; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">validation and quality control. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">New York law also mandates proficiency testing for
laboratories licensed under New York state law, regardless of whether such laboratories are located in New York. If a laboratory is out of compliance with New&nbsp;York statutory or regulatory standards, the NYDOH may suspend, limit, revoke or annul
the laboratory&#146;s New York license, censure the holder of the license or assess civil money penalties. Statutory or regulatory noncompliance may result in a laboratory&#146;s operator being found guilty of a misdemeanor under New York law. NYDOH
also must approve the LDT before the test is offered in New York. We have received written approval from NYDOH to offer our products in New York. If we were to be found out of compliance with New York laboratory requirements, we could be subject to
such sanctions, which could harm our business. We maintain a current license in good standing with NYDOH for our laboratory. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other States&#146;
Laboratory Licensing </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to New York and California, other states, including Florida, Maryland, Pennsylvania and Rhode Island,
require licensing of out-of-state laboratories under certain circumstances. We have obtained licenses from states where we believe we are required to be licensed, and believe we are in compliance with applicable licensing laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, we may become aware of other states that require out-of-state laboratories to obtain licensure in order to accept specimens
from the state, and it is possible that other states currently have such requirements or will have such requirements in the future. If we identify any other state with such requirements or if we are contacted by any other state advising us of such
requirements, we intend to comply with such requirements. Collecting specimens from a state that requires us to obtain and maintain an out-of-state laboratory license, without receiving such license, may result in sanctions, any of which could harm
our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Federal Oversight of Laboratory Developed Tests </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The laws and regulations governing the marketing of diagnostic products are evolving, extremely complex, and in many instances there are no
significant regulatory or judicial interpretations of these laws and regulations. Clinical laboratory tests like Avise CTD, Avise SLE Prognostic and Avise MTX are regulated under CLIA, as administered by CMS, as well as by applicable state laws. In
addition, the Federal Food, Drug and Cosmetic Act, or FDCA, defines a medical device to include any instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related article, including a component part,
or accessory, intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, in man or other animals. Our in vitro diagnostic products are considered by the FDA to be subject to
regulation as medical devices. Among other things, pursuant to the FDCA and its implementing regulations, the FDA regulates the research, testing, manufacturing, safety, labeling, storage, recordkeeping, pre-market clearance or approval, marketing
and promotion, and sales and distribution of medical devices in the United States to ensure that medical products distributed domestically are safe and effective for their intended uses. In addition, the FDA regulates the export of medical devices
manufactured in the United States to international markets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although the FDA has statutory authority to assure that medical devices are
safe and effective for their intended uses, the FDA has generally exercised its enforcement discretion and not enforced applicable regulations with respect to in vitro diagnostics that are developed, validated, and offered within a single laboratory
for use only in that laboratory. We believe that the Avise CTD and Avise MTX are LDTs, as are our near term pipeline candidate tests. As a result, we believe our diagnostic services should not be subject to regulation under established FDA policies.
However, one of the devices we market under license is subject to a 510(k) clearance held by Orgentec Diagnostika GmbH and is subject to the FDA&#146;s regulations applicable to 510(k)-cleared devices. In addition, reagents, instruments, software or
components provided by third parties and used to perform LDTs may be subject to regulation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 90 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;3, 2014, the FDA issued two draft guidance documents entitled &#147;Framework for
Regulatory Oversight of Laboratory Developed Tests (LDTs),&#148; or the Framework Guidance, and &#147;FDA Notification and Medical Device Reporting for Laboratory Developed Tests (LDTs), or the Reporting Guidance. The Framework Guidance states that
FDA intends to modify its policy of enforcement discretion with respect to LDTs in a risk-based manner consistent with the classification of medical devices generally in Classes I through III. The FDA further states its intention in the Framework
Guidance to publish general LDT classification guidance within 18&nbsp;months of date on which the Framework Guidance is finalized. The Reporting Guidance would further enable FDA to collect information regarding the LDTs currently being offered for
clinical use through a notification process, as well as to enforce its regulations for reporting safety issues and collecting information on any known or suspected adverse events related to the use of an LDT. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the FDA begins to actively regulate LDTs, we may be required to obtain premarket clearance under Section&nbsp;510(k) of the FDCA or a
premarket approval, or PMA. The process for submitting a 510(k) premarket notification and receiving FDA clearance usually takes from three to twelve months, but it can take significantly longer and clearance is never guaranteed. The process for
submitting and obtaining FDA approval of a PMA is much more costly, lengthy and uncertain. It generally takes from one to three years or even longer and approval is not guaranteed. PMA approval typically requires extensive clinical data and can be
significantly longer, more expensive and more uncertain than the 510(k) clearance process. If premarket review is required for some or all of our products, the FDA could require that we stop selling our products pending clearance or approval and
conduct clinical testing prior to making submissions to FDA to obtain premarket clearance or approval. If our diagnostic services are allowed to remain on the market but there is uncertainty about the legal status of our services, if we are required
by the FDA to label them as investigational, or if labeling claims the FDA allows us to make are limited, order levels may decline and reimbursement may be adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite the FDA&#146;s issuance of the draft Framework Guidance and Reporting Guidance, we cannot predict the ultimate form of any LDT
guidance or other agency action with respect to LDTs and the potential effect on our solutions or materials used to perform our diagnostic services. While we qualify all materials used in our diagnostic services according to CLIA regulations, we
cannot be certain that the FDA might not ultimately promulgate rules or issue guidance documents that could affect our ability to purchase materials necessary for the performance of our diagnostic services. Should any of the reagents obtained by us
from vendors and used in conducting our diagnostic services be affected by future regulatory actions, our business could be adversely affected by those actions, including increasing the cost of service or delaying, limiting or prohibiting the
purchase of reagents necessary to perform the service. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Legislative proposals addressing oversight of LDTs have been introduced in recent
years and we expect that new legislative proposals will be introduced in the future. It is possible that legislation could be enacted into law or regulations or guidance could be issued by the FDA which may result in new or increased regulatory
requirements for us to continue to offer our diagnostic services or to develop and introduce new services. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Health Insurance Portability and
Accountability Act </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, and the Health Information
Technology for Economic and Clinical Health Act, or HITECH Act, the U.S. Department of Health and Human Services, or HHS, has issued regulations to protect the privacy and security of protected health information used or disclosed by certain
entities including health care providers, such as us. HIPAA also regulates standardization of data content, codes and formats used in certain health care transactions and standardization of identifiers for health plans and providers. Penalties for
violations of HIPAA and HITECH laws and regulations include civil and criminal penalties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Three standards have been promulgated under
HIPAA&#146;s and HITECH&#146;s regulations: the Standards for Privacy of Individually Identifiable Health Information, which restrict the use and disclosure of certain individually identifiable health information, the Standards for Electronic
Transactions, which establish standards for common healthcare transactions, such as claims information, plan eligibility, payment information and the use of electronic signatures, and the Security Standards for the Protection of Electronic Protected
Health Information, which require covered entities and business associates to implement and maintain certain security measures to safeguard certain electronic health information, including the adoption of administrative, physical and technical
safeguards to protect such information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2009, Congress passed the American Recovery and Reinvestment Act of 2009, or ARRA, which
included sweeping changes to HIPAA, including an expansion of HIPAA&#146;s privacy and security standards. ARRA includes the HITECH Act, which, among other things, made HIPAA&#146;s security standards directly applicable to business associates of
covered entities effective February&nbsp;17, 2010. A business associate is a person or entity that performs certain functions or activities on behalf of a covered entity that involve the use or disclosure of protected health information for or on
behalf of the covered entity. As a result, business associates are now subject to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 91 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
significant civil and criminal penalties for failure to comply with applicable standards. Moreover, HITECH creates a new requirement to report certain breaches of unsecured, individually
identifiable health information and imposes penalties on entities that fail to do so. This requirement was modified and expanded by the final HIPAA Omnibus Rule of 2013. HITECH also increased the civil and criminal penalties that may be imposed
against covered entities and business associates and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney fees and costs associated with
pursuing federal civil actions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">HIPAA also governs patient access to laboratory test reports. Effective October&nbsp;6, 2014, individuals
(or their personal representatives, as applicable) have the right to access test reports directly from laboratories and to direct that copies of those reports be transmitted to persons or entities designated by the individual. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have developed and implemented policies and procedures designed to comply with these regulations. The requirements under these regulations
may change periodically and could have an effect on our business operations if compliance becomes substantially more costly than under current requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to federal privacy regulations, there are a number of state laws governing confidentiality of health information that are
applicable to our business, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">New laws governing privacy and security may be adopted in the future as well. We have taken steps to comply with federal and state health
information privacy and security requirements to which we are aware that we are subject. However, we can provide no assurance that we are or will remain in compliance with diverse privacy and security requirements in all of the jurisdictions in
which we do business. Failure to comply with privacy and security requirements could result in civil or criminal penalties, which could have a materially adverse effect on our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Federal and State Physician Self-Referral Prohibitions </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to the federal physician self-referral prohibitions, commonly known as the Stark Law, and to similar state law restrictions,
such as California&#146;s Physician Ownership and Referral Act, or PORA, and other comparable state laws. Together these restrictions generally prohibit us from billing a patient or any governmental or private payer for certain designated health
services, including clinical laboratory services, when the physician ordering the service, or any member of such physician&#146;s immediate family, has a financial interest, such as an ownership or investment interest in or compensation arrangement
with us, unless the arrangement meets an exception to the prohibition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Both the Stark Law and PORA, as well as many other state law
equivalents, contain an exception for compensation paid to a physician for personal services rendered by the physician provided that the arrangement meets certain regulatory requirements. We have compensation arrangements with a number of physicians
for personal services, such as speaking engagements, serving on advisory boards, and consulting activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, we cannot be certain
that regulators would find these arrangements to be in compliance with Stark, PORA or similar state laws. We would be required to refund any payments we receive pursuant to a referral prohibited by these laws to the patient, the payer or the
Medicare program, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sanctions for a Stark Law violation include the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">denial of payment for the services provided in violation of the prohibition; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">refunds of amounts collected by an entity in violation of the Stark Law; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a civil penalty of up to $15,000 for each bill or claim for a service arising out of the prohibited referral; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the imposition of up to three times the amounts for each item or service wrongfully claimed; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">possible exclusion from federal healthcare programs, including Medicare and Medicaid; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a civil penalty of up to $100,000 for each arrangement or scheme that the parties know (or should know) has the principal purpose of circumventing the Stark Law&#146;s prohibition. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These prohibitions apply regardless of any intent by the parties to induce or reward referrals or the reasons for the financial relationship
and the referral. In addition, knowing violations of the Stark Law may also serve as the basis for liability under the Federal False Claims Act, which can result in additional civil and criminal penalties. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 92 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, a violation of PORA is a misdemeanor and could result in civil penalties and
criminal fines. Other states also have self-referral restrictions with which we have to comply, some of which differ from those imposed by the Stark Law or California law. It is possible that some of our financial arrangements with physicians could
be subject to regulatory scrutiny at some point in the future, and we cannot provide assurance that we will be found to be in compliance with these laws following any such regulatory review. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Federal and State Fraud and Abuse Laws </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Federal Anti-kickback Statute makes it a felony for a person or entity, including a clinical laboratory, to knowingly and willfully offer,
pay, solicit or receive any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, in order to induce business that is reimbursable under any federal health care program. A violation of the Anti-kickback Statute may result in
imprisonment for up to five years and fines of up to $25,000 for each violation and administrative civil money penalties of $50,000 plus up to three times the amount of the remuneration paid. Convictions under the Anti-kickback Statute result in
mandatory exclusion from federal health care programs for a minimum of five years. In addition, The U.S. Department of Health and Human Services, or HHS, has the authority to impose civil assessments and fines and to exclude health care providers
and others engaged in prohibited activities from Medicare, Medicaid and other federal health care programs. In addition, the government may now assert that a claim that includes items or services resulting from a violation of the Anti-kickback
Statute constitutes a false or fraudulent claim under the Federal False Claims Act, which is discussed in greater detail below. Additionally, the intent standard under the Anti-Kickback Statute was amended by the Patient Protection and Affordable
Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010, collectively the ACA, to a stricter standard such that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate
it in order to have committed a violation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although the Anti-kickback Statute applies only to items and services reimbursable under any
federal health care program, a number of states, including California, have passed statutes substantially similar to the Anti-kickback Statute that apply to all third-party payers, including commercial insurers. The California Attorney General and
courts have interpreted the California anti-kickback and fee-splitting laws in substantially the same way as HHS and the courts have interpreted the Anti-kickback Statute. Penalties of such state laws include imprisonment and significant monetary
fines. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Federal and state law enforcement authorities scrutinize arrangements between health care providers and potential referral sources
to ensure that the arrangements are not designed as a mechanism to induce patient care referrals or induce the purchase or prescribing of particular products or services. The law enforcement authorities, the courts and Congress have also
demonstrated a willingness to look behind the formalities of a transaction to determine the underlying purpose of payments between health care providers and actual or potential referral sources. Generally, courts have taken a broad interpretation of
the scope of the Anti-kickback Statute, holding that the statute may be violated if merely one purpose of a payment arrangement is to induce referrals or purchases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to statutory exceptions to the Anti-kickback Statute, regulations provide for a number of safe harbors. If an arrangement meets
the provisions of a safe harbor, it is deemed not to violate the Anti-kickback Statute. An arrangement must fully comply with each element of an applicable safe harbor in order to qualify for protection. There are no regulatory safe harbors under
California laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Among the safe harbors that may be relevant to us is the discount safe harbor. The discount safe harbor potentially
protects certain discounts provided by providers and suppliers, including laboratories, to physicians or institutions. If the terms of the discount safe harbor are met, the discounts will not be considered prohibited remuneration under the
Anti-kickback Statute. Although California does not have a discount safe harbor, the California statute has generally been interpreted consistent with the Anti-kickback Statute. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The personal services safe harbor to the Anti-kickback Statute protects certain remuneration paid to a referral source for personal services,
provided all of the elements of that safe harbor are met. One element is that if the agreement is intended to provide for the services of the physician on a periodic, sporadic or part-time basis, rather than on a full-time basis for the term of the
agreement, the agreement specifies exactly the schedule of such intervals, their precise length, and the exact charge for such intervals. Some of our current and prior personal services arrangements with some physicians may not meet the specific
requirement of this safe harbor that the agreement specify exactly the schedule of the intervals of time to be spent on the services because the nature of the services, such as speaking engagements and blood-draw fee agreements, does not lend itself
to exact scheduling. Failure to meet the requirements of the safe harbor, however, does not render an arrangement illegal. Rather, the government may evaluate such arrangements on a case-by-case basis, taking into account all facts and
circumstances. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 93 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There can be no assurance that our relationships with physicians, academic institutions and other
customers will not be subject to investigation or challenge under such laws. If imposed for any reason, sanctions under these laws could have a negative effect on our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the breadth of these laws and the limits of safe harbors and exceptions, it is possible that some of our business activities could
be subject to challenge under one or more of such laws. Such a challenge, regardless of the outcome, could have a material adverse effect on our business, business relationships, reputation, financial condition, and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other Federal and State Health Care Laws </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the requirements discussed above, several other health care fraud and abuse laws could have an effect on our business. For
example, provisions of the Social Security Act permit Medicare and Medicaid to exclude an entity that charges the federal health care programs substantially in excess of its usual charges for its services. The terms &#147;usual charge&#148; and
&#147;substantially in excess&#148; are subject to varying interpretations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, the Federal civil False Claims Act prohibits, among
other things, a person from knowingly presenting, or causing to be presented, a false or fraudulent claim for payment or approval and from, making, using, or causing to be made or used, a false record or statement material to a false or fraudulent
claim in order to secure payment or retaining an overpayment by the federal government. In addition to actions initiated by the government itself, the statute authorizes actions to be brought on behalf of the federal government by a private party
having knowledge of the alleged fraud. Because the complaint is initially filed under seal, the action may be pending for some time before the defendant is even aware of the action. If the government intervenes and is ultimately successful in
obtaining redress in the matter or if the plaintiff succeeds in obtaining redress without the government&#146;s involvement, then the plaintiff will receive a percentage of the recovery. Finally, the Social Security Act includes its own provisions
that prohibit the filing of false claims or submitting false statements in order to obtain payment. Violation of these provisions may result in fines, imprisonment or both, and possible exclusion from Medicare or Medicaid programs. Several states,
including California, have enacted comparable false claims laws that apply to all payers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, the civil monetary penalties
statute imposes penalties against any person or entity that, among other things, is determined to have presented or caused to be presented a claim to a federal health program that the person knows or should know is for an item or service that was
not provided as claimed or is false or fraudulent. A person who offers or provides to a Medicare or Medicaid beneficiary any remuneration, including waivers of co-payments and deductible amounts (or any part thereof), that the person knows or should
know is likely to influence the beneficiary&#146;s selection of a particular provider, practitioner or supplier of Medicare or Medicaid payable items or services may be liable for civil monetary penalties of up to $10,000 for each wrongful act and
up to three times the amount improperly claimed. Moreover, in certain cases, providers who routinely waive copayments and deductibles for Medicare and Medicaid beneficiaries can also be held liable under the Anti-Kickback Statute and False Claims
Act. One of the statutory exceptions to the prohibition is non-routine, unadvertised waivers of copayments or deductible amounts based on individualized determinations of financial need or exhaustion of reasonable collection efforts. The Office of
Inspector General of the Department of Health and Human Services, or OIG, emphasizes, however, that this exception should only be used occasionally to address special financial needs of a particular patient. Although this prohibition applies only to
federal healthcare program beneficiaries, applicable state laws related to, among other things, unlawful schemes to defraud, excessive fees for services, tortious interference with patient contracts and statutory or common law fraud, may also be
implicated for similar practices offered to patients covered by commercial payers. It is possible that some of our business practices, including the waiver and/or reduction of co-payments and deductible amounts, could be subject to regulatory
scrutiny at some point in the future, and we cannot provide assurance that we will be found to be in compliance with these laws following any such regulatory review. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, HIPAA created new federal criminal statutes that prohibit, among other actions, knowingly and willfully executing, or attempting
to execute, a scheme to defraud any healthcare benefit program, including private third-party payers, and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent
statement in connection with the delivery of or payment for healthcare benefits, items or services. Like the Federal Anti-kickback Statute, the ACA amended the intent standard for certain healthcare fraud under HIPAA such that a person or entity no
longer needs to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also, many
states have similar fraud and abuse laws that may be broader in scope and may apply regardless of payer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our operations are found to
be in violation of any of the fraud and abuse laws described above or any other laws that apply to us, we may be subject to penalties, including potentially significant criminal and civil and/or administrative penalties, damages, fines,
disgorgement, imprisonment, exclusion from participation in government healthcare programs, contractual damages, reputational harm, administrative burdens, diminished profits and future earnings, and the curtailment or restructuring of our
operations, any of which could adversely affect our ability to operate our business and our results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 94 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ACA, among other things, also imposed new reporting requirements on manufacturers of certain
devices, drugs and biologics for certain payments and transfers of value by them and in some cases their distributors to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family
members. Any failure to comply with these reporting requirements could result in significant fines and penalties. Because we manufacture our own LDTs solely for use by or within our own laboratory, we believe that we are exempt from these reporting
requirements. We cannot assure you, however, that the government will agree with our determination, and a determination that we have violated these laws and regulations, or a public announcement that we are being investigated for possible
violations, could adversely affect our business, prospects, results of operations or financial condition </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employees </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September 30, 2015, we had 108 employees, all but one of whom are full-time, 21 of whom work in laboratory operations, seven in research
and development, 41 in sales and marketing and 39 in general and administrative functions. None of our employees is represented by a labor union or covered by a collective bargaining agreement. We consider our relationship with our employees to be
good. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Suppliers </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on
sole suppliers for critical supply of reagents, equipment and other materials that we use to perform the tests that comprise our Avise products. We also purchase components used in our Avise product transportation kits from sole-source suppliers.
Some of these items are unique to these suppliers and vendors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Facilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We lease approximately 14,000 square feet of office and laboratory space in Vista, California, under a lease that expires in 2017, with options
to extend the lease for two additional 36-month periods. We also lease an additional approximately 19,500 square feet of office space in Vista, California, under a lease that expires in 2018, with an option to extend for an additional 24 months. We
also lease approximately 3,200 square feet of office space in Albuquerque, New Mexico, under a lease that expires at the end of November 2015. We believe that our existing facilities and arrangements are adequate to meet our business needs for at
least the next 12 months and that additional space will be available on commercially reasonable terms, if required. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Environmental Matters
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our operations require the use of hazardous materials (including biological and chemical materials) which subject us to a variety of
federal, state and local environmental and safety laws and regulations. We could be held liable for damages and fines as a result of our business operations. We cannot predict how changes in laws or regulations will affect our business, operations
or the cost of compliance. We mitigate this risk by being in compliance with these laws and the CAP checklists. We have established Universal Precautions, as mandated by the Occupational Safety&nbsp;&amp; Health Administration, to be practiced to
prevent employee exposure to blood and other potentially infectious materials. Engineering and work practice controls are used to eliminate or minimize employee exposure. Personal protective equipment is used when occupational exposure may occur
even though the engineering and work practice controls are in place. This Injury and Illness Prevention Program, or IIPP, is designed to furnish employees with a safe and healthy place of employment. This IIPP describes specific requirements for
program responsibility, compliance, communication, hazard assessment, accident/exposure investigations, hazard correction, training and recordkeeping. In addition, appropriate biohazardous, chemical and sharps waste disposal are in place. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Proceedings </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are not currently a
party to any material legal proceedings, and we are not aware of any pending or threatened legal proceeding against us that we believe are likely to have a material adverse effect on our business, operating results or financial condition. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 95 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx693329_11"></A>MANAGEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officers and Directors </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
following table sets forth the name, age and position of each of our executive officers, key employees and directors as of October 31, 2015. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="46%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:20.00pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Age</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Position</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Executive Officers</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fortunato Ron Rocca</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">54</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">President, Chief Executive Officer and Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Wendy Swedick</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">50</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chief Financial Officer</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Thierry Dervieux, Ph.D.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">47</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chief Scientific Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B><I>Key Employees</I></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Claudia Ibarra</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">53</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Vice President, Laboratory Operations</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">John Wegener</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">47</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Vice President, Sales and Managed Markets</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dennis Takasugi</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">59</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Vice President, Business Development and Marketing</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Brian Littlefield</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">54</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Vice President, Information Services</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B><I>Non-Employee Directors</I></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Frank Witney, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">62</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chairman of the Board of Directors</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Arthur Weinstein, M.D.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">71</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">John M. Radak<SUP STYLE="font-size:85%; vertical-align:top">(1)(2)(3)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">55</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Brian Birk<SUP STYLE="font-size:85%; vertical-align:top">(2)(3)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">55</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">James L.L. Tullis<SUP STYLE="font-size:85%; vertical-align:top">(1)(3)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">68</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Ebetuel Pallares, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">41</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>(1)</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Member of the compensation committee</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>(2)</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Member of the audit committee</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>(3)</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Member of the nominating and corporate governance committee</I> </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Fortunato Ron Rocca</I> has served as our President and Chief Executive Officer and as a member of our board of directors since December
2011. From 2005 to October 2011, Mr.&nbsp;Rocca served as Vice President, Sales and Marketing, and as General Manager, at Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company which was acquired by Nestl&eacute; SA in 2011,
where he was responsible for leading the commercial organization, strategic planning and implementing projects designed to maximize brand sales. Prior to Prometheus, Mr.&nbsp;Rocca was the General Manager of Alpharma Inc., a specialty pharmaceutical
company. Earlier in his career, Mr.&nbsp;Rocca served in senior sales and marketing management positions for Elan Pharmaceuticals, Inc., a neuroscience-focused biotechnology company and Janssen Pharmaceuticals, Inc., a pharmaceutical company of
Johnson&nbsp;&amp; Johnson. Mr.&nbsp;Rocca received a B.A. in Marketing and Personnel Management from Towson State University. Mr.&nbsp;Rocca&#146;s extensive knowledge of our business, as well as his over 25 years of experience in the diagnostic
and pharmaceutical industries, contributed to our board of directors&#146; conclusion that he should serve as a director of our company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Wendy Swedick </I>has served as our Chief Financial Officer since June 2010. Prior to joining Exagen, Ms.&nbsp;Swedick founded Vector B
Consulting, a business consulting practice, in 2003 and she served as its President until August 2010. Ms.&nbsp;Swedick previously served as the Director of Product Development for Qynergy Corporation, a company which designs and develops energy and
power solutions, and Chief Financial Officer of Zia Laser, Inc., a semiconductor laser manufacturing company. Prior to that, Ms.&nbsp;Swedick served as Vice President and Controller at the cable division of Media One Group, Inc., a
telecommunications company which was acquired by AT&amp;T Corp. in 2000, and as a senior accountant at KPMG LLP. Ms.&nbsp;Swedick is currently a senior mentor for the New Directions Institute and graduated with honors with a B.A. in Business
Administration&nbsp;&amp; Accounting from the University of New Mexico. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Thierry Dervieux, Ph.D. </I>has served as our Chief Scientific
Officer and Medical Laboratory Director since October 2010. Dr.&nbsp;Dervieux has nearly 20 years of experience with the development of drug monitoring and molecular diagnostic assays in partnership with academia and diagnostic industry. Prior to
joining Exagen, Dr.&nbsp;Dervieux was Vice President of Research and Development with Cypress Bioscience, Inc., a pharmaceutical company with a focus on drugs to treat central nervous system </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 96 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
disorders, where he developed our current portfolio in the rheumatology space from 2008 to October 2010. He previously served as Senior Director Research&nbsp;and Development with Proprius
Pharmaceuticals, Inc., a specialty pharmaceutical and personalized medicine company focused in rheumatology and pain management, until its acquisition by Cypress Bioscience. Prior to that, he served as Principal Scientist and Director of
Research&nbsp;and Development at Prometheus Laboratories. Dr.&nbsp;Dervieux is board certified by the American Board of Clinical Chemistry and holds certificates of qualification as medical laboratory director in the categories of cellular
immunology, clinical chemistry, drug monitoring, genetic testing and diagnostic immunology. Dr.&nbsp;Dervieux holds Pharm.D. and Ph.D. degrees from Claude Bernard University in Lyon, France, an inter-university diploma in biostatistics from the
University of Pierre et Marie Curie in Paris, France, and trained at St. Jude Children&#146;s Research Hospital in Memphis, Tennessee. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Key Employees
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Claudia Ibarra </I>has served as our Vice President, Laboratory Operations since January 2014, after joining Exagen in February
2012 as our Senior Director, Laboratory Operations. Ms.&nbsp;Ibarra previously served in numerous positions at Genoptix, Inc., a diagnostic services company focused on the needs of community hematologists and oncologists, from 2006 to January 2012,
including as the Director, Molecular Laboratory and as the Molecular Genetic Training Program Coordinator. Prior to Genoptix, Ms.&nbsp;Ibarra worked in a variety of clinical laboratories in the fields of clinical chemistry, endocrinology and
immunology. Ms.&nbsp;Ibarra holds a degree in Biochemistry with specialization in clinical laboratory science from the University of Buenos Aires, Argentina. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>John Wegener </I>has served as our Vice President, Sales and Managed Markets since November 2013. Prior to joining Exagen, Mr.&nbsp;Wegener
served in various capacities with Prometheus Laboratories from 1999 to October 2013, including as the National Director, Managed Care and a Regional Sales Director. During his time at Prometheus, Mr.&nbsp;Wegener launched five new diagnostic tests
and managed diagnostic channels with national general reference laboratories. Prior to Prometheus, Mr.&nbsp;Wegener worked in sales for Novartis. Mr.&nbsp;Wegener holds a B.S. in Business from the University of Arizona. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Dennis Takasugi </I>has served as our Vice President, Business Development and Marketing since April 2011. Prior to joining Exagen, from
2005 to April 2011, Mr.&nbsp;Takasugi served as the Head of Strategic Business Development, Gastroenterology, at Prometheus Laboratories. Prior to Prometheus, Mr.&nbsp;Takasugi served as the Senior Director of Marketing for Santarus, Inc., a
gastroenterology-focused specialty pharmaceutical company, from 2002 to 2005. Prior to that, Mr.&nbsp;Takasugi worked in business development and marketing for Maxim Pharmaceuticals, Inc., a biopharmaceutical company developing cancer therapeutics,
from 2000 to 2002, and for Ligand Pharmaceuticals, Inc., a pharmaceutical company, from 1998 to 2000. Mr.&nbsp;Takasugi began his career by spending 15 years at Eli Lilly and Company. Mr.&nbsp;Takasugi holds a B.S. in Pharmacy from Idaho State
University, where he graduated with honors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Brian Littlefield </I>has served as our Vice President, Information Services since April
2014. Prior to joining Exagen, Mr.&nbsp;Littlefield served as the Senior Director, Information Services at Prometheus Laboratories from 1998 to March 2014. At Prometheus, Mr.&nbsp;Littlefield led the establishment of the IT function and was highly
involved with the creation and execution of controls necessary for regulatory compliance. Prior to Prometheus, Mr.&nbsp;Littlefield worked as a consultant with Deloitte and as the Director of Support Services at Quidel Corporation, a diagnostics
company. Mr.&nbsp;Littlefield holds a B.S. in Biochemistry from Purdue University and an M.B.A. from Pepperdine University. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Non-Employee Directors
</B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Frank Witney, Ph.D.</I> has served as a member of our board of directors since September 2014, and was appointed the chairman
of our board of directors in May 2015. Since July 2011, Dr.&nbsp;Witney has served as president, chief executive officer and a director of Affymetrix, Inc., a company focused on genomics analysis, and previously served as Affymetrix&#146;s executive
vice president and chief commercial officer from December 2008 to April 2009. Dr.&nbsp;Witney served as president and chief executive officer of Dionex Corporation, a manufacturer of chromatography systems, from April 2009 to May 2011. Previously,
Dr.&nbsp;Witney served as president and chief executive officer of Panomics, Inc., a provider of life sciences research reagents, from 2002 to 2008. Since March 2014, Dr.&nbsp;Witney has served as a member of the board of directors of Cerus
Corporation, a biomedical products company focused in the field of blood safety. Dr.&nbsp;Witney was a post-doctoral fellow at the National Institutes of Health and holds a Ph.D. in Molecular and Cellular Biology and an M.S. in Microbiology from
Indiana University, and a B.S. in Microbiology from the University of Illinois. Dr.&nbsp;Witney&#146;s industry experience serving in various management roles of other biotechnology companies contributed to our board of directors&#146; conclusion
that he should serve as a director of our company. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Arthur Weinstein, M.D.</I> has served as a member of our board of directors
since December 2013. Dr.&nbsp;Weinstein has served as a Professor of Medicine at Georgetown University since 2002, and as the Chief of Rheumatology and Associate Chair of Medicine at the Washington Hospital Center since 2001. He has served as the
co-chair of the board of directors for the Lupus Foundation of America&#146;s regional chapter for Washington, D.C., Maryland and Virginia since September 2013, and prior to that, served as its vice chair from September 2012 to September 2013, and
has served as a member of the board since 2002. He also served as the chair of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 97 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
that board&#146;s medical scientific advisory committee from 2005 to September 2012. Dr.&nbsp;Weinstein was a Fellow at the Royal College of Physicians (UK) in 2011 and was recognized as a Master
by the American College of Rheumatology in 2009. Dr.&nbsp;Weinstein received an M.D. from the University of Toronto, and completed his residency and fellowship training in Internal Medicine and Rheumatology at the University of Toronto and
University of London (UK). Dr.&nbsp;Weinstein&#146;s academic and professional work, specifically in the areas of rheumatology and lupus, contributed to our board of directors&#146; conclusion that he should serve as a director of our company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>John M. Radak</I> has served as a member of our board of directors since September 2014. Since August 2014, Mr.&nbsp;Radak has served as
chief financial officer of ArborGen Inc., a developer of biotechnology tree seedling products. From March 2012 to September 2013, he served as chief financial officer of SkinIt Inc., a company specializing in the personalization of consumer
electronic devices. From February 2007 to October 2011, Mr.&nbsp;Radak served as the chief financial officer of Quidel Corporation, a medical diagnostics company, after which he continued to serve as special advisor to the chief executive officer of
Quidel from November 2011 to July 2012. Before his time with Quidel, Mr.&nbsp;Radak served as chief accounting officer and vice president of finance at Life Technologies Corporation, a life science tools manufacturing company, from 2003 to 2007, as
vice president of finance and corporate controller of Sunrise Medical Inc., a durable home medical device company, from 1994 to 2001, and as vice president of finance for Bird Products Corporation, a medical device manufacturer, from 1992 to 1994.
Mr.&nbsp;Radak also served as an independent consultant for various companies from 2001 to 2003. Mr.&nbsp;Radak has served on several non-profit boards, including Project Concern International, an organization promoting disease prevention and the
improvement of community health worldwide, where he has served from 2002 to 2008. Mr.&nbsp;Radak received a B.A. in Business Administration, Accounting and Finance from California State University, Fullerton and an M.B.A. from the University of
Southern California. Mr.&nbsp;Radak&#146;s significant financial experience with other companies in the healthcare, life sciences and emerging technologies industries contributed to our board of directors&#146; conclusion that he should serve as a
director of our company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Brian Birk</I> has served as a member of our board of directors since June 2008. In 2006, Mr.&nbsp;Birk
co-founded Sun Mountain Capital, a boutique private equity firm focused on the Southwest and Rocky Mountain regions which currently manages direct investment funds and funds of funds vehicles. Prior to forming Sun Mountain Capital, Mr.&nbsp;Birk was
a Vice President and Director of Private Equity at Fort Washington Capital Partners, a professional investment management services company. Mr.&nbsp;Birk was also a senior executive at MetaWeb Technologies, Inc., a technology and web development
company acquired by Google Inc. in 2010, the vice president of technology commercialization at Applied Minds, LLC, a technology consulting company, and the president of a division at BiosGroup Inc., a company which commercialized complex science
software<I>.</I> In addition, Mr.&nbsp;Birk held a senior manager position at the Boston Consulting Group, Inc., a global management consulting firm, and finance manager positions at General Electric Company and GE Capital Corporation. Mr.&nbsp;Birk
is a currently a member of the board of directors of several private companies, including Aspen Avionics, Inc., an aircraft avionics manufacturer, and American Clay Enterprises, LLC, a plaster manufacturing and sales company. Mr.&nbsp;Birk received
a B.S. in Economics from Carleton College and an M.B.A. from Northwestern University&#146;s Kellogg School of Management. Mr.&nbsp;Birk&#146;s experience as a venture capitalist and prior executive experience contributed to our board of
directors&#146; conclusion that he should serve as a director of our company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>James L.L. Tullis</I> has served as a member of our
board of directors since May 2015.&nbsp;Mr. Tullis founded Tullis Health Investors, a venture capital firm specializing in investments in the healthcare industry, in 1986, and has served as its chief executive officer since its inception.&nbsp;Prior
to that, Mr.&nbsp;Tullis was a senior vice president at E.F. Hutton&nbsp;&amp; Co., a stock brokerage firm, and a principal at Morgan Stanley&nbsp;&amp; Co., where he worked with the healthcare investment research and banking teams.&nbsp;Since 2006,
Mr.&nbsp;Tullis has served as a member of the board of directors of Lord Abbett&nbsp;&amp; Co. Mutual Funds, an investment management firm, where he also serves on the investment committee, contract committee and proxy committee.&nbsp;Since 1998, he
has served as a member of the board of directors of Crane Co., an industrial products manufacturing company, where he also serves as Chair of the Management Organization and Compensation Committee.&nbsp;Mr. Tullis also currently serves as a member
of the board of directors of several private companies, including LivHOME, Inc., an at-home senior care company, where he also serves on the audit committee and compensation committee, SupplyPro, Inc., an inventory management solutions company,
electroCore, LLC, an electroceutical healthcare company, and SafeOp Surgical, Inc., a medical device and technology company.&nbsp;Mr. Tullis holds a B.A. from Stanford University and an M.B.A. from Harvard Business School.&nbsp;Mr. Tullis&#146;s
extensive experience serving as a venture capitalist and board member for numerous companies in the health care industry contributed to our board of directors&#146; conclusion that Mr.&nbsp;Tullis should serve as a director of our company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Ebetuel Pallares, Ph.D.</I> has served as a member of our board of directors since October 2012. Dr.&nbsp;Pallares founded Joseph Advisory
Services, LLC, a strategic consulting firm, in 2006, and has served as its manager since that time. In June 2009, he co-founded Cottonwood Capital Partners, the general partner of Cottonwood Technology Fund, a seed and early-stage venture fund with
headquarters in El Paso, Texas, and he served as its managing partner until December 2014. In December 2014, Dr.&nbsp;Pallares founded Proficio Capital Management (PCM), LLC, a seed and early-stage venture fund headquartered in El Paso, TX, and he
has served as its general partner since that time. Through PCM, Dr.&nbsp;Pallares manages several investments, including PCM/Exagen L.P. Dr.&nbsp;Pallares also serves on several corporate and non-profit boards, as an advisor to the UT Horizon Fund,
the venture capital investment fund of the University of Texas system, as an Investor in Residence for New Mexico State University&#146;s Arrowhead Center and on the limited partnership advisory committee for several venture
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 98 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
funds. He received a B.A. in economics from Brandeis University, an M.B.A. from The University of Texas at El Paso, or UTEP, and a Ph.D. in International Business from UTEP.
Dr.&nbsp;Pallares&#146;s extensive venture capital experience and his service as a director for numerous companies contributed to our board of directors&#146; conclusion that he should serve as a director of our company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Composition and Election of Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Director
Independence </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors currently consists of seven members. Our board of directors has determined that all of our
directors, other than Mr.&nbsp;Rocca, are independent directors in accordance with the listing requirements of The NASDAQ Global Market. The NASDAQ independence definition includes a series of objective tests, including that the director is not, and
has not been for at least three years, one of our employees and that neither the director nor any of his family members has engaged in various types of business dealings with us. In addition, as required by NASDAQ rules, our board of directors has
made a subjective determination as to each independent director that no relationships exist, which, in the opinion of our board of directors, would interfere with the exercise of independent judgment in carrying out the responsibilities of a
director. In making these determinations, our board of directors reviewed and discussed information provided by the directors and us with regard to each director&#146;s business and personal activities and relationships as they may relate to us and
our management. There are no family relationships among any of our directors or executive officers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Classified Board of Directors </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with the terms of our amended and restated certificate of incorporation that will go into effect immediately prior to the
completion of this offering, our board of directors will be divided into three classes with staggered, three-year terms. At each annual meeting of stockholders, the successors to directors whose terms then expire will be elected to serve from the
time of election and qualification until the third annual meeting following election. Effective upon the completion of this offering, our directors will be divided among the three classes as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Class I directors will be James L.L. Tullis and Ebetuel Pallares, Ph.D., and their terms will expire at our first annual meeting of stockholders following this offering; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Class II directors will be Brian Birk and Arthur Weinstein, M.D., and their terms will expire at our second annual meeting of stockholders following this offering; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Class III directors will be John Radak, Fortunato Ron Rocca and Frank Witney, Ph.D., and their terms will expire at our third annual meeting of stockholders following this offering. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation that will go into effect immediately prior to the completion of this offering will
provide that the authorized number of directors may be changed only by resolution of the board of directors. Any additional directorships resulting from an increase in the number of directors will be distributed among the three classes so that, as
nearly as possible, each class will consist of one-third of the directors. The division of our board of directors into three classes with staggered three-year terms may delay or prevent a change of our management or a change in control of our
company. Our directors may be removed only for cause by the affirmative vote of the holders of at least two thirds of our outstanding voting stock then entitled to vote in the election of directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Leadership Structure </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of
directors is currently led by its chairman, Frank Witney, Ph.D. Our board of directors recognizes that it is important to determine an optimal board leadership structure to ensure the independent oversight of management as the company continues to
grow. We separate the roles of chief executive officer and chairman of the board in recognition of the differences between the two roles. The chief executive officer is responsible for setting the strategic direction for the company and the
day-to-day leadership and performance of the company, while the chairman of the board of directors provides guidance to the chief executive officer and presides over meetings of the full board of directors. We believe that this separation of
responsibilities provides a balanced approach to managing the board of directors and overseeing the company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors has
concluded that our current leadership structure is appropriate at this time. However, our board of directors will continue to periodically review our leadership structure and may make such changes in the future as it deems appropriate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 99 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Role of Board in Risk Oversight Process </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors has responsibility for the oversight of the company&#146;s risk management processes and, either as a whole or through
its committees, regularly discusses with management our major risk exposures, their potential impact on our business and the steps we take to manage them. The risk oversight process includes receiving regular reports from board committees and
members of senior management to enable our board to understand the company&#146;s risk identification, risk management and risk mitigation strategies with respect to areas of potential material risk, including operations, finance, legal, regulatory,
strategic and reputational risk. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The audit committee reviews information regarding liquidity and operations, and oversees our management
of financial risks. Periodically, the audit committee reviews our policies with respect to risk assessment, risk management, loss prevention and regulatory compliance. Oversight by the audit committee includes direct communication with our external
auditors, and discussions with management regarding significant risk exposures and the actions management has taken to limit, monitor or control such exposures. The compensation committee is responsible for assessing whether any of our compensation
policies or programs has the potential to encourage excessive risk-taking. The nominating/corporate governance committee manages risks associated with the independence of the board, corporate disclosure practices, and potential conflicts of
interest. While each committee is responsible for evaluating certain risks and overseeing the management of such risks, the entire board is regularly informed through committee reports about such risks. Matters of significant strategic risk are
considered by our board as a whole. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Committees and Independence </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board has established three standing committees&#151;audit, compensation and nominating and corporate governance&#151;each of which
operates under a charter that has been approved by our board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board has determined that all of the members of each of the
board&#146;s three standing committees are independent as defined under the rules of The NASDAQ Global Market. In addition, all members of the audit committee meet the independence requirements contemplated by Rule 10A-3 under the Exchange Act. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Audit Committee </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The audit
committee&#146;s main function is to oversee our accounting and financial reporting processes and the audits of our financial statements. This committee&#146;s responsibilities include, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">appointing our independent registered public accounting firm; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">evaluating the qualifications, independence and performance of our independent registered public accounting firm; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approving the audit and non-audit services to be performed by our independent registered public accounting firm; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing the design, implementation, adequacy and effectiveness of our internal accounting controls and our critical accounting policies; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">discussing with management and the independent registered public accounting firm the results of our annual audit and the review of our quarterly unaudited financial statements; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing, overseeing and monitoring the integrity of our financial statements and our compliance with legal and regulatory requirements as they relate to financial statements or accounting matters; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing on a periodic basis, or as appropriate, any investment policy and recommending to our board any changes to such investment policy; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing with management and our auditors any earnings announcements and other public announcements regarding our results of operations; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">preparing the report that the SEC requires in our annual proxy statement; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing and approving any related party transactions and reviewing and monitoring compliance with our code of conduct and ethics; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing and evaluating, at least annually, the performance of the audit committee and its members including compliance of the audit committee with its charter. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The members of our audit committee are John M. Radak, Brian Birk and Ebetuel Pallares, Ph.D. Mr.&nbsp;Radak serves as the chairperson of the
committee. All members of our audit committee meet the requirements for financial literacy under the applicable rules and regulations of the SEC and The NASDAQ Global Market. Our board of directors has determined that Mr.&nbsp;Radak is an
&#147;audit committee financial expert&#148; as defined by applicable SEC rules and has the requisite financial sophistication as defined under the applicable NASDAQ rules and regulations. Our board of directors has determined each of Mr.&nbsp;Radak
and Dr.&nbsp;Pallares is independent under the applicable rules of the SEC and The NASDAQ Global Market. Under the applicable NASDAQ Global Market rules, we are </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 100 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
permitted to phase in our compliance with the independent audit committee requirements of The NASDAQ Global Market on the same schedule as we are permitted to phase in our compliance with the
independent audit committee requirements pursuant to Rule 10A-3 under the Exchange Act, which require: (1)&nbsp;one independent member at the time of listing, (2)&nbsp;a majority of independent members within 90 days of listing and (3)&nbsp;all
independent members within one year of listing. We will comply with the phase-in requirements of the NASDAQ Global Market rules, and within one year of our listing on the NASDAQ Global Market, all members of our audit committee will be independent
under NASDAQ rules and Rule 10A-3. Upon the listing of our common stock on The NASDAQ Global Market, the audit committee will operate under a written charter that satisfies the applicable standards of the SEC and The NASDAQ Global Market. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Compensation Committee </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
compensation committee approves policies relating to compensation and benefits of our officers and employees. The compensation committee approves corporate goals and objectives relevant to the compensation of our chief executive officer and other
executive officers, evaluates the performance of these officers in light of those goals and objectives and approves the compensation of these officers based on such evaluations. The compensation committee also approves the issuance of stock options
and other awards under our equity plan. The compensation committee will review and evaluate, at least annually, the performance of the compensation committee and its members, including compliance by the compensation committee with its charter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The members of our compensation committee are Frank Witney, Ph.D., James L.L. Tullis and John&nbsp;M. Radak. Mr.&nbsp;Radak serves as the
chairperson of the committee. Our Board has determined that each member of this committee is independent under the applicable rules and regulations of The NASDAQ Global Market, is a &#147;non-employee director&#148; as defined in Rule 16b-3
promulgated under the Exchange Act and is an &#147;outside director&#148; as that term is defined in Section&nbsp;162(m) of the U.S. Internal Revenue Code of 1986, as amended, or Section&nbsp;162(m). Upon the listing of our common stock on The
NASDAQ Global Market, the compensation committee will operate under a written charter, which the compensation committee will review and evaluate at least annually. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Nominating and Corporate Governance Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The nominating and corporate governance committee is responsible for assisting our board of directors in discharging the board&#146;s
responsibilities regarding the identification of qualified candidates to become board members, the selection of nominees for election as directors at our annual meetings of stockholders (or special meetings of stockholders at which directors are to
be elected), and the selection of candidates to fill any vacancies on our board of directors and any committees thereof. In addition, the nominating and corporate governance committee is responsible for overseeing our corporate governance policies,
reporting and making recommendations to our board of directors concerning governance matters and oversight of the evaluation of our board of directors. The members of our nominating and corporate governance committee are Brian Birk, James&nbsp;L.L.
Tullis, and John Radak. Mr.&nbsp;Birk serves as the chairman of the committee. Our board has determined that each member of this committee is independent under the applicable rules and regulations of The NASDAQ Global Market relating to nominating
and corporate governance committee independence. Upon the listing of our common stock on The NASDAQ Global Market, the nominating and corporate governance committee will operate under a written charter, which the nominating and corporate governance
committee will review and evaluate at least annually. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation Committee Interlocks and Insider Participation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During 2014, the following individuals served as members of our compensation committee: Mr.&nbsp;Birk, Dr.&nbsp;Witney, Mr.&nbsp;Radak and
former directors Curt LaBelle, Ph.D. and Michael Walsh. Effective July 2015, the current members of our compensation committee are Dr.&nbsp;Witney, Mr.&nbsp;Tullis and Mr.&nbsp;Radak. Dr.&nbsp;LaBelle, Mr.&nbsp;Birk and Mr.&nbsp;Tullis are each
affiliated with certain of our principal stockholders. See &#147;Certain Relationships and Related Person Transactions&#148; for additional information on the securities acquired by such principal stockholders and related agreements such
stockholders are party to with us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None of the members of our compensation committee has ever been one of our officers or employees. None
of our executive officers currently serves, or has served, as a member of the board of directors or compensation committee of any entity that has one or more executive officers serving as a member of our board of directors or compensation committee.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 101 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Diversity </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the completion of this offering, our nominating and corporate governance committee will be responsible for reviewing with the board of
directors, on an annual basis, the appropriate characteristics, skills and experience required for the board of directors as a whole and its individual members. In evaluating the suitability of individual candidates (both new candidates and current
members), the nominating and corporate governance committee, in recommending candidates for election, and the board of directors, in approving (and, in the case of vacancies, appointing) such candidates, will take into account many factors,
including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">personal and professional integrity, ethics and values; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">experience in corporate management, such as serving as an officer or former officer of a publicly-held company; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">experience as a board member or executive officer of another publicly-held company; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">strong finance experience; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">diversity of expertise and experience in substantive matters pertaining to our business relative to other board members; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">diversity of background and perspective, including, but not limited to, with respect to age, gender, race, place of residence and specialized experience; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">experience relevant to our business industry and with relevant social policy concerns; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">relevant academic expertise or other proficiency in an area of our business operations. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Currently, our board of directors evaluates, and following the completion of this offering will evaluate, each individual in the context of
the board of directors as a whole, with the objective of assembling a group that can best maximize the success of the business and represent stockholder interests through the exercise of sound judgment using its diversity of experience in these
various areas. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Code of Business Conduct and Ethics </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have adopted a written code of business conduct and ethics that applies to our directors, officers and employees, including our principal
executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. Upon the completion of this offering, our code of business conduct and ethics will be available under the Corporate
Governance section of our website at www.exagen.com. In addition, we intend to post on our website all disclosures that are required by law or the listing standards of The NASDAQ Global Market concerning any amendments to, or waivers from, any
provision of the code. The reference to our website address does not constitute incorporation by reference of the information contained at or available through our website, and you should not consider it to be a part of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 102 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx693329_12"></A>EXECUTIVE AND DIRECTOR COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This section discusses the material components of the executive compensation program for our executive officers who are named in the
&#147;2014 Summary Compensation Table&#148; below. In 2014, our chief executive officer and our two other highest-paid executive officers, or our named executive officers, were as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Fortunato Ron Rocca, President and Chief Executive Officer; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Wendy Swedick, Chief Financial Officer; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Thierry Dervieux, Ph.D., Chief Scientific Officer. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion may contain
forward-looking statements that are based on our current plans, considerations, expectations and determinations regarding future compensation programs. Actual compensation programs that we adopt following the completion of this offering may differ
materially from the currently planned programs summarized in this discussion. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2014 Summary Compensation Table </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information concerning the compensation of our named executive officers during the fiscal year ended
December&nbsp;31, 2014: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="55%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:97.90pt; font-size:8pt; font-family:Times New Roman"><B>Name and Principal Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option</B><br><B>Awards</B><br><B>($)(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Non-Equity</B><br><B>Incentive Plan</B><br><B>Compensation</B><br><B>($)(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other</B><br><B>Compensation</B><br><B>($)(3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fortunato Ron Rocca</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">311,446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">311,148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">155,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">787,511</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>President and Chief Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2013</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">300,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">135,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,919</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">440,919</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wendy Swedick</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">228,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,920</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,589</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104,759</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">453,805</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Financial Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2013</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">205,746</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">258,271</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thierry Dervieux, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">244,578</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,337</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">361,968</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Scientific Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2013</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">240,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">299,291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">The amounts in the &#147;Option Awards&#148; column reflect the aggregate grant date fair value of stock options granted computed in accordance with the provisions of Accounting Standards Codification (ASC) 718,
<I>Compensation&#151;Stock Compensation</I>. The assumptions that we used to calculate these amounts are discussed in Note&nbsp;12 to our financial statements appearing at the end of this prospectus. These amounts do not reflect the actual economic
value that will be realized by the named executive officer upon the vesting of the stock options, the exercise of the stock options, or the sale of the common stock underlying such stock options. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Bonuses under our 2014 Management Bonus Program for fiscal year 2014 were paid in February 2015. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Represents employer contributions under our 401(k) plan on behalf of each executive. Also includes $66,329 in relocation expenses and $31,574 in a tax gross up related to such relocation expenses paid to
Ms.&nbsp;Swedick in 2014. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Narrative Disclosure to Compensation Tables </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Employment Agreements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Offer
Letter with Thierry Dervieux. Ph.D. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2010, we entered into an offer letter with Dr.&nbsp;Dervieux, which was amended in
September 2011. The offer letter with Dr.&nbsp;Dervieux will be terminated effective upon consummation of this offering and will be superseded by Dr.&nbsp;Dervieux&#146;s new employment agreement, as described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the offer letter, Dr.&nbsp;Dervieux receives an annual base salary of $240,000. Dr.&nbsp;Dervieux is eligible to participate in
our management bonus plan, with the goals and payments under the management bonus plan to be defined and approved by our board of directors. Pursuant to the offer letter, Dr.&nbsp;Dervieux received options to purchase 100,000 shares of our common
stock in connection with the commencement of his employment. Such options vest as to 25% of the total number of option shares on the first anniversary of the date of grant and in equal monthly installments over the ensuing 36 months, and will become
fully vested (1)&nbsp;upon the acquisition of our company and (2)&nbsp;the termination of Dr.&nbsp;Dervieux&#146;s employment by us without cause. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 103 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Dr.&nbsp;Dervieux&#146;s offer letter, if we terminate Dr.&nbsp;Dervieux&#146;s
employment without cause or Dr.&nbsp;Dervieux resigns for good reason (as defined below), Dr.&nbsp;Dervieux will be entitled to the following payments and benefits: (1)&nbsp;his fully earned but unpaid base salary through the date of termination at
the rate then in effect, plus all other amounts under any compensation plan or practice to which he is entitled, and (2)&nbsp;a lump sum cash payment in an amount equal to his monthly base salary as in effect immediately prior to the date of
termination for the 12-month period following the date of termination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of Dr.&nbsp;Dervieux&#146;s offer letter, &#147;good
reason&#148; generally means: (1)&nbsp;a material reduction in Dr.&nbsp;Dervieux&#146;s duties or responsibilities; (2)&nbsp;the relocation of our company&#146;s principal business location to a point more than 250 miles east of its Albuquerque
location or more than 1,000 miles from Dr.&nbsp;Dervieux&#146;s principal residence; or (3)&nbsp;a material reduction by us of Dr.&nbsp;Dervieux&#146;s base salary as the result of a company-wide compensation reduction or in connection with similar
decreases for the management team of our company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Employment Agreements with Fortunato Ron Rocca, Wendy Swedick and Thierry Dervieux,
Ph.D. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into employment agreements with each of Mr.&nbsp;Rocca, Ms.&nbsp;Swedick and Dr.&nbsp;Dervieux, to be effective
as of the date prior to the date on which our common stock commences trading pursuant to this offering. The following is a summary of the material terms of the employment agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the employment agreements, Mr.&nbsp;Rocca, Ms.&nbsp;Swedick and Dr.&nbsp;Dervieux will have initial annual base
salaries of $440,000, $295,000 and $295,000, respectively, which amounts will be subject to review annually by and at the sole discretion of the compensation committee of our board of directors or its designee. In addition, each of Mr.&nbsp;Rocca,
Ms.&nbsp;Swedick and Dr.&nbsp;Dervieux shall participate in any bonus plan our board of directors or its designee may approve for our senior executives. Mr.&nbsp;Rocca, Ms.&nbsp;Swedick and Dr.&nbsp;Dervieux&#146;s target bonus under any such bonus
plan shall be 55%, 35% and 30%, respectively, of each such executive&#146;s then-applicable base salary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the
employment agreements, if the company terminates any of Mr.&nbsp;Rocca, Ms.&nbsp;Swedick or Dr.&nbsp;Dervieux without &#147;cause&#148; or if any such executive resigns for &#147;good reason&#148; (each as defined in the applicable employment
agreement), such executive will be entitled to the following payments and benefits: (1)&nbsp;his or her fully earned but unpaid base salary through the date of termination at the rate then in effect, accrued and unused paid time off, plus all other
benefits, if any, under any group retirement plan, nonqualified deferred compensation plan, equity award plan or agreement, health benefits plan or other group benefit plan to which such executive may be entitled to under the terms of such plans or
agreements; (2)&nbsp;a lump sum cash payment in an amount equal to 12 months of his or her base salary as in effect immediately prior to the date of termination; (3)&nbsp;continuation of health benefits for a period of 12 months following the date
of termination; and (4)&nbsp;the automatic acceleration of the vesting and exercisability of any outstanding unvested stock awards as to the number of stock awards that would have vested over the 12-month period following termination had the
executive remained continuously employed by the company during such period. In addition, in the event the company terminates any of Mr.&nbsp;Rocca, Ms.&nbsp;Swedick or Dr.&nbsp;Dervieux without cause or if any such executive resigns for good reason
within 12 months following a &#147;change in control&#148; (as defined in the applicable employment agreement), such executive will be entitled to receive, in addition to the severance benefits described in clauses (1), (2)&nbsp;and (3)&nbsp;above,
a lump sum cash payment in an amount equal to such executive&#146;s target bonus for the year in which the date of termination occurs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the employment agreements, in the event of any of Mr.&nbsp;Rocca, Ms.&nbsp;Swedick or Dr.&nbsp;Dervieux&#146;s
separation from service by reason of such executive&#146;s death or discharge following such executive&#146;s permanent disability, such executive will be entitled to the automatic acceleration of the vesting and exercisability of any outstanding
unvested stock awards as to the number of stock awards that would have vested over the 12-month period following termination had the executive remained continuously employed by the company during such period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in the event the company terminates any of Mr.&nbsp;Rocca, Ms.&nbsp;Swedick or Dr.&nbsp;Dervieux without cause or if any such
executive resigns for good reason within three months prior to or 12 months following a change in control, the vesting and/or exercisability of any outstanding unvested portion of the executive&#146;s stock awards will be automatically accelerated
on the later of the date of such executive&#146;s separation from service and the date of the change in control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The employment
agreements also contain standard confidentiality, non-competition and non-solicitation covenants. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Executive Relocation Agreement with
Wendy Swedick </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2014, we entered into an executive relocation agreement with Wendy Swedick. Pursuant to the terms of the
relocation agreement, Ms.&nbsp;Swedick is entitled to certain benefits in connection with her relocation to the San Diego, California area. Specifically, Ms.&nbsp;Swedick was entitled to reimbursement of home selling expenses up to a maximum of
$30,000 and household and vehicle moving expenses up to a maximum of $20,000, as well as a make-whole payment for any discount below fair market value necessary to sell her home in an expedited manner. The company reimbursed Ms.&nbsp;Swedick for
income taxes payable in connection with the moving expenses and make-whole payments that were deemed taxable to Ms.&nbsp;Swedick as well as income taxes payable on the reimbursed amount. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 104 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Base Salaries </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, base salaries for our named executive officers are initially established through arm&#146;s length negotiation at the time the
executive officer is hired, taking into account such executive officer&#146;s qualifications, experience and prior salary. Base salaries of our named executive officers are generally reviewed annually and are based on the scope of an executive
officer&#146;s responsibilities, individual contribution, prior experience and sustained performance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2014 base salaries for
Mr.&nbsp;Rocca, Ms.&nbsp;Swedick and Dr.&nbsp;Dervieux were $312,000, $235,000 and $245,000, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2014 Exagen Management Bonus Program
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our named executive officers were eligible to participate in the 2014 Exagen Management Bonus Program, or the Bonus Program. The
Bonus Program was administered by our board of directors, and our board of directors was responsible for the approval of participation, award targets, performance measures and earned awards under the Bonus Program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Bonus Program, our board of directors made awards based on an annual revenue objective determined for the performance
measurement period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Bonus Program allowed for annual cash incentive awards, which are determined by applying a target bonus
multiplier, as set forth below, to each covered employee&#146;s base salary (with 0% credit awarded for performance below 85% of the targeted level and 150% credit awarded for performance at or above 150% of the targeted level). Our board of
directors, however, retained the discretion to increase or reduce the final bonus payments, regardless of actual company performance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
target bonuses for our named executive officers for 2014 were as follows (and remain unchanged for 2015 until a public offering is achieved): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="19%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Target&nbsp;Bonus&nbsp;as&nbsp;a</B><br><B>Percentage of</B><br><B>Base Salary</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fortunato Ron Rocca</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wendy Swedick</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thierry Dervieux, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The annual revenue objective for the Bonus Program for 2014 was established in December 2013. Specifically,
the objective was a Cash Basis Net Revenue Objective for the year ending December&nbsp;31, 2014 of $12.0 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors
determined that our net revenues for 2014 of $11.725 million substantially met our goal, and thus our board of directors awarded an achievement level of 100% relative to the Net Revenue Objective for 2014 bonus purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result, the bonuses paid to our named executive officers under the Bonus Program for 2014 were as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014&nbsp;Bonus&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fortunato Ron Rocca</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">155,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wendy Swedick</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,589</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thierry Dervieux, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Equity Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We offer stock options to our employees, including our named executive officers, as the long-term incentive component of our compensation
program. We typically grant equity awards to key new hires upon their commencing employment with us. Our stock options allow employees to purchase shares of our common stock at a price per share equal to the fair market value of our common stock on
the date of grant and may or may not be intended to qualify as &#147;incentive stock options&#148; for U.S. federal income tax purposes. In the past, our board of directors has determined the fair market value of our common stock based upon inputs
including valuation reports prepared by third-party valuation firms from time to time. Generally, the stock options we grant vest as to 25% of the total number of option shares on the first anniversary of the date of grant and in equal monthly
installments over the ensuing 36 months, subject to the employee&#146;s continued employment with us on the vesting date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 105 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock options granted to our named executive officers may be subject to accelerated vesting in
certain circumstances. For additional discussion, please see &#147;&#151;Employment Agreements&#148; above and &#147;&#151;Other Elements of Compensation&#151;Change in Control Benefits&#148; below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2014, each of Mr.&nbsp;Rocca, Ms.&nbsp;Swedick and Mr.&nbsp;Dervieux was granted an option to purchase 3,015,000, 600,000 and 475,000
shares of our common stock, respectively, with an exercise price of $0.18 per share. The stock options vest as to 25% of the total number of option shares on the first anniversary of the date of grant and in equal monthly installments over the
ensuing 36 months, subject to the employee&#146;s continued employment with us on the vesting date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the effectiveness of this
offering, we intend to adopt a 2015 Incentive Award Plan, referred to below as the 2015 Plan, in order to facilitate the grant of cash and equity incentives to directors, employees (including our named executive officers) and consultants of our
company and certain of our affiliates and to enable our company and certain of our affiliates to obtain and retain services of these individuals, which is essential to our long-term success. For additional information about the 2015 Plan, please see
the section titled &#147;Equity Incentive Award Plans&#148; below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Elements of Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Retirement Plans </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
currently maintain a 401(k) retirement savings plan that allows eligible employees to defer a portion of their compensation, within limits prescribed by the Internal Revenue Code, on a pre-tax basis through contributions to the plan. Our named
executive officers are eligible to participate in the 401(k) plan on the same terms as other full-time employees generally. Currently, we make employer contributions under the 401(k) plan up to a specified percentage, and these employer
contributions are fully vested as of the date on which the contribution is made. We believe that providing a vehicle for tax-deferred retirement savings though our 401(k) plan, and making employer contributions, adds to the overall desirability of
our executive compensation package and further incentivizes our employees, including our named executive officers, in accordance with our compensation policies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Employee Benefits and Perquisites </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our named executive officers are eligible to participate in our health and welfare plans to the same extent as all full-time employees
generally. We do not provide our named executive officers with any other perquisites or other personal benefits. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>No Tax Gross-Ups
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, we generally have not made gross-up payments to cover our named executive officers&#146; personal income taxes that may
pertain to any of the compensation paid or provided by our company. However, we have agreed to provide Ms.&nbsp;Swedick with a gross-up for certain relocation expenses in connection with her move to the San Diego, California area. For additional
discussion, please see &#147;&#151;Employment Agreements&#151;Executive Relocation Agreement with Wendy Swedick.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Change in
Control Benefits </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our named executive officers may become entitled to certain benefits or enhanced benefits in connection with a change
in control of our company. In addition, stock options granted to our employees, including our named executive officers, may be subject to acceleration in connection with a change in control under our equity plans. For additional discussion, please
see &#147;&#151;Employment Agreements&#148; above and &#147;&#151;Equity Incentive Award Plans&#148; below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 106 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Outstanding Equity Awards at 2014 Fiscal Year-End </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents the outstanding equity incentive plan awards held by each named executive officer as of December&nbsp;31, 2014.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of</B><br><B>Securities</B><br><B>Underlying</B><br><B>Unexercised</B><br><B>Options (#)</B><br><B>Exercisable&nbsp;(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of</B><br><B>Securities</B><br><B>Underlying</B><br><B>Unexercised</B><br><B>Options (#)</B><br><B>Unexercisable&nbsp;(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Equity</B><br><B>Incentive</B><br><B>Plan</B><br><B>Awards:</B><br><B>Number
of</B><br><B>Securities</B><br><B>Underlying</B><br><B>Unexercised</B><br><B>Unearned</B><br><B>Options (#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option</B><br><B>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option</B><br><B>Expiration</B><br><B>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fortunato Ron Rocca</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/9/2012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,383,090</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">981,272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/9/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/10/2014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,015,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/10/2024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wendy Swedick</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5/18/2010</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5/18/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/1/2011</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,917</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,083</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/2/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/9/2012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">465,692</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">191,755</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/9/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/10/2014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">600,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/10/2024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thierry Dervieux, Ph.D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/1/2010</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/1/2010</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/1/2011</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,917</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,083</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/1/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/9/2012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">465,692</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">191,755</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/9/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/10/2014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">475,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/10/2024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">The options vest at the rate of 25% of the total number of shares subject to the option on the first anniversary of the grant date, and 1/48th of the total number of shares subject to the option monthly thereafter.
</TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Compensation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2014
Director Compensation Table </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information for the year ended December&nbsp;31, 2014 regarding the
compensation awarded to, earned by or paid to our non-employee directors who served on our board of directors during 2014. Employees of our company who also serve as directors do not receive additional compensation for their performance of services
as directors. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:20.00pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fees&nbsp;Earned</B><br><B>or Paid in</B><br><B>Cash ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option</B><br><B>Awards</B><br><B>($)(3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other</B><br><B>Compensation</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Curt LaBelle, M.D.(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ebetuel Pallares, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Brian Birk</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Samuel D. Riccitelli(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,512</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72,512</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael J. Walsh(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,977</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,977</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Arthur Weinstein, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,900</TD>
<TD NOWRAP VALIGN="bottom">(4)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Frank Witney, Ph.D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John M. Radak</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Effective May 2015, Dr.&nbsp;LaBelle no longer serves as a director. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Effective September 2014, Mr.&nbsp;Riccitelli and Mr.&nbsp;Walsh no longer serve as directors. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">In conjunction with the departure of Mr.&nbsp;Riccitelli and Mr.&nbsp;Walsh as directors in September 2014, we modified the vesting term of 259,959 outstanding and unvested stock options previously granted to these
departing board members such that these options became immediately exercisable upon their departure. All other terms and conditions applicable to the modified options, including the exercise prices and remaining contractual terms, remained
unchanged. The impact of this acceleration is discussed further in Note 13 to the consolidated financial statements. Amounts in this column reflect the incremental fair value of the option awards as of the modification date, computed in accordance
with the provisions of ASC 718. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">Reflects amounts paid to Dr.&nbsp;Weinstein for his services as a consultant. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 107 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below shows the aggregate numbers of option awards held as of December&nbsp;31, 2014 by
each non-employee director who served during the fiscal year ended December&nbsp;31, 2014. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="85%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:20.00pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Options</B><br><B>Outstanding</B><br><B>at Fiscal</B><br><B>Year End</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Curt LaBelle, M.D.(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ebetuel Pallares, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Brian Birk</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Samuel D. Riccitelli(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael J. Walsh(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Arthur Weinstein, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">125,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Frank Witney, Ph.D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John M. Radak</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Effective May 2015, Dr.&nbsp;LaBelle no longer serves as a director. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Effective September 2014, Mr.&nbsp;Riccitelli and Mr.&nbsp;Walsh no longer serve as directors. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2013, we entered into a director and consulting services agreement with Dr.&nbsp;Weinstein, pursuant to which he receives $18,000
per year, payable monthly, for his service as a member of our board of directors. In addition, Dr.&nbsp;Weinstein has provided and may continue to provide consulting services to us from time to time, for which he is compensated at the rate of $300
per hour or $2,400 per full day worked. The director and consulting services agreement with Dr.&nbsp;Weinstein will be terminated effective upon consummation of this offering and will be superseded by our new non-employee director compensation
program, as described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On the effective date of this offering, each non-employee director shall automatically be granted an option
to purchase&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock, other than Dr.&nbsp;Weinstein, who shall automatically be granted an option to
purchase&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock due to his existing holdings, or the IPO Awards. Each IPO Award shall vest on the first to occur of (1)&nbsp;the
first anniversary of the date of grant, subject to the non-employee director continuing in service on our board of directors through such vesting date, or (2)&nbsp;in the event a non-employee director does not stand for re-election or fails to be
re-elected at the first annual meeting of our stockholders, the date of such annual meeting, subject to the non-employee director continuing in service on our board of directors through such vesting date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors has approved a compensation program for our non-employee directors, to be effective on the date prior to the date on
which our common stock commences trading pursuant to this offering, that will consist of annual retainer fees, meeting fees and long-term equity awards. Pursuant to the terms of the non-employee director compensation program, each non-employee
director will receive an annual cash retainer for his or her services in an amount equal to $25,000. In addition, the chair of our board of directors will receive an additional annual cash retainer of $32,000, the chair of our audit committee will
receive an additional annual cash retainer of $10,000, the chair of our compensation committee will receive an additional annual cash retainer of $7,500 and the chair of our nominating and corporate governance committee will receive an additional
annual cash retainer of $5,000. Audit committee members will receive an additional annual cash retainer of $5,000, compensation committee members will receive an additional annual cash retainer of $5,000 and nominating and corporate governance
committee members will receive an additional annual cash retainer of $4,000. Each non-employee director shall be eligible to receive $2,500 for each board meeting attended in person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, non-employee directors initially elected or appointed to our board of directors shall automatically be granted an option to
purchase&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock on the date of such initial election or appointment, or the Initial Awards. Each Initial Award shall vest in
substantially equal installments on each of the first three anniversaries of the date of grant, subject to the non-employee director continuing in service on our board of directors through each such vesting date. A non-employee director who
(1)&nbsp;is serving on our board of directors as of the date of any annual meeting of our stockholders after the effective date and (2)&nbsp;will continue to serve as a non-employee director immediately following such annual meeting, shall
automatically be granted an option to purchase&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock on the date of such annual meeting, or the Subsequent Awards. Each Subsequent
Award shall vest as to one-third of the total number of shares subject to such Subsequent Award on the first anniversary of the date of grant, and one thirty-sixth of the total number of shares subject to such Subsequent Award following each
one-month period of the non-employee director&#146;s service on our board of directors thereafter, so that all of the shares subject to each Subsequent Award shall be fully vested and exercisable on the third anniversary of the date of grant,
subject to the non-employee director continuing in service on our board of directors through each such vesting date. The per share exercise price of each option shall equal the fair market value of a share of our common stock on the date the option
is granted; provided, however, that the per share exercise price of each IPO Award shall equal the initial public offering price of our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 108 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of a non-employee director&#146;s IPO Awards, Initial Awards and Subsequent Awards shall vest
in full upon the occurrence of a Change in Control of our company (as defined in the 2015 Plan). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity Incentive Award Plans </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>2015 Incentive Award Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrently with this offering, we intend to establish the Exagen Diagnostics, Inc. 2015 Incentive Award Plan, or the 2015 Plan. We expect our
board of directors to adopt, and our stockholders to approve, the 2015 Plan prior to the completion of this offering. The 2015 Plan will become effective on the day prior to the public trading date of our common stock. The material terms of the 2015
Plan, as it is currently contemplated, are summarized below. Our board of directors is still in the process of developing, approving and implementing the 2015 Plan and, accordingly, this summary is subject to change. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Authorized Shares</I>. A total of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of
our common stock will initially be reserved for issuance under the 2015 Plan. In addition, the number of shares initially reserved under the 2015 Plan will be increased by (1)&nbsp;the number of shares that, as of the effective date of the 2015
Plan, have been reserved but not issued pursuant to any awards granted under our 2013 Plan (as defined below) and are not subject to any awards granted thereunder, and (2)&nbsp;the number of shares subject to stock options or similar awards granted
under our 2013 Plan or our 2002 Plan (as defined below) that expire or otherwise terminate without having been exercised in full and unvested shares issued pursuant to awards granted under the 2013 Plan or 2002 Plan that are forfeited to or
repurchased by us, with the maximum number of shares to be added to the 2015 Plan pursuant to clauses (1)&nbsp;and (2)&nbsp;above equal to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares. In
addition, the number of shares available for issuance under the 2015 Plan will be annually increased on the first day of each calendar year during the term of the 2015 Plan, beginning with January&nbsp;1, 2016, by an amount equal to the lesser of:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">4% of the outstanding shares of our common stock as of the last day of the preceding calendar year; or </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">such lesser amount as our board of directors may determine. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Up
to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock may be issued upon the exercise of incentive stock options under the 2015 Plan. The 2015 Plan will also provide for an
aggregate limit of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock that may be issued under the 2015 Plan over the course of its ten-year term. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shares issued pursuant to awards under the 2015 Plan that we repurchase or that are forfeited, as well as shares used to pay the exercise
price of an award or to satisfy the tax withholding obligations related to an award and any shares subject to a stock appreciation right that are not issued in connection with the stock settlement of the stock appreciation right on exercise thereof,
will become available for future grant under the 2015 Plan. In addition, to the extent that an award is paid out in cash rather than shares, such cash payment will not reduce the number of shares available for issuance under the 2015 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Plan Administration</I>. The compensation committee of our board of directors will administer the 2015 Plan (except with respect to any
award granted to &#147;independent directors&#148; (as defined in the 2015 Plan), which must be administered by our full board of directors). Following the completion of this offering, to administer the 2015 Plan, our compensation committee must
consist solely of at least two members of our board of directors, each of whom is a &#147;non-employee director&#148; for purposes of Rule 16b-3 under the Securities Exchange Act of 1934, as amended, or the Exchange Act, an &#147;outside
director&#148; for purposes of Section&nbsp;162(m) of the Internal Revenue Code of 1986, as amended, or the Code and an &#147;independent director&#148; under the rules of any securities exchange or automated quotations system on which the shares
are listed, quoted or traded. Subject to the terms and conditions of the 2015 Plan, our compensation committee has the authority to select the persons to whom awards are to be made, to determine the type or types of awards to be granted to each
person, the number of awards to grant, the number of shares to be subject to such awards, and the terms and conditions of such awards, and to make all other determinations and decisions and to take all other actions necessary or advisable for the
administration of the 2015 Plan. Our compensation committee is also authorized to establish, adopt, amend or revise rules relating to administration of the 2015 Plan. Our board of directors may at any time revest in itself the authority to
administer the 2015 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Eligibility</I>. Options, stock appreciation rights, or SARs, restricted stock and other awards under the
2015 Plan may be granted to individuals who are then our officers or employees or are the officers or employees of any of our subsidiaries. Such awards may also be granted to our non-employee directors and consultants but only employees may be
granted incentive stock options, or ISOs. As of December&nbsp;31, 2014, there were six non-employee directors and 53 employees who would have been eligible for awards under the 2015 Plan had it been in effect on such date. At such time after the
completion of this offering when we are subject to the requirements of Section&nbsp;162(m) of the Code, the maximum number of shares that may be subject to awards granted under the 2015 Plan to any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 109 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
individual other than a non-employee director in any calendar year cannot exceed&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and the maximum
amount that may be paid to a participant in cash during any calendar year with respect to one or more cash based awards under the 2015 Plan is $20,000,000. In addition, the maximum number of shares of our common stock that may be subject to one or
more awards granted to any non-employee director pursuant to the 2015 Plan during any calendar year cannot exceed&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Awards</I>. The 2015 Plan provides that our compensation committee (or the board of directors, in the case of awards to non-employee
directors) may grant or issue stock options, SARs, restricted stock, restricted stock units, dividend equivalents, stock payments and performance awards, or any combination thereof. Our compensation committee (or the board of directors, in the case
of awards to non-employee directors) will consider each award grant subjectively, considering factors such as the individual performance of the recipient and the anticipated contribution of the recipient to the attainment of our long-term goals.
Each award will be set forth in a separate agreement with the person receiving the award and will indicate the type, terms and conditions of the award. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Nonqualified stock options, or NQSOs, will provide for the right to purchase shares of our common stock at a specified price which may not be less than the fair market value of a share of common stock on the date of
grant, and usually will become exercisable (at the discretion of our compensation committee or our board of directors, in the case of awards to non-employee directors) in one or more installments after the grant date, subject to the
participant&#146;s continued employment or service with us and/or subject to the satisfaction of performance targets established by our compensation committee (or our board of directors, in the case of awards to non-employee directors). NQSOs may be
granted for any term specified by our compensation committee (or our board of directors, in the case of awards to non-employee directors). </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">ISOs will be designed to comply with the provisions of the Code and will be subject to specified restrictions contained in the Code. Among such restrictions, ISOs must have an exercise price of not less than the fair
market value of a share of common stock on the date of grant, may only be granted to employees, must expire within a specified period of time following the optionee&#146;s termination of employment, and must be exercised within ten years after the
date of grant. In the case of an ISO granted to an individual who owns (or is deemed to own) more than 10% of the total combined voting power of all classes of our capital stock, the 2015 Plan provides that the exercise price must be at least 110%
of the fair market value of a share of common stock on the date of grant and the ISO must expire upon the fifth anniversary of the date of grant. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Restricted stock may be granted to participants and made subject to such restrictions as may be determined by our compensation committee (or our board of directors, in the case of awards to non-employee directors).
Typically, restricted stock may be forfeited for no consideration or repurchased for consideration if the conditions or restrictions are not met, and it may not be sold or otherwise transferred to third parties until the restrictions are removed or
expire. Recipients of restricted stock, unlike recipients of options, may have voting rights and may receive dividends, if any, prior to the time when the restrictions lapse. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Restricted stock units may be awarded to participants, typically without payment of consideration or for a nominal purchase price, but subject to vesting conditions including continued employment or performance criteria
established by our compensation committee (or our board of directors, in the case of awards to non-employee directors). Like restricted stock, restricted stock units may not be sold or otherwise transferred or hypothecated until vesting conditions
are removed or expire. Unlike restricted stock, stock underlying restricted stock units will not be issued until the restricted stock units have vested, and recipients of restricted stock units generally will have no voting or dividend rights prior
to the time when vesting conditions are satisfied. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">SARs granted under the 2015 Plan typically will provide for payments to the holder based upon increases in the price of our common stock over the exercise price of the SAR. Except as required by Section&nbsp;162(m) of
the Code with respect to SARs intended to qualify as performance-based compensation as described in Section&nbsp;162(m) of the Code, there are no restrictions specified in the 2015 Plan on the exercise of SARs or the amount of gain realizable
therefrom. Our compensation committee (or the board of directors, in the case of awards to non-employee directors) may elect to pay SARs in cash or in common stock or in a combination of both. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Dividend equivalents represent the value of the dividends, if any, per share paid by us, calculated with reference to the number of shares covered by the stock options, SARs or other awards held by the participant.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Performance awards may be granted by our compensation committee on an individual or group basis. Generally, these awards will be based upon the attainment of specific performance goals that are established by our
compensation committee and relate to one or more performance criteria on a specified date or dates determined by our compensation committee. Any such cash bonus paid to a &#147;covered employee&#148; within the meaning of Section&nbsp;162(m) of the
Code may be, but need not be, qualified performance-based compensation as described below and will be paid in cash. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 110 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Stock payments may be authorized by our compensation committee (or our board of directors, in the case of awards to non-employee directors) in the form of common stock or an option or other right to purchase common
stock as part of a deferred compensation arrangement, made in lieu of all or any part of compensation, including bonuses, that would otherwise be payable to employees, consultants or members of our board of directors. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Transferability of Awards</I>. Unless the administrator provides otherwise, our 2015 Plan generally does not allow for the transfer of
awards and only the recipient of an option or SAR may exercise such an award during his or her lifetime. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Qualified Performance-Based
Compensation</I>. The compensation committee may designate employees as &#147;covered employees&#148; whose compensation for a given fiscal year may be subject to the limit on deductible compensation imposed by Section&nbsp;162(m) of the Code. The
compensation committee may grant to such covered employees restricted stock, dividend equivalents, stock payments, restricted stock units, cash bonuses and other stock-based awards that are paid, vest or become exercisable upon the attainment of
company performance criteria which are related to one or more of the following performance criteria as applicable to our performance or the performance of a division, business unit or an individual: operating or other costs and expenses,
improvements in expense levels, cash flow (including, but not limited to, operating cash flow and free cash flow), return on assets, return on capital, stockholders&#146; equity, return on stockholders&#146; equity, total stockholder return, return
on sales, gross or net profit or operating margin, working capital, net earnings (either before or after interest, taxes, depreciation and amortization), gross or net sales or revenue, net income (either before or after taxes), adjusted net income,
operating earnings or profits, earnings per share, adjusted earnings per share, price per share of common stock, regulatory body approval for commercialization of a product, capital raised in financing transactions or other financing milestones,
market recognition (including but not limited to awards and analyst ratings), financial ratios, implementation or completion of critical projects, market share, economic value, comparisons with various stock market indices, and implementation,
completion or attainment of objectively determinable objectives relating to research, development, regulatory, commercial, or strategic milestones or development. These performance criteria may be measured in absolute terms or as compared to any
incremental increase or decrease or as compared to results of a peer group or to market performance indicators or indices. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
compensation committee may provide that one or more objectively determinable adjustments will be made to one or more of the performance goals established for any performance period. Such adjustments may include one or more of the following: items
related to a change in accounting principle, items relating to financing activities, expenses for restructuring or productivity initiatives, other non-operating items, items related to acquisitions, items attributable to the business operations of
any entity acquired by us during the performance period, items related to the disposal of a business or segment of a business, items related to discontinued operations that do not qualify as a segment of a business under applicable accounting
standards, items attributable to any stock dividend, stock split, combination or exchange of stock occurring during the performance period, any other items of significant income or expense that are determined to be appropriate adjustments, items
relating to unusual or extraordinary corporate transactions, events or developments, items related to amortization of acquired intangible assets, items that are outside the scope of our core, on-going business activities, items related to acquired
in-process research and development, items relating to changes in tax laws, items relating to major licensing or partnership arrangements, items relating to asset impairment charges, items relating to gains and losses for litigation, arbitration or
contractual settlements, or items relating to any other unusual or nonrecurring events or changes in applicable laws, accounting principles or business conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Forfeiture, Recoupment and Clawback Provisions</I>. Pursuant to its general authority to determine the terms and conditions applicable to
awards under the 2015 Plan, the compensation committee has the right to provide, in an award agreement or otherwise, that an award shall be subject to the provisions of any recoupment or clawback policies implemented by us, including, without
limitation, any recoupment or clawback policies adopted to comply with the requirements of the Dodd-Frank Wall Street Reform and Consumer Protection Act and any rules or regulations promulgated thereunder, to the extent set forth in such recoupment
or clawback policy and/or in the applicable award agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Adjustments</I>. If there is any stock dividend, stock split, combination
or exchange of shares, merger, consolidation or other distribution (other than normal cash dividends) of our assets to stockholders, or any other change affecting the shares of our common stock or the share price of our common stock other than an
equity restructuring (as defined in the 2015 Plan), the plan administrator may make such equitable adjustments, if any, as the plan administrator in its discretion may deem appropriate to reflect such change with respect to (1)&nbsp;the aggregate
number and type of shares that may be issued under the 2015 Plan (including, but not limited to, adjustments of the number of shares available under the 2015 Plan and the maximum number of shares which may be subject to one or more awards to a
participant pursuant to the 2015 Plan during any calendar year), (2)&nbsp;the number and kind of shares, or other securities or property, subject to outstanding awards, (3)&nbsp;the number and kind of shares, or other securities or property, for
which automatic grants are to be subsequently made to new and continuing non-employee directors, (4)&nbsp;the terms and conditions of any outstanding awards (including, without limitation, any applicable performance targets or criteria with respect
thereto), and (5)&nbsp;the grant or exercise price per share for any outstanding awards under the 2015 Plan. If there is any equity restructuring, (1)&nbsp;the number and type of securities subject to each outstanding award and/or the grant or
exercise price per share for each outstanding award, if </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 111 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
applicable, the grant of new awards, and/or the making of a cash payment to holders of awards, will be proportionately adjusted, and (2)&nbsp;the plan administrator will make proportionate
adjustments to reflect such equity restructuring with respect to the aggregate number and type of shares that may be issued under the 2015 Plan (including, but not limited to, adjustments of the number of shares available under the 2015 Plan and the
maximum number of shares which may be subject to one or more awards to a participant pursuant to the 2015 Plan during any calendar year). Adjustments in the event of an equity restructuring will not be discretionary. Any adjustment affecting an
award intended as &#147;qualified performance-based compensation&#148; will be made consistent with the requirements of Section&nbsp;162(m) of the Code. The plan administrator also has the authority under the 2015 Plan to take certain other actions
with respect to outstanding awards in the event of a corporate transaction, including provision for the cash-out, termination, assumption or substitution of such awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Corporate Transactions</I>. In the event of a change in control where the acquirer does not assume awards granted under the 2015 Plan,
awards issued under the 2015 Plan will be subject to accelerated vesting such that 100% of the awards will become vested and exercisable or payable, as applicable. Under the 2015 Plan, a change in control is generally defined as: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a transaction or series of related transactions (other than an offering of our stock to the general public through a registration statement filed with the Securities and Exchange Commission, or SEC) whereby any person
or entity or related group of persons or entities (other than us, our subsidiaries, an employee benefit plan maintained by us or any of our subsidiaries or a person or entity that, prior to such transaction, directly or indirectly controls, is
controlled by, or is under common control with, us) directly or indirectly acquires beneficial ownership (within the meaning of Rule 13d-3 under the Exchange Act) of more than 50% of the total combined voting power of our securities outstanding
immediately after such acquisition; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">during any two-year period, individuals who, at the beginning of such period, constitute our board of directors together with any new director(s) whose election by our board of directors or nomination for election by
our stockholders was approved by a vote of at least two-thirds of the directors then still in office who either were directors at the beginning of the two-year period or whose election or nomination for election was previously so approved, cease for
any reason to constitute a majority of our board of directors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our consummation (whether we are directly or indirectly involved through one or more intermediaries) of (x)&nbsp;a merger, consolidation, reorganization, or business combination or (y)&nbsp;the sale or other disposition
of all or substantially all of our assets in any single transaction or series of transactions or (z)&nbsp;the acquisition of assets or stock of another entity, in each case other than a transaction: </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">which results in our voting securities outstanding immediately before the transaction continuing to represent (either by remaining outstanding or by being converted into our voting securities or the voting securities of
the person that, as a result of the transaction, controls us, directly or indirectly, or owns, directly or indirectly, all or substantially all of our assets or otherwise succeeds to our business (we or such person being referred to as a successor
entity)) directly or indirectly, at least a majority of the combined voting power of the successor entity&#146;s outstanding voting securities immediately after the transaction; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">after which no person or group beneficially owns voting securities representing 50% or more of the combined voting power of the successor entity; provided, however, that no person or group is treated as beneficially
owning 50% or more of combined voting power of the successor entity solely as a result of the voting power held in us prior to the consummation of the transaction. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Amendment, Termination</I>. Our board of directors has the authority to amend, suspend or terminate the 2015 Plan at any time. However,
stockholder approval of any amendment to the 2015 Plan will be obtained to the extent necessary to comply with any applicable law, regulation or stock exchange rule. Additionally, stockholder approval is required within 12 months of an increase in
the maximum number of shares issuable under the 2015 Plan or that may be issued to an individual in any calendar year. Except as necessary to comply with Section&nbsp;409A of the Code, no amendment, suspension or termination of the 2015 Plan will
impair the rights or obligations of a holder under an award theretofore granted, unless such award expressly so provides or such holder consents. If not terminated earlier by our board of directors, the 2015 Plan will terminate on the tenth
anniversary of the date it becomes effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Repricing Permitted</I>. Our compensation committee (or the board of directors, in the
case of awards to non-employee directors) shall have the authority, without the approval of our stockholders, to authorize the amendment of any outstanding award to reduce its price per share and to provide that an award will be canceled and
replaced with the grant of an award having a lesser price per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Securities Laws and Federal Income Taxes</I>. The 2015 Plan is
designed to comply with various securities and federal tax laws as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Securities Laws</I>. The 2015 Plan is intended to conform
to all provisions of the Securities Act and the Exchange Act and any and all regulations and rules promulgated by the SEC thereunder, including, without limitation, Rule 16b-3 of the Exchange Act. The 2015 Plan will be administered, and awards will
be granted and may be exercised, only in such a manner as to conform to such laws, rules and regulations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 112 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Federal Income Tax Consequences</I>. The material federal income tax consequences of the 2015
Plan under current federal income tax law are summarized in the following discussion, which deals with the general tax principles applicable to the 2015 Plan. The following discussion is based upon laws, regulations, rulings and decisions now in
effect, all of which are subject to change. Foreign, state and local tax laws, and employment, estate and gift tax considerations are not discussed due to the fact that they may vary depending on individual circumstances and from locality to
locality. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Stock Options and Stock Appreciation Rights.</I> A 2015 Plan participant generally will not recognize taxable income and we generally will not be entitled to a tax deduction upon the grant of a stock option or stock
appreciation right. The tax consequences of exercising a stock option and the subsequent disposition of the shares received upon exercise will depend upon whether the option qualifies as an ISO as defined in Section&nbsp;422 of the Code. The 2015
Plan permits the grant of options that are intended to qualify as ISOs as well as options that are not intended to so qualify; however, ISOs generally may be granted only to our employees and employees of our parent or subsidiary corporations, if
any. Upon exercising an option that does not qualify as an ISO when the fair market value of our stock is higher than the exercise price of the option, a 2015 Plan participant generally will recognize taxable income at ordinary income tax rates
equal to the excess of the fair market value of the stock on the date of exercise over the purchase price, and we (or our subsidiaries, if any) generally will be entitled to a corresponding tax deduction for compensation expense, in the amount equal
to the amount by which the fair market value of the shares purchased exceeds the purchase price for the shares. Upon a subsequent sale or other disposition of the option shares, the participant will recognize a short-term or long-term capital gain
or loss in the amount of the difference between the sales price of the shares and the participant&#146;s tax basis in the shares. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Upon exercising an ISO, a 2015 Plan participant generally will not recognize taxable income, and we will not be entitled to a tax deduction for
compensation expense. However, upon exercise, the amount by which the fair market value of the shares purchased exceeds the purchase price will be an item of adjustment for alternative minimum tax purposes. The participant will recognize taxable
income upon a sale or other taxable disposition of the option shares. For federal income tax purposes, dispositions are divided into two categories: qualifying and disqualifying. A qualifying disposition generally occurs if the sale or other
disposition is made more than two years after the date the option was granted and more than one year after the date the shares are transferred upon exercise. If the sale or disposition occurs before these two periods are satisfied, then a
disqualifying disposition generally will result. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Upon a qualifying disposition of ISO shares, the participant will recognize long-term
capital gain in an amount equal to the excess of the amount realized upon the sale or other disposition of the shares over their purchase price. If there is a disqualifying disposition of the shares, then the excess of the fair market value of the
shares on the exercise date (or, if less, the price at which the shares are sold) over their purchase price will be taxable as ordinary income to the participant. If there is a disqualifying disposition in the same year of exercise, it eliminates
the item of adjustment for alternative minimum tax purposes. Any additional gain or loss recognized upon the disposition will be recognized as a capital gain or loss by the participant. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">We will not be entitled to any tax deduction if the participant makes a qualifying disposition of ISO shares. If the participant makes a
disqualifying disposition of the shares, we should be entitled to a tax deduction for compensation expense in the amount of the ordinary income recognized by the participant. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Upon exercising or settling an SAR, a 2015 Plan participant will recognize taxable income at ordinary income tax rates, and we should be
entitled to a corresponding tax deduction for compensation expense, in the amount paid or value of the shares issued upon exercise or settlement. Payments in shares will be valued at the fair market value of the shares at the time of the payment,
and upon the subsequent disposition of the shares the participant will recognize a short-term or long-term capital gain or loss in the amount of the difference between the sales price of the shares and the participant&#146;s tax basis in the shares.
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Restricted Stock and Restricted Stock Units</I>. A 2015 Plan participant generally will not recognize taxable income at ordinary income tax rates and we generally will not be entitled to a tax deduction upon the
grant of restricted stock or restricted stock units. Upon the termination of restrictions on restricted stock or the payment of restricted stock units, the participant will recognize taxable income at ordinary income tax rates, and we should be
entitled to a corresponding tax deduction for compensation expense, in the amount paid to the participant or the amount by which the then fair market value of the shares received by the participant exceeds the amount, if any, paid for them. Upon the
subsequent disposition of any shares, the participant will recognize a short-term or long-term capital gain or loss in the amount of the difference between the sales price of the shares and the participant&#146;s tax basis in the shares. However, a
2015 Plan participant granted restricted stock that is subject to forfeiture or repurchase through a vesting schedule such that it is subject to a &#147;risk of forfeiture&#148; (as defined in Section&nbsp;83 of the Code) may make an election under
Section&nbsp;83(b) of the Code to recognize taxable income at ordinary income tax rates, at the time of the grant, in an amount equal to the fair market value of the shares of common stock on the date of grant, less the amount paid, if any, for such
shares. We will be entitled to a corresponding tax deduction for compensation, in the amount recognized as taxable income by the participant. If a timely Section&nbsp;83(b) election is made, the participant will not recognize any additional ordinary
income on the termination of restrictions on restricted stock, and we will not be entitled to any additional tax deduction. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 113 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Dividend Equivalents, Stock Payment Awards and Cash-Based Awards</I>. A 2015 Plan participant will not recognize taxable income and we will not be entitled to a tax deduction upon the grant of dividend equivalents,
stock payment awards or cash-based awards until cash or shares are paid or distributed to the participant. At that time, any cash payments or the fair market value of shares that the participant receives will be taxable to the participant at
ordinary income tax rates and we should be entitled to a corresponding tax deduction for compensation expense. Payments in shares will be valued at the fair market value of the shares at the time of the payment, and upon the subsequent disposition
of the shares, the participant will recognize a short-term or long-term capital gain or loss in the amount of the difference between the sales price of the shares and the participant&#146;s tax basis in the shares. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Section&nbsp;409A of the Code.</I> Certain types of awards under the 2015 Plan may constitute, or provide for, a deferral of compensation under Section&nbsp;409A. Unless certain requirements set forth in
Section&nbsp;409A are complied with, holders of such awards may be taxed earlier than would otherwise be the case (e.g., at the time of vesting instead of the time of payment) and may be subject to an additional 20% federal income tax (and,
potentially, certain interest penalties). To the extent applicable, the 2015 Plan and awards granted under the 2015 Plan will be structured and interpreted to comply with Section&nbsp;409A and the Department of Treasury regulations and other
interpretive guidance that may be issued pursuant to Section&nbsp;409A. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Section&nbsp;162(m) Limitation</I>. In general, under Section&nbsp;162(m) of the Code, income tax deductions of publicly held corporations may be limited to the extent total compensation (including base salary,
annual bonus, stock option exercises and non-qualified benefits paid) for certain executive officers exceeds $1.0 million (less the amount of any &#147;excess parachute payments&#148; as defined in Section&nbsp;280G of the Code) in any one year.
However, under Section&nbsp;162(m), the deduction limit does not apply to certain &#147;performance-based compensation&#148; if an independent compensation committee determines performance goals and if the material terms of the performance-based
compensation are disclosed to and approved by our stockholders. In particular, stock options and SARs will satisfy the &#147;performance-based compensation&#148; exception if the awards are made by a qualifying compensation committee, the plan sets
the maximum number of shares that can be granted to any person within a specified period and the compensation is based solely on an increase in the stock price after the grant date. Specifically, the option exercise price must be equal to or greater
than the fair market value of the stock subject to the award on the grant date. Under a Section&nbsp;162(m) transition rule for compensation plans of corporations which are privately held and which become publicly held in an initial public offering,
certain awards under the 2015 Plan will not be subject to Section&nbsp;162(m) until a specified transition date, which is the earlier of (1)&nbsp;the material modification of the 2015 Plan, (2)&nbsp;the issuance of all employer stock and other
compensation that has been allocated under the 2015 Plan, or (3)&nbsp;the first annual meeting of stockholders at which directors are to be elected that occurs after the close of the third calendar year following the calendar year in which the
initial public offering occurs. After the transition date, rights or awards granted under the 2015 Plan, other than options and SARs, will not qualify as &#147;performance-based compensation&#148; for purposes of Section&nbsp;162(m) unless such
rights or awards are granted or vest upon pre-established objective performance goals, the material terms of which are disclosed to and approved by our stockholders. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">We have attempted to structure the 2015 Plan in such a manner that, after the transition date, the compensation attributable to stock options
and SARs which meet the other requirements of Section&nbsp;162(m) will not be subject to the $1.0 million limitation. We have not, however, requested a ruling from the Internal Revenue Service or an opinion of counsel regarding this issue. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>2013 Stock Option Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors and certain of our stockholders approved the Exagen Diagnostics, Inc. 2013 Stock Option Plan, or the 2013 Plan, which
became effective in December 2012. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September 30, 2015, a total of 8,839,081 shares of our common stock were reserved for
issuance under the 2013 Plan. As of September 30, 2015, 7,725,500 shares of our common stock were subject to outstanding option awards and 1,113,581 shares of our common stock remained available for future issuance. The 2013 Plan will expire in
December 2022 unless earlier terminated by our board of directors. Following the effectiveness of the 2015 Plan, no additional awards will be granted under the 2013 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Administration </I>. The board of directors administers the 2013 Plan. Subject to the terms and conditions of the 2013 Plan, the
administrator has the authority to select the persons to whom awards are to be made, to determine the type or types of awards to be granted to each person, determine the number of awards to grant, determine the number of shares to be subject to such
awards, and the terms and conditions of such awards, and make all other determinations and decisions and to take all other actions necessary or advisable for the administration of the 2013 Plan. The plan administrator is also authorized to
establish, adopt, amend or revise rules relating to administration of the 2013 Plan, subject to certain restrictions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 114 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Eligibility</I>. Options may be granted to individuals who are then our employees, consultants
and members of our board of directors. Only employees may be granted ISOs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Awards</I>. The 2013 Plan permits the award of stock
options. Only stock options have been granted under the 2013 Plan to date. Each award is set forth in a separate agreement with the person receiving the award and indicates the type, terms and conditions of the award. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">NQSOs provide for the right to purchase shares of our common stock at a specified price which may not be less than the fair market value of a share of stock on the date of grant, and usually will become exercisable (at
the discretion of our board of directors) in one or more installments after the grant date, subject to the participant&#146;s continued employment or service with us and/or subject to the satisfaction of performance targets established by our
compensation committee (or the board of directors, in the case of awards to non-employee directors). NQSOs may be granted for any term specified by our compensation committee (or the board of directors, in the case of awards to non-employee
directors), but the term may not exceed ten years. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">ISOs are designed to comply with the provisions of the Internal Revenue Code and are subject to specified restrictions contained in the Internal Revenue Code applicable to ISOs. Among such restrictions, ISOs must have
an exercise price of not less than the fair market value of a share of common stock on the date of grant, may only be granted to employees, must expire within a specified period of time following the optionee&#146;s termination of employment, and
must be exercised within the ten years after the date of grant. In the case of an ISO granted to an individual who owns (or is deemed to own) more than 10% of the total combined voting power of all classes of our capital stock on the date of grant,
the 2013 Plan provides that the exercise price must be at least 110% of the fair market value of a share of common stock on the date of grant and the ISO must expire on the fifth anniversary of the date of its grant. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Corporate Transactions</I>. In the event of a corporate transaction, all outstanding stock options will become fully vested and exercisable
for the 30-day period immediately preceding the closing of such transaction (provided that the exercise of any stock option that would have been unvested but for the consummation of the change in control will be subject to the closing of the
transaction). In addition, in the event of a corporate transaction, the board of directors may provide for the cash-out of outstanding stock options for an amount equal to the fair market value of the shares of our common stock subject to the stock
option immediately prior to the consummation of such transaction less the exercise price of such option. Any options that are outstanding as of the consummation of a corporate transaction will terminate unless the acquirer assumes such awards or are
otherwise continued in effect pursuant to the terms of the transaction. Under the 2013 Plan, a corporate transaction is generally defined as: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a merger or consolidation in which securities possessing more than 50% of the total combined voting power of our outstanding securities are transferred to a person or persons different from the persons holding those
securities immediately prior to such transaction; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the sale, transfer or other disposition of all or substantially all of our assets in complete liquidation or dissolution of our company. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Amendment or Termination of the 2013 Plan</I>. Our board of directors may terminate, amend or modify the 2013 Plan, provided that any
termination of the plan must be upon 30 days&#146; written notice to participants. However, stockholder approval of any amendment to the 2013 Plan must be obtained to reduce the option price per share after the option has been granted or the extent
necessary and desirable to comply with any applicable law, regulation or stock exchange rule. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Securities Laws and Federal Income
Taxes</I>. The 2013 Plan is designed to comply with applicable securities laws in the same manner as described above in the description of the 2015 Plan under the heading &#147;&#151;2015 Incentive Award Plan&#151;Securities Laws and Federal Income
Taxes&#151;Securities Laws.&#148; The general federal tax consequences of awards under the 2013 Plan are the same as those described above in the description of the 2015 Plan under the heading &#147;&#151;2015 Incentive Award Plan&#151;Securities
Laws and Federal Income Taxes&#151;Federal Income Taxes.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>2002 Stock Option Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;29, 2002, our board of directors and our stockholders approved the Exagen Corporation Stock Option Plan, as amended, or the
2002 Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 115 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September 30, 2015, 6,312,658 shares of our common stock were subject to outstanding
option awards under the 2002 Plan. The 2002 Plan expired in accordance with its terms in December 2012 and no additional awards will be granted under the 2002 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Administration</I>. The board of directors administers the 2002 Plan. Subject to the terms and conditions of the 2002 Plan, the
administrator has the authority to select the persons to whom awards are to be made, to determine the type or types of awards to be granted to each person, determine the number of awards to grant, determine the number of shares to be subject to such
awards, and the terms and conditions of such awards, and make all other determinations and decisions and to take all other actions necessary or advisable for the administration of the 2002 Plan. The plan administrator is also authorized to
establish, adopt, amend or revise rules relating to administration of the 2002 Plan, subject to certain restrictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Eligibility</I>.
Options were able to be granted to individuals who are then our employees, consultants and members of our board of directors. Only employees may be granted ISOs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 116 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Awards</I>. The 2002 Plan permitted the award of stock options. Only stock options were
granted under the 2002 Plan. Each award is set forth in a separate agreement with the person receiving the award and indicates the type, terms and conditions of the award. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">NQSOs provide for the right to purchase shares of our common stock at a specified price which may not be less than the fair market value of a share of stock on the date of grant, and usually will become exercisable (at
the discretion of our board of directors) in one or more installments after the grant date, subject to the participant&#146;s continued employment or service with us and/or subject to the satisfaction of performance targets established by our
compensation committee (or the board of directors, in the case of awards to non-employee directors). NQSOs may be granted for any term specified by our compensation committee (or the board of directors, in the case of awards to non-employee
directors), but the term may not exceed ten years. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">ISOs are designed to comply with the provisions of the Internal Revenue Code and are subject to specified restrictions contained in the Internal Revenue Code applicable to ISOs. Among such restrictions, ISOs must have
an exercise price of not less than the fair market value of a share of common stock on the date of grant, may only be granted to employees, must expire within a specified period of time following the optionee&#146;s termination of employment, and
must be exercised within the ten years after the date of grant. In the case of an ISO granted to an individual who owns (or is deemed to own) more than 10% of the total combined voting power of all classes of our capital stock on the date of grant,
the 2002 Plan provides that the exercise price must be at least 110% of the fair market value of a share of common stock on the date of grant and the ISO must expire on the fifth anniversary of the date of its grant. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Corporate Transactions</I>. In the event of a corporate transaction where the acquirer does not assume awards granted under the 2002 Plan,
awards issued under the 2002 Plan will terminate as of a date to be fixed by our board of directors. Under the 2002 Plan, a corporate transaction is generally defined as a merger or consolidation in which securities possessing more than 50% of the
total combined voting power of our company&#146;s outstanding securities are transferred to a person or persons different from the persons holding those securities immediately prior to such transaction, or the sale, transfer or other disposition of
all or substantially all of our assets in a complete liquidation or dissolution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Amendment of the 2002 Plan</I>. Our board of
directors may amend or modify the 2002 Plan. However, stockholder approval of any amendment to the 2002 Plan must be obtained to reduce the option price per share after the option has been granted or the extent necessary and desirable to comply with
any applicable law, regulation or stock exchange rule. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Securities Laws and Federal Income Taxes</I>. The 2002 Plan is designed to
comply with applicable securities laws in the same manner as described above in the description of the 2015 Plan under the heading &#147;&#151;2015 Incentive Award Plan&#151;Securities Laws and Federal Income Taxes&#151;Securities Laws.&#148; The
general federal tax consequences of awards under the 2002 Plan are the same as those described above in the description of the 201 Plan under the heading &#147;&#151;2015 Incentive Award Plan&#151;Securities Laws and Federal Income
Taxes&#151;Federal Income Taxes.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Employee Stock Purchase Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrently with this offering, we intend to establish the Exagen Diagnostics, Inc. Employee Stock Purchase Plan, or the ESPP. We expect our
board of directors to adopt, and our stockholders to approve, the ESPP prior to the completion of this offering. The ESPP will become effective on the business day prior to the public trading date of our common stock. Our executive officers and all
of our other employees will be allowed to participate in our ESPP, subject to the eligibility requirements described below. The material terms of the ESPP, as it is currently contemplated, are summarized below. Our board of directors is still in the
process of developing, approving and implementing the ESPP and, accordingly, this summary is subject to change. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A total of shares of our
common stock will initially be reserved for issuance under our ESPP. In addition, the number of shares available for issuance under the ESPP will be annually increased on the first day of each calendar year during the term of the ESPP, beginning
with January&nbsp;1, 2016, by an amount equal to the least of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">1% of the outstanding shares of our common stock as of the last day of our immediately preceding calendar year; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">such other amount as may be determined by our board of directors. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ESPP will also provide
for an aggregate limit of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock that may be issued under the ESPP during the term of the ESPP. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 117 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors or its committee has full and exclusive authority to interpret the terms
of the ESPP and determine eligibility. We expect that our compensation committee will be the initial administrator of the ESPP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
employees are eligible to participate in the ESPP if they are customarily employed by us or any participating subsidiary for at least 20 hours per week and more than five months in any calendar year. However, an employee may not be granted rights to
purchase stock under our ESPP if such employee, immediately after the grant, would own (directly or through attribution) stock possessing 5% or more of the total combined voting power or value of all classes of our common or other class of stock.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ESPP is intended to qualify under Code Section&nbsp;423 and stock will be offered under the ESPP during offering periods. The length
of the offering periods under the ESPP will be determined by our compensation committee and may be up to 27 months long. Employee payroll deductions will be used to purchase shares on each purchase date during an offering period. The purchase dates
will be determined by the compensation committee for each offering period, but will generally be the last day in each offering period. Offering periods under the ESPP will commence when determined by our compensation committee. The compensation
committee may, in its discretion, modify the terms of future offering periods. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ESPP permits participants to purchase common stock
through payroll deductions of up to 20% of their eligible compensation, which includes a participant&#146;s gross base compensation for services to the company, excluding overtime payments, sales commissions, incentive compensation, bonuses, expense
reimbursements, fringe benefits and other special payments. A participant may purchase a maximum of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock during each offering period. In addition, no employee
will be permitted to accrue the right to purchase stock under the ESPP at a rate in excess of $25,000 worth of shares during any calendar year during which such a purchase right is outstanding (based on the fair market value per share of our common
stock as of the first day of the offering period). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On the first trading day of each offering period, each participant automatically is
granted an option to purchase shares of our common stock. The option expires at the end of the offering period or upon termination of employment, whichever is earlier, but is exercised at the end of each purchase period to the extent of the payroll
deductions accumulated during such purchase period. The purchase price of the shares will be 85% of the lower of the fair market value of our common stock on the first trading day of the offering period or on the applicable purchase date, unless
designated otherwise by the administrator. Participants may end their participation at any time during an offering period, and will be paid their accrued payroll deductions that have not yet been used to purchase shares of common stock.
Participation ends automatically upon termination of employment with us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A participant may not transfer rights granted under the ESPP
other than by will, the laws of descent and distribution or as otherwise provided under the ESPP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of certain significant
transactions or a change in control (as defined in the ESPP), the compensation committee may provide for: (1)&nbsp;either the termination of outstanding rights in exchange for cash or replacement of outstanding rights in exchange for other rights or
property selected by the administrator; (2)&nbsp;the assumption or substitution of outstanding rights by the successor or survivor corporation or parent or subsidiary thereof, if any; (3)&nbsp;the adjustment in the number and type of shares of stock
subject to outstanding rights and/or in the terms and conditions of outstanding rights and rights that may be granted in the future; (4)&nbsp;the use of participants&#146; accumulated payroll deductions to purchase stock on a new purchase date prior
to the next purchase date and termination of any rights under ongoing offering periods; or (5)&nbsp;the termination of all outstanding rights without being exercised. Under the ESPP, a change in control has the same definition as given to such term
in the 2015 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The compensation committee may amend, suspend or terminate the ESPP. However, stockholder approval of any amendment to
the ESPP will be obtained for any amendment which changes the aggregate number or type of shares that may be sold pursuant to rights under the ESPP, changes the corporations or classes of corporations whose employees are eligible to participate in
the ESPP or changes the ESPP in any manner that would cause the ESPP to no longer be an employee stock purchase plan within the meaning of Section&nbsp;423(b) of the Code. The ESPP will terminate no later than the tenth anniversary of the
ESPP&#146;s initial adoption by our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Securities Laws</I>. The ESPP has been designed to comply with various
securities laws in the same manner as described above in the description of the 2015 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Federal Income Taxes</I>. The material
federal income tax consequences of the ESPP under current federal income tax law are summarized in the following discussion, which deals with the general tax principles applicable to the ESPP. The following discussion is based upon laws,
regulations, rulings and decisions now in effect, all of which are subject to change. Foreign, state and local tax laws, and employment, estate and gift tax considerations are not discussed due to the fact that they may vary depending on individual
circumstances and from locality to locality. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 118 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ESPP, and the right of participants to make purchases thereunder, is intended to qualify
under the provisions of Section&nbsp;423 of the Code. Under the applicable Code provisions, no income will be taxable to a participant until the sale or other disposition of the shares purchased under the ESPP. This means that an eligible employee
will not recognize taxable income on the date the employee is granted an option under the ESPP (i.e., the first day of the offering period). In addition, the employee will not recognize taxable income upon the purchase of shares. Upon such sale or
disposition, the participant will generally be subject to tax in an amount that depends upon the length of time such shares are held by the participant prior to disposing of them. If the shares are sold or disposed of more than two years from the
first day of the offering period during which the shares were purchased and more than one year from the date of purchase, or if the participant dies while holding the shares, the participant (or his or her estate) will recognize ordinary income
measured as the lesser of: (1)&nbsp;the excess of the fair market value of the shares at the time of such sale or disposition over the purchase price; or (2)&nbsp;an amount equal to 15% of the fair market value of the shares as of the first day of
the offering period. Any additional gain will be treated as long-term capital gain. If the shares are held for the holding periods described above but are sold for a price that is less than the purchase price, there is no ordinary income and the
participating employee has a long-term capital loss for the difference between the sale price and the purchase price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the shares are
sold or otherwise disposed of before the expiration of the holding periods described above, the participant will recognize ordinary income generally measured as the excess of the fair market value of the shares on the date the shares are purchased
over the purchase price and we will be entitled to a tax deduction for compensation expense in the amount of ordinary income recognized by the employee. Any additional gain or loss on such sale or disposition will be long-term or short-term capital
gain or loss, depending on how long the shares were held following the date they were purchased by the participant prior to disposing of them. If the shares are sold or otherwise disposed of before the expiration of the holding periods described
above but are sold for a price that is less than the purchase price, the participant will recognize ordinary income equal to the excess of the fair market value of the shares on the date of purchase over the purchase price (and we will be entitled
to a corresponding deduction), but the participant generally will be able to report a capital loss equal to the difference between the sales price of the shares and the fair market value of the shares on the date of purchase. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitations of Liability and Indemnification Matters </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation and our amended and restated bylaws provide that we will indemnify our directors and
officers to the fullest extent permitted by the Delaware General Corporation Law, which prohibits our amended and restated certificate of incorporation from limiting the liability of our directors for the&nbsp;following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any breach of the director&#146;s duty of loyalty to us or our stockholders; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">unlawful payment of dividends or unlawful stock repurchases or redemptions; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any transaction from which the director derived an improper personal benefit. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and
restated certificate of incorporation and our amended and restated bylaws also provide that if Delaware law is amended to authorize corporate action further eliminating or limiting the personal liability of a director, then the liability of our
directors will be eliminated or limited to the fullest extent permitted by Delaware law, as so amended. This limitation of liability does not apply to liabilities arising under the federal securities laws and does not affect the availability of
equitable remedies such as injunctive relief or rescission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation and our amended and
restated bylaws also provide that we shall have the power to indemnify our employees and agents to the fullest extent permitted by law. Our amended and restated bylaws also permit us to secure insurance on behalf of any officer, director, employee
or other agent for any liability arising out of his or her actions in this capacity, regardless of whether our amended and restated bylaws would permit indemnification. We have obtained directors&#146; and officers&#146; liability insurance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into separate indemnification agreements with our directors and executive officers, in addition to indemnification provided
for in our amended and restated certificate of incorporation and amended and restated bylaws. These agreements, among other things, provide for indemnification of our directors and executive officers for expenses, judgments, fines and settlement
amounts incurred by this person in any action or proceeding arising out of this person&#146;s services as a director or executive officer or at our request. We believe that these provisions in our amended and restated certificate of incorporation
and amended and restated bylaws and indemnification agreements are necessary to attract and retain qualified persons as directors and executive officers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 119 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The above description of the indemnification provisions of our amended and restated certificate
of incorporation, our amended and restated bylaws and our indemnification agreements is not complete and is qualified in its entirety by reference to these documents, each of which is filed as an exhibit to the registration statement of which this
prospectus is a part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The limitation of liability and indemnification provisions in our amended and restated certificate of incorporation
and amended and restated bylaws may discourage stockholders from bringing a lawsuit against directors for breach of their fiduciary duties. They may also reduce the likelihood of derivative litigation against directors and officers, even though an
action, if successful, might benefit us and our stockholders. A stockholder&#146;s investment may be harmed to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions.
Insofar as indemnification for liabilities under the Securities Act may be permitted to directors, officers or persons controlling us pursuant to the foregoing provisions, we have been informed that in the opinion of the SEC such indemnification is
against public policy as expressed in the Securities Act and is therefore unenforceable. There is no pending litigation or proceeding naming any of our directors or officers as to which indemnification is being sought, nor are we aware of any
pending or threatened litigation that may result in claims for indemnification by any director or&nbsp;officer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 120 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx693329_13"></A>CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following includes a summary of transactions since January&nbsp;1, 2011 to which we have been a party in which the amount involved
exceeded or will exceed $120,000, and in which any of our directors, executive officers or, to our knowledge, beneficial owners of more than 5% of our capital stock or any member of the immediate family of any of the foregoing persons had or will
have a direct or indirect material interest, other than equity and other compensation, termination, change in control and other arrangements, which are described under &#147;Executive and Director Compensation.&#148; We also describe below certain
other transactions with our directors, executive officers and stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock Financings and Convertible Notes and Warrant Financing
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Series A-1, A-2 and A-3 Redeemable Convertible Preferred Stock Financings</I>. In December 2011, in connection with our Series A-2
and Series B-2 redeemable convertible preferred stock financing, all 3,896,531 of our outstanding shares of Series A-1 redeemable convertible preferred stock and 273,182 outstanding warrants to purchase shares of Series A-1 redeemable convertible
preferred stock were converted into 3,896,531 shares of our common stock and warrants to purchase an aggregate of 273,182 shares of our common stock, and we converted 1,598,226 shares of common stock into 1,598,226 shares of our Series A-2
redeemable convertible preferred stock. In February and April 2012, we converted an additional 45,710 shares of common stock into Series A-2 redeemable convertible preferred stock. In September 2012, in connection with our Series C redeemable
convertible preferred stock financing described below, all 1,643,396 of our Series A-2 redeemable convertible preferred stock were converted into 1,643,396 shares of common stock. In September 2012, in connection with our Series C redeemable
convertible preferred stock financing described below, we converted 1,474,795 shares of common stock into 1,474,795 shares of Series A-3 redeemable convertible preferred stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Series B-1, B-2 and B-3 Redeemable Convertible Preferred Stock, Note and Warrant Financings</I>. Between January 2011 and October 2011, we
issued and sold 1,896,367 shares of our Series B-1 redeemable convertible preferred stock and 1,090,514 warrants to purchase shares of our Series B-1 redeemable convertible preferred stock. In December 2011, in connection with our Series A-2 and
Series B-2 redeemable convertible preferred stock financing, all 1,896,367 shares of our Series B-1 redeemable convertible preferred stock were converted into 1,896,367 shares of common stock, and all of our outstanding Series B-1 warrants to
purchase up to an aggregate of 1,812,288 shares of Series B-1 redeemable convertible preferred stock were converted into warrants to purchase an aggregate of up to 1,812,288 shares of our common stock. In December 2011, we issued 24,283,557 shares
our Series B-2 redeemable convertible preferred stock at a purchase price of $0.25 per share, for aggregate consideration of approximately $6.0 million, and we also converted an aggregate principal amount of $5,810,422 of promissory notes plus
interest of $105,418 into 23,663,361 shares of Series B-2 redeemable convertible preferred stock. In February 2012 and April 2012, we also issued 1,651,134 shares of our Series B-2 redeemable convertible preferred stock at a purchase price of $0.25
per share, for aggregate consideration of approximately $0.4 million. In September 2012, in connection with the sales of Series C redeemable convertible preferred stock, all 49,598,052 outstanding shares of our Series B-2 redeemable convertible
preferred stock were converted into 49,598,052 shares of common stock. In September 2012, we converted 44,539,977 shares of common stock into 44,539,977 shares of our Series B-3 redeemable convertible preferred stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Series C Redeemable Convertible Preferred Stock Financing</I>. From September 2012 to December 2012, we issued and sold to investors in
private placements an aggregate of 23,750,389 shares of our Series C redeemable convertible preferred stock at a purchase price of $0.25 per share, for aggregate consideration of approximately $5.9 million. In connection with this financing, in
September 2012 all 1,643,396 outstanding shares of our Series&nbsp;A-2 redeemable convertible preferred stock and 49,598,052 shares of our Series B-2 redeemable convertible preferred stock were converted into 1,643,396 and 49,598,052 shares of
common stock, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Series D Redeemable Convertible Preferred Stock, Note and Warrant Financings</I>. In May 2013,&nbsp;June
2013 and August 2013, we issued a total of $2,430,531 in unsecured convertible promissory notes, or the 2013 Notes, which accrued interest at 10%. In October 2013, the 2013 Notes and $66,653 in accrued interest were converted into
12,485,914&nbsp;shares of Series D redeemable convertible preferred stock, at a 20% discount to the offering price of $0.25 per share. In October 2013, we also issued and sold to investors in private placements an aggregate of 10,079,172 shares of
our Series D redeemable convertible preferred stock at a purchase price of $0.25 per share, for aggregate consideration of approximately $2.5 million. From October 2013 to November 2013, we also issued warrants to purchase up to an aggregate of
4,174,430 shares of our Series D redeemable convertible preferred stock at an exercise price of $0.25 per share and warrants to purchase up to 3,186,430 shares of our common stock at an exercise price of $0.01 per share. We expect the 2013 Warrants
to be net exercised in connection with the completion of this offering, resulting in the issuance of an aggregate of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock,
assuming an initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus.
If these 2013 Warrants are not exercised prior to the completion of this offering, they will terminate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 121 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2014, we sold an aggregate of $4.0 million of convertible promissory notes to certain
existing investors in a private placement with certain existing investors, or the July 2014 Notes. The July 2014 Notes accrued interest at a rate of 12%&nbsp;per annum, became due and payable nine months from the date of issuance and allowed the
holders to convert the outstanding principal (and accrued interest thereon) into shares of Series D redeemable convertible preferred stock at the stated conversion rate of $0.25 per share. In May 2015, the holders of these notes elected to convert
these notes to shares of Series D redeemable convertible preferred stock, resulting in the issuance of 17,384,324 shares of Series D redeemable convertible preferred stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>February 2015 Convertible Note Financing</I>. In February 2015, we entered into a note purchase agreement, or the February 2015 Note
Purchase Agreement, with existing holders of our redeemable convertible preferred stock. Under this agreement, we issued convertible promissory notes in three tranches, which we collectively refer to as the February 2015 Notes. In February
2015,&nbsp;May 2015 and June 2015 we issued an aggregate of $1.8 million, $1.9 million, and $833,000 representing the first, second, and third tranches of the February 2015 Notes, respectively. All borrowings under the February 2015 Notes are
subordinated to borrowings under our 2013 term loan with Capital Royalty. The February 2015 Notes accrue interest at 10%&nbsp;per annum, and the February 2015 Notes issued in the first, second, and third tranche closings become due and payable in
December 2015,&nbsp;May 2016, and June 2016, respectively. The February 2015 Notes provide that a majority of holders for a given tranche may elect to extend the maturity date of such tranche by up to one additional year. The February 2015 Notes
contain a feature such that if an IPO occurs prior to the initial stated maturity date for a tranche, the unpaid principal and interest for that tranche will convert into shares of our common stock at a 20% discount to the IPO price. If investors
have previously elected to extend the maturity date for a tranche, the unpaid principal and interest for such tranche will convert into shares of our common stock at a 30% discount to the IPO price. In the event that an IPO has not occurred by the
maturity date for a particular tranche borrowed of the February 2015 Notes, and a majority of holders has not elected to extend the maturity date of such tranche, holders of that tranche may elect to either (1)&nbsp;receive all unpaid principal and
accrued interest due or (2)&nbsp;convert the unpaid principal and interest at maturity into shares of our Series&nbsp;D redeemable convertible preferred stock at a rate of $0.25 per share. If a liquidation (as defined in our current amended and
restated certificate of incorporation) occurs prior to the completion of this offering, the holders of the February 2015 Notes may elect to (1)&nbsp;receive the repayment of the notes or (2)&nbsp;convert the notes into shares of Series D redeemable
convertible preferred stock at a conversion price of $0.25 per share, subject to adjustment pursuant to the terms thereof. In connection with the completion of this offering, the aggregate principal amount outstanding (including accrued interest
thereon) under the February 2015 Notes will automatically convert into&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock, assuming an initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus and assuming the conversion occurs
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2015 (the expected closing date of this offering). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>July 2015 Convertible Note Financing</I>. In July 2015, we issued $3.0 million of convertible promissory notes, or the July 2015 Notes, to
existing holders of our redeemable convertible preferred stock. The July 2015 Notes are subordinated to borrowings under our 2013 term loan with Capital Royalty. The July 2015 Notes accrue interest at 10%&nbsp;per annum and become due and payable in
July 2016. The July 2015 Notes provide that a majority of holders may elect to extend the maturity date by up to one additional year. The July 2015 Notes contain a feature such that if an IPO occurs prior to December 31, 2015, the unpaid principal
and interest will convert into shares of our common stock at a 20% discount to the IPO price and, if an IPO occurs after December&nbsp;31, 2015, the unpaid principal and interest will convert into shares of our common stock at a 30% discount to the
IPO price. In the event that an IPO has not occurred by the maturity date and a majority of holders has not elected to extend the maturity date, holders may elect to either (1)&nbsp;receive all unpaid principal and accrued interest due or
(2)&nbsp;convert the unpaid principal and interest at maturity into shares of our Series D redeemable convertible preferred stock at a rate of $0.25 per share. If a liquidation (as defined in our current amended and restated certificate of
incorporation) occurs prior to the completion of this offering, the holders of the July 2015 Notes may elect to (1)&nbsp;receive the repayment of the notes or (2)&nbsp;convert the notes into shares of Series D redeemable convertible preferred stock
at a conversion price of $0.25 per share, subject to adjustment pursuant to the terms thereof. In connection with the completion of this offering, the aggregate principal amount outstanding (including accrued interest thereon) under the July 2015
Notes will automatically convert into&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock, assuming an initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus and assuming the conversion occurs
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2015 (the expected closing date of this offering). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>October 2015 Convertible Note Financing</I>. In October 2015, we issued $3.4 million of convertible promissory notes, or the October 2015
Notes, to existing holders of our redeemable convertible preferred stock. The October 2015 Notes accrue interest at 10%&nbsp;per annum and become due and payable in October 2016. The October 2015 Notes provide that a majority of holders may elect to
extend the maturity date by up to one additional year, and borrowings under these notes are subordinated to borrowings under our 2013 term loan with Capital Royalty. In conjunction with these notes, we also issued a variable number of warrants, or
the 2015 Warrants, which only become exercisable upon (1)&nbsp;a qualified equity financing resulting in aggregate gross proceeds to us of more than $10.0 million, excluding the conversion of the October 2015 Notes, in which investors purchase
shares of a newly issued series of our preferred stock prior to the maturity date of the October 2015 Notes; or (2)&nbsp;a conversion of the associated October 2015 Notes by holders thereof in certain circumstances. In the case of a qualified equity
financing, the 2015 Warrants will become exercisable for a number of shares of the newly-issued preferred stock sold in the qualified equity financing as is equal to 20% of the initial principal </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 122 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
amount of the October 2015 Notes divided by the lowest price per share paid by investors in the qualified equity financing. In the case of certain conversions of the associated October 2015
Notes, the 2015 Warrants will become exercisable for a number of shares of our Series D redeemable convertible preferred stock as is equal to 20% of the initial principal amount of each such October 2015 Note divided by the then applicable
conversion price (as defined in our current amended and restated certificate of incorporation). The 2015 Warrants expire in October 2020. If the 2015 Warrants are not exercised prior to the completion of the offering, they will terminate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of a qualified equity financing prior to the maturity date of the October 2015 Notes, the majority of the holders of these notes
may elect either (1)&nbsp;to convert the unpaid principal and interest into shares of our Series D redeemable convertible preferred stock at a rate of $0.25 per share or (2)&nbsp;to convert the unpaid principal and interest into shares of the newly
issued series of preferred stock sold in the qualified equity financing at the lowest price per share paid by investors in the qualified equity financing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The October 2015 Notes contain a feature such that if an IPO occurs prior to December&nbsp;31, 2015, the unpaid principal and interest will
convert into shares of our common stock at a 20% discount to the IPO price and if an IPO occurs after December&nbsp;31, 2015, the unpaid principal and interest will convert into shares of our common stock at a 30% discount to the IPO price. In the
event that an IPO has not occurred by the maturity date and a majority of holders has not elected to extend the maturity date, holders may elect to either (1)&nbsp;receive all unpaid principal and accrued interest due or (2)&nbsp;convert the unpaid
principal and interest at maturity into shares of our Series D redeemable convertible preferred stock at a rate of $0.25 per share. If a liquidation (as defined in our current amended and restated certificate of incorporation) occurs prior to the
completion of this offering, the holders of the October 2015 Notes may elect to (1)&nbsp;receive the repayment of the notes or (2)&nbsp;convert the notes into shares of Series D redeemable convertible preferred stock at a conversion price of $0.25
per share, subject to adjustment pursuant to the terms thereof. In connection with the completion of this offering, the aggregate principal amount outstanding (including accrued interest thereon) under the October 2015 Notes will automatically
convert into&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock, assuming an initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus and assuming the conversion occurs
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2015 (the expected closing date of this offering). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 123 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the aggregate number of these securities acquired by the listed
directors, executive officers or holders of more than 5% of our capital stock, or their affiliates. Each share of, or warrants exercisable for shares of, redeemable convertible preferred stock identified in the following table will convert into one
share of, or warrants exercisable for, one share of common stock, upon completion of this offering. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:41.70pt; font-size:8pt; font-family:Times New Roman"><B>Participants</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:8pt"><B>Series A-3</B></FONT><br><FONT STYLE="font-size:8pt"><B>Redeemable<BR>Convertible<BR>Preferred<BR>Stock</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:8pt"><B>Series B-3</B></FONT><br><FONT STYLE="font-size:8pt"><B>Redeemable<BR>Convertible<BR>Preferred<BR>Stock</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:8pt"><B>Series C</B></FONT><br><FONT STYLE="font-size:8pt"><B>Redeemable<BR>Convertible<BR>Preferred<BR>Stock</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:8pt"><B>Series D</B></FONT><br><FONT STYLE="font-size:8pt"><B>Redeemable<BR>Convertible<BR>Preferred<BR>Stock </B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:8pt"><B>Warrants<BR>to Purchase<BR>Series D<BR>Redeemable<BR>Convertible<BR>Preferred<BR>Stock</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:8pt"><B>Common<BR>Stock</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:8pt"><B>Warrants<BR>to<BR>Purchase<BR>Common<BR>Stock </B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:8pt"><B>Principal<BR>Amount of<BR>February&nbsp;2015<BR>Notes <SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:8pt"><B>Principal<BR>Amount&nbsp;of<BR>July&nbsp;2015<BR>Notes</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:8pt"><B>Principal<BR>Amount&nbsp;of<BR>October&nbsp;2015<BR>Notes
<SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP></B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>5% or Greater Stockholders <SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Entities affiliated with NMSIC Co-Investment Fund, L.P.<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">607,168</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">18,215,069</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">8,081,136</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">17,278,467</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">2,217,248</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">426,525</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">1,400,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">1,000,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">1,419,858</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Tullis-Dickerson Capital Focus III, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">468,321</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">14,049,638</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">8,000,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">10,022,778</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">18,237</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">250,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">1,635,740</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">1,000,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">820,412</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Hunt Holdings, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">219,548</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">6,586,444</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">4,922,084</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">8,370,163</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">131,581</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">263,347</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">900,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">1,000,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">756,079</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Entities affiliated with Capital Royalty Partners<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">3,186,430</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">3,186,430</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Entities affiliated with vSpring Partners<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">5,953,112</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">159,493</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Directors</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Ebetuel Pallares, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">15,900</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">768,788</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">542,800</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">828,668</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">32,971</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">36,654</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">144,042</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">274,972</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Samuel Riccitelli <SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">4,200</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">20,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">100,287</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">56,506</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Additional details regarding these stockholders and their equity holdings are provided herein under &#147;Principal Stockholders.&#148; </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Represents securities held by NMSIC Co-Investment Fund, L.P. and NMSIC Focused LLC. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Represents securities held by Capital Royalty Partners II L.P., Capital Royalty Partners II Parallel Fund &#147;A&#148; L.P. and Parallel Investment Opportunities Partners II L.P. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">Represents securities held by vSpring SBIC, L.P., vSpring L.P. and vSpring Partners, L.P. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">Represents securities held by PCM/Exagen, L.P. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top">Effective September 2014, Mr.&nbsp;Riccitelli no longer serves as a director. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top">Includes notes issued in February 2015,&nbsp;May 2015 and June 2015 in first, second and third tranche closings of the February 2015 Notes, respectively. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top">The holders of October 2015 Notes also hold the 2015 Warrants, which may become exercisable as described above. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some of our directors are associated with our principal stockholders as indicated in the table below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:28.85pt; font-size:8pt; font-family:Times New Roman"><B>Director</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Principal Stockholder</B></P></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Brian Birk</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">NMSIC&nbsp;Co-Investment&nbsp;Fund,&nbsp;L.P.</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">James L.L. Tullis</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Tullis-Dickerson&nbsp;Capital&nbsp;Focus&nbsp;III,&nbsp;L.P.</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investors&#146; Rights Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We entered into a fourth amended and restated investors&#146; rights agreement in October 2013 with the holders of our redeemable convertible
preferred stock, including entities with which certain of our directors are affiliated. This agreement provides for certain rights relating to the registration of their shares of common stock issuable upon conversion of their redeemable convertible
preferred stock and certain additional covenants made by us. Except for the registration rights (including the related provisions pursuant to which we have agreed to indemnify the parties to the investors&#146; rights agreement), all rights under
this agreement will terminate upon completion of this offering. The registration rights will continue following this offering and will terminate three years following the completion of this offering, or for any particular holder with registration
rights, at such time following this offering when such holder holds less than one percent of our outstanding common stock and may immediately sell all of such shares pursuant to Rule 144 under the Securities Act in a 90-day period. See
&#147;Description of Capital Stock&#151;Registration Rights&#148; for additional information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 124 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stockholders&#146; Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We entered into a fourth amended stockholders&#146; agreement in October 2013 by and among us and certain of our stockholders, pursuant to
which the following directors were each elected to serve as members on our board of directors and, as of the date of this prospectus, continue to so serve: Brian Birk, Ebetuel Pallares, Ph.D., Fortunato Ron Rocca, Frank Witney, Ph.D. and John M.
Radak. Pursuant to the stockholders&#146; agreement, Mr.&nbsp;Rocca, as our Chief Executive Officer, was initially selected to serve on our board of directors as a representative of holders of our common stock, as designated by a majority of our
common stockholders. Mr.&nbsp;Birk, Dr.&nbsp;LaBelle and Dr.&nbsp;Pallares were initially selected to serve on our board of directors as representatives of holders of our redeemable convertible preferred stock, as designated by NMSIC Co-Investment
Fund, L.P., Tullis-Dickerson Capital Focus III, L.P. and PCM/Exagen, L.P. (formerly known as CCP/Exagen, L.P.) and Hunt Holdings, L.P., respectively. In May 2015, James L.L. Tullis replaced Dr.&nbsp;LaBelle as the representative of our board of
directors designated by Tullis-Dickerson Capital Focus III, L.P. Dr.&nbsp;Witney and Mr.&nbsp;Radak were selected to serve on our board of directors as designated by a majority of our common and redeemable convertible preferred stockholders, voting
together as a single class. The stockholders&#146; agreement also provides for certain other rights, including among others, a right of first refusal to purchase future securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The stockholders&#146; agreement, and all the rights granted pursuant to it, will terminate upon the completion of this offering, and members
previously elected to our board of directors pursuant to this agreement will continue to serve as directors until they resign, are removed or their successors are duly elected by holders of our common stock. The composition of our board of directors
after this offering is described in more detail under &#147;Management&#151;Board Composition and Election of Directors.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employment Agreements
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into an offer letter with Dr.&nbsp;Dervieux. For more information regarding this agreements, see the section in this
prospectus entitled &#147;Executive and Director Compensation&#151;Narrative Disclosure to Compensation Tables&#151;Employment Agreements.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2011, we entered into a license agreement with Dr.&nbsp;Dervieux, the Company&#146;s Chief Scientific Officer, and his company,
DeNovo. The license agreement, covering novel methods for monitoring low-dose methotrexate therapy, relates to technology developed by Dr.&nbsp;Dervieux prior to joining the Company. The technology has yet to be used by us. Under the agreement,
Dr.&nbsp;Dervieux would be eligible to receive up to $600,000 when and if we achieve certain sales milestones and a single-digit percentage royalty on sales on an ongoing basis. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Loan Arrangements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2010, we entered
into a subordinated secured promissory note agreement with existing equity holders and a mezzanine lender, and $750,000 of the loan proceeds committed under such agreement were provided by NMSIC Co-Investment Fund L.P., or the NMSIC Note. The NMSIC
Note was secured by substantially all of our assets, bore interest at 6.0% and matured in October 2012, at which time, it was repaid in full. In conjunction with the NMSIC Note, NMSIC received warrants to purchase up to 131,250 shares of our common
stock at a price of $3.75 per share. These warrants contained the right to require us to purchase the warrants for a total of $150,000, which right NMSIC exercised in October 2013. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indemnification Agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have
entered into indemnification agreements with each of our directors and executive officers prior to the completion of this offering. These agreements, among other things, require us or will require us to indemnify each director (and in certain cases
their related venture capital funds) and executive officer to the fullest extent permitted by Delaware law, including indemnification of expenses such as attorneys&#146; fees, judgments, fines and settlement amounts incurred by the director or
executive officer in any action or proceeding, including any action or proceeding by or in right of us, arising out of the person&#146;s services as a director or executive officer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation and our amended and restated bylaws provide that we will indemnify each of our directors
and officers to the fullest extent permitted by the Delaware General Corporation Law. Further, we have entered into indemnification agreements with each of our directors and officers, and we have purchased a policy of directors&#146; and
officers&#146; liability insurance that insures our directors and officers against the cost of defense, settlement or payment of a judgment under certain circumstances. For further information, see &#147;Executive and Director
Compensation&#151;Limitations of Liability and Indemnification Matters.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 125 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stock Option Grants to Executive Officers and Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have granted stock options to our executive officers and certain of our directors as more fully described in the section entitled
&#147;Executive and Director Compensation.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Policies and Procedures for Related Person Transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors will adopt written related person transaction policy, to be effective upon the completion of this offering, setting
forth the policies and procedures for the review and approval or ratification of related-person transactions. This policy will cover, with certain exceptions set forth in Item&nbsp;404 of Regulation S-K under the Securities Act, any transaction,
arrangement or relationship, or any series of similar transactions, arrangements or relationships in which we were or are to be a participant, where the amount involved exceeds $120,000 and a related person had or will have a direct or indirect
material interest, including, without limitation, purchases of goods or services by or from the related person or entities in which the related person has a material interest, indebtedness, guarantees of indebtedness and employment by us of a
related person. In reviewing and approving any such transactions, our audit committee is tasked to consider all relevant facts and circumstances, including, but not limited to, whether the transaction is on terms comparable to those that could be
obtained in an arm&#146;s length transaction and the extent of the related person&#146;s interest in the transaction. All of the transactions described in this section occurred prior to the adoption of this policy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 126 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx693329_14"></A>PRINCIPAL STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information with respect to the beneficial ownership of our common stock as of September 30, 2015, and as
adjusted to reflect the sale of shares of common stock in this offering, by: </P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">each of our named executive officers; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">each of our then-current directors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">all of our executive officers and directors as a group; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">each person or group of affiliated persons known by us to beneficially own more than 5% of our common stock. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares beneficially owned by each stockholder is determined under rules issued by the SEC. Under these rules, beneficial
ownership includes any shares as to which a person has sole or shared voting power or investment power. Applicable percentage ownership is based on 121,250,410 shares of common stock outstanding on September 30, 2015, which gives effect to the
automatic conversion of all outstanding shares of redeemable convertible preferred stock into shares of common stock. Our calculation of beneficial ownership after the offering gives additional effect to (1)&nbsp;the issuance of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock in connection with the completion of this offering as a result of the automatic conversion of the $4.5 million in aggregate principal amount
(including accrued interest thereon) of the February 2015 Notes, assuming an initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the
price range set forth on the cover page of this prospectus, and assuming the conversion occurs on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2015 (the expected closing
date of this offering); (2)&nbsp;the issuance of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock in connection with the completion of this offering as a result of the
automatic conversion of the $3.0 million in aggregate principal amount (including accrued interest thereon) of the July 2015 Notes, assuming an initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and assuming the conversion occurs
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015 (the expected closing date of this offering); and (3)&nbsp;the issuance
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock in connection with the completion of this offering as a result of the automatic conversion of the $3.4 million in
aggregate principal amount (including accrued interest thereon) of the October 2015 Notes, assuming an initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share,
which is the midpoint of the price range set forth on the cover page of this prospectus, and assuming the conversion occurs on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2015 (the expected closing date of this offering). In computing the number of shares beneficially owned by a person and the percentage ownership of that person, shares of common stock subject to options, warrants or other rights held by such person
that are currently exercisable or will become exercisable within 60 days of September 30, 2015 are considered outstanding, although these shares are not considered outstanding for purposes of computing the percentage ownership of any other person.
</P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, the address of each beneficial owner listed below is c/o Exagen Diagnostics, Inc., 1261 Liberty Way,
Suite C, Vista, California 92081. We believe, based on information provided to us, that each of the stockholders listed below has sole voting and investment power with respect to the shares beneficially owned by the stockholder unless noted
otherwise, subject to community property laws where applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 127 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares Beneficially Owned<BR>Prior to Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;Beneficially&nbsp;Owned<BR>After Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Name of Beneficial Owner</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>5% or Greater Stockholders</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with NMSIC Co-Investment Fund, L.P.(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,825,613</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">301 Griffin Street</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Santa Fe, NM 87501</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tullis-Dickerson Capital Focus III, L.P.(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,808,975</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">One Stamford Plaza</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">263 Tresser Boulevard</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stamford, CT 06901</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hunt Holdings, L.P.(3).</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,493,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">c/o Joseph Advisory Services, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3800 N. Mesa St., Suite A-2, #371</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">El Paso, TX 79902</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with vSpring Partners(4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,112,605</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">c/o Signal Peak Ventures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2795 E. Cottonwood Parkway, Suite #360</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Salt Lake City, UT 84121</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Capital Royalty<BR>Partners(5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,372,860</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1000 Main Street, Suite 2500</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Houston TX, 77002</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Named Executive Officers and Directors</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fortunato Ron Rocca(6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,159,088</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wendy Swedick(7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">966,356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thierry Dervieux, Ph.D.(8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">924,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James L.L. Tullis(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,808,975</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Brian Birk(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,825,613</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ebetuel Pallares, Ph.D.(9)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,225,781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John M. Radak</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Arthur Weinstein, M.D.(10)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Frank Witney, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All executive officers and directors as a group (9&nbsp;persons)&nbsp;(11)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87,952,168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Less than 1%. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 128 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Consists of (a)&nbsp;45,565,908 shares of common stock and 426,525 shares of common stock issuable upon the exercise of warrants to purchase common stock, which warrants will terminate if not exercised upon completion
of this offering, held by NMSIC Co-Investment Fund, L.P., or NMSIC, and (b)&nbsp;833,180 shares of common stock held by NMSIC Focused, LLC, or NMSIC Focused. In addition, beneficial ownership after the offering gives additional effect to (a) the
issuance of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock issuable upon the conversion of the February 2015 Notes held by NMSIC Focused, assuming an initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range listed on the cover page of this prospectus, and assuming the conversion occurs
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015 (the expected closing date of this offering); (b) the issuance
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock issuable upon conversion of the July 2015 Notes held by NMSIC Focused, assuming an initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and assuming the conversion occurs
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015 (the expected closing date of this offering); and (c)&nbsp;the issuance
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock issuable upon conversion of the October 2015 Notes held by NMSIC Focused, assuming an initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and assuming the conversion occurs
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015 (the expected closing date of this offering). The general partner of NMSIC is Sun Mountain Capital Partners LLC,
or Sun Mountain. NMSIC is the sole member of NMSIC Focused. The members of Sun Mountain are Brian Birk, one of our directors, Sally Corning, Lee Rand and Leslie Shaw. As a result, each of Sun Mountain, Mr.&nbsp;Birk, Ms.&nbsp;Corning, Mr.&nbsp;Rand
and Ms.&nbsp;Shaw may be deemed to possess voting and investment control over, and may be deemed to have indirect beneficial ownership with respect to, all shares held by NMSIC or NMSIC Focused. Neither Sun Mountain, Mr.&nbsp;Birk, Ms.&nbsp;Corning,
Mr.&nbsp;Rand nor Ms.&nbsp;Shaw owns directly any of the shares. Each of Sun Mountain, Mr.&nbsp;Birk, Ms.&nbsp;Corning, Mr.&nbsp;Rand and Ms.&nbsp;Shaw disclaims beneficial ownership of the shares held by NMSIC or NMSIC Focused, except to the extent
of their pecuniary interest therein. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Consists of 32,558,975 shares of common stock and 250,000 shares of common stock issuable upon the exercise of warrants to purchase common stock, which warrants will terminate if not exercised upon completion of this
offering. In addition, beneficial ownership after the offering gives additional effect to (a)&nbsp;the issuance of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock issuable upon
the conversion of the February 2015 Notes held by Tullis-Dickerson Capital Focus III, L.P., or Tullis, assuming an initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range listed on the cover page of this prospectus, and assuming the
conversion occurs on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015 (the expected closing date of this offering); (b)&nbsp;the issuance
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock issuable upon conversion of the July 2015 Notes held by Tullis, assuming an initial public offering price of $&nbsp;per
share, which is the midpoint of the price range set forth on the cover page of this prospectus, and assuming the conversion occurs
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015 (the expected closing date of this offering); and (c)&nbsp;the issuance
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock issuable upon conversion of the October 2015 Notes held by Tullis, assuming an initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and assuming the conversion occurs
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015 (the expected closing date of this offering). Tullis-Dickerson Partners&nbsp;III, LLC is the sole general partner
of Tullis. James L.L. Tullis, one of our directors, is a Principal of Tullis-Dickerson Partners III, LLC. As a result, each of Tullis-Dickerson Partners III, LLC and Mr.&nbsp;Tullis may be deemed to possess voting and investment control over, and
may be deemed to have an indirect beneficial ownership with respect to, all shares held by Tullis. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Consists of 20,229,820 shares of common stock and 263,347 shares of common stock issuable upon the exercise of warrants to purchase common stock, which warrants will terminate if not exercised upon completion of this
offering, held by Hunt Holdings, L.P., or Hunt. In addition, beneficial ownership after the offering gives additional effect to (a)&nbsp;the issuance of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock issuable upon the conversion of the February 2015 Notes held by Hunt, assuming an initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range listed on the cover page of this prospectus, and assuming the conversion occurs
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2015 (the expected closing date of this offering); (b)&nbsp;the issuance
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock issuable upon conversion of the July 2015 Notes held by Hunt Focused, assuming an initial public
offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and assuming the conversion
occurs on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015 (the expected closing date of this offering); and (c)&nbsp;the issuance
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock issuable upon conversion of the October 2015 Notes held by Hunt, assuming an initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and assuming the conversion occurs
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015 (the expected closing date of this offering). </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">Consists of (a)&nbsp;5,079,948 shares of common stock and 139,727 shares of common stock issuable upon the exercise of warrants to purchase common stock, which warrants will terminate if not exercised upon completion of
this offering, held by vSpring SBIC, L.P., or vSpring SBIC, (b)&nbsp;773,714&nbsp;shares of common stock and 17,515 shares of common stock issuable upon the exercise of warrants to purchase common stock, which warrants will terminate if not
exercised upon completion of this offering, held by vSpring L.P., or vSpring, and (c)&nbsp;99,450 shares of common stock and 2,251&nbsp;shares of common stock issuable upon the exercise of warrants to purchase common stock, which warrants will
terminate if not exercised upon completion of this offering, held by vSpring Partners, L.P., or vSpring Partners. The general partner of vSpring SBIC, L.P. is vSpring SBIC Management LLC. The general partner of vSpring and vSpring Partners is
vSpring Management, LLC. The managing members of vSpring SBIC Management LLC and vSpring Management, LLC are Scott Petty and Dinesh Patel. As a result, each of vSpring SBIC Management LLC, vSpring Management, LLC, Mr.&nbsp;Petty and Mr.&nbsp;Patel
may be deemed to possess voting and investment control over, and may be deemed to have indirect beneficial ownership with respect to, all shares held by vSpring, vSpring SBIC and vSpring Partners. Neither vSpring SBIC Management LLC, vSpring
Management, LLC, Mr.&nbsp;Petty nor Mr.&nbsp;Patel owns directly any of the shares. Each of vSpring SBIC Management LLC, vSpring Management, LLC, Mr.&nbsp;Petty and Mr.&nbsp;Patel disclaims beneficial ownership of the shares held by vSpring, vSpring
SBIC and vSpring Partners, except to the extent of their pecuniary interest therein. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 129 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">Includes (a)&nbsp;1,614,300 shares of common stock issuable upon the exercise of the 2013 Warrants held by Capital Royalty Partners II L.P., which warrants will terminate if not exercised upon completion of this
offering, (b)&nbsp;2,702,302 shares of common stock issuable upon the exercise of the 2013 Warrants held by Capital Royalty Partners II Parallel Fund &#147;A&#148; L.P., which warrants will terminate if not exercised upon completion of this
offering, and (c)&nbsp;2,056,258 shares of common stock issuable upon the exercise of the 2013 Warrants to purchase common stock held by Parallel Investment Opportunities Partners II L.P., which warrants will terminate if not exercised upon
completion of this offering. In addition, beneficial ownership after the offering gives additional effect to the issuance of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock to
Capital Royalty Partners II L.P., Capital Royalty Partners II Parallel Fund &#147;A&#148; L.P. and Parallel Investment Opportunities Partners II L.P., respectively, as a result of the expected net exercise of the 2013 Warrants in connection with the
completion of this offering. Capital Royalty Partners II L.P.&#146;s general partner is Capital Royalty Partners II GP L.P., whose general partner is Capital Royalty Partners II GP LLC. Capital Royalty Partners II&#151;Parallel Fund &#147;A&#148;
L.P.&#146;s general partner is Capital Royalty Partners II&#151;Parallel Fund &#147;A&#148; GP L.P., whose general partner is Capital Royalty Partners II&#151;Parallel Fund &#147;A&#148; GP LLC. Parallel Investment Opportunities Partners II
L.P.&#146;s general partner is Parallel Investment Opportunities Partners II GP L.P., whose general partner is Parallel Investment Opportunities Partners II LLC. Capital Royalty Partners II GP LLC, Capital Royalty Partners II&#151;Parallel Fund
&#147;A&#148; GP LLC and Parallel Investment Opportunities Partners II LLC are controlled by Charles Tate, as is Capital Royalty LP, the investment manager for all of the foregoing. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top">Consists of 4,159,088 shares which Mr.&nbsp;Rocca has the right to acquire pursuant to outstanding options which are or will be immediately exercisable within 60 days of September 30, 2015. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top">Consists of 966,356 shares which Ms.&nbsp;Swedick has the right to acquire pursuant to outstanding options which are or will be immediately exercisable within 60 days of September 30, 2015. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top">Consists of 924,689 shares which Dr.&nbsp;Dervieux has the right to acquire pursuant to outstanding options which are or will be immediately exercisable within 60 days of September 30, 2015. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top">Consists of 2,189,127&nbsp;shares of common stock and 36,654&nbsp;shares of common stock issuable upon the exercise of warrants to purchase common stock, which warrants will terminate if not exercised upon completion of
this offering, held by PCM/Exagen, L.P., or PCM. In addition, beneficial ownership after the offering gives additional effect to (a)&nbsp;the issuance of shares of common stock issuable upon the conversion of the February 2015 Notes held PCM,
assuming an initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range listed on the cover page of this prospectus, and
assuming the conversion occurs on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2015 (the expected closing date of this offering); and (b)&nbsp;the issuance of shares of
common stock issuable upon the conversion of the October 2015 Notes held PCM, assuming an initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the
midpoint of the price range listed on the cover page of this prospectus, and assuming the conversion occurs on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015 (the
expected closing date of this offering). Dr.&nbsp;Pallares, one of our directors, is a co-manager of PCM. As a result, each of PCM and Dr.&nbsp;Pallares may be deemed to possess voting and investment control over, and may be deemed to have an
indirect beneficial ownership with respect to, all shares held by PCM. Prior to August&nbsp;6, 2015, PCM was previously known as CCP / Exagen L.P. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top">Consists of 41,666&nbsp;shares which Dr. Weinstein has the right to acquire pursuant to outstanding options which are or will be immediately exercisable within 60&nbsp;days of September&nbsp;30, 2015. </TD></TR></TABLE>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top">Includes shares of common stock issuable upon the exercise of outstanding options, which are or will be immediately exercisable within 60 days of September 30, 2015, as set forth in the previous footnotes. In addition,
beneficial ownership after this offering includes shares of common stock issuable upon the conversion of the February 2015 Notes, the July 2015 Notes, and the October 2015 Notes, as set forth in the previous footnotes. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 130 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx693329_15"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the completion of
this offering, our authorized capital stock will consist of 200,000,000 shares of common stock, $0.001 par value per share, and 10,000,000 shares of preferred stock, $0.001 par value per share. The following description summarizes some of the terms
of our fifteenth amended and restated certificate of incorporation and amended and restated bylaws, our outstanding warrants, the investors&#146; rights agreement and of the Delaware General Corporation Law. Because it is only a summary, it does not
contain all the information that may be important to you. For a complete description you should refer to our amended and restated certificate of incorporation, amended and restated bylaws, warrants and investors&#146; rights agreement, copies of
which have been filed or incorporated by reference as exhibits to the registration statement of which the prospectus is a part, as well as the relevant provisions of the Delaware General Corporation Law. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September 30,
2015, there were&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock outstanding and held of record by 53&nbsp;stockholders, assuming (1)&nbsp;the automatic conversion of all
outstanding shares of our redeemable convertible preferred stock into shares of common stock, which will automatically occur immediately prior to the completion of this offering and (2)&nbsp;the issuance
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock as a result of the expected net exercise of outstanding warrants we issued in 2013, or the 2013 Warrants, in connection with
the completion of this offering, assuming an initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range on the cover page of this prospectus,
which 2013 Warrants will terminate if not exercised prior to the completion of this offering. Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders, including the election of
directors, and do not have cumulative voting rights. Accordingly, the holders of a majority of the outstanding shares of common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they so
choose, other than any directors that holders of any preferred stock we may issue may be entitled to elect. Subject to preferences that may be applicable to any then outstanding preferred stock, holders of common stock are entitled to receive
ratably those dividends, if any, as may be declared by the board of directors out of legally available funds. In the event of our liquidation, dissolution or winding up, the holders of common stock will be entitled to share ratably in the assets
legally available for distribution to stockholders after the payment of or provision for all of our debts and other liabilities, subject to the prior rights of any preferred stock then outstanding. Holders of common stock have no preemptive or
conversion rights or other subscription rights and there are no redemption or sinking funds provisions applicable to the common stock. All outstanding shares of common stock are, and the common stock to be outstanding upon the completion of this
offering will be, duly authorized, validly issued, fully paid and nonassessable. The rights, preferences and privileges of holders of common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of
preferred stock that we may designate and issue in the future. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon completion of this offering, all of our previously outstanding shares of redeemable convertible preferred stock will have been converted
into common stock, there will be no authorized shares of our previously redeemable convertible preferred stock and we will have no shares of preferred stock outstanding. Under the terms of our amended and restated certificate of incorporation, which
will become effective immediately prior to the completion of this offering, our board of directors has the authority, without further action by our stockholders, to issue up to 10,000,000 shares of preferred stock in one or more series, to establish
from time to time the number of shares to be included in each such series, to fix the dividend, voting and other rights, preferences and privileges of the shares of each wholly unissued series and any qualifications, limitations or restrictions
thereon, and to increase or decrease the number of shares of any such series, but not below the number of shares of such series then outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting
power or other rights of the holders of the common stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying,
deferring or preventing a change in our control and may adversely affect the market price of the common stock and the voting and other rights of the holders of common stock. We have no current plans to issue any shares of preferred stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Options </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September 30, 2015,
options to purchase 14,038,158 shares of our common stock were outstanding under our 2002 and 2013 stock option plans, of which 7,774,837 were vested and exercisable as of that date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 131 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September 30, 2015, 4,881,900 shares of our common stock were issuable upon exercise of outstanding warrants to purchase common stock
with a weighted average exercise price of $1.31 per share. Of these warrants, we expect warrants to purchase &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock to be net exercised in connection with the
completion of this offering, resulting in the issuance of an aggregate of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock assuming an initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus. If the remaining warrants are not exercised prior to the completion of
this offering, they will terminate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September 30, 2015, 4,174,430 shares of our Series D redeemable convertible preferred stock
were issuable upon exercise of outstanding warrants with a weighted average exercise price of $0.25 per share. We expect these warrants to be net exercised in connection with the completion of this offering, resulting in the issuance of an aggregate
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock assuming an initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus. If these warrants are not exercised prior to
the completion of this offering, they will terminate. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of the above warrants has a net exercise provision under which the holder
may, in lieu of payment of the exercise price in cash, surrender the warrant and receive a net amount of shares of our common stock based on the fair market value of our common stock at the time of the net exercise of the warrant after deduction of
the aggregate exercise price. These warrants also contain provisions for the adjustment of the exercise price and the aggregate number of shares issuable upon the exercise of the warrants in the event of stock dividends, stock splits,
reorganizations and reclassifications and consolidations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Convertible Promissory Notes </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2014, we sold an aggregate of $4.0 million of convertible promissory notes to certain existing investors in a private placement with
certain existing investors. We refer to these notes as the July 2014 Notes. The July 2014 Notes accrued interest at a rate of 12%&nbsp;per annum, became due and payable nine months from the date of issuance and allowed the investors to convert the
outstanding principal (and accrued interest thereon) into shares of Series D redeemable convertible preferred stock at the stated conversion rate of $0.25 per share. In May 2015, the holders of these notes elected to convert these notes to shares of
Series D Preferred Stock, resulting in the issuance of 17,384,324 shares of Series D redeemable convertible preferred stock. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
February 2015, we entered into the February 2015 Note Purchase Agreement with existing holders of our redeemable convertible preferred stock. Under this agreement we issued convertible promissory notes in three tranches. In February 2015,&nbsp;May
2015 and June 2015, we issued $1.8 million, $1.9 million, and $833,000 representing the first, second, and third tranches of the February 2015 Notes, respectively. The February 2015 Notes accrue interest at a rate of 10%&nbsp;per annum, and the
February 2015 Notes issued in the first, second, and third tranche closings become due and payable in December 2015&nbsp;May 2016, and June, 2016, respectively. If holders of the February 2015 Notes do not elect to extend the maturity of the
February 2015 Notes, the principal amount (including accrued interest thereon) of the February 2015 Notes will automatically convert into shares of our common stock upon completion of this offering at a conversion price equal to 80% of our initial
public offering price. If holders of the February 2015 Notes elect to extend the maturity of these notes, the principal amount (including accrued interest thereon) of the February 2015 Notes will automatically convert into shares of our common stock
upon completion of this offering at a conversion price equal to 70% of our initial public offering price. If a liquidation (as defined in our current amended and restated certificate of incorporation) occurs prior to the completion of this offering,
the holders of the February 2015 Notes may elect to (1)&nbsp;receive the repayment of the notes or (2)&nbsp;convert the notes into shares of Series D redeemable convertible preferred stock at a conversion price of $0.25 per share, subject to
adjustment pursuant to the terms thereof. In connection with the completion of this offering, the aggregate principal amount outstanding (including accrued interest thereon) under the February 2015 Notes will automatically convert into
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock, assuming an initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus and assuming the conversion occurs on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015 (the expected closing date of this offering). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2015, we issued $3.0 million of convertible promissory notes, or the July 2015 Notes, to existing holders of our redeemable
convertible preferred stock. The July 2015 Notes are subordinated to borrowings under our 2013 term loan with Capital Royalty. The July 2015 Notes accrue interest at 10%&nbsp;per annum and become due and payable in July 2016. The July 2015 Notes
provide that a majority of holders may elect to extend the maturity date by up to one additional year. The July 2015 Notes contain a feature such that if an IPO occurs prior to December 31, 2015, the unpaid principal and interest will convert into
shares of our common stock at a 20% discount to the IPO price and if an IPO occurs after December&nbsp;31, 2015, the unpaid principal and interest will convert into shares of our common stock at a 30% discount to the IPO price. In the event that an
IPO has not occurred by the maturity date and a majority of holders has not elected to extend the maturity date, holders may elect to either (1)&nbsp;receive all unpaid principal and accrued interest due or (2)&nbsp;convert the unpaid principal and
interest at maturity into shares of our Series D redeemable convertible preferred stock at a rate of $0.25 per share. If a liquidation (as defined in our current amended and restated certificate of incorporation) occurs prior to the completion of
this offering, the holders of the July 2015 Notes may elect to (1)&nbsp;receive the repayment of the notes </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 132 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or (2)&nbsp;convert the notes into shares of Series D redeemable convertible preferred stock at a conversion price of $0.25 per share, subject to adjustment pursuant to the terms thereof. In
connection with the completion of this offering, the aggregate principal amount outstanding (including accrued interest thereon) under the July 2015 Notes will automatically convert
into&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock, assuming an initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus and assuming the conversion occurs
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2015 (the expected closing date of this offering). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2015, we issued $3.4 million of convertible promissory notes, or the October 2015 Notes, to existing holders of our redeemable
convertible preferred stock. The October 2015 Notes accrue interest at 10%&nbsp;per annum and become due and payable in October 2016. The October 2015 Notes provide that a majority of holders may elect to extend the maturity date by up to one
additional year, and borrowings under these notes are subordinated to borrowings under our 2013 term loan with Capital Royalty. In conjunction with these notes, we also issued a variable number of the 2015 Warrants, which only become exercisable
upon (1)&nbsp;a qualified equity financing resulting in aggregate gross proceeds to us of more than $10.0 million, excluding the conversion of the October 2015 Notes, in which investors purchase shares of a newly issued series of our preferred stock
prior to the maturity date of the October 2015 Notes; or (2)&nbsp;a conversion of the associated October 2015 Notes by holders thereof in certain circumstances. In the case of a qualified equity financing, the 2015 warrants will become exercisable
for a number of shares of the newly-issued preferred stock sold in the qualified equity financing as is equal to 20% of the initial principal amount of the October 2015 Notes divided by the lowest price per share paid by investors in the qualified
equity financing. In the case of certain conversions of the associated October 2015 Notes, the 2015 Warrants will become exercisable for a number of shares of our Series D redeemable convertible preferred stock as is equal to 20% of the initial
principal amount of each such October 2015 Note divided by the then applicable conversion price (as defined in our current amended and restated certificate of incorporation). The 2015 Warrants expire in October 2020. If the 2015 Warrants are not
exercised prior to the completion of the offering, they will terminate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of a qualified equity financing prior to the
maturity date of the October 2015 Notes, the majority of the holders of these notes may elect either (1)&nbsp;to convert the unpaid principal and interest into shares of our Series D redeemable convertible preferred stock at a rate of $0.25 per
share or (2)&nbsp;to convert the unpaid principal and interest into shares of the newly issued series of preferred stock sold in the qualified equity financing at the lowest price per share paid by investors in the qualified equity financing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The October 2015 Notes contain a feature such that if an IPO occurs prior to December&nbsp;31, 2015, the unpaid principal and interest will
convert into shares of our common stock at a 20% discount to the IPO price and if an IPO occurs after December&nbsp;31, 2015, the unpaid principal and interest will convert into shares of our common stock at a 30% discount to the IPO price. In the
event that an IPO has not occurred by the maturity date and a majority of holders has not elected to extend the maturity date, holders may elect to either (1)&nbsp;receive all unpaid principal and accrued interest due or (2)&nbsp;convert the unpaid
principal and interest at maturity into shares of our Series D redeemable convertible preferred stock at a rate of $0.25 per share. If a liquidation (as defined in our current amended and restated certificate of incorporation) occurs prior to the
completion of this offering, the holders of the October 2015 Notes may elect to (1)&nbsp;receive the repayment of the notes or (2)&nbsp;convert the notes into shares of Series D redeemable convertible preferred stock at a conversion price of $0.25
per share, subject to adjustment pursuant to the terms thereof. In connection with the completion of this offering, the aggregate principal amount outstanding (including accrued interest thereon) under the October 2015 Notes will automatically
convert into&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock, assuming an initial public offering price of $&nbsp;per share, which is the midpoint of the price range set
forth on the cover page of this prospectus and assuming the conversion occurs on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015 (the expected closing date of this offering). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September
30, 2015, holders of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock, which includes all of the shares of common stock issuable upon the automatic conversion of our
redeemable convertible preferred stock immediately prior to the completion of this offering and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock issuable
in connection with the completion of this offering as a result of the automatic conversion of the (1)&nbsp;$4.5 million in aggregate principal of the February 2015 Notes (including accrued interest thereon); (2)&nbsp;$3.0 million in aggregate
principal of the July 2015 Notes (including accrued interest thereon); and (3)&nbsp;$3.4 million in aggregate principle of the October 2015 Notes (including accrued interest thereon), assuming an initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range listed on the cover page of this prospectus and assuming the conversion occurs on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015 (the expected closing date of this offering), will be entitled to the following rights with respect to the registration of
such shares for public resale under the Securities Act, pursuant to an investor rights agreement by and among us and certain of our stockholders. The registration of shares of common stock as a result of the following rights being exercised would
enable holders to trade these shares without restriction under the Securities Act when the applicable registration statement is declared effective. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 133 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Demand Registration Rights </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Form S-1. </I>If at any time for a period of three years following the completion of this offering, the holders of at least 50% of the
registrable securities request in writing that we effect a registration with respect to their shares in an offering, we may be required to register their shares. We are obligated to effect at most two registrations for the holders of registrable
securities in response to these demand registration rights, subject to certain exceptions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Form S-</I>3. If at any time beginning 180
days following the completion of this offering and we become entitled under the Securities Act to register our shares on Form S-3, a holder of registrable securities requests in writing that we register their shares for public resale on Form S-3 and
the price to the public of the offering is $1.0 million or more, we will be required to provide notice to all holders of registrable securities and to use our best efforts to effect such registration; provided, however, that we will not be required
to effect such a registration if, within the preceding 12 months, we have already effected two registrations on Form S-3 for the holders of registrable securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In each of the above registrations, if the holders requesting registration intend to distribute their shares by means of an underwriting, the
managing underwriter of such offering will have the right to limit the numbers of shares to be underwritten for reasons related to the marketing of the shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Piggyback Registration Rights </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If at any
time for a period of three years following the completion of this offering we propose to register any shares of our common stock under the Securities Act, subject to certain exceptions, the holders of registrable securities will be entitled to
notice of the registration and to include their shares of registrable securities in the registration. If our proposed registration involves an underwriting, the managing underwriter of such offering will have the right to limit the number of shares
to be underwritten for reasons related to the marketing of the shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ordinarily, other than underwriting discounts and commissions, we will be required to pay all expenses incurred by us related to any
registration effected pursuant to the exercise of these registration rights. These expenses may include all registration and filing fees, printing expenses, fees and disbursements of our counsel, reasonable fees and disbursements of a counsel for
the selling securityholders, blue sky fees and expenses and the expenses of any special audits incident to the registration. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Termination of
Registration Rights </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The registration rights terminate upon the earlier of three years after the completion of this offering, or for
any particular holder with registration rights, at such time following this offering when such holder holds less than one percent of our outstanding common stock and may immediately sell all of such shares pursuant to Rule 144 under the Securities
Act in a 90-day period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-Takeover Effects of Delaware Law and Our Certificate of Incorporation and Bylaws </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some provisions of Delaware law, our amended and restated certificate of incorporation and our amended and restated bylaws contain provisions
that could make the following transactions more difficult: an acquisition of us by means of a tender offer; an acquisition of us by means of a proxy contest or otherwise; or the removal of our incumbent officers and directors. It is possible that
these provisions could make it more difficult to accomplish or could deter transactions that stockholders may otherwise consider to be in their best interest or in our best interests, including transactions which provide for payment of a premium
over the market price for our shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These provisions, summarized below, are intended to discourage coercive takeover practices and
inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors. We believe that the benefits of the increased protection of our potential ability to
negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could result in an improvement of their terms. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Undesignated Preferred Stock </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ability
of our board of directors, without action by the stockholders, to issue up to 10,000,000 shares of undesignated preferred stock with voting or other rights or preferences as designated by our board of directors could impede the success of any
attempt to change control of us. These and other provisions may have the effect of deferring hostile takeovers or delaying changes in control or management of our company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 134 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stockholder Meetings </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated bylaws provide that a special meeting of stockholders may be called only by our chairman of the board, chief executive
officer or president, or by a resolution adopted by a majority of our board of directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Requirements for Advance Notification of Stockholder
Nominations and Proposals </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated bylaws establish advance notice procedures with respect to stockholder proposals to
be brought before a stockholder meeting and the nomination of candidates for election as directors, other than nominations made by or at the direction of the board of directors or a committee of the board of directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Elimination of Stockholder Action by Written Consent </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation and amended and restated bylaws eliminate the right of stockholders to act by written
consent without a meeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Staggered Board </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors is divided into three classes. The directors in each class will serve for a three-year term, one class being elected
each year by our stockholders. For more information on the classified board, see &#147;Management&#151;Board Composition and Election of Directors.&#148; This system of electing and removing directors may tend to discourage a third-party from making
a tender offer or otherwise attempting to obtain control of us, because it generally makes it more difficult for stockholders to replace a majority of the directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Removal of Directors </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and
restated certificate of incorporation provides that no member of our board of directors may be removed from office by our stockholders except for cause and, in addition to any other vote required by law, upon the approval of not less than two thirds
of the total voting power of all of our outstanding voting stock then entitled to vote in the election of directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stockholders Not Entitled to
Cumulative Voting </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation does not permit stockholders to cumulate their votes in the
election of directors. Accordingly, the holders of a majority of the outstanding shares of our common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they choose, other than any directors
that holders of our preferred stock may be entitled to elect. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Delaware Anti-Takeover Statute </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to Section&nbsp;203 of the Delaware General Corporation Law, which prohibits persons deemed to be &#147;interested
stockholders&#148; from engaging in a &#147;business combination&#148; with a publicly held Delaware corporation for three years following the date these persons become interested stockholders unless the business combination is, or the transaction
in which the person became an interested stockholder was, approved in a prescribed manner or another prescribed exception applies. Generally, an &#147;interested stockholder&#148; is a person who, together with affiliates and associates, owns, or
within three years prior to the determination of interested stockholder status did own, 15% or more of a corporation&#146;s voting stock. Generally, a &#147;business combination&#148; includes a merger, asset or stock sale, or other transaction
resulting in a financial benefit to the interested stockholder. The existence of this provision may have an anti-takeover effect with respect to transactions not approved in advance by the board of directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Choice of Forum </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our restated certificate
of incorporation provides that, unless we consent in writing to the selection of an alternative form, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for: (1)&nbsp;any derivative action or proceeding brought on
our behalf; (2)&nbsp;any action asserting a claim of breach of a fiduciary duty or other wrongdoing by any of our directors, officers, employees or agents to us or our stockholders; (3)&nbsp;any action asserting a claim against us arising pursuant
to any provision of the General Corporation Law of the State of Delaware or our certificate of incorporation or bylaws; (4)&nbsp;any action to interpret, apply, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 135 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
enforce or determine the validity of our certificate of incorporation or bylaws; or (5)&nbsp;any action asserting a claim governed by the internal affairs doctrine. Our restated certificate of
incorporation also provides that any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock will be deemed to have notice of and to have consented to this choice of forum provision. It is possible that a court
of law could rule that the choice of forum provision contained in our restated certificate of incorporation is inapplicable or unenforceable if it is challenged in a proceeding or otherwise. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Amendment of Charter Provisions </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
amendment of any of the above provisions, except for the provision making it possible for our board of directors to issue preferred stock, would require approval by holders of at least two thirds of the total voting power of all of our outstanding
voting stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The provisions of Delaware law, our amended and restated certificate of incorporation and our amended and restated bylaws
could have the effect of discouraging others from attempting hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of our common stock that often result from actual or rumored hostile takeover
attempts. These provisions may also have the effect of preventing changes in the composition of our board and management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders may otherwise
deem to be in their best interests. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transfer agent and registrar for our common stock will be &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NASDAQ Global Market </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have
applied to have our common stock listed on The NASDAQ Global Market under the symbol &#147;EXDX.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 136 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx693329_16"></A>SHARES ELIGIBLE FOR FUTURE SALE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Immediately prior to this offering, there was no public market for our common stock. Future sales of substantial amounts of common stock in
the public market, or the perception that such sales may occur, could adversely affect the market price of our common stock. Although we have applied to have our common stock listed on The NASDAQ Global Market, we cannot assure you that there will
be an active public market for our common stock. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the number of shares of our common stock outstanding as of September 30,
2015 and assuming (1)&nbsp;the issuance of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares in this offering, (2)&nbsp;the conversion of the $4.5&nbsp;million in aggregate principal amount (including accrued interest
thereon) of the February 2015 Notes into&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock, which will occur immediately prior to the completion of the offering, (3)&nbsp;the
conversion of the $3.0&nbsp;million in aggregate principal amount (including accrued interest thereon) of the July 2015 Notes into&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common
stock, which will occur immediately prior to the completion of the offering, (4)&nbsp;the conversion of the $3.4&nbsp;million in aggregate principal amount (including accrued interest thereon) of the October 2015 Notes
into&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock, which will occur immediately prior to the completion of the offering, (5)&nbsp;the conversion of all outstanding shares
of our redeemable convertible preferred stock into&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock, which will occur automatically occur immediately prior to the completion
of the offering, (6)&nbsp;no exercise of the underwriters&#146; over-allotment option to purchase additional shares of common stock, (7)&nbsp;the expected net exercise of the 2013 Warrants, and (8)&nbsp;no exercise of outstanding options or warrants
(other than the 2013 Warrants), we will have outstanding an aggregate of approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Of these shares, all shares sold in this offering will be freely tradable without restriction or further registration under the Securities
Act, except for any shares purchased by our &#147;affiliates,&#148; as that term is defined in Rule 144 under the Securities Act. Shares purchased by our affiliates would be subject to the Rule 144 resale restrictions described below, other than the
holding period requirement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The remaining
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock will be &#147;restricted securities,&#148; as that term is defined in Rule 144 under the Securities Act.
These restricted securities are eligible for public sale only if they are registered under the Securities Act or if they qualify for an exemption from registration under Rule 144 or 701 under the Securities Act, each of which is summarized below. We
expect that substantially all of these shares will be subject to the 180-day lock-up period under the lock-up agreements described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, of the 14,038,158 shares of our common stock that were subject to stock options outstanding as of September 30, 2015, options to
purchase 7,774,837 of such shares of common stock were vested as of such date and, upon exercise, these shares will be eligible for sale subject to the lock&#150;up agreements described below and Rules 144 and 701 under the Securities Act. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Lock-Up Agreements </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We, along with
our directors, executive officers and substantially all of our other stockholders, option holders and warrant holders, have agreed with the underwriters that for a period of 180 days, after the date of this prospectus, subject to specified
exceptions, we or they will not offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to sale of, or otherwise dispose of or transfer any shares of
common stock or any securities convertible into or exercisable or exchangeable for shares of common stock, request or demand that we file a registration statement related to our common stock or enter into any swap or other agreement that transfers
to another, in whole or in part, directly or indirectly, the economic consequence of ownership of the common stock. Upon expiration of the lock-up period, certain of our stockholders and warrantholders will have the right to require us to register
their shares under the Securities Act. See &#147;&#151;Registration Rights&#148; below and &#147;Description of Capital Stock&#151;Registration Rights.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Leerink Partners LLC and Robert W. Baird&nbsp;&amp; Co. Incorporated may, in their sole discretion and at any time or from time to time before
the termination of the lock-up period, without public notice, release all or any portion of the securities subject to lock-up agreements. There are no existing agreements between the underwriters and any of our stockholders who will execute a
lock-up agreement providing consent to the sale of shares prior to the expiration of the lock-up period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the expiration of the
lock-up period, substantially all of the shares subject to such lock-up restrictions will become eligible for sale, subject to the limitations discussed above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 137 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule 144 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Affiliate Resales of Restricted Securities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, beginning 90 days after the effective date of the registration statement of which this prospectus is a part, a person who is an
affiliate of ours, or who was an affiliate at any time during the 90 days before a sale, who has beneficially owned shares of our common stock for at least six months would be entitled to sell in &#147;broker&#146;s transactions&#148; or certain
&#147;riskless principal transactions&#148; or to market makers, a number of shares within any three-month period that does not exceed the greater of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">1% of the number of shares of our common stock then outstanding, which will equal approximately shares immediately after this offering; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the average weekly trading volume in our common stock on The NASDAQ Global Market during the four calendar weeks preceding the filing of a notice on Form 144 with respect to such sale. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Affiliate resales under Rule 144 are also subject to the availability of current public information about us. In addition, if the number of
shares being sold under Rule 144 by an affiliate during any three-month period exceeds 5,000 shares or has an aggregate sale price in excess of $50,000, the seller must file a notice on Form 144 with the Securities and Exchange Commission and The
NASDAQ Global Market concurrently with either the placing of a sale order with the broker or the execution of a sale directly with a market maker. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Non-Affiliate Resales of Restricted Securities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, beginning 90 days after the effective date of the registration statement of which this prospectus is a part, a person who is not an
affiliate of ours at the time of sale, and has not been an affiliate at any time during the three months preceding a sale, and who has beneficially owned shares of our common stock for at least six months but less than a year, is entitled to sell
such shares subject only to the availability of current public information about us. If such person has held our shares for at least one year, such person can resell under Rule&nbsp;144(b)(1) without regard to any Rule 144 restrictions, including
the 90-day public company requirement and the current public information requirement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Non-affiliate resales are not subject to the manner
of sale, volume limitation or notice filing provisions of Rule 144. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule 701 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, under Rule 701, any of an issuer&#146;s employees, directors, officers, consultants or advisors who purchases shares from the
issuer in connection with a compensatory stock or option plan or other written agreement before the effective date of a registration statement under the Securities Act is entitled to sell such shares 90 days after such effective date in reliance on
Rule 144. An affiliate of the issuer can resell shares in reliance on Rule 144 without having to comply with the holding period requirement, and non-affiliates of the issuer can resell shares in reliance on Rule 144 without having to comply with the
current public information and holding period requirements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity Plans </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to file one or more registration statements on Form S-8 under the Securities Act to register all shares of common stock subject to
outstanding stock options and common stock issued or issuable under the 2015 plan, 2013 plan, 2002 plan and ESPP. We expect to file the registration statement covering shares offered pursuant to these stock plans shortly after the date of this
prospectus, permitting the resale of such shares by non-affiliates in the public market without restriction under the Securities Act and the sale by affiliates in the public market subject to compliance with the resale provisions of Rule 144. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September
30, 2015, holders of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock, which includes all of the shares of common stock issuable upon the automatic
conversion of our redeemable convertible preferred stock immediately prior to the completion of this offering and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of
common stock issuable in connection with the completion of this offering as a result of the automatic conversion of the (1)&nbsp;$4.5 million in aggregate principal of the February 2015 Notes (including accrued interest thereon); (2)&nbsp;$3.0
million in aggregate principal of the July 2015 Notes (including accrued interest thereon); and (3)&nbsp;$3.4 million in aggregate principle of the October 2015 Notes (including accrued interest thereon), assuming an initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range listed on the cover page of this prospectus and assuming the conversion occurs
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2015 (the expected closing date of this offering), or their transferees will be entitled to various
rights with respect to the registration of these shares under the Securities Act upon the completion of this offering. Registration of these shares under the Securities Act would result </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 138 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in these shares becoming fully tradable without restriction under the Securities Act immediately upon the effectiveness of the registration, except for shares purchased by affiliates. See
&#147;Description of Capital Stock&#151;Registration Rights&#148; for additional information. Shares covered by a registration statement will be eligible for sale in the public market upon the expiration or release from the terms of the lock-up
agreement. </P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 139 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx693329_17"></A>MATERIAL UNITED STATES FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S.
HOLDERS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following discussion is a summary of the material U.S. federal income tax consequences to Non-U.S. Holders (as defined
below) of the purchase, ownership and disposition of our common stock issued pursuant to this offering, but does not purport to be a complete analysis of all potential tax effects. The effects of other U.S. federal tax laws, such as estate and gift
tax laws, and any applicable state, local or non-U.S. tax laws are not discussed. This discussion is based on the U.S. Internal Revenue Code of 1986, as amended, or the Code, Treasury regulations promulgated thereunder, judicial decisions, and
published rulings and administrative pronouncements of the U.S. Internal Revenue Service, or the IRS, in each case in effect as of the date hereof. These authorities may change or be subject to differing interpretations. Any such change or differing
interpretation may be applied retroactively in a manner that could adversely affect a Non-U.S. Holder of our common stock. We have not sought and will not seek any rulings from the IRS regarding the matters discussed below. There can be no assurance
the IRS or a court will not take a contrary position to that discussed below regarding the tax consequences of the purchase, ownership and disposition of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion is limited to Non-U.S. Holders that hold our common stock as a &#147;capital asset&#148; within the meaning of
Section&nbsp;1221 of the Code (generally, property held for investment). This discussion does not address all U.S. federal income tax consequences relevant to a Non-U.S. Holder&#146;s particular circumstances, including the impact of the Medicare
contribution tax on net investment income. In addition, it does not address consequences relevant to Non-U.S. Holders subject to special rules, including, without limitation: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">U.S. expatriates and former citizens or long-term residents of the United States; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons subject to the alternative minimum tax; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons holding our common stock as part of a hedge, straddle or other risk reduction strategy or as part of a conversion transaction or other integrated investment; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">banks, insurance companies, and other financial institutions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">brokers, dealers or traders in securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&#147;controlled foreign corporations,&#148; &#147;passive foreign investment companies,&#148; and corporations that accumulate earnings to avoid U.S. federal income tax; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">partnerships or other entities or arrangements treated as partnerships for U.S. federal income tax purposes (and investors therein); </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">tax-exempt organizations or governmental organizations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons deemed to sell our common stock under the constructive sale provisions of the Code; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons who hold or receive our common stock pursuant to the exercise of any employee stock option or otherwise as compensation; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">tax-qualified retirement plans. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an entity treated as a partnership for U.S. federal income
tax purposes holds our common stock, the tax treatment of a partner in the partnership will depend on the status of the partner, the activities of the partnership and certain determinations made at the partner level. Accordingly, partnerships
holding our common stock and the partners in such partnerships should consult their tax advisors regarding the U.S. federal income tax consequences to them. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THIS DISCUSSION IS FOR INFORMATIONAL PURPOSES ONLY AND IS NOT TAX ADVICE. INVESTORS SHOULD CONSULT THEIR TAX ADVISORS WITH RESPECT TO THE
APPLICATION OF THE U.S. FEDERAL INCOME TAX LAWS TO THEIR PARTICULAR SITUATIONS AS WELL AS ANY TAX CONSEQUENCES OF THE PURCHASE, OWNERSHIP AND DISPOSITION OF OUR COMMON STOCK ARISING UNDER THE U.S. FEDERAL ESTATE OR GIFT TAX LAWS OR UNDER THE LAWS OF
ANY STATE, LOCAL OR NON-U.S. TAXING JURISDICTION OR UNDER ANY APPLICABLE INCOME TAX TREATY. </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Definition of a Non-U.S. Holder </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this discussion, a &#147;Non-U.S. Holder&#148; is any beneficial owner of our common stock that is neither a &#147;U.S.
person&#148; nor an entity treated as a partnership for U.S. federal income tax purposes. A U.S. person is any person that, for U.S. federal income tax purposes, is or is treated as any of the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an individual who is a citizen or resident of the United States; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 140 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a corporation created or organized under the laws of the United States, any state thereof, or the District of Columbia; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an estate, the income of which is subject to U.S. federal income tax regardless of its source; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a trust that (1)&nbsp;is subject to the primary supervision of a U.S. court and the control of one or more &#147;United States persons&#148; (within the meaning of Section&nbsp;7701(a)(30) of the Code), or (2)&nbsp;has
a valid election in effect to be treated as a United States person for U.S. federal income tax purposes. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Distributions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As described in the section entitled &#147;Dividend Policy,&#148; we do not anticipate declaring or paying dividends to holders of our common
stock in the foreseeable future. However, if we do make distributions of cash or property on our common stock, such distributions will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated
earnings and profits, as determined under U.S. federal income tax principles. Amounts not treated as dividends for U.S. federal income tax purposes will constitute a return of capital and first be applied against and reduce a Non-U.S. Holder&#146;s
tax basis in its common stock, but not below zero. Any excess will be treated as capital gain from a sale or other taxable disposition and will be treated as described below under &#147;&#151;Sale or Other Taxable Disposition.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the discussion below on effectively connected income, dividends paid to a Non-U.S. Holder of our common stock will be subject to
U.S. federal withholding tax at a rate of 30% of the gross amount of the dividends (or such lower rate specified by an applicable income tax treaty, provided the Non-U.S. Holder furnishes a valid IRS Form W-8BEN or W-8BEN-E (or other applicable
documentation) certifying qualification for the lower treaty rate). If a Non-U.S. Holder holds the stock through a financial institution or other agent acting on the Non-U.S. Holder&#146;s behalf, the Non-U.S. Holder will be required to provide
appropriate documentation to the agent, who then will be required to provide certification to the applicable withholding agent, either directly or through other intermediaries. A Non-U.S. Holder that does not timely furnish the required
documentation, but that qualifies for a reduced treaty rate, may obtain a refund of any excess amounts withheld by timely filing an appropriate claim for refund with the IRS. Non-U.S. Holders should consult their tax advisors regarding their
entitlement to benefits under any applicable income tax treaty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If dividends paid to a Non-U.S. Holder are effectively connected with the
Non-U.S. Holder&#146;s conduct of a trade or business within the United States (and, if required by an applicable income tax treaty, are attributable to a permanent establishment in the United States maintained by the Non-U.S. Holder), the Non-U.S.
Holder will be exempt from the U.S. federal withholding tax described above. To claim the exemption, the Non-U.S. Holder must furnish to the applicable withholding agent a valid IRS Form W-8ECI, certifying that the dividends are effectively
connected with the Non-U.S. Holder&#146;s conduct of a trade or business within the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any such effectively connected
dividends will be subject to U.S. federal income tax on a net income basis at the regular graduated rates. A Non-U.S. Holder that is a corporation may also be subject to a branch profits tax at a rate of 30% (or such lower rate specified by an
applicable income tax treaty) on such effectively connected dividends, as adjusted for certain items. Non-U.S. Holders should consult their tax advisors regarding any applicable tax treaties that may provide for different rules. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sale or Other Taxable Disposition </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A
Non-U.S. Holder will not be subject to U.S. federal income tax on any gain realized upon the sale or other taxable disposition of our common stock unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the gain is effectively connected with the Non-U.S. Holder&#146;s conduct of a trade or business within the United States (and, if required by an applicable income tax treaty, is attributable to a permanent
establishment in the United States maintained by the Non-U.S. Holder); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Non-U.S. Holder is a nonresident alien individual present in the United States for 183 days or more during the taxable year of the disposition and certain other requirements are met; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our common stock constitutes a U.S. real property interest, or USRPI, by reason of our status as a U.S.&nbsp;real property holding corporation, or USRPHC, for U.S. federal income tax purposes. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gain described in the first bullet point above generally will be subject to U.S. federal income tax on a net income basis at the regular
graduated rates. A Non-U.S. Holder that is a corporation may also be subject to a branch profits tax at a rate of 30% (or such lower rate specified by an applicable income tax treaty) on such effectively connected gain, as adjusted for certain
items. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 141 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gain described in the second bullet point above will be subject to U.S. federal income tax at a
rate of 30% (or such lower rate specified by an applicable income tax treaty), which may be offset by U.S. source capital losses of the Non-U.S. Holder (even though the Non-U.S. Holder is not considered a resident of the United&nbsp;States),
provided the Non-U.S. Holder has timely filed U.S. federal income tax returns with respect to such losses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to the third
bullet point above, we believe we currently are not, and do not anticipate becoming, a USRPHC. However, because the determination of whether we are a USRPHC depends on the fair market value of our USRPIs relative to the fair market value of our
non-U.S. real property interests and our other business assets, there can be no assurance we currently are not a USRPHC or will not become one in the future. Even if we are or were to become a USRPHC, gain arising from the sale or other taxable
disposition by a Non-U.S. Holder of our common stock will not be subject to U.S. federal income tax if our common stock is &#147;regularly traded,&#148; as defined by applicable Treasury regulations, on an established securities market, and such
Non-U.S. Holder owned, actually or constructively, 5% or less of our common stock throughout the shorter of the five-year period ending on the date of the sale or other taxable disposition or the Non-U.S. Holder&#146;s holding period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Non-U.S. Holders should consult their tax advisors regarding potentially applicable income tax treaties that may provide for different rules.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Information Reporting and Backup Withholding </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payments of dividends on our common stock will not be subject to backup withholding, provided the applicable withholding agent does not have
actual knowledge or reason to know the holder is a United States person and the holder either certifies its non-U.S. status, such as by furnishing a valid IRS Form W-8BEN, W-8BEN-E or W-8ECI, or otherwise establishes an exemption. However,
information returns are required to be filed with the IRS in connection with any dividends on our common stock paid to the Non-U.S. Holder, regardless of whether any tax was actually withheld. In addition, proceeds of the sale or other taxable
disposition of our common stock within the United States or conducted through certain U.S.-related brokers generally will not be subject to backup withholding or information reporting, if the applicable withholding agent receives the certification
described above and does not have actual knowledge or reason to know that such holder is a United&nbsp;States person, or the holder otherwise establishes an exemption. Proceeds of a disposition of our common stock conducted through a non-U.S. office
of a non-U.S. broker generally will not be subject to backup withholding or information reporting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Copies of information returns that are
filed with the IRS may also be made available under the provisions of an applicable treaty or agreement to the tax authorities of the country in which the Non-U.S. Holder resides or is established. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules may be allowed as a refund or a credit
against a Non-U.S. Holder&#146;s U.S. federal income tax liability, provided the required information is timely furnished to the IRS. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Additional
Withholding Tax on Payments Made to Foreign Accounts </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Withholding taxes may be imposed under Sections 1471 to 1474 of the Code (such
Sections commonly referred to as the Foreign Account Tax Compliance Act, or FATCA) on certain types of payments made to non-U.S. financial institutions and certain other non-U.S. entities. Specifically, a 30% withholding tax may be imposed on
dividends on, or gross proceeds from the sale or other disposition of, our common stock paid to a &#147;foreign financial institution&#148; or a &#147;non-financial foreign entity&#148; (each as defined in the Code), unless (1)&nbsp;the foreign
financial institution undertakes certain diligence and reporting obligations, (2)&nbsp;the non-financial foreign entity either certifies it does not have any &#147;substantial United States owners&#148; (as defined in the Code) or furnishes
identifying information regarding each substantial United States owner, or (3)&nbsp;the foreign financial institution or non-financial foreign entity otherwise qualifies for an exemption from these rules. If the payee is a foreign financial
institution and is subject to the diligence and reporting requirements in (1)&nbsp;above, it must enter into an agreement with the U.S. Department of the Treasury requiring, among other things, that it undertake to identify accounts held by certain
&#147;specified United States persons&#148; or &#147;United States-owned foreign entities&#148; (each as defined in the Code), annually report certain information about such accounts, and withhold 30% on certain payments to non-compliant foreign
financial institutions and certain other account holders. Foreign financial institutions located in jurisdictions that have an intergovernmental agreement with the United States governing FATCA may be subject to different rules. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the applicable Treasury regulations and IRS guidance, withholding under FATCA generally applies to payments of dividends on our common
stock made on or after October&nbsp;1, 2014 and will apply to payments of gross proceeds from the sale or other disposition of our common stock on or after January&nbsp;1, 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prospective investors should consult their tax advisors regarding the potential application of withholding under FATCA to their investment in
our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 142 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx693329_18"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Leerink Partners LLC and Robert W. Baird&nbsp;&amp; Co. Incorporated are acting as representatives of each of the underwriters named below.
Subject to the terms and conditions set forth in an underwriting agreement among us and the underwriters, we have agreed to sell to the underwriters, and each of the underwriters has agreed, severally and not jointly, to purchase from us, the number
of shares of common stock set forth opposite its name below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:43.10pt; font-size:8pt; font-family:Times New Roman"><B>Underwriter</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Shares</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leerink Partners LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert W. Baird&nbsp;&amp; Co. Incorporated</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">William Blair&nbsp;&amp; Company, L.L.C.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the terms and conditions set forth in the underwriting agreement, the underwriters have agreed,
severally and not jointly, to purchase all of the shares sold under the underwriting agreement if any of these shares are purchased. If an underwriter defaults, the underwriting agreement provides that the purchase commitments of the non-defaulting
underwriters may be increased or the underwriting agreement may be terminated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have agreed to indemnify the underwriters against
certain liabilities, including liabilities under the Securities Act, or to contribute to payments the underwriters may be required to make in respect of those liabilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters are offering the shares, subject to prior sale, when, as and if issued to and accepted by them, subject to approval of legal
matters by their counsel, including the validity of the shares, and other conditions contained in the underwriting agreement, such as the receipt by the underwriters of officers&#146; certificates and legal opinions. The underwriters reserve the
right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Commissions and Discounts </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The representatives have advised us that the underwriters propose initially to offer the shares to the public at the public offering price set
forth on the cover of this prospectus and to dealers at that price less a concession not in excess of $&nbsp;per share. After the initial offering, the public offering price, concession or any other term of the offering may be changed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows the public offering price, underwriting discount and proceeds before expenses to us. The information assumes either
no exercise or full exercise by the underwriters of their option to purchase additional shares of our common stock. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per&nbsp;Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Without&nbsp;Option</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>With&nbsp;Option</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds, before expenses, to us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate expenses payable by us in connection with this offering, other than the underwriting discounts and
commissions referred to above, will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We also have agreed to reimburse the underwriters for up to $&nbsp;for their FINRA counsel fee. In accordance with FINRA
Rule 5110, this reimbursed fee is deemed underwriting compensation for this offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Option to Purchase Additional Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have granted an option to the underwriters, exercisable for 30 days after the date of this prospectus, to purchase up to additional shares
at the public offering price, less the underwriting discount. If the underwriters exercise this option, each will be obligated, subject to conditions contained in the underwriting agreement, to purchase a number of additional shares proportionate to
that underwriter&#146;s initial amount reflected in the above table. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 143 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Sales of Similar Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We, our executive officers and directors and all of our other existing security holders have agreed not to sell or transfer any common stock or
securities convertible into or exchangeable or exercisable for common stock, for 180 days after the date of this prospectus without first obtaining the written consent of Leerink Partners LLC and Robert W. Baird&nbsp;&amp; Co. Incorporated.
Specifically, we and these other persons have agreed, with certain limited exceptions, not to directly or indirectly: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">offer, pledge, sell or contract to sell any common stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">sell any option or contract to purchase any common stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">purchase any option or contract to sell any common stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">grant any option, right or warrant for the sale of any common stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">otherwise dispose of or transfer any common stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">request or demand that we file a registration statement related to the common stock; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">enter into any swap or other agreement or any transaction that transfers, in whole or in part, the economic consequence of ownership of any common stock, whether any such swap, agreement or transaction is to be settled
by delivery of shares or other securities, in cash or otherwise. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This lock-up provision applies to common stock and to
securities convertible into or exchangeable or exercisable for common stock. It also applies to common stock owned now or acquired later by the person executing the agreement or for which the person executing the agreement later acquires the power
of disposition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NASDAQ Global Market Listing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have applied to list our common stock on The NASDAQ Global Market, subject to notice of issuance, under the symbol &#147;EXDX.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before this offering, there has been no public market for our common stock. The initial public offering price will be determined through
negotiations between us and the representatives. In addition to prevailing market conditions, the factors to be considered in determining the initial public offering price are: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the valuation multiples of publicly traded companies that the representatives believe to be comparable to us; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our financial information; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the history of, and the prospects for, our company and the industry in which we compete; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an assessment of our management, its past and present operations, and the prospects for, and timing of, our future revenues; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the present state of our development; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the above factors in relation to market values and various valuation measures of other companies engaged in activities similar to ours. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An active trading market for the shares may not develop. It is also possible that after the offering the shares will not trade in the public
market at or above the initial public offering price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters do not expect to sell more than 5% of the shares in the aggregate
to accounts over which they exercise discretionary authority. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Price Stabilization, Short Positions and Penalty Bids </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until the distribution of the shares is completed, SEC rules may limit underwriters and selling group members from bidding for and purchasing
our common stock. However, the representatives may engage in transactions that stabilize the price of the common stock, such as bids or purchases to peg, fix or maintain that price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the offering, the underwriters may purchase and sell our common stock in the open market. These transactions may include
short sales, purchases on the open market to cover positions created by short sales and stabilizing transactions. Short sales involve the sale by the underwriters of a greater number of shares than they are required to purchase in the offering.
&#147;Covered&#148; short sales are sales made in an amount not greater than the underwriters&#146; option described above. The underwriters may close out any covered short position by either exercising their option or purchasing shares in the open
market. In determining the source of shares to close out the covered short position, the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared to the price at which they may
purchase shares through the option </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 144 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
granted to them. &#147;Naked&#148; short sales are sales in excess of such option. The underwriters must close out any naked short position by purchasing shares in the open market. A naked short
position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of our common stock in the open market after pricing that could adversely affect investors who purchase in the offering.
Stabilizing transactions consist of various bids for or purchases of shares of common stock made by the underwriters in the open market prior to the completion of the offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters may also impose a penalty bid. This occurs when a particular underwriter repays to the underwriters a portion of the
underwriting discount received by it because the representatives have repurchased shares sold by or for the account of such underwriter in stabilizing or short covering transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similar to other purchase transactions, the underwriters&#146; purchases to cover the syndicate short sales may have the effect of raising or
maintaining the market price of our common stock or preventing or retarding a decline in the market price of our common stock. As a result, the price of our common stock may be higher than the price that might otherwise exist in the open market. The
underwriters may conduct these transactions on The NASDAQ Global Market, in the over-the-counter market or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we nor any
of the underwriters make any representation or prediction as to the direction or magnitude of any effect that the transactions described above may have on the price of our common stock. In addition, neither we nor any of the underwriters make any
representation that the representatives will engage in these transactions or that these transactions, once commenced, will not be discontinued without notice. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Electronic Distribution </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection
with the offering, certain of the underwriters or securities dealers may distribute prospectuses by electronic means, such as e-mail. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other
Relationships </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some of the underwriters and their affiliates may in the future engage in investment banking and other commercial
dealings in the ordinary course of business with us or our affiliates. They may in the future receive customary fees and commissions for these transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in the ordinary course of their business activities, the underwriters and their affiliates may make or hold a broad array of
investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Such investments and securities activities may involve securities and/or instruments of ours or our affiliates. The underwriters and their
affiliates may also make investment recommendations and/or publish or express independent research views in respect of such securities or financial instruments and may hold, or recommend to clients that they acquire, long and/or short positions in
such securities and instruments. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in the European Economic Area </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In relation to each Member State of the European Economic Area (each, a &#147;Relevant Member State&#148;), no offer of shares may be made to
the public in that Relevant Member State other than: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">A. to any legal entity which is a qualified investor as defined in the Prospectus
Directive; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">B. to fewer than 100 or, if the Relevant Member State has implemented the relevant provision of the 2010 PD Amending Directive,
150, natural or legal persons (other than qualified investors as defined in the Prospectus Directive), as permitted under the Prospectus Directive, subject to obtaining the prior consent of the representatives; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">C. in any other circumstances falling within Article 3(2) of the Prospectus Directive, provided that no such offer of shares shall require the
Company or the representatives to publish a prospectus pursuant to Article 3 of the Prospectus Directive or supplement a prospectus pursuant to Article 16 of the Prospectus Directive. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 145 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each person in a Relevant Member State who initially acquires any shares or to whom any offer is
made will be deemed to have represented, acknowledged and agreed that it is a &#147;qualified investor&#148; within the meaning of the law in that Relevant Member State implementing Article 2(1)(e) of the Prospectus Directive. In the case of any
shares being offered to a financial intermediary as that term is used in Article 3(2) of the Prospectus Directive, each such financial intermediary will be deemed to have represented, acknowledged and agreed that the shares acquired by it in the
offer have not been acquired on a non-discretionary basis on behalf of, nor have they been acquired with a view to their offer or resale to, persons in circumstances which may give rise to an offer of any shares to the public other than their offer
or resale in a Relevant Member State to qualified investors as so defined or in circumstances in which the prior consent of the representatives has been obtained to each such proposed offer or resale. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The company, the representatives and their affiliates will rely upon the truth and accuracy of the foregoing representations, acknowledgements
and agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus has been prepared on the basis that any offer of shares in any Relevant Member State will be made
pursuant to an exemption under the Prospectus Directive from the requirement to publish a prospectus for offers of shares. Accordingly any person making or intending to make an offer in that Relevant Member State of shares which are the subject of
the offering contemplated in this prospectus may only do so in circumstances in which no obligation arises for the company or any of the underwriters to publish a prospectus pursuant to Article 3 of the Prospectus Directive in relation to such
offer. Neither the company nor the underwriters have authorized, nor do they authorize, the making of any offer of shares in circumstances in which an obligation arises for the company or the underwriters to publish a prospectus for such offer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purpose of the above provisions, the expression &#147;an offer to the public&#148; in relation to any shares in any Relevant Member
State means the communication in any form and by any means of sufficient information on the terms of the offer and the shares to be offered so as to enable an investor to decide to purchase or subscribe the shares, as the same may be varied in the
Relevant Member State by any measure implementing the Prospectus Directive in the Relevant Member State and the expression &#147;Prospectus Directive&#148; means Directive 2003/71/EC (including the 2010 PD Amending Directive, to the extent
implemented in the Relevant Member&nbsp;States) and includes any relevant implementing measure in the Relevant Member State and the expression &#147;2010 PD Amending Directive&#148; means Directive 2010/73/EU. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 146 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx693329_19"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The validity of the shares of common stock offered hereby will be passed upon for us by Latham&nbsp;&amp; Watkins LLP, San Diego, California.
The underwriters are being represented by Cooley LLP, San Diego, California. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx693329_20"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements as of December&nbsp;31, 2013 and 2014 and for each of the two years in the period ended
December&nbsp;31, 2014 included in this prospectus have been so included in reliance on the report (which contains an explanatory paragraph relating to the Company&#146;s ability to continue as a going concern as described in Note&nbsp;1 to the
consolidated financial statements) of PricewaterhouseCoopers LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx693329_21"></A>CHANGE IN INDEPENDENT ACCOUNTANT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;25, 2013, the Audit Committee of the board of directors determined to dismiss McGladrey LLP and retain PricewaterhouseCoopers
LLP, or PwC, as our independent registered public accounting firm. Effective February&nbsp;13, 2014, we retained PwC as our independent registered public accounting firm. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The reports of McGladrey LLP on our consolidated financial statements for each of the two fiscal years prior to its dismissal did not contain
any adverse opinion or disclaimer of opinion, nor were such reports qualified or modified as to uncertainty, audit scope or accounting principles. However, the reports of McGladrey LLP included an emphasis of matter regarding the Company&#146;s
ability to continue as a going concern. We had no disagreements with McGladrey LLP on any matter of accounting principles or practices, consolidated financial statement disclosure or auditing scope or procedure, which disagreements, if not resolved
to its satisfaction, would have caused McGladrey LLP to make reference in connection with its opinion to the subject matter of the disagreement during its audits for each of the two fiscal years prior to its dismissal or the subsequent interim
period through November&nbsp;25, 2013. During the two most recent fiscal years preceding McGladrey LLP&#146;s dismissal, and the subsequent interim period through November&nbsp;25, 2013, there were no &#145;&#145;reportable events&#146;&#146; as
such term is defined in Item&nbsp;304(a)(1)(v) of Regulation&nbsp;S-K. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the two years ended December&nbsp;31, 2012 and the
subsequent interim period through February&nbsp;13, 2014, neither we, nor anyone acting on our behalf, consulted with PwC on matters that involved the application of accounting principles to a specified transaction, either completed or proposed, the
type of audit opinion that might be rendered on our consolidated financial statements, and neither a written report nor oral advice was provided to us by PwC that PwC concluded was an important factor considered by us in reaching a decision as to
the accounting, auditing or financial reporting issue or any other matter that was the subject of a disagreement as that term is used in Item&nbsp;304 (a)(1)(iv) of Regulation&nbsp;S-K and the related instructions to Item&nbsp;304 of
Regulation&nbsp;S-K or a reportable event as that term is used in Item&nbsp;304(a)(1)(v) and the related instructions to Item&nbsp;304 of Regulation&nbsp;S-K. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have provided McGladrey LLP with a copy of the foregoing disclosure and have requested that McGladrey LLP furnish us with a letter
addressed to the SEC stating whether or not McGladrey LLP agrees with the above statements and, if not, stating the respects in which it does not agree. A copy of the letter from McGladrey LLP is filed as an exhibit to the registration statement of
which this prospectus is a part. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx693329_22"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have filed with the Securities and Exchange Commission a registration statement on Form S-1 under the Securities Act with respect to the
shares of common stock offered hereby. This prospectus, which constitutes a part of the registration statement, does not contain all of the information set forth in the registration statement or the exhibits and schedules filed therewith. For
further information about us and the common stock offered hereby, we refer you to the registration statement and the exhibits and schedules filed thereto. Statements contained in this prospectus regarding the contents of any contract or any other
document that is filed as an exhibit to the registration statement are not necessarily complete, and each such statement is qualified in all respects by reference to the full text of such contract or other document filed as an exhibit to the
registration statement. Upon the completion of this offering, we will be required to file periodic reports, proxy statements and other information with the Securities and Exchange Commission pursuant to the Securities Exchange Act of 1934. You may
read and copy this information at the Public Reference Room of the Securities and Exchange Commission, 100 F Street, N.E., Room 1580, Washington, D.C. 20549. You may obtain information on the operation of the public reference rooms by calling the
Securities and Exchange Commission at 1-800-SEC-0330. The Securities and Exchange Commission also maintains an Internet website that contains reports, proxy statements and other information about registrants, like us, that file electronically with
the Securities and Exchange Commission. The address of that website is <I>www.sec.gov</I>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 147 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exagen Diagnostics, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx693329_23"></A>Index to Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="96%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin693329_1">Report of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin693329_2">Consolidated Balance Sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin693329_3">Consolidated Statements of Operations and Comprehensive Loss</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin693329_4">Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders&#146; Deficit</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin693329_5">Consolidated Statements of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin693329_6">Notes to Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>    <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin693329_1"></A>Report of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the Board of Directors and Stockholders of </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Exagen
Diagnostics, Inc.: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In our opinion, the accompanying consolidated balance sheets and the related consolidated statements of operations and comprehensive
loss, consolidated statements of redeemable convertible preferred stock and stockholders&#146; deficit, and consolidated statements of cash flow present fairly, in all material respects, the financial position of Exagen Diagnostics, Inc. and its
subsidiary at December&nbsp;31, 2014, and 2013, and the results of their operations and their cash flows for each of the two years in the period ended December&nbsp;31, 2014 in conformity with accounting principles generally accepted in the United
States of America. These financial statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits of these statements in
accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the
overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial
statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the consolidated financial statements, the Company has suffered recurring losses from operations since inception and has negative
cash flows from operating activities that raise substantial doubt about its ability to continue as a going concern. Management&#146;s plans in regard to these matters are also described in Note 1. The consolidated financial statements do not include
any adjustments that might result from the outcome of this uncertainty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ PricewaterhouseCoopers LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Diego, California </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">February&nbsp;17, 2015 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exagen Diagnostics, Inc. </B></P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin693329_2"></A>Consolidated Balance Sheets </B></P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except share and per share data) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:8pt"><B>December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-size:8pt"><B>September&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>September&nbsp;30,</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2015</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Pro
Forma</B></P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Balance&nbsp;Sheet</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>(Unaudited)</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,605</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">474</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">897</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,079</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,634</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,228</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,538</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Intangible assets, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">805</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">560</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Goodwill</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,506</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,506</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,506</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Noncurrent deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,719</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,546</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">665</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,451</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman"><B>Liabilities, Redeemable Convertible Preferred Stock and Stockholders&#146; Deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">442</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">957</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Deferred tax liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,884</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,884</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Capital lease obligations, current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">123</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Derivative liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">559</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Acquisition-related liabilities, current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Borrowings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,811</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,394</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,406</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,579</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Redeemable convertible preferred stock warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,085</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,461</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Acquisition-related liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Other noncurrent liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">679</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">265</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,399</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Commitments and Contingencies (Note 7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Redeemable convertible preferred stock, $0.001 par value &#151;145,000,000; 145,000,000, and 185,000,000 shares authorized at
December&nbsp;31, 2013, 2014, and September 30, 2015 (unaudited), respectively; 92,330,247, 92,330,247, and 109,714,571 shares issued and outstanding at December&nbsp;31, 2013, 2014, and September 30, 2015 (unaudited), respectively; $49,052
liquidation preference at September 30, 2015 (unaudited); no shares issued or outstanding pro forma (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,617</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Stockholders&#146; deficit:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Common stock, $0.001 par value&nbsp;&#151;&nbsp;163,000,000, 163,000,000, and 203,000,000 shares authorized at December&nbsp;31, 2013,
2014, and September 30, 2015 (unaudited), respectively; 9,943,214, 11,518,132, and 11,535,839 shares issued and outstanding at December&nbsp;31, 2013 and 2014, and September 30, 2015 (unaudited) respectively; shares issued and outstanding pro forma
(unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Additional paid-in capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,890</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,516</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(74,288</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(89,269</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(105,919</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,388</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(38,673</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(55,391</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Total liabilities, redeemable convertible preferred stock, and stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,451</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exagen Diagnostics, Inc. </B></P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin693329_3"></A>Consolidated Statement of Operations and Comprehensive Loss </B></P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except share and per share data) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine Months Ended</B><br><B>September 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,055</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,663</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,425</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,497</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Costs of revenues (excluding amortization of purchased technology)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,830</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,885</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,727</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general&nbsp;&amp; administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,993</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,066</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,077</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">897</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of acquisition-related liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,265</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(239</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,144</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,556</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,741</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,834</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(941</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,941</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,008</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,533</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on extinguishment of notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,286</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,258</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other (expense) / income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(83</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(497</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(626</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,454</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,994</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,375</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,440</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax (expense) / benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(42</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(210</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,496</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(14,981</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,372</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,650</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,226</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,759</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,678</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,198</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common stockholders - basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.85</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.62</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.37</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.58</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares used to compute net loss per share attributable to common stockholders - basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,856,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,350,442</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,984,156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,524,744</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per share attributable to common stockholders - basic and diluted (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares used to compute pro forma net loss per share attributable to common stockholders - basic and diluted
(unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exagen Diagnostics, Inc. </B></P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin693329_4"></A>Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders&#146; Deficit
</B></P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except per share data) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Redeemable<BR>Convertible<BR>Preferred<BR>Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common<BR>Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Additional<BR>Paid-In</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Accumulated</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Total<BR>Stockholders&#146;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Capital</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Deficit</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Deficit</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balances at December&nbsp;31, 2012</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69,765</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,775</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">56,126</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(60,792</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4,656</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of Series D redeemable convertible preferred stock at $0.25 per share for cash, net of issuance costs of $8</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,079</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,511</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deemed dividend on issuance of Series D redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,419</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,419</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conversion of 2013 Notes into Series D redeemable convertible preferred stock at a fair value of $0.49 per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,486</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion of redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,311</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,311</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of common stock warrants in connection with 2013 Loan at relative fair value, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of common stock to consultants in exchange for services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,496</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,496</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balances at December&nbsp;31, 2013</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,943</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,890</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(74,288</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,388</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion of redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,778</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,778</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,778</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,575</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">195</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,981</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,981</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balances at December&nbsp;31, 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,617</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,518</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(89,269</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(38,673</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion of redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,549</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,548</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,548</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Beneficial conversion feature</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,265</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,265</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conversion of July 2014 Notes to Series D Preferred Redeemable Convertible Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,384</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,650</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,650</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balances at September 2015 (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109,714</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36,784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50,516</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(105,919</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(55,391</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exagen Diagnostics, Inc. </B></P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin693329_5"></A>Consolidated Statements of Cash Flows </B></P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Years Ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Nine Months Ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:8pt"><B>December 31,</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:8pt"><B>September 30,</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Cash flows from operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,496</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(14,981</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,372</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,650</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Revaluation of acquisition-related liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,265</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(239</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">455</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">558</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">395</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Impairment of intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Amortization of debt discount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">425</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">506</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">306</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Amortization of deferred financing costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Noncash interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">516</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">949</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Revaluation of embedded derivatives and warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">497</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">626</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(166</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Loss on extinguishment of notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,286</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,258</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Deferred income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Loss on disposal of assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Issuance of common stock in exchange for services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Changes in assets and liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(55</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(107</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(105</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(146</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(400</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">273</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,398</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">526</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(994</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">966</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">964</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(39</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Acquisition-related liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(110</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:9.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,865</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,773</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,330</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,523</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Cash flows from investing activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(172</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(649</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(606</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(641</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Proceeds from sale of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">707</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:9.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Net cash (used in) provided by investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">549</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(649</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(606</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(641</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Cash flows from financing activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Proceeds from borrowings of long-term debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Payments on borrowings of long-term debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,875</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Payments for deferred financing costs and costs paid to lender</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(647</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,511</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Proceeds from issuance of convertible promissory notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Proceeds from issuance of convertible debt, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Payments on warrant obligation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(400</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Payments on line of credit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(686</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Proceeds from issuance of common stock, net of repurchases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">195</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Payments on capital lease obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(39</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(208</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(118</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(52</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Deferred offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(635</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(597</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(57</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Payment of acquisition-related liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(90</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:9.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,284</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,316</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Net change in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,138</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(620</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,868</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Cash and cash equivalents, beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,605</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Cash and cash equivalents, end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,605</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,123</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Years Ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Nine Months<BR>Ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:8pt"><B>December 31,</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:8pt"><B>September 30,</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Supplemental disclosure of cash flow information:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Cash paid for interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">339</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,344</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,084</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Supplemental disclosure of noncash items:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Cost incurred, but not paid, in connection with initial public offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">646</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Costs incurred, but not paid, in connection with capital expenditures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Accretion to redemption value of redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,778</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,306</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Conversion of notes payable and accrued interest into redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,497</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Deemed dividend on issuance of Series D redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Issuance of warrants to purchase redeemable convertible preferred stock and common stock in 2013</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Equipment purchased under capital lease obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">458</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>


 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exagen Diagnostics, Inc. </B></P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin693329_6"></A>Notes to Consolidated Financial Statements </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Description of Business and Basis of Financial Statements </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Description of Business
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Exagen Diagnostics, Inc. (the Company) was incorporated under the laws of the state of New Mexico in 2002, under the name Exagen
Corporation. In 2003, Exagen Corporation changed its state of incorporation from New Mexico to Delaware by merging with and into Exagen Diagnostics, Inc., pursuant to which the Company changed its name to Exagen Diagnostics, Inc. The Company is a
commercial-stage diagnostics company committed to addressing the significant unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases (ARDs). These chronic diseases can cause lifelong inflammation in
the joints, tissues and internal organs, resulting in serious complications, such as irreversible organ damage. The accurate, timely and differential diagnosis for patients suffering from the approximately 30 ARDs is critical as treatment for each
disease varies, and inappropriate or delayed therapy may expose patients to unnecessary risks or the hazards of uncontrolled disease activity. Physicians face significant difficulties in making a definitive diagnosis of a specific ARD because
patients with different diseases often present with a common set of symptoms. The Company currently markets five products under its Avise brand to provide an accurate, timely and differential diagnosis and to optimize the treatment of ARDs. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Basis of Presentation and Consolidation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or
GAAP. The consolidated financial statements include the accounts of the Company and its 60% owned subsidiary, Computational Engines Inc. Computational Engines, Inc. has been an inactive subsidiary since inception and was dissolved in May 2014.
Intercompany balances and transactions have been eliminated in consolidation. The Company operates in one segment. Management uses one measurement of profitability and does not segregate its business for internal reporting. All long-lived assets are
maintained in the United States. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Liquidity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements have been prepared on a going concern basis that contemplates the realization of assets and
discharge of liabilities in their normal course of business. The Company has suffered recurring losses from operations since inception and negative cash flows from operating activities during the years ended December&nbsp;31, 2013 and 2014 and the
nine months ended September 30, 2015 (unaudited). As of December&nbsp;31, 2014 and September 30, 2015 (unaudited) the Company had working capital deficits of $21.2 million and $28.8 million, respectively, and accumulated deficits of $89.3 million
and $105.9 million respectively. The Company anticipates that it will continue to incur net losses into the foreseeable future as it: (i)&nbsp;expands sales and marketing efforts to promote its Avise product line (ii)&nbsp;develops additional
products and prepares to commercialize any new products, and (iii)&nbsp;expands its corporate infrastructure, including the costs associated with becoming a public company. These factors raise substantial doubt about the Company&#146;s ability to
continue as a going concern. The Company needs to raise additional funds through equity or debt financing and, when and if necessary, to reduce discretionary spending. Although management has been successful in raising capital in the past, most
recently in February, July and October 2015, there can be no assurance that they will be successful or that any needed financing will be available in the future at terms acceptable to the Company. Failure to achieve these plans may result in the
Company not being able to achieve its business objectives. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company plans to fund its losses from operations and capital funding needs through current cash on hand and future debt and equity
financings. If the Company is not able to secure adequate additional funding, the Company may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, and/or suspend or curtail planned programs.
Any of these actions could materially harm the Company&#146;s business, results of operations, and future prospects. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Summary of Significant Accounting Policies </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Use of Estimates </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The preparation of the accompanying consolidated financial statements in accordance with GAAP requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities as of the date of the consolidated financial statements, and the reported amounts of revenue and expenses during the
reporting period. Actual results could materially differ from those estimates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The accompanying interim consolidated balance sheet as of September 30, 2015, consolidated
statements of operations and comprehensive loss and cash flows for the nine months ended September 30, 2014 and 2015 and the consolidated statements of redeemable convertible preferred stock and stockholders&#146; deficit for the nine months ended
September 30, 2015 are unaudited. The unaudited interim consolidated financial statements have been prepared on a basis consistent with the audited financial statements and, in the opinion of management, reflect all adjustments (consisting of any
normal recurring adjustments) considered necessary to fairly state the Company&#146;s financial position as of September 30, 2015 and the Company&#146;s results of operations and cash flows for the nine months ended September 30, 2014 and 2015. The
results for the nine months ended September 30, 2015 are not necessarily indicative of the results to be expected for the year ended December&nbsp;31, 2015 or for any other period. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Unaudited Pro Forma Balance Sheet Information </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma balance sheet information as of September 30, 2015 in the accompanying consolidated balance sheet gives effect to:
(i)&nbsp;the automatic conversion of all outstanding shares of convertible preferred stock into shares of common stock, (ii)&nbsp;the net exercise of warrants to purchase shares of our common stock and Series&nbsp;D redeemable convertible preferred
stock, (iii)&nbsp;the resultant reclassification of the redeemable convertible preferred stock warrant liabilities to additional paid-in-capital, a component of stockholders&#146; deficit, and (iv)&nbsp;the automatic conversion of the Company&#146;s
unpaid principal and accrued interest on the Company&#146;s convertible promissory notes issued in February 2015 and July 2015, which we refer to as the February 2015 Notes and the July 2015 Notes, respectively (Note 5), into shares of common stock,
assuming an initial public offering price of $&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus and assuming the conversion occurs on 2015, the expected closing date of this offering. The
unaudited pro forma balance sheet information excludes any shares of common stock issued in the proposed initial public offering, or IPO, and related proceeds. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Unaudited Pro Forma Net Loss per Share </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma basic and diluted net loss per share reflects the automatic conversion of all outstanding shares of redeemable
convertible preferred stock, net exercise of warrants, the reclassification of certain redeemable convertible preferred stock warrants to common stock warrants in additional paid-in capital and the conversion of the Company&#146;s unpaid principal
and accrued interest on the Company&#146;s February 2015 Notes and July 2015 Notes (Note 5) into shares of common stock, as if the conversions had occurred at the beginning of the period presented. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma basic and diluted net loss per share amounts do not give effect to the issuance of shares from the planned initial
public offering nor do they give effect to potential dilutive securities where the impact would be anti-dilutive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Unaudited pro forma
basic and diluted net loss per share attributable to common stockholders is computed as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="92%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended</B><br><B>December&nbsp;31,</B><br><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine&nbsp;Months</B><br><B>Ended&nbsp;September&nbsp;30,</B><br><B>2015</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Numerator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholders &#151; basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion of redeemable convertible preferred stock to redemption value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Noncumulative dividends on redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conversion of principle and accrued interest on the Company&#146;s convertible promissory notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revaluation of redeemable convertible preferred stock warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss attributable to common stockholders &#151; basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denominator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average number of common shares outstanding &#151; basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma adjustments to assume conversion of redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma adjustments to assume conversion of the Company&#146;s convertible promissory notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma weighted-average number of shares outstanding &#151; basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per share attributable to common stockholders &#151; basic and&nbsp;diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Concentration of Credit Risk and Other Risk and Uncertainties </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially subject the Company to credit risk consist principally of cash, cash equivalents, and accounts
receivable. Substantially all the Company&#146;s cash and cash equivalents are held at one financial institution that management believes is of high credit quality. Such deposits may, at times, exceed federally insured limits. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Approximately 25%, 27%, 30%, and 35% of the Company&#146;s revenue is derived from sales billed to Medicare for the years ended
December&nbsp;31, 2013 and 2014 and the nine months ended September 30, 2014 (unaudited) and 2015 (unaudited), respectively. The Company&#146;s revenues are derived from transactions with customers in the United States. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Approximately 78%, 94%, 94%, and 92% of the Company&#146;s revenue for the years ended December&nbsp;31, 2013 and 2014 and the nine months
ended September 30, 2014 (unaudited) and 2015 (unaudited), respectively, were related to the Avise SLE diagnostic product. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The
Company is dependent on key suppliers for certain laboratory materials. An interruption in the supply of these materials would temporarily impact the Company&#146;s ability to perform testing services. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value of Financial Instruments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The carrying value of the Company&#146;s cash and cash equivalents, prepaid expenses and other current assets, other assets, accounts payable,
accrued liabilities, and convertible notes payable approximate fair value due to the short-term nature of these items. Based on the borrowing rates currently available to the Company for debt with similar terms and consideration of default and
credit risk, the carrying value of the term loan approximates their fair value and is classified as Level II liability. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Fair value is
defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the
measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The fair value hierarchy defines a three-level valuation hierarchy for disclosure of fair value measurements as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="90%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Level&nbsp;I</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Unadjusted quoted prices in active markets for identical assets or liabilities;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Level&nbsp;II</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Inputs other than quoted prices included within Level I that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for
substantially the full term of the related assets or liabilities; and</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Level&nbsp;III</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Unobservable inputs that are supported by little or no market activity for the related assets or liabilities.</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The categorization of a financial instrument within the valuation hierarchy is based upon the lowest
level of input that is significant to the fair value measurement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s redeemable convertible preferred stock warrant
liabilities, bifurcated embedded derivatives, and acquisition-related liabilities are measured at fair value on a recurring basis and are classified as Level III liabilities. We record subsequent adjustments to reflect the increase or decrease in
estimated fair value at each reporting date as a gain or loss. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Cash and Cash Equivalents </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company considers all highly-liquid investments purchased with an original maturity of three months or less to be cash equivalents and are
stated at cost, which approximates market value. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Restricted Cash </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">At December&nbsp;31, 2012, a deposit of $707,000 was restricted from withdrawal and held by a bank as collateral in accordance with the terms
of a line of credit agreement. In 2013, the restriction was released upon repayment of the line of credit. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Deferred Offering Costs
</I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In accordance with SEC Staff Accounting Bulletin Topic No.&nbsp;5 (&#147;SAB Topic No.&nbsp;5&#148;), the Company has
identified specific incremental costs directly attributable to a proposed Initial Public Offering (&#147;IPO&#148;), which have been deferred and capitalized as non-current assets, and will be charged against the gross proceeds of the proposed IPO.
These costs include accounting, legal and printing fees and expenses. Indirect costs associated with the future issuance of corporate securities are expensed as incurred. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s intent has been, and continues to be, accessing the public market through the offering of securities and registration of
shares when market conditions are favorable. As such, the Company has consistently sustained a state of readiness and maintained current filings with the Securities and Exchange Commission. If the Company determines that market conditions preclude
its ability to successfully complete an IPO, all previously deferred costs will be charged to the consolidated statements of operations and comprehensive loss as of the date this determination is made. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2013 and 2014, and September&nbsp;30, 2015, the accumulated deferred and capitalized costs associated with the IPO were
$0, $2.1 million, and $2.8&nbsp;million, respectively. All deferred and capitalized costs have been reflected in &#147;Other assets&#148; on the consolidated balance sheets. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Long Lived Assets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s long lived assets are comprised principally of our property and equipment, finite lived intangible assets, and goodwill.
</P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives
of the assets, generally between three and ten years. Leasehold improvements are amortized on a straight-line basis over the lesser of their useful life or the term of the lease. Maintenance and repairs are charged to expense as incurred, and
improvements and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the consolidated balance sheet and any resulting gain or loss is reflected in operations in the
period realized. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Finite lived intangible assets are amortized over their respective estimated useful lives using the straight-line
method. The Company analyzed and determined that the use of straight-line amortization method was appropriate to reflect the pattern over which the economic benefits of the assets are realized. In considering whether intangible assets are impaired,
intangible assets and other long lived assets (excluding goodwill) are combined into groupings, a determination which is made principally on the basis of whether the assets are specific to a particular test offered or technology under development.
If events or circumstances are identified that indicate that the associated carrying amount of assets within a group may not be recoverable, the Company will consider the assets in the group impaired if the carrying value of the group&#146;s assets
and directly associated liabilities exceed the estimated cash flows expected to be generated over the estimated useful life of the assets in the group. Management&#146;s estimates of future cash flows are impacted by projected levels of tests and
levels of reimbursement, as well as expectations related to the future cost structure of the entity. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Goodwill is not amortized but is
tested for impairment at least annually or more frequently whenever a triggering event or change in circumstances occurs, at the reporting unit level. The Company operates in a single reporting unit, and allocates all goodwill to this reporting
unit. The Company is required to recognize an impairment charge if the carrying amount of the reporting unit exceeds its fair value. Management uses all available information to make this fair value determination, including the present values of
expected future cash flows using discount rates commensurate with the risks involved in the assets and observed market multiples of operating cash flows. If the estimated fair value of the reporting unit is less than the book value (including the
goodwill), further management judgment must be applied in determining the fair values of individual assets and liabilities for purposes of the hypothetical purchase price allocation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The judgments and estimates involved in identifying and quantifying the impairment of long lived assets or goodwill involve inherent
uncertainties, and the measurement of the fair value is dependent on the accuracy of the assumptions used in making the estimates and how those estimates compare to the Company&#146;s future operating performance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Following the completion of this offering, the Company&#146;s stock price and associated
market capitalization will also be considered in the determination of reporting unit fair value. A prolonged or significant decline in the Company&#146;s share price could provide evidence of a need to record a material impairment of goodwill. </P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Redeemable Convertible Preferred Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company has multiple classes of redeemable convertible preferred stock, all of which are classified as temporary equity in the consolidated
balance sheets. Shares of Series B-3, Series C and Series D redeemable convertible preferred stock are redeemable at any time after October&nbsp;4, 2018 upon the written request of the holders of 60% of the outstanding shares of these issuances,
voting together as a single class. Holders of the Series A-3 redeemable convertible preferred stock can cause redemption of the Series A-3 redeemable convertible preferred shares due to certain change in control events that are outside the
Company&#146;s control, including liquidation, sale or transfer of the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock which is redeemable
on or after a certain date upon the option of the holder is accreted to its redemption value from the date of issuance to the earliest redemption date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Redeemable Convertible Preferred Stock Warrants </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company accounts for its redeemable convertible preferred stock warrants as liabilities based upon the characteristics and provisions of
each instrument. The redeemable convertible preferred stock warrants classified as liabilities are recorded on the Company&#146;s consolidated balance sheet at their fair value on the date of issuance and are revalued on each subsequent balance
sheet, with fair value changes recognized as increases or reductions in the consolidated statements of operations and comprehensive loss. The Company adjusts the liability for changes in fair value of these redeemable convertible preferred stock
warrants until the earlier of: (i)&nbsp;exercise of warrants; (ii)&nbsp;expiration of redeemable convertible preferred stock warrants; (iii)&nbsp;a change of control of the Company; or (iv)&nbsp;the consummation of the Company&#146;s initial public
offering. At that time, the redeemable convertible preferred stock warrant liabilities will be adjusted to fair value in the consolidated statements of operations and comprehensive loss with the final fair value reclassified to additional paid-in
capital. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Revenue Recognition </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company derives its revenue from sales of its diagnostic, prognostic and monitoring products. The Company primarily markets its testing
services to rheumatologists and their physician assistants. The healthcare professionals who order the Company&#146;s products and to whom test results are reported are generally not responsible for payment for these products. The parties that pay
for these services (the Payers) consist of commercial third-party companies, Medicare and other government payers, and patients. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The
Company recognizes revenue when the following criteria have been met: (1)&nbsp;persuasive evidence of an arrangement exists; (2)&nbsp;delivery has occurred or services have been rendered; (3)&nbsp;the fee is fixed or determinable; and
(4)&nbsp;collectability is reasonably assured. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s service is completed upon the delivery of test results to the
prescribing physician which triggers billing for the service. The Company recognizes revenue related to billings to Payers on an accrual basis, net of contractual adjustments, only when the Company has established pricing with its Payers as
indicated by contractual pricing arrangements or predictable patterns of payments for its services. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In the absence of a predictable
pattern of reimbursement or a contract with a Payer, revenue is recognized upon the earlier of payment notification, if applicable, or cash receipt. In those instances where payment notification is received in advance of the cash receipt, the
notification received from third-party payers is generally received no more than one business day in advance of the cash receipt. The Company currently recognizes revenue on a cash basis from sales of its products. The assessment of the fixed or
determinable nature of the fees charged and the collectability of those fees requires significant judgment by management. Accordingly, the Company expects to recognize revenue on a cash basis until it has sufficient history to reliably estimate
payment patterns. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">During the years ended December&nbsp;31, 2013 and 2014, and September 30, 2015 (unaudited),
substantially all of the Company&#146;s revenue was recognized upon the earlier of payment notification, if applicable, or cash receipt. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses are expensed as incurred and include, but are not limited to, payroll and personnel-related expenses,
stock-based compensation expense, materials, laboratory supplies, consulting costs, costs associated with setting up and conducting clinical studies and allocated overhead including rent and utilities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Advertising and Marketing Costs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Costs incurred for advertising and marketing are expensed as incurred. Total advertising and marketing costs were approximately $429,000, $1.1
million, $727,000 and $1.1 million for the years ended December&nbsp;31, 2013 and 2014, and the nine months ended September 30, 2014 (unaudited) and 2015 (unaudited), respectively, and are included in selling, general and administrative expenses in
the accompanying consolidated statements of operations and comprehensive loss. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Shipping and Handling Costs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Costs incurred for shipping and handling are included in cost of revenues in the accompanying consolidated statements of operations and
comprehensive loss and totaled approximately $272,000, $506,000, $369,000, and $484,000 for the years ended December&nbsp;31, 2013 and 2014, and the nine months ended September 30, 2014 (unaudited) and 2015 (unaudited), respectively. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes compensation expense for all stock-based awards to employees and directors based on the grant-date estimated fair
values, net of an estimated forfeiture rate. The fair value of stock options is determined using the Black-Scholes-Merton, or BSM, option pricing model, which requires management to make certain assumptions regarding a number of complex and
subjective variables. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes stock-based compensation cost for employees and directors on a straight-line basis over the
requisite service period of the award. Stock-based compensation expense is recognized only for those awards that are ultimately expected to vest. The Company estimates forfeitures based on an analysis of historical employee turnover and will
continue to evaluate the appropriateness of the forfeiture rate based on actual forfeiture experience, analysis of employee turnover and other factors. The Company will revise the forfeiture estimate, if necessary, in subsequent periods if actual
forfeitures differ from those estimates. Changes in forfeiture estimates impact stock-based compensation cost in the period in which the change in estimate occurs. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The BSM option pricing model incorporates various highly sensitive assumptions, including the fair value of the Company&#146;s common stock,
expected volatility, expected term and risk-free interest rates. The weighted-average expected life of options was calculated using the simplified method as prescribed by the Securities and Exchange Commission&#146;s Staff Accounting
Bulletin&nbsp;No.&nbsp;107, or SAB&nbsp;No.&nbsp;107. This decision was based on the lack of relevant historical data due to the Company&#146;s limited historical experience. In addition, due to the Company&#146;s limited historical data, the
estimated volatility also reflects the application of SAB&nbsp;No.&nbsp;107, incorporating the historical volatility of comparable companies whose share prices are publicly available. The risk-free interest rate for periods within the contractual
life of the option is based on the U.S.&nbsp;Treasury yield in effect at the time of grant. The dividend yield was zero, as the Company has never declared or paid dividends and has no plans to do so in the foreseeable future. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Common Stock Valuation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Due to the absence of a public market trading for the Company&#146;s common stock, it is necessary to estimate the fair value of the common
stock underlying the Company&#146;s stock-based awards when performing fair value calculations using the BSM option pricing model. The fair value of the common stock underlying the Company&#146;s stock-based awards was assessed on each grant date by
the Company&#146;s board of directors. All options to purchase shares of the Company&#146;s common stock have been granted with an exercise price per share no less than the fair value per share of the Company&#146;s common stock underlying those
options on the date of grant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In the absence of a public trading market for the Company&#146;s common stock, the estimated fair
value of the Company&#146;s common stock was determined using methodologies, approaches, and assumptions consistent with the American Institute of Certified Public Accountants, or AICPA, Practice Aid: <I>Valuation of Privately-Held-Company Equity
Securities Issued as Compensation</I>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Comprehensive Loss </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions from nonowner
sources. There have been no items qualifying as other comprehensive income (loss) and, therefore, for all periods presented, the Company&#146;s comprehensive loss was the same as its reported net loss. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The
Company accounts for income taxes under the liability method. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax
rates in effect for the year in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. The Company assesses all material
positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial
determination of the position&#146;s sustainability and is measured at the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement. As of each balance sheet date, unresolved uncertain tax
positions must be reassessed, and the Company will determine whether (i)&nbsp;the factors underlying the sustainability assertion have changed and (ii)&nbsp;the amount of the recognized tax benefit is still appropriate. The recognition and
measurement of tax benefits requires significant judgment. Judgments concerning the recognition and measurement of a tax benefit might change as new information becomes available. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Net Loss Per Share </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company follows the two-class method when computing net loss per share, as the Company has issued shares that meet the definition of
participating securities. The two-class method determines net loss per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class
method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the
weighted-average number of shares of common stock outstanding for the period. Diluted net loss attributable to common stockholders is computed by adjusting loss attributable to common stockholders to reallocate undistributed earnings based on the
potential impact of dilutive securities, including outstanding stock options, and warrants for the purchase of redeemable convertible preferred stock. Diluted net loss per share attributable to common stockholders is computed by dividing the diluted
net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, including potential dilutive common shares assuming the dilutive effect of outstanding stock options and warrants. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">A reconciliation of the numerator used in the calculation of the basic and diluted net loss per share is as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine Months Ended<BR>September 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Numerator:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,496</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(14,981</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,372</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,650</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deemed dividend (contribution) on issuance of Series D redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,419</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion of redeemable convertible preferred stock to redemption value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,311</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,778</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,306</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,548</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) attributable to common stockholders - basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,226</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,759</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,678</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,198</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s redeemable convertible preferred stock contractually entitles the holders of
such shares to participate in dividends but does not contractually require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reports a net loss attributable to common stockholders,
diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The following outstanding shares of potentially dilutive securities were excluded from the
computation of diluted net loss per share of common stock for the periods presented, because including them would have been anti-dilutive: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="52%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine Months Ended</B><br><B>September 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,330,247</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,330,247</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,330,247</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109,714,571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options to purchase common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,810,386</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,701,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,095,498</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,038,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrants to purchase redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,174,430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,174,430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,174,430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,174,430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrants to purchase common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,881,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,881,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,881,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,881,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110,196,963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">115,088,202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">116,482,075</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">132,809,059</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Recent Accounting Pronouncements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB), or other standard setting
bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company&#146;s consolidated financial
position or results of operations upon adoption. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In July 2013, the FASB issued ASU 2013-11, which provides for changes to the
presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. These changes require an entity to present an unrecognized tax benefit as a liability in the financial
statements if (i)&nbsp;a net operating loss carryforward, a similar tax loss, or a tax credit carryforward is not available at the reporting date under the tax law of the applicable jurisdiction to settle any additional income taxes that would
result from the disallowance of a tax position, or (ii)&nbsp;the tax law of the applicable jurisdiction does not require the entity to use, and the entity does not intend to use, the deferred tax asset to settle any additional income taxes that
would result from the disallowance of a tax position. Otherwise, an unrecognized tax benefit is required to be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or
a tax credit carryforward. These changes became effective for us on January&nbsp;1, 2014. There was no material impact to our consolidated financial statements upon adoption of this ASU. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In May 2014, the FASB issued Accounting Standards Update (ASU) 2014-09, Revenue from Contracts with Customers, which provides a five-step
analysis of transactions to determine when and how revenue is recognized. The core principle is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to
which the entity expects to be entitled in exchange for those goods or services. This ASU is effective for annual periods beginning after December&nbsp;15, 2017 (fiscal 2018 for public companies) and shall be applied retrospectively to each period
presented or as a cumulative-effect adjustment as of the date of adoption. The Company is currently in the process of evaluating the impact of adoption of this ASU on the consolidated financial statements. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In August 2014, the FASB issued ASU 2014-15, <I>Presentation of Financial Statements&#151;Going Concern</I>, which defines management&#146;s
responsibility to evaluate whether there is substantial doubt about an organization&#146;s ability to continue as a going concern and to provide related footnote disclosures. The new standard provides management with principles to evaluate whether
substantial doubt exists by (i)&nbsp;providing a definition of substantial doubt, (ii)&nbsp;requiring an evaluation every annual and interim reporting period, and (iii)&nbsp;providing principles for considering the mitigating effects of
management&#146;s plans. If substantial doubt is identified, the ASU requires that an organization provide enhanced disclosures about (i)&nbsp;principal conditions or events that raise substantial doubt, (ii)&nbsp;management&#146;s evaluation of the
significance of these events in relation to its ability to meet obligations, and (iii)&nbsp;management&#146;s plans that are either intended to mitigate the conditions that raise substantial doubt, or alleviate substantial doubt. The ASU is
effective for annual periods ending after December&nbsp;15, 2017. The Company does not anticipate the adoption of this standard will have a material impact on its financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In April 2015, the FASB issued ASU 2015-03, <I>Interest&#151;Imputation of
Interest&#151;Simplifying the Presentation of Debt Issuance Costs, </I>which requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt
liability, consistent with debt discounts. The amendment is effective for annual periods beginning after December&nbsp;15, 2015, and shall be applied retrospectively to each period presented. The Company is in the process of evaluating the impact of
adoption of this ASU on its consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Other Financial Information </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Property and Equipment </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Property and equipment consist of the following (in&nbsp;thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>September&nbsp;30,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Furniture and fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,880</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,785</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">729</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">861</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">285</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">285</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Construction in progress</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">493</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,517</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,460</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: accumulated depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,289</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,628</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,051</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,228</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,538</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Depreciation expense for the years ended December&nbsp;31, 2013 and 2014, and the nine months ended
September 30, 2014 (unaudited) and 2015 (unaudited) was approximately $241,000, $339,000, $240,000, and $544,000, respectively. At December&nbsp;31, 2013 and 2014, and September 30, 2015 (unaudited), the gross book value of assets recorded under
capital leases, all of which are included in laboratory equipment, was approximately $654,000, $654,000 and $196,000, respectively. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Accrued Liabilities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Accrued Liabilities consist of (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>September&nbsp;30,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:8pt"><B>2013</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:8pt"><B>2014</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:8pt"><B>2015</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued payroll and related</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">938</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,075</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,708</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">299</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued royalties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">518</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">686</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">204</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">944</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Goodwill and Intangible Assets </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The following table provides information about goodwill
and intangible asset balances (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="59%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Weighted-Average</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Amortization</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Net</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Period</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Gross</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Accumulated</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Book</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:8pt"><B>(In years)</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:8pt"><B>Amount</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:8pt"><B>Amortization</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:8pt"><B>Value</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible assets subject to amortization:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchased technologies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,345</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(541</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">804</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade name and trademarks</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(149</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(690</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible assets not subject to amortization:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goodwill</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,506</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="59%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Weighted-Average</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Amortization</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Net</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Period</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Gross</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Accumulated</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Book</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:8pt"><B>(In years)</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:8pt"><B>Amount</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:8pt"><B>Amortization</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:8pt"><B>Value</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible assets subject to amortization:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchased technologies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,345</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(715</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade name and trademarks</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(195</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(910</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">805</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible assets not subject to amortization:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goodwill</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,506</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="59%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Weighted-Average</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>September 30, 2015 (Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Amortization</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Net</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Period</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Gross</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Accumulated</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Book</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(In years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amortization</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible assets subject to amortization:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchased technologies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(700</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">420</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade name and trademarks</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(230</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,490</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(930</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">560</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible assets not subject to amortization:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goodwill</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,506</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In June 2015, the Company identified that certain lots of the anti-MCV analyte licensed from
a third party failed to meet the Company&#146;s performance specifications. The Company replaced the anti-MCV analyte with an anti-CCP analyte in the Avise Lupus test, and the Company does not believe that patient care was impacted. However, the
Company has not yet determined whether modifications to the manufacturing processes will be corrected such that the anti- MCV analyte will ever meet the Company&#146;s performance specifications. Accordingly, in the three months ended
September&nbsp;30, 2015, the Company determined that the long lived assets directly associated with the performance of MCV tests, which consist solely of the license to use the MCV technology, and were included in &#147;purchased technologies&#148;
in the tables above, were impaired. As a result, the Company recorded an impairment charge of $84,000 representing the net carrying value of these intangible assets on the date of impairment. The impairment charge was reflected in &#147;amortization
of intangible assets&#148; in the consolidated statement of operations and comprehensive loss. The initial cost basis of these assets was $225,000. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Total expense related to the amortization of intangible assets, including any impairment charges, was approximately $214,000, $220,000,
$155,000 and $245,000 for the years ended December&nbsp;31, 2013 and 2014, and the nine months ended September 30, 2014 (unaudited) and 2015 (unaudited), respectively. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Total future amortization expense related to intangible assets subject to amortization is set forth in the table below (in thousands): </P>
 <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:95.55pt; font-size:8pt; font-family:Times New Roman"><B>Years Ending December 31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:8pt"><B>2014</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:8pt"><B>2015</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total future amortization expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">805</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">560</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Borrowings </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Line of Credit Arrangement (Line) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In 2010, the Company entered into a secured Line with a financial institution to borrow up to $750,000. The Line accrued interest at 6.0% and
matured in June 2012. The Company amended the Line in 2012 to extend the maturity to June 2013. In accordance with the terms of the amendment, the amount available for borrowing was decreased to $707,725 and required the Company to maintain a
restricted cash balance of $707,725 to secure the Line. The amendment in 2012 was accounted for as a modification. The Line was fully repaid in June 2013. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Royalty Pharma Collection Trust Secured Promissory Note (RP Note) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In connection with a historical acquisition, the Company was required to pay $2.0 million to Royalty Pharma Collection Trust, in October 2012.
This additional consideration was recorded at its initial present value amount of $1.7 million on the date of acquisition using a discount rate of 9.5% and accreted to $2.0&nbsp;million. In October 2012, the obligation to pay $2.0 million was
converted to a secured promissory note, accruing interest at 10%&nbsp;per year, payable over four years and was collateralized by the intellectual property purchased by the Company in the acquisition. The Company accounted for this amendment as a
modification. The principal outstanding as of December&nbsp;31, 2012 was $1.9 million and the outstanding RP Note was fully repaid in October 2013. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Convertible Notes with Related Parties (2013 Notes) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In May 2013,&nbsp;June 2013 and August 2013, the Company entered into unsecured convertible promissory notes with existing equity holders to
borrow $2.4 million. The 2013 Notes accrued interest at 10.0%&nbsp;per annum and were convertible into shares of either an anticipated new series of preferred stock sold in a qualified financing (defined as a financing of $10.0 million or greater),
at a 20% discount to the issuance price or, if no additional qualified financing occurred, into shares of Series C redeemable convertible preferred stock at a price of $0.25 per share. The conversion into shares at a 20% discount was determined to
be an embedded put feature which required bifurcation and separate accounting as the discount was substantial. The embedded derivative was recorded as a liability at a fair value of approximately $668,000 upon issuance and debt discount to the 2013
Notes. The Company valued the embedded derivative using a probability weighted scenario based option pricing model using the following inputs &#150; expected life of approximately 0.5 years, estimated volatility of approximately 40%, expected
risk-free rate of 0.1% and a probability of 99% for a qualified financing to occur. The embedded derivative was remeasured just prior to extinguishment of the 2013 Notes and the change in fair value was recorded in other income (expense), net, in
the accompanying consolidated statements of operations and comprehensive loss. In October 2013, the Company amended the 2013 Notes to modify the definition of a qualified financing to reduce the amount of required financing from $10.0 million to
$4.0 million and contemporaneously converted the 2013 Notes into Series D redeemable convertible preferred stock. The Company recorded this amendment as an extinguishment and recorded a loss of $3.3 million as the difference between the
reacquisition price and the net carrying amount of the 2013 Notes. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Term Loan (2013 Loan) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In October&nbsp;2013, the Company executed a term loan agreement with Capital Royalty Partners II L.P. and its affiliates Parallel Fund
&#147;a&#148; L.P. and Parallel Investment Opportunities Partners II L.P. (collectively Capital Royalty). The 2013 Loan may be drawn in two tranches. The first tranche in the amount of $10.0 million or $15.0&nbsp;million was required to be drawn
prior to March&nbsp;31, 2014, and the Company drew $10.0&nbsp;million in October 2013 and another $5.0&nbsp;million in March 2014. The 2013 Loan bears interest at 14.0%&nbsp;per annum with interest-only payments due on a quarterly basis with payment
dates fixed at the end of each calendar quarter, or Payment Dates, through September&nbsp;30, 2016. Prior to December&nbsp;31, 2016, the Company may at its election pay the interest as follows: 10.0%&nbsp;per annum in cash and 4.0%&nbsp;per annum
paid in-kind in the form of additional term loans, or PIK Loans. In connection with the 2013 Loan, the Company paid a financing fee of $200,000 that was recorded as debt discount and issued warrants to purchase 3,186,430 shares of each of common
stock and Series D redeemable convertible preferred stock. Since the Company has issued multiple instruments (2013 Loan, Series D redeemable convertible preferred stock warrants and common stock warrants) in a bundled transaction, the Company
recorded the Series D redeemable convertible preferred stock warrants at full fair value, while the common stock warrants and 2013 Loan have been recorded at relative fair value. Likewise, the debt issuance costs have been allocated to all
instruments based on their relative fair value (Note 6). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The 2013 Loan had a prepayment premium of 3% of the aggregate outstanding
principal, including PIK Loans, if the loan was prepaid prior to September&nbsp;30, 2014. The amount of the prepayment premium decreases by 1% during each subsequent 12-month period thereafter. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company has elected the paid in-kind interest option paying 10%&nbsp;per annum in cash
and issuing PIK Loans for the remaining 4%&nbsp;per annum totaling $71,000, $569,000, $390,000, and $479,000 in the years ended December&nbsp;31, 2013 and 2014, and the nine months ended September 30, 2014 (unaudited) and 2015 (unaudited),
respectively. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The 2013 Loan is collateralized by a first priority security interest on substantially all of the Company&#146;s
personal property, including intellectual property. The Company must maintain a minimum liquidity of $2.0&nbsp;million and achieve certain minimum amounts of annual revenue under the terms of the 2013 Loan. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The 2013 Loan contains customary representations and warranties, covenants, events of defaults and termination provisions. The affirmative
covenants include, among other things, that the Company timely file taxes, maintain good standing and government compliance, maintain liability and other insurance, furnish audited financial statements within 120 days of fiscal year end without
qualification as to the scope of the audit or as to going concern and without any other similar qualification. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The negative covenants
provide, among other things, that without the prior consent of Capital Royalty, subject to certain exceptions, the Company may not dispose of certain assets, engage in certain business combinations or acquisitions, incur additional indebtedness or
encumber any of the Company&#146;s property, pay dividends on the Company&#146;s capital stock or make prohibited investments. The 2013 Loan agreement provides that an event of default will occur if, among other triggers, (1)&nbsp;the Company
defaults in the payment of any amount payable under the agreement when due, (2)&nbsp;there occurs any circumstance or circumstances that could reasonably be expected to result in a material adverse effect on the Company&#146;s business, operations
or condition, or on the Company&#146;s ability to perform its obligations under the agreement, (3)&nbsp;the Company becomes insolvent, (4)&nbsp;the Company undergoes a change in control or (5)&nbsp;the Company breaches any negative covenants or
certain affirmative covenants in the agreement or, subject to a cure period, otherwise neglects to perform or observe any material item in the agreement. The repayment of the 2013 Loan may be accelerated, at the option of Capital Royalty, following
the occurrence of an event of default, which would require the Company to pay to Capital Royalty an amount equal to the sum of: (i)&nbsp;all outstanding principal plus accrued interest, (ii)&nbsp;the final payment, plus (iii)&nbsp;all other sums,
that shall have become due and payable but have not been paid, including interest at the default rate with respect to any past due amounts plus the prepayment premium. The Company has obtained a waiver to relinquish the going concern qualification
requirement for the year ended December&nbsp;31, 2014. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Though the Company&#146;s borrowings under the 2013 Loan have stated maturities
in excess of one year, the outstanding balance of the 2013 Loan has been classified as a current liability as of December&nbsp;31, 2013 and 2014, and September 30, 2015 (unaudited) due to the subjective nature of the material adverse clause included
in the term loan agreement. This clause permits the lender to accelerate the maturity of the debt upon factors that are subjective in nature, such as material changes in the business, operations, performance or prospects of the Company, other than
those resulting from changes in interest rates or economic and political conditions. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>July 2014 Notes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In July 2014, the Company executed $4.0 million of convertible promissory notes, or the July 2014 Notes, with existing holders of the
Company&#146;s redeemable convertible preferred stock, which accrue interest at an annual rate equal to 12%. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The July 2014 Notes
contained a feature such that a majority of the holders of the July 2014 Notes may elect to convert the unpaid principal and interest at maturity into shares of Series D redeemable convertible preferred stock at a rate of $0.25 per share. In May
2015, the holders of these notes elected to convert these notes into shares of the Company&#146;s Series D redeemable convertible preferred stock at the stated conversion rate of $0.25 per share resulting in the issuance of 17,384,324 shares of
Series D redeemable convertible preferred stock. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company accounted for the conversion of this debt as an extinguishment and
recorded a loss of $5.3 million, which is equal to the difference between the fair value of the Series D redeemable convertible preferred stock issued and the carrying value of the July 2014 Notes and fair value of the bifurcated embedded derivative
representing the conversion feature on the conversion date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>February 2015 Notes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In February 2015, the Company entered into the February 2015 Note Purchase Agreement with existing holders of its redeemable convertible
preferred stock. Under this agreement, the Company issued convertible promissory notes in three tranches. In February 2015,&nbsp;May 2015 and June 2015, the Company issued an aggregate of $1.8 million, $1.9 million, and $833,000 representing the
first, second, and third tranches of the February 2015 Notes, respectively. All borrowings under the February 2015 Notes are subordinated to borrowings under the 2013 Loan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The February 2015 Notes accrue interest at 10%&nbsp;per annum. The February 2015 Notes issued in
the first, second, and third tranche closings become due and payable in December 2015,&nbsp;May 2016, and June 2016, respectively, and have been classified as current liabilities. The February 2015 Notes provide that a majority of holders for a
given tranche may elect to extend the maturity date of that tranche by up to one additional year. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The February 2015 Notes contain a
feature such that if an IPO occurs prior to the initial stated maturity date for a tranche, the unpaid principal and interest for such tranche will convert into shares of the Company&#146;s common stock at a 20% discount to the IPO price. If
investors have previously elected to extend the maturity date for a tranche, the unpaid principal and interest for such tranche will convert into shares of the Company&#146;s common stock at a 30% discount to the IPO price. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In the event that an IPO has not occurred by the maturity date for a particular tranche borrowed of the February 2015 Notes, and a majority of
holders has not elected to extend the maturity date of such tranche, holders of that tranche may elect to either (1)&nbsp;receive all unpaid principal and accrued interest due or (2)&nbsp;convert the unpaid principal and interest at maturity into
shares of the Company&#146;s Series&nbsp;D redeemable convertible preferred stock at a rate of $0.25 per share. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The features which allow
the conversion of a given tranche into shares at either a 20% discount or a 30% discount to the issuance price upon the IPO were determined to be embedded put features which required bifurcation and separate accounting as these discounts were
substantial. The Company valued these embedded derivatives using a method that considered the value of an instrument that contained these discount features upon IPO to the value of a similar instrument that did not contain such discount features
upon IPO. The application of this method incorporated management&#146;s assumptions related to the expected timing and probability of an IPO, the likelihood management associated the extension of the maturity of each tranche of the February 2015
Notes, and the appropriate discount rates attributable to each tranche of the February 2015 Notes. The embedded derivatives associated with the first, second, and third tranche closings were recorded as liabilities with fair values of approximately
$218,000, $303,000, and $131,000, respectively, and as a discount to the carrying value of the respective tranche upon issuance in the consolidated balance sheets. The related discounts are being amortized to interest expense using the effective
interest method to the stated maturity date of each tranche. The Company has classified the bifurcated embedded derivative liabilities as current in the consolidated balance sheets as borrowings under each tranche mature within one year of the
balance sheet date. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In accordance with authoritative guidance, the Company will remeasure the bifurcated embedded derivatives arising
from the issuance of each tranche of the February 2015 Notes to fair value each reporting period until the earlier of the maturity of the respective tranche of the February 2015 Notes or exercise of the conversion feature. The related remeasurement
adjustments are recognized in other income (expense), net, in the consolidated statements of operations and comprehensive loss. For the nine months ended September 30, 2015 (unaudited), the Company recorded an expense of $80,000 associated with the
change in the fair value of these derivatives. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Additionally, the Company identified that the feature which allows conversion of the
each tranche into shares of Series&nbsp;D redeemable convertible preferred stock at a fixed rate of $0.25 per share results in a beneficial conversion feature which is equal to the difference between fair value of underlying shares into which the
tranche is convertible and the per share value which the proceeds allocated to the tranche would be converted into, multiplied by the number of shares into which the tranche would convert on the issuance date. Using this methodology, the beneficial
conversion features associated with the first, second and third tranche closings were recorded as a component of additional paid in capital in the amounts of $364,000, $303,000 and $131,000, respectively, and as a discount to the carrying value of
the respective tranche upon issuance in the consolidated balance sheets. The related discounts are being amortized to interest expense using the effective interest method to the stated maturity date of each tranche. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>July 2015 Notes </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In
July 2015, the Company issued $3.0 million of convertible promissory notes, or the July 2015 Notes, to existing holders of its redeemable convertible preferred stock. The July 2015 Notes are subordinated to borrowings under the 2013 term loan with
Capital Royalty. The July 2015 Notes accrue interest at 10%&nbsp;per annum, and the principal and accrued interest of the July 2015 Notes is due in July 2016, and have been classified as current liabilities. The July 2015 Notes provide that a
majority of holders may elect to extend the maturity date of these notes by up to one additional year. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The July 2015 Notes contain a feature such that if an IPO occurs prior to December&nbsp;31,
2015, the unpaid principal and accrued interest will convert into shares of the Company&#146;s common stock at a 20% discount to the IPO price. If the IPO occurs after December&nbsp;31, 2015, the unpaid principal and interest will convert into
shares of the Company&#146;s common stock at a 30% discount to the IPO price. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In the event that an IPO has not occurred by the maturity
date for the July 2015 Notes, and a majority of holders has not elected to extend the maturity date of these notes, holders may elect to either (1)&nbsp;receive all unpaid principal and accrued interest due or (2)&nbsp;convert the unpaid principal
and interest at maturity into shares of the Company&#146;s Series D redeemable convertible preferred stock at a rate of $0.25 per share. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The feature which allows the conversion of these notes into shares at either a 20% discount or a 30% discount to the issuance price upon the
IPO was determined to be embedded put feature which requires bifurcation and separate accounting as these discounts were substantial. The Company valued this embedded derivative using a method that considered the value of an instrument that
contained these discount features upon IPO to the value of a similar instrument that did not contain such discount features upon IPO. The application of this method incorporated management&#146;s assumptions related to the expected timing and
probability of an IPO, the likelihood management associated the extension of the maturity of the July 2015 Notes, and the appropriate discount rates attributable the July 2015 Notes. The embedded derivative associated with this note was recorded as
a liability with a fair value of approximately $468,000, and as a discount to the carrying value of the July 2015 Notes upon issuance in the consolidated balance sheets. The related discount is being amortized to interest expense using the effective
interest method to the stated maturity date of each these notes. The Company classified the bifurcated embedded derivative liability as current in the consolidated balance sheets, as borrowings under these notes mature within one year of the balance
sheet date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In accordance with authoritative guidance, the Company will remeasure the bifurcated embedded derivative arising from the
issuance of the July 2015 Notes to fair value each reporting period until the earlier of the maturity of the July 2015 Notes or exercise of the conversion feature. The related remeasurement adjustments are recognized in other income (expense), net,
in the consolidated statements of operations and comprehensive loss. For the nine months ended September&nbsp;30, 2015 (unaudited), the Company recorded an expense of $101,000 associated with the change in the fair value of this derivative. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Additionally, the Company identified that the feature which allows conversion of the July 2015 Notes into shares of its Series&nbsp;D
redeemable convertible preferred stock at a fixed rate of $0.25 per share results in a beneficial conversion feature which is equal to the difference between fair value of underlying shares into which the notes are convertible and the per share
value which the proceeds allocated to the notes would be converted into, multiplied by the number of shares into which the notes would convert on the issuance date. Using this methodology, the beneficial conversion feature associated with the
issuance of the July 2015 Notes was recorded as a component of additional paid in capital in the amount of $468,000, and as a discount to the carrying value of the notes upon issuance in the consolidated balance sheets. The related discount is being
amortized to interest expense using the effective interest method to the stated maturity date of the notes. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The future minimum
aggregate payments for the above borrowings are as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:95.55pt; font-size:8pt; font-family:Times New Roman"><B>Years Ending December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:8pt"><B>2014</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:8pt"><B>2015</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,396</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,944</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,282</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,742</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,741</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,648</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unamortized debt discount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,196</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,260</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,058</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,780</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total borrowings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,394</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,406</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Warrants to Purchase Common or Preferred Stock </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Common Stock Warrants </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>2010 SSPN Common Stock Warrants </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In connection with the 2010 SSPNs, the Company issued warrants to purchase 390,000 shares of common stock at a price of $3.75 per share. The
warrants expired October 2013 and contained an automatic exercise or put feature, which was to be effected immediately prior to the expiration of the warrants based on the highest value to the holders if no earlier exercise or put has been affected
by the holders. The put feature allowed the holders, upon the earlier of the occurrence of a change in control or the expiration date, to require the Company to repurchase the warrants for an aggregate purchase price of $400,000. The value of this
put feature was recorded as a warrant liability on the consolidated balance sheet at the higher of the fair value, or $400,000, and as a discount against the 2010 SSPNs, with such discount being amortized to interest expense over the initial term of
the 2010 SSPNs. The put feature was exercised in October 2013 and the Company repurchased these warrants for $400,000. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>2013 Loan Common
Stock Warrants </I></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In connection with the 2013 Loan issued in October 2013, the Company issued warrants to purchase 3,186,430 shares
of common stock at $0.01 per share. The relative fair value of approximately $319,000, net of issuance costs, was recorded in additional paid-in capital determined by using the option pricing model with the following assumptions: risk-free interest
rate of 0.4%, expected life of 2 years, dividend yield of 0% and expected volatility of 61%, and as a discount against 2013 Loan, which is being amortized to interest expense over the term of the 2013 Loan. The Company amortized approximately
$13,000, $82,000, $59,000, and $69,000 as interest expense for the years ended December&nbsp;31, 2013 and 2014, and the nine months ended September 30, 2014 (unaudited) and 2015 (unaudited), respectively. The warrants expire in October 2023 and
remain outstanding as of September 30, 2015 (unaudited). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In addition to the above, the Company has 1,695,470 common stock warrants
outstanding as of December&nbsp;31, 2014 and September 30, 2015 (unaudited) at an exercise price of $3.75 per share. These common stock warrants expire between June 2018 and October 2021. No amounts have been recorded for these common stock warrants
as their fair value was determined to be immaterial. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Redeemable Convertible Preferred Stock Warrants </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>2013 Loan Redeemable Convertible Preferred Stock Warrants </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In connection with the 2013 Loan issued in October 2013, the Company issued warrants to purchase 3,186,430 shares of Series D redeemable
convertible preferred stock at $0.25 per share. The fair value of approximately $0.8 million was determined using the residual approach and was recorded as a liability using the option pricing model with the following assumptions: risk-free interest
rate of 0.4%, expected life of 2 years, dividend yield of 0% and expected volatility of 61%, and as a discount against 2013 Loan, which is being amortized to interest expense over the term of the 2013 Loan. The Company amortized approximately
$30,000, $171,000, $124,000, and $145,000 as interest expense for the years ended December&nbsp;31, 2013 and 2014, and the nine months ended September 30, 2014 (unaudited) and 2015 (unaudited), respectively. The warrants expire in October 2023 and
remain outstanding as September 30, 2015 (unaudited). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In 2013, the Company engaged an investment advisor to provide financial advisory
services in connection with raising capital. In connection with the consummation of the 2013 Loan in November 2013, the Company paid $500,000 to the investment advisor and also issued warrants to purchase 988,000 shares of Series D redeemable
convertible preferred stock at an exercise price of $0.25. The fair value of approximately $240,000 was recorded as a liability and was determined using the option pricing model with the following assumptions: risk-free interest rate of 0.4%,
expected life of 2 years, dividend yield of 0% and expected volatility of 61%. The total debt issuance cost of approximately $740,000 (fair value of the Series D redeemable convertible preferred stock warrant plus cash payment of $500,000) was
allocated to the 2013 Loan, 2013 Loan common stock warrants and 2013 Loan redeemable convertible preferred stock warrants based on relative fair value allocation. The amount allocated to the 2013 Loan was recorded as debt issuance cost, the amount
allocated to 2013 Loan common stock warrants was offset against the amount recorded in additional paid-in capital, and the amount allocated to 2013 Loan redeemable convertible preferred stock warrants was recorded as an expense. The warrants expire
in November 2023 and remain outstanding as of December&nbsp;31, 2014 and September 30, 2015 (unaudited). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company remeasured the fair
value of the preferred stock warrants noted above using a probability weighted expected return methodology to arrive at the relative fair value of the Company&#146;s equity securities, with updated valuation assumptions for volatility of 61.2%,
48.3%, 53.5% and 52.0%, and a discount for lack of marketability of 41.1%, 34.0%, 26.0% and 40.0% for the years ended December&nbsp;31, 2013 and 2014, and the nine months ended September 30, 2014 (unaudited) and 2015 (unaudited), respectively. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">For the years ended December&nbsp;31, 2013 and 2014, and the nine months ended September 30,
2014 (unaudited) and 2015 (unaudited), the Company recognized changes in fair value of $83,000, $376,000, $417,000 and $877,000, respectively, for all liability classified redeemable convertible preferred stock warrants, which was recorded in other
income / (expense), net in the accompanying consolidated statements of operations and comprehensive loss. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">All outstanding warrants to
purchase shares of common stock and Series D redeemable convertible preferred stock terminate if not exercised prior to the completion of an initial public offering. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Commitments and Contingencies </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Operating and Capital Leases </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company leases approximately 14,000 square feet of office and laboratory space in Vista, California, under a lease that expires in 2017,
with options to extend the lease for two additional 36-month periods. In addition, the Company also leases approximately 19,500 square feet of office space in Vista, California, under a lease that expires in 2018, with an option to extend the lease
for an additional 24 month period. The Company&#146;s lease payments under each of these leases are subject to escalation clauses. The Company also leases approximately 3,200 square feet of office space in Albuquerque, New Mexico, under a lease that
expires at the end November 2015. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In 2012 and 2013, the Company leased certain lab equipment under capital leases. The equipment and
related liability have been recorded at the present value of the future payments under the leases with an interest rate of 8.2% and 16.0%, respectively. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Minimum annual lease payments under noncancelable lease arrangements at December&nbsp;31, 2014 are as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Capital</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Operating</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:96.20pt; font-size:8pt; font-family:Times New Roman"><B>Years Ending December&nbsp;31:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Leases</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Leases</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">345</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">386</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total minimum lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">483</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">962</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: amount representing interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(95</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Present value of future minimum lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(123</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term capital lease obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">265</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>   <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">For the years ended December&nbsp;31, 2013 and 2014, and the nine months ended September 30, 2014
(unaudited) and 2015 (unaudited), rent expense was $141,000, $261,000, $177,000, and $263,000, respectively. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Acquisition-related liabilities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In connection with the acquisition of the medical diagnostics division of Cypress Bioscience, Inc. in 2010, or the Cypress acquisition, the
Company is required to pay an amount not to exceed $9.0 million in the event that certain revenue milestones are achieved and upon the first commercial sale of a product associated with this historical acquisition. These milestones have no
expiration date. The acquisition also included amounts that may be due under several licensing agreements. The revenue milestones are summarized as follows: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="38%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:68.45pt; font-size:8pt; font-family:Times New Roman"><B>Amount Payable To</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:8pt"><B>Maximum</B></FONT><br><FONT STYLE="font-size:8pt"><B>Additional</B></FONT><br><FONT STYLE="font-size:8pt"><B>Payment</B></FONT><br>
<FONT STYLE="font-size:8pt"><B>Amount</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Milestone</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:8pt"><B>Weighted</B></FONT><br><FONT STYLE="font-size:8pt"><B>Probability&nbsp;
of</B></FONT><br><FONT STYLE="font-size:8pt"><B>Achievement</B></FONT><br><FONT STYLE="font-size:8pt"><B>as of</B></FONT><br><FONT STYLE="font-size:8pt"><B>December&nbsp;31,<BR>2014</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:8pt"><B>Weighted<BR>Probability&nbsp;of<BR>Achievement<BR>as of<BR>September&nbsp;30,<BR>2015</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:8pt"><B>Fair Value</B></FONT><br><FONT STYLE="font-size:8pt"><B>as
of</B></FONT><br><FONT STYLE="font-size:8pt"><B>December&nbsp;31,<BR>2014</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:8pt"><B>Fair&nbsp;Value</B></FONT><br><FONT STYLE="font-size:8pt"><B>as&nbsp;of<BR>September&nbsp;30,<BR>2015</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(in&nbsp;millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(in&nbsp;millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(in&nbsp;millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cellatope Corporation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">3.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">Launch a monitoring product using CB-CAPs technology</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">25</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">1.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">0.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Royalty Pharma</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">1.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">Launch a monitoring product using CB-CAPs technology</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">25</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">0.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">0.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Royalty Pharma</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">2.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">Achieve certain annual worldwide net sales levels for CB-CAPs products</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">100</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">100</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">1.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">1.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prometheus<BR>Laboratories</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">2.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">Achieve certain revenue levels from Avise PG</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">85</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">0.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">University of Pittsburgh</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">Achieve certain revenue levels from products utilizing CB-CAPs technology in a calendar year</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">100</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">N/A</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">0.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Royalty Pharma</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">1.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">Execution of agreement for initiation of certain commercial programs</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The fair value of the acquisition-related liability is determined using widely accepted valuation
techniques, which include the income approach for estimating future consideration to be paid based on projected earnings. The income approach involves the use of a probability-weighted discounted revenue model based on significant inputs not
observable in the market such as revenue projections, the interest rate and the probabilities assigned to the milestones being achieved. The significant inputs include discount rates of 3.2% to 14.2%. A significant change in such projected earnings
may result in a material change to the fair value of such acquisition-related liability with a corresponding adjustment to net loss and comprehensive loss. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">During 2014, the Company determined that it had met the University of Pittsburgh milestone and increased the related liability to 100%
achievement probability. The corresponding payment of $200,000 is presented as acquisition-related liabilities, current portion, in the accompanying balance sheet and the Company remitted payment in the first quarter of 2015. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-27 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company determined that it was probable that it would achieve the Royalty Pharma annual
sales milestone during the calendar year ended December&nbsp;31, 2015. Achievement of this milestone would obligate the Company to pay Royalty Pharma $2.0 million within 30 days of the achievement of such milestone. Accordingly, the Company has
presented the estimated fair value of its obligation to Royalty Pharma of $1.9 million within acquisition&#151;related liabilities, current portion, in the accompanying balance sheets. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Licensing Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company is a party to various licensing agreements, the most significant of which were acquired in connection with the Cypress acquisition.
In accordance with the terms of these agreements, rights to the ownership and use of specified technology are defined. In addition to the milestone payments required by these agreements as described above, the agreements generally provide for
ongoing royalty payments on net sales of products, as defined, ranging from 3% to 10%. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Contingencies </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and
provide for general indemnifications. The Company&#146;s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but have not yet been made. The Company accrues a liability for such
matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Litigation
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company is not a party to any litigation and does not have contingent reserves established for any litigation liabilities.
</P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Fair Value Measurements </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the Company&#146;s financial
instruments that were measured at fair value on a recurring basis within the fair value hierarchy (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level 3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquisition-related liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;3,657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,085</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,085</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquisition-related liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;3,418</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,418</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,461</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,461</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derivative liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">559</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">559</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>September 30, 2015 (Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level 3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquisition-related liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;3,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derivative liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-28 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The inputs and assumptions used to estimate the fair value of embedded derivatives and warrant
liabilities are discussed in Note 5 and Note 6, respectively. The inputs and assumptions used to estimate the fair value of acquisition-related liabilities are discussed in Note 7. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-29 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The following table includes a roll forward of the financial instruments classified within
Level&nbsp;3 of the fair value hierarchy (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Amounts</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Acquisition-<BR>Related<BR>Liabilities</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Liability<BR>Classified<BR>Warrants</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Embedded<BR>Derivatives</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balances at December&nbsp;31, 2012</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,392</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of 2013 Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">668</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">668</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise of put feature</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(400</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(400</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of Series D redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Remeasurement of financial instruments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,304</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,265</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(44</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Extinguishment and conversion of 2013 Notes into Series D redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(624</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(624</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balances at December&nbsp;31, 2013</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,742</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,085</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of July 2014 Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">437</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">437</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Remeasurement of financial instruments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">259</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(239</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">376</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balances at December&nbsp;31, 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,438</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,418</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,461</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">559</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of February 2015 Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">652</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">652</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of July 2015 Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">468</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">468</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Remeasurement of financial instruments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(135</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(877</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Extinguishment and conversion of July 2014 Notes into Series D redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,088</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,088</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payment of acquisition-related liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(200</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(200</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balances at September 30, 2015 (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Redeemable Convertible Preferred Stock </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">At December&nbsp;31, 2013, the Company&#146;s
redeemable convertible preferred stock consists of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="52%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:20.40pt; font-size:8pt; font-family:Times New Roman"><B>Series</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares<BR>Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per Share<BR>Liquidation<BR>Preference</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per Share<BR>Redemption&nbsp;Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Carrying&nbsp;Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A-3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,800,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,474,795</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">811</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B-3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,700,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,539,977</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,889</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series C</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,750,389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,082</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,565,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,057</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">145,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,330,247</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-30 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">At December&nbsp;31, 2014, the Company&#146;s redeemable convertible preferred stock consists of
the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="52%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:20.40pt; font-size:8pt; font-family:Times New Roman"><B>Series</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares<BR>Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per Share<BR>Liquidation<BR>Preference</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per Share<BR>Redemption&nbsp;Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Carrying&nbsp;Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A-3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,800,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,474,795</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">811</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B-3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,700,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,539,977</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,853</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series C</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,750,389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,565,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,057</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">145,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,330,247</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,617</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-31 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">At September 30, 2015 (unaudited), the Company&#146;s redeemable convertible preferred stock
consists of the following: </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="56%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:20.40pt; font-size:8pt; font-family:Times New Roman"><B>Series</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares<BR>Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per Share<BR>Liquidation<BR>Preference</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per Share</B><br><B>Redemption<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Carrying</B><br><B>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A-3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,800,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,474,795</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">811</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B-3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,700,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,539,977</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series C</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,750,389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,568</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,949,410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,675</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">185,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109,714,571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36,784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The significant rights and preferences of redeemable convertible preferred stock are as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Dividends </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">With the
exception of Series A-3 redeemable convertible preferred stock, each holder of preferred stock is entitled to noncumulative dividends at an annual rate of 8.0% of the original issue price when and if declared by the Board of Directors. Dividends are
paid in the following order of preference: (i)&nbsp;Series D, (ii)&nbsp;Series C, (iii)&nbsp;Series&nbsp;B-3, (iv)&nbsp;Series A-3 and (v)&nbsp;common stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">No dividend shall be declared or be payable on the outstanding shares of the Series B-3 redeemable convertible preferred stock without the
consent of the holders of at least two-thirds of the outstanding shares of the Series C and Series D redeemable convertible preferred stock, voting together as a single class, and no dividend shall be declared or be payable on the outstanding shares
of the Series A-3 redeemable convertible preferred stock or the common stock, other than a dividend on shares of common stock payable entirely in shares of common stock, without the consent of the holders of at least 60% of the outstanding shares of
the Series B-3, Series C and Series D redeemable convertible preferred stock. As of September&nbsp;30, 2015 (unaudited) the board of directors has not declared any dividends. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Liquidation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The
Series A-3, B-3, C and D redeemable convertible preferred shares have liquidation preferences of $7.50, $0.25, $0.50 and $0.38 per share, respectively. In the event of a liquidation, the Series D liquidation preference is paid prior to any other
preferences, the Series C liquidation preference is paid prior to the preferences for Series B-3 and A-3, the Series B-3 liquidation preference is paid prior to the preference for Series A-3, then the Series A-3 preference is paid. Following the
satisfaction of the liquidation preferences, all shares participate in any remaining distribution based on the number of common shares into which their shares are convertible. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Conversion </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">All
shares of the Company&#146;s Series A-3, B-3, C and D redeemable convertible preferred stock are convertible at the option of the holder, into shares of common stock by dividing the initial conversion prices by the conversion price in effect at the
time of conversion. The initial conversion price is $7.50 for Series A-3 redeemable convertible preferred stock and $0.25 for Series B-3, C and D redeemable convertible preferred stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Automatic Conversion </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Each share of redeemable convertible preferred stock is automatically convertible into common stock at its then effective conversion price,
(i)&nbsp;upon the election of the holders of at least 60% of the outstanding of Series B-3, C, and D redeemable convertible preferred stock, voting together as a single class, or (ii)&nbsp;upon the completion of a firm underwritten public offering
of the Company&#146;s common stock with aggregate proceeds of at least $30.0 million and an initial public offering price of at least $0.75 per share. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-32 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Voting </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">With the exception of the Series A-3 redeemable convertible preferred stock, the holder of each share of preferred stock is entitled to one
vote for each share of common stock into which it would convert. The holders of Series A-3 redeemable convertible preferred stock have no voting rights. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Redemption </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Upon
the request in writing of the holders of 60% of the outstanding shares of Series B-3, C and D redeemable convertible preferred stock, voting together as a single class, at any time after October&nbsp;4, 2018, the holders may redeem the outstanding
Series B-3, C and D redeemable convertible preferred stock at the stated redemption price as noted in the table above, plus any declared but unpaid dividends. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In addition, upon the request in writing of the holders of 60% of the outstanding shares of Series B-3, C and D redeemable convertible
preferred shares, voting together as a single class, on or after a Redemption Event, as defined in the certificate of incorporation, the Company may be required to purchase the outstanding Series B-3, C and D redeemable convertible preferred shares
at the stated redemption price as noted in the table above, plus any declared but unpaid dividends. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company is accreting the carrying
amounts of the preferred stock up to the redemption amount at October&nbsp;4, 2018, the earliest possible date, using the effective interest method. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Shares of Series A-3 redeemable convertible preferred stock have been included as temporary equity in the consolidated balance sheets as
holders of these shares can cause redemption of the Series A-3 redeemable convertible preferred shares due to certain change in control events that are outside the Company&#146;s control, including liquidation, sale or transfer of the Company. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Stockholders&#146; Deficit </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Common Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Common stockholders are entitled to dividends as and when declared by the Board of Directors, subject to the rights of holders of all classes
of stock outstanding having priority rights as to dividends. There have been no dividends declared to date. The holder of each share of common stock is entitled to one vote. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">During 2013, the Company&#146;s certificate of incorporation was amended to increase the number of authorized shares of common stock from
112,000,000 shares to 163,000,000 shares. In 2015, the Company&#146;s certificate of incorporation was amended to increase the number of authorized shares of common stock from 163,000,000 shares to 203,000,000 shares, and to increase the number of
authorized Series D redeemable convertible preferred stock from 51,000,000 to 91,000,000. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company had common shares reserved for
future issuance upon the exercise or conversion of the following as of December&nbsp;31, 2014: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of</B><br><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,330,247</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrants to purchase redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,174,430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrants to purchase common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,881,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock option grants issued and outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,701,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common shares available for grant under the stock option plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,468,788</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total common shares reserved for future issuance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">116,556,990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-33 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company had common shares reserved for future issuance upon the exercise or conversion of
the following as of September 30, 2015 (unaudited): </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of</B><br><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109,714,571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrants to purchase redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,174,430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrants to purchase common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,881,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock option grants issued and outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,038,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common shares available for grant under the stock option plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,113,581</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total common shares reserved for future issuance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">133,922,640</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Stock Option Plan </B></TD></TR></TABLE>  <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s 2002 Stock Option Plan expired on
December&nbsp;31, 2012 and was replaced by the 2013 Stock Option Plan, which was adopted in December 2012 (collectively, the &#147;Plans&#148;). Pursuant to the Plans, employees, consultants, and directors may be granted either incentive stock
options or nonqualified stock options to purchase shares of the Company&#146;s common stock. As of December&nbsp;31, 2014 and September 30, 2015 (unaudited), 1,468,788 and 1,113,581 shares, respectively, remained available for future awards. </P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The exercise price of each stock option is established by the board of directors and is based on the estimated fair value of the
Company&#146;s common stock on the grant date. The options generally expire ten years after the date of grant and are exercisable to the extent vested. Vesting is established by the board of directors and is generally no longer than four years from
the date of grant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Activity under the Company&#146;s stock option plans is set forth below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="58%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:8pt"><B>Number of</B></FONT><br><FONT STYLE="font-size:8pt"><B>Options</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:8pt"><B>Weighted-<BR>Average<BR>Exercise</B></FONT><br><FONT STYLE="font-size:8pt"><B>Price</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:8pt"><B>Weighted-<BR>Average<BR>Remaining</B></FONT><br><FONT STYLE="font-size:8pt"><B>Contractual<BR>Term&nbsp;(Years)</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:8pt"><B>Aggregate</B></FONT><br><FONT STYLE="font-size:8pt"><B>Intrinsic&nbsp;Value</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding, December&nbsp;31, 2012</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,670,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">358,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(86,352</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cancelled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(131,632</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding, December&nbsp;31, 2013</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,810,386</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">439,079</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,345,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,574,918</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cancelled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(878,843</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding, December&nbsp;31, 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,701,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,970,976</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">815,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,707</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cancelled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(460,760</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding, September 30, 2015 (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,038,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,317,779</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested and expected to vest, December&nbsp;31, 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,832,465</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,609,038</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested and expected to vest, September 30, 2015 (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,724,991</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,246,684</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options exercisable, December&nbsp;31, 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,676,662</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,146,988</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options exercisable, September 30, 2015 (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,774,837</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">887,070</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The aggregate intrinsic value of options is calculated as the difference between the exercise price of the
options and the deemed fair value of the Company&#146;s common stock for those shares that had exercise prices lower than the deemed fair value of our common stock. The number of options vested and expected to vest is calculated as the total number
of options vested plus the number of unvested options remaining after applying the Company&#146;s estimated forfeiture rate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-34 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes certain information about stock options for the periods presented
(in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="56%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Aggregate intrinsic value of options exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash received upon exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">195</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation Expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The estimated weighted-average grant date fair value of each share of common stock was $0.01 and $0.11 at December&nbsp;31, 2013 and 2014,
respectively. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The fair value of employee stock options was estimated using the following assumptions used to determine the fair value of
stock options granted for the periods presented: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014 </B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014 </B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51.80</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51.05</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51.05</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">49.0%-49.8</FONT></TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.23</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.20</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.20</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">1.94%-2.16</FONT></TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.08-7.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Total noncash stock-based compensation expense recorded related to options granted in the consolidated
statement of operations and comprehensive loss is as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2014, there was total unrecognized compensation cost of $586,000, which is
expected to be recognized over a remaining weighted-average vesting period of 3.1 years. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Related Party Transactions </B></TD></TR></TABLE>  <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company has entered into various agreements under
which directors of the Company are paid for consulting services and for serving on the board of directors. Total compensation expense related to these agreements for the years ending December&nbsp;31, 2013 and 2014, and the nine months ended
September 30, 2014 (unaudited) and 2015 (unaudited) was $50,000, $81,000, $46,000, and $93,000, respectively, which has been recorded in sales, general and administrative expense in the accompanying consolidated financial statements. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">A total of $750,000 of the loan commitment under the 2010 SSPNs was provided by NMSIC Co-Investment Fund L.P. (NMSIC), an organization that is
a significant stockholder in the Company and maintains a seat on the board of directors of the Company. In addition, 131,250 of the 390,000 warrants with the put feature (Note 6) were held by NMSIC. When NMSIC exercised the put feature in October
2013, the Company made a payment of $150,000 to NMSIC to repurchase these warrants. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In September 2011, the Company entered into a license
agreement with the Company&#146;s Chief Scientific Officer, and a related company, DeNovo. The license agreement, covering novel methods for monitoring low-dose methotrexate therapy, relates to technology developed by the Company&#146;s Chief
Scientific Officer prior to joining the Company. The technology has yet to be used by the Company. Under the agreement, the Company&#146;s Chief Scientific Officer will be eligible to receive up to $600,000 upon the achievement of certain sales
milestones and an ongoing royalty of 5% on sales. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-35 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In 2013, the Company issued 2013 Notes to existing equity holders and converted the outstanding
principal and unpaid accrued interest into Series D redeemable convertible preferred stock at a discount of 20% to the issue price of $0.25 per share, as described in Note&nbsp;5. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In July 2014,&nbsp;February 2015,&nbsp;May 2015, June 2015, and July 2015 the Company issued convertible promissory notes payable to existing
equity holders as described in Note 5. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In conjunction with the departure of two members of the Company&#146;s board of directors in
September 2014, the Company modified the vesting term of 259,959 outstanding and unvested stock options previously granted to these departing board members, such that these options became immediately exercisable upon their departure from the
Company. All other terms and conditions applicable to the modified options, including the exercise prices and remaining contractual terms, remained unchanged. In accordance with authoritative guidance, the Company immediately recognized compensation
expense of approximately $72,000 reflecting the fair value of these awards at the date they were modified, and all compensation expense was recorded in selling, general, and administrative expenses in the consolidated statements of operations and
comprehensive loss. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>13.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Income Taxes </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The provision for taxes consists of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(44</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(42</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for income tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company recorded an income tax benefit of $3,000 and an income tax expense of $210,000 in the nine
months ended September 30, 2014 (unaudited) and 2015 (unaudited), respectively. The increase in income tax expense is primarily related to an increase in the deferred tax liabilities associated with tax deductible amortization of goodwill and
intangible assets and the difference between the revenue we recognize for tax purposes and for financial statement purposes. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The
effective tax rate of our provision for incomes taxes differs from the federal statutory rate as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federal statutory tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State income taxes, net of federal tax benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on recapitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion of redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5.0</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on extinguishment of 2013 Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7.1</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in accounting method</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3.0</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current year uncertain tax positions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1.9</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State net operating loss adjustment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2.3</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1.2</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2.8</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23.9</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27.6</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effective tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.3</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-36 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Significant components of the Company&#146;s deferred tax assets at December&nbsp;31, 2013
and 2014 are shown below (in thousands). A valuation allowance has been established of December&nbsp;31, 2013,&nbsp;December&nbsp;31, 2014, and September 30, 2015 (unaudited) as realization of such deferred tax assets has not met the more
likely-than-not threshold requirement. If the Company&#146;s judgment changes and it is determined that the Company will be able to realize these deferred tax assets, the tax benefits relating to any reversal of the valuation allowance on deferred
tax assets will be accounted for as a reduction to income tax expense. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net operating loss carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,939</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued revenue(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,866</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accruals, reserves and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">458</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">534</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basis differences in fixed and intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total gross deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,867</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,687</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,828</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financing and acquisition-related liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(181</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(239</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Indefinite lived assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(135</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(165</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net deferred income tax liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(135</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(165</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">The deferred tax liability for uncollectible accounts has been netted with the accrued revenue deferred tax asset for presentation purposes as the nature of these deferred items are related. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Changes in the valuation allowance for deferred tax assets during the years ended December&nbsp;31, 2013 and 2014, which related primarily to
increases in net operating loss carryforwards, accrued revenue and accruals and reserves, were as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation allowance at the beginning of the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,687</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Decreases recorded as benefits to income tax provision</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increases recorded to income tax provision</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation allowance at the end of the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,687</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,828</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">At December&nbsp;31, 2013 and 2014, the Company had federal net operating loss carryforwards of approximately
$31.4 million and $39.1 million, respectively. At December&nbsp;31, 2013 and 2014, the Company had state net operating loss carryforwards of $29.6 million and $26.2&nbsp;million, respectively. The federal and state tax loss carryforwards will begin
to expire in 2015 and 2022, respectively, unless previously utilized. Included in the net operating loss deferred tax asset above is approximately $175,000 of deferred tax assets attributable to excess stock compensation deductions. Excess tax
benefits are not recorded in additional paid in capital until the deduction reduces income taxes payable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-37 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Internal Revenue Code (IRC), Section&nbsp;382 and 383, use of the Company&#146;s U.S.
federal and state net operating loss and research and development income tax credit carryforwards may be limited in the event of a cumulative change in ownership of more than 50.0% within a three-year period. The Company had an ownership change in
2008 and, as a result, certain carryfowards are subject to an annual limitation, reducing the amount available to offset income tax liabilities absent the limitation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Uncertain Tax Positions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance, beginning of the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">652</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">653</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additions based on prior period tax positions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reductions based on prior period tax positions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(57</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(70</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(583</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additions based on current period tax positions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance, end of the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">653</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company does not believe that the balance of unrecognized tax benefits will change within the next twelve
months. A tax benefit in the amount of $44,000 is currently impacting the effective income tax rate as of December&nbsp;31, 2014. The amount of unrecognized tax benefit that, if recognized, would favorably impact the effective income tax rate is
$430,000. During the years ended December&nbsp;31, 2013 and 2014, the Company recognized no amounts related to interest or penalties. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The
Company is subject to taxation in the United States and various state jurisdictions. The Company currently has no years under examination by any jurisdiction. The Company&#146;s tax years for 2002 and forward are subject to examination by the
federal tax authorities and tax years for 2010 and forward are subject to examination by the state tax authorities due to the carryforward of unutilized net operating losses and research and development credits. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>14.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Subsequent Events </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company has evaluated subsequent events through February&nbsp;17,
2015, the date the consolidated financial statements were available for issuance. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>15.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Subsequent Events (Unaudited) </B></TD></TR></TABLE>  <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company has evaluated subsequent events through
November 12, 2015, the date the consolidated financial statements were available for issuance. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In October 2015, the Company issued $3.4
million of convertible promissory notes, or the October 2015 Notes, to existing holders of its redeemable convertible preferred stock. The&nbsp;October 2015 Notes accrue interest at 10%&nbsp;per annum and become due and payable in October 2016. The
October 2015 Notes provide that a majority of holders may elect to extend the maturity date by up to one additional year. In conjunction with these notes, the Company also issued a variable number of warrants, or the 2015 Warrants, which only become
exercisable upon (1)&nbsp;a qualified equity financing resulting in aggregate gross proceeds to the Company of more than $10.0 million, excluding the conversion of the October 2015 Notes, in which investors purchase shares of a newly-issued series
of the Company&#146;s preferred stock prior to the maturity date of the October 2015 Notes or (2)&nbsp;a conversion of the associated October 2015 Notes by the holders thereof in certain circumstances. In the case of a qualified equity financing,
the 2015 Warrants will become exercisable for a number of shares of the newly-issued preferred stock sold in such qualified equity financing as is equal to 20% of the initial principal amount of each such October 2015 Note divided by the lowest
price per share paid by investors in the qualified equity financing. In the case of certain conversions of the associated October 2015 Notes, the 2015 Warrants will become exercisable for a number of shares of the Company&#146;s Series D redeemable
convertible preferred stock as is equal to 20% of the initial principal amount of each such October 2015 Note divided by the then applicable conversion price (as defined in the Company&#146;s current amended and restated certificate of
incorporation). The 2015 Warrants expire in October 2020. The October 2015 Notes are subordinated to borrowings under the Company&#146;s 2013 term loan with Capital Royalty. If the 2015 Warrants are not exercised prior to the completion of the
offering, they will terminate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-38 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In the event of a qualified equity financing prior to the maturity date of the October 2015
Notes, the majority of the holders of these notes may elect either (1)&nbsp;to convert the unpaid principal and interest into shares of the Company&#146;s Series D redeemable convertible preferred stock at a rate of $0.25 per share or (2)&nbsp;to
convert the unpaid principal and interest into shares of the newly issued series of preferred stock sold in the qualified equity financing at the lowest price per share paid by investors in the newly issued series of preferred stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The October 2015 Notes contain a feature such that if an IPO occurs prior to December 31, 2015, the unpaid principal and interest will convert
into shares of common stock at a 20% discount to the IPO price and if an IPO occurs after December&nbsp;31, 2015, the unpaid principal and interest will convert into shares of common stock at a 30% discount to the IPO price. In the event that an IPO
has not occurred by the maturity date and a majority of holders has not elected to extend the maturity date, holders may elect to either (1)&nbsp;receive all unpaid principal and accrued interest due or (2)&nbsp;convert the unpaid principal and
interest at maturity into shares of Series D redeemable convertible preferred stock at a rate of $0.25 per share. If a liquidation (as defined in our current amended and restated certificate of incorporation) occurs prior to the completion of this
offering, the holders of the October 2015 Notes may elect to (1)&nbsp;receive the repayment of the notes or (2)&nbsp;convert the notes into shares of Series D redeemable convertible preferred stock at a conversion price of $0.25 per share, subject
to adjustment pursuant to the terms thereof. In connection with the completion of this offering, the aggregate principal amount outstanding (including accrued interest thereon) under the October 2015 Notes will automatically convert into&nbsp;shares
of common stock, assuming an initial public offering price of $&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus and assuming the conversion occurs on , 2015 (the expected closing date of this
offering). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In October 2015, the Company&#146;s certificate of incorporation was amended to increase the number of authorized shares of
common stock from 203,000,000 to 229,500,000 and of Series D redeemable convertible preferred stock from 91,000,000 to 117,500,000. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-39 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g693329dsp_195.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>SHARES OF COMMON STOCK </B></P>
<P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" ALIGN="center">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" NOWRAP><B>Leerink Partners</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP><B>Baird</B></TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>William Blair </B></P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:24pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015 (25 days after the commencement of this offering), all dealers that buy, sell or trade shares of our common stock, whether or not participating in this offering, may be
required to deliver a prospectus. This delivery requirement is in addition to the obligation of dealers to deliver a prospectus when acting as underwriters and with respect to their unsold allotments or subscriptions. </P>
<P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Part II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;13. Other Expenses of Issuance and Distribution. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table indicates the expenses to be incurred in connection with the offering described in this registration statement, other than
underwriting discounts and commissions, all of which will be paid by us. All amounts are estimated except the Securities and Exchange Commission registration fee, the Financial Industry Regulatory Authority, Inc., or FINRA, filing fee and The NASDAQ
Global Market listing fee. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Securities and Exchange Commission registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,887</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FINRA filing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">NASDAQ Global Market listing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accountants&#146; fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Blue Sky fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transfer Agent&#146;s fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printing and engraving expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">To be provided by amendment. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;14. Indemnification of Directors and Officers. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;102 of the General Corporation Law of the State of Delaware permits a corporation to eliminate the personal liability of directors
of a corporation to the corporation or its stockholders for monetary damages for a breach of fiduciary duty as a director, except where the director breached his duty of loyalty, failed to act in good faith, engaged in intentional misconduct or
knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an improper personal benefit. Our certificate of incorporation provides that no director of the
Registrant shall be personally liable to it or its stockholders for monetary damages for any breach of fiduciary duty as a director, notwithstanding any provision of law imposing such liability, except to the extent that the General Corporation Law
of the State of Delaware prohibits the elimination or limitation of liability of directors for breaches of fiduciary duty. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;145 of the General Corporation Law of the State of Delaware provides that a corporation has the power to indemnify a director,
officer, employee or agent of the corporation, or a person serving at the request of the corporation for another corporation, partnership, joint venture, trust or other enterprise in related capacities against expenses (including attorneys&#146;
fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with an action, suit or proceeding to which he was or is a party or is threatened to be made a party to any threatened, ending or
completed action, suit or proceeding by reason of such position, if such person acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the corporation, and, in any criminal action or proceeding,
had no reasonable cause to believe his conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation, no indemnification shall be made with respect to any claim, issue or matter as to which such person shall
have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the case, such
person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation, which will become effective immediately prior to the completion of this offering,
provides that we will indemnify each person who was or is a party or threatened to be made a party to any threatened, pending or completed action, suit or proceeding (other than an action by or in the right of us) by reason of the fact that he or
she is or was, or has agreed to become, a director or officer, or is or was serving, or has agreed to serve, at our request as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership,
joint venture, trust or other enterprise (all such persons being referred to as an &#147;Indemnitee&#148;), or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys&#146; fees),
judgments, fines and amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding and any appeal therefrom, if such Indemnitee acted in good faith and in a
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
manner he or she reasonably believed to be in, or not opposed to, our best interests, and, with respect to any criminal action or proceeding, he or she had no reasonable cause to believe his or
her conduct was unlawful. Our amended and restated certificate of incorporation provides that we will indemnify any Indemnitee who was or is a party to an action or suit by or in the right of us to procure a judgment in our favor by reason of the
fact that the Indemnitee is or was, or has agreed to become, a director or officer, or is or was serving, or has agreed to serve, at our request as a director, officer, partner, employee or trustee of, or in a similar capacity with, another
corporation, partnership, joint venture, trust or other enterprise, or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys&#146; fees) and, to the extent permitted by law, amounts
paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding, and any appeal therefrom, if the Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, our
best interests, except that no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to us, unless a court determines that, despite such adjudication but in view of all
of the circumstances, he or she is entitled to indemnification of such expenses. Notwithstanding the foregoing, to the extent that any Indemnitee has been successful, on the merits or otherwise, he or she will be indemnified by us against all
expenses (including attorneys&#146; fees) actually and reasonably incurred in connection therewith. Expenses must be advanced to an Indemnitee under certain circumstances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into indemnification agreements with each of our directors and officers. These indemnification agreements may require us,
among other things, to indemnify our directors and officers for some expenses, including attorneys&#146; fees, judgments, fines and settlement amounts incurred by a director or officer in any action or proceeding arising out of his or her service as
one of our directors or officers, or any of our subsidiaries or any other company or enterprise to which the person provides services at our request. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain a general liability insurance policy that covers certain liabilities of directors and officers of our corporation arising out of
claims based on acts or omissions in their capacities as directors or officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In any underwriting agreement we enter into in connection
with the sale of common stock being registered hereby, the underwriters will agree to indemnify, under certain conditions, us, our directors, our officers and persons who control us within the meaning of the Securities Act of 1933, as amended, or
Securities Act, against certain liabilities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;15. Recent Sales of Unregistered Securities. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Set forth below is information regarding shares of capital stock issued by us since January 2011. Also included is the consideration received
by us for such shares and information relating to the section of the Securities Act, or rule of the Securities and Exchange Commission, under which exemption from registration was claimed. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">Issuances of Capital Stock and Warrants to Purchase Capital Stock </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">In December 2011, in connection with our Series A-2 and Series B-2 redeemable convertible preferred stock financing, all 3,896,531 of our outstanding shares of Series A-1 redeemable convertible preferred stock and
273,182 outstanding warrants to purchase shares of Series A-1 redeemable convertible preferred stock were converted into 3,896,531 shares of our common stock and warrants to purchase an aggregate of 273,182 shares of our common stock, and we
converted 1,598,226 shares of common stock into 1,598,226 of shares of our Series A-2 redeemable convertible preferred stock. In February and April 2012, we converted an additional 45,710 shares of common stock into Series A-2 redeemable convertible
preferred stock. In September 2012, in connection with our Series C redeemable convertible preferred stock financing described below, all 1,598,226 of our Series A-2 redeemable convertible preferred stock were converted into 1,598,226 shares of
common stock. In September 2012, in connection with our Series C redeemable convertible preferred stock financing described below, we converted 1,474,795 shares of common stock into 1,474,795 shares of Series A-3 redeemable convertible preferred
stock. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Between January 2011 and October 2011, we issued and sold 1,896,367 shares of our Series B-1 redeemable convertible preferred stock and 1,090,514 warrants to purchase shares of our Series B-1 redeemable convertible
preferred stock. In December 2011, in connection with our Series A-2 and Series B-2 redeemable convertible preferred stock financing, all 1,896,367 shares of our Series B-1 redeemable convertible preferred stock were converted into 1,896,367 shares
of common stock, and all of our outstanding Series B-1 warrants to purchase up to an aggregate of 1,812,288 shares of Series B-1 redeemable convertible preferred stock were converted into warrants to purchase an aggregate of up to 1,812,288 shares
of our common stock. In December 2011, we issued 24,283,557 shares our Series B-2 redeemable convertible preferred stock at a purchase price of $0.25 per share, for aggregate consideration of approximately $6.0 million, and we also converted an
aggregate principal amount of $5,810,422 of promissory notes plus interest of $105,418 into 23,663,361 shares of Series B-2 redeemable convertible preferred stock. In February 2012 and April 2012, we also issued 1,651,134 shares of our Series B-2
redeemable convertible preferred stock at a purchase price of $0.25 per share, for aggregate consideration of approximately $0.4 million. In September 2012, in connection with the sales of Series C redeemable convertible preferred stock, all
49,598,052 outstanding shares of our Series B-2 redeemable convertible preferred stock were converted into 49,598,052 shares of common stock. In September 2012, we converted 44,539,977 shares of common stock into 44,539,977 shares of our
Series&nbsp;B-3 redeemable convertible preferred stock. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">From September 2012 to December 2012, we issued and sold to investors in private placements an aggregate of 23,750,389 shares of our Series C redeemable convertible preferred stock at a purchase price of $0.25 per
share, for aggregate consideration of approximately $5.9 million. In connection with this financing, in September 2012 all 1,598,226 outstanding shares of our Series A-2 redeemable convertible preferred stock and 49,598,052 shares of our Series B-2
redeemable convertible preferred stock were converted into 1,598,226 and 49,598,052 shares of common stock, respectively. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">In May 2013,&nbsp;June 2013 and August 2013, we issued a total of $2,430,531 in unsecured convertible promissory notes, or the 2013 Notes, which accrued interest at 10%. In October 2013, the 2013 Notes and $66,653 in
accrued interest were converted into 12,485,914 shares of Series D redeemable convertible preferred stock, at a 20% discount to the offering price of $0.25 per share. In October 2013, we also issued and sold to investors in private placements an
aggregate of 10,079,172 shares of our Series D redeemable convertible preferred stock at a purchase price of $0.25 per share, for aggregate consideration of approximately $2.5 million. From October 2013 to November 2013, we also issued warrants to
purchase up to an aggregate of 4,174,430 shares of our Series D redeemable convertible preferred stock at an exercise price of $0.25 per share. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">In July 2014, we issued $4.0 million of convertible promissory notes which accrue interest at an annual rate equal to 12%. In May 2015, the holders of these notes elected to convert these notes into shares of our Series
D redeemable convertible preferred stock at the stated conversion rate of $0.25 per share resulting in the issuance of 17,384,324 shares of Series D redeemable convertible preferred stock. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top">In February 2015,&nbsp;May 2015 and June 2015, we issued $1.8&nbsp;million, $1.9 million and $833,000, respectively, of convertible promissory notes which accrue interest at an annual rate equal to 10%. In connection
with the completion of this offering, any outstanding principal of these convertible promissory notes (including accrued interest thereon) will automatically convert into &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
of common stock, assuming an initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share (the midpoint of the price range listed on the cover page of the prospectus). </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top">In July 2015, we issued $3.0 million of convertible promissory notes which accrue interest at an annual rate equal to 10%. In connection with the completion of this offering, any outstanding principal of these
convertible promissory notes (including accrued interest thereon) will automatically convert into &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock, assuming an initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share (the midpoint of the price range listed on the cover page of the prospectus). </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top">In October 2015, we issued $3.4 million of convertible promissory notes which accrue interest at an annual rate equal to 10%. In connection with the completion of this offering, any outstanding principal of these
convertible promissory notes (including accrued interest thereon) will automatically convert into &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock, assuming an initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share (the midpoint of the price range listed on the cover page of the prospectus). In connection with the issuance of such notes, we also issued associated warrants,
which only become exercisable upon (1)&nbsp;a qualified equity financing resulting in aggregate gross proceeds to us of more than $10.0 million, excluding the conversion of the October 2015 Notes, in which investors purchase shares of a newly issued
series of our preferred stock prior to the maturity date of the October 2015 Notes or (2)&nbsp;a conversion of the associated October 2015 Notes by the holders thereof in certain circumstances. In the case of a qualified equity financing, the 2015
Warrants will become exercisable for a number of shares of the newly-issued preferred stock sold in such qualified equity financing as is equal to 20% of the initial principal amount of each such October 2015 Note divided by the lowest price per
share paid by investors in the qualified equity financing. In the case of certain conversions of the associated October 2015 Notes, the 2015 Warrants will become exercisable for a number of shares of our Series D redeemable convertible preferred
stock as is equal to 20% of the initial principal amount of each such October 2015 Note divided by the then applicable conversion price (as defined in our current amended and restated certificate of incorporation). If the 2015 Warrants are not
exercised prior to the completion of the offering, they will terminate. </TD></TR></TABLE>  <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">No underwriters were involved in the foregoing
sales of securities. The securities described in this section (a)&nbsp;of Item&nbsp;15 were issued to investors in reliance upon the exemption from the registration requirements of the Securities Act, as set forth in Section&nbsp;4(2) under the
Securities Act and Regulation D promulgated thereunder relative to transactions by an issuer not involving any public offering, to the extent an exemption from such registration was required. All purchasers of shares of redeemable convertible
preferred stock described above represented to us in connection with their purchase that they were accredited investors and were acquiring the shares for their own account for investment purposes only and not with a view to, or for sale in
connection with, any distribution thereof and that they could bear the risks of the investment and could hold the securities for an indefinite period of time. The purchasers received written disclosures that the securities had not been registered
under the Securities Act and that any resale must be made pursuant to a registration statement or an available exemption from such registration. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">Grants and Exercise of Stock Options </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">From January&nbsp;1, 2011 through October 31, 2015, we granted stock options to purchase an aggregate of 17,066,182&nbsp;shares of our common stock at a weighted average exercise price of $0.16 per share, to certain of
our employees, consultants and directors in connection with services provided to us by such persons. Of these, options to purchase 1,592,625 shares have been exercised through October 31, 2015. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The stock options and the common stock issuable upon the exercise of such options as described in this section (b)&nbsp;of Item&nbsp;15 were
issued pursuant to written compensatory plans or arrangements with our employees and directors, in reliance on the exemption from the registration requirements of the Securities Act provided by Rule 701 promulgated under the Securities Act or the
exemption set forth in Section&nbsp;4(2) under the Securities Act and Regulation D promulgated thereunder relative to transactions by an issuer not involving any public offering. All recipients either received adequate information about us or had
access, through employment or other relationships, to such information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of the foregoing securities are deemed restricted securities
for purposes of the Securities Act. All certificates representing the issued shares of capital stock described in this Item&nbsp;15 included appropriate legends setting forth that the securities had not been registered and the applicable
restrictions on transfer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;16. Exhibits and Financial Statement Schedules. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(a) Exhibits.</B> The list of exhibits is set forth under &#147;Exhibit Index&#148; at the end of this registration statement and is incorporated by
reference herein. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(b) Financial Statement Schedules.</B> Schedules not listed above have been omitted because the information required to be set forth
therein is not applicable or is shown in the financial statements or notes thereto. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;17. Undertakings. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned registrant hereby undertakes to provide to the underwriter, at the closing specified in the underwriting agreement,
certificates in such denominations and registered in such names as required by the underwriter to permit prompt delivery to each purchaser. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of
the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is,
therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful
defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by
controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned hereby undertakes that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of
prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">For the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities
offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">That, for the purpose of determining liability under the Securities Act to any purchaser: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt">If the registrant is subject to Rule 430C, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering,
other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness.
Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that
is part of the registration </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was
part of the registration statement or made in any such document immediately prior to such date of first use. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">That, for the purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial distribution of the securities: The undersigned registrant undertakes that in a primary offering
of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the
following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act, the registrant has duly caused this registration statement to be signed on its behalf by
the undersigned, thereunto duly authorized, in the City of Vista, State of California, on this 12th day of November, 2015. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">EXAGEN DIAGNOSTICS, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Fortunato Ron Rocca</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Fortunato Ron Rocca</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President and Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed
by the following persons in the capacities held on the dates indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="15%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Fortunato Ron Rocca</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Fortunato Ron Rocca</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">President, Chief Executive Officer and Director</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>(Principal Executive Officer)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">November&nbsp;12,&nbsp;2015</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Wendy Swedick</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Wendy Swedick</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief Financial Officer</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>(Principal Financial
and Accounting Officer)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">November 12, 2015</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Frank Witney, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chairman of the Board of Directors</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">November 12, 2015</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Ebetuel Pallares, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">November 12, 2015</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">James L.L.Tullis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">November 12, 2015</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Brian Birk</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">November 12, 2015</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Arthur Weinstein, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">November 12, 2015</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">John M. Radak</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">November 12, 2015</TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="89%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">*By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Fortunato Ron Rocca</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Fortunato Ron Rocca</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><I>Attorney-in-Fact</I></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit Index </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description of Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;1.1<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Underwriting Agreement.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.1<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Fifteenth Amended and Restated Certificate of Incorporation (currently in effect).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.2<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Bylaws (currently in effect).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.3<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Amended and Restated Certificate of Incorporation (to be effective immediately prior to the completion of this offering).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.4<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Amended and Restated Bylaws (to be effective immediately prior to the completion of this offering).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.5<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certificate of Amendment of Fifteenth Amended and Restated Certificate of Incorporation.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certificate of Amendment of Fifteenth Amended and Restated Certificate of Incorporation.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Specimen stock certificate evidencing the shares of common stock.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.2<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Fourth Amended and Restated Investors&#146; Rights Agreement, dated October&nbsp;4, 2013, by and among the Registrant and certain of its stockholders.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.3<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Fourth Amended and Restated Stockholders&#146; Agreement, dated October&nbsp;4, 2013, by and among the Registrant and certain of its stockholders.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.4<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Warrant to purchase common stock issued to investors in connection with private placement financings.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.5<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Warrant issued to lenders and related advisors in connection with the Registrant&#146;s term loan agreement.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.6<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Convertible Promissory Note issued to investors by the Registrant in February 2015,&nbsp;May 2015,&nbsp;June 2015 and July 2015.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Convertible Promissory Note issued to investors by the Registrant in October 2015.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;5.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Opinion of Latham &amp; Watkins LLP.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1#<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Exagen Corporation Stock Option Plan, as amended, and form of option agreement thereunder.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.2#<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Exagen Diagnostics, Inc. 2013 Stock Option Plan, as amended, and form of option agreement thereunder.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.3#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Exagen Diagnostics, Inc. 2015 Incentive Award Plan and form of option agreement thereunder.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.4#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Exagen Diagnostics, Inc. Employee Stock Purchase Plan.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.5&#134;<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">License Agreement, dated September&nbsp;13, 2007, by and between Prometheus Laboratories Inc. and the Registrant (as successor in interest to Proprius, Inc.).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.6&#134;<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">First Amendment to License Agreement, dated October&nbsp;23, 2013, by and between Prometheus Laboratories Inc. and the Registrant (as successor in interest to Cypress Bioscience, Inc.).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.7&#134;<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">License Agreement, dated February&nbsp;19, 2008, by and between Orgentec Diagnostika GmbH and the Registrant (as successor in interest to Proprius, Inc.).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.8<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Asset Purchase Agreement, dated February&nbsp;9, 2009, by and between the Registrant (as successor in interest to Cypress Bioscience, Inc.) and Cellatope Corporation.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.9<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amendment No. One to Asset Purchase Agreement, dated December&nbsp;14, 2012, by and between the Registrant and Cellatope Corporation.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.10&#134;<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Asset Purchase Agreement, dated October&nbsp;8, 2010, by and between Cypress Bioscience, Inc., Proprius, Inc. and the Registrant.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.11&#134;<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amendment No. One to Asset Purchase Agreement, dated March&nbsp;10, 2011, by and between Cypress Bioscience, Inc., Proprius, Inc. and the Registrant.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.12<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amendment No. Two to Asset Purchase Agreement, dated August&nbsp;21, 2012, by and between Royalty Pharma Collection Trust, Proprius, Inc. and the Registrant.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.13&#134;<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amendment No. Three to Asset Purchase Agreement, dated February&nbsp;6, 2013, by and between Royalty Pharma Collection Trust, Proprius, Inc. and the Registrant.</TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="92%"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description of Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.14#<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Offer Letter, dated October&nbsp;12, 2010, by and between Thierry Dervieux, Ph.D. and the Registrant, as amended on September&nbsp;9, 2011.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.15&#134;<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amended and Restated Exclusive License Agreement, dated August&nbsp;2, 2011, by and between the University of Pittsburgh &#150; Of the Commonwealth System of Higher Education and the Registrant.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.16&#134;<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">First Amendment to Amended and Restated Exclusive License Agreement, dated May&nbsp;17, 2012, by and between the University of Pittsburgh &#150; Of the Commonwealth System of Higher Education and the Registrant.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.17&#134;<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Second Amendment to Amended and Restated Exclusive License Agreement, dated September&nbsp;30, 2013, by and between the Registrant and the University of Pittsburgh &#150; Of the Commonwealth System of Higher Education.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.18&#134;<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Exclusive License Agreement, dated September&nbsp;30, 2013, by and between the Registrant and the University of Pittsburgh&#151;Of the Commonwealth System of Higher Education.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.19&#134;<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Exclusive License Agreement, dated September&nbsp;5, 2011, by and between Thierry Dervieux, Ph.D. and the Registrant.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.20<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Standard Industrial/Commercial Multi-Tenant Lease, dated January&nbsp;13, 2012, by and between RGS Properties and the Registrant.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.21<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">First Amendment to Standard Industrial/Commercial Multi-Tenant Lease, dated December&nbsp;1, 2013, by and between RGS Properties and the Registrant.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.22<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Lease of Real Property, dated May&nbsp;7, 2013, by and between The Regents of the University of New Mexico and the Registrant.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.23<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">First Amendment to Lease of Real Property, dated May&nbsp;7, 2013, by and between The Regents of the University of New Mexico and the Registrant.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.24<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Standard Industrial/Commercial Single-Tenant Lease, dated September&nbsp;4, 2014, by and between Geiger Court, LLC and the Registrant.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.25<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Term Loan Agreement, dated October&nbsp;10, 2013, by and between Capital Royalty Partners II L.P., Capital Royalty Partners II&#151;Parallel Fund &#147;A&#148; L.P., Parallel Investment Opportunities Partners II L.P. and the
Registrant.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.26<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Security Agreement, dated October&nbsp;10, 2013, by and between Capital Royalty Partners II L.P., Capital Royalty Partners II&#151;Parallel Fund &#147;A&#148; L.P., Parallel Investment Opportunities Partners&nbsp;II L.P. and the
Registrant.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.27<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Indemnity Agreement for Directors and Officers.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.28#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Non-Employee Director Compensation Program.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.29#<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Employment Agreement by and between Fortunato Ron Rocca and the Registrant.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.30#<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Employment Agreement by and between Wendy Swedick and the Registrant.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.31#<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Employment Agreement by and between Thierry Dervieux and the Registrant.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.32#<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Executive Relocation Agreement, dated April&nbsp;1, 2014, by and between Wendy Swedick and the Registrant</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.33<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Second Amendment to Lease of Real Property, dated May&nbsp;7, 2013, by and between The Regents of the University of New Mexico and the Registrant.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.34<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Third Amendment to Lease of Real Property, dated May&nbsp;7, 2013, by and between The Regents of the University of New Mexico and the Registrant.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>16.1<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Letter from McGladrey LLP addressed to the SEC provided in connection with the change in independent accountant.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of PricewaterhouseCoopers LLP, independent registered public accounting firm.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of Latham &amp; Watkins LLP (included in Exhibit 5.1).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>24.1<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Power of Attorney (included on signature page).</TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="92%"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description of Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>24.2<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Power of Attorney of James L.L.Tullis</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Filed with the Registrant&#146;s Registration Statement on Form S-1 on September&nbsp;19, 2014. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Filed with Amendment No.&nbsp;1 to the Registrant&#146;s Registration Statement on Form S-1 on October&nbsp;9, 2014. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Filed with Amendment No.&nbsp;2 to the Registrant&#146;s Registration Statement on Form S-1 on November&nbsp;7, 2014. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">Filed with Amendment No.&nbsp;3 to the Registrant&#146;s Registration Statement on Form S-1 on February&nbsp;17, 2015. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">Filed with Amendment No.&nbsp;5 to the Registrant&#146;s Registration Statement on Form S-1 on August&nbsp;12, 2015. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">To be filed by amendment. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#134;</TD>
<TD ALIGN="left" VALIGN="top">Portions of this exhibit (indicated by asterisks) have been omitted pursuant to a request for confidential treatment pursuant to Rule 406 under the Securities Act of 1933. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">#</TD>
<TD ALIGN="left" VALIGN="top">Indicates management contract or compensatory plan. </TD></TR></TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.6
<SEQUENCE>2
<FILENAME>d693329dex36.htm
<DESCRIPTION>EX-3.6
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.6</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.6 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF AMENDMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FIFTEENTH AMENDED AND
RESTATED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF INCORPORATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXAGEN DIAGNOSTICS,
INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Exagen Diagnostics, Inc. (the &#147;<B><I>Corporation</I></B>&#148;) originally filed its Certificate of Incorporation with the
Secretary of State of Delaware on November&nbsp;17, 2003, and is organized and existing under the General Corporation Law of the State of Delaware, hereby certifies as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. That the Board of Directors of said Corporation duly adopted resolutions proposing and declaring advisable the following amendment to the
Fifteenth Amended and Restated Certificate of Incorporation (as amended, the &#147;<B><I>Certificate</I></B>&#148;) of said Corporation. The resolutions setting forth the proposed amendments are as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">RESOLVED, that Part A of Article Fourth of the Certificate is hereby amended and restated in its entirety as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;A. The Corporation is authorized to issue two classes of stock: Common Stock and Preferred Stock. The total number of shares which the
Corporation may issue is 441,000,000 shares, of which: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) 1,800,000 shares are Series A-3 Convertible Preferred Stock and
of a par value of one-thousandth of one cent ($0.001) each (hereinafter referred to as the &#147;<U>Series A-3 Preferred Stock</U>&#148;); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) 49,700,000 shares are Series B-3 Convertible Preferred Stock and of a par value of one-thousandth of one cent ($0.001)
each (hereinafter referred to as the &#147;<U>Series B-3 Preferred Stock</U>&#148;); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) 42,500,000 shares are Series C
Convertible Preferred Stock and of a par value of one-thousandth of one cent ($0.001) each (hereinafter referred to as the &#147;<U>Series C Preferred Stock</U>&#148;); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) 117,500,000 shares are Series D Convertible Preferred Stock and of a par value of one-thousandth of one cent ($0.001) each
(hereinafter referred to as the &#147;<U>Series D Preferred Stock</U>&#148;); and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) 229,500,000 shares are Common Stock
and of a par value of one-thousandth of one cent ($0.001) each (hereinafter referred to as the &#147;<U>Common Stock</U>&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of authorized shares of Common Stock may be increased or decreased (but not below the number of shares of Common
Stock then outstanding) by the affirmative vote of the holders of a majority of the outstanding stock of the Corporation entitled to vote (voting together on an as-if-converted basis).&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. That thereafter, pursuant to a resolution of the Board of Directors and in lieu of a meeting of stockholders, the stockholders gave their
approval of said amendment by written consent in accordance with the provisions of Section&nbsp;228 of the General Corporation Law of the State of Delaware. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. That the aforesaid amendment was duly adopted in accordance with the provisions of Sections
242 and 228 of the General Corporation Law of the State of Delaware. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. That said amendment shall be executed, filed and recorded in
accordance with Section&nbsp;103 of the General Corporation Law of the State of Delaware. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, Exagen Diagnostics, Inc. has caused this Certificate of Amendment to be
signed by an authorized officer thereof, this Fifth day of October, 2015. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Exagen Diagnostics, Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Ron Rocca</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Ron Rocca</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">President and Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.7
<SEQUENCE>3
<FILENAME>d693329dex47.htm
<DESCRIPTION>EX-4.7
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.7</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.7 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THIS NOTE AND THE SECURITIES ISSUABLE UPON THE CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
&#147;<B>ACT</B>&#148;), OR UNDER THE SECURITIES LAWS OF CERTAIN STATES. THESE SECURITIES MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS PURSUANT TO
AN EFFECTIVE REGISTRATION STATEMENT OR AN EXEMPTION THEREFROM. THE ISSUER OF THESE SECURITIES MAY REQUIRE EVIDENCE REASONABLY SATISFACTORY TO THE ISSUER THAT SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION OTHERWISE COMPLIES WITH THE ACT AND
ANY APPLICABLE STATE SECURITIES LAWS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THE SALE OF THE SECURITIES WHICH ARE THE SUBJECT OF THIS NOTE HAS NOT BEEN QUALIFIED WITH THE COMMISSIONER OF
CORPORATIONS OF THE STATE OF CALIFORNIA OR ANY OTHER STATE AND THE ISSUANCE OF SUCH SECURITIES OR THE PAYMENT OR RECEIPT OF ANY PART OF THE CONSIDERATION FOR SUCH SECURITIES PRIOR TO SUCH QUALIFICATION IS UNLAWFUL, UNLESS THE SALE OF SUCH SECURITIES
IS EXEMPT FROM QUALIFICATION BY SECTION 25100, 25102 OR 25105 OF THE CALIFORNIA CORPORATIONS CODE OR SUCH PROVISIONS OF THE CORPORATIONS CODE OF ANY SUCH OTHER STATE. THE RIGHTS OF THE HOLDER OF THIS NOTE ARE EXPRESSLY CONDITIONED UPON SUCH
QUALIFICATION BEING OBTAINED, UNLESS THE SALE IS SO EXEMPT. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THIS NOTE AND THE INDEBTEDNESS EVIDENCED HEREBY IS SUBORDINATED IN THE MANNER AND TO THE
EXTENT SET FORTH IN THE SUBORDINATION AGREEMENT, DATED AS OF [OCTOBER <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>], 2015, BY THE INVESTOR (DEFINED BELOW) IN FAVOR OF THE LENDERS (AS DEFINED IN THE SUBORDINATION AGREEMENT), AND THE HOLDER
OF THIS NOTE, BY ITS ACCEPTANCE HEREOF, SHALL BE BOUND BY THE PROVISIONS OF SUCH SUBORDINATION AGREEMENT (AS AMENDED FROM TIME TO TIME). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXAGEN DIAGNOSTICS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONVERTIBLE PROMISSORY NOTE </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><U></U>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>,&nbsp;2015</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I></I></B>FOR VALUE RECEIVED, Exagen Diagnostics, Inc., a Delaware corporation (the
&#147;<B><I>Company</I></B>&#148;) promises to pay to <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, or its registered
assigns (&#147;<B><I>Investor</I></B>&#148;), in lawful money of the United States of America the principal sum of
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</U>Dollars ($<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>) (the &#147;<B><I>Issue Price</I></B>&#148;), or such lesser amount as shall equal
the outstanding principal amount hereof, together with interest from the date of this Convertible Promissory Note (this &#147;<B><I>Note</I></B>&#148;) on the unpaid principal balance at a rate equal to 10%&nbsp;per annum, computed on the basis of
the actual number of days elapsed and a year of 365 days. This Note is one of a series of notes (the &#147;<B><I>Notes</I></B>&#148;) issued pursuant to that certain Note and Warrant Purchase Agreement dated [October
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>], 2015 by and among the Company and the entities and persons listed on the Schedule of Investors thereto (the &#147;<B><I>Agreement</I></B>&#148;), and the Investor and the Company shall be
bound by all the terms, conditions and provisions of the Agreement. <B><I> </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a statement of the rights of Investor
and the conditions to which this Note is subject, and to which Investor, by the acceptance of this Note, agrees: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <B>Payments.</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I></I>(a) <I>Interest</I>. Accrued interest on this Note shall be payable at maturity.<I> </I></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Payment.</I> Subject to the provisions of Section&nbsp;1(d) regarding consent and
Section&nbsp;4 regarding conversion of this Note, the Issue Price plus all accrued but previously unpaid interest thereon shall become due and payable (i)&nbsp;on the later of (x)&nbsp;[October
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, 2016]<SUP STYLE="font-size:85%; vertical-align:top">1</SUP> (the &#147;<B><I>Initial Maturity Date</I></B>&#148;), or (y)&nbsp;if the Majority in Interest of Investors elect, on behalf of all
holders of the Notes, to extend the Initial Maturity Date by one (1)&nbsp;additional year upon prior written notice to the Company, which notice shall be delivered to the Company at least five days prior to the Initial Maturity Date, [October
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, 2017]<SUP STYLE="font-size:85%; vertical-align:top">2</SUP> (the &#147;<B><I>Maturity Date</I></B>&#148;), or (ii)&nbsp;when, upon the occurrence and during the continuance of an Event of
Default, such amounts are declared due and payable by Investor or made automatically due and payable, in each case, in accordance with the terms hereof. Payment shall be made at the offices of Investor, or such other place as Investor shall have
designated to the Company in writing, in lawful money of the United States of America. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I></I>(c) <I>Voluntary Prepayment</I>. Upon the
consent of the Majority in Interest of Investors, the Company may prepay this Note in whole or in part, provided that (i)&nbsp;any prepayment of this Note may only be made in connection with the prepayment of all Notes on a pro rata basis, based on
the respective aggregate outstanding principal amounts of each such Note and (ii)&nbsp;any such prepayment will be applied first to the payment of expenses due under this Note, second to interest accrued on this Note and third, if the amount of
prepayment exceeds the amount of all such expenses and accrued interest, to the payment of principal of this Note.<I> </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I></I>(d)
<I>Consent of Lenders</I>. Notwithstanding anything herein to the contrary, the Company may not, at any time any Obligations (as defined in the Term Loan Agreement (as defined below)) remain outstanding, pay any amounts to the Investor pursuant to
Section&nbsp;1(b) or 1(c) hereof unless (i)&nbsp;it has first obtained the written consent of the Lenders (as defined in the Term Loan Agreement) to such payment, or (ii)&nbsp;all Obligations shall have been indefeasibly paid in full in cash (other
than inchoate indemnity or reimbursement obligations or the Warrant Obligations (as defined in the Term Loan Agreement)) (the &#147;<I></I><B><I>CRG Discharge</I></B><I></I>&#148;); <U>provided</U>, <U>however</U>, that with respect to
Section&nbsp;1(b), in the event that the written consent of the Lenders is not obtained prior to the Maturity Date and the CRG Discharge has not occurred as of the Maturity Date, the Investor shall be deemed to have elected to convert this Note
pursuant to Section&nbsp;4(b)(iii)(B) without any further action required on the part of the Investor. <I> </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <B>Events of
Default.</B> The occurrence of any of the following shall constitute an &#147;Event of Default&#148; under this Note: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I></I>(a) <I>Breach
of Covenant</I>. A breach of any covenant or obligation of the Company, after written notice by Investor to the Company, which the Company has not cured within 7 days after receipt of such notice, unless otherwise waived by a Majority in Interest of
Investors; <I> </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I></I>(b) <I>Failure to Pay</I>. The Company shall fail to pay (i)&nbsp;when due any principal payment on the due
date hereunder or (ii)&nbsp;any interest payment or other payment required under the terms of this Note on the date due;<I> </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">NTD: Insert date that is one year after issuance of Note. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">NTD: Insert date that is two years after issuance of Note. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I></I>(c) <I>Voluntary Bankruptcy or Insolvency Proceedings</I>. The Company shall
(i)&nbsp;apply for or consent to the appointment of a receiver, trustee, liquidator or custodian of itself or of all or a substantial part of its property, (ii)&nbsp;admit in writing its inability to pay its debts generally as they mature,
(iii)&nbsp;make a general assignment for the benefit of its or any of its creditors, (iv)&nbsp;be dissolved or liquidated, (v)&nbsp;commence a voluntary case or other proceeding seeking liquidation, reorganization or other relief with respect to
itself or its debts under any bankruptcy, insolvency or other similar law now or hereafter in effect or consent to any such relief or to the appointment of or taking possession of its property by any official in an involuntary case or other
proceeding commenced against it, or (vi)&nbsp;take any action for the purpose of effecting any of the foregoing; or<I> </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I></I>(d)
<I>Involuntary Bankruptcy or Insolvency Proceedings</I>. Proceedings for the appointment of a receiver, trustee, liquidator or custodian of the Company, or of all or a substantial part of the property thereof, or an involuntary case or other
proceedings seeking liquidation, reorganization or other relief with respect to the Company or any of its Subsidiaries, if any, or the debts thereof under any bankruptcy, insolvency or other similar law now or hereafter in effect shall be commenced
and an order for relief entered or such proceeding shall not be dismissed or discharged within 45 days of commencement.<I> </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.
<B>Rights of Investor upon Default.</B> Upon the occurrence of any Event of Default (other than an Event of Default described in Sections 2(c) or 2(d)) and at any time thereafter during the continuance of such Event of Default, Investor may, with
the written consent of a Majority in Interest of Investors, by written notice to the Company, declare all outstanding Obligations payable by the Company hereunder to be immediately due and payable without presentment, demand, protest or any other
notice of any kind, all of which are hereby expressly waived, anything contained herein or in the other Notes to the contrary notwithstanding. Upon the occurrence of any Event of Default described in Sections 2(c) and 2(d), immediately and without
notice, all outstanding Obligations payable by the Company hereunder shall automatically become immediately due and payable, without presentment, demand, protest or any other notice of any kind, all of which are hereby expressly waived, anything
contained herein to the contrary notwithstanding. In addition to the foregoing remedies, upon the occurrence and during the continuance of any Event of Default, Investor may, with the written consent of a Majority in Interest of Investors, exercise
any other right power or remedy granted to it or otherwise permitted to it by law, either by suit in equity or by action at law, or both. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"><B>Conversion.</B> </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I></I>(a) <I>Automatic Conversion</I>. In the event the Company
completes, prior to the Maturity Date, an initial public offering pursuant to an effective registration statement filed under the Securities Act, covering the offer and sale of Common Stock (an &#147;<I></I><B><I>IPO</I></B><I></I>&#148;), the Issue
Price plus all accrued and previously unpaid interest thereon shall be automatically converted into that number of fully paid and nonassessable shares of the Company&#146;s Common Stock as is equal to the Issue Price plus all accrued and previously
unpaid interest thereon divided by the IPO Conversion Price. The shares of Common Stock shall be issued contemporaneously with, but in a separate transaction from, the closing of the IPO, and shall be deemed to be &#147;restricted securities&#148;
under the federal securities laws. <I> </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I></I>(b) <I>Optional Conversion at Election of Investor</I>. <I> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) Upon the occurrence of a Change of Control, the Majority in Interest of Investors may elect, on behalf of all holders of the Notes, to
receive the following: (A)&nbsp;the repayment of this Note in accordance with Section&nbsp;1(b) above; or (B)&nbsp;that number of fully paid and nonassessable shares of Series D Preferred Stock, as is equal to the Issue Price plus all accrued and
previously unpaid interest thereon divided by the then-applicable Conversion Price (as defined in the Company&#146;s Fifteenth Amended and Restated Certificate of Incorporation, as the same may be amended from time to time) for the Series D
Preferred Stock. The Company agrees to use commercially reasonable efforts to obtain the requisite approvals to authorize sufficient Series D Preferred Stock in the event of any such conversion pursuant to this Section&nbsp;4(b)(i). Investor
acknowledges that any such election by the Majority in Interest of Investors in accordance with this Section&nbsp;4(b)(i) shall be binding upon Investor. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ii) In the event the Company completes an equity financing which results in aggregate gross proceeds to the Company of at least Ten Million
Dollars ($10,000,000), excluding the conversion of the Notes, and in which investors purchase shares of a newly authorized series of the Company&#146;s Preferred Stock (a &#147;<B><I>Qualified Equity Financing</I></B>&#148;), the Majority in
Interest of Investors may elect, on behalf of all holders of the Notes, the following effective as of the closing date of such Qualified Equity Financing: (A)&nbsp;to receive that number of fully paid and nonassessable shares of Series D Preferred
Stock, as is equal to the Issue Price plus all accrued and previously unpaid interest thereon divided by the then-applicable Conversion Price (as defined in the Company&#146;s Fifteenth Amended and Restated Certificate of Incorporation, as the same
may be amended from time to time) for the Series D Preferred Stock; or (B)&nbsp;that the Issue Price plus all accrued and previously unpaid interest thereon shall be converted into that number of fully paid and nonassessable shares of the newly
authorized series of the Company&#146;s Preferred Stock sold in the Qualified Equity Financing (the &#147;<B><I>New Equity Shares</I></B>&#148;) as is equal to the Issue Price plus all accrued and previously unpaid interest thereon divided by the
lowest price per share paid by investors for the New Equity Shares in the Qualified Equity Financing. Investor acknowledges that any such election by the Majority in Interest of Investors in accordance with this Section&nbsp;4(b)(ii) shall be
binding upon Investor. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iii) In the event that an IPO has not occurred prior to the Maturity Date, the Majority in Interest of Investors
may elect, on behalf of all holders of the Notes, to receive the following effective as of the Maturity Date: (A)&nbsp;the repayment of this Note in accordance with Section&nbsp;1(b) above; or (B)&nbsp;that number of fully paid and nonassessable
shares of Series D Preferred Stock, as is equal to the Issue Price plus all accrued and previously unpaid interest thereon divided by the Optional Conversion Price. The Company agrees to use commercially reasonable efforts to obtain the requisite
approvals to authorize sufficient Series D Preferred Stock in the event of any such conversion pursuant to this Section&nbsp;4(b)(iii). Investor acknowledges that any such election by the Majority in Interest of Investors in accordance with this
Section&nbsp;4(b)(iii) shall be binding upon Investor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I></I>(c) <I>Election of Investor Upon a Liquidation</I>. Upon the occurrence of
a Liquidation (as defined in the Company&#146;s Fifteenth Amended and Restated Certificate of Incorporation, as the same may be amended from time to time), the Majority in Interest of Investors may elect, on behalf of all holders of the Notes, to
receive the following: (i)&nbsp;the <I> </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
repayment of this Note in accordance with Section&nbsp;1(b) above; or (ii)&nbsp;that number of fully paid and nonassessable shares of the Series D Preferred Stock as is equal to the Issue Price
plus all accrued and previously unpaid interest thereon divided by the Optional Conversion Price. Investor acknowledges that any such election by the Majority in Interest of Investors in accordance with this Section&nbsp;4(c) shall be binding upon
Investor. The Company agrees to use commercially reasonable efforts to obtain the requisite approvals to authorize sufficient Series D Preferred Stock in the event of any such conversion pursuant to this Section&nbsp;4(c). The Company shall provide
Investor with written notice of a Liquidation at least ten (10)&nbsp;days prior to the occurrence of such event, which notice shall describe the material terms and conditions of such Liquidation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I></I>(d) <I>Conversion Procedure. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) <U>Conversion Pursuant to Section&nbsp;4(a)</U>. If this Note is to be automatically converted pursuant to Section&nbsp;4(a), written
notice shall be delivered to Investor at the address last shown on the records of the Company for Investor or given by Investor to the Company for the purpose of notice, notifying Investor of the conversion to be effected, specifying the IPO
Conversion Price, the principal amount of the Note to be converted, together with all accrued and unpaid interest, the date on which such conversion is expected to occur and calling upon such Investor to surrender to the Company, in the manner and
at the place designated, the Note. In connection with any potential IPO, Investor hereby agrees to execute and deliver to the Company or the underwriters in any such IPO a 180-day lock-up agreement. Investor also agrees to deliver the original of
this Note (or a notice to the effect that the original Note has been lost, stolen or destroyed and an agreement acceptable to the Company whereby the holder agrees to indemnify the Company from any loss incurred by it in connection with this Note)
at the closing of such IPO for cancellation; <U>provided</U>, <U>however</U>, that upon the closing of the IPO, this Note shall be deemed converted and of no further force and effect, whether or not it is delivered for cancellation as set forth in
this sentence. The Company shall, as soon as practicable thereafter, issue and deliver to such Investor a certificate or certificates (or book-entry statement) for the number of shares to which Investor shall be entitled upon such conversion,
including a check payable to Investor for any cash amounts payable as described in Section&nbsp;4(d)(v). Upon conversion of this Note pursuant to Section&nbsp;4(a), the Persons entitled to receive the shares issuable upon such conversion shall be
treated for all purposes as the record holder of such shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ii) <U>Conversion Pursuant to Section&nbsp;4(b)(i)(B)</U>. The Company
shall provide the Investor with written notice of a Change of Control at least fifteen (15)&nbsp;calendar days prior to the occurrence of such Change of Control (the &#147;<B><I>Change of Control Conversion Date</I></B>&#148;), at the address last
shown on the records of the Company for Investor or given by Investor to the Company for the purpose of notice, which notice shall describe the material terms and conditions of such Change of Control and the then-applicable Conversion Price, and
thereafter the Investor shall provide the Company such Investor&#146;s written election under Section&nbsp;4(b)(i) at least five (5)&nbsp;days prior to the Change of Control Conversion Date, provided that if no such election is made by the Majority
in Interest on behalf of all holders of the Notes, this Note shall be repaid in accordance with Section&nbsp;1(b) above. If this Note is converted pursuant to Section&nbsp;4(b)(i)(B), Investor agrees to deliver the original of this Note (or a notice
to the effect that the original Note has been lost, stolen or destroyed and an agreement acceptable to the Company whereby the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
holder agrees to indemnify the Company from any loss incurred by it in connection with this Note) upon the occurrence of such Change of Control for cancellation, and the Company shall, as soon as
practicable thereafter deliver to such Investor a certificate or certificates for (or in lieu of such certificate(s), the consideration payable pursuant to the Change in Control in respect of) the number of shares to which Investor shall be entitled
upon such conversion, including, if applicable, a check payable to Investor for any cash amounts payable as described in Section&nbsp;4(d)(v). Upon conversion of this Note pursuant to Section&nbsp;4(b)(i)(B), the Persons entitled to receive the
shares issuable upon such conversion shall be treated for all purposes as the record holder of such shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iii) <U>Conversion Pursuant
to Section&nbsp;4(b)(ii)(B)</U>. Any New Equity Shares issued to the Investor upon conversion of the Issue Price plus all accrued and previously unpaid interest thereon in accordance with Section&nbsp;4(b)(ii)(B) shall have the same rights,
preferences and privileges as the New Equity Shares purchased by the other investors in the Qualified Equity Financing, and the Investor agrees to be bound by any agreements related to the New Equity Shares that such other investors enter into in
connection with such Qualified Equity Financing. The Investor shall have no right (other than the Investor&#146;s right as a stockholder) to negotiate any of the terms or conditions upon which any New Equity Shares shall be issued, which negotiation
shall be conducted solely among the Company and the purchasers of the New Equity Shares. Written notice of any Qualified Equity Financing shall be delivered by the Company to the Investor at least fifteen (15)&nbsp;days in advance of the scheduled
closing date of the Qualified Equity Financing (the &#147;<B><I>Qualified Financing Conversion Date</I></B>&#148;), at the address last shown on the records of the Company for the Investor or given by the Investor to the Company for the purpose of
notice, which notice shall describe the material terms and conditions of such Qualified Equity Financing, and thereafter the Investor shall provide the Company written notice at least five (5)&nbsp;days prior to the Qualified Financing Conversion
Date of its election as to whether to convert this Note into such New Equity Shares in accordance with Section&nbsp;4(b)(ii)(B), provided that if no such election is made by the Majority in Interest on behalf of all holders of the Notes, this Note
shall not be converted into New Equity Shares and shall remain outstanding in accordance with its terms. If this Note is converted pursuant to Section&nbsp;4(b)(ii)(B), Investor agrees to deliver the original of this Note (or a notice to the effect
that the original Note has been lost, stolen or destroyed and an agreement acceptable to the Company whereby the holder agrees to indemnify the Company from any loss incurred by it in connection with this Note) upon the occurrence of such Qualified
Equity Financing for cancellation, and the Company shall, as soon as practicable thereafter, deliver to such Investor a certificate or certificates for the number of shares to which Investor shall be entitled upon such conversion, including, if
applicable, a check payable to Investor for any cash amounts payable as described in Section&nbsp;4(d)(v). Upon conversion of this Note pursuant to Section&nbsp;4(b)(ii)(B), the Persons entitled to receive the shares issuable upon such conversion
shall be treated for all purposes as the record holder of such shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iv) <U>Conversion Pursuant to Sections 4(b)(i), 4(b)(ii)(A),
4(b)(iii) or 4(c)</U>. Before Investor shall be entitled to convert this Note into shares of Common Stock or Series D Preferred Stock, it shall surrender this Note (or a notice to the effect that the original Note has been lost, stolen or destroyed
and an agreement acceptable to the Company whereby the holder agrees to indemnify the Company from any loss incurred by it in connection with this Note) and give written notice to the Company at its principal corporate office of the election to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
convert the same pursuant to Section&nbsp;4(b)(i), Section&nbsp;4(b)(ii)(A), Section&nbsp;4(b)(iii) or Section&nbsp;4(c), and shall state therein the amount of the unpaid principal amount of this
Note to be converted. Upon such conversion of this Note into shares of Common Stock, Investor hereby agrees to execute and deliver to the Company a purchase agreement and other ancillary agreements, with customary representations and warranties and
transfer restrictions (including, without limitation, a 180-day lock-up agreement in connection with an initial public offering). The Company shall, as soon as practicable thereafter, issue and deliver to such Investor a certificate or certificates
for the number of shares to which Investor shall be entitled upon such conversion, including a check payable to Investor for any cash amounts payable as described in Section&nbsp;4(d)(v). Any conversion of this Note pursuant to Section&nbsp;4(b)(i),
Section&nbsp;4(b)(ii)(A), Section&nbsp;4(b)(iii) or Section&nbsp;4(c) shall be deemed to have been made upon the satisfaction of all of the conditions set forth in this Section&nbsp;4(d)(iv) and on and after such date the Persons entitled to receive
the shares issuable upon such conversion shall be treated for all purposes as the record holder of such shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(v) <U>Fractional Shares;
Interest; Effect of Conversion</U>. No fractional shares shall be issued upon conversion of this Note. In lieu of the Company issuing any fractional shares to Investor upon the conversion of this Note, the Company shall pay to Investor an amount
equal to the product obtained by multiplying the applicable conversion price by the fraction of a share not issued pursuant to the previous sentence. In addition, to the extent not converted into shares of capital stock, the Company shall pay to
Investor any interest accrued as of the effective date of conversion on the amount converted and on the amount to be paid to Company pursuant to the previous sentence. Upon conversion of this Note in full and the payment of the amounts specified in
this paragraph, Company shall be forever released from all its obligations and liabilities under this Note and this Note shall be deemed of no further force or effect, whether or not the original of this Note has been delivered to the Company for
cancellation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <B>Subordination</B>. Investor acknowledges that the indebtedness evidenced by this Note is subordinated and subject in
right of payment to the prior payment in full of the indebtedness of the Company under that certain Term Loan Agreement, dated as of October&nbsp;10, 2013, among the Company and the Lenders, as the same may be amended from time to time (the
&#147;<B><I>Term Loan Agreement</I></B>&#148;). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <B>Definitions.</B> As used in this Note, the following capitalized terms have the
following meanings: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) &#147;<B>Change of Control</B>&#148; shall mean (i)&nbsp;any &#147;person&#148; or &#147;group&#148; (within the
meaning of Section&nbsp;13(d) and 14(d) of the Securities Exchange Act of 1934, as amended), becomes the &#147;beneficial owner&#148; (as defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended), directly or indirectly, of more
than 50% of the outstanding voting securities of the Company having the right to vote for the election of members of the Board of Directors, (ii)&nbsp;any reorganization, merger or consolidation of the Company, other than a transaction or series of
related transactions in which the holders of the voting securities of the Company outstanding immediately prior to such transaction or series of related transactions retain, immediately after such transaction or series of related transactions, at
least a majority of the total voting power represented by the outstanding voting securities of the Company or such other surviving or resulting entity or (iii)&nbsp;a sale, lease or other disposition of all or substantially all of the assets of the
Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) &#147;<B>Common Stoc</B><B>k</B>&#148; shall mean the Company&#146;s common stock, par value
$0.001 per share. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) &#147;<B>Event of Default</B>&#148; has the meaning given in Section&nbsp;2 hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) &#147;<B>Investor</B>&#148; shall mean the Person specified in the introductory paragraph of this Note or any Person who shall at the time
be the registered holder of this Note. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) &#147;<B>Investors</B>&#148; shall mean the investors that have purchased Notes. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) &#147;<B>IPO Conversion Price</B>&#148; shall mean a price per share equal to 80% of the price per share paid by the other purchasers of
the Common Stock sold in the IPO, <U>provided</U>, <U>however</U>, if the IPO is consummated after December&nbsp;31, 2015, &#147;IPO Conversion Price&#148; shall mean a price per share equal to 70% of the price per share paid by the other purchasers
of the Common Stock sold in the IPO. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) &#147;<B>Majority in Interest of Investors</B>&#148; shall mean Investors holding more than 50%
of the aggregate outstanding principal amount of the Notes. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) &#147;<B>Obligations</B>&#148; shall mean and include all loans, advances,
debts, liabilities and obligations, howsoever arising, owed by the Company to Investor of every kind and description, now existing or hereafter arising under or pursuant to the terms of this Note and the other Notes, including, all interest, fees,
charges, expenses, attorneys&#146; fees and costs and accountants&#146; fees and costs chargeable to and payable by the Company hereunder and thereunder, in each case, whether direct or indirect, absolute or contingent, due or to become due, and
whether or not arising after the commencement of a proceeding under Title 11 of the United States Code (11 U. S. C. Section&nbsp;101 <I>et seq</I>.), as amended from time to time (including post-petition interest) and whether or not allowed or
allowable as a claim in any such proceeding. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) &#147;<B>Optional Conversion Price</B>&#148; shall mean a price per share of Series D
Preferred Stock equal to $0.25 (subject to any stock splits, sub-divisions, stock dividends, combinations and the like affecting the Series D Preferred Stock). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) &#147;<B>Person</B>&#148; shall mean and include an individual, a partnership, a corporation (including a business trust), a joint stock
company, a limited liability company, an unincorporated association, a joint venture or other entity or a governmental authority. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k)
&#147;<B>Securities Act</B>&#148; shall mean the Securities Act of 1933, as amended. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) &#147;<B>Series D Preferred Stock</B>&#148; shall
mean the Company&#146;s Series D Convertible Preferred Stock, par value $0.001 per share. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <B>Miscellaneous</B>.<B></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Successors and Assigns; Transfer of this Note or Securities Issuable on Conversion Hereof</I>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) Subject to the restrictions on transfer described in this Section&nbsp;7(a), the rights and obligations of the Company and Investor shall
be binding upon and benefit the successors, assigns, heirs, administrators and transferees of the parties. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ii) With respect to any offer,
sale or other disposition of this Note or securities into which such Note may be converted, Investor will give written notice to the Company prior thereto, describing briefly the manner thereof, together with a written opinion of Investor&#146;s
counsel, or other evidence if reasonably satisfactory to the Company, to the effect that such offer, sale or other distribution may be effected without registration or qualification (under any federal or state law then in effect). Upon receiving
such written notice and reasonably satisfactory opinion, if so requested, or other evidence, the Company, as promptly as practicable, shall notify Investor that Investor may sell or otherwise dispose of this Note or such securities, all in
accordance with the terms of the notice delivered to the Company. If a determination has been made pursuant to this Section&nbsp;7(a) that the opinion of counsel for Investor, or other evidence, is not reasonably satisfactory to the Company, the
Company shall so notify Investor promptly after such determination has been made. Each Note thus transferred and each certificate representing the securities thus transferred shall bear a legend as to the applicable restrictions on transferability
in order to ensure compliance with the Securities Act, unless in the opinion of counsel for the Company such legend is not required in order to ensure compliance with the Securities Act. The Company may issue stop transfer instructions to its
transfer agent in connection with such restrictions. Subject to the foregoing, transfers of this Note shall be registered upon registration books maintained for such purpose by or on behalf of the Company. Prior to presentation of this Note for
registration of transfer, the Company shall treat the registered holder hereof as the owner and holder of this Note for the purpose of receiving all payments of principal and interest hereon and for all other purposes whatsoever, whether or not this
Note shall be overdue and the Company shall not be affected by notice to the contrary. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iii) Neither this Note nor any of the rights,
interests or obligations hereunder may be assigned, by operation of law or otherwise, in whole or in part, by the Company without the prior written consent of a Majority in Interest of Investors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Waiver and Amendment</I>.<I></I> Any provision of this Note may be amended, waived or modified upon the written consent of the Company
and a Majority in Interest of Investors; <U>provided</U>, <U>however</U>, that no such amendment, waiver or consent shall: (i)&nbsp;reduce the principal amount of this Note without Investor&#146;s written consent, or (ii)&nbsp;reduce the rate of
interest of this Note without Investor&#146;s written consent. Any amendment or waiver effected in accordance with this Section&nbsp;7(b) shall be binding upon each Investor (and of any securities into which this Note is convertible), and each
future holder of all such securities and the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Notices.</I> All notices, requests, demands, consents, instructions or other
communications required or permitted hereunder shall be in writing and faxed, mailed, emailed or delivered to, the receiving party at the address or facsimile number shown on the signature page of this Note or at such other address or facsimile
number as such receiving party shall have most recently furnished in writing or by email to the sending party. All such notices and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
communications will be deemed effectively given the earlier of (i)&nbsp;when received, (ii)&nbsp;when delivered personally, (iii)&nbsp;one business day after being delivered by facsimile or email
(with receipt of appropriate confirmation), (iv)&nbsp;one business day after being deposited with an overnight courier service of recognized standing or (v)&nbsp;four days after being deposited in the U.S. mail, first class with postage prepaid.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Pari Passu Notes.</I> Investor acknowledges and agrees that the payment of all or any portion of the outstanding principal amount
of this Note and all interest hereon shall be pari passu in right of payment and in all other respects to the other Notes. In the event Investor receives payments in excess of its pro rata share of the Company&#146;s payments to Investors of all of
the Notes, then Investor shall hold in trust all such excess payments for the benefit of the holders of the other Notes and shall pay such amounts held in trust to such other holders upon demand by such holders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>Payment.</I> Unless converted into the Company&#146;s equity securities pursuant to the terms hereof, payment shall be made in lawful
tender of the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I>Usury.</I> In the event any interest is paid on this Note which is deemed to be in excess of the then
legal maximum rate, then that portion of the interest payment representing an amount in excess of the then legal maximum rate shall be deemed a payment of principal and applied against the principal of this Note. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <I>Waivers.</I> The Company hereby waives notice of default, presentment or demand for payment, protest or notice of nonpayment or
dishonor and all other notices or demands relative to this instrument. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <I>Governing Law.</I> This Note and all actions arising out of
or in connection with this Note shall be governed by and construed in accordance with the laws of the State of Delaware, without regard to the conflicts of law provisions of the State of Delaware, or of any other state. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <I>Waiver of Jury Trial; Judicial Reference.</I> By acceptance of this Note, Investor hereby agrees and the Company hereby agrees to waive
their respective rights to a jury trial of any claim or cause of action based upon or arising out of this Note. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <I>Counterparts.</I>
This Note may be executed in any number of counterparts and by different parties on separate counterparts, each of which, when executed and delivered, shall be deemed to be an original, and all of which, when taken together, shall constitute but one
and the same Note. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> F<SMALL>OLLOWS</SMALL>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has caused this Note to be issued as of the date first written above. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>EXAGEN DIAGNOSTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B></B>a Delaware corporation<B></B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-size:10pt">Name: Fortunato Ron Rocca</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-size:10pt">Title: Chief Executive Officer</FONT></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1261 Liberty Way</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Vista, CA
92081</P></TD></TR>
</TABLE></DIV> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ACKNOWLEDGED AND AGREED BY INVESTOR: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[HOLDER] </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"><FONT STYLE="font-size:10pt">Title:</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">Facsimile No.:</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>d693329dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We hereby consent to the use in this Registration Statement on Form S-1/A of Exagen Diagnostics, Inc. of our report dated February&nbsp;17, 2015, relating to
the financial statements of Exagen Diagnostics, Inc., which appears in such Registration Statement. We also consent to the reference to us under the heading &#147;Experts&#148; in such Registration Statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ PricewaterhouseCoopers LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Diego, California </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">November 12, 2015 </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g693329dsp_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g693329dsp_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!217AI9@  24DJ  @    ! &F'!  !
M    &@         ! (:2 @ >    +         !,14%$(%1E8VAN;VQO9VEE
M<R!);F,N(%8Q+C Q  #_VP!#  $! 0$! 0$! 0$! 0$! 0(! 0$! 0(! 0$"
M @(" @(" @(# P0# P,# P(" P0# P0$! 0$ @,%!00$!00$! 3_VP!# 0$!
M 0$! 0(! 0($ P(#! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 3_P  1" !Q 4L# 2(  A$! Q$!_\0 'P   04!
M 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%! 0   %]
M 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*%A<8&1HE
M)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J#
MA(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3
MU-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M+/'Q%\!XZ?\ (W:?G_T;2?\ "TOAC_T47P)QT_XJ[3__ ([0VKZ+0GGF^I_
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MV*?V;-<UKP[INC:!-8Z7)X>^&OA'2[5+&UFOY49+=8H4P0B,P=F'/?FOG?\
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MXMO-8/@3Q?XZ\%(;O7M7U"1S;3Z1HLB<C#%XY)U(7 8YV\US?[(?_!LGKGQ
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ME\+ZSYQ@O](NQ)@1J\R.RYVXD9\DY%4K7-X-^S]W<9_Q#)?MW_\ 1X_PY_\
M!KXF_P#C-'_$,E^W?_T>/\.?_!KXF_\ C-?V_P $\%U!'<6TT5Q!,@E@G@D$
ML4JMR&5AP0?45,!GN!WYJKP,_:36A_#U_P 0R/[=[?*?VQOAP0P*LK:MXF(8
M'@Y'D<U]E_\ !,?_ (()?M$_L-_ME>!_VB?&_P ;OACXP\/Z!H^K6FMZ1X;A
MU3^VK\7UJT$?S3P*O,A5B2V?W9]*^Y/^"U/_  56\(_L1_ K7?A]\+_%]C=?
MM.?$2V.B^$-/TN2/4+KP1"[*+G5KM.0C1H6$*.#ND9<@@&N:_P""!EW^V?\
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M*%?\%[/VY(V^&OPL^%_BGX6:9XB46-\? /PZ/A*X:-R S?VS=H;B)%!^;RI
M=N>N:^N_V;O^")-M^QS\ /VA?VQ_VT_$UG\0?CAI_P $_$TWA_P^]ZVK:+X*
MO-1TFXM%O9[J0YN;PM<A%9MH0N?ESS7]@"QVUI 51(+2VB0L0BK;P1*!DGC
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M*BC\,8].E%<YH%%%% !1110 4?UZ^]%% !1110 4444 %%%% !1110 4444
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M3,DGIP/7TKSWQKXPN/\ @IE\;_@UH?P:T+Q3+^R;\"_&T'Q1\<_&KQ!X:O\
MP;H7Q!UZR+)IVD>'XKZ*&YNT@WO)+.D7D_O$^?.,_,OAKXQZY\#?AU_P5';P
MO%>-\2_BE^W/J'PR^%EE;6\C75]JNM:1IT$+I@918D,LAE/RC8O/(->CBL-B
ML?@,/EU=?[?[L:C;]Y)U+4U5[2@KWYM8PY5*UM/+C7I8;,'BZ7^ZQ<G&WPMJ
MG>3@NS=EIHY7L-^*'P1\2?\ !0?QQ^V%^U-X4GNKF3X#SI\.OV0]0BN?(M)]
M3\'W2WVI:A9O]X+/=P7,)QC?YN!G%?9GQF_;QUG5O^":FD?M#?"TK!\4_BK:
M:%\*]"MBHM[CPQXJ\07]MH%P[1L05-G<SS2X;'^J'%9'PG_X(_?#7P9\.O"^
M@7_QF_:'TG65T>&Z\4VGAKXKZAHNB3:G/&)-0>*V@D$0#S/*<@?-USS7Q@_[
M(VI^"-=_:4_X)H:-XBU:+3?'5A:_M1_L@>*?$MT\Z?\ "1:'=P:K/IT]V02S
MBYA5Y7X 1)#R>#Z$*F1YM.G2I5G.&%G"<8RIJ*5"/+"JK\S<U:,:DE9.W.UN
MS+V>89?"=25+EG7C)2<97;JRO*#LTK;N"WL^7M=_L%^S7^QI\"OV9_ NFV=_
MH?AGQ1\0M6MQ>>._B?XYM+;5/%OC'4ID5KN>:[N0TN"^<(#@#'%8'C[]COX(
MZS\9/A]\>_A5XKT?X'_$SPAK"2>(=2\ 26.FZ=\0]*8,MSI>KV<;)%,K_*RR
ML"R%<X.:^2I?V@?V-OVJO"/ASX:?MZW$/[/_ ,=/AGF#Q9\//BMXLN?A1#!?
MHGE3W>G:JTD5E?6TQ5F1X)I!M(/0@U\5?%G]FC]D?]H_Q=X7^ ?_  3^\/>*
M?&.NR^*[/4/BS^T#H/C/6[KX4_"_0+282WT46KRR"TO;R["K!%#9M,=LCMC"
MEAQ8/ UWBJE?,\57IUO>]K+V4:E'E=]>=U5&<)*UO=:=THIZ'36Q>$="-+"4
M:<X:<D5-QJ<RZ64>:,DUJ[JUKR:U/2?V@_V>/%7QR_X**?M4^*_A%J3:+\>?
M@G\#?!/Q*^#>LP7#1"ZOH;R\\_3'=>L5]"ODD-E2VS/&37U[\8?VDM'_ &H?
M^"5O[0?CR* Z+XTTGX8W_A#XJ>#[C]WJ7@SQ)8M;QZE93Q\%5+_O8B?O12H?
M6M']G#01X9_X*>_M0:#"UU<6>A_LM?#_ $.VO+G+RW2VES<0*S,>K$1@DYZF
MODW_ (*T?"[QY^S?X:^./[0?P:T"_P!:^&7[0_@-_A]^T5X*T8!DT_4R4&D^
M*8[;(RP D@G=<G!0G &:[\)/#8W.<MRRLTIP6&G1EMT@YTWY32YHW>DU;[;9
MRN,\'@<5F$4W"4JT:D5K]N24U;K%Z/O'7[*OH:;9ZC^U1KG[!'[$.I:MJ6D_
M!_0OV*?!WQ\^,VFZ;>RV$GC^VFTZ#3M-TB61/F$)DL;AI$. X8#/%?M=IG[/
M?P,TCPE;>!=/^$/PYA\(V=D-.AT ^#=/?3O*V[2&C,7S$CJS<GOZU^. \)_$
M?X#^'?V$/V\?A]X'U[XA^'O#?['_ (2^$7QY\(^%[-M3\66OA\Z59WEMJ=E8
MC]Y/]DDNKHR)$&DPP^7&2/T+T_\ X*5?L)ZAX.C\;?\ #3WPJL+)K(WLN@:K
MXA72O'UN5X>"3PY*%U19U.5,/V??D< UY?$E',\55BLK4IX:,IW5--\M7VDN
M?G4=5)Z.+EO"UM%IW91/"4HR>8.,:K4=9V5Z?+'EY;Z66J=OM7ONF_SN\3?#
MGQM^RU^T=\4/V.?@)K5[I?PO_:T_9[\1^,_@[X7EOY!8_"[Q/8P7@N;'2R6_
M=0W.PE$&U$^TJ,C9FN1^!'C?]A;QS^S-I'["/[0/A&']F?XS+X<C\%ZUIGQ5
M\&CP7KR^(64(-5T?7+F-8KFZ>X42Q2Q3,[,5.3D5ZI;:G\?_ -H7XQ?$3_@H
M=X ^$FN1^$?@C\&M3\$?LF>"?&UE+X;\3_%R6<33:CKC:7,HGA@F6:9;?SEC
MDD B"H?F(TOVE?VS/V$_VF/V+/$0\=>(/!7B?XG^)_!#Z7HOP5$!G^-NE^+Y
MH/)M["TT(I_:,%Q%> *LS1)&FT,74<UZ%2=;$2H4/93E5?L?:U*4KSIUHJ2O
M)6<6^1Q4E)Q]^,DY)J5^&'LZ7M:G-&,%[3V<:B]V5)VTCJFO>3:M?W7'36+6
MI_P4A^"GP^\%_LS? '3$\.^&_$&KZ;^T/\,/#M]XSO\ P]8R^(O$<2^(]+MI
M)+RZ\O?+YR;@X=B&#\YKI?VWO#'A3P7\:_\ @FU!X6\-:!X9L7_:;DO+FU\/
M:/;:+;3NOA#7LNZ0HJEL#&X@FO)OVEO#7Q&\-_\ !.W]C3P[\3DU*3Q]I?QJ
M^$\&OP7JM-J=FZ>)-*Q%<MDYDC7:KG)Y'6O?OV^K=[CXZ_\ !-=?)DEC'[2[
MK<;4+!%/A+7E.['3KCGUKP\#5KJM3HU*O.E/%*Z>CM1CJNEKW:Z:GI3A2DJE
M6%/E;C0=K6:O/9];]&>:_LK?"_1/VY/CM\9OVK_CW9P^/_"?P]^)E]\*_P!G
MSX?^(5&I>#/#%MI)\J]U,Z<Y,+7<TK &1E/$:XQ7Z'?&[]D#]G_X]^"[[P7X
MT^&WA6)9+;R]&U_1-%M=&\2^&)E'[FYL+R%%DB>,X8;2!\HSQ7YU?#WXC/\
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M;XHUW2M7^.%OXY\3:!X2\/OXHU?4M/T!1>!19(09%,JH#V YKS/]I/XGZ/\
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MX\4^(?A%IWQ=^,OQ(U?2/^$B3X=6&I'R+.QTNR=E2:\NY5N&C,S!4CMW8@D
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M1?[36L?"ZWLM+\.M^S9H?B+QMHNF6X&@6_C"\U36['3Y#;J!''<3V<%GYJJ
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4_</\A4R]!]***SENS-?%_7D?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g693329dsp_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g693329dsp_003.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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M 2(  A$! Q$!_\0 'P   04! 0$! 0$           $" P0%!@<("0H+_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% 'SY^U1^TU%^SU=^&X[G28=337$N&)>9HS'
MY9CZ8ZYW_I7E&D_\%(/!4Y4:SHFHVQ/WF@D5P/SK@/\ @K9<-!J/PS"G :'4
M<_G;U^?B7I<]_I7HT%#V:O$X*T)N;:9^O'AW]LSX3^([@D>(Y;"6<@".^@**
MGT8<5Z#_ &KH_C#3_M7AG4[#5(L;A):SK)CZXY'XU^*=I.[\1/@^A/6NK\(?
M$CQ!X%U)+CP_J=]IEPIR#%(5#?T-=$.5:['.U):'[2^#M7-U:&UN#^]M^.>I
M%=&"*_-OX8?MU:A')!;>.X'+ @'4[!@DW_ @<@_ABOKWP+\=[+5X+21[Q;NT
MOAN@E8J6(],C@D>AP:FIAG)N4!QK16DCVBD)P,FHK:ZBNK>.:W<21R*&5AT(
M-29R"3TKDL;#3ZB@MQ03Q]::1\O49I^0F@/0@]^E-I<FD)P*+V$QI84SOZTK
M#!Q2521+8QU).12+P<TKGFD_A]Z8=!&)ZD4PG<.!C\:7.129[\8JDA#6R ,=
MJ8!FE<DT@H8TM3E_&$HC5-QP":\ZUF\@B)+,,BNY^(LRV]F)'Z UX7KNH/="
M=HV(V@XKT</&\4<&*GRL]@\.:XESH%Q'$0V5.*\?\;0ND<^.IS@8K8^$?B$W
MMC+#.V2K%:L^,K-9I2 F1CTK6$>2;,)R]K23/GIKF2TF8YVGD'%9-_=95FSU
MK;\8VXM-1F"<#K7&SW!D!&376V>,H.Y"9?-EY/W>:V+;Y+($XYK'BB ?W;BM
MB9!'"$'\(I1-;:HAL;K9>A"3A_EJ&>V1-2:-ONC+9JLK@7\(/4R#^==;KNAI
M9W),IY>-6!^HIK4U2M(^_OV>!CX*^$1_U#DKT:O._P!GP!?@QX2"G(&G)S7H
ME?(U_P"++U9]I0_A1]$%%%%9&H4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110!^<?_!7"%I=2^&6WM#J6?SMZ^ K
M73B3EJ_0;_@K&ZIJ7PUW=X=1_G!7P;:L'7BO3P\5[-'+5;YB*.Q"D<?E5Z&U
MD*GRV.!V89'ZU8AA60#U[U;BA,><=#74HHYI,SFM7QDHR'^]'_A72^#/B'XC
M\#7*OHUVDL 8,T$I*@X]CWJIM  X_2EDB23@*#^%6HM.Z9A+E:LT??OP,_;>
M\+6WAA;;XG7#:-<* 4,?^D*3W^[R!WYKW/PO^TY\+_&,T<.B^,-+,\IPL5PY
MA8GT^:OR(.G M\HVYIT>DR1'>O&#D8K*=%2=RHR<5:Y^X2RK)&CQE61QE64Y
M!![@B@]>E?G9^R%^TUJO@C6[3PMXXOIK[PY?N(K>6X<LUC(> 03_  'N.U?H
MB&#J&4@AE!!!ZBN6I3=-ZFL9\R%IA;@_6G$XIA//'-9H!".>>:**2K)W&=\@
MTASN-.;@'WZ4SZTQW&9Z@4AX'M3B.::_2FA#,<T8P,9ZTOUI#2;+6ARWC[3E
MOM(?=GY1FO -<$=NLZQ+D[3QBOI^^MH[JW9)@"&XYKQ;X@^%H;::068"-C/
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 ?G?_P %77(U?X9*,X:+4<_G
M!7P=+X;5[S^T+N8Q)'@@@X((Z8-??7_!4^)9=<^&0/WO*U''YP5\!>,M09$%
MNK84#D#O7JX>WL4V<55OVMD;UG\8]8OIH-)U+4KZ^T^$!+<7,Y<Q#T!/;VK4
MU:".Y1;A$7YNI KRK1(&6X64J2 >N*]$T*ZD>)Q=W-OY4GW8BV7_  KII5')
M69RUZ48RYHD221QM^\# #O6E;R6YB9R[!4ZYK,O(%9FV'(SZT0J611C.3C [
MU2DTR79JYO64VG^8/](.>X*&NKT:YL7N4BMI'EE;&%53S7':KX4NM :UDO)+
M?==('$,<F]H@>@?L#CM72^%=&NXIX[V M"RD;".N:Z*4I7M8QJ62O<^@?!.E
MZ*NGV=VUI>ZQ)-F&]TQ+3SO-C;@E,<@@=S7U-\#6T3P3H9\*6&L--;P2&>Q@
MN3B6VB?GR6]U).!Z5\K?":TU^R\16=[X6+P!6VWGGMB-E/WACT-?2$_AZPL=
M9.HZ=8>5+=,,!!@%@!G';UHQ$%/21E0F[72/= <@%2"/YTN?2N#T*37G0%$C
M@MU[M)N/Y"MRTU(W"NT=V\HB;:W[HKSZ<UYDJ33W.].Z-[:=U-=SD^E8TGB6
M&WNQ;R2#S67(3')%68M8@F.&8(?<U/(T5?L73C&>M,)H659,%&5A[&DY!Y_E
M1L);AC%)FE:D.!EF. !DFI13T+-G;).V93A5//->=?$SQO;Z%++!IEP1< <*
MISDUUZN[6\\]RQ2'G8 <5\^_$+0M2U37&DM/EM]V0QZXS77A:2E.\F8XBI*$
M/=6IZ/H.JZ@^E)>7$JEYATSR*\^^+OA.[\4:%(\,22W$9W#CFMO1-/U4Z?%#
MII:7:!DOTKM],L)Q;B#5%7>1R5KIYE"5T8RA[6'*SY8\$?"23Q/+#!<Q/&T<
MG[Q3QQ7TCIWPVL]!T>*"VB5 B]A6JOA>/3I3>:0!',.2O]ZM*VU^*\A,%Z##
M.."&K.K5E/5;!AL)"DK/<R]#M_LS>7CY1TXKG?BMIL%YI$@F"!2IY-=3J-PF
MEPM+E2O4$&O ?C7\6X([&2RMI09<$8!Z44XN4DT:5I1A!IGRA\2M/BM]3F\I
ML!7(4BN'CUS4]+(-G<R8!^Z3D5T?B?5#J%Q(SG<>M<LQWM@\5M/?0XZ$6HZG
M6:3\3ERB:U;?./\ EJHKM;35+'7DBDTZZCWJ?NDX->,RP+(Q]J(XY;5UDMY'
MC93P5.*J-:2T>IJZ$7MH?LI^SZI3X->$E?J-.3->B5Y1^RM/+=?L]^!I;ES)
M*VDQ[F/<UZO7S59WJ2?FSWJ2M!+R"BBBLRPHHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\_O\ @J3$?[7^&\P_
MY90ZC^I@K\^M:TR74M40(I(;OBOT._X*B.!=?#]>[17_ /."OAO0;N*XO5C=
M!E><D5Z^%BI4DCSZTFJC:*=SI-OH6D*S(ID;CD5!%<1Z=IKW*HHD<<$BI/'5
MTSRPP(<C.<"J&O)(^G6MM;@EW Z"NB32;MT,HW:5^I3TK5;C4+\IC,9Y8^E=
MCIFD3W[A;=2Q!R,5B6.DKHM@H;'VB?&1WKW#X7V=AI-YI<^OINM"R&Y0G!=2
M>:NA3;TD88FHHZQ*FE^#=5U$6\=\Z-;VV7C&W W'JQ]3756%A#I,1:Y*J(N=
M[G %=KXSO=.\/?\ $NTU%N+F^N/^)?'&=SR(Y^13^=8WB+X*:MK&JV5E=:]I
M,M_<CY;"TN/,"-C[A _B]Z[ERQV/,Y:E5V>B,F+XDSI.T&ASSN\K .8?E#8X
M ]37V'^SYX4\3P::^K^-IIXDNX@+73YL, /^>A!Z'I@5S7P/_93L?!;6NK>-
M%AN]3AP\-HO,4+=BQ_B;]*^C54DCCI7!B<2I+EB=^'PRA9D:6\=K$$@C2-6.
M2J+@56N+?S#T YS^-7V(7ODU S8;+?6N!7.Y:F:]HI8LR+O/!8C)JK+IP<\*
MM:CG.2>]0E@HK6,F*QSEU8W,.XVEQ-"W;:>/RK 'Q+U+PM>B#Q3:&ZL6.%NX
M%Y3_ 'A7=RE''(^;UK&UG18;RVE,T(E!4Y!Z&MH2B])HSG![Q=CH-'UJRU^P
M2\TFXCN()/XE/0^A'8U)=N2$AC)S(>:^;/$.K:Q\'_$J7^@*?L$^&GM"<QR#
MN/8^]>W_  W\;Z;\1+/^UM+DQY:@36S'YX7[@C^M35P[A[RU1%'$*<G"6DD:
M?BF64BVT^Q4O)*0NT=:;J'@M[73-]XJM,1A5KJ= TQ/M$VJ7:Y;D19_A%0:G
M?OJ,_P O$8Z"N=59<RC'IN=7(K79Y_I5MKNF1RK;V<#0KR#G!IUCXG$DNV^C
M\J3=AB>@KMK^==/TR3GYBM<7IMK#?6DS2(K;V/-=,9J2;:,N6SLF;?GB3#0L
M&3M@UR_CRXM[;37E92LBC.Y>U1R6E[8W'_$LD+J.L;&J6O\ B*UEM6M==A-N
M[#&6'!_&KC"ST)G+1IZ'A?B3XLWULKVB2^=$P(5F/(KYY\?:C>2327$H>19"
M27'(%>S_ !B\-6NGXO-*D5A(>0K<5X3>^(;BRD>.5%FC/#(_I7?[O+V/(3FZ
MEI:V.$N+T2D@-R>O-0I\S5TEQHVF:\[/IS_8[OKY3'Y6K%OM'O=+?%U$P&?O
M@9!_&N=Q=[G?!ID;Q# *9S2I"S]N12V[%L8K6M(%?&[&35)%MV/U>_947;^S
MUX&!ZC28Z]8KRS]E]-GP"\$KZ:7'7J=?-UOXDO5GLT_@04445F6%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[T'>*84445!04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%<!\!5*_!_PJ",$:>E=_7Q>(_BR]6?7T/X4?1!11161J%%%% !1110 4444
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M"-/E)=,C:>GX5Z[X$TY_ MX+NQ5;_0[]=LW<HI]_4>M?G?$.&3A9KWNG9_\
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M4445D:!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MTK_KW6M^L'P*,>$M*![6RUO5\M5_B2]6>Q3^!!1116984444 %%%% !1110
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MAI%IU]!=)+#F!PP&S&:ZR$$+SR15M<>7SUJ6--CA*0X''XU(ESMD.0#QZ<5
MN=ZC/:A3AC]/2IL!]"^!SO\ ">EGIFW6MVL'P*?^*1TK_KW6MZOEJO\ $EZL
M]BG\""BBBLRPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=!7RM;^)+U9[%/X$%%%%9EA1110 4444 %%%% !1110 4444 %%%% !1110
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M$_??_OHUM'$8E_\ +S\$9/#8;^3\6?KPG[.O@!>?^%J61_[>;3_XJIA^SUX
M[_%"R/\ V]6O_P 57Y&QN^/OOU_O&K<2./XW_P"^C71&>)?_ "\?W(PE3PR_
MY=_BS]<K3X#?#ZV;)^)-A)];NU'_ +-6A_PISP"5Q_PL33>F,_:[;_XJOR'B
MCD)R7?\ [Z-651R1AY..VXUI;$?\_?P1FY8>.BI_BS]8;GX"_#^[.3\1K 8]
M+JU_^*JO_P ,Y_#YO^:C61_[>+7_ .*K\M(=P&-[_P#?1K1MMP'#O_WT:/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% 'YJ_\ !8%<ZG\+CZ0ZE_.WK\[40FOT6_X*^+NU/X7_ /7'4OYV
M]?GE'&1771C>*.>H]0BCQ5N*/..*;$G/2KL$73(KJA"YRSF-2, C/6K4:X/
MS3D@)Z#I4\5OSQS79"%CEE-$T );Y:TH(R<9Y-06MJ002*U+:W.>173$XJLD
M2PP8'(S5R*USC(^E2VML3VYK7LM/+LH"DYILXY3(].T=[D@1H6)/85MPZ')
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MBMYHZ'C-9=X9'CVXPK>U:VM1-@^4,'..*HMF.#;<9R>AKU*;5DT>%53NTS]
M_P!G)!'\%/":C^&P4?J:])KSG]G="GP9\+!CD_85_F:]&KX?%?QY^K_,_3L
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M7J<= *R6U@3PP_V?+97+P$E7G&Q-X/4^U)KVKFZCD33YI)G $1AM0,D^A;'
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MZ)!>++&4<D@C%0VVFVME.;E?OCFL2ROB0.:TWN#);.J_>(J8IK1#45<Q]?\
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M,7WB"//17))'H<YXK+L_'EM;W 1F4G->A:+K\-] KJR]*F4)1+==E:R\#P(
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M:^*Q'\:?J_S/O,-_!AZ+\@HHHK$W"BBB@ HHHH **** "BBB@ HHHH ****
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MGW>&_@P]%^04445B;A1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MCXSU#3$V1SN0/4U]F'_@FQI^/^1[U'_P71__ !5,/_!-73R?^1[U'_P6Q_\
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M_P $[+ ?\SOJ'_@O3_XJJ6;87^;\&+^R<9_+^*/C2>?C@UDW4V2>>E?<#_\
M!.JP?KXWU#_P7I_\55=_^";VGN<GQSJ/_@NC_P#BJ;S;"?S?@R?[(QK?P_BO
M\SX2N'ZGUJLDA5LYK[OD_P"":NG/_P SUJ/_ (+H_P#XJF'_ ()GZ=_T/>H_
M^"V/_P"*J?[5PO\ -^#*64XVVL?Q1[]^RDV[]GSP4?73E_F:]:KD?A5X"C^&
M'@'1?"]O=O?Q:/;B%;ET"-)@]2!P*ZZOE*TE*K*2V;9]?0BXTHQ>Z2"BBBLS
M4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MA_44]E\T)6/6''(Q4;G+9J1LY'I4+=ZZ"$,DZ-]*@?O]*FD/7'I4#'!Y]*:
M8<X%1GZ5(3T J-L"K6A(S.:8W.:?]:8W%3$;(SWJ)_NCGO4AXS]*B?L*M"(7
MYZ5 V=QQV%6'.0:KL!EC5H2/LGP"/^**T/\ Z\8O_016_6!X"_Y$K1/^O&+_
M -!%;]?"U?XDO5GV%+X(^@4445F:!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% '"?$S[^G_23_ -EKB".E=O\
M$O\ UFG_ $D_]EKB">AKZ/ ?P(_UU/E\P_WF7R_)$3?>I@ZTYC\_)I!ZUV+<
MX^@V3J:0'M2N,DTT#G-2MAH8PRU1'H,U,QY-0M3 :3G I.C4[@8I@.YB:I;
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M"BBBLS0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH X3XF?ZS3_ *2?^RUQ!''TKM_B9_K-/^DG_LM<1C&:^CP/
M^[Q_KJ?+YC_O,OE^2(9#SBFBGR=_K31U^M=AQ".>M,SBG2?>Q^-(1DU*V+1&
M3EC43=14C\&HFXQBF(,9(I  IXI5ZY-(IZYII; 5VYD''2HV/S,<U-G,IQVJ
M!N_O3 BDY KR?XJKN\<^%<^D_P#2O6'YQ7EGQ,C#^._#'?;'-_2IG\)4=SI)
M  W'0 =:81[8J60?-C/0"HWX-:6#H0NF2*XY1_Q?:R/?^PY1_P"/"NT89Q7'
MJ,_'2T8< :'+_P"A"IGT]45$]);[QR3[5$2,\U+C/7M41%;"(W&%-5WJ=N<_
M6H'XIK82&GK4;<5F:_XGTSPVL3:U=K:B=ML8()+GT %9C>/M(928I;EQCJ+9
M\?RH<TM Y6=$W2HWZ5SJ>/=&()ENVA"]?-B90/TK<BN([F))8&#QR ,C \$&
MB+$T.8YSV[5&QP3[5(RU$W\5:HD@>JY&5'N:G<\9J#L/K5H$?9G@+_D2M$_Z
M\8O_ $$5OU@> ?\ D2M$_P"O&+_T$5OU\)6_B2]6?84OX<?0****S- HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@#A/B9]_3_I)_[+7$9KM_B;]_3_ *2?^RUQ'?FOH\#_ +O'^NI\OF%OK,OE
M^2(7Y8T@%+)]XXI :[$<0UOF;-%!ZT5)1$WWCZ5"]3-]XU$PR:8#0<8I!U-.
MQ3 <4T!#TE..G_UJA/WC[U(#N=OQJ-N<YI@B-Z\R^(2%_'?AS X$4W\Q7IK"
MO-O'(W^/= Z_+!+Q^(I36A4=S>E7#GZ"HF7%6)^)".]0MUYK1#Z$9Y%<C$I_
MX79;$]/[$D_]#%=@P^7CUKD[<?\ %Y(6/;17_P#0Q2J=!Q/03P3S4;=*>^.K
M#-,;GZ5;)1 W\Z@;D5._#?2H7.<8JEL,X+XEVJ2S^'GD169-34 GL"#FM&?3
MH2Q 4@>@)J+XB1JZZ-O.-NIQX_6M*5<,?:ITYF'0XCQII\,6B:@0IPUN<C/O
M7<Z2@CTRS6,806Z #_@(KC_'8SH5Z#_SQ-=GIH_XEUG_ -<$_P#015))-B>Q
M,W7\:C<XS4I(X)J%^<XK5$HA<9!]JK]#CVJQ(>#[U6(&>*M"Z'V=X!_Y$G0_
M^O"+_P!!%;]8'@'_ )$K0_\ KQB_]!%;]?"5?XDO5GV%+^''T"BBBLS0****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MAE.%_&JS< X[5/-PO/K4'(!JT)'V?X .?!.AY_Y\8O\ T$5OU@> ?^1)T/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH **** "BBB@ HHHH \_^*?#Z<?:3_V6N"SQ7>?%,XDT[Z2?^RUP1..IKZ3
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M- HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHI,T +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:S\41*1_8&K[!T;^V8>?_'*8VK?%1LB+0+\?[^MP_P#Q%>^G:3@J/RI'49X
M&*/9/^9_A_D/VB['@8U'XJA<G1+K/H=9B/\ [)3X]0^*[?>TP0C_ &M2B?\
M]DKW9P!R0.E02*H'./RH5)_S/\/\@51=CPG6=9^+EI;AM/LM+E8#)$TZ #ZG
M;73_  F\5^*/$J7;>,+'3H4M7\M;FTE)$CCJ,'T]:[CQ' L^F2!P.@K!^&T*
MP>&55 .;F5CQW+&B,&JGQ,JZ<=CJ';)-?#O_  4,!?7_  CMZ"TFS\N?XJ^X
M6Y!]Z^)_V_0)=?\ "J H-UK(,OT'SUEF6F%D=.7_ .\1.U^ $H_X12SCV2*4
MB7DQ[ >.WK7KC#@^W%>1_!=H=)\(6!N[FW56C!#+\JGCM7JT%S%=VZS6KK)$
MXRK*>#7\^R?[V3\V?2XM/GN?/?[2?RZ5SQ^_C_\ 0A76_ * _P#"U=1E;_H"
M1C/_  *N2_:6^;2F(( ,J8S_ +PKL_@#_P E%U#+ _\ $FBX_&OT;@I7H_\
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M%1<2#C_>J8O]X7]DZYFP,BOA3_@H)=;?%7AF/&=EE(03S@[J^Y&?@^E?"O\
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M?</['Q'_  J=O^PI<?\ H5>EE^(JRS>I"4FXVV/:Q4(PIP2ZGN+$'.*^(?\
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M&XY XKN/'_B&7PKX2U#5+1(WN;=%%NK]&D=@J@_BPI-V5R*DXTX.<MEJ=$7
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ME"+ND%%%%9FAYI\8<>9I>[^[+_[+7FN>/:O2?C'_ *S2_P#=E_\ 9:\U;W(
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ME?Y$BG+QGGN5A8<>JBH=9^$TVDZYIEYHEE>:O:6^F&S9(-9DT^:.0N7:8LK
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MU>E,]&\6$^?98/ MQ_.M/X=3.GBO2L.X!G (#'D>E4_$&EWEZ]I):VTTR"
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M#L$$(P+:(DR,0"I,G3ZBOK,!)5,9*O&_*E^/Y'M5ZDY\JEO^G0]H^*?Q4M?
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MM'!'3FL^?68$C/F2K\GX5S^J>+H4B;R&'(Y).*TE/0X,+E]1S3DBCXOOE8E
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MOX<?1!11169H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/O#O_8.A_P#0!735\%6_B2]6?:TOX<?1!11169H%%%% !1110 4444 %%%%
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M_&>_/_"+:O\ ]^!_C7W715?VM4_E1M'(J*^T_P #X63X/>-%?/\ PB^K]/\
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M3_!&A6M_"]O<V]A$DL3C#(P49!]ZZ&BBO%G+FDY=SUHQY8I=@HHHJ2@HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
$B@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g693329dsp_084b.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g693329dsp_084b.jpg
M_]C_X0FS17AI9@  34T *@    @ # $   ,    ! %$   $!  ,    ! $
M  $"  ,    #    G@$&  ,    !  (   $2  ,    !  $   $5  ,    !
M  ,   $:  4    !    I $;  4    !    K $H  ,    !  (   $Q  (
M   >    M $R  (    4    TH=I  0    !    Z    2  "  (  @ #J8
M   G$  .I@   "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q
M-3HQ,3HQ," Q.3HP,3HP.      $D   !P    0P,C(QH $  P    '__P
MH ( !     $   !9H , !     $   !#          8! P #     0 &   !
M&@ %     0   6X!&P %     0   78!*  #     0 "   " 0 $     0
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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M#6.<3  ))7!OZ;UO+ZIZS*K',>_<VTZ-V@I$TQ9LIQ\/# S,CT>RNLS,BO\
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M$DE/U.DOEA))3__9_^$,M6AT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\
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M(" @(" @(" \/WAP86-K970@96YD/2)W(C\^_^T15%!H;W1O<VAO<" S+C
M.$))30/M       0 &     !  $ 8     $  3A"24T#\P      "0
M     0 X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:
M  8       $ ,@    $ 6@    8       $ -0    $ +0    8       $X
M0DE- _@      '   /____________________________\#Z     #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z   .$))300$       /
M' %:  ,;)4<< @   @   #A"24T$!@      !P (     0$ .$))300(
M   0     0   D    )      #A"24T$"@       0  .$))300,      A)
M     0   %D   !#   !#   1B0   @M !@  ?_8_^T #$%D;V)E7T--  +_
M[@ .061O8F4 9(     !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5
M$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.
M#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,
M# P,# P,# P,# P,# S_P  1" !# %D# 2(  A$! Q$!_]T !  &_\0!/P
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MEA))3__9 #A"24T$#0      !    !XX0DE-!!$       $! #A"24T$%
M    !     $X0DE-!!D       0    >.$))300:      -%    !@
M        0P   %D    ( &0 <P!P %\ ,  X #0 8@    $
M             0              60   $,                      0
M                       0     0       &YU;&P    "    !F)O=6YD
M<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<          $QE
M9G1L;VYG          !"=&]M;&]N9P   $,     4F=H=&QO;F<   !9
M!G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '<VQI
M8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE;G5M
M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M
M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M0G1O;6QO;F<   !#     %)G:'1L;VYG    60    -U<FQ415A4     0
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M:6=H=$]U='-E=&QO;F<      #A"24T$'@      !      X0DE-!"$
M %4    ! 0    \ 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '     3
M $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P "  0P!3 #8    ! #A"
M24T$)0      $,W/^GVHQ[X)!7!VKJ\%PTXX0DE-!"8       X
M    /X   #A"24T$*       #     (_\        #A"24T$.@      Y0
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M;G,    7     $-P=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP
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M;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D
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MWL;OV?YBW9K")=P_>)*N!5E!,?:&XT%2 /GT\;F=>;;';Q</]&EI70#12>X
MT_(?*G2>^=G?G='R,^>C_ ;8?=-3\8.KNLNN#VCVAV'BZH4NY]UQ5$$E2*+
M.7B:I^UHXVC-.K?VBWU ]^Y<V[8.5>1QS]N^VK?[DUP8XHF_LU7X6,G$ Z26
M!;%0!QZ1[QNLTNZ7.U+>FTL8(#+-**:J :NSUX9IY>72T^ /\MWL796\MK?)
M]_E+V^^+R^9SM1FNOL^\C0;^V[!>CV[D\U-)4&9WD>,SI&5*B-Q8^PIN'/-M
MN^R7.V-R5M]F79?#EC%) JY#$@=Q?A4GAGHF]OMJNKEY>;[JZ?QKMG 5EHSQ
M@E8VD/FU!J&* &G07_S/:KNCLC^8_P#$CXT[$^079?2.U.UZ'*8W,5>P,G44
M[1/%1/6QU9H(I(DJIU:F*C41;5>_L<>W7[LVSD/G#FBYV:WNKRVD7$H##350
M%%:Z::B:@9Z/N8&N;G>MEVN.]E@MY5:I3#&E?\W1E=N?RA^X]O[EV[GZC^91
M\I<M2X'/8O,U&'K)0:++4^,KH:V7&5O^Y-[TF02#Q2\'T,;>TEY[I[3=65W:
MKR'81O)$Z:U JI92 R]G%:U'SZ5P\N744J2MOURX!':>! X@_(CJSO:_3NXM
MN=ES[ZD[9W1F]OSXZ2ECV%D(U?%15TM+]N:]:HR,X8&[A=-@WY]Q'+<0M9K;
MM9()D:JN"=6D\0PX&I\_+H0K&XE,HE/A,,J>%1BH/ECH=?:#IWK_TMV_Y%=Q
MX'X_]'=F]O[BR$&+HME;4R^3IZJJ(\3Y<44R8JF-_P"U4UY1%']3[6[)M5QN
M^Z6.UV\9,LLBCU[:Y/Y#/2*YN([*WEGD8:46O&E2,@5/KPZU*_@/\OOBCL+X
MS?(O"?(;;'?.7[5^6NXM_;FWOD,)U+N/<N-H8-WU-8::DQ6;BIGBFIAY$E)4
MD"Y ]Y'<]<K<P[ES!LG[GO-OBM-I@A$1DN$0ZE.>P\#10/L(ZC[8MUVZ+;=S
M^JM[D374CEET,V&KITGS K0?,=6*?\)Z_D!0;PZ+[7^*V8FKY:KHG>F;&UL9
MFZ2?%UU/UEN6KF? XF;&5H2I@J8H26EB*WC\AO\ 7V"?>O:I+??[#F'L$-[;
MI4H=598Q^H01@@DBF<@5\NC+D6],]A<V+1L/IY*#5@Z6R 1Y4IG[>D_\-'/P
MA_FZ?+/XU9^=,-UKW_C*#NC8]1)((L7/E,E2R5_\-HE.E6.-ID:.8C]#<'VY
MS,&YF]J^5N8NXWNWL;>0,0S,H;2)'/$!B0:>0ZKMSQ[;SANVVAP$N4$@ %!J
MI4Z?(T&.GC^7W1Y/YI_S.OEM\X-PTKU6Q.D,@>B^GJJ4>FARF,B2FS=/2"2Y
M>AFH]%2K+QJGO]3[9YO=.5/;_E;E.VD47MZOU5S3\2$_IFHP36J>M$'3VRJ^
M[[_NV\SAO"@/@1+P TGNQ\\'Y5ZX?(?_ +B >CSSQ\:]MWMQ8G<V=M>W!*VO
M_L??K !O8[F'^']X#\\Q=;D(_K]:BAT_1?Y7IT+W\T7X#;9^6G?'4LO2^>JM
MB_*V/#9S(9;=%!.Z8.EZVQL3015N\TI_W2\^9D@I:5+DR+*_IL.0GR;S]'RR
M+G8-TVI;W8[\ZI8V/ *",5Q0UR,5;SZ#_/L WC=]@Y?LK<R;I+K:6F!':C#2
M2$9H7THH_%4^0Z!SIKYK?-OX"=[=/?$_^8=M/ [IZP[5J8-D].][[)=7QZ96
MD4+18S)2:(Y)9$I"GW".%,"6/T/L8;URERMSCM5US#[?'P+BU75<6;5JJ?Q)
MQ 4<% PP^?1S9[IN.Q3VFU;];@P3,JPR14T+0 !"./')/D#T&'\U+ =G;S_F
MF?"K ](;KQVS.SLSC,M'LC>%>'?'XFO..DJ$KITC!>6%J176PN27'LR]NYMM
MM_;+G>?=86DVM91XJJ1J([%HM<?$0>K\P1W$G,O+Z6[JLP#$$UI@'C3UZ/3U
MM\9OYNF$W]LW-=@?,+KW/;,QVYL;6;KP%+AZR.?)X"FJHY:^D@E>!4$M73JT
M8!X%[^P/O.[>W<]G+;[)RQ<VUX(QIE:57#/P(9/VD$>?1Q86>_Q.7W'<XYHV
M>I4+I*@"H"D<<\:YH.KI38M>PM;TEN2!8%@0!8\\C_ ^X\H.CRISGK%[8ZWU
M_]/8N_G0;*^1G?/5W7/QFZ(ZIWGOC%=D;PP4_:&Z,/'$NW\'M Y5:"L@R4[.
MC+6T,8:L"\^BWY]RI[3G9-OW&[YBWG>(K>:TC8PQLW=(Y%:<*%2,?:>@AS8E
MY<;>+"UM7ECF90Y K12:5^T<:^G5L'5O5>U.J^M-@]:8G"8-\?L79NW-I13#
M%45ZW^ X>DQ<E=*3#=YJYJ8R2,;EF8D^XOW&^DW&_OK]P0T\SR4))(UL6I4^
ME:#T QT);>/Z:W@MD/9&BJ/L4 ?Y.J6-T?'7O'XZ_P X3#_(CIKJ#/[HZ&[]
MV]C<=VED=MPP+A]L[HJXCC,[GLU#&T0C2AHZ2GEC])N6:W/N7+?=MHYA]KGV
M;<=TAAWK;W)A5ZU:,=RHG](U9?M(Z"36UWM_-+WT5O(VW7*J&"#'B<-3?T0.
M/3#_ #K/C9W+OO??1/>?Q:V[7;W[RV3A]T;+R&U]K- =SP;.W"'D&YYJ;RQS
M/14LA^V5V_27 'MWVFYCV.TM>8.7^9)8HMLGT35<Y8H-&D#YC-!YCI/S?;7$
MMWMK;24?=E5E"!@'"-4>(/.@;!/ 8ZL-_EA?&'+?$_X?]==>[NHQ3]D[@>OW
M]V7)*$^^;=6Z)C6?;Y)T)U5V)QQ@I9!<Z7B(]@WW"YABYBYGOKBR-=LB"Q0C
M@HC3';\B:D?(]'W+VVMM>U6]M/7Z@U9ZFI+,:DD^HX'[.J\_EYL/M#97\WCJ
MSY03=?[DR/3&"Z*V_LN/=U#2+48VOW]+G,W/2;6IPI\TN2G$L9*A2%CNQ^GL
M0;9O.T+[2<P[#)N<46YFZ,H1\:E_3(TGS)*$ >M.@WS#N"\O;_;\PW<+/9&W
M,<87)>;N*Q@<26_D 3TJ-P?([YY_%3N?L?>FX_@7N[Y&8KM_^!Y3#[EZNS>'
MGW-M_&4='4)#LZOI:F4O14F*+H3&JVD?U'E?9)RYR9ROO&VF_GYWMK'F$M^K
M%.I$=#\(B(RP &:?BZ+>7H=]V2?<-[W;9GN=RW J[LC+XD<8_LX"I. GF.!/
M0/[DZZ^;W\UOY"_'O<?<_P :,Q\1/C+\<=Y5'8BT/8E52MV%N;=!@2D&-I:2
MF)>6DK*6(*SJ D?U/UY%=ON/+?MUM>^VFT;X-RY@O;41:X5(MXA75KU'XB/A
M*\>A"8-TW^^VVXO=M%KMMM+K42']5S33I*C@//IV_F5]:?*';/S^^)_R5Z"^
M-6^^_-M])XRLGJL/M2.#36N,>:"+%R5<\B"GF$4NH,>"%]N^W]WR]<\C<U<K
M;QO\5C+=R !FJ2%[3J \\K0]5YA%_%O>S[A9;;)<)$&+:?S%,\.(Z'*@_F5?
MS"*S)4-)4_RB>^*"FJZVFIZC(397#M%0P5$RQRUDX$X.FF5M;?DA?97-[?<J
M)#-)%[DV+SA&*KI85:F!7RJ?/I^+F'=I)8XWY8G5"0":C )I6GRZNKP-?793
M"8C(Y/%SX/)5^,HZNOPE2RO48FKJ($DFQU1(G#RTTK%21_3W%+D*[J'#!6H#
MZT\_L/0I4U"DI0GR].G3VQU;K__4WV@[@65W0&YLC,HN?J;*0/::IX5QTT"1
M2G7'W[K77(.X%E=U'Y"L5!_UP" ?>ZG/6ZFE/+JO+:F4,7\S#MC&UM<T4D_0
M.PO[OTE3*T0J(E?RY),8&95J"M0-4JI<AN3[8MY(Q>WR39D\%#&*9^+OH?LX
M_LZA2QG;_7WWZ&60D?N>'PU/IQ;1^>6IT>C=F[L!L?&2YG<5:::/D044:FIR
MF2JB#XZ+&T,6JIJJN:X  6_/M]Y$C_M) ,''^QY\:=2[>7UIM\0ENY@J $@'
M+-\E7B6K0?GT6G);(WSV"FX^V-^U%-MBKQ&W\K'T[LK*52+B]G25%'(8MX;J
M#N:3^\U8Q4(S _:)Q<$GVWH-S'IN(M2 ,RHM*UIVDGS(X^@ST$KC;KG<3=<R
M[A2VN([=UM(I3VV]0?U9/P^*V!J_T-:?/JD-(>W=J;1WCN+OG"_(G<.ZXLY7
MU5%WSTGO:/=6S]NXZFJF:(5-+C<A]J(Z.$C7<75;@^PU/%>-''+<QRM**,KJ
MP;2@SY5III^76*Z'F#:=KW._YQVS>KG=_&8C<+*82P+&&ID!J-0'C3'GT.-)
M\@<[NWLKX 0;%[RWIO[ Y3/9/$;LRN9DFQ-9GJBED9X*7<% \GA>:GALH:Y\
M@%R?9Y9W:S7^T117+-;EC'(:: Z@&FI1ZX->/0AEYYN;S>?9=-AYKN;RUDD<
M3M(*,[5J%D!P2JX!]!U97_,:W;NG9'P_[;W'LW<F1VQGL=0T#4.7PE>U+74>
MO(TX8QRT\@D1"O#?X>];K/<6UDSV\I25B%J*5 /IZ-\QU-/O?N5_M7MIS%?[
M9?-;WB*NEU-",_+_  =5I]'+O#=>&ZES.=VC\YLGE\S_ ';FJ=T4>[XSLNM?
M)5$7ESKJ<F&_@*D:W#KJ$=^/=;66"2T598;]KC2>\2#23ZT(^?#S ZB'E"6>
M_M.79MRV'FAKZ7P294*F%]5/U=6OM2N6Q@9ZO_IJ<4U/2TWFEF\$,,333.99
MI3&@#-))]7>X]3?U]F(IQ"DGS^=!_JKUEM0DI4Y%/V 4_;_AZS^Z_EU[K__5
MWV?:;IGHIG<7SC^,G0N_(NKNR^P)J#L!\)'N-]LX7;V=W)D:7"SRO%#6UL>%
MH*P4L;&(GUZ>.?I[$FU<J;SO%HVX6=L/H0Y36[HBE@ 2 6(K0$5IC(Z076Y6
M5BPCN)CXIS0*6('E6@-*^5>EUU)\H?CSWEL:E['ZS[=V3GMH5=37T*Y*HS-+
MAI::OQDOV^2HJRCRSTE535-#,0L@918FWM/N'+N\[9=O87>V3+<@ T"EL,*J
M05J"#QQQ'5[3<+.]@-Q;7*M%4@GA0BF#7A0]!KWET[\?.Y=][(SF=[5Q.Q^V
M-KTS1;3S.T]]83#[LGQ^183I3?;-6K49&EF?U1 JP(/''LIDVB^G2._2"=8H
M0U)%5J*/Q M2@ .37AT%.9N2MBYGO;&]NIVM]\M_[*:%],NGT/\ $M?(XZ$_
M;F ZIZPR5/CMS=D8?-;[AIWJOXCV)N_$-NAX"=?W?V-;51M B!AID5!86Y]N
M0V5R]NLRV;2QH36303Q-,L!Y<!]G1WM^RV.VRK)).T]\PIKF;4Y\S0'A04X>
M5.EKN'=?5^6Q];M_<.^]A-19ZEJ,55T-9NO!QO64^1IV1H8TDK%9I)H9;J!R
M>"/=OH;W0S_1RB+(+:6\\'-./$=&TJ6\\<T$_AM$Z$,I(R"*&ORH>J[<O_+]
M^,&UWK=BQ?('=G7^$WI6/D:WKG_2AC<529>&LU2)%1XFKKHYGIIRUO2I$BG\
M^RRWY9G>VFFMHK@VP)#,H8J#0@@D"E?48^?4.-[)<LCQ[*TWW<(+.X8L]NDU
M$<,:D!?(4QV\1TH^Q/@A\-ZS']8['K]]4G6]7L"GJEVE3XO?6&P.>K)<BVJ7
M(L)ZN*KJ*N139)$%]/T][CY;>Z@0V]O,8HA4LBL:'S9B!^7'%.E6Z^RW(U[;
M[%9L)+5+!62$QR:&JV2Q/$L?+T'#H"LIU%\!]JQ=Z=2[@^3.[MUU^%Z]ILIV
M3M6MWW)N&NQ&VZ_*4*P5]#"[RT\]=]W''&4B9Y(Q)R!?V9IR;NUU#8E[6<VU
MTQ$3.**SJ*]K'A\JX;RK3I,/9_DR.RW?9+C=KV>":"DD;SLY4%AW!37-5IYD
M9Z$?:?PR^+='%LF?%_)KL7#1Y&EQ&4VKM;*=N4^&J9Z)O'/04D>WZFO@J!%(
MBA!$(^1P ?:#^K5TB2:1<:(3I8BK*K5I0D5''Y].6WM!R[:"WMX.9MTC5%&F
M/ZE@-(X (?PT'#TZM3H*48^CHJ!'EFCHJ6"GCFD.J6:.&((LLC_EW47/]?K[
M>+$\1W#C\SU,B!454'P@  _(4'^SU)]M_EU[K__6WV1:XN;"XN?Z#\GVFZ9Z
MI4S/\N;MON;YK?)CO_L+?V;ZLVENZFV[M7J^IV7D:"NR>5VGC,#CZ*K&3I]9
MDQJS5ZSMH-F:]_S[E.+G:PL>5>7]C@VV.YGB,CS>(#I#ER0%QD%2 ?LZ#DVR
MW-SN>XW4EX8H9%C":*AB%K4-^WRX@#I';-_E#;;V_P#("OI'P+)\<-E=0T^#
MZ_A;<12KW7VGF9<KD-V;IW+BZ682/)492>"0F0>KQ@#Z>U%Y[G7=SR\ML:_O
MZ2]:1I*:1%"FD0QQGC@ @>@J",];M^7HK6\:6*0C;_!5-''4U269O4DT/SH!
MT5R'^6G\L*W:%;UON7J7:L&\Z?N3-;YF^6O]_(,GN;^X4&2^[V_M[;FW8*J3
M,X_^'XR(4Z4ZJ%M]/9_=\]<OM-'?1;C(=KDM!$^WB.D9:G<SN: AVS7CZ])+
M/:;V/Z@W<"O>N[-XX;(#&BJ@XC2O'^71']P[;WOV'1]D=&XK;.7[@[PW]\A:
M:DH.TLH<O#V9MS8>+GBH9\;4XRKE%=@,'0)3J7=@L,Z'5S['4$J6PLN8)[J.
MUV*+;<VT:KX+NQ_#+33)(3W#S7'RZ)I[>X>"YL(R[WCW8*NU?$"@#4*<50J
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D/K^LZKV^G_%?^"\^[GR]?Y_YJ=;7@/2AX</S\^O>V>M=?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g693329dsp_084c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g693329dsp_084c.jpg
M_]C_X0F017AI9@  34T *@    @ # $   ,    ! %X   $!  ,    ! #P
M  $"  ,    #    G@$&  ,    !  (   $2  ,    !  $   $5  ,    !
M  ,   $:  4    !    I $;  4    !    K $H  ,    !  (   $Q  (
M   >    M $R  (    4    TH=I  0    !    Z    2  "  (  @ #J8
M   G$  .I@   "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q
M-3HQ,3HQ," Q.3HP,3HQ-0     $D   !P    0P,C(QH $  P    '__P
MH ( !     $   !9H , !     $    _          8! P #     0 &   !
M&@ %     0   6X!&P %     0   78!*  #     0 "   " 0 $     0
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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M;W @,RXP #A"24T#[0      $ !@     0 ! &     !  $X0DE- _,
M  D           $ .$))30/U      !( "]F9@ ! &QF9@ &       ! "]F
M9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    ! "T    &
M       !.$))30/X      !P  #_____________________________ ^@
M    _____________________________P/H     /__________________
M__________\#Z     #_____________________________ ^@  #A"24T$
M!       #QP!6@ #&R5'' (   (    X0DE-! 8       < "     $! #A"
M24T$"       $     $   )    "0      X0DE-! H       $  #A"24T$
M#      ()@    $   !9    /P   0P  $'T   ("@ 8  '_V/_M  Q!9&]B
M95]#30 "_^X #D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,
M# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,_\  $0@ /P!9 P$B  (1 0,1 ?_=  0
M!O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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M &,    !                          $              %D    _
M                  $                         $     $       !N
M=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O
M<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<    _
M %)G:'1L;VYG    60    9S;&EC97-6;$QS     4]B:F,    !       %
M<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P
M       &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R
M871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U
M;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M3&5F=&QO;F<          $)T;VUL;VYG    /P    !29VAT;&]N9P   %D
M   #=7)L5$585     $       !N=6QL5$585     $       !-<V=E5$58
M5     $       9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,
M8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T
M   /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU
M;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP
M965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S
M971L;VYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T
M<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!!X
M  0     .$))300A      !5     0$    / $$ 9 !O &( 90 @ %  : !O
M '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\
M<  @ $, 4P V     0 X0DE-!"4      !#-S_I]J,>^"05P=JZO!<-..$))
M300F       .             #^    X0DE-!"@       P    "/_
M   X0DE-!#H      .4    0     0      "W!R:6YT3W5T<'5T    !0
M  !0<W138F]O; $     26YT965N=6T     26YT90    !#;')M    #W!R
M:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585     $
M  ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U
M '        IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN
M4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2
M<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O
M;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP
M $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B
M;V]L      !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U
M8D!OX            $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M          !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M              !2<VQT56YT1B-0>&Q 6             IV96-T;W)$871A
M8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&
M(U)L=                %1O<"!5;G1&(U)L=                %-C;"!5
M;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC
M<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M    #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<
M     #A"24TG$       "@ !          '_[@ .061O8F4 9$     !_]L
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M<K_F#DOG6,'FO:BC/*H0)-'+71(@0*HP. 4$"A:A/5@9_ )OP/:TUP#2O4N
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M4:;W869F294XZ :'-*=P(*ZOQ:LTZW>[=)R9NFW;AMTK';[F8(\989+$"A/
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g693329dsp_084d.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g693329dsp_084d.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MRI.\*2O5JMZ*G"6MVD^"U_\ 8]^$WC#P3#H/B+2(U\3BTD9O&6GJ(-5AU6X
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JM/.:M/%.5>-:E&G&-.5*2E5C'V_*FIQA'EA"3DY\THR4&?9U=A^FG__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g693329dsp_084e.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g693329dsp_084e.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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J55WN6;"@9P*EMV2N[15DNRNW9=E=MZ=6WNQVM?I??[DOR27HD6J0S__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g693329dsp_086.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g693329dsp_086.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!217AI9@  24DJ  @    ! &F'!  !
M    &@         ! (:2 @ >    +         !,14%$(%1E8VAN;VQO9VEE
M<R!);F,N(%8Q+C Q  #_VP!#  $! 0$! 0$! 0$! 0$! 0(! 0$! 0(! 0$"
M @(" @(" @(# P0# P,# P(" P0# P0$! 0$ @,%!00$!00$! 3_VP!# 0$!
M 0$! 0(! 0($ P(#! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 3_P  1" &C :,# 2(  A$! Q$!_\0 'P   04!
M 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%! 0   %]
M 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*%A<8&1HE
M)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J#
MA(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3
MU-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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MC//% !165?:[HFF6L]]J6KZ986=M&9;BYO+Z*WA@5022[%L#@'KZ5\!?$/\
MX*I_L1?#3Q-J'A+7OC%IMWJVEL([W^P;.;6;2%R =AFC!7<,C(!IJ+>P'Z)4
M9[?A7XW:G_P78_8%TO4)K%O%/CZ[$$QB:[L_A]?RVKX&=R-M!92>,CTKXU\?
M?\'$_@"Q\1ZG9^ /@SXCU[PS;R^58:W?WL.EW=\,X$I@<[D!QG#*",\\]&HO
MJ-+6S/Z7,9Y'(]>QI/3W&:_EFN_^#C'=:S)9? G4X[WRG^SRW.LVSP[R!L\Q
M0/N@C^'U^E?'&H?\%ZOVQ+B[N9K2P\&6MI-,\EK$MK(_DQGE$)SR5!49[D'.
M>::@WN/E5KH_M2U/4]-T6RN=2U?4++2]/LX6N+N^U"Z2SL[9%!+,\CD*  "2
M2:^(_BA_P4@_8X^%^G>(GU'XY>!=3UW0M+DU&/0-)U8:A>:BZJ2D,31AD+,R
M[<9ZU_%U^TG_ ,%'?VI/VH+RTB\7>.-1TK2K>R?3?^$=\,74ECI5ZLNW=YD0
MPS%MO0D_>/K6Y^SA_P $S?VO?VGH;K5_"WPSO;#0F5''B7QE?KX9M)A(K,CP
M><P,HR.< CFKY(I76H15Y6/U]OO^#C6:'4K^&P^ ,=YIT=RR6$\FN?9YYHU8
MA7=<GEA@X[>]8VL?\'&'B:>QN(=(^ 5EI6HR0LUK>WFM?:8HV .,H>HR!^1'
M4\4/V3?^" _CR/QKJ&I?M5:IH=AX,M=->+3](\*:M#J^I:C<LP"2%UW(BH 3
M\W)W=#7Z(M_P0A_8T9T=CXM;9@;?M,(1L>N%!Y[X(SFFE37Q.WIK^H7[GY&O
M_P '"7[2[ *G@7P(H#9.ZQ+[EZD=L'W]^E?*OC;_ (+'_MS^,O$]YJ^B?$_5
MO"UK?3*;?P_X?S%I]LH&"(HE&03U[_2OZA]*_P""/'["FF:;#8R_"I;R>!4'
MVZ2^,=R^W!)Y!ZD'.<\,:])^'O\ P3&_8N^&?B=/%GAOX-Z-)JT0;R#K!&K6
MT!90ORQ.N!C&?QJ5**]T>EM'^!_(E_P]:_X*!E&8_&/QWD< [Y2Y].-G-> ?
M'C]K3]I;]J+3M T/XT^,/&OC:P\/Z@][HVFW44MPL<TJ!&91M^\0 .A^E?WZ
MO^S;\ 44N_PB\ *JKN9V\.6P5 ,DY.WIU_*LA_@M^S'8;KI_ GPIM/LA\YIW
ML;"'[.4.=Q;MC'X8K1RHV=D[_(:=K.*7W'\CO[%O_!%7XV_M#:3X4^)7Q)D7
MX=?#+7)6N#9Z@S6OBW4+96 $B6Y&Y%?YB&8#.*_H1^'_ /P1E_85\&0"/5/A
M=;>-YS:1V[W'BB3[2Q=%VM( . 6/)]\<UZ+X@_X*(?#3P]XP\6_#[P-\+_BA
M\2%\ 7D6C7NI_#OPO_;'AJ-C"LB+#/&=NT*2 !Q\M9%W_P %%REN@TS]E[]H
MG4M1E8"WL6\&O8B7([S/A1SZ\>]2^>]HZ$72V1M?\.H_V R23^SAX&S_ ->A
M_#O3'_X)2_\ !/\ C7<_[.7@1%'5GM=JC/'))KPGX^?M9_M+^+_"VF^&O!_P
M1^(/[/\ J&M:M;0W/CSQGJVE6FFV5J[+YAW&4'(4DX'H?2N<U#X'^(/&ATZ'
MXD_\%$O#]WH%HWVR\TW0/%MEIU^2$!9=_G8^7T[XIJ$VKR8]=D?1&A_LP?\
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M;K06?B:&]^*_QGTS4?#449+Z9X/L;E[VX?! R\Z( ,E>Y_"OZ-C\9/A.<_\
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M[CG_ .M6KX3_ .";_P !-%\0:=XH\5W?C#XFZUIMRUS;2^.M975+9"XV\0!
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M"-YUOIFX?+/<$CYIL>G"YKU/)Z>^>G-)12;N)NX4444A!7\;/_!Q(S'_ (*
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M0?UH_M'3_P#G^L__  )3_&DW<'=Z%RBJ?]HZ?_S_ %G_ .!*?XT?VCI__/\
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MN&F8<L>Q->I?\(MX9_Z%[0O;_B3V_'M]RMW_ /5124FGH)R;=T87_"+^&?\
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M /@G4-KKMU.V3++A7_XG!;*GTYQGU!JZ?Q%PW?HS^P[0_P#D"Z/_ -@NW_\
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M;5MI;1=&+!K;0$;E3G)#2$8RW;FO5.M%%2W<3=PHHHH$%%%% !1110 4444
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M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_C?_ .#BC'_#?_\
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M-C8*PDL_#D+DDQP\??8%0S_[/6O1:.?\ . /I12;NP;N%%%%(04444 %%%%
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MQHKP[_A=P/'_  JGXNCW_L'3>/\ R?K.O/CY+;L!%\'?B]*@X:231=.@7.>
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MJ331RDX\LK*6!//KS^%?#7_!/.QG\6_MS_LV0/NFFE^)EKJ *J)#_HD$UT6
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M?X4RH#?:AJ,UW;Z3IULPDN+]GN#RBCDHH.21QC'-?=7A?PC,M_/XM\4F._\
M%%\JI;L5_=:';KG9;0+]U<9RY ^9B35U$E)C2T3*7AWPE=K)J?C#Q6XO?$^J
M6C"&&3$MKX<@V';:VBG(0#:"Q7!9BQ)))KK_  E_R+.@_P#8*@_] %;5V?\
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M6:9B1$H()STJ+4_V,_@A_H,$>BZ[+:6'A%O <$JZK-E=, *;0FXL>A'FG!)
MP:^C!>7:&3$^[S;9;=MH4GRPJX4G'!&T#(YXZFMRZNK-;"WAM4+2S$3QN7,W
M]FJQ6-ER<\LREL< %LCL:=Y)K4'%?(^4KG]C3X-7VD:I:/H&J3V^M>%X?".H
MEM7N!?6MK$$5)(3NWJT91<3(<@@<Y&1JW'[&/P0NK/7=*U2+Q3J0\3V-G9:E
MJ&I^(;F_O=6M[*XMY(?])>0NQ#QQL5)+';GKBOI18-2B;[9<->S3 I%:72W"
MO $RQD5R2>HR,9ZD@]:ANIYY)4^P2I#:V&Z:RCEE5VMR.2N3R3\F0I)QCCK0
MG):7'RZGB_Q[_9[A^(W@7P3HO@^5+'6/!'BO2_$6@W=ZKK;;M/GB#Q2 @L!)
M 9DXP.!TJE:?L@?"8^.(OB!>V.I6OBR _P!J7,":C-'X<M[PQ&-M0MK;?Y0N
M%4X690'4,?F%<7^VW\=?$_[/W[)7QN^*'AB:\E\:Z'X<BTSPW>I.\[:==:I=
MP:7;3JN<!H);M)LX. A]37X=?&O]J7]K#1=0U?4[3X^?$K0[SX _!GP3\0QH
M.GZL8=/^*=]KVLP65_'J<7'VB,QN5C /#8/T<8RDG=[$-/FL?T=S?L\^"-1O
M? ^H:MJGBGQ!<^ M2GUGPYJ6L>(KK6'AGN2(WW.\C%L  #=D**YSQM^R+\'O
MB-XZ_P"$_P!?TW6'U,2V]U/9KJD]OH&HO;Y:!Y[)76*3R\C;N7*X'>OF+]N_
MQY?6'[%J_&6Z^*7Q;^#>K:/H%KJ>G+\*?$,OA;Q!KNJW\2Q6EA<R@G<KR-G;
MSR#FOR<^+UQ_P4>^$?P,_9L\,7GQ]^+'B[Q.O@W6OC=\<_$Z?%&+PIXRGTZ.
M,3VVEPW9D69TBAV, BD%BP)]5"+DEKJ"U/WBN/V+/A/9^(KWQMID.J'6A?2Z
M_I^CW>L7#^#;74F3:+M=-9S L@P"7VYK^/S_ (+,_!F3X+?ME_L*Z#?SV]YK
MNM>,(_$FN7MGCR+N>[UR65=HQPH#8 K]9?BCXZ^,OQHG_8CL?V</VJ/VF/"G
MC3X^^'M,\6:]I$_CR670])T*Q2#^UKB_A;.^1W)3S1C?EC[U^%?_  5\\5?$
M ?\ !6CX9?#+QKXVUGQUIO@/XC^'D\(7FOW!N[[2[29;1I;?>>H:9Y9!_O\
M6K2DEJQQ5[OR9_H*^#_^14\-?]@*U_\ 1"44>#_^14\-=_\ B16O/_;!**Y3
M,Z.BBB@ HHKEO&7C?PA\/- O/%7CGQ'I/A;PYIR^9?:QK5ZEA86X_P!J1N.>
MPH2;=D!U-%?+_@+]M3]EGXG>)(?"?@CXU^!M;\174IALM*BU,075\W3; 'P)
M">VS.:^GGDCC5Y9'2)%&&:1PD:CU)/ JI0E!VFK,+=C^(W_@[&('Q _92+8
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MF=#1114""BBB@ KPC]H?_D2-(_['W1/_ $M2O=Z\(_:'_P"1(TC_ +'W1/\
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ME>RQZMK/B_Q$YU*\BNRA#-#OSM&7;'I^>/O"OXYS_P '07Q<*/Y7[ GQ(5E
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M /C='_"!^!_^A,\*?^$[9_\ QNNKH')Q[9HYF!RG_"!^!_\ H3/"G_A.V?\
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M\?\ XNZ?\"/@]X]^*^I:?J&JV_@[0I-2CTS2[&;4KZ_FX2&-(8E9VR[+G /
M-?R]> _VN_$7BAOVU[:\^,7B#5_&?Q,N?AY?7$<=CJ6CVO@+2=1UIM-U*QMO
M/C18S'%<J'?@GS!C.VOZXIH(+F)H;F"*XA<C?%/&)8FQZJ00?QKP7Q!^R_\
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M/1N.W3MDYHH%%<H/<**** "C&2./UHH_S]: /Y</^"C^I_$CQE^UE\=+_P
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MU3Q'-<QE+2:&P(AALD94C$T;&?<"PRIYJW3HIV;"VNA^I&I_\%*O@QJ=@9O
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,* "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g693329dsp_195.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g693329dsp_195.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!217AI9@  24DJ  @    ! &F'!  !
M    &@         ! (:2 @ >    +         !,14%$(%1E8VAN;VQO9VEE
M<R!);F,N(%8Q+C Q  #_VP!#  $! 0$! 0$! 0$! 0$! 0(! 0$! 0(! 0$"
M @(" @(" @(# P0# P,# P(" P0# P0$! 0$ @,%!00$!00$! 3_VP!# 0$!
M 0$! 0(! 0($ P(#! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 3_P  1" !R 4D# 2(  A$! Q$!_\0 'P   04!
M 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%! 0   %]
M 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*%A<8&1HE
M)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J#
MA(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3
MU-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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MOB-X=L?%W@/Q+H_BWPQJ8+:?KFA7J:AIMWM.&V2*2#@\$>M?B!^V;^W-XL^
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M>\MKM)Z,_?.C^G6HIYX;6&2YN9H;>WA0RS3W$@BAB4#)9V/  [DU^:/[0/\
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M%_?^"=UQ\+O&MK^VY\$M!FTSPEXJU*)?B99Z!"\ \.ZPA!AUCY.8Q<%06<8
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M]I>R_;#_ ."RGP$_:#L=+?0I/'WQ7\-WVIZ5(<I8WD%L(KI(R>2A=&*@\X8
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M@B[%!O[&WNSA>P_?=*I[7Z_\,.I9^]%':4445!D%%%% !1110 4444 %%%%
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M=V?(()C:3+?.2V&!R>K*,VJ8K%OA:KB)4\MK2BL3)=OY4^G-HJC6JA\C^?\
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M<UNR75J+=+[D?Q+#_@U6_: S_P GD>$<>O\ 9VL__$52N_\ @U%^-]^%%_\
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M,2*01YH& /C_ ,.?MA_\'#G[),2_#_Q3\(_B5X_@T.(:=;3^(? $WQ M(%B
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MDMCYL_:7^'.N_LH_M#_LL?'?Q5\/OB-^TU^S_P#![X2W?POUO5X=.B\;>-_
MMW)-(8=:FT\[5N&,+HADP&Q&0"" :^J?V6=4_8R_:"^.OB+]J+]G7QC/#\0V
M\%Q^!OB%X!@L'\)26R!Q-%+JFC21(PN4P%\U-PQQNKE/$7[;_P 5?V<?BQ\+
M-(_;(\,>'OA[\)_B=\+;:^N?B#X;L[K4/"W@GQ:DFZ_TR_OOG"1*C1A2W/\
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M/%E=;2T]K<AE1DE8['C7 ^<UKZW^SC^TE\&?C?\ $KXL_LHZ[\+=0\*_&O\
ML^[\>_"_XHM?Z=9Z-JNFVWV.#5=)N[5'PKVZQQ2P,!N,4; D@UU.J?LM?&/X
MK_!SXY>#OCY\:IM;\4_&KP]'H=II'A2*6T^&OPU6V(EMAI=LX661WE"M//)A
MI H ' -&ETKZ: FK_P!?U_6IU'P^^)7C'P5^PKI'Q;^+&MR3^-+#X*3^.]>U
MF[ \QKJYM9KVT# =_P!_;1C'H*_+SQM^T%\;=.\'?LKZ%^T=\;/BC^S]\,_B
M+\!;;Q_XD_:#\%Z'<7D5SXFUAVO+/3-5U*VB<V$-O!=0)F38C% ":^C/B)^R
MQ^W_ /&_X#V7[.'C/XF_ KX?>!M*T_2_#6JZ[X+M]6O_ !!\1=*TY[=#:W*2
M1*EHDT-N%<(6)8]Q77?%_P#9*_:R\:'XQ_!O0/B?\/;_ /9G^,6F67A_3K3Q
MQ;7>I>)_@SI,.F6VFW6G:!9K$;=]ZP-+$TC )),2<52=M>K'I:[_ *_KY'S]
MX\_;5U[0O$7@K]E#QS^TY9^!O$/@/X7:)?\ QP_:"\$^ -6\7:CXQO[VRADB
M308K2SN8H&N(F2X:=B,"X4H3UJ#X1?MBZ=\(?C9/H_A_]H_XE?M-_ *\^&7B
M'QSXOO?'O@?7++Q)\,+C0+%[\NNI7ME )(+E(FC6)G8[R, 5]+:C^QK\9/@;
M\49_B5^RA>_##7-%\1^!-!\"^+_AU\9H;@P7'_".Z=;:3IVHV>H0Q22)(+:T
M@21" &*9SSQZ_P"#_P!DGQ5XG\-?&#_AHOQYI_BOQ+\:O!%[X U'0O VF'1O
M /@+3+RWDMS#I$+JLDDP$FYKB8!F*]!3G.GRVC_7?3_@^A.SU?N]NOWGE/@O
MX6?M+?M6^#=-^,GC;]H3XB_ 2T\8V:^(OA[\,OA@\>E)X9L)U\RQ;5K@8>ZF
M="CR1N6C ? %<+_P3 T;XL:[X^_;#^+'QK\0Z?XV\8_\+(TWX$Z7XOLH%MQJ
M6G>#X+RX1]B_*K2?V["TFS@O'_LUWW@WX0?\%#_!O@*R^!.E_$WX()X3T'13
MX:T+XVW-OJ5S\1H["-#%;;]+\K[.;I$VIYA?:"-PY%=/^SQ^R3\:OV=?@;\&
MOA5X3^+6B3Z]HWQ<N_'WQV\87VFSWES\2+.\-Y)<P6^<,D\[G3PTDG 6%\=A
M4MQY6KKT_P"#^ VT]S[A^(_B2'P?X \9^*K@$P^'_#-[JL@SM)$,$C\'\*\$
M_8J\,MHG[-W@.2_0R7GBQ+SQGJ2SH&=Y=6NYKM_,_O'$@Y->C_M$?#_Q5\5/
M@WXX^'_@O5]-T/Q!XHTY=,M=2U=9'TZ*-IHS<+*(P7(>)9$P/[WI7A.C?"_]
MKQ_#6D^![SXE_"KP)X;TW2X=#.I>"M$OM1\1BWBC6,& W"JB.54X8,""V>U>
M?-RCB54Y6TE96MNVK[OR_'<^1Q]3%T.(Z>+CA:E6$*+C!P4;.=2<7)-RE%1L
MJ<;WT][39GRMX^\2R?"7XA?MJ:M\*%CT_1-;C\,>%+6WTR)?[*?QEJT:0W96
M'!1I3$5$@ (SD'K6QX]\:?$AOC%JGPAUCXT^)/@)JGAFWT+1/@9*VAS6OPZ^
M),ZVENMP;NZ1/)E,D^^(6TKC 7 '//U/K?[)FFQ^&OA'X&\*:C%;^&?!WQ1M
MOB;X^NM:>2YUWQS>6S>=]HFE7.Z9YF9B7X48 QBN O/V;?CUX^NM$\#?%[QM
MX0\4_#+PM\2AX]L_$\L=Q>?$?7+>'4GU&QTQV= D*PYB@9U8DQQC%<DZ6(NX
M13M>]D]+WDW>S32]Y)-=8K3O\17R#/Z4IT(4YI3GS*--M4KSG5J3IN4)PG"*
M=9<M1*RG1NXM-1?4V>K?$K]I?Q=X^M?"OC[6?A?\*_ 'BJ\\!_VGX82,>)O&
M&IZ?(;;4'CG8;H8(9XYH@R$,3$3TK.U77OB]^RQX9\>ZEXQ\8R_%SPC*;+3/
MA+)XAG#>-+G6M2N(K2#3KN0#]Y#YLRL)&8D*#S5S3/@[^T3\'?%/CX?!/6/A
MMK?@+XA^,K_QP-)\>F]L]0\(7^JW#W=^T30(PEA::61U0D'YS73>*?V;O&'Q
M ^$'B#PCXZ^*>IZ[\0=7\06_C72/$[0%= \'ZK97"75G%IUEQMM(WC52I^9U
MR3SQ6RC6<7)J7M==;Z=;*U]5M96[-ZGNQPV;U:%;$0HUEFD8U??<[4N:S4(0
MBY>SE!W3@N71I.HT[WX;Q?\ "+]H&W\!ZS\3]2_:,\3Z-\1-%T.;Q4OA_3(8
MH/AU9M;0FX;3Y+3I+&1&R&20%LL2,<8SO@U^T!XS\2?&OX??\)I?#2_!7Q9_
M9ED\<Z+I<X"V5IK>AZI90ZK)&W99(-0$G.!MA%=E=?#']I_XI:/%X$^,'BWX
M?^'/ SJEIXIN/AZ+N;Q)XVMTVEH2TR*EM'-M <(=VTD<U7_:2_9*U#XMK\%(
MOA[XJ@^'L?PSO+GP]J[JDIDU#PQJ%@UGJ&G6VP8623;;%6;@>7G.<4N6JDZM
M&,E:VC>LG=7>K>EOO^1E7P6<4;YGD%&LE!TFZ=2H^:M+VB51M3FU%*DYW;:4
MY6T:@F>#?$?]KWQ5HM[JWQ0T_67TCP'XJ\3K\&_@KIEUIUQ>Z?K$T!ENM=\6
MW4$,3S2PVXAA@A"J<EF.-K$UP/B[XY1>!],MO'O@/]JOXC?$GXAV.J6ESJ?P
M[UCX?:[!X2\7P37$45U:6ENU@D5L465F1P5^Y@]:^X?C%^S6_B+PC\*+3X4Z
MCH_@_P 6? _65U;P&^K:=]M\/W,36C65Y97L2@MLN(V!+J"P:,'D9K*T+X0_
M&WQQX@\-ZU\7]:\">$M$\+7PU%/"'PL@E \37$8(1]1NY8U;RAD$0KN!)Y[8
MQGA\7*HZ;D^C3UT;W>DEL]DT]$DKZHXL;D_%M7&5,/5K2<GRNG-1FXPE))U)
MJ2Q%.,'";:C&=.?N1@DI-S1YI!J/QH^/O[1?C/1?#/Q.UKX<?"'P+X4\.G7-
M-T2W0:Y=:S>VRZE/:"5L&,(KQI(5Y(+"M_PC^T9=?#;3_P!J _%?6+O7KSX2
M_$NYM?#=I%$)-5UFTU"VMKK1],LH@-TDLCW!@15&22 *]]^"OPEU'X:WWQ3U
MS7=4M-5UKXE?$:]\97%Q9!TAL[1TBAL[7#\YBCCP<<?-Q7R5X$^#>F_&']K[
MXB_&^*>YN/A9X6U2RLK'1[E2VD>*_%6E1/;3:DJ$8=+3*QHQ_P"6D1(/%;N-
M>GR.G=SG)WN]$M7>VJM'316N_4[*F$SW+WA,1AYRECL17K<T9SE*,:<U4Y7R
M7Y5&C[DG&/7W;WDC[(^!&E_$RQ^'^G7WQ>U5[WQ[XAED\1ZWIJ.KV/A5KMVF
M32;=@<,EHKB'?GYO+SWKPG]F!6\7_%_]JKXISQM+'>_$]OAUH-]D/;SV7AU6
MT]Q&1P1YL!.1W/KS7VS+YFQC%L\S83&7SLW8^7=CG'TK\Z?@]\"OVQ?@_P""
MV\!Z!X]^"BV,OB'4=?N/$5[INJ:CK4TVI7<EU/,\;)L=]TAZL!ZFM*T)PJT5
M:4E&^N[O9)7OWN]>Y[V8T<1@<5EE.G1J5Z-!5).2M*3FH*$.;F<;N2G4?-=*
MZZ70S]H(:3X3_:Q^"_C?PA#:67B_1O 'BS5?B!<VB!$F\/VFD3RQ?;@O4&Z6
MV6(R=6*@=:\JT;Q)\?\ 2?V9-7^/?Q+^*6K:EX@\=6G_  CW@;P+'91PZ%HR
M:[J\-OITTR=9YUC=0N[("OZYKZEN_P!E:\/P]^*=JWC2?Q+\8_BSH:Z'KWQ,
M\20D&W@+Q[K6U@3/DVR*) L:=?EST '8>/\ X!7OBKP?\$? NEZU8V&@_#+Q
MEH^O:]!/;N_]MVFCVLPAMX0!\K&X^S2?-QMC-<\J%>52=6"<;IM)/[3M'6SW
M2C?JDWI=GS]?(<\JXK&XZG"4'54YPA"I:*JU%3I)S2:4IPA2565[QYJC2YFE
M)^<_"7XCZ]X)^,GQK^'/Q(\1(OASPS\*_"7Q/\'_ &P"""PL9X=5LM7V8X 6
M?38G*C[OG].:^??%?[6WC;1GT[Q'=^(_^$1A^/&O36?PMMM1T.[UVR\#^&=)
M5(YM?N;*WBDF>:]FF)C!0C &< 8KZ%_:%_9*U'XV?&+X<^/K#Q9!X;\,67AF
MZ\$_%K1XXW.H>,='%]::GIUE ZC:J+<0S^9O/*W# =375_&_X >(/$6L_#'X
M@?!Z_P##?ASQW\*;.YT'2=*\1V!NO"OB'1[L0B;3KA4!:/:;=&C=5R"S9IU8
MXQJ<:>B3T=]9*3N^J^&+:2NKO;9!C,!Q='"XC"X2<XPH56Z<K\TJL*M13DTN
M>+<:-*<J<(.46Y*ZLX0;^+-2^.T?P^U_P3XG^&O[2'Q)^-6JZIXRL-(\7_#O
MQ)X(UM--UBSNY]EU/IYFLDBM6A!+ *RK\H]Z]N\+V'QC_:$^+OQ\:U^,_B?P
M1\(/!OC6/P9X7M/!Y2UU.ZNK.U@^W_Z1P\:K*\BG:>2*]E\'?"CXPZ[XIT7Q
MI\6-9\%:"/#2/-HW@/X;VTBZ)-=,I47&H7,J*\NT[2J*-HP><UW_ .SU\([S
MX.>!+OP_JVH6FK>(]:\8ZWXRU[4K%'2SN;C5M4NKY516^;$<<T4?/_//THHX
M>K)Q4VU#>VJV5M?>D];WM?ILKCRW(<XQ&+IT\=.:P+<IN*=2EK&'(E).O5J6
MJ.HY.+E:])-Q3D[^<?LD^,/&^NZ=\6O"'C;Q+<^-)OA7\5]1\!Z/XLO8ECU+
M6K2WVO&;K: &FCW^6[CJR&OKNOD+P!\#?BGX \(:/I6C>-M!LO$VL?&2^^(_
MQ/U>"RGDA\165_J5Q?3V5N#\RR,LL<6YN %/I7U]D?['_??_ ->NO"PJ1I*$
M[MKOYZV\[*RO^+9]CPY'%T<KI87,(252,5=S=][M1OS2;<%:,F]WLWN(_P!\
MCMP<?@:4 'J,\'K]***W>Y[JW0U/X/I_4T\@8''^<"BBA;,2V8X_>C'8IDCL
M34*$YD.3D. #GD<=J**:W^?Z(1*O(;/..1GMUJ+^ GN$)![@X-%%..W]>1<M
MV2-_4C^5+W7_ 'R/UHHI1_5$K<12<1\GE%)]ZC/4#MQQ^=%%);,.A(?O =BQ
MR.QQC%./\0[948[8)&:**.@X[D2]5_W\?SI2!SQ_?_3I113^W\R16) R"02O
M)!Y/6A>1SSRPY]NE%%$ME_78K[2^0[H6 X&3P.!]T?XTG_+-:**'\*)'8!4$
M@$\\GKT-,_C4=L=.W:BBE'=%QV_KR&9.%Y_S@U*0-ZC P6.1CVS111T#^OP&
M G/4_P"K!Z_2D;@ICO( ?<;1110]Q?:7R'=#@<#S,8_[YIN3DG)R.G/3E?\
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@B/7T"GL_7]1X .W(_BQ_*JV3ZG\Z**:W^[]"([(__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g693329g34j21.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g693329g34j21.jpg
M_]C_X0N_17AI9@  34T *@    @ # $   ,    !!3(   $!  ,    ! WD
M  $"  ,    $    G@$&  ,    !  4   $2  ,    !  $   $5  ,    !
M  0   $:  4    !    I@$;  4    !    K@$H  ,    !  (   $Q  (
M   >    M@$R  (    4    U(=I  0    !    Z    2  "  (  @ "  .
MI@   "<0  ZF    )Q!!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R
M,#$U.C$Q.C$P(#$Y.C Q.C Q   $D   !P    0P,C(QH $  P    '__P
MH ( !     $   !9H , !     $    _          8! P #     0 &   !
M&@ %     0   6X!&P %     0   78!*  #     0 "   " 0 $     0
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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M  ,;)4<< @   @  ' (% !)!=FES92!#5$0@,#@Q-S(P,34X0DE-!"4
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M;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L
M BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T
M;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP
M     $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M
M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !        4D="
M0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M     $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M    0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0%@
M       *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',
M4&=00P    !,969T56YT1B-2;'0               !4;W @56YT1B-2;'0
M              !38VP@56YT1B-0<F- 60           !!C<F]P5VAE;E!R
M:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P
M4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P         +
M8W)O<%)E8W14;W!L;VYG       X0DE- ^T      !  8     $  0!@
M 0 !.$))300F       .             #^    X0DE-! T       0    >
M.$))3009       $    'CA"24T#\P      "0           0 X0DE-! H
M      $  #A"24TG$       "@ !          $X0DE- _4      $@ +V9F
M  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8
M      $ -0    $ +0    8       $X0DE- _@      '   /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H     /__________________
M__________\#Z   .$))300(       0     0   D    )      #A"24T$
M'@      !      X0DE-!!H      T$    &               _    60
M  8 9P S #0 :@ R #$    !                          $
M     %D    _                      $
M$     $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C
M=#$    $     %1O<"!L;VYG          !,969T;&]N9P          0G1O
M;6QO;F<    _     %)G:'1L;VYG    60    9S;&EC97-6;$QS     4]B
M:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G
M<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X
M   -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E
M $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @
M;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG    /P    !2
M9VAT;&]N9P   %D    #=7)L5$585     $       !N=6QL5$585     $
M      !-<V=E5$585     $       9A;'1486=415A4     0      #F-E
M;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO
M<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )
M=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=
M  MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N
M90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P
M   ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG
M   X0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$
M%       !     (X0DE-! P     "E4    !    60   #\   $,  !!]
M"CD &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D@     '_VP"$  P(
M" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,
M$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$( #\
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M]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@ , P$  A$#$0 _ /54DDQ< 8)
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M%A+WW-]^0[^K^8MWZ^=&Q>H],KR'VG'S<2P.PK6_2-CB&LI_ZXY8>%]8^O\
MU2=5A?63"#L%Y_I]/N)<XRZRT_GO_?\ STV!D8Q&*0$A?'']*?;^\MGKD )]
M(]1_Z,75_P 9A?1]3K?3>YKJ[*0'!Q#M' ?2:JF-_BUZ??C4WGJ6<#:QKR!<
M>7 .5G_&9;3=]2[;6.W4V/I<U[=9:7 M<U"Q;_\ &3]EI]'&P#5Z;?3EYG;
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M3V-MK=L:*M-@,;K'2/=M<[V)OM&_F%$VQC$034B(&7N&/#ZK/];]UIYK7_\
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M "  4 !H &\ = !O ', : !O '     3 $$ 9 !O &( 90 @ %  : !O '0
M;P!S &@ ;P!P "  0P!3 #8    ! #A"24T$!@      !P (     0$ _^$1
M*FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\ /#]X<&%C:V5T(&)E9VEN
M/2+ON[\B(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC.60B/SX*/'@Z>&UP
M;65T82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(@>#IX;7!T:STB6$U0($-O
M<F4@-2XQ+C(B/@H@/')D9CI21$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S
M+F]R9R\Q.3DY+S R+S(R+7)D9BUS>6YT87@M;G,C(CX*(" \<F1F.D1E<V-R
M:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @>&UL;G,Z9&,](FAT=' Z+R]P=7)L
M+F]R9R]D8R]E;&5M96YT<R\Q+C$O(@H@(" @>&UL;G,Z>&UP/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O(@H@(" @>&UL;G,Z>&UP34T](FAT=' Z
M+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B"B @("!X;6QN<SIS=%)E9CTB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F
M(R(*(" @('AM;&YS.G-T179T/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q
M+C O<U1Y<&4O4F5S;W5R8V5%=F5N=",B"B @("!X;6QN<SII;&QU<W1R871O
M<CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]I;&QU<W1R871O<B\Q+C O(@H@(" @
M>&UL;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O(@H@(" @
M>&UL;G,Z<&AO=&]S:&]P/2)H='1P.B\O;G,N861O8F4N8V]M+W!H;W1O<VAO
M<"\Q+C O(@H@(" @>&UL;G,Z>&UP4FEG:'1S/2)H='1P.B\O;G,N861O8F4N
M8V]M+WAA<"\Q+C O<FEG:'1S+R(*(" @9&,Z9F]R;6%T/2)I;6%G92]J<&5G
M(@H@("!X;7 Z0W)E871O<E1O;VP](D%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I
M;F1O=W,I(@H@("!X;7 Z0W)E871E1&%T93TB,C Q-2TP."TR-U0Q-#HT,CHT
M,2TP-SHP,"(*(" @>&UP.DUO9&EF>41A=&4](C(P,34M,3$M,3!4,3DZ,#$Z
M,#$M,#<Z,# B"B @('AM<#I-971A9&%T841A=&4](C(P,34M,3$M,3!4,3DZ
M,#$Z,#$M,#<Z,# B"B @('AM<$U-.D1O8W5M96YT240](GAM<"YD:60Z.#@S
M,&0X-3,M.&-A,BTU-#1C+6$X-S4M.&1E9#4W,C9C-35F(@H@("!X;7!-33I)
M;G-T86YC94E$/2)X;7 N:6ED.C(X1D$R,48S,3<X.$4U,3$Y1D0T0S1".#4V
M0S4U,S5!(@H@("!X;7!-33I296YD:71I;VY#;&%S<STB<')O;V8Z<&1F(@H@
M("!X;7!-33I/<FEG:6YA;$1O8W5M96YT240](G5U:60Z,#E!03 U1#<U1D8V
M13 Q,3DR-C8Y-C(V04$X1C R-# B"B @(&EL;'5S=')A=&]R.E-T87)T=7!0
M<F]F:6QE/2)0<FEN="(*(" @<&1F.E!R;V1U8V5R/2)!9&]B92!01$8@;&EB
M<F%R>2 Q,2XP,"(*(" @<&AO=&]S:&]P.DQE9V%C>4E05$-$:6=E<W0](D(Y
M.$8X-S)%,T4V,3,S-3$P,#1%.#,W-C@S-C!$-3-%(@H@("!P:&]T;W-H;W Z
M0V]L;W)-;V1E/2(S(@H@("!X;7!2:6=H=',Z36%R:V5D/2)&86QS92(^"B @
M(#QD8SIT:71L93X*(" @(#QR9&8Z06QT/@H@(" @(#QR9&8Z;&D@>&UL.FQA
M;F<](G@M9&5F875L="(^079I<V4@0U1$(# X,3<R,#$U/"]R9&8Z;&D^"B @
M(" \+W)D9CI!;'0^"B @(#PO9&,Z=&ET;&4^"B @(#QX;7!-33I$97)I=F5D
M1G)O;0H@(" @<W12968Z:6YS=&%N8V5)1#TB=75I9#IC-3$P9&8W-BUD,60X
M+30Q8C4M.#$Y92UC96(S,35A,CDY83@B"B @("!S=%)E9CID;V-U;65N=$E$
M/2)X;7 N9&ED.C8Q-V)A,V,W+30R-S(M-6(T,BTY-C4T+68S8C1A-C<V83,U
M92(*(" @('-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#TB=75I9#HP.4%!,#5$
M-S5&1C9%,#$Q.3(V-CDV,C9!03A&,#(T,"(*(" @('-T4F5F.G)E;F1I=&EO
M;D-L87-S/2)P<F]O9CIP9&8B+SX*(" @/'AM<$U-.DAI<W1O<GD^"B @(" \
M<F1F.E-E<3X*(" @(" \<F1F.FQI"B @(" @('-T179T.F%C=&EO;CTB<V%V
M960B"B @(" @('-T179T.FEN<W1A;F-E240](GAM<"YI:60Z1C<W1C$Q-S0P
M-S(P-C@Q,3A#,30X,S=%-#5&-$1!0S0B"B @(" @('-T179T.G=H96X](C(P
M,3(M,#<M,#)4,3@Z,3,Z,C8M,#0Z,# B"B @(" @('-T179T.G-O9G1W87)E
M06=E;G0](D%D;V)E($EL;'5S=')A=&]R($-3-2(*(" @(" @<W1%=G0Z8VAA
M;F=E9#TB+R(O/@H@(" @(#QR9&8Z;&D*(" @(" @<W1%=G0Z86-T:6]N/2)S
M879E9"(*(" @(" @<W1%=G0Z:6YS=&%N8V5)1#TB>&UP+FEI9#HR.$9!,C%&
M,S$W.#A%-3$Q.49$-$,T0C@U-D,U-3,U02(*(" @(" @<W1%=G0Z=VAE;CTB
M,C Q-2TQ,2TQ,%0Q.3HP,3HP,2TP-SHP,"(*(" @(" @<W1%=G0Z<V]F='=A
M<F5!9V5N=#TB061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RDB"B @(" @
M('-T179T.F-H86YG960](B\B+SX*(" @(#PO<F1F.E-E<3X*(" @/"]X;7!-
M33I(:7-T;W)Y/@H@(" \<&AO=&]S:&]P.D1O8W5M96YT06YC97-T;W)S/@H@
M(" @/')D9CI"86<^"B @(" @/')D9CIL:3XU-#,R,$-$-C0X13 T-S P-38Y
M,44Q-34V.#8Q-3(V-SPO<F1F.FQI/@H@(" @/"]R9&8Z0F%G/@H@(" \+W!H
M;W1O<VAO<#I$;V-U;65N=$%N8V5S=&]R<SX*(" \+W)D9CI$97-C<FEP=&EO
M;CX*(#PO<F1F.E)$1CX*/"]X.GAM<&UE=&$^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_N  Y!9&]B90!D0     '_
MVP"$  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$" @(" @(" @(" @,# P,# P,# P,! 0$! 0$! 0$! 0(" 0(" P,# P,#
M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# __
M !$( #\ 60,!$0 "$0$#$0'_W0 $  S_Q &B    !@(# 0             '
M" 8%! D#"@(!  L!   & P$! 0            8%! ,' @@!"0 *"Q   @$#
M! $# P(# P,"!@EU 0(#!!$%$@8A!Q,B  @Q%$$R(Q4)44(6820S%U)Q@1AB
MD25#H;'P)C1R"AG!T34GX5,V@O&2HD14<T5&-T=C*%565QJRPM+B\F2#=).$
M9:.SP]/C*3AF\W4J.3I(24I865IG:&EJ=G=X>7J%AH>(B8J4E9:7F)F:I*6F
MIZBIJK2UMK>XN;K$Q<;'R,G*U-76U]C9VN3EYN?HZ>KT]?;W^/GZ$0 " 0,"
M! 0#!00$! 8&!6T! @,1!"$2!3$& "(305$',F$4<0A"@2.1%5*A8A8S";$D
MP=%#<O 7X8(T)9)3&&-$\:*R)C495#9%9"<*<X.31G3"TN+R565U5C>$A:.S
MP]/C\RD:E*2TQ-3D])6EM<75Y?4H1U=F.':&EJ:VQM;F]F=WAY>GM\?7Y_=(
M6&AXB)BHN,C8Z/@Y25EI>8F9J;G)V>GY*CI*6FIZBIJJNLK:ZOK_V@ , P$
M A$#$0 _ -_CW[KW7O?NO=>]^Z]U[W[KW73"X_UN?]M[]]G'KW5?7R._F;_$
M/XK]DT_5/:^_ZNGWC'C(\WN6CV]@LCN*+8^(J::6HQM9NR;'0S#&-E1&!!"
M\S!@Q54(;V27V_;=MT[PW$QUHFN0J"WAIY-)2H4,<+7)\NH>YW]]?;CV_P!\
MLN7>8MY*[I,::$0OI)!8!J?B8 =HJPJI:@(/2BVEMS?GRTVJ-X=KU>2V%TKO
M:DILELCJ/:.<DH-P;BV=6Q&IQ>=[*WEA*B.K+[GQL\<QQ&/FCAIHF5))I7U
M*DC>]C#S,1;-0JH/$<:D_/&!PZ]M%GOON=MIW?F=Y+'E*[0-;V,,FF62!AVR
M7<\9K652&\")@J @,[&O1'-Y=&[3_E__ #=^)6\?CQ#7;*ZE^3NZLWT7V]U5
M29')5NV*[<$N$J<QL_>M)39"KJ1!E:>JIV65AR50\^MO91/;KM>[[7+:$K!<
M.T3H/A)*ED>GKVFOK7Y=13?<F;5[)^Z/M]N'(\36?+.^3O9WEJ'=XS(5!BD
M=F[B2/\ 2B.BTUMU>(OYXL;G_8VXOQ_7V)PNFHKUEOUS][Z]U[W[KW7O?NO=
M?__0W^/?NO=1):RD@FAIYZJFAGJF(IX)IXHYJ@K;5X(W=7F*W%](-O>PKL"0
MITCS_P!7#K6H @:LGA\_LZYSU$%+$T]5/%301@%YZB6.&)02%!>21E1;L1:Y
M_/O2@N=(4EO3C^?7BP4:F( ]3@=<XY(Y8XY(G22.15>.2-P\<B.+JZNI*NK
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M&MIGKZMZ*EUQD7CED!XO[M[.[';;ANVZ[UN*C]VV%JS,3@ L"*@^1"!V!\B
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M[KOKS?U9\U?GM1UF]-C[0W=6T=-WKF5I8*S<6"H,S50TZ&1C'3I-5E42YTJ
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M.UR[YO.W;1;YFGF2/]IR?R%2?LZ0[G=K86%U>.P C0D$UI7@M:>1-*]:GO\
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M(LI?-']S/\XX/!3EQYY2^1V- ACC!+.#-*JW^EV'TO[4^U+(FR\\"1NUK4J
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M(TT)R,@DG%!6M>I"YOW2QW79VL;'5++)+'G2P5 K!R26 R0"H JQ)H!T&O\
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MOUADN/K9C*MN6$9/Q,R$J 0H[TDHK(: J-5?+K<MQSCXD<0M8=#R :Q2J*'
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M4JZ_'1T^6BQ.7S$4>,:L:60XZ[3+%+J !5LT?)MQ:>!NDYA=3(QD4,6*ZJ(
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M>&:=$9@NN-FD).E%*#*-6KOQH@' G#FW[GO\EXENFVQBT9@I94*JGXG:M:,
<.T>98D\!U<'Z/]I_VP]QQ^1_GT.>_P!3^SK_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g693329tx_pg078a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g693329tx_pg078a.jpg
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M"P !  $#!0$!              <%!@@" P0)"@$+ 0$  04! 0$!
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M!<NW[4 J%DB!&%O9)KRZZE#3%*JE51<[YP*VBYH*85"*13IJ^<<V ;J7$,N
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M*D!L#_WIEEC8[-I)KO-[4+M NT3.JE.XWQHYA]G.VN8(!G$6YAZTSCG]]L,
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MA_\ !-^\.K5>:?DBY/G#Y8_0FVE?HK;:?R!8?_-]7M=,S]2C\$?-']#6R/\
M93JS^K^'_HC,9!ZRQZ%#2$-(0TA#2$-(0TA#2$-(0TA%@M<7T1GDJ7S"C7D#
MY*FJE&4-Y:W3N1?/4*=$R3N9;UV';O7CB/KT8YEW8NGA&"+;K!=) [H5C-VX
MI(3LEN1?VD(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI",=-P
M> 7&?&]-C5,FW3'<15)&;GEDZ,X3CY2:G7,(O$5M=W**&.9"/KJSY=WS*:8+
M*N 1,FN@9+E&F\%QA.#EUP4[3[KB4I^DM"4A04J0\*I 3)D!,$&<HAL8PA6+
M!I&?=8;;4I7T=A4HI*4S/@3,F0$R9$%)$XQ^4VI[JS(K='WYWV/,O$/4QCT,
M=U]\R0GG8N5.FM9*9F)*P)Q9%T69B-SN5%$2]+(DJ1-=$C29&L6KLQ>P=E4E
M"W.J!NB5A"0$SE>MD)\$D$I)5$=08]N8L\D739FTD7C.T%1*I9)"9EP@#)0"
M=Y;:?N93)#"QWT9+649Q;U"<2EZG$K-+%(K3"H(<OJN4BG\+'>" H,#BR72?
M)OFPR"+E-=PL4:#6+ 257\(IP"H7;JU32+OC!"C?FKA I*3<*2$B+OA_&@$W
M<5?) X4T)DHS/@(*1<DG@D*"A?"@5&-;C:KN"B;)3'U.W46R.@8R#Q12;6R<
MI/UGDO5Z7 -HBZ3/(FI"U1+FY7%4CY=!X1NQ=M'LH5RN[>$CD6KB@UAP9UAU
M%5AS1>4MYQ!$I)6M1*$\$((0C@@I)4DI1="4E94FBL QAMYI5-B#@:2EI"P9
MDJ0A("SPBL%:^$0J22%+!*E! 2J@97V,Y$R?/3LH3<?.U=&;O\Y9W#B%CKJC
M./*])FL@U^O2BX93+7%38W:3Z3."491<>5)&/256*HX444UFP[6VBP]I#9H4
M.%#*4"\470H7+RA]%>^E*2IP*6J940)) $8Z_5:LK75."M6@*=4HR"YE*K]U
M)^EN_1!0#=U*9703,DF+AR-LWRCD&5OCDVZ*XP?AM'C"A:8R#?,<@P]:7A:^
MS<U*-<P-QKV.V$",Y7 ?E4:UMO(\9)Z .2+*%<ZP4.L]!1(9'5[2\TJ]<*@6
MU*O*(60I"G"JZJ[(NE/!1P2!=C+6ZMUU8MY7/W4%T7;X!#B4W4BX"E:6PF\F
M],-A7"5)0)O15L8[1<CXXR)4[]ZSN0K$5S*VNQ9KJ\HP2"L9/FI[P@7B$H>*
M+)G)2(:MOK(J9%,#2#E1!LV047,FW;\Q97ZR4-=1.4?5[#<DH2PL'AM)3="K
MQE](I02)G@@$J( *E3R4.KM;15C=6:]]SA+4\D@7'2J\0$B? 2DK,O.) 2DF
M03=M2&V8YKJ#Y=*B[M[=6:FX= _5II:RY?1YI!_(/Y68?=:N[@>R$50DE6YV
M)"/"(E9MPCW!%V7!+6P[K1A54D&KPUIRH E?O@&0 "1((N6B=[@SO&^DA=L8
M&M6L3IE2I<1=0P3,HNS$S,DS*[]AD4\*5T!!!39'(:;/MP,+&M(JO[W,II,6
M/-1S1K-1'77-5\D%$,@:C('L3:95EVMF:N9=)X=R8PD.E&G*+ %DU[5:S8,Z
MLN/833WS:2E5WA7E&<KI3=*"$%,O"X.'(BJ=7,6:0&VL4J+@L 4)\&Z!*=Z]
M,+!7>GX&_,F#8,OM(WJ03:'BJ-O%EYZ,!9ZI,K6$9&G2*2B$F69C7T:K%M+F
MB=^_;NG<,X1$J,4FT,D],R<OTRJDW6M9-575*<J\+0ARRZ$R6+1=(,RBP$!P
M&U9,T!:4&1U'-7M9F@ENEQ-:T6WBJ:#.]>!$@NT@ELBQ$I+NJ6 1G%X 9*\A
MG@)Y6I/RO>"?-^6#JB/X^4/_ /5/"#P7YOJ_P4\(OM>I^/#JC^9\]RONVN2Y
MY0];<[YLGJW.?4WC]7DNW\M^[]_Z?"EN1U'-*[JKFG.%=8YOZZZ/K,MZYDN7
MOO/0X,]V/SPM<%'\VD:3_P 0_P#@F_>'5JO-/R1<GSA\L?H3;2OT5MM/Y L/
M_F^KVNF9^I1^"/FC^AK9'^RG5G]7\/\ T1F,-^U+[4C%_9H8HAIV9A1R)F;(
MQY1CB7%+62+%A+*1*;?K:UVN5!!VM!TFO*OFY5U2(JN7CA9-NW)Q%59#T?9[
ML^Q#7W$5,M*S&%L2+SQ$Y3R(0++RU2,ID!(!)W K)K]K]A^HN')??3G<0>F&
MF@93EE4H[B1,9+5&P2 4I/BWRM^L$]J1DR?=2L1G2'Q%#J.55F-2Q;CFD,XF
M.1.813;!*6^%N%JD 2+P#E.'ZG*'N\ X\-?56&[%=GU P&W:152[*U;KKA4?
MN(4A ^XD1\LXEMJU\KGRXQ4IIFIV(;;1='W5)4O?68BGWW7:J^V3??Q3Q3X@
M:D>Z79WV6SZ[O*1'=[FT+M%SU&_8B9,*=IQVVNXJ?F:OAG<OD*[3\!#-9Z3C
M$8W T(L1A(62"IT4FT4LM7AF\E*3-KL\?',6+8ZKUZ\>))(I',;AJ*Q;9_LG
MP-E-1BE RTRM12#.H5:$J69W5*D$H0I2E&24I222!$KA.T#:ICCRJ?#*UQUU
M"0HB3*;"I*!*\!,E:TI2D34HJ 2"8D]IO6[?5U!^$2NX.W1$4.**QG%)2RS6
MUBJNW&*[E-FK-<MC2+LC2*E':4A911CA:)HF?H/GK-!9!-1ZU*M'JU3V-)=S
M HFU.<Y73\%-6L!Y";ZD$IF!),U3)NE*5$$A"I2 UMVPYO.JJU)1S=#_  E4
MR9M+5<2L!1!(*I)D 5!2D@@%29U5YNW_ %A5B+E%7,F2UI%G5<E7AW L!VUR
M=G;U##]H?4O(]B5J\=%.K"6,K=GBW+0RG1OYT=NH9L"Q""8,:-6=BBY$4S 0
M7&FPH\Y"+[Z XTF^2$S4@A66R8O2)E&16L^VA,YONW@VZX4CFY5<944.*NB:
MI)4",ELC=F!.++N^_P"[=;';6FN;9N4M3)3(&2IS#U0BH^4VPV*Q2^2JQ/%J
MUDJ85BN1TM86+Z!L2J3-VHY:HMT%W* '4#I"/+VJ34O9!7*=334+9#+"7EDB
MJ2D-+3>2N^HA)"DS(D22 JS@F6M5:Y[7J-+1J*M0+SZF4 &F4HN(,E(NI)4"
MDV&8 M%O"$[H/O$_6$B'LY?*UE]0*9DJV8?LZS>(V_N6L1D>DUV(MM@K*[QO
M7U6JJI*U/-7K-RF<[*305XLUE^0<"X!JML5.;_LU-]+3H>1-50"6G%*0E4BJ
M?G)*5 \)!'#"9B,QUJVS#.?3O_15"V%6,D!U"0M29@2\U04"."H'@%4C%ORF
M_'MYX;(+7&4EN"O;:SO*K9[TDZY_;2M24Z72)>5KMUM3W)R$4KC6,@Z?9(-W
M&2B[F62*PDT!:+\AP)4S96]3]CCM$:]NC9-.'$-R_M.<OK2E2$AHG.E2TJ2I
M(""5)-X33;%J];ML3=8*%52YGRVI<_H"BZDJ2HET3: "DJ225R"A=)"K(O)3
M=A^L--D&[F1S#DJ$05DK;&.U+$MMDKH02E&0R.ZLS^U]=Q[ :C ,VN(;.JC)
MR?18YZG"N3-EUB@43ZPU;V)J)2W3,+-U!%WG2KV<S00$72;ZB7F@4(O*27$W
M@(SJUEVSH%Y=0XE-Y8-[FZ99L.E15>E<2 RZ0I=U*KBKI,<,=X/ZP2FM$M7N
M<KY$.YVTVVGQ#2=D-KT$ZD)6B59W=[<];(2S)FHI5(2G,S2:DZ =2'8F353=
MG(LD)[OAC8L0I2*1I24-H62D52@ XL-H!ND\-2S<#?UEZ8*0096G6C;*%)2J
MI6"IQ:!,TR9E""XLB](W @%5_P R[(A5HBBQ.][]8 G7&164/F+,$B_Q-*9'
MA<@QS6!P.K(UZ3Q)#0-AR*T%B6M"ZE3UJ"L[!V<S(KDCA!P!FXJ@4_)RN:I;
M&&DL*=IJ9**E+2FR55$E!XJ2T9WI"^I*API2(D961C3K9ME67DH??)8+H7)+
M,P60"[9*9NA0-@,QDG;%1D]YW;^0LM#P<QG^X14I-1EWG4VTC-;5F)8BMXXL
M,G4;E;+<Z=MD6='J$3:8=Q'%E9A1C'NWI2HMEECJ)E/8C578RZVMUJC;4VA3
M:9A-6;RG4A:$( M<64*"KB I24VJ  ,KE:T[9$.):<JEI6I+BK54PDEI10M2
MC.2$A8*0I=U*C8DF8BLI;I_UBA88Y,N3LPE>2CVZ1R$2K';=D9UL]Q^SR:_L
MR,M JPI)F$YMMAJTBR.\003EC0C@C$SD_-E/B.KFQ$7B:>FNI#9)G4W9.%H(
MDJ=U5K[5ZZ3<OI*[HG+)\2;:K!GG[RE+ $F+TVPZ5321>38P[=O 7[AN7C%K
M*[X.WV;&LX2.=,D0J5)K>%KA<'E@2VYUZ.J]8W"E8J8BFIV2FH5BPC65G2D4
ME%A44*,2F)CR(-"IJ"78&J.QI6;S=(PLNK?0@)YRHK533SR4A)))1(RD.&9!
M%Z8GKG6[;$D.*<J7$):0PM95S=(2FHNYE2BJ5T+"@9F5VV_=D97$ZW;?K![.
MSOJBMG*ZC+Q4U8:U++HS>U)>O1%GJLQ1ZU-UB7N"2)ZE&65M:<DP<0FP7?)N
MW4M(D9()J.2*IIX$ZM;%54Z:D4C6:4A*D\&K"E(6EQ25)0>&4E#3B[P3((25
M$A,B=CXEVS\X53<Y7G4*4E7"IBD*0IM*DE8)0%!3J$W2H$J5= *K(C;(O:']
MNYB.DQ61LEYTS!2Z9--*V\C)N;JN%T"."6V5OL)"-S,B4]22;R1Y?&$ZW<M%
M42.F"C'@Z31YYOSN_0ZC['\3JU4-!24SM4@J!2E;]EP-J49WY$2=;((,E!7!
M)DJ6A7:\;7,,I4UM=4OMTJ@DA12U;>+B19=G.;+@(E--WA 33/'WWW7:J^V3
M??Q3Q3X@:F^Z79WV6SZ[O*1!][FT+M%SU&_8B0\;]OUVI^/9]K,O-Q+7)4>B
MLDH\JN2L<8]E(&313.4YVJ[BO5RL61D18H<D3LY!NH #W#:TJ_8QL\K6"TBB
M+"R+%M.N!0\8"E*2?^\DB-V@VSZ_4;X==JP^WNH<;;*3\I"0KU5)^6/:YV5?
M:?8][2[#,K9V,(EC_,V-W,9#YAQ@$@,DWB7<J@X4A;75GZR:+F2I5I!BXZ*9
M4A7+1PW6;+<H4R+K_*.T39_7:A8HFG6HO86^"IEV4I@2O(6,@6B8G*P@A0E,
MI'U5L_U\H=>L,54-)#6(LR#K<YRG.ZI.[=5(RG:D@@S%U2KZ[2?M&L3=FW@U
M+*%]CW-QNMMD'-;Q+BV*?(Q\K>[*V:E=O#N)%9%T6#JM>:J)K2DB**W1RJI)
MIIJN%T4CZFHFHV):]8OU?1J#5(V IYTB8;23(2%EY:C,(3,3D22$@D;6O&NV
M':CX3UA6 N5+A*6F@9%:AE)-MU"9B\J1E,  E0$>)+,_ZPUVG>5K \D:QENM
MX,KJCE16.I^+*!45&S!N)ON*#FQ7J)N%GE%B)@ '4,Y23.;B8J28#R0^L,*V
M):@X<P&ZFF75ORM6ZXN9/B2VI"!O$^,Q\IXMMLUZQ!\KI*A%*Q,R0VVB4MR9
M6%KG++PI3W!DB$_?==JK[9-]_%/%/B!J6[I=G?9;/KN\I$5WN;0NT7/4;]B'
MONNU5]LF^_BGBGQ T[I=G?9;/KN\I#O<VA=HN>HW[$/?==JK[9-]_%/%/B!I
MW2[.^RV?7=Y2'>YM"[1<]1OV(R0PKVA?;=;@*/E7(>-=VTZ_KF&T(Y>Z*3".
M%X!XF$G7KG:T$XM&2H*2#U0E>Q_+.#<M5$@BW(@0QW*Z"*L#BVI&R?!:NFHJ
M_#4!^J)")%]0L4A%LEF7"<0,ARS,D@D3^$Z\;4\9HJFNH\046:4 JF&AE2XJ
MR:1]ZTL_<D.$4@S-9MR/;^52T7JF2>Z]0UEH<M)UI>)3DL),GMPND#3IG(=C
MHV-6D[CR&>7ZUUVC0#B4=(QZ:C<6QD 1665=-DU8EC MC-13LU2,.^@>2% R
M?(0A2PVE;A2X0VE2U!(*I&<Y@!*B)I_&ML3#S['/[SM/,$?0@J4E)4I* 0+Y
M2D3-V<YI F5H"J<&Z?M[BLLER3C=FY:Q^)&V5G-U=F6P^](T+AF[0F/+N1BC
M$8TDG;\4+386J+=0J8(*HG%<RB:)#G#+\.;';U.A.' KJ2R&Q],)Y]M3C<[S
M@ FA))&4&R1-D8$ZQ[7"FH6K$)(I@^5F31^H6EM<I))/"4)')*W);',/NA[=
MMM8+I49'>Y6HBWX_-BM&S5>5LV%&DLD]S18&%2QXPBA\FBD?8%)RT2K9@5=B
MX<,A66(<BYT1!76/X?V0%EJI1A3BJ9[.W5A+Y$F4E;A/TDTR2"J2@%2!! -D
M;"<;VN*==ISB214LAN\DEF<W)  625:0"4DIM!G(SCDR.XC]8.B8Z"G)/<S(
M,*S/PK2S)6YW+8 ;52)K1XG)D[+SUCG5J81G!,*C#XGE5Y<JX@X:%68 "2AY
M%F54C ]BSBUM-T -0A91< J"LKFTE*4IOS45J>0$2L,EV@(7+$O'ML3:4.N5
MI33K2%7R6 A*).J4I2LB0@,J*IR(FBSAHO6OCS=[V\>52925HN[&0ETL07Z.
MQO;3N38>@^<L,DDH[37AR3V-XU5W#H1B)G:CA8K810  3(HL8J0YZW5C8_AY
MIQ5X<$FI9+J)9Y7!$K#=<-I)E(3MRR%L8:/67:W7)?538@5)IW0V;&A,DD3%
MY(L 23XQDM,HKDAN6_6"(6.DY"Q;E+!4S04.YL=@B[B;"=0G*]62W+(^.HBS
MSD39:#%NXVN6V_XP>PT.].',2$@^BR$,!9)J8^)& ;%W5I0Q0H<"UA*2C/K2
MI=QIU2$E*R"I#;J5K2+4I2X3]6J61>L&V)I"EOUJFU(05J2O,H4E%]UM*E!0
M!"5N-%"";"I2 //3/BS6ZOMY*Y*75C8=X;2!B\:6&S5G)5RG)K!\+2<?R-/@
M\>3<^K:)^5QZS*VCT5<J0,<V602<!(RC\C=F#CB!QJUJ[L>?::<9PPK<?0E;
M2$I?4MP+4ZE-U(<,S)EQ1!E=0DJ5=BJ]8-KC3[C+N(A*&G%(<6<R$(*4M$S)
M'A>;0)><HR3>,4AEO![>>2A9.QL-U,H\@HF6VZPZ\H@XP<9LX5W2LJK(8G?Q
M_&B%5?Q!VM[A#3#E,HIPHR[0'/)%8NLJ]6-CS;J6',.2'E)J2!)^?]D*P\#P
M[#-MRX#Y]Q5V<C&%G6?:X^VMUNOFT@TPG]  >=)2ILB8M$EHO2\TK0%2*A$4
M[@NTG[;+:]<&5#S/NJN-;M$@QFY)M'M(S#,V12.@KS;<>KORNXRBKM%&,C.4
MIXLP6(<Z3Z-.W=I&,BX3,,G@NH6RC6"F-9A>'M.4Z2D$DO)M4VAR4BL&82XD
M*&5*KR3:"(BL;U^VIZOU(H\3KEH?(4976C8EQ;<YA)$B6R4F<BDA0F""8(]]
MUVJOMDWW\4\4^(&ICNEV=]EL^N[RD0W>YM"[1<]1OV(>^Z[57VR;[^*>*?$#
M3NEV=]EL^N[RD.]S:%VBYZC?L0]]UVJOMDWW\4\4^(&G=+L[[+9]=WE(=[FT
M+M%SU&_8C*_;)^L?=H)AVWQ"V;+%7=S6-NF(EL58M57JU/N/5AE2=+5JMWI4
M+!@SF"(@(H]9M))J8WVIB%Y7++S>L&PO4S$Z90PE"Z"NEP5(6M:)[E]#BE3'
MANE!\>Y'2:O;<M;L.J4]<+16T15P@I*4J _S5H2D@^-06/\ -,>U;WB.V+U'
MO>">&"_D \!/#+I/14_"?K/IO4/D[ZEZ1R?*#X9_Z#Z%SW-]9_:\[S/W;7RG
M\$X_\6_!F:_\9SUR5MV4KV<G+ZNY])>E.[N3LCZG^,L"^%OB_._^$9J].R]>
MG=S<IRSE_@2G*]]]=MCP>:\IC^<N-)_XA_\ !-^\.K5>:?DBY/G#Y8_0FVE?
MHK;:?R!8?_-]7M=,S]2C\$?-']#6R/\ 93JS^K^'_HC,>57ME^S0W_\ :";[
M[Y?\$4.O7/%F)Z;CC#T$XF<FTRJ*QTH2I1V3K$U0AK!+,WI2*O<DE4,N"?(6
MX@4#"*8@'U1LMU]U-U*U09H\7>6UB%2XZ\H!IQ<Q?+23>2DC(UDG9]V/)MI^
MH>MNNFM3M7A+27**F0VR)N-IE]&ETBZI:3E=-LK9Y?!U7_5V.U;\R-%].&+_
M !@UZ)WX;.]+=XA[V(\[[D-?M&1QK/*0^KL=JWYD:+Z<,7^,&G?AL[TMWB'O
M8AW(:_:,CC6>4B7,5]B7VUF$V>2VV+L=52G.,L40N-[9-PF>,<QMC)5/"ZKW
M1=I SL?:6DC!.7LM46B:ZR!P.JS,L@/VBIM1>);6-E6+J85B#SCJ:=[.H2IA
MTIOW%MS4DH(5(+) .14CE$2N%[*MI^#A[J]I+:WVLVI0>9!NYQ#A .<F)EL
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MK]HR.-9Y2'U=CM6_,C1?3AB_Q@T[\-G>EN\0][$.Y#7[1D<:SRD37B_L8>W
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M%NDL1S*Y/,"0_* 0-T0?YD -PRL[3MD5.M+C#CB%H<O@I:J!)>8%->$A8<P
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MU022D"1!F3("T6Y3*,N+JQ%-)+"Q_:RX@;D@DJ 43,$  3),C9D$XQ;4SGO
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M;( "?"EE//G'<?!)Y@LI1>! "YK*96IF))29V3F3+@SR"_ZKF[/U@L],C9G
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MS5HBFL+%77J#J?4>Y-BHF:G2*3A(QNQ32H<BHJ=)<IT&BS11<RJB/<#&C"<
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M'3,-M-53[:D)J+[+12$)* AI #:U--(6XF2EN7E+6XM?MMVE?HK;:?R!8?\
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M5-H,?S1#+&>VYJ;A7&"L3Q\%=(B<;O4:1*.Z?!9197!C25XW'SR'*9] MZ-
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MK!0YOG6"TZ,ZV%I_M"C-))$[&S*U)L,C*1E(B>=C9;@U3?S-8XJXNZKZ/(9
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M.Y=(^;Q^"/?]K;]97ZHZJ5;B"BG:H2Q(K65%2&Z=84I"ZAZ14TML!<FU*2D
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M.8P$* "(\-0M1@&L-4^NI>8!><45*(6R 23,F07(3-MF[$@TXPPTEEM+V;2
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M#,VA1V[>RS-F@M"'HD.4$Y-6/(DU4;+NRF<',53FD@267=?8YIE7QSGM1<<
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M8*MK2Z4,C%\V\,JHLHW.X(V:+&=HNO<<TRKXYSVHNZ@P/0Z3BF_9BAR-JPC
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M!!*2#9V1=I%UH67=W-%:Y]W77.'VN1=26:P5-C;',9?R,>VS<S &N;*FO[A
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MJNCM49(ZP-*PZOQ%G#:53%(IE+9$CGB^6UMJ2 @D#,/,J(D3G%+0+$A2H]O
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MU<7= /P9_P!O@_"/^*R7\ !Q$?\ W.^P :I_$IJGH&([S/*P[H\3TFGWU\G
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M76CJU2)AVW:D1J,=&P\](1K<[12Q'DF\X]7YA(&HLW+,I#%436)IUIB>DO\
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M7FIP=Z>[W_9SU$9G -)J^CM^\Q+9[']&I.D.>[0Z_P!S7FIP=Z>[W_9STS.
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M/YZ8FW(E?7B:'4WSC;[8\:!))1JC?(LJ_OCB,NQ%(4S@W5Z%A2+74QE2*%?
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MX*&0,'!) K?5>H<0]*EZ53<M%.OL/]&JZ-4\E%^U"XR$$RG&,WF?/L\]DDH
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MC824*(V;@@K,5ULUY\#)GZN%09!0JB!RM"4B_@RG..+ YDW4>$9*[9=MS,&
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MN$R9F[;%AW*&09'/5PC)"X7&GL)F>>L(6&J\?$M7#]T4RIT8Y@B1%(O< B9
M ->C/ZY:U8+1T5!A-?4T]$FC00A"RE(*E+)( \)M,9:?5/5K&*NMK<4HJ=^K
M-8L%:TS,@$@"?B$7O[I/LSO8@VZ^CN'_  >M3O(U\[6K>,,;G=]J3V92>I#W
M2?9G>Q!MU]'</^#T[R-?.UJWC##N^U)[,I/4A[I/LSO8@VZ^CN'_  >G>1KY
MVM6\88=WVI/9E)ZD/=)]F=[$&W7T=P_X/3O(U\[6K>,,.[[4GLRD]2'ND^S.
M]B#;KZ.X?\'IWD:^=K5O&&'=]J3V92>I#W2?9G>Q!MU]'</^#T[R-?.UJWC#
M#N^U)[,I/4A[I/LSO8@VZ^CN'_!Z=Y&OG:U;QAAW?:D]F4GJ0]TGV9WL0;=?
M1W#_ (/3O(U\[6K>,,.[[4GLRD]2'ND^S.]B#;KZ.X?\'IWD:^=K5O&&'=]J
M3V92>I#W2?9G>Q!MU]'</^#T[R-?.UJWC##N^U)[,I/4A[I/LSO8@VZ^CN'_
M  >G>1KYVM6\88=WVI/9E)ZD/=)]F=[$&W7T=P_X/3O(U\[6K>,,.[[4GLRD
M]2'ND^S.]B#;KZ.X?\'IWD:^=K5O&&'=]J3V92>I#W2?9G>Q!MU]'</^#T[R
M-?.UJWC##N^U)[,I/4A[I/LSO8@VZ^CN'_!Z=Y&OG:U;QAAW?:D]F4GJ0]TG
MV9WL0;=?1W#_ (/3O(U\[6K>,,.[[4GLRD]2'ND^S.]B#;KZ.X?\'IWD:^=K
M5O&&'=]J3V92>I#W2?9G>Q!MU]'</^#T[R-?.UJWC##N^U)[,I/4A[I/LSO8
M@VZ^CN'_  >G>1KYVM6\88=WVI/9E)ZD/=)]F=[$&W7T=P_X/3O(U\[6K>,,
M.[[4GLRD]2'ND^S.]B#;KZ.X?\'IWD:^=K5O&&'=]J3V92>I#W2?9G>Q!MU]
M'</^#T[R-?.UJWC##N^U)[,I/4A[I/LSO8@VZ^CN'_!Z=Y&OG:U;QAAW?:D]
MF4GJ1H/V2O9H%(<Q=CNW90Q2F,5,,>0I1.8 $0(!CD*4!,/<XB(!IWD:^=K5
MO&&'=]J3V92>I'6F\I?8]PU'VTV&Q=GC@V'M^XW.L5@\F.PKE$DY/&Z[[,%A
MPLYN5QFXY1>$"NIVVO'39 BH9:64.8C,JO,.3HN\C7SM:MXPQ?W=ZE6_^&4E
M@]".R_W2?9G>Q!MU]'</^#T[R-?.UJWC#%G=]J3V92>I#W2?9G>Q!MU]'</^
M#T[R-?.UJWC##N^U)[,I/4A[I/LSO8@VZ^CN'_!Z=Y&OG:U;QAAW?:D]F4GJ
M0]TGV9WL0;=?1W#_ (/3O(U\[6K>,,.[[4GLRD]2'ND^S.]B#;KZ.X?\'IWD
M:^=K5O&&'=]J3V92>I#W2?9G>Q!MU]'</^#T[R-?.UJWC##N^U)[,I/4A[I/
MLSO8@VZ^CN'_  >G>1KYVM6\88=WVI/9E)ZD/=)]F=[$&W7T=P_X/3O(U\[6
MK>,,.[[4GLRD]2'ND^S.]B#;KZ.X?\'IWD:^=K5O&&'=]J3V92>I#W2?9G>Q
M!MU]'</^#T[R-?.UJWC##N^U)[,I/4A[I/LSO8@VZ^CN'_!Z=Y&OG:U;QAAW
M?:D]F4GJ0]TGV9WL0;=?1W#_ (/3O(U\[6K>,,.[[4GLRD]2'ND^S.]B#;KZ
M.X?\'IWD:^=K5O&&'=]J3V92>I&+GNPNST]=3P"]3K O@=ZKGA=X.^ D9U5X
M2^5CJ;KKH?)YCK'JO[ASO#E\U]KQX=S70_'^NGPGSSK.LYUUC<O9PSNYF]=G
MX)VR\,<]\#:G_%?->KJ7F_5]^[<LO9Z4_EE9'D+'X!X_!P'CKY^.2W)'\^@R
MQE5FBO9FA,2XZ7R%DBLSE8DTH9Q5J(B+V/M,*Q/4FK^%E%XV6IE:7?11(64*
MW%RT=2"":IR@H?[HD<][H=2WPU32<@\%EAR#YS'KFN>'ZX4>J>%KQ_$:5_#'
M,R6*87T/MI+"5-K*'&&BIL-K";[:W4A1 41>05>WK:5^BMMI_(%A_P#-]7M=
M$S]2C\$?-'[?[(_V4ZL_J_A_Z(S&SM[_ ,;G?_Q$Y$_Z%6]=#C>2C_(6OG7'
M3X+EK/RYSYDQUH[H^V@KFV7/N2,$N]OEAN+G'4C"QR]F:Y"BH5M+'F*I7[2"
MJ$8M6)%9J1NG/%0$#+&$QDA-W $ URC]>EATM%"B0!:);ORF/F?:M^]SJ=LE
MUWJ=1L8PS$:FOIFV5EQHLYM0>:2ZF5]858%R,P+0962,0%]85J?LKVCTK0WB
M5K%UHC[-?^CY8\Y_Z@6SOL7&-^GY2'UA6I^RO:/2M#>)6G6B/LU_Z/EA_P!0
M+9WV+C&_3\I#ZPK4_97M'I6AO$K3K1'V:_\ 1\L/^H%L[[%QC?I^4A]85J?L
MKVCTK0WB5IUHC[-?^CY8?]0+9WV+C&_3\I#ZPK4_97M'I6AO$K3K1'V:_P#1
M\L/^H%L[[%QC?I^4A]85J?LKVCTK0WB5IUHC[-?^CY8?]0+9WV+C&_3\I#ZP
MK4_97M'I6AO$K3K1'V:_]'RP_P"H%L[[%QC?I^4A]85J?LKVCTK0WB5IUHC[
M-?\ H^6'_4"V=]BXQOT_*1D-MO[8I#<K:;)5:SMU>U]S6JTG973J=RHT.W<-
MU9=I$%;(%CZ"Y5Y_G78'$3 !>24>[QX!K(WB"')\!0E+++=GX#XH]<V6_O1Z
MJ;5>>]48=B%/S'-7LZ6N%G;\KMU9R7#.?AC,+UPK5YH87TH.OFVUEYVGP&/6
M^\7#='?_ -#VH>N%:O-#"^E!U\VVG.T^ P[Q<-T=_P#T/:AZX5J\T,+Z4'7S
M;:<[3X##O%PW1W_]#VH>N%:O-#"^E!U\VVG.T^ P[Q<-T=__ $/:AZX5J\T,
M+Z4'7S;:<[3X##O%PW1W_P#0]J'KA6KS0POI0=?-MISM/@,.\7#='?\ ]#VH
M>N%:O-#"^E!U\VVG.T^ P[Q<-T=__0]J'KA6KS0POI0=?-MISM/@,.\7#='?
M_P!#VH^16\"WS$\]@6V(*^DLPA(V;5<.<J/B)'1DI&5CDD$BHXO7.*J:D2<Q
MA'DEY)R\.(\>'QM^]G^^WJ/^Z,O D:X8/BN*''DU9:YF:<9OFA8"\YGG&_.S
MZ;MV>0SE9'J&SJA7M':JW<-4*<4BVTJSMM[.!1$KE[)=,YQ35=ZEI0FK#!K8
M<A>DUY['LG"R64W9V[@TA!14\F= 3XS25 J:$J5,P&* \L@\.(<!UUNP']ZW
M53]X+9JQM-U>PS$:'"ZBKJ:<-5!9+H53+"%*.;<4FZHG@VS\(CTIC9+BS]^5
M73"XJ[D7X ?1\<;OKH6?S/1'I0<_-OKV?O"P_1W]]'EC8[G<7TREWG/9AZZ%
MG\ST1Z4'/S;Z=X6'Z._OH\L.YW%],I=YSV8>NA9_,]$>E!S\V^G>%A^CO[Z/
M+#N=Q?3*7><]F'KH6?S/1'I0<_-OIWA8?H[^^CRP[G<7TREWG/9CJ<KG:>[I
MC=J9<-NZNT2DM=M#7;]5+<TBF=II*%NC91KDV?"$S]+6!" /+NZE*7%5W'(0
M(,1D(X01F>:2,NYXRRM;<-3A0Q22[I7<N2MO@!13/S9A)G.<B; 9Q )V=8TO
M'#@=YL.);SA<GP<V24A<O.D5"4I7@+2)1VQ^NA9_,]$>E!S\V^HGO"P_1W]]
M'EB>[G<7TREWG/9AZZ%G\ST1Z4'/S;Z=X6'Z._OH\L5[G<7TREWG/9C43>=9
MSG*0,/0X"<Q2@(Y0<\ Y0@'$?_AM^WJG>%A^CO[Z/+#N=Q?3*7><]F.J*W?K
M&M0I]NMM/?;2KBZ>5&TV.JNW;3+5>Z*[<UR9>PR[IMS]/26!NY59"<@'*4P%
M, "''4=4;5,+IWU,*I:DJ293!1[4?4NJ7_IY[0-;M5\/UII-8,$:I<0I4/H0
MM-7?0EP3"5762F\-V1(\<6]]97H_LA7GTLUGQ3UA[V\)T2IWV_:CHO\ IH[2
M?_,F >I6<A#ZRO1_9"O/I9K/BGIWMX3HE3OM^U#_ *:.TG_S)@'J5G(0^LKT
M?V0KSZ6:SXIZ=[>$Z)4[[?M0_P"FCM)_\R8!ZE9R$/K*]']D*\^EFL^*>G>W
MA.B5.^W[4/\ IH[2?_,F >I6<A#ZRO1_9"O/I9K/BGIWMX3HE3OM^U#_ *:.
MTG_S)@'J5G(0^LKT?V0KSZ6:SXIZ=[>$Z)4[[?M0_P"FCM)_\R8!ZE9R$/K*
M]']D*\^EFL^*>G>WA.B5.^W[4/\ IH[2?_,F >I6<A#ZRO1_9"O/I9K/BGIW
MMX3HE3OM^U#_ *:.TG_S)@'J5G(1VI=G+VBT)VAE=RK8(7%$WBLN+;%7*^Y:
M35HC;0:9-8HAW*I.VRT=&1@-"M2M!(8ARF$PB @/V-=IJSK+3:STCE72MN-(
M;<N$+NS)NA4Q=)LMCY1V_P"P+'OW?=8Z+5O'Z^BKZFNH>=)73!T)2G.N-759
MU"#>FV38")$6SG$O?\0+_<Y_VUZ],_P5_>G]!'R__C/^[/Z>/ Z;^*/[@_#\
M'P:\M.0Q_.2,HC-_=:XR?8L:8"GK;C&SU"HU^H-*G6+3+(S8QEE1=56K/&9D
M592\W!FTD%TXATL+9DWAFQ40*;HA515 F6H*RA)4DA-T@'PV#QGP'P?)'NNU
M-S6C$M6M7J_%L+J:/":>E0PR^L.W'@665)(+E54)2HW%JN-HIT!,CF@J^![1
MMI7Z*VVG\@6'_P WU>UT#/U*/P1\T?M-LC_93JS^K^'_ *(S&SM[_P ;G?\
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MH>V2$/$P+^4=HQ)VT4DZDK"Q06*X,DHR4=I Z*CRPU3-K\!C$<%Q89:=R9)
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M7>5@6)A\,!LDDI%X>;-20NT^('A&4@01,Q%IUIP55*JJ+P2$I4JZ?/(2LMS
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MJS_^&I_]6(OUHQZ=#2$7Q4LDW>B15LA:C8'4"RNY*JG9!8E1([>%I5G9W*M
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MWT"@]VA[@?L[_P"C67?3%:_PFG=UJCHQXQWVX?QS_O-=OM] H/=H>X'[._\
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M+,!8+1)5Y<JJCPZR0HLB+-@^XH*$:_< JXN\V$RE=$IVVV;LX]&UHUXJ=9,
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MNNWKTS9K-LU2,P>MDT7,>V3*L5L5<BF*DJM0^;-IK6'S4YE 61,"^ B]=NJ
M$RE0O73,*497I$9JNFUZYRXJB?8%-GEE"3(FX2N[>O)),@I) O  I2)W9@T/
MJOM1WDY=63&Z8M9QL0Y2&'E):L5Y-M.*NXIU(E9U=BW:*.>JHT))%!561=<Z
MI(-4TBJ@B5TLMESFSU++2UM5!<4.$ M4TR($UDF4S(D!(E=),IE(&'-[05/.
MH2[3AM)L)0GA3!,D"603 )4?. $Y!1-<KE%[1LUOH[&YY0HK['L5DB'D;6_B
M$8F)MLQ463VPO7@F<L8-%HK'NU%6Z9H<K9)0&R;,AGRW"0!;$_6:C<V>72T[
MPK5,*" J90E9"0+"J<Q:;\R)E1N#@2RL4>O'.645=0R:)+Z2LID%E *B;0D"
M1L%R62Z"L\.=E2N->U*GV;9Y(Y=QQ 3J:L44K>B+LF$'_HV1>RR#B3:SU0DS
M/43*$10=I("V%ZD;FU!.WY20;3=?L\944HIGULR/U@)5: ) I6);I23.Z;1)
M5L:KE#M">2%+J6$.S'U<@FPDS(4@SW 0)7A89ILB5LA-NT</8DS8Z>8>2@>D
M/E7_ %L]9 D=FX94M&):0;56K.))H[C'1)=9XL\=.2.E#&(D1)/HXA'4*M10
MQ_;A59Z0E=!R@KF5&_(@BX$A(!&4DF]$C6IUY+W]A-+F9F=XC(0B02+A((-\
MJ*B9Y  +L63'4WM/8D&3-KD7%DBV(]3<RLK91CY.9DRLBQ"2R94VE3CXF/1F
M5&!P3(T0:D;LG"YC$Z:9-<NVNJV?NS4IBH2J4@$S"1.]X5E1NSMF3-0$C<F(
MU&Z77]J24OTZDSF2N1492\" !>E8   DF8OR,5.XX@WX+DM4A3,S#%RLOFB3
MFH1@>?B74'#8NC$XI[3(HC6:I\FJ4@R;1WUHU(J"CTKLJ2JRC4A4$\=+B>IP
M+:*JEO-II E1ND*4Z9A9FE8W"+AE),I@!1F;ZK#-<"'%TE5=<55E21>!2EH2
M*!)2#N@WQ/A7I$E(D*D]JO:..8>D3*%YQ(TR"QE,A(V^/0072QZ[K[VQU.1I
M+!"*6:/W<@*,?#O&QY$1:2:#-X=,OW817-8BIU%2Z\TIFI-$4MW#_M H)6'"
M3, 6J2;MJ"I(.2R,JZ?7A33+J7J85H4Y?'^S*2I!0)2)-B5"]8L)41EMC@XK
MJW:2PTQ7T<AWG&DI5QD;.\LI4F\;+6 &TU%Y!DXT6DD>/B$7#F)O<G"))QZ2
M+)BC7&@H)+@OW2W8C4:B.M+-"S4)J+J FTI3-);!F)JD"V'#>)4HNF9%V+,.
MI]>FG4"N>853WEE>12I*#A$C)-J7"@79)2&A(&]'#7A>U)=M&8-K=@Z&D"0;
M]23%=%C+L%IY!O*+0[:+%.HQ[E-H_,2-1>J+E'FUS/SHEYH6G(O#NSQ*C>:J
MUHOB4II-TRO$\,B8X12!E%P&V].Q36T)21=<I$+N&>10O"=T#@ R/!"B<AOR
MLNRNJY5#?L^CKFWKETJ*+QY7,3RM4?MG;*"7:Y"KCS";B^%7:N8ZSM4JU9R0
MUL36C0/T(B"R90,X.]4.TUZ6JU-0MI3[3MT./!8(*IMJ#X;M!0;Z+S)"_.F#
MYH0 K8JJ77%:'4L.M!10R4$$)DXDL%RPA8NKNO I\V1'G%9*;7-5.U$!TUD$
MLFX0&0?NHYC-QB\"W3I$/%I6N^J24E66R<.ZMCN4Z@7A ;G>O0(NWY::S=-R
M@*[G/SG9[=*#3U=P E)O'.*-QN06;P0!>SD[J;#(A129)P&FV@7@M-127R0%
M I&;2+[DR@72LF[<E>5:+"D*%Y5QT"$[21.U4UQD6[X7<U5M8:NM<(^"KC9F
MY?5LR/-VMH@\.9XX%^BY=+&;F1*UYTC5HIRDA6=-B8:UW40TSJ:%JK%24+N%
M2B0%?>&5@E("<YR)4+9)4<U$UKT*AHUSM*:<+1?"4@$I^_ -IG:92E,!)F)J
M2+JA\=;M?"VZK6>^-'<*_P UXLNU8=P%H<Q<<THU<LL%X>5-.MN(9T\C8"R4
M9VNUZM.^= I)11W)UP,_Y1=9VNU:YLT*=DAU-(\VL*0"2XI*LVN\% %27 #?
MNB25A(' MV6J'63G+IJ'@6C5LN(*5D -I6G.(NE)(2ILD7;QFI!43PXBUU6.
MTVGI%,DI;<4058=7J'4>QU=D6R%@846/RB28638V0E3;'<R3ZA"6/>\44.?;
MI&YD&[I4RH2*:C4!E$VVJE=0&52*@2DN%J[:F^9 .<)-ID3;>2)1'JI]?7G)
M..TR*<O)F$D!0;#MZQ5P3);X*K!,"R2C.)4QW1=V$ [KCZ\6;PJ5K>8LC65^
MV0OH)1UNQU:ZE<(B'KSQJ:KMBH)P5U+&S,<U/RB1K-V#0BAQ:?;1U=6:MO)<
M12-YL.4K20<W:AU"T*4H&^?.;O(4?OE)O2%Z)"AH]8V5-KJW,X6ZIU1&<L6T
MM"TI21<'FKNK2/O4FZ";L9RZY".NAI"&D(:0AI"&D(:0AI"+*OF1J-C&%&P7
MRS1E:C#*E:M#/E3G?2T@I_\ EXB B&I'$O8IQZ?@1NP8H.'CE00(DD<X@ [=
M'0U>(.YBC;4XY*9ED W5*49)2D;JE$) M) C4K*ZDH&L]6.);;R">4G<"4B:
ME*.XE(*B; #&'W@9DGPM]<?P/L/AQTKJ/R0<XU\+_5BZ%S7@ET'GN@^5#PA_
M[:=7\]QZ3_H3G.=_G&NGYU0<V^%\ZCFDKV>MN<[GY\\N:N_07I9/I92X,<SS
M6OYS\49I?.YW<S9?YK*5R63.WOI[L\OT4Y\*/":/P#\/P#\'P_!]C]O7D9R1
M_.F,L9S[NQ*&+-IJ)5L='YO%+TQD<<)@BV0,JVJIQ\+4P<N \.E"\!D3<""<
MW)'DZRU'U:,GF')]S+XX]ZVN$?"^J* <-,L+-E&) 32Q^,"\?[4?]L;)F1E'
ML^VE?HK;:?R!8?\ S?5[70,_4H_!'S1^T.R/]E.K/ZOX?^B,Q/$@JP18/EI5
M1HE%I-'*LDK('138),$T3G>*/CN1!N1H1N!A5%00(! 'E=SCK.@+*P&YEPD2
MEEGN2E;.>2/0%E 02Y(-@&<\DMV<[)2RQTI9*WV=B+BZT2-?G-PF'Z[--W2R
M<I'86FLG.(%)Z0YBN <A@1%U4P=E5 ><XCSG+X\KN\=>K4&J&UC$*=+S-%4K
M:(L+Z6@J6Y+G$ER\$>7U^M6RZ@>+;U73H7,S#!>*9[OXN"B?A\<1][SGL,?:
MB7^4-X?>_6]\ [7.SQO47EC1^.ME&G*_/O9A[SGL,?:B7^4-X?>_3X!VN=GC
M>HO+#XZV4:<K\^]F'O.>PQ]J)?Y0WA][]/@':YV>-ZB\L/CK91IROS[V8>\Y
M[#'VHE_E#>'WOT^ =KG9XWJ+RP^.ME&G*_/O9A[SGL,?:B7^4-X?>_3X!VN=
MGC>HO+#XZV4:<K\^]F'O.>PQ]J)?Y0WA][]/@':YV>-ZB\L/CK91IROS[V8>
M\Y[#'VHE_E#>'WOT^ =KG9XWJ+RP^.ME&G*_/O9A[SGL,?:B7^4-X?>_3X!V
MN=GC>HO+#XZV4:<K\^]F'O.>PQ]J)?Y0WA][]/@':YV>-ZB\L/CK91IROS[V
M8>\Y[#'VHE_E#>'WOT^ =KG9XWJ+RP^.ME&G*_/O9A[SGL,?:B7^4-X?>_3X
M!VN=GC>HO+#XZV4:<K\^]F'O.>PQ]J)?Y0WA][]/@':YV>-ZB\L/CK91IROS
M[V8>\Y[#'VHE_E#>'WOT^ =KG9XWJ+RP^.ME&G*_/O9A[SGL,?:B7^4-X?>_
M3X!VN=GC>HO+#XZV4:<K\^]F'O.>PQ]J)?Y0WA][]/@':YV>-ZB\L/CK91IR
MOS[V8>\Y[#'VHE_E#>'WOT^ =KG9XWJ+RP^.ME&G*_/O9A[SGL,?:B7^4-X?
M>_3X!VN=GC>HO+#XZV4:<K\^]F'O.>PQ]J)?Y0WA][]/@':YV>-ZB\L/CK91
MIROS[V8>\Y[#'VHE_E#>'WOT^ =KG9XWJ+RP^.ME&G*_/O9A[SGL,?:B7^4-
MX?>_3X!VN=GC>HO+#XZV4:<K\^]F'O.>PQ]J)?Y0WA][]/@':YV>-ZB\L/CK
M91IROS[V8>\Y[#'VHE_E#>'WOT^ =KG9XWJ+RP^.ME&G*_/O9A[SGL,?:B7^
M4-X?>_3X!VN=GC>HO+#XZV4:<K\^]F'O.>PQ]J)?Y0WA][]/@':YV>-ZB\L/
MCK91IROS[V8>\Y[#'VHE_E#>'WOT^ =KG9XWJ+RP^.ME&G*_/O9A[SGL,?:B
M7^4-X?>_3X!VN=GC>HO+#XZV4:<K\^]F'O.>PQ]J)?Y0WA][]/@':YV>-ZB\
ML/CK91IROS[V8>\Y[#'VHE_E#>'WOT^ =KG9XWJ+RP^.ME&G*_/O9A[SGL,?
M:B7^4-X?>_3X!VN=GC>HO+#XZV4:<K\^]F'O.>PQ]J)?Y0WA][]/@':YV>-Z
MB\L/CK91IROS[V8>\Y[#'VHE_E#>'WOT^ =KG9XWJ+RP^.ME&G*_/O9A[SGL
M,?:B7^4-X?>_3X!VN=GC>HO+#XZV4:<K\^]F'O.>PQ]J)?Y0WA][]/@':YV>
M-ZB\L/CK91IROS[V8>\Y[#'VHE_E#>'WOT^ =KG9XWJ+RP^.ME&G*_/O9A[S
MGL,?:B7^4-X?>_3X!VN=GC>HO+#XZV4:<K\^]F'O.>PR]J)Q\H;P^]^GP#M<
M[/&]1>6'QSLHTY7Y][,99[3=WO949AO;>-VQYCP?9<LO"*-XU*5<RL;EN636
M**:[*"<97:1]]FB*)F'G$&9U@$O$3%X<1US6L>K6T3#*0N8_2U;>'"TW9%D>
M-09);3XBJ4=)J]K%J!B-2$X%44RZ\V)O7DNJ\(27@'%>,)G':-KSZ.\C\U<W
MP#^X/[VN5.0Q_-$,L9Y;K6$(CB' <LPHU';3DW3:Z-FR!&L9J-N[U>&JK&,C
M(6P=(L(0TR@Y9@)A=)0R)D^@I)E7$.6"F5]*4H"@D7BFT[ID)"?AWMR/H#:J
MU1C4_5VI8HJ)-8[2,YVI0EU%02AA*4MN7GLTX"FTK33I(S:$AP\*][,]I7Z*
MVVG\@6'_ ,WU>UT#/U*/P1\T?LWLC_93JS^K^'_HC,>/W]95[0O)$YG ^PK'
M5GDJSBS'];K4]FQO"O5F*^1;M;XY"R0U6GW#50BCNH56KO&+GH F!%U(/3&<
M$.+5OR/KK8/J30M83\8US:7,0><4EB\)YMM!NE:9Y%K6%"]E"4@)(O*GXIMT
MUWKE8F=4:!PMT;2$EZZ9%:UI"PE7A2E"DD"<KQ42)I01Y2  "@ %    X  !
MP  #[  '< -?1T?.!))F;3'W2*0TA#2$-(0TA#2$-(0TA#2$-(0TA&3VU%U@
MUI>+@IF\M+ #8QL2>*'&4HW($SB)GELTQ6QAW.4HK%A5+V]K'@D6:3; S353
M),G8G<$,W*KPYW61.+KHVAA.=^O3G@T6P\6;JIAHN_1A5_-SO$<"^$F\1'2Z
MKKP=NL<5B^;^I.:S@<+8=O)EG U-=VY? N@R64$@H"H[):U<>R$"Y5U^UIL8
MUK\KD3-%/?Q&08O*KB.K&-J/ 9]L&%,FR3ID2P/7,EEZRWRBPJ[84)!S&M:<
MHJ];@+I8Z_"/TNTLTKB%NJ+R6&%@MED%;KBJ=+[0!N@!E#=0L&:0HO (5P0$
M]VQ6;.4U39;0 T7WT26'B$MH34*8<*A>)+JW&$$25<#*BH<,E7 KEJ[)UE&X
M,E;K7ZU*2N,Y&W6G-L#6ZKE1V7,736V84:O0Z[PE*;'R\6$XXJ[ATHZ7K?06
M#5$K14W/ODD[WZ;:.M=6W2K<2W4)0AA2ELC,RS-]Q7!60;N= "0[>425"Q!-
M&:S9X@4KE0A"U,*<6\ E_P"EF7KB$<) /"S5XJ+=U'FDDJE#M@H>P)1M.15/
MS7B;FUMO.6J)4[!:87/;&53SK&;HYR<QID^SMH_',FW:-[%MH!E'I';@Y33=
M"*3EFBJ KZDVJS7,%#E325,Q6LN+2A5.1F#2)2ZT@ET$E-5>49R)%J5$61%K
MI-3;JFF:I@@T;K:%*34@YY-6M2'% -D +I;J1*8"K%)!MCD8))V:2N"<05#,
MT]U=F6;LEK#,=_&GY!D$Z;4<LQ>5<>U]U!.H=ZJUFY[;K*PU+NW1$XHB3M&1
MD&Q',@H86C>F,?'@Q>JJ<+1>PM#:,PW?:%];*FG5!5X32FI2I]B\5S24H44H
M'"4P@ZB]44E/B*[N)*<5GUW'5!"'DNM BZ9*+"DL/W0B2@IQ%Y9X(O)>W=F/
M98&VOV]1HN.'4C *NX-NI%YBLEGB'L9N2S,>$ID?7 :JUATZN. U*AUM9#S;
M5Q"&1#F&SY11ZW+K"EU^IWFD*<=?2E<E&;"4$&E8O+*IWP$5&>N-YLA<^$I
M"%1L\\U$J&77 VVRI39NCZ=2@14U!2@)\PE3&8O.%8*2."E1*DQ9=]EMB1\W
M[MGN.T\'MH!W U4VT\;? 9MDL',X].:=!?F<M$UBMP=X0RDZJI&H0BTLQ7AT
M70N0<K'<"W<!GHVM<>J<-16\[+P6KGEQ3 ?)E]&05+4WF@J=\(4%D7;H";R8
MMJZC4WK7$7*3F]PH'-;PJ,T!+A A* YG)>;?24><%&\4*%^TO(O9P6)T9WD2
M@X*JL(TQ[M'&T1D12,\-9^;6<8_OCW>%%8R/7YB1189B3R$XA&U>?2#AI MR
MI\054:%<"IJU5#KRPF[1/5CCI>K+A*Z<I3)QL41=O)$V<V'"XE(4X9Y J[+9
M8Q'4BH6553=,AH-T@6 FIFI.;6:L-R,@]G2@-J64MB7HA4XZP:X[.F/PQ@!#
M)(04_G"$RHM?,QH71ME& JE@QO;!R=4$<8/;E2XNUF6D<9(P53M146]>!F]<
M23EHH^<)*+HM-W%DZ\N8K6FAOHPE=/FV;A94M+B,TO.A"RBQV\\U,NWDA"5!
M"2 5:.%.:CM872)JPA>*)J,X[?SZ4%"LXBY?0%6HN-.@9N1OK25*M"9KI\KV
M639W#];/L52"D?%;EXMJK+4/,\;&W"6=VQ-[@[)5W26@K 7'+M2!4-'M*@R1
MLT6R;(%=+/DUE3H!$U36T-2%YL5"0HTI,G&"4 (D^TCA)S@O<(O*+2E$W0@@
M3B6HZC9\EQM3BF3=YT+45 "B5S9<6+JKA*>"&TAQ*0+RE7C*([/(=G(YJ)FR
MRF+*Y9)':8ZA7+J'@<XW)6BY\C$ %E.U\9BLUUODVW92?HB#TDB,,PHI' '8
MOI9)/F0W\WKRFJO#G#E.G$@H JIT9RG)M2JZI6:0T/-NWU/RDM#9,XCP[J0:
M.ZHLHJ%8:4D@5"\V^!84WDISBG5>=>N(9GP5N!,HR2<VOL5U[,Y5JU;J,<DN
M^ODP0EQA<S^"S%\YQE-4FF5E@?JBRN#U1G=:''VLJ[E@Y5!Y=%&ZI#(LS)HP
M0IMJB:<"H6XHA+:> IB^0'4N+6;4B^4.*9D% 76 H&:YF;%9LP55380E*;SB
MN&*BZ"6E-H2)!1*0MM+LRDF;UTV(DF)*]?.RMAH;!T@>B463N;%7'E1SS%VF
MM9=G*9.QS#;A?)FTY*K ,WL4[82TGGZ6B(21:I<@O^AT7C5$&CMP*<E44>T1
MUZK0EUU-(K.KIRA3*5I)J6TH:7,$$"G2MQ*K?/*5&\E,]"DK]GK+-.XIM!K4
MI:0Z%)?*%2IU*4XF1!!+R@A2;!P M(NJ5'2T^>FDGKR1,QCXPT@[<OC1D2B=
MM%1QG:QW L(QLJNY4;QS,5.;03,HH8B12@)C"'$?56T9MM+9)44I F;29#*<
MEIRFS+'DU2M#E0MQL!+:ED@#( 38!.V.-K)&&&D(:0AI"&D(:0AI"&D(:0AI
M"&D(W6SAPS=-7S)RX9/F+E!ZQ?,UU6KUB\:J%6:O&3MN=-PT=MEB =-5,Q3I
MG #%$! !U:I*5I*%@%!$B#:"#E!&Z(R-.N,K#K2BEP&8(\5L>JWW]67_ '//
M@SX;/O77\H_JV^4OG0\*/)MX->$_EHZ7_&\./!?_ $!TWASW6_\ I+E<]KYS
M[G,-[SL_FA\*YCG.:EP,[>NYB7H7OI+N2Y]'DCZ-[X,0[M,WG#\39[F^<GPL
MU=O9Z<YWY?17IWI_23O1UP&_BC^X/P\.'P?M]S7Q <AC\3AE$=@^[N+5=88V
MY3\\JYK<U'T"NQ$!59)3)KY>WUZ4@P7?76-7N=>AJ[$A"#"1[:10C5G NW$D
MBN(%2!,ZN>H'T:2;%7;!;:/#;X+)_*(^B=K5*MW4S5NOKRNFK&Z%AMIA9K5<
MX:6T2JH0:AEME&;S;2'4LJ7?4\E<@BZI7L>VE?HK;:?R!8?_ #?5[4\S]2C\
M$?-'[);(_P!E.K/ZOX?^B,QT=9O[+C9ENHW#[C\T9KHENL.09O-$S"2,G%Y+
MMU;8J1M7J5*AX5%*)B'J#% S:/0*0QBEXG$.(]W7JJ=JVNFJ5!18)@;S#>'H
MHD+ 4RA9O+4XI7"-MIW-R/.]8=3]7\:U@KJ_$62NJ54D$WU"Q*$ 6#P"(Y]Q
MAV;?FHOWIGR#WSU;W][2]*INCMQ$=W6J.C*XQ7EA[C#LV_-1?O3/D'OGIW][
M2]*INCMP[NM4=&5QBO+#W&'9M^:B_>F?(/?/3O[VEZ53=';AW=:HZ,KC%>6'
MN,.S;\U%^],^0>^>G?WM+TJFZ.W#NZU1T97&*\L/<8=FWYJ+]Z9\@]\]._O:
M7I5-T=N'=UJCHRN,5Y8>XP[-OS47[TSY![YZ=_>TO2J;H[<.[K5'1E<8KRQJ
M+V%_9MF,!?)1?NZ(!_7/D'[(\/C/5._O:7I5-T=N'=UJCHRN,5Y8QE=]F[V1
M[!*70=X=S.$]&+6UDU@FV3<C.AG)2HO7R#N)B9<DH6+5?JQ[5-^H4YR%;-%P
M$QC*$,GKJ4;3=KSA0I%70<W4&R5EEH74N $*4F5Z4R4"4[RA9808AE:K:B(O
M)52NYU)4+H4LWB@F8!G*<A>\0/A$HYE5[-?L@;FG&)P.-<LN9*8A[7+Q;$^2
M\H-VLD6C5U.QVQ*.F7+Y"-<I1#=4J)EN40IUC  %^$ LJ]I^V*B*C45%$&D+
M;2HYEDE.=7<;)2)J%XVR\&[%S&JNH50$YJG<*U)40+RP#<3>5(FRS)/PQ;M4
M[/;LA+!&MW,GB+,->E!0;.I&+\I^499K"M7\V6"CG4O-E5C6L.V=.!,J*D@F
MQ*F@D<YOM>;%38J]H^V*G=*6JJA<:F0E69925$)O$)3-140+)(*ID@#=EA9U
M:U#=1-=,ZA=DQ>60)JNB:K )Y>%*R?BGSENSI[(9.8,P;XAS1*Q*==:V%>P1
M&3L@O6[)%>LS-Q60D(TTTA)H UKL6FJ95,BQ"*.!*J"14%E"V)VE;82SG%5=
M A[.% 0IEL$D+2V"%2*3-:B)$B8$Q,J2#<=6-0PY<%,ZI%P*O!2C+@E=HG.Q
M(G.W+;*1,9-M^PX[-5VW;NVV+;VLV=MT';99+-=]526;N4B+H+)*I2JB2J:J
M2@&*8AC%, \0$0X#KEE;>=IB%%"JFF"@2".;-V$6'<B:3L[U04D*%.J1$_K%
M>6-WW&'9M^:B_>F?(/?/5._O:7I5-T=N*]W6J.C*XQ7EA[C#LV_-1?O3/D'O
MGIW][2]*INCMP[NM4=&5QBO+#W&'9M^:B_>F?(/?/3O[VEZ53=';AW=:HZ,K
MC%>6'N,.S;\U%^],^0>^>G?WM+TJFZ.W#NZU1T97&*\L/<8=FWYJ+]Z9\@]\
M]._O:7I5-T=N'=UJCHRN,5Y8>XP[-OS47[TSY![YZ=_>TO2J;H[<.[K5'1E<
M8KRQ'.5NQ3[/&JU%&7A,7WIN^/=\60AE%LP7QT08ZTY1IM7FDN:6D3$!1>&F
M'"9#_P 9,Y@.7[8H:DL)VY;1:NL++]33%O,/JLIVQ:VPXXG>4D3\(LC3KMG^
MJC-/G&Z=05G6AYZLBG4)/\A,20;L,.S: Q@#%%_[@B']=&0?L#_UGJ,&WO:7
MI5-T=N-SNZU1T97&*\L:?<8=FWYJ+]Z9\@]\]5[^]I>E4W1VX=W6J.C*XQ7E
MA[C#LV_-1?O3/D'OGIW][2]*INCMP[NM4=&5QBO+#W&'9M^:B_>F?(/?/3O[
MVEZ53=';AW=:HZ,KC%>6'N,.S;\U%^],^0>^>G?WM+TJFZ.W#NZU1T97&*\L
M/<8=FWYJ+]Z9\@]\]._O:7I5-T=N'=UJCHRN,5Y8>XP[-OS47[TSY![YZ=_>
MTO2J;H[<.[K5'1E<8KRQ%F1^R.[+3%KRNMK-A[+"R-D:SBS-:$RQD.6=%<0T
MA4XTK(L8C*%=.%7[BVI"4Q1 B1$3F.(!PU*X9MBVJXLAQ5+5T84T4SO,-I$E
M!Q4[Q$@ &SXR2)1HUFI.I=$I >I7)+!E):CD*1*4YVWA\DC.(Y8=G/V/$@[.
MP2Q=F[IX/U6*35.]9/>"N4;,^J\<]*O'R[ILW:33B.6=-1<'14%D0QU"IG**
M>I-S:5ME;1G#4T&;NSGFFA+@!PB1 )*0H)5($7C($BV--.K&H*E7!3O7IRE-
M9^^*0;#D,B1.5EIEDC6GV<W8Z+&223QKFPSI9Q"LR,PNF6#NA>V"/D9B)9\V
ME(J =PO!QAWQRD$_,M#D.IR1,)2T.TO;, 2:B@N@*,\VS*2"$J/R!2@BW*J8
M$\L5&J^H!,A3O7I@2FY.:@2!ZHO>(2G%,#L].Q].@P53Q/F0AEXN'FI@'65+
ML1"J1TTTB'K=2P.F%CE$P<)I2IDCHLP=J)NVJJ2@)AR5!R]X^V,*4DU5#8M2
M4R81-Q22H&X"E-G!G-5T%*@1.T19\-:A2$J9VU()X:I)! /"()\.03M!!EEB
M0ZAV5G9*WBSMZ? XPR]UZX065YF2R+DZ/:MW"+64D0BW3Y23.U2EEXB%<O4T
M0,8#-4N4)@,($&.K=K6UV@I365%319@$":66B2"4B\!ENA2DI)](Y)6QMT^I
MVHM2\*=JG<SI&ZI8$Y$R)G*<@3+P#[D3-[C#LV_-1?O3/D'OGJ$[^]I>E4W1
MVXD>[K5'1E<8KRP]QAV;?FHOWIGR#WST[^]I>E4W1VX=W6J.C*XQ7EA[C#LV
M_-1?O3/D'OGIW][2]*INCMP[NM4=&5QBO+#W&'9M^:B_>F?(/?/3O[VEZ53=
M';AW=:HZ,KC%>6'N,.S;\U%^],^0>^>G?WM+TJFZ.W#NZU1T97&*\L/<8=FW
MYJ+]Z9\@]\]._O:7I5-T=N'=UJCHRN,5Y8>XP[-OS47[TSY![YZ=_>TO2J;H
M[<.[K5'1E<8KRQ#ON9]@'K$^3+R;WSP,\@_E$ZK\K]ZYSPM\I/@KUATSK'I'
M-=2?<N:X\CE?;<..IKOLV@_#76O.*;GO6.9GS=N6;S&<E+).];/[D1_P%JOU
MOS3,*YOS6_+.*\[.79Y?!9'2.;X!_<']K['[/V-?-IR&/Q/&6,S=U#]%:C8'
MBEJM8H=[#TI K*==-ZPRK5@C)2J4N9? P8Q3%"Q,)YM.R"R[QO**"<B;Q)9$
M@(.4Q'(^9I *2))RV2(D,DK9S\,>V[4GFU8'J_2KIJAI]JC3=<(92RXA;-,X
MJZE" ZET.+4MQ+RB0'$+2 AQ,_:QM*_16VT_D"P_^;ZO:Z%GZE'X(^:/VNV1
M_LIU9_5_#_T1F,4ZOB',EVN>?IFF7_%U=@#9^NZ+>-M.-+=9YE-=&'JB#M1>
M7B,K5-BJDLND)DR%9$%,@@4QCB'*UU6*M8.I%&JL;JE/\Q:F4.MI3(%<I!3*
MSDR\+>C6^'L2Q*NK:FEJ&&VN>+%U32UFQ*)VAU _T=^+X]7#<=YW,&^A3(/S
M]ZB,UJ[]E7<>U[M&3X.QK3*7B'.7AZN&X[SN8-]"F0?G[TS6KOV5=Q[7NT/@
M[&M,I>(<Y>'JX;CO.Y@WT*9!^?O3-:N_95W'M>[0^#L:TREXASEX>KAN.\[F
M#?0ID'Y^],UJ[]E7<>U[M#X.QK3*7B'.7AZN&X[SN8-]"F0?G[TS6KOV5=Q[
M7NT/@[&M,I>(<Y>'JX;CO.Y@WT*9!^?O3-:N_95W'M>[0^#L:TREXASEX>KC
MN.\[F#?0ID'Y^],SJ[]E7<>U[M#X.QK3*7B'.7C%;<(P@]N9*XUW 9KVQ51I
M?%ECQ1Y7:IDBP13SC?,945](3+F-RU*,HMFWN64*Z#IT]%-)%)87:IP0:+JI
M;"'\*;4%-]9I4,A%4@2L(LE3V6$CY"8QG47$W 0JHH2#EG3*,]W[?Q1 KG<A
M@N$;O)<VX'!K-N1U$-X^30V.YY;-K5-VA#':?4E.E1R*WC[/96\?F.O*2C-L
MN9RT92X*KE! CDZ0O80H75=9%,A8:I!R6C_A]P@$>"+AJ)B@,Q4T0/Y,K[O^
MWB3PLU*=P.9+BZS+@5*'V_6.O4O,T@_V3YQ,ZHMHF)=HC"UV6:IY$<R+E\V,
M>.E5"H)K),(B0CI54Z3%VV<F!_"0))ZS";?^*1N@@_\ #[H)!\()BAU%Q2<S
M444S_P#3*W+?M]P_-$LI8?56RZZVXM\G;4ELJMZ"KEZ0HC?:U=U$VM*5G0JA
M[#(2"67!K;9X[EYXR(-57(2"J+I14$A0.8XW\ZPV]?O8I?E*?.TSE99/,>(6
M>(> 19\"8C=^OH;L]%5+=_\ ?^,[YB>B[;MQA"D(3+6"R)ID*FFF3"-_(1-,
MA0*1,A"YZ I"$*       !P#6H6M7B9EJNF?_?M>[1F^#L9%@JZ67^X<Y>/O
MJX;CO.Y@WT*9!^?O3-:N_95W'M>[0^#L:TREXASEX>KAN.\[F#?0ID'Y^],U
MJ[]E7<>U[M#X.QK3*7B'.7AZN&X[SN8-]"F0?G[TS6KOV5=Q[7NT/@[&M,I>
M(<Y>'JX;CO.Y@WT*9!^?O3-:N_95W'M>[0^#L:TREXASEX>KAN.\[F#?0ID'
MY^],UJ[]E7<>U[M#X.QK3*7B'.7AZN&X[SN8-]"F0?G[TS6KOV5=Q[7NT/@[
M&M,I>(<Y>(:SUM\W!L<?-%GV5<*N$#Y/P2U!-MAR^M52N'F<L<M&2PJJ9P>%
M%!N\6345(!.4JD4Q"F3,8#EE\#:P#GY*&JV]S:IRO-&SFSL_^'%LIR\!MD<D
M1N+:I8PU1A2JNF*2^P+&%BTOM@'Z\Y"9GPBRS+$S#MQW'"(CY7,&]T1'^I3(
M/V?_ /?>HC,ZN_95W'M>[1)?!V-:92\0YR\?/5PW'>=S!OH4R#\_>F:U=^RK
MN/:]VA\'8UIE+Q#G+P]7#<=YW,&^A3(/S]Z9K5W[*NX]KW:'P=C6F4O$.<O#
MU<-QWG<P;Z%,@_/WIFM7?LJ[CVO=H?!V-:92\0YR\/5PW'>=S!OH4R#\_>F:
MU=^RKN/:]VA\'8UIE+Q#G+P]7#<=YW,&^A3(/S]Z9K5W[*NX]KW:'P=C6F4O
M$.<O&#DEN2H<5=K-C9SNVPHI?JE9<@4V9J+':SGZ2G1MV-+)CJG6&L13!AE=
MPO.3DE:LKP4?!MV@+*6%VZ43C@<F:N>:9K5W[*NX]KW:+_@O&\O/*7B'.7BW
M+!N6Q6U92DQ:-R6(0C:E"2LM*3$YLKW$GCX&4BXFV6.:QZO(2&1Q1BLN,8S&
M4PX<U50R,V485<#-Q.W,!;T=1M3#:,02#EE4-B>7+*GMRG?/ABU6I&+K(OU5
M&3N3IUF7\_\ )_)'!D<UX4BVV4G<OGK D'Y+*77+AD8Z^RG.361BZU>!Q\:*
M%JK&Y+5=R\H*^5J]S[9B=5VV5DB'X<4ECI9N<X4)?\S(!! -2@B8\1IY?^RS
M)&/X"Q/2**VRRF6/Y<_.+@I=PH:]RIV$:MD;$T/9'F1YW$U*K[[8QG*NQJUR
MQ3'0<C,JQ,Q,909QB\96(Z\L%R3)%SHG+*E436.*JAM5=JL,J'5OO'$U.N%5
MXFJ;F;TKP/\ 9\AD)C)8!*P2HC4+$FFPANHH0A $@*9=DLG^WRB9MRVGPQ:T
M!F[ <@J[1K^>MN15H:ROF,X1GL>S:V-50KTA 0#G(-I%OD "5;&\?(W2-:A:
M7HH1"1I%,HN" *G(*JL,6.&K%#9*VJ0;#E%K&0[H@-0L23YK]"-VRF5EW/\
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MZ2OW:-M6U;D$"E.MB3":)3*)(E,KN%N"93*KJ$102*)]N0 *BRQRD(7X3&$
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MM2E*4I23<G)*4W;"#(D@@R(UAJU3)67$-XN%%5[(U8HE2E* ORO*4J]:")@
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BVAW%5UH(SBK\ITG28 @HB14R8%3Y*?-HM)B8=(I#2$?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g693329tx_pg078b.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g693329tx_pg078b.jpg
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M P,# P,# P,# P,# P,# P,# P,# P/_P  1" &U 50# 1$  A$! Q$!_\0
M]    00" P$!              4&!P@#! $""@D+ 0$  04  P$
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M^1#>4/ELCS"64I0I><KP]VH3)L,)55$C[,+05)F7P;>&RB1IU_64)S%F>&6
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MBD[=[0@MI-T*"G'0VD%:YE144@2R<\)!ENR,HT#?6[Y7QU6F;P;Z<KH].K\
M1:YBS*V?/+A@JR)9['2RI[SK5*<:)BA[14)01;S.7$)4 \O.?"3XF:T^ >S*
MZA-*G:(FI6NP$Y!$RHH2X$RRN E"T&1X0&/!$';V_P ,J?U0K))3:)MKE+*+
M;F/L\(MH4/R&'(%ZQ?-B0*9#%],:8R^_*@0362=D3P ^9J5@J99XN(4;(4P4
M)N2DH#8D$4.PIQ+CS<J/W,94ONXL+\#-DD)*U;2B0258&$$V0IQ!,@Z3(*:<
M!.(6%3Q1=1MMM(XH(%SJ!*@G"M8%HI;6!,MRF4NMD#&;0ECA!F_6&YC3\!:H
M57IOO!MEU2U(.*7M<Y"@X3$:S&R=C8:)JS&#X8)<\.A!;65B$$.)8;=4[G*,
M9#'@?LK3U+3_ 'B)*74$#HZ<*K5H(,G,"C9,P<(&$B46G-M=H7F7$:ID,FN9
MRBOJRD5#>84[X '$3@!G"9CUD^7FK8:ETVT>F]*0QHA@>I(=J>V%8XB3G+=3
M8!+4K$BQA%)P0N2  B5D&(1A;0:,X\1:<*1E5Q?@9LO>50]64^T04E4WS990
MH)0XJ8,P[*1*I)\JO(,!E;[\;0T+3=._="TJ"@R)J6"5H3(B1;\DL.Y,3QP\
M)+UC>:\.6@&1],::8)<,L<<TE&Q;$4T](4^/L4K:P&2@Z40(^;7(^I23IK2%
MJ<'P$YA>,*QC&<-OP,V2=1;;VE!2 D_<H&!92E!D79R45I"3Y;0E&2[MMM*P
MYDW+F6%34/K+PE"5*4!]GC2$*)'DEAB )C](WV/7I(J'G.&%:BI4++/F@#=O
M6!DEC!(S)@REHS1?A00(0VZVK&<I6VM*DYSC.,];MK_C3=S[8=9OMU39Q$4Z
M)8,!_K?(<$:-[Q:JJ=PM/7>E*QY"XH?S(3?UE"Y?= J'TQS_ ,A>KGPR4?;+
MWJZ=+%OWP.]01G5<B&I;/TA;-[%&"N7![7UC$$P;@4:3V_8G6F/:+"!C<H2B
MD-]BB&&TIRK\.,8_%SC/P]9=)_QS- LKHK^J&EF4RFG1,R,Q_6^0QCO^*R*H
M!-1=S2TB> NJ\N _HPR<>N?2,,"CX]/W6OA!!OQPO;NFYY<:CB@G8XB.\?-5
MR^X \$[X:F5J4CL;;SV=YIK*,[W#5]HJ[Q5,U*"C_P!LW]8&8,LI*8.&>/"?
M(3/&]Y=)(#5;4@)?>KQ$2E]7%+R?-N"-A[UVJ>2W*,D>G]K%]B:)D"Y09S<5
ML4*8_*R\?/R2EC9J/@-H-G8H<QQ#:4(R2C+F,84M>54I\ ZU)04[1504@ )/
M1VY@)24)PY2>!"BD$_HF7D$5'Q-I%3"KK9(422,JJ6$A1P6?*H _/AW846/7
MQAAVYEG'!*A$HL<E$3-@]I;MN<NY-S$"XT]&2DJ]*U0U\^0:?80XZZXI2RG$
M]]_+BNW/5M7_ !]J%%!U_4 M)4E%FF;392N84E(2X !(D #ZHP)D(K'BBP H
M:M;-M0*INK,RG$3-)F9X9^4XYPVD^N%1&0)>/#]/_70C4VRILYQ.ZKB8\I?B
MA$L$(]IU(]KQ@S8T=]K"D*;2\RE7=S^-C.3[B;P4XAQ>T-2HMG!_VS8W01O7
M!@(40?+(G#%CWD480I";K: 5C^U6=P^5)Q$ CY1':L^N56*N(,R-P<JDF>W)
M1TX?/36^+F;-S]ABIE5@"L-A);IXPTK+MS&4/9<6SC"_!92K"DLMX2JO >KJ
MUE2K^=0V4J0$)I6PE"%)L%"!E"4ILX) X)J(PJ,Y9\2J9A( NY"E6@HDO+)4
MH&T%*WN$SPSEY!N")KS^DH7+.<YSQ J&<Y^'/_\ ,<_^'\Q>M'\,E'VR]ZLG
M2QLO? [U!&=5R(/UE"Y?= J'TQS_ ,A>GPR4?;+WJZ=+#WP.]01G5<B#]90N
M7W0*A],<_P#(7I\,E'VR]ZNG2P]\#O4$9U7(@_64+E]T"H?3'/\ R%Z?#)1]
MLO>KITL/? [U!&=5R(C[^_\ +7[V/?C]ENK>9]V_N@^+7O5F_+>7^-7QX]O^
MT_B9XWC^+_HWE_"[O=_'[_;^+ULOAZI-3:AUJ[9Z5TBWD$SGD\E8LY3%^E.?
MR2C%]Z3O3=9="1]SDK.4/#M3G9_)**R]?B6/3_'12L92O&,XSG"5=N,9QVX^
M#/X>J2000,<HK2"% G%./T)N)/\ 96XT_P! 6G_ZOJ]UTS/W*/U1]$?0QX1?
MPIV9_=^[_P!D9CRT\HO0 W-SHY4\G>3-0Y#ZOHD#?-Z7H,2K6.HVR5F(U=1+
M8J!*BSHTM@%[!I$(I]OPT_BMN)QG/>QGK]1[/>,UV;(;/4%PU-$^\\U2-DK2
MM !MBV) X<$Y1XMVA\'JW;"_JV_&*MIIMRJ<394%3%A13Y$D89;L5PC_ -%R
MW%+13\[%<W..<E!BR,G#E3,?6K29%#2\++DUZ8BWY$::<$9D8F?#>!)84O#K
M!C2V5I2XE2<;?XC;E[-JLXW&H^':\^OL>9?)A#>_1F;Z/+AU\CG[Q88GI!RO
ML@0CP$RU+G/6ULMZJM!QJ[$DTERS,@/JCTH0K)J67,L]_"%=CXC;E[-JLXW#
MX=KSZ^QYE\F-:7_1I;E -$OSWJ#\3X1@*S+I1CTN/*QK0ER:'#+<J1+AED90
MQ9FQ9$=U0"LX*PV^VK+?8M.<OB-N7LVJSC</AVO/K['F7R8>ROT5K?")1B$7
MS(T*B:* +E1HA5-N290B+ (#$.DF(_,M@MX ,N1':=>2C+;;C[:59QE:<9?$
M;<O9M5G&X?#M>?7V/,ODPFUG]%SW#=8S,U3>;G'.VPZ338Y4M6:U:)Z,Q(1I
M"Q)$#)\5-%BX- *;4T^UW^^TXG*58QG&<=/B-N7LVJSC</AVO/K['F7R8</Z
MJ+R,^]MI3\P;U_*/3XC;E[-JLXW$?#M>77V/,ODP?JHO(S[VVE/S!O7\H]/B
M-N7LVJSC</AVO+K['F7R8/U47D9][;2GY@WK^4>GQ&W+V;59QN'P[7EU]CS+
MY,'ZJ+R,^]MI3\P;U_*/3XC;E[-JLXW#X=KRZ^QYE\F#]5%Y&?>VTI^8-Z_E
M'I\1MR]FU6<;A\.UY=?8\R^3!^JB\C/O;:4_,&]?RCT^(VY>S:K.-P^':\NO
ML>9?)B<=5?H['/O2$-/U_5//?4]+AK3(QDO8@8W6EA?;F).#RAR!.,<D<&OK
M)KY"/' 5A6,A$Y4\SW'5*7G47CXW['WLZA^\;GJ'76TD))<3O0KZP$B,"A@5
MPA@,Q@C<7=X*[4W4RMB[[U:::605 ).$I,TDS09E)PIX)PB1PQNZW]&KU+YN
MY[,M<'ZA>L +77MBV*KV.<-U*Z>_/3C]=A#I>96V3%+8RH\:PI0KO(5GQ4*<
M[<JSV]4UWBEL(S2T],[<KZJ9;"5I2'964A2@$X%>0I\V")H?#';-ZKJ*EJ]V
MA4(?4A2B@&THI22K"V<85Y\,/MKT-/4\9PE37J(Z>;)3)CSR9%&DF4RV+&U'
MEPQ=IQ+)A,2/QLGX$YR-EY7Q?:$Q&YP(:\^.E+>,(^+FP1P&Y*FS9LRRYE9F
M%!$K4K"5 *0B5E"M\@)5AC.'A/MH,(O=@*M6IY,3M2*2N>3G;*24J7.TM.]6
M5)P0W[#Z!/J,6EZ,)F^?6E"BHFWT6_"E-:6<")<N&LX9RO42</?"C!W),BN0
M[RV64$9<97A>5.(6KX>K['C+L33A09N:J"5-.-D9:8L.JM.)$U&04J1,I'<(
MBP_X/[7U%G+7LP2EUMP')@&VT++:C)H3LC )S&Z"8QL>@/ZB8JG7%\]M'$LO
MTHN@2(TEI'!\?+U@Z0ITK))L )D4Z'/S4H9KR#R9*G(?E"VXD9MXA;3>$=%>
M,VQ2A_\ AZH$.AP$/R*5@+ LD*FE(#KEE"2$)*U$)!,X)\'MKDDG6M/A:+9!
M;!"D**"0H%HA1);;FM0*S9 *B!*$D'T4.?7M:P7 +U.N/Y,EL5Z?GK7+?$ 4
MYB]N78:&^-,E/H<:> L;%N;U*.\?EY#K1SL.^^YWW$DK52KQAV%4RW3FY*C)
M,A(;&6E8"+=BP0J:;&46$RE9"I"0  J'A#MDE]RH%[M95Y2BX;$[978MV@6R
M%6\FBU:G:(F9DDG<N'H1^H1:Y^(L5^]1'1%AMU,BIXF/LEIU&R?:HJM66NR-
M.LK!T[(1ZIDFJ34,62T4.6ZX X0I;^4>9[7>II_&38BD:73TMS5+=.Y9*D)>
MDDE"PM*K(59"DJ (4 #(69V<$14>$&V%6XAZIO9AQY$Y*4V"J2D%"@5%LDI*
M5$%))$R3*T9PZ,>C'ZENPZY(!O\ J7:)V+6+#C+TUF0U#&W2/L>92!B61R9D
MTJ*DL3#N8%H%T1UYQQ;;:6'FE8[&U]8[7BSX?L.I>I[DJ6W42LE#Y39D2K>V
M5"SA)F!*<S/'&0[X5;;OMJ9J+X9<;7.T%MA5J8"=]::-HR D3,B0E(B-<;T.
M_4K'G+^\'ZCNF6I/9T\]<]C0[6I.^!;IM]-29.EYZLKCW(HE)[%5CF24Y&PP
M^PIUIQ*FC"D/UJ\7=@E-LMJN2H(IT6&SEM\A._D$JM6A(K409S!D09I210/"
M;;4+><%\,SJ%VG!DQ96K>S*DY.R9V$S$I$3!$E*"ND3Z%_J/-RZ;.'Z@7'Z6
ML8,O%%?&<_0D1/V!B9IEFF+%7,/3LA FR62:5.SAZ(UMQW/LL<MX-C#0JLL=
M2KQ?V%6V6=3588*5)LBH*4R6D(6+(6!OPE-O!OE *5-6&)'A/MH%I<UM3EQ*
M@H$M)40I*K2534T3-))LX=Z-Z))P1Q-^@[ZEEBI,GK68]0S4A>OYB,]AGT[W
M1&,0"X' [3*(!D$8%I L&T\S@I C>4,(D,J,PG!:U/*J9\8=A6*M-<U<E0*Q
M"K07EM]:X4RK"KR3.&SO?JR$4/>$FVE13*HW;X:-*H2*;$A+<D&\ GAD)"UO
MY6IF%69]#KU2+"T4Q.>I+K:59.F("P'-FZLD'D&S=5L$+9JQ)EXR#V$&5Z4K
MH20UJ[<CAC)$1V"=K.;;7BWX?L$%JXGDD)4D2=&!*TJ0L#?8 H*5:W2;1WV&
M*G?"?;=\$.WTVH*4E1FG&I"DJ23]GA*2E,MP"R))P0@R7HF>IE1=>6H=/J#Z
M=*K$?25AR<41I1HUXZK5&-),B:Y[0/A2C\1D3E+S@3/B9:&((>=0G"W7,JO-
M^*^PE97-JU+4BH4],'+D26L@%4@H"9P6C*9  . "5ESPKVSI*%Q(O=@L)9D1
MDP9I0"4IF6B9)PV1.0))&$DE/CO1"]23:<)2+U/^H!J.=5)CU&^!IL&I9 PY
MPMO7\M5(!$W(CB"'S.(:GW$X%M#SJF^Z0I64Y5A.4UN>+.PUWO.TC%S5"+)6
MV;+H EE M5D3(3:6A*L G@B&_"O;&\&&JE^]F5A80YOD3,\F4)F<G,R0HIPD
MB1,2&WZ*GJL#D21(7J4ZQC796PN6PO$9J-Z/:3922IPR1FPV!8MIF./FEV4]
M$@H=+29 <I;!&'&,);3@GQ5\/"E*57$^H)18$WI[T!("3-6$)LI*9SLD33(X
M8S?==MW;4L7TT"I=LR1(6M],@!L2G:4%2E:!LJF,$4JNWZ-AN^]6F<M5FYV\
M7U3AM@AZI)H$JTW%B V),9'1-?J#,:+--#QDEB*%&9$CL)2\IO".ZC/;CMZ.
MD_Y![/T5.FF8NVKR29XW$$S)))).$DDDD_+'.UG@#?-<^:A^\*>V0,25   2
M  " ) 8!\D=!OT4_D&:,.8'R^T:6(6PT2*4-1KL^,2,^A+K! [[4FMIYAYM>
M%(6G.4J3G&<9[,]9'Q&W+V;59QN,7X=KSZ^QYE\F-9/Z*WOA89,BGF1H14>&
MAYPL]--N2@Q6QFO&(<)*Q+9880PS^.O*E8PE/PY[,=/B-N7LVJSC</AVO/K[
M'F7R83C/T7/<,>:?&G\W>.8,C%129V4 ,K=H&-C81;OET3)XKTTA\.*4_P#B
M8(<2EG*_@[W;\'3XC;E[-JLXW$_#M>?7V/,ODQJO_HP.U!?*Y)YT<:A_/3KU
M7"\:"LC?G+,,_P"5(KHO?G<>8G!R?W-P1':0A?XN48ST^(VY>S:K.-P^':\^
MOL>9?)AS.?HIO(5IQAEWE[HYMTE:T#-.46[H<(6VVMYQ#"%2>%.K0RVI><)Q
MG.$ISG/P8Z?$;<O9M5G&XCX=KRZ^QYE\F,)_Z*KOZ*"+DI/F'HF.C@!WBSCS
MZ3=! @Q!T9<?)**(E&V!QV6\94M:U82G&.W.>SI\1MR]FU6<;A\.UY=?8\R^
M3&!_]%>WH+'8ER>9>@AXG+(Q.)1^GW!J.R.8I" R,&N2R1LLEK=3AM?>[KF5
M8PG.>W'3XC;E[-JLXW$_#M>?7V/,ODPB/_HP>TA4QZRN=?&<9$M+DU^+6_"6
M)E,E/!%Y ,A(]3D\G!DN(=C++HS?>>;=_$4G"O@Z?$;<O9M5G&X?#M>?7V/,
MODPO%_HK6^ '6F#N9&A0GG\=YADNFW(=UY.%H;SEIMZ60MS&''$I^#&?QE8Q
M^'/3XC;E[-JLXW$?#M>?7V/,ODQL*_13^0:26@U<OM&I+?9?)9%51KM@EX<5
M8[1)#3&9/Q7&1W"VDN+QC*4*=1C.<95CM?$;<O9M5G&X?#M>77V/,ODQG_51
M>1GWMM*?F#>OY1Z?$;<O9M5G&X?#M>77V/,ODQ&'ZM9O?WS?9X^T[J+VY[LO
M?3\8?B3<_9GLKXT_$7V+Y3SWF?/>;_=_$[W<\/\ %[.WX>MA[^+IU5KOH%3D
MND9"S;1.=C*6I[DL$:_W%WCK;4O36;71LM:DK%E+$OJ_EQ?EBEZO\57['XN?
MA_:^#K\'J^J?FCTOIQCYXOYR^)Q":OT'6Q(""CPK/1:W<GC6:UI<,]QX&H0H
MHWL.;UR(U<LP;[D\6DQ%B=<)*,'0KM6IA:NLBHF$)3@D4SQ#<&*7DW9Q^@_%
MQP4.S&SUW,T[#;-51,5!4&;M2J::=M(R;E&D5.3475AP5:E+6X@&9+9,>RCB
M3_96XT_T!:?_ *OJ]UOF?N4?JCZ(]R_A%_"G9G]W[O\ V1F(DTW?[O!(V[%P
MNB]C72/9Y![NRS9*]8M. 1ABGKY*NNI&%MVSJW.-+$=7EI?C!MX4M&<H[R,I
M5GLKTHJ1[HSCM8PTLT3&]4E\D?9CRH:4G#CP*^?#&WNNLJV>DMM4C[R.FO[Y
M*F0#]H?(MU"L'S?-%/6?3YT>,RP.QQ*Y389%,8E VB]]:?EFA9K%K!OTE--L
MS6])%E<A/[ !Q.FY<2MIR4<4\A#?8A*-5JR[^T*7B5.@C;:UO'L^IX]-IXD%
MWB30W+57+>CB]RD'E:NO5SD:H7=^EAW5.ZC;FV*L47+M[OQ97I)T.PE!EFX.
M2:Y%.KC&WFHQU\-UJV[^T*;B5.@AK2\.SZGCTVGAM3/!C3D^/:PYCB/R=D@;
MG?S-K3@<CO;44DAS9D@^V[(7@4B2WR8<'-GC@QXS^&WL#/"Q8K:VE82[XLZM
MN_M"EXE3H(:TO'L^IX]-IX1[]P4J%UHM7H@6B.6=8&J]MFK(U-M[>T989H^.
MMEQJUON=9)<F-[^6\I8'*B*.@E;;KX;F5G(PN26HO,&[:#M"EXE3H("]+P!G
MJ^IX]-IXMSH:NRO'.EDT'7_&OD4577IMZ:'9MNTM#V8B*1F)AX$&$AWC=VXQ
M&U^(AH$5@85I.,=J%O.9<(>>=<G5MW]H4O$J=!$&\[P)F;OJ>/3:>)K][&R_
MNO[?_.WCS]=O35MW]H4O$J=!$:RK^SZGCTVG@][&R_NO[?\ SMX\_7;TU;=_
M:%+Q*G00UE7]GU/'IM/![V-E_=?V_P#G;QY^NWIJV[^T*7B5.@AK*O[/J>/3
M:>#WL;+^Z_M_\[>//UV]-6W?VA2\2IT$-95_9]3QZ;3P>]C9?W7]O_G;QY^N
MWIJV[^T*7B5.@AK*O[/J>/3:>#WL;+^Z_M_\[>//UV]-6W?VA2\2IT$-95_9
M]3QZ;3P>]C9?W7]O_G;QY^NWIJV[^T*7B5.@AK*O[/J>/3:>($T=M#8@\KOW
M+'&[:QN2-^60A] ]JT*C(+ZJ70$*"(R5N,9*R$(;2O.6<NM=U>,87E6%8QN+
MWN^A4W13KZ82HTC"BHP_:.81)@X/GD?DC371>%<ERME05!G6J.!=/@^S;P&;
MPP_-,?+$]^]C9?W7]O\ YV\>?KMZT^K;O[0I>)4Z"-SK*O[/J>/3:>#WL;+^
MZ_M_\[>//UV]-6W?VA2\2IT$-95_9]3QZ;3QT=VKLQUIQO'&/<367&UHPXW;
M>._B-Y6G*>^WW]U+1WT=O;CM3G';^'&>FK;O[0I>)4Z"&LJ_L^IX]-IXK:C5
MO:Q66#>-G(Z336X]@)Q9NRN.B7+*0-(7.2:F;1D+;@:9*:43L6=R\\C#."LR
MCRGTN+PVMMJV[^T*7B5.@B=9WAV?4\>FT\:-8TX%2W[$Y4^,G(J#8M50;ITW
M'#[(XZ$1Q88LO)SD;*>6.V\4IF:C#Y9WN.MK0AYG#;3Z'6VFTI:MN_M"EXE3
MH(:SO#L^IX]-IXCN9XIUHIM_-9XV<DZ26^]'*0]%[.T+(@QS HL:!(-PL%*;
MR<AXDB6"!6K+C37<8/?\ZAKS# JF8U;=_:%+Q*G01.M+P\MWU/'IM/"VSQHJ
M30TP.KB]R<=5/K<=F#,;HTH))2+KZR%/K+DHW> 1I"'DO(1X2UJ92AAM*$)Q
MA7>G5MW]H4O$J=!$:TO#L^IX]-IXL?K>2M>K:VFK5GC#NU48@I92<R%TXZOO
MX5D80)MO"F=S#M);9#!:1CL1C.>[E2NU2LYRU;=_:%+Q*G01!O*\#_\ 7U/'
MIM/#]][&R_NO[?\ SMX\_7;TU;=_:%+Q*G00UE7]GU/'IM/![V-E_=?V_P#G
M;QY^NWIJV[^T*7B5.@AK*O[/J>/3:>&-L_:FR'=:;#:<XS;;&;<HMM;<(>MG
M'Y33"%P$@E3SB6-T//J;:3GO9PA"U=F/@QG/P=9=WW=0"O8(O"F)RR,%BIP[
MX?@1AWA>->:!\&@J0,BO#;IN"?QXU-0[4V.SJ;5[+7&?;1;36NJ2VV4Q:^/Z
M626T5J,2A]I).YV"$MNIQWDX6A"\8S\*<9^#JJ\[NH#>5037TP)?<P6*G!OC
MN,2BF[+QKA=M.!05)&0;PVZ?#O1NOSAV6&]7JT0<K79CBYNAR+F@7XX]L.^:
M(BREBDHRVZEB0C-ZB2 CF4Y^!;3J%X_;ZPM6W?VA2\2IT$9VLKP[/J>/3:>(
M1LVN1+A#L05CXH;RDH[%A19CVG+[QX97+2 \+%0$<@M8VY6/*L0P$#'^2\G@
M9P18366E)SW^\U;=_:%+Q*G01.L[P[/J>/3:>(:7Q3B$E0R0="\JXZ#C!C&C
M8AG;>AR#ITA_P4#/'V@W>!$RP*(RES"V&,MY*7EA3KF?)B):C5MW]H4O$J=!
M$ZTO#L^IX]-IX<Z..568#C A.+7)$)F&PQB+9&VUHA  >1DR;;*D0?OJ]@.+
M0-(-L]Y0N59;!%^'O,X5F=6W?VA3<2IT$1K2\.SZGCTVGB8,P)[\<_'2'%K>
M<EYBD-:^46_?./(CR*V@>?'>':'BMSQ\<APWXQON/]K&4.O-CN*3E8[*D-6W
M?VA2\2IT$1K.\.SZGCTVGB/S]-A'"Q(:.,O(R/:A;=.7,)0&RN.J"$R<]'P\
M.\QYHC;I+[(8,)!#""J:4V2TA'B>-DC]VZ:MH.T*7B5.@B=9WAV?4\>FT\->
M&XY1L6VALOCWRHEL,+GE!MJW!H>%%!1/S@\J5Y(.O;JBV1'\  "1REM=Q*A!
M\]U"%OOY<C5MW]H4O$J=!$F]+P/_ -?4\>FT\;#G':"=$0!GC7R>2!B;C+ X
M&WMW0+;;Q\0(< "TMQ&XL$HBTAG*2Z$VX@,E[+A+S;A9)CY#5MW]H4W$J=!$
M:SO#L^IX]-IXE(6IFM0@4$;Q@WS*#Q]>G:RP^1>^.8+RXNQ2;LK(I*9A=Q1@
M)[^'UIPRM]IW+'AX<1W7E..KG5M!VA2\2IT$-9WAV?4\>FT\-)[3,"6'"1DA
MQ*WO)1<#)6J5$CC-CZ"4.Z;:8@*O^(2XSNMDE7Q?A(Y@>/[BT*;RRAYW+Q"<
M/=-6W?VA2\2IT$-9WAV?4\>FT\-YGCM64%@&$\6N1TB['FB2 [9VT^/[@B"F
M!WPRG& 6=QL!1_M4$E8[^!6V.Z+V,,^$RE+>&K;O[0I>)4Z"&M+P[/J>/3:>
M']K"@N:CLK]JJ?&7D4]*E1CD:6Y8MIZ)L:BLO#PHY,@^7+;N(DG#BE0N'7.U
M_+2GR'EX1C*D]UJV@[0I>)4Z"!O.\#_]?4\>FT\6"][&R_NO[?\ SMX\_7;T
MU;=_:%+Q*G01&LJ_L^IX]-IXIW[R]@?W@'M+[.^T//\ V._)?%_XSZ-]I^4]
M]7C^V/,>]SV+Y'QOW'N>;\UXGP^#W/Q^NGZ!1=R\GTZGL:TG:L5$IY#ZLLC:
MGY<4OEG@CF.GUO?*WT&HMZLE9ML3EE\<\M9EY,<_DE'B;&*?!)'-%7X9(;[)
M8SF4(<PV0,XE]AS*'$K;7W'48SV*QE.>SLSC..O"IQ3CYY6'7&'D/-&3J% @
MX#(@S& S'GP1]">=TX=9:AQBL$E@!H^:UK*2D@, Q30&&Y T:I.OOA0]6B(=
M^#B2F,LJ8#=;R*PO#J1U+7@EQS(JB2E!..R=SY-R/T3XZ5S]YW1LM>%3DP^_
M=ZEK2D4R0%J#!)2VPVV6FU"S9;4+"3:#94K*J5[%.)/]E;C3_0%I_P#J^KW6
M]9^Y1^J/HCW&^$7\*=F?W?N_]D9B(].;EK513MV!D*WMF0,$Y![N6LRKZ2VW
M<H-SS-\E26_*S]5ITM"G9;0[A+F&B%9:<PIM?=6E6,=E>EUU%5T9Y#E,E)HF
M,"WV4*P-C&E:TJ'R3&$81@C;77>C%+TEE;=2I0K7\*&'EIPN'$I"%)/RR.#R
MQ1N(X]V>#A?B\!S$Y_XALSIUH>CU<9MWBLGSUAV&WM.X.23L-4H@\F*FK<\6
MTR(A]I(L(3F-4I]C#F7=5J.JYVC]:I]+&XU]2<S6>JU&BASF:+CBMAT^_P"-
MV<P/.55[11+B2>)NZ#2Y,S2K%D!\XIMZF_% ?-DBK,\+Y94(]'BY2D]P8N90
MS*-3J.JYVC]:I]+$:^I)2R-9ZK4:*$VK:&>I5UL%[@=^\MCI:1W_ &O?,(';
M>(F_IV%AI"ZB3,1/P1D2!&P(4N,J"E$-B]Q(@ A0K;[8/=RME34=5SM'ZU3Z
M6&OJ0_U-9BZK4:*$"Y:9W)-1.MXB'Y?\STECUZ'H6[+J7QDWU 6O8%/A9G;\
MV/+1;5>UR0&Q=<#[-8B$+==8'P%'H)>408V,IB-1U?.T?K5/I8D7]2<S6>JU
M&CB^6@[S6]+:FJFLY)C?%T)K'MU"9]GB5O"IBK#E;),3D=%1]?"H\FW'1=<C
MY-J.%PX442X,(A;[SSZG'%3J.JYVC]:I]+%!ORE)GDJSU6HT43#]HNF?S.WW
M_NV;\^KKIJ.JYVC]:I]+#7E+S59ZK4:*#[1=,_F=OO\ W;-^?5UTU'5<[1^M
M4^EAKREYJL]5J-%!]HNF?S.WW_NV;\^KKIJ.JYVC]:I]+#7E+S59ZK4:*#[1
M=,_F=OO_ ';-^?5UTU'5<[1^M4^EAKREYJL]5J-%!]HNF?S.WW_NV;\^KKIJ
M.JYVC]:I]+#7E+S59ZK4:*#[1=,_F=OO_=LWY]7734=5SM'ZU3Z6&O*7FJSU
M6HT4'VBZ9_,[??\ NV;\^KKIJ.JYVC]:I]+#7E+S59ZK4:*($T=OVH!2N_%.
M5+>#F#M]V0YK O'G>!BFFG*906L-%I%H+R@B\*9SG++V$/)3E*LIPE2<YW-[
MW+4J;HI.TF"C2,-33C^L<Q3<PCY1@\T::Z+YIDN5I+57AK%'!3/G^K;QR;P'
MY#AB>_M%TS^9V^_]VS?GU==:;4=5SM'ZU3Z6-SKREYJL]5J-%!]HNF?S.WW_
M +MF_/JZZ:CJN=H_6J?2PUY2\U6>JU&B@^T72\_!\3=]_P"[9OSZNNFHZKG:
M/UJGTL->4O-5GJM1HHJP</7R,5,0.S\HHZ)KM<@J^<,WQDY"/'S":\SL $0A
M$FY5L9!P;%[&+9+2MDEQ]8@3B76\L9PY&HZOG:/UJGTL3KVDYJL]5J-%&G7T
MD0)%M<)V;RMMPUIH;=1\&X\8>0TD;$R0TS+RC$U%RK-;9R*,8-)-AFBY'<4\
MR,E33K+BW,K:CJN=H_6J?2PU[2<U6>JU&BB-E4^V5>.="UGO?E_'#(<A&8N#
MLO&_D 1#Q8@D5!PISKLB'K\BPRRPV8S)03#[W9WVF!'G5"^:24U'5\[1^M4^
MEB=>TGE9K/5:C1PYF(6R-YF2E\AN:29F8P^A4N/Q;W:I<<P0M65AQ($K2Y>-
MBQ&D,C8;PPTV[WFEK<<<6YWD3J.JYVC]:I]+#7M)S-9ZK4:*+):PVI 4"M*@
MYAOD;=3ER11[DW*\:N0"2W<DMCMJPYAVA%*\4AUA1#V>_P!W)#[F<?!V=-1U
M7.T?K5/I8I-^4I_JJSU6HT<2)]HNF?S.WW_NV;\^KKIJ.JYVC]:I]+#7E+S5
M9ZK4:*#[1=,_F=OO_=LWY]7734=5SM'ZU3Z6&O*7FJSU6HT4,;9_(6G$ZUV&
M.BH;V0M^C6UE"W^.6]QV4J=@)!"5/$/Z];88:3E7:I:U)0G'PYSC&.WK+N^Y
M*I->PHNT<@\C_P JGX0_$C#O"^J55 ^G)5F%E?\ XU0/T3^'&IJ'D)3A=3ZO
M%<J&]5K&UW2F%K'XY[V*'6MFM1C:E,$C:^='(95E/:EQM2D+3V93G.,XSU5>
M=R52KRJ%!VCD7W#AJ:<?I'R%S!%-V7U2INVG26JR88;Q4U0?T1Y0W(P[+!OB
MK34'*Q(,1R-K9DB"0(-/0_&K=JY2)>>;RA!P*9/5T@!DAA6>U/BLK3_P8SV9
MQA:CJN=H_6J?2QG:\I>:K/5:C1Q6:T1%-LL5D!N9Y1UXP[8(&PIJ9KO''D;'
M2#TK"P<-%0+L6XY5#'1C(\R 9+><*=,0<Z07DAMW#V4XC4=5SM'ZU3Z6)U[2
M\U6>JU&BB/6H;9T<JNQ,1R+Y:-P$?'$#RTD=Q7WLN<[S*!AXP"!APZ$/!,"*
M91A3SY3C[C.16DLM=U\W+[4=7SM'ZU3Z6)U[2<S6>JU&BAP-04H/$#0S&\^9
M:P&F^X8"9QDWJ6/.96Q)"$XFI(NE&64I)PC@*7<Y.5G+@KKG9GS*DHG4=5SM
M%ZU3Z6&O:3F:SU6HT<2<9)4^7;F"IA[DJJ?FM9#ZW-EHSC5R!'\=M&)]TF9+
M4;1S9$LUR0E!2&EH('(85'-H0]AMU]#C4=5SM'ZU3Z6(U[2\U6>JU&CB-I>L
M0\D+7AV[KR<0[ ;+L>R&S)#BOR$EG73)<6'%CF/*DUO BS(MV,<.4^[AP9V3
M*=?2(VVK+'4:CJN=H_6J?2PU[2<U68NJU&BC%$CWI.!53F_>6;CD:_85QN(G
MB?O)Q;&)67:0"0\=8J9,%%J#JHF!FV7\/9'+,)<\=]/@]R=1U7.T?K5/I8G7
MM)S-9ZK4:*.\G&6&6B'X$[>O+LF-.DPGY'!'%+?3Q14$P">#(57Q5UWR^(J=
M6;DDIUQEXW!"E(8>9$0&*&U'5<[1^M4^EAKVDYFL]5J-%$F(L$:74@:O,SW)
MMQL6KRM>(5%\;.1+(IY!4O[0A9@C$E3CSFBZT.TTV-Y9X5:E)5AU;C'<81&H
MZOG:/UJGTL1KRE\C59ZK4:*(VD*?4Y<&J1LG<>6JF*O:;E<&C >./((27=FI
M\,(>"(8+)I<BD9Z&D0_:A3F<+P;)N.N-(%:>6SB=1U7.T?K5/I8G7M+S59ZK
M4:*.CL+)'GQADSN[F,<U&E"/H$&XR<@0&_!PVXS)!)?Q6R"BA'FO"R,DY9WE
MWV$$.^9)QAW#4=5SM'ZU3Z6(U[2<S6>JU&BB1]8V1^D6U5GMNP>5FT4*AC(_
M$?9.+V[8]@4N0:KJC2 !HG7K<<.$\?#O/I9PSWVL/-MX<4EM2G&HZOG:+UJG
MTL#?E(1]U6>JU&CBQ/VBZ9_,[??^[9OSZNNFHZKG:/UJGTL1KREYJL]5J-%%
M._?M4_[P#VY\5=T^5^QW[*\K[@MT^V/,>^KSGC^P_B+[8]F^'^+YOP/+>+^Y
M^)W_ ,7KJ-3U/<O)92DM:TG/I#%F60E];*69_).<L,I1S&N*;OEE<G56=62E
MT=^U]_/ZN3M2^64IX)SCQ+*^#&<]O9V8S\/[7P?A_9Z\*' "8^>$8XOYRJ@J
M/3M*Z,BX[7-(K5PN-7IUO,LU<AH80J3CQ*0PQ(-MGQ9A,HXF5D9M@F2]J.E+
M=D6\^54RVTZWFZ\VVV@64I"U"9( $\'R?*9F<\,?H?Q5IKHNO8K9^D:N^CI[
MUJJ:F?+S2$ J0FF 4 I"E+-M3B5O98K*GD_9%"4*2?91Q)_LK<:?Z M/_P!7
MU>ZZ!G[E'ZH^B/<GX1?PIV9_=^[_ -D9B(].;ZTE1T;>K=QVWKBK6('D'NY9
M<'8;C!1$H*DN]RI8F20336B64DC/(<1G*/QD+PK';C/797I<][5?1GZ6F?<9
M-$Q)24*4#)L X0)8#@C;W7?%U48J6*NI8;>%:_O5+2DX7"1@)!PQ1N)LO)F*
MA<PB_5'XN2#:ITVPDGN)K/MLKXP[";OTQ669F:<LI,5 0$8455HG+*5*3!I:
M<PV.3A&6-5W=O_J55FE^B-OWBV>ZY2YU'IA;LUDW&859,UWU(^.H0EIU94Z0
M>MVYH$*A[/%TR\0LO;:*TLZ<$IQ!5DF8B1+?7B1EY=P!S+1T.E33+;N[?W4Z
MK-+]$1WBV?ZY2YU'IA^V*T2I^ZH?8L)ZC.IHFF9L4,NU:Y'O$8W5Y.OQ%)]G
MDF0T')3=A5 R]AL1QC!(+1V &ATB22%J/'RTX[NW_P!3JLTOT0[Q7!*73*6?
M]JCTQ#VJ[[R2;V33I#;?/?C+(:YUC<*]%AQ8NQHD S9-($@ZLU9K?-,U&7&*
MF)Z36)(@AQ]C+=9:,)<EG&^W P+;N[?W4JK-+]$#M%L]+!64L_[5'ICZI?:H
MXT_/[J#Z0ZM_*?4]W;^ZE59I?HBGO#</7:7.H],'VJ.-/S^Z@^D.K?RGT[NW
M]U*JS2_1#O#</7:7.H],'VJ.-/S^Z@^D.K?RGT[NW]U*JS2_1#O#</7:7.H]
M,'VJ.-/S^Z@^D.K?RGT[NW]U*JS2_1#O#</7:7.H],'VJ.-/S^Z@^D.K?RGT
M[NW]U*JS2_1#O#</7:7.H],'VJ.-/S^Z@^D.K?RGT[NW]U*JS2_1#O#</7:7
M.H],'VJ.-/S^Z@^D.K?RGT[NW]U*JS2_1#O#</7:7.H],'VJ.-/S^Z@^D.K?
MRGT[NW]U*JS2_1#O#</7:7.H],0'HWDQQV!E=^J,WEJ@5)^_+(>$I^^UIG!8
M3M,H#+90^7)%.'AUNL+3A:>U.5(SCM^#/6YO>X+\6W16:.I,J-(/V:\!RCF
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M<Z9-S@GS&&4;X0\X@]IQO\(@_E8_^<Z9-S@GS&&4;X0\X@]IQO\ "(/Y6/\
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MA@=H.V-G3<,W+M.U7Q28MF.)\5$QA#<@7D1:O"9-S@J\T,HSPAYXR#G\U<-
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M9J=+!]FS67_3MO\ ^\9R'^M+IKZ\-RE]6IM%#45!NU/K-3I8/LV:R_Z=M_\
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M^%&'>%QT":!]0-3,,K_\FH/Z)\A=C4U#QSUJ5J;5Y3IFVL.DZ[I+[F&.0O(
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M.,]U/?<6OLQ\*LY[<]57G>E*+RJ :"C)#[F&=1AWQPX'Y13=EV51NVG(KZP
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M!AI*RS +LL91-E":BMB(/S&^&VYAF&OT@,&MYA2V5M$M%(6H5Q+W4#PL\+U
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MJ-CI@M^WZ0B]>MYC)2TR5*#-$S?=F5O,@,JU1B@5K8PXEHAYA"\I40SA>?\
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M-* !&15(A-F0ETC$+".*-P2E*)_1]K?M&%9D(WU;=VW>#$L.),8]>N_;(F;
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M56'@@0(ZC$(NG$QF/@ZM!XH[A>B=KN)CZO),W>8KS(_G=VK=0UX-1GU"MO\
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MD5/B+W\)$384O(BMCI.2A]DE:$MMNJ[,8Z979WF*W/M>SPR>T?E?H\P[[1&
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MRA;:4_=B4@IM1Q8YG'&VNQ-\'I)HUTR6.FOR"T+4K[PSF4N)'S8,450%XO\
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MB/B&N+J+_'')B$_UE;2?VC?M$_9?VY[)]RGN5^+GQQI'M+VE\>?CU[;\S_\
M*>0\K^X=SM\3Q/A[.[UMO</>^HM2=/ILKTO+VK"Y2R>3LRGCGA^:-3[\KGU]
MKGH;^1Z'D96Q.>5MS^KN?)^6/D2E:VE)=;4M#C:DN-K;5E#B'$9PI"T+3G"D
M+2K&,XSC.,XS\/7XR.*/2 A2D+"T$A0,P1Y#^2+F<HQMDRM2UM<=E;*@Y_$I
M#QYM!IC$7=T2<?4[/ A2Q\NBQVR$:=F%(F@NX<,1)GFB.$L.X5D<IO.+CP7(
M*409C ,,Y$8<?R_.?EPQYL\4&MI:NZ;JOC::\F:@N-(52TX14VTL/MI6IS+5
M#0+A#B9.H6^XX@J;4-XZDQ[5>)/]E;C3_0%I_P#J^KW70L_<H_5'T1[K/"+^
M%.S/[OW?^R,QY N:'H8<U.:7,CE3R*T_,:+$H%VWE<1(9BZ7NQPUC0[5<A56
M3\]&QM$G!1TJE(9[+782O*V<I5G"<J[,?KG93Q=V5V4V7N^Y+S35FL:I$%10
MVE2=^+0D2XDXB)X,<>%MK/";:;:S:6NOJ[%THI%U+B0%K4E4T**3,!"AC&##
M%9T?HQGJ..(RXBS<7EH2IQ"EHVE<%(2ME:FGDY5C5^<84TXA258_"E6,XS\.
M.M_\0&PW K\TC2QSWN!VVYRASJ]%&-/Z,EZBRWD#(M?%I1#@_FVV$[5MRGEB
M=]+?FD-8UAE:A^^O">_C'=[<XQV_#T^(#8;@5^:1I8>X';;G*'.KT4=L?HR'
MJ,9(4)BT\7,E(:2^L;&U+?DA#*U*0AY3.-8>(EI:TYQA6<=F<XSCI\0&PW K
M\TC2P]P.VW.4.=7HHZ,_HR?J*D-,OCVSBR^P1G"1WF=K6UUI]6<95C#+B-8*
M0[G*4YS^+G/P8Z?$!L-P*_-(TL/<#MMSE#G5Z*.ZOT8_U&48=4NT<74)8RE+
MRE;3MZ<,J5A*DX=SG5^,-Y4E>,X[>SMQG'[?3X@-AN!7YI&EA[@=MN<H<ZO1
M1W;_ $8OU'74]]JR\7W$=Y:.\WM&XK3WFUJ;<3WDZOSCO(<3E.<?AQG&<9^'
MI\0&PW K\TC2P]P.VW.4.=7HH[_JP_J0_P X>,7TGW+ZKNGQ ;#<"OS2-+#W
M [;<Y0YU>B@_5A_4A_G#QB^D^Y?5=T^(#8;@5^:1I8>X';;G*'.KT4'ZL/ZD
M/\X>,7TGW+ZKNGQ ;#<"OS2-+#W [;<Y0YU>B@_5A_4A_G#QB^D^Y?5=T^(#
M8;@5^:1I8>X';;G*'.KT4'ZL/ZD/\X>,7TGW+ZKNGQ ;#<"OS2-+#W [;<Y0
MYU>BCC/Z,-ZD&<9Q\8N,>.W&<=N-GW+&<=N.SMQGW7?!G'3X@-AN!>&:1I8#
MP"VV!G;H,ZO11<FK>FYZT%LJUYUU 6GA9'UZL0<'QQG@V9"P1JOB[K:MFKI<
M?'D@T%;KCE.C=E&>SY)?=DDN%OH<6MM2DKY:HV[\+*:H9KGF[U4^XM54DR2=
M\ZH90D%S],M)M)^KO00 <754^PWB94T[U"RN[4LMH33*%HC>M)-@ AK] .JL
MJ^MA()(,;#/I"^MP%/6&RQ>S.)D/+VB&1 2YD;<+2T2[%*V<=M<\4<][69$F
M(F7GI)\,K+;^._%.*'1W,J4XJA7B7X3K90PXQ>2FVU6@"A$IAH,@RRLC)(!$
MQ]<6ODB\CPY\4VW%N(>NT+6E22;:YR4YE#AR<QAP8",& S&"'WCTQ/7)<E8Z
M=.N?"F1F8M_&1Y)RRWN->7&.RU6G)*O$LUZDPH1,).2=(B%&(4UE]U@/(V'4
MBE&L$XG?_P ) VIE#5ZI:4,(L-G#):0H6G%$*2'%V<,IJM2M)04Y V!\4[8=
M<<NU3J3CMK&":%%)LM 244(G@F0FS.RI05J1GI?>NS#N]L?M#AT."R/4PHR"
M3,2^*] 1U*KGQ:@HRO0Z=5)$AP$,J44^AG&,D&+RI><MX0TFISQ!\(71OZ>\
MRLE9*K(M*+BK2BI66FH^03Q#%AF8I3L#XKMD6'[M" E "0HV0$)*4@#(R&.9
MD!/!.$Q/I7^L["DQ4U&6#@C69>H4![6%?L ULV$Z=6M>.E1ID/6FG+!598(I
MB /BVG@BY!HJ06[V^9()QGLQ6?$;PK6A;3R;W6RX\'5I*&P%.2(*S96"+0)"
M@DA,OJI3%/N[\34K2ZRJZT/(9+2%!:R4MS!2D6FR#9(!!4"KA*,(TMZ27K1S
ML?0Q)6^\/"3J/9M=V<&S)V1LT2UV&5U@M$I4\3\\#5!BG'4RG?D2B0/(211+
MRU+)\+NMINM^)?A4RMY3;5YA#S;B"C)-%"0[@7925D?5DD)5:2 !O9S,6G/#
M;Q.=0RE;MW%QEQM5O*N6E%K"F:K$YSFHJ$E$D[[%)UU/TN?7'ILJ;+0-[X6-
M,2$*NO9@79ZU.U4.#S<=IWP&/AJ^G7;<?"CPUBVX>X!Y1+61& 8YEO.&A,)7
MCU/B%X2530;>9O4E*K5JRBV56&6R2K*S5:2RD*G.94LG"K!?I]@/%2F=4XV[
M=LE)*;)6JR 5O.  9*0"5/$ID!*RD# )1M_W8OK<*ADUMRR<&'*8.=YEBJ9L
MVPVXH1H>*%A&(M$LQ5&;:L(-N/9<3XLFLCQVNU;JDJ<0JGW@>$^5Z0$7MTHB
M178;F3:*B;-NQ,S(P(E(XL1%7<#Q0R?1RJZ^B S"+:Y2LA(%K)VY"0.%4YC"
M3AF6?TP_7*NNOIW65LN?">;JMAHTQK^0:7/W.+/Q#3C +,@8.=!4.+4B65[+
M&RA:DK8;0.VREK Z<-=*?Q \)*2M17TS5ZHJ$/)<&]01:3.0DIPX,)^4S)G:
MPP?V!\5*JB705#EV+86RIL[Y0,E2F=ZT,. ?)( 2LX(;LOZ2_K435<@ZR3/\
M&QA*Q&T.!K1T5+VR(EH.MZXGJ]/UJNA%QVOQVW8U"JE&"/+(;?+<!"0VEY"E
M.+7?:\2/"MI]=0E%[E3BG%*!2A04IU*DJ407#AWZR )"THF6*5ESPY\376$L
M*5=<FTMI00I0*4MJ2I*1)H8!80)F9DD">.:=GTB/6M3+4.>'NG#(>:UY8UW&
M$D\V*T2#Y-N%@QJ[5[+)-S.MY,3VG1XP 3V9Y1L-A1 ;1!K9C_B..5^\OPJ+
M;S*FKT+3R+"A90 $%14M LN@R<)5:F29*(04B0%(\./%!*VG$.7:'6E6@JVH
MDK  0O?-$ MA*;,@ 2 5!1F3L7[TP/6M<@@IJ<MO"T.&UG%W&4B0:_/6^.1'
M0DG*4R[3<&*TS1&,OPZ)O7;!0@;KO@BNFFI:[B"<X1%%X@^%0>+3+=ZEU]2
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MRLV?+.<_)&)[E-KNGZGMT?2LAEIY15FS;L8\G.<_)+%Y8B=7^+G_ (L_X/\
M[^O7N<1CT]#&(OKR\G8.2U3QL&Q)Q%CLV*$)E^6C+:!8W8J&C*W6X?$')@!6
M28)@)5N4&<:<9(0IK+(;6&'$90^RF_4$%"<5JS_^P_Z^B/T!XMUU!4[*[,MA
MUFIO,4*)K14(>*&T-,MY):$O.%I86E0*5"4D(#:A9<0/9?Q)_LK<:?Z M/\
M]7U>ZWS/W*/U1]$>YKPB_A3LS^[]W_LC,0YJ';954QMR$:U+N2T)'Y [N6F<
MJ=4B)*!)R1?99[L!,*LH#Q'ELK\-WO,H[KR%IQVXQWL]G>=VIJ>C.FII6R:)
MC>K60H2;&,!)Q^3#BC:W9>2J;I+0IJIR5:_OD(24X7%8B5#%Y<$4>C.&]0AX
M;XN@2'J5MP6)TBU^Q,R58:@R+3+; 8VO9YR2A )4&)E"K/L9+TF3E]E:D>9<
M':4@?/A=:S4J>NT6<5R(VVO%]2K<VGEP[IWC;''%I/K9WJ'T25=#U<'(6>K1
M>M1[X:-JH/,?$PB=@$Y(MH%(FQTMN25=8*;A"#&O,)&0ZZ1EYJ5/7:+.*Y$-
M>+ZE6YM/+AMA\1H*,N$G>(NQ>IW'S\HFMAD2;4]7B9EV"K)H!X, 98Y"7-L,
MC',OBK4RE\ES#2U(5G"\MY[[4J.N46<5R(:\7U*MS:>7#:@>%@4"Z3&"7#U(
M@*&(-#,T^EUMNNUAFKO!-R34L3@R-M/E%OR#4AA KT>'%E (PO&'G5+PI$:E
M3URAE_:*Y$->+ZE6S_LTZ2%3;'$9O:TR"S(RW/<+7TW6 J]N"I*AH0N1VF_
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MKF<7#.<(1WNW/9C\&.LN[[G2FO85TRB,GD?UBN$/Y$8E??"U4#Z>AUHFRO\
MJT\$_P N-34>^#!=4:Q%QHCD"1@?7E*8P0Q28)3#^&JW&(PZRI5O2K+3G=[4
M]N,9[,]57E<Z57C4*Z91";[G]8KA'^1%-VWPI-W4Z>AUIDPC^K3P1_+B0OM
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MLT^<1Z8/??I?YWM7_G_5/Y6Z:HO7JM1FU^B&MKJZS3YQ'I@]]^E_G>U?^?\
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M5[U]:&J*R\[AHDSWZL>4<^6-+=%#1%VMM,M8*U4MXG%DVODB?_=CK;YO:/\
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MQ5,RLD)4VV+( )RJ0,./K[GO7IU$VJOOBLIZLN*"IN*4)!; $@""+275FT<
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M .MI.((>M)XU\.[1LB)@9#T0?8NOK78*A$PMMD='-0QU7BIY^.C9BS;  G6
M&XT"!/(=(=8'RLI$>G#BT86EQ"7O(V\[6K<X8@^'FQ,O_P ;1S_4$,2 TWPR
MLU^B]9!^BY48^QUNQZR W,>K3Y,^!48W8I.$@8BHR&B\2+3KT:@B0\_,+C8X
M*."<=)4EYX,4A[R=N^UJW.&*O=WL3*>K:27ZD?5S^Z1],W[D'';Z/8K_ )O3
MWD;>=K5N<,6_=]L3V92<2#^Z1],W[D'';Z/8K_F]/>1MYVM6YPP]WVQ/9E)Q
M(/[I'TS?N0<=OH]BO^;T]Y&WG:U;G##W?;$]F4G$@_ND?3-^Y!QV^CV*_P";
MT]Y&WG:U;G##W?;$]F4G$@_ND?3-^Y!QV^CV*_YO3WD;>=K5N<,/=]L3V92<
M2#^Z1],W[D'';Z/8K_F]/>1MYVM6YPP]WVQ/9E)Q(A+3GI8^G1.R>[FICA?H
M$UNO[MGX"%;)H4<XF/A1JC1S1P!,.85X0B"I!YQ*$]B<*=5G&/AZVUZ>(6V[
M+=(6KTK 5TB5*DX<*BMP$GY9 #\D:FZ]A-CG7*L.7;2D(JU)3O,20ALR'R3)
M/Y8FW^Z1],W[D'';Z/8K_F]:GWD;>=K5N<,;;W?;$]F4G$@_ND?3-^Y!QV^C
MV*_YO3WD;>=K5N<,/=]L3V92<2(AVIZ:WIWT4$M=?].72]I);KLK,"G ZH7+
MQ*Y(%QAD"MNBU6-GK'B4EWR$]Q>0D!LLX6ZM_P#<U(R/B3MX/_MJW.&)'A[L
M4?\ ZRDX@BO$/PDXFR\?=GU^CYJ")D:]'2)%>C3Z";C%H,9M$#%1[0ASU2"#
M2.5$S#[JL=[S2%@.NJ80-G#B7O)V\[6K<X8GW>;$]FTG$ARG\'N#P(1DD'Z1
M5#LH2567,?[*U>Q%R! ]?2^:.^[#V2)C)1M<_'/BI!:RTEQXSQVNS'AX5E[R
M=O#BO:MSAA[O=B?+=M)Q(QW#@SPC@Q*5*UCTH-37<"7IE>L=PCHO5Q4?::])
MSAZXI^+ @YF!CW#G(:2:[I+)"A"4BKR7W/ :7E0>).W9Q7M6YPP]WFQ7ENRD
M'_HAM?9;]/4IZ1B8?T@8"0M<6F&4?7,ZKB_$AFYJ-G)$4FQGQ<=,#PS#S4,A
M3*.QXMYHQG/@)=\1EN/>5MV?_MJW.&)]W>Q0QW92<2'W <&.!$S9(*M&>DU2
M:Y@UVMLRMHL&JX,*L-.S$C"BR#4:XTZ5(D+BHZ926YEUEM",,O,JSWV",M3[
MR=O.UJW.&(]WFQ4IB[*3B1:[^Z1],W[D'';Z/8K_ )O3WD;>=K5N<,4^[[8G
MLRDXD']TCZ9OW(..WT>Q7_-Z>\C;SM:MSAA[OMB>S*3B0S=B^E!Z;47KZ]R<
M=PGX]C2$=3;0<"2QK^,0\.8)"'$"OLK0G"T.M/MI4G.,XSC./@ZRZ'Q%VZ<K
M66UWK6E"G4 C*'""H QBUVP&QC=$\M%VT@6EI9&\\H290EZY]*KTWS=24.PR
M'![0LW+EZZJ\R:AJ@0CDI+R3]9!-)2VLYX5A9YY2E8QEYYM&7%]JUIQVJQ-X
M^(NW+5X/MMWK6AM+RP '#@ 40!YHIN[8'8QR[V''+MI2M3*"38QDI!,5KNG"
M?AA!S( 57])'5-H -9@5R#_NHL01-5=F 9%XMF4QBD$ SOL/*17RE1#QF.[E
MX9KQB$8SUA^\G;SM:MSAC/\ =YL3*>K*3B".UAX3<-:\=%NM^D)J^SPC\)6G
MII%7UVT78H2PS5<C["3'N1AD.$P3%"^,4(X2EW#PI8R&WV$J(2EM[R=O.UJW
M.&'N\V)[-I.)">YQ6]/F1-F(>J>D-69N5@I<F%FE^ZF/=BH P5,(X0)*R41'
MRH;TTRQ+J<\B*Z_E26DY4\VVYXK<>\K;OR7M6S_M##W=[%8S=E)+]2)#@N"_
MI]S-QBJT;Z4E%J$<7,#1!5BMNL($2-6X^],1SC\8N.5(J($'F(K"<//89:>%
M?9(QE+3["G9/B3MV#+6U;G#$>[S8J4]64G$B/P^%G#LFXLP37I#ZJ.K3DFVP
MU<!]5SD6T>!BT&1+BVHFRT^'?AI J&PT6SB2=$":\)S!!3.%M]CWD[>'%>U;
MG# ^'FQ(QW;2<0>F%:6X/<-XZ<EHD#T@-:SH $M* B6(+7T>-&'A#WFFP@IK
M8Q0.)#L&J,](2!&$(<P^3'8:$R\RH@D5[R=O.UJW.&'N\V)\MVTG$C7D.&W
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M:2X'J5MMJE4W9<RU:ZLV&RV$A-15/,MI(-HI9:; ( 2$H%F/>!Q)_LK<:?Z
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M89?1VN\5[<-K,LZ.)[N75P7,\]I(SR%JX^1,.F3E=&<A!5*AX.743C86V5P
M3<LN) +:E9=W8+!P.82?D'A25X!<0VV,HA64M=_+3O%>W#:S+.CAW<NH_HN9
MY[21OWR;T!0+Q)UN0TSO&PU8%V!%9O%-V9N"R ER4Y6I6S-AN@#79M,8VN.
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MK45;Z3$&R$L9A^3EEQS"#GR&D>'U8'BAX/Y);'0*HLK"@06DD65(6V4B;V!
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M7\9F%5@"+*AT#,+,'4Y(-/-N#.8<7XV!4W>]2T[%4LA3-0V5I(M2$EK04JF
M+4VR9"8E(SQRV%+>+554/TB 4O4[@0H&4S-"' I(!)LD. 3(!G,2B '..7I<
MRS;SS]YY$EQMBFQY\Z49CY:($=GX61R\L]J8"UU&R$<SYAMT5UL5U F$/K:Q
MA.>WLPHV$UC<BT^G+'Q#XJ;!GKA#S>XEG6P)N"=DYJ K"("=@K JK74BRJ!I
M]1J?BL5;S+CK0ZD.OQXJY10HN$J)[$4FTH1<)?.31V 5SN"+.W4Q(HR7D[,?
M7#HI@-@(Z)C7!QX61P-9Y8_),X*OPQ GL)%7E_*O#PG*D19,:K7/?CJ4HL8"
M8MI\J+$DS.(9FC6-@X@405TI]MMZ0""BF",9#*9Q@@EE*B W6\*RK",+0LF,
MBN<VF#(J<DZZU;;"Y4G*\NXQP]>*CRJ]'V UP)!:B)7RD7,$BJ;[^1 2""7V
M\]YE#F,9[$+)C?:YQ<?#)%V"B;!-3%EQ#3$V+7 *S,*DC!(:M'VI_&%O#-
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M.8(VLDT@QMA(Y6$(1.'%*.O@\8K94-A50#DI:5Q0<-"EDE46OR$#.%0NMJY
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M#@"1<2"'&1H#"!@H\ 9D0(0=O'8VP,,.AMEEI&/P)3C&,=(B*"_^Y=_Z8_\
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M_J'\R.+_ -^?Z?\ SX\+^?P?#_\ C_\ X_9Z\/G%'SK1.^R)';YFO*</=MP
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MYY\3"\I;::2I*B65HB9C$=KGAS=8ARN'.;)]M4K7TA#Q%4(ND,%Y6JPFS[#
M"RQKF&504&]8I&P.R!JC6TI]A/N./M*900G*$U0@1'V8]MWN<UR;KO<<:[M\
M_P!ZENE6[H#&U&))APW[-7[2F59S'H=1'24\7$*8>PMAUXY;9#1B?)N)1.$8
M8>[%:XF;0IE+O"@]S-0471;8 08.<_7O9D%2Y+.QWX*9A<-CQ$\66DM8F'AV
MG,-L,99*4,K.<=(C?#!">5$<4[=+PY!:-ZNKVJ'K$VND%3O@R<I7C6$Z^ D7
M(K(SLG&1,-&UQM2P7.\>;@Q[* U,*>5A$[[%#3>J7$(<LV3N=6W^.[5Y>KZS
MC!@)G-L'/9EE2\A7SHAFLMYDL1\^S3F"E%O(:*/<>'?7XCSBW<IPWT))IW "
M6FPAGX7=$J'!TZJU=J3$&<DX9K-,BF:XU$/55C#[0\UB :2080-')'4WA:E+
M:4AI.8AOI1>CBK==/2%@M%?UV-L8*:F*3JZVR8-S?1(Q4=! :\IL/6XJ$D17
MR(YLF/@#P<%MLK<0X0XMQ#BT_P"+,4J!\L-+_P!R[_TQ_P#BOKMO]A?ZA_,C
MB?\ ?G^G_P ^/"_G\&?^+KP^<4?.L,<6MY&ZIHFNM?\ 'F<I\'<H>2V%KTNP
MVYZZ.YP_*S*68%>3J^*CPQFJJM1SF0W$M)6ZG.>^I>4XSU<=0E"4E,YJ229_
M_M\D>7?$;92X=G;@V;KKG8K&:F\* NOFIP%QR31M- 2&0)4<F93(G,JE./;M
MQ)_LK<:?Z M/_P!7U>ZZ%G[E'ZH^B/=[X1?PIV9_=^[_ -D9C%Q[_P OOG_S
M$[!_[MJ_70WU]6C_ ,BW]*XZBY<=9_GG/H1#"N,IS(:N=B:INNM*GT429:3
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M]F+K-:XII-$VOHPJ%.M?=("7LD'EH94 HI0 V@J2XL@_7$>R7B3_ &5N-/\
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MLS&"1Q#&?*/-+S1YQ\56+SI+CV?:JT,)H7*-M;1%,&W1*FI I*GY!;S<BA2
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M P+B)FO04=9:Z1*GH9*0"S'3K\4U!5H0-*FW<NNDNKPA#>/#SC*&#=A#<-Y
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M+EM&5I>PXE$X-V+):#3M!4[;R+]I*G:@#>B*M@!59EXR>)G9,3,M$F-%'QR
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MQ&#FTC.0KPSOU*BDNTEH!$YK4F64<4RGZR!-*G@&TK$T**DJ2HH)4)'B7<1
M5DJNR2N4FTF=AM+ROJK)"DLJ+BD&2TA*DJ2% )*1#>J]0-C776]/U5KNTNNW
M"D;(N\Z1L1Z#JI$2%4-8;4O$ Q"0\=.SD[:@YZ2UDMIR7"%>@6QB4X0<LWM$
MQ==\.:VAI'ZJ\7VP&G6FTY*TL$K=9;5:44I2@I#LPA1#A(^H$;Z*$>(E'65C
M-)=S#A+C3JU962" AIYQ-E(4I2PHM2*P"V <"BO>QMZI]6?4VPJQKTH_66RX
M^V7.ESEF?%CG]:%45)-!UY#[#VIB*V:;L@&C+AJ+&6B$;*(,/$4P5.B"$)9-
M;.'$IO'PVO*BJ'THJ*=5,TZE$SE0Y)QU33,V@T7+3A0Y()2J8;4I,T%"E3=_
MB/=M8PR5T[XJ76E+(&2R<VVDNNR=+@19;"VYE2DR+B4JDH+"?J_UXXCR+!TA
M!TA!TA!TA!TA!TA!TA!TA!TA!TA!TA!TA!TA!TA!TA!TA%-=&\]>-O(GD!OK
MC+J^U2DKM;CB8Z%L6..@#XR)6X'-D5F8=J\T2G =E%K]C&R"<X/G*1R5)1GM
M[V.NGO;8^_+DN:COZ\&TINZN$VR% G"D+3:'Z)4DVD@XQ..<NO:NY+XO:JN6
M@=MU](2'$RE]510J6[94+)Q82)3A_P#'WE+J;DP_N0'6AD[B8T'N*U:+V? V
M>!,KDU 7VH)#<D&D@FYRLR%-8.0X$<WE3!:,*RC.>[GK#OG9^\;A%*NO",E6
M4J*AI2%!25-KG+",2A+?).$8)XXR[HOV[[Z-2FB*\I25"F' I)20M$IR!QIP
MR"A@)!'D,?-KU/\ 9_'O=\/N/BC<MBV:D.\8M51_,G?-LKE"FKK\2J1%#S$9
M4H84$4R)B)ZT6-<B\9[+=,:(\@/AYI.5Y2MJZSL+?E^7?1U-,&DT]=6]'9M+
M 4MT89A)_JP<"EX@9#''@OQ_V0NWQ9N)6P%36JH*6C(KZE]+:W5-AM"D-(2V
M%-H65EZVH..)DA(*0HX42GKK>_%KTX>&/%^ /NVR=B ;5B!CM'U6NT"=M^[M
MT2M\85LDH:FZHK+4E)BI "LJ77F%+2+%LJ;;?)RZM*G;ER;$7U75E1=-,&D]
M *A4.N.);9:LK*25N*(2 5 A($R0#(2!ET?AW=.S/@QX9W1LM35556TX;4MD
MELJJ*A3RE5"RAA-HI +N!$S8!2E2U+,U:7 KEWK2XZ.Y9[X-IN[]?1<!LG;?
M(V\1^T-16>D26=>S@<O.4V1J"Y!I<5>_&U?0Q77E19)"6C%>"K/XS:W)J]C[
MQNZMI:$5%!5+KWK+2Z:H0\V2I24 *4F11A4/K #'*<C+%\(+SHF]F[[VG=#H
M9KKWKKT)L*LFF>6H4RFU2LN$TE.T56"9*,@2"E2M[77K"<<MJN4ARD::YMS$
M)L,NNCU:WL\/=S*I)P=H+$%BIY5L:@781%;5@U#SA^'LC-CX4[E7<QG/6^KO
M#2^[N#O2ZJZDNLA5M'3&<H"D$E-BU:M8)693G@CNJ/;^Z:]3?1:>\5-.D65]
M&<L$'$JV!*SY9XI1](*KL.(MTS8H$&+M<=(U=Y+$GF?JTS" .J648*TN)EC1
M6XJ;;=R$IS"A'GL):4A2N[W\8ZXBHHG*9I#RU-J0X,%E:5'$#A2#-..6^ PS
MCKV*M#[JV4I<2M&.TD@8R,!(DK%/ 3@E.&[?L8]XNBO^"W7#L_X/_P",+EU?
MHO\  UG]DC_W41C5O^.H_P"U7_[2XE[K61LX.D(Q/OL"L/$DO-#C#M./D$/N
M(:888:1EQUYYUS*6VFFFTY4I2LXPG&.W/2*''$-(4ZZH);2"229  8223@
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M#D9&:FK%TO\ <8W>P6X]37!%>DJ]+FOURI;'88OM3T?%GR-1K5'JLW!\]J)
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M'2$'2$'2$'2$'2$'2$'2$'2$'2$'2$'2$'2$'2$,,S:6M8ZTE4>1O].C[B$
M'*%U@^QQ(<X/'2#GA!&.1I);126"G.S"%=W\;MQ^WCMS$7?7.4XJT,NJIB2
ML)44S&,3 E@C$57T2'S2K>:%2 "4E0"I'$9$SPQM9V+KY+O@*O5-P_A2499S
M9X3#O?7EK"$>'D[O]Y>7T8QCL[<]]/[>.J>A5LIY%V7ZBO1%73:.<LJU/]9/
MIBH&WI TS=>H>0&DK-JG81&O:7L&C[&HLILR%J[TEK;92JC9@;A7K"IB7CAB
M*_,44<GL*;0*?'O/>&^A2$YS9?NV\VW4.9!W&4R*5"9F, P?6!$I8_RQXDVS
MNR_3MO<VW^QXHJYZ@I*RCJJ5RH#!<I:PT[H=9=LN(2MEVE0HI6D)=;4H!:2
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;^M;&R@Z0@Z0@Z0@Z0@Z0@Z0@Z0@Z0@Z0C__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
